

# EAU Guidelines on Paediatric Urology

C. Radmayr (Chair), G. Bogaert, (Vice-chair), A. Bujons,  
B. Burgu, M. Castagnetti, L.A. 't Hoen, F. O'Kelly,  
N.A. Pakkasjärvi, J. Quaedackers, Y.F.H. Rawashdeh,  
M.S. Silay

Guidelines Associates: U.K. Kennedy, M. Gnech,  
M. Skott, A. van Uitert, A. Zachou

Guidelines Office: C. Bezuidenhout



European Society for Paediatric Urology



European  
Association  
of Urology

© European Association of Urology 2024

# TABLE OF CONTENTS

# PAGE

1.	INTRODUCTION	9
	1.1 Aim	9
	1.2 Panel composition	9
	1.3 Available publications	9
	1.4 Publication history	9
	1.5 Summary of changes	9
2.	METHODS	10
	2.1 Introduction	10
	2.2 Peer review	10
3.	THE GUIDELINE 10	
	3.1 Phimosis and other abnormalities of the penile skin	10
	3.1.1 Terminology, epidemiology and pathophysiology	10
	3.1.2 Classification and diagnostic evaluation	12
	3.1.3 Management	12
	3.1.4 Complications	13
	3.1.5 Follow-up	13
	3.1.6 Summary of evidence and recommendations for the management of phimosis	13
	3.2 Management of undescended testes	14
	3.2.1 Background	14
	3.2.2 Classification	14
	3.2.2.1 Palpable testes	15
	3.2.2.2 Non-palpable testes	15
	3.2.3 Diagnostic evaluation	15
	3.2.3.1 History	15
	3.2.3.2 Physical examination	15
	3.2.3.3 Imaging studies	16
	3.2.4 Management	16
	3.2.4.1 Medical therapy	16
	3.2.4.1.1 Medical therapy for testicular descent	16
	3.2.4.1.2 Medical therapy for fertility potential	16
	3.2.4.2 Surgical therapy	17
	3.2.4.2.1 Palpable testes	17
	3.2.4.2.1.1 Inguinal orchidopexy	17
	3.2.4.2.1.2 Scrotal orchidopexy	17
	3.2.4.2.2 Non-palpable testes	17
	3.2.4.2.3 Complications of surgical therapy	18
	3.2.4.2.4 Surgical therapy for undescended testes after puberty	18
	3.2.5 Undescended testes and fertility	19
	3.2.6 Undescended testes and malignancy	19
	3.2.7 Summary of evidence and recommendations for the management of undescended testes	19
	3.3 Testicular Tumours in prepubertal boys	20
	3.3.1 Introduction	20
	3.3.2 Clinical presentation	20
	3.3.3 Evaluation	20
	3.3.4 Treatment/Management	21
	3.3.5 Tumour entities in prepubertal boys	21
	3.3.6 Follow-up	22
	3.3.7 Congenital Adrenal Hyperplasia	22
	3.4 Fertility preservation in children and adolescents	23
	3.4.1 Ovarian tissue cryopreservation in prepubertal and adolescent girls	23
	3.4.2 Cryopreservation in prepubertal and adolescent boys	24
	3.4.3 Summary of evidence and recommendations fertility preservation in children and adolescents	25

3.5	Hydrocele	25
	3.5.1	Epidemiology, aetiology and pathophysiology 25
	3.5.2	Diagnostic evaluation 25
	3.5.3	Management 25
	3.5.4	Summary of evidence and recommendations for the management of hydrocele 26
3.6	Acute scrotum	26
	3.6.1	Epidemiology, aetiology and pathophysiology 26
	3.6.2	Diagnostic evaluation 27
	3.6.3	Management 27
		3.6.3.1 Epididymitis 27
		3.6.3.2 Testicular torsion 28
		3.6.3.3 Surgical treatment 28
	3.6.4	Follow-up 28
		3.6.4.1 Fertility 28
		3.6.4.2 Subfertility 29
		3.6.4.3 Androgen levels 29
		3.6.4.4 Unanswered questions 29
3.7	Hypospadias	29
	3.7.1	Epidemiology, aetiology and pathophysiology 29
		3.7.1.1 Epidemiology 29
	3.7.2	Risk factors 29
	3.7.3	Classification systems 30
	3.7.4	Diagnostic evaluation 30
	3.7.5	Management 30
		3.7.5.1 Indication for reconstruction and therapeutic objectives 30
		3.7.5.2 Pre-operative hormonal treatment 31
		3.7.5.3 Age at surgery 31
		3.7.5.4 Penile curvature 31
		3.7.5.5 Urethral reconstruction 31
		3.7.5.6 Re-do hypospadias repairs 32
		3.7.5.7 Penile reconstruction following formation of the neo-urethra 33
		3.7.5.8 Urine drainage and wound dressing 33
		3.7.5.9 Outcome 33
	3.7.6	Follow-up 33
	3.7.7	Summary of evidence and recommendations for the management of hypospadias 34
3.8	Congenital penile curvature	34
	3.8.1	Epidemiology, aetiology and pathophysiology 34
	3.8.2	Diagnostic evaluation 35
	3.8.3	Management 35
	3.8.4	Summary of evidence and recommendations for the management of congenital penile curvature 35
3.9	Varicocele in children and adolescents	36
	3.9.1	Epidemiology, aetiology and pathophysiology 36
	3.9.2	Classification systems 36
	3.9.3	Diagnostic evaluation 36
	3.9.4	Management 36
		3.9.4.1 Surgical management 37
		3.9.4.2 Radiological management 37
	3.9.5	Summary of evidence and recommendations for the management of varicocele 38
3.10	Urinary tract infections in children	38
	3.10.1	Epidemiology, aetiology and pathophysiology 38
	3.10.2	Classification systems 39
		3.10.2.1 Classification according to site 39
		3.10.2.2 Classification according to severity 39
		3.10.2.3 Classification according to episode first/persistent/recurrent/breakthrough 39
		3.10.2.4 Classification according to symptoms 40
		3.10.2.5 Classification according to complicating factors 40

3.10.3	Diagnostic evaluation	40
3.10.3.1	Medical history	40
3.10.3.2	Clinical signs and symptoms	40
3.10.3.3	Physical examination	40
3.10.3.4	Urine sampling, analysis and culture	40
3.10.3.4.1	Urine sampling	40
3.10.3.4.2	Urinalysis	41
3.10.3.4.3	Urine culture	41
3.10.3.5	Imaging	42
3.10.3.5.1	Ultrasound	42
3.10.3.5.2	Radionuclide scanning/MRI	42
3.10.3.5.3	Voiding cystourethrography/urosonography	43
3.10.4	Management	43
3.10.4.1	Administration route of antibacterial therapy	43
3.10.4.2	Duration of therapy	44
3.10.4.3	Antimicrobial agents	44
3.10.4.4	Preventative measures	44
3.10.4.4.1	Chemoprophylaxis	44
3.10.4.4.2	Dietary supplements	45
3.10.4.4.3	Preputium	45
3.10.4.4.4	Bladder and bowel dysfunction	45
3.10.4.5	Monitoring of UTI	45
3.10.5	Summary of evidence and recommendations for the management of UTI in children	46
3.11	Day-time lower urinary tract conditions	46
3.11.1	Terminology, classification, epidemiology and pathophysiology	46
3.11.1.1	Filling-phase (storage) dysfunctions	47
3.11.1.2	Voiding-phase (emptying) dysfunctions	47
3.11.2	Diagnostic evaluation	47
3.11.3	Management	48
3.11.3.1	Specific interventions	49
3.11.4	Summary of evidence and recommendations for the management of day-time lower urinary tract conditions	50
3.12	Monosymptomatic nocturnal enuresis – bedwetting	50
3.12.1	Epidemiology, aetiology and pathophysiology	50
3.12.2	Diagnostic evaluation	51
3.12.3	Management	51
3.12.3.1	Supportive treatment measures	51
3.12.3.2	Wetting alarm treatment	52
3.12.3.3	Medical treatment	52
3.12.3.4	Electrical neuromodulation	52
3.12.3.5	Complementary treatments:	52
3.12.3.6	Conservative “wait and see” approach	52
3.12.4	Summary of evidence and recommendations for the management of monosymptomatic enuresis	53
3.13	Management of neurogenic bladder	54
3.13.1	Epidemiology, aetiology and pathophysiology	54
3.13.2	Classification systems	54
3.13.3	Diagnostic evaluation	55
3.13.3.1	History and clinical evaluation	55
3.13.3.2	Laboratory and urinalysis	55
3.13.3.3	Ultrasound	55
3.13.3.4	Urodynamic studies/videourodynamic	55
3.13.3.4.1	Preparation before urodynamic studies	55
3.13.3.4.2	Uroflowmetry	56
3.13.3.5	Urodynamic studies	56
3.13.3.6	Voiding cystourethrogram	56
3.13.3.7	Renal scan	56

3.13.4	Management	56
3.13.4.1	Early management with intermittent catheterisation	56
3.13.4.2	Medical therapy	57
3.13.4.3	Management of faecal incontinence	58
3.13.4.4	Urinary tract infection	58
	3.13.4.4.1 Urinary tract infection and clean intermittent catheterisation	59
3.13.4.5	Sexuality	59
3.13.4.6	Bladder augmentation	59
3.13.4.7	Bladder outlet procedures	60
3.13.4.8	Catheterisable cutaneous channel	61
3.13.4.9	Continent and incontinent cutaneous urinary diversion	61
3.13.5	Follow-up	61
3.13.6	Self-organisation of patients	61
3.13.7	Summary of evidence and recommendations for the management of neurogenic bladder	65
3.14	Dilatation of the upper urinary tract (UPJ and UVJ obstruction)	66
3.14.1	Epidemiology, aetiology and pathophysiology	66
3.14.2	Diagnostic evaluation	67
	3.14.2.1 Antenatal ultrasound	67
	3.14.2.2 Postnatal ultrasound	67
	3.14.2.3 Voiding cystourethrogram	67
	3.14.2.4 Diuretic renography	67
3.14.3	Management	68
	3.14.3.1 Prenatal management	68
	3.14.3.1.1 Antibiotic prophylaxis for antenatal hydronephrosis	68
	3.14.3.2 UPJ obstruction	69
	3.14.3.3 Megaureter	69
	3.14.3.3.1 Non-operative management	69
	3.14.3.3.2 Surgical management	69
3.14.4	Conclusion	70
3.14.5	Summary of evidence and recommendations for the management of UPJ-, UVJ-obstruction	70
3.15	Vesicoureteric reflux	70
3.15.1	Epidemiology, aetiology and pathophysiology	71
3.15.2	Diagnostic evaluation	71
	3.15.2.1 Recommendations for diagnosis of VUR	72
	3.15.2.2 Infants presenting with prenatally diagnosed hydronephrosis	72
	3.15.2.3 Siblings and offspring of reflux patients	73
	3.15.2.4 Recommendations for paediatric screening of VUR	73
	3.15.2.5 Children with febrile urinary tract infections	73
	3.15.2.6 Children with lower urinary tract symptoms and vesicoureteric reflux	73
3.15.3	Disease management	74
	3.15.3.1 Non-surgical therapy	74
	3.15.3.1.1 Follow-up	74
	3.15.3.1.2 Continuous antibiotic prophylaxis	74
	3.15.3.2 Surgical treatment	75
	3.15.3.2.1 Subureteric injection of bulking materials	75
	3.15.3.2.2 Open surgical techniques	76
	3.15.3.2.3 Laparoscopy and robot-assisted	76
3.15.4	Summary of evidence and recommendations for the management of vesicoureteric reflux in childhood	77
3.16	Urinary stone disease	79
3.16.1	Epidemiology, aetiology and pathophysiology	79
3.16.2	Classification systems	79
	3.16.2.1 Calcium stones	79
	3.16.2.2 Uric acid stones	80
	3.16.2.3 Cystine stones	81
	3.16.2.4 Infection stones (struvite stones)	81

3.16.3	Diagnostic evaluation	81
3.16.3.1	Imaging	81
3.16.3.2	Metabolic evaluation	81
3.16.3.3	Urolithiasis in infants	83
3.16.4	Management	83
3.16.4.1	Extracorporeal shockwave lithotripsy	83
3.16.4.2	Percutaneous nephrolithotomy	84
3.16.4.3	Ureterorenoscopy	85
3.16.4.4	Open or laparoscopic stone surgery	86
3.16.5	Summary of evidence and recommendations for the management of urinary stones	87
3.17	Obstructive pathology of renal duplication: ureterocele and ectopic ureter	88
3.17.1	Epidemiology, aetiology and pathophysiology	88
3.17.1.1	Ureterocele	88
3.17.1.2	Ectopic ureter	88
3.17.2	Classification systems	88
3.17.2.1	Ureterocele	88
3.17.2.1.1	Ectopic (extravesical) ureterocele	88
3.17.2.1.2	Orthotopic (intravesical) ureterocele	88
3.17.2.2	Ectopic ureter	88
3.17.3	Diagnostic evaluation	89
3.17.3.1	Ureterocele	89
3.17.3.2	Ectopic ureter	89
3.17.4	Management	89
3.17.4.1	Ureterocele	89
3.17.4.1.1	Early treatment	89
3.17.4.1.2	Re-evaluation	90
3.17.4.2	Ectopic ureter	90
3.17.5	Summary of evidence and recommendations for the management of obstructive pathology of renal duplication: ureterocele and ectopic ureter	91
3.18	Disorders/Differences of sex development	91
3.18.1	Introduction	91
3.18.2	International Consensus Statements on DSD Management	92
3.18.3	Current classification of DSD conditions	93
3.18.4	Diagnostic evaluation	93
3.18.4.1	The neonatal emergency	93
3.18.4.2	Family history and clinical examination	94
3.18.5	Gender assignment	95
3.18.6	Risk of tumour development	96
3.18.7	Quality of life	97
3.18.8	Recommendations for the management of disorders/differences of sex development	97
3.19	Congenital lower urinary tract obstruction (CLUTO)	98
3.19.1	Posterior urethral valves	98
3.19.1.1	Epidemiology and pathophysiology	98
3.19.2	Classification systems of the urethral valves	98
3.19.3	Diagnostic evaluation	99
3.19.4	Management	99
3.19.4.1	Prenatal treatment	99
3.19.4.2	Postnatal treatment	100
3.19.5	Follow-up	101
3.19.6	Summary of evidence and recommendations for the management of posterior urethral valves	104
3.20	Rare Conditions in Childhood	104
3.20.1	Urachal remnants	104
3.20.1.1	Introduction	104
3.20.1.2	Epidemiology	105
3.20.1.3	Symptoms	105
3.20.1.4	Diagnosis	105
3.20.1.5	Treatment	105

	3.20.1.6	Pathology of removed remnants	106
	3.20.1.7	Urachal cancer	106
	3.20.1.8	Conclusion	106
	3.20.1.9	Recommendation for management of urachal remnants	106
3.20.2		Papillary tumours of the bladder in children and adolescents (Papillary urothelial neoplasm of low malignant potential or transitional cell carcinoma)	107
	3.20.2.1	Incidence	107
	3.20.2.2	Differences and similarities of papillary tumours of the bladder in children and adults	107
	3.20.2.3	Risk factors	107
	3.20.2.4	Presentation	107
	3.20.2.5	Investigations and treatment	107
	3.20.2.6	Histology	107
	3.20.2.7	Additional treatment	107
	3.20.2.8	Prognosis, recurrence and surveillance	107
	3.20.2.9	Summary of evidence and recommendations for papillary tumours of the bladder in children	109
3.20.3		Penile rare conditions	109
	3.20.3.1	Cystic lesions	109
	3.20.3.2	Vascular malformations	110
	3.20.3.3	Neurogenic lesions	110
	3.20.3.4	Soft tissue tumours of penis	111
	3.20.3.5	Penile Lymphedema	111
3.21		Emergencies in Paediatric Urology	112
	3.21.1	Acute Scrotum	112
	3.21.2	Paraphimosis	112
	3.21.3	Priapism	112
	3.21.3.1	Epidemiology, aetiology and pathophysiology	112
	3.21.3.2	Classification	112
	3.21.3.3	Diagnostic evaluation	113
	3.21.3.4	Disease Management	114
	3.21.4	Summary of evidence and recommendations for the diagnosis and management of Priapism	115
3.22		Paediatric urological trauma	115
	3.22.1	Paediatric renal trauma	116
	3.22.1.1	Epidemiology, aetiology and pathophysiology	116
	3.22.1.2	Classification systems	116
	3.22.1.3	Diagnostic evaluation	116
	3.22.1.3.1	Choice of imaging method	117
	3.22.1.4	Disease management	117
	3.22.1.5	Recommendations for the diagnosis and management of paediatric renal trauma	118
	3.22.2	Paediatric ureteral trauma	118
	3.22.2.1	Diagnostic evaluation	118
	3.22.2.2	Management	118
	3.22.2.3	Recommendations for the diagnosis and management of paediatric ureteral trauma	118
	3.22.3	Paediatric bladder injuries	118
	3.22.3.1	Diagnostic evaluation	119
	3.22.3.2	Management	119
	3.22.3.2.1	Intraperitoneal injuries	119
	3.22.3.2.2	Extraperitoneal injuries	119
	3.22.3.3	Recommendations for the diagnosis and management of paediatric bladder injuries	119
	3.22.4	Paediatric urethral injuries	119
	3.22.4.1	Diagnostic evaluation	120
	3.22.4.2	Disease management	120
	3.22.4.3	Recommendations for the diagnosis and management of paediatric trauma	121
	3.22.5	Urosepsis	121

3.23	Peri-operative management	121
3.23.1	Pre-operative fasting, intra-operative fluid therapy, post-operative feeding, fasting and fluid management	121
3.23.1.1	Epidemiology, aetiology and pathophysiology	121
3.23.1.2	Disease management	121
3.23.1.2.1	Pre-operative fasting	121
3.23.1.2.2	Maintenance therapy and intra-operative fluid therapy	122
3.23.1.2.3	Post-operative feeding, fasting and fluid management	122
3.23.1.3	Summary of evidence and recommendations for the management of peri-operative fluid management	123
3.23.2	Post-operative pain management: general information	123
3.23.2.1	Epidemiology, aetiology and pathophysiology	123
3.23.2.2	Diagnostic evaluation	123
3.23.2.3	Disease management	123
3.23.2.3.1	Drugs and route of administration	123
3.23.2.3.2	Circumcision	123
3.23.2.3.3	Penile, inguinal, and scrotal surgery	124
3.23.2.3.4	Bladder and kidney surgery	124
3.23.2.4	Summary of evidence and recommendations for the management of post-operative pain	124
3.23.3	Antibiotics management: general information	124
3.23.4	Thromboprophylaxis management: general information	125
3.23.4.1	Epidemiology, aetiology, pathophysiology	125
3.23.4.2	Diagnostic evaluation	125
3.23.4.3	Disease management	125
3.23.4.4	Pharmacological treatment for thromboprophylaxis	125
3.23.4.5	Prevention of CVL-related VTE	126
3.23.4.6	Summary of evidence and recommendations for the management of thromboprophylaxis management	126
3.23.5	Premedication management: general information	126
3.23.5.1	Recommendations for premedication management: general recommendations	126
3.24	Basic principles of laparoscopic surgery in children	127
3.24.1	Epidemiology, aetiology and pathophysiology	127
3.24.2	Technical considerations and physiological consequences	127
3.24.2.1	Pre-operative evaluation	127
3.24.2.2	Abdominal insufflation	127
3.24.2.3	Pulmonary effects	127
3.24.2.4	Cardiovascular effects	128
3.24.2.5	Effects on renal function	128
3.24.2.6	Effects on neurological system	128
3.24.2.7	Comparison of robot-assisted laparoscopic surgery versus laparoscopic surgery	128
3.24.3	Summary of evidence and recommendations for laparoscopy in children	129
4.	REFERENCES	130
5.	CONFLICT OF INTEREST	211
6.	CITATION INFORMATION	211



# 1. INTRODUCTION

## 1.1 Aim

The European Association of Urology (EAU) Paediatric Urology Guidelines Panel has prepared these Guidelines with the aim of increasing the quality of care for children with urological conditions. This Guideline document is limited to a number of common clinical pathologies in paediatric urological practice, as covering the entire field of paediatric urology in a single guideline document is unattainable.

The majority of urological clinical problems in children are specialised and in many ways differ to those in adults. This publication intends to outline a practical and preliminary approach to paediatric urological conditions. Complex and rare conditions that require special care with experienced doctors should be referred to designated centres where paediatric urology practice has been fully established and a multidisciplinary team is available.

Over time, paediatric urology has developed and matured, establishing its diverse body of knowledge and expertise and may now be ready to distinguish itself from its parent specialties. Thus, paediatric urology has recently emerged in many European countries as a distinct subspecialty of both urology and paediatric surgery and presents a unique challenge in the sense that it covers a large area with many different schools of thought and a huge diversity in management.

Knowledge gained by increasing experience, new technological advances and non-invasive diagnostic screening modalities has had a profound influence on treatment modalities in paediatric urology, a trend that is likely to continue in the years to come.

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of children and their caregivers into account. Guidelines are not mandates and do not purport to be a legal standard of care.

## 1.2 Panel composition

The EAU Paediatric Urology Guidelines Panel consists of an international group of clinicians with particular expertise in this area. All experts involved in the production of this document have submitted potential conflict of interest statements, which can be viewed on the EAU Website: <http://uroweb.org/guideline/paediatric-urology/>.

## 1.3 Available publications

A quick reference document (Pocket guidelines) is available this is an abridged versions which may require consultation together with the full text version. A number of translated versions, alongside several scientific publications are also available [1-7]. All documents can be viewed through the EAU website: <http://uroweb.org/guideline/paediatric-urology/>.

## 1.4 Publication history

The Paediatric Urology Guidelines were first published in 2001 [8]. This 2024 publication includes a number of updated chapters and sections as detailed below.

## 1.5 Summary of changes

The literature for the complete document has been assessed and updated, wherever relevant. Key changes in the 2024 publication:

- Section 3.4 Fertility preservation in children and adolescents (new section)
- Section 3.5 Hydrocele
- Section 3.19 Congenital lower urinary tract obstruction
- Section 3.21 Emergencies in Paediatric Urology (new section)
- Section 3.22 Paediatric urological trauma
- Section 3.23 Peri-operative fluid management
- Section 3.24 Basic principles of laparoscopic surgery in children

## 2. METHODS

### 2.1 Introduction

These Guidelines were compiled based on current literature following a structured review. Databases covered by the searches included Pubmed, Ovid, EMBASE and the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. Application of a structured analysis of the literature was not possible in many conditions due to a lack of well-designed studies. The limited availability of large randomised controlled trials (RCTs) - influenced also by the fact that a considerable number of treatment options relate to surgical interventions on a large spectrum of different congenital problems - means this document is largely a consensus document. Clearly there is a need for continuous re-evaluation of the information presented in this document.

Recommendation within the Guidelines are developed by the panels to prioritise clinically important care decisions. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and the nature and variability of patient values and preferences. This decision process, which can be reviewed in the strength rating forms which accompany each guideline statement, addresses a number of key elements:

1. the overall quality of the evidence which exists for the recommendation [9];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact and certainty of patient values and preferences on the intervention

Strong recommendations typically indicate a high degree of evidence quality and / or a favourable balance of benefit to harm and patient preference. Weak recommendations typically indicate availability of lower quality evidence, and/or equivocal balance between benefit and harm, and uncertainty or variability of patient preference [10].

Additional information can be found in the general Methodology section online at the EAU website; <http://www.uroweb.org/guideline/>.

A list of Associations endorsing the EAU Guidelines can also be viewed online at the above address.

### 2.2 Peer review

All chapters of the Paediatric Urology Guidelines were peer-reviewed in 2015.

## 3. THE GUIDELINE

### 3.1 Phimosis and other abnormalities of the penile skin

The prepuce or foreskin of the penis is often a cause of concern to parents of young boys and physicians alike [11] with 10% seeking medical advice [12]. While there are some pathological abnormalities of the foreskin, these are in fact quite rare and must be discerned from physiological variations or developmental stages. In this chapter we highlight normal development, its variations and how to discern this from abnormal foreskin requiring treatment, as well as various treatment options.

#### 3.1.1 *Terminology, epidemiology and pathophysiology*

At birth the foreskin can be retracted in 4% of boys. In 42% of neonates the tip of the glans cannot be visualised. By the end of the first year of life, retraction of the foreskin behind the glandular corona is possible in approximately 50% of boys; this increases to 89% by the age of three years. Non-retractability of the foreskin can be a physiological phase which does not require treatment in the absence of symptoms, such as painful erections or balanitis.

### Phimosis

In phimosis the inability to retract the foreskin over the glans penis is due to a narrow ring in the prepuce. Several factors have been suggested to aid in the gradual dilation of this ring: histological changes in the prepuce, hormonal factors and stretching due to erections. While erections occur even antenatally, these may be insufficient to stretch the foreskin if it is relatively long, and therefore relative phimosis can be present for a prolonged period [13].

Epidemiological studies of the natural course of phimosis are difficult, as they are affected by treatment of a subgroup of subjects. Nonetheless, the incidence of phimosis is 9-20% in five to thirteen year-olds and just 1% in males aged sixteen to eighteen years [13, 14].

### Preputial adhesions

Another cause of non-retractability of the prepuce are adhesions of the foreskin to the glans, and this must be distinguished from phimosis. Usually when adhesions are present, partial retraction is possible and the meatus can be visualised [14]. Adhesions are a physiological phenomenon of variable duration, present in 63% of 6-7 year-olds and 3% of 16-17 year-olds without phimosis [14]. Progressive separation of the inner prepuce from the glans is associated with build-up of epithelial debris (smegma) and aided by penile erections. During this process smegma can accumulate into nodules that may be mistaken for cysts. When released from between the skin layers smegma can resemble purulent discharge, especially when mixed with urine. There may temporarily be focal erythema. In the absence of other signs of infection, this should not be confused with balanitis.

Once adhesions between the glans and inner prepuce are resolved there may be ballooning of the foreskin during voiding, particularly if the opening of the prepuce is still relatively narrow. Ballooning is not a sign of obstructed voiding and uroflows have been shown to be normal with ballooning [15]. Therefore, ballooning may be a physiological phase, and it should only be considered a problem in case of (recurring) balanitis.

### Paraphimosis

In paraphimosis the foreskin has been retracted and cannot be brought back down to cover the glans of the penis. In children it is most likely due to manipulation, with an incidence reported to be as low as 0,2% [12]. The risk of paraphimosis is higher if there is relative phimosis. The narrow ring in the retracted prepuce may constrict the shaft at the level of the sulcus, leading to edema of the glans and retracted foreskin. Impaired perfusion may lead to necrosis of the prepuce and ultimately of the glans. Paraphimosis must be regarded as a medical emergency requiring urgent treatment [16].

### Balanitis/balanoposthitis

Balanoposthitis may be defined as erythema and swelling of the glans (balanitis) and/or foreskin (posthitis), with discharge of pus. It should not be confused with focal irritation due to retention of droplets of urine under the foreskin. Balanoposthitis may be seen in 6% of uncircumcised boys [12, 17].

### Balanitis xerotica obliterans

Balanitis xerotica obliterans (BXO) is a non-painful chronic inflammatory disease which may affect the glans, foreskin, meatus and urethra. As such it is a genital form of lichen sclerosus et atrophicus [13]. Balanitis xerotica obliterans may lead to scarring, phimosis and urethral outflow problems. Histological analysis of the prepuces of children and adolescents undergoing circumcision for medical reasons shows signs of BXO in 35%-53% [18]; in boys younger than ten years this is 17% [19, 20].

### Inconspicuous penis

There are several types of concealed or inconspicuous penis, which should be differentiated from truly small penis such as micropenis with abnormal size of the corporeal bodies or even aphallia.

- Buried penis and megaprepuce are congenital anomalies in which the skin is folded abnormally around the shaft. The opening of the prepuce can be narrow, prohibiting retraction similar to regular phimosis, but may also be normal. Occasionally buried penis may be due to abnormal prepubic fat distribution, which may be self-limiting with growth or weight loss.
- In webbed penis the penoscrotal angle is abnormal due to the scrotum being attached high on the ventral side of the shaft.
- Trapped penis is an iatrogenic form of buried penis which may be caused by resection of too much skin during circumcision [21].

### 3.1.2 **Classification and diagnostic evaluation**

In order to determine which cases require treatment, phimosis should be divided into a physiological and pathological type. Physiological phimosis is most likely to resolve over time without intervention, whereas pathological phimosis may not.

In physiological phimosis there is no sign of scarring, and upon retraction the inner prepuce is seen bulging outward from the narrow ring in the prepuce ("pouting"). In pathological or secondary phimosis there is scarring, the narrow ring in the prepuce is fibrous, often white and thickened, and the inner layer of the prepuce is not seen coming out [22]. Balanitis xerotica obliterans is a special form of pathological phimosis.

The diagnosis of adhesions, phimosis and paraphimosis is made by physical examination alone, and this can differentiate between physiological variations or pathological abnormalities. If the prepuce is not retractable, or only partly retractable, and shows a constrictive ring upon retraction back over the glans penis, a disproportion between the width of the foreskin and the diameter of the glans penis has to be assumed. In addition to the constricted foreskin, the inner prepuce may be adherent to the glans and/or frenulum breve.

Balanitis xerotica obliterans remains a histopathological diagnosis as clinically discerning BXO from simple pathological phimosis may be difficult, particularly to the untrained eye. Histopathological examination of resected foreskin is warranted due to the consequences of this diagnosis with regards to follow-up [23, 24].

In buried penis, the shaft itself appears shorter upon inspection but is of normal size upon palpation, hence the name. In megaprepuce the shaft may have a normal appearance or it may resemble buried penis. The diagnosis is made based on the aspect of the penis during voiding. When the enlarged space between shaft and inner prepuce fills up with urine during voiding, this causes the entire penis to swell. Megaprepuce can be discerned from regular phimosis, in which only the tip of the penis may demonstrate ballooning. It may be helpful if caregivers show a photo or even video of the aspect of the penis during voiding.

### 3.1.3 **Management**

#### Hygiene

The foreskin should not be retracted for cleaning until this can be done easily. It should be stressed to parents/caregivers that forced retraction of a narrow foreskin may cause scar formation resulting in secondary pathological phimosis [25]. Care should be taken to reduce the foreskin back down over the glans to prevent paraphimosis. Once the foreskin is retractable this may be regularly done during bathing and becomes necessary for hygienic reasons from puberty. The production of smegma appears to increase at puberty, coinciding with the age at which most boys can retract their foreskin [22].

#### Conservative / medical management

Physiological phimosis and adhesions do not need treatment, unless there are accompanying urogenital abnormalities. Conservative medical treatment is a valid option for primary pathological phimosis. Class 4 corticosteroid therapies were more effective over placebo and manual stretching [26]. Topical corticoid (0.05-0.1%) can be administered twice a day over a period of 4-8 weeks with a success rate of > 80% [26-29]. A publication showed that lower class corticosteroids may be almost equally effective [30]. A recurrence rate of up to 17% can be expected [31]. Effectivity of topical corticosteroids is likely to be influenced by correct application, which must be directly onto the narrow ring under gentle retraction. Similarly, after finishing the corticosteroid treatment recurrence should be prevented by continuing daily retraction of the prepuce [32]. While all types of phimosis may respond to corticosteroid treatment, the success rate may be lower in pathological phimosis. If BXO is suspected, consultation with a dermatologist should be considered [33].

Corticosteroid treatment has no systemic side effects and mean blood cortisol levels are not significantly different from an untreated group of patients [34]. The hypothalamic pituitary-adrenal axis was not influenced by local corticoid treatment [35]. However, if treatment is continued for too long or too much product is used this may cause focal atrophy and vulnerability of the skin. In general, cream may be associated with dryness and irritation, due to the nature of the product compared to ointment. Adhesion of the foreskin to the glans does not respond to corticosteroid treatment [27].

#### Operative management

Circumcision for non-medical reasons, such as routine circumcision for cultural, religious or hygienic considerations, is not discussed in this chapter.

Medical indications for surgical intervention for phimosis are recurrent balanoposthitis or symptomatic therapy-resistant phimosis. Simple ballooning of the foreskin during micturition is not an indication for surgery per se. Several indications for circumcision in the absence of symptomatic phimosis have been proposed. In boys with increased risk of urinary tract infections (UTIs) due to congenital upper tract

abnormalities, circumcision may be performed to reduce the risk of UTIs [36-39]. Male circumcision significantly reduces the bacterial colonisation of the glans penis with regard to both non-uropathogenic and uropathogenic bacteria [40]. However, resolution of phimosis by corticosteroid treatment may have similar results as it was also associated with substantial reduction in recurrent UTI in uncircumcised infants [41]. (See Chapter 3.10 on urinary tract infections in children and Chapter 3.15 on vesicoureteric reflux).

Routine neonatal circumcision to prevent penile carcinoma is not indicated. A meta-analysis could not find any risk in uncircumcised patients without a history of phimosis [42].

The type of operative treatment of phimosis in children is dependent on the caregivers' preferences and can be preputioplasty or circumcision. In preputioplasty the objective is to preserve the prepuce while achieving a wider foreskin circumference with full retractability. Several surgical techniques have been described to achieve this goal: dorsal incision, partial circumcision, trident preputial plasty, combining two Z-plasties and Y-plasty [43, 44]. The main disadvantage of preputioplasty is the inherent potential for recurrence of phimosis [45].

In circumcision, the prepuce is resected completely. Contra-indications for circumcision are: an acute local infection and congenital anomalies of the penis, particularly hypospadias, buried penis and megaprepuce, epispadias and congenital penile curvature, as the foreskin may be required for a reconstructive procedure [46, 47].

When surgically correcting phimosis, additional issues should be addressed during the same session: adhesions are released, an associated frenulum breve is corrected by frenulotomy and the meatus is calibrated with meatoplasty added if necessary.

#### Paraphimosis treatment

Treatment of paraphimosis consists of manual compression of the oedematous tissue with a subsequent attempt to retract the tightened foreskin over the glans penis [48, 49]. If this maneuver fails, a dorsal incision of the constrictive ring is required. Following acute redressing of the foreskin, additional treatment is recommended to correct any anomalies which increase the chance of recurrence. Patients should be counselled regarding prevention of paraphimosis by correctly redressing their foreskin after retraction.

#### 3.1.4 Complications

Complications following circumcision vary and have been reported between 0-30% [50]. Hung *et al.* found 2.9% complications in non-neonates during a 5-year follow-up period; 2.2% were early (within 30 days after circumcision). Non-healing wounds, haemorrhage, wound infection, meatal stenosis, redundant skin, non-satisfying cosmetic appearance and trapped penis all may occur [51]. The incidence of post-circumcision meatal stenosis is higher in boys with confirmed BXO compared to those who underwent circumcision for phimosis without BXO (20% vs 6%) [23]. Overall, the risk of complications appears low when done by professionals in a medical setting.

#### 3.1.5 Follow-up

Any preputial surgery requires early follow-up of four to six weeks after surgery. In case of BXO, prolonged follow up is warranted and may involve a dermatologist. Balanitis xerotica obliterans is associated with meatal pathology (stenosis) after circumcision in up to 20% of boys [20, 52, 53].

#### 3.1.6 Summary of evidence and recommendations for the management of phimosis

Summary of evidence	LE
Non-retractability of the foreskin, preputial adhesions and ballooning may be a physiological phase before puberty and do not require treatment in the absence of symptoms.	3
Forced retraction of a narrow foreskin should be avoided to prevent scar formation which may result in secondary pathological phimosis.	3
Conservative treatment of phimosis with topical corticosteroids (ointment or cream) has a high success rate, but surgical treatment may be considered if preferred by caregivers or patients.	1b
Balanitis xerotica obliterans warrants prolonged follow up due to risk of meatal stenosis or urethral involvement.	2

Recommendations	Strength rating
Offer topical corticosteroids (ointment or cream) as first-line treatment in symptomatic phimosis.	Strong
Consider surgical intervention if patient/caregivers prefer for symptomatic phimosis.	Strong
Offer circumcision in case of Balanitis xerotica obliterans (BXO) or phimosis refractory to treatment.	Strong
Offer treatment for asymptomatic phimosis in infants with a risk of recurrent urinary tract infection due to upper urinary tract abnormalities (vesicoureteral reflux or posterior urethral valves).	Strong
Inform patients about the risk of meatal stenosis in BXO.	Strong
Await spontaneous resolution of asymptomatic preputial adhesions before puberty.	Weak
Treat paraphimosis by manual reposition and proceed to surgery if this fails.	Strong
Do not perform simple circumcision if phimosis is associated with other penile anomalies such as buried penis, congenital penile curvature, epispadias or hypospadias.	Strong

### 3.2 Management of undescended testes

#### 3.2.1 Background


Cryptorchidism or undescended testis is one of the most common congenital malformations of male neonates. Incidence varies and depends on gestational age, affecting 1.0-4.6% of full-term and 1.1-45% of preterm neonates. Following spontaneous descent within the first months of life, nearly 1.0% of all full-term male infants still have undescended testes at one year of age [54]. This congenital malformation may affect both sides in up to 30% of cases [55]. In newborn cases with non-palpable or undescended testes on both sides and any sign of disorders of sex development (DSDs) like concomitant hypospadias, urgent endocrinological and genetic evaluation is required [56].

#### 3.2.2 Classification

The term cryptorchidism is most often used synonymously for undescended testes. The most useful classification of undescended testes is distinguishing into palpable and non-palpable testes, and clinical management is decided by the location and presence of the testes (see Figure 1). Approximately 80% of all undescended testes are palpable [57]. Acquired undescended testes can be caused by entrapment after herniorrhaphy or spontaneously referred to as ascending testis.

Palpable testes include true undescended testes and ectopic testes. Non-palpable testes include intra-abdominal, inguinal, absent, and sometimes also some ectopic testes. Most importantly, the diagnosis of palpable or non-palpable testis needs to be confirmed once the child is under general anaesthesia, as this is the first step of any surgical procedure for undescended testes.

Figure 1: Classification of undescended testes



### 3.2.2.1 *Palpable testes*

#### *Undescended testes*

A true undescended testis is on its normal path of descent but is halted on its way down to the scrotum. Depending on the location, the testes may be palpable or not, as in the case of testes arrested in the inguinal canal.

#### *Ectopic testes*

If the position of a testis is outside its normal path of descent and outside the scrotum, the testis is considered to be ectopic. The most common aberrant position is in the superficial inguinal pouch. Sometimes an ectopic testis can be identified in a femoral, perineal, pubic, penile or even contralateral position. Usually, there is no possibility for an ectopic testis to descend spontaneously to the correct position; therefore, it requires surgical intervention. In addition, an ectopic testis might not be palpable due to its position.

#### *Retractile testes*

Retractile testes have completed their descent into a proper scrotal position but can be found again in a suprascrotal position along the path of their normal descent. This is due to an overactive cremasteric reflex [58]. Retractile testes can be easily manipulated down to the scrotum and remain there at least temporarily.

They are typically normal in size and consistency. However, they may not be normal and should be monitored carefully since up to one-third can ascend and become undescended [59].

### 3.2.2.2 *Non-palpable testes*

Among the 20% of non-palpable testes, 50-60% are intra-abdominal, canalicular or peeping (right inside the internal inguinal ring). The remaining 20% are absent and 30% are atrophic or rudimentary.

#### *Intra-abdominal testes*

Intra-abdominal testes can be located in different positions, with most of them being found close to the internal inguinal ring. However, possible locations include the kidney, anterior abdominal wall, and retrovesical space. In the case of an open internal inguinal ring, the testis may be peeping into the inguinal canal.

#### *Absent testes*

Monorchidism can be identified in up to 4% of boys with undescended testes, and anorchidism (bilateral absence) in < 1%. Possible pathogenic mechanisms include testicular agenesis and atrophy after intrauterine torsion with the latter one most probably due to an *in utero* infarction of a normal testis by gonadal vessel torsion. The term "vanishing testis" is commonly used for this condition [60].

### 3.2.3 **Diagnostic evaluation**

History taking and physical examination are key in evaluating boys with undescended testes. Localisation studies using different imaging modalities are usually without any additional benefit.

#### 3.2.3.1 *History*

Caregivers should be asked for maternal and paternal risk factors, including hormonal exposure and genetic or hormonal disorders. If the child has a history of previously descended testes this might be suggestive of testicular ascent [61]. Prior inguinal surgery is indicative of secondary undescended testes due to entrapment.

#### 3.2.3.2 *Physical examination*

An undescended testis is pursued by carefully advancing the examining fingers along the inguinal canal towards the pubis region, perhaps with the help of lubricant. A possible inguinal testis can be felt to bounce under the fingers [62]. A non-palpable testis in the supine position may become palpable once the child is in a sitting or squatting position. If no testis can be identified along the normal path of descent, possible ectopic locations must be considered.

In the event of unilateral non-palpable testis, the contralateral testis needs to be examined. Its size and location can have important prognostic implications. Any compensatory hypertrophy suggests testicular absence or atrophy [63]. Nevertheless, this does not preclude surgical exploration since the sign of compensatory hypertrophy is not specific enough [64, 65].

In the event of bilateral undescended testes and any evidence or sign of DSDs, such as genital ambiguity, or scrotal hyperpigmentation, further evaluation including endocrinological and genetic assessment becomes mandatory [66].

### 3.2.3.3 *Imaging studies*

Imaging studies cannot determine with certainty that a testis is present or not [67]. Ultrasound (US) lacks the diagnostic sensitivity to detect the testis confidently or establish the absence of an intra-abdominal testis [68]. Consequently, the use of different imaging modalities, such as US or Magnetic resonance imaging (MRI) [69], for undescended testes is limited and only recommended in specific and selected clinical scenarios (e.g. identification of Müllerian structures in cases with suspicion of DSDs) [68].

### 3.2.4 **Management**

Treatment should be started at the age of six months. After that age, undescended testes rarely descend [70]. Any kind of treatment leading to a scrotally positioned testis should be finished by twelve months, or eighteen months at the latest, because histological examination of undescended testes at that age has already revealed a progressive loss of germ cells and Leydig cells [71]. The early timing of treatment is also driven by the final adult results on spermatogenesis and hormone production, as well as on the risk of tumour development [72].

#### 3.2.4.1 *Medical therapy*

Unfortunately, most of the studies on hormonal treatment have been of poor quality, with heterogeneous and mixed patient populations, testis location, schedules and dosages of hormonal administration. Additionally, long-term data are almost completely lacking.

Short-term side effects of hormonal treatment include increased scrotal erythema and pigmentation, and induction of pubic hair and penile growth. Some boys experience pain after intramuscular injection of human chorionic gonadotropin (hCG). All of these tend to regress after treatment cessation [73, 74].

##### 3.2.4.1.1 *Medical therapy for testicular descent*

Hormonal therapy using hCG or gonadotropin-releasing hormone (GnRH) is based on the hormonal dependence of testicular descent, but has a limited success rate of only 20% [75]. However, it must be taken into account that almost 20% of these descended testes have the risk of re-ascending later [76]. In general, success rates depend on testicular location. The higher the testis is located prior to therapy, the lower the success rate, suggesting that testicular position is an important determinant of success [73]. Some authors recommend combined hCG-GnRH treatment. Unfortunately, it is poorly documented and the treatment groups were diverse. Some studies reported successful descent in up to 38% of non-responders to monotherapy [77]. The Panel consensus is that endocrine treatment to achieve testicular descent is not recommended (LE: 4).

##### *Human chorionic gonadotropin*

Human chorionic gonadotropin (hCG) stimulates endogenous testosterone production and is administered by intramuscular injection. Several dose and administration schedules are reported. There is no proven difference between 1.5 IU and weight-based doses up to 3.0 IU every other day for fourteen days [78]. Similar response rates were achieved with 500 IU once weekly and 1.50 IU three times weekly [79]. However, there is evidence that dosing frequency might affect testicular descent rates. Fewer lower dose injections per week for five weeks seem to be superior to one higher dose every seven to ten days for three weeks with regard to testicular descent [80].

##### *Gonadotropin-releasing hormone*

Gonadotropin-releasing hormone (GnRH) analogues (e.g., buserelin and gonadorelin) are available as nasal sprays, thus avoiding painful intramuscular injections. A typical dosage regimen consists of 1.2 mg per day in three divided doses, for four weeks. Success rates are wide ranging, from 9 to 60%, due to multiple treatment strategies and heterogeneous patient populations [81].

##### 3.2.4.1.2 *Medical therapy for fertility potential*

Hormonal treatment may improve fertility indices [81, 82] and therefore serve as an additional tool to orchidopexy. There is no difference in treatment with GnRH before (neo-adjuvant) or after (adjuvant) surgical orchidolysis and orchidopexy in terms of increasing fertility index, which may be a predictor for fertility later in life [83]. It is still unknown whether this effect on testicular histology persists into adulthood but it has been shown that men who were treated in childhood with buserelin had better semen analyses compared with men who had childhood orchidopexy alone or placebo treatment [81].

It is reported that hCG treatment may be harmful to future spermatogenesis through increased apoptosis of germ cells, including acute inflammatory changes in the testes and reduced testicular volume in adulthood [84].

Identification of specific subgroups of boys with undescended testes who would benefit from such an approach using hormones is difficult. Since these important data on specific groups as well as additional support on the long-term effects are still lacking, the Nordic consensus does not recommend hormonal therapy [85]. The consensus of the Panel is to recommend endocrine treatment with GnRH analogues in a dosage described above for boys with bilateral undescended testes to preserve the fertility potential (LE: 4).



### 3.2.4.2 Surgical therapy

If a testis has not concluded its descent at the age of six months (corrected for gestational age), and since spontaneous testicular descent is unlikely to occur after that age, surgery should be performed within the subsequent year, and by age eighteen months at the latest [72]. In addition, early orchidopexy can be followed by partial catch-up testicular growth, which is not the case in delayed surgery [83]. All these findings recommend performing early orchidopexy between the ages of six and twelve months [70]. But despite early and successful orchidopexy within the first year of life up to 25% of boys with non-syndromic undescended testes may be at risk for infertility based on hormonal and histological data, as a published series on 333 boys showed. This is especially true for bilateral cases, but in addition in about 5% of unilateral cases reduced numbers of germ cells were detected in testicular biopsies as well [86].

#### 3.2.4.2.1 Palpable testes

Surgery for palpable testes includes orchidofunicolysis and orchidopexy, either via an inguinal or scrotal approach. The latter approach is mainly reserved for low-positioned, undescended testes, with the pros and cons of each method being weighed against each other [87].

##### 3.2.4.2.1.1 Inguinal orchidopexy

Inguinal orchidopexy is a widely used technique with a high success rate of up to 92% [88]. Important steps include mobilisation of the testis and spermatic cord to the level of the internal inguinal ring, with dissection and division of all cremasteric fibres, to prevent secondary retraction and detachment of the gubernaculum testis. The patent processus vaginalis needs to be ligated proximally at the level of the internal ring, because an unidentified or inadequately repaired patent processus vaginalis is an important factor leading to failure of orchidopexy [89]. Any additional pathology has to be taken care of, such as removal of an appendix testis (hydatid of Morgagni). At this moment the size of the testis can be measured and the connection of the epididymis to the testis can be judged and described in the protocol. Some boys have a significant dissociation between testis and epididymis which is prognostically bad for fertility. Finally, the mobilised testicle needs to be placed in a sub-dartos pouch within the hemi-scrotum without any tension. If the length achieved using the above-mentioned technique is still inadequate, the Prentiss manoeuvre, which consists of dividing the inferior epigastric vessels and transposing the spermatic cord medially, in order to provide a straight course to the scrotum, might be an option [90]. With regard to fixation sutures, if required, they should be made between the tunica vaginalis and the dartos musculature [91]. Lymph drainage of a testis that has undergone surgery for orchidopexy may have changed from high retroperitoneal drainage to iliac and inguinal drainage, which might become important in the event of later malignancy [92].

##### 3.2.4.2.1.2 Scrotal orchidopexy

Low-positioned, palpable undescended testis can be fixed through a scrotal incision including division of the gubernaculum, and the processus vaginalis needs to be probed to check for patency [93]. Otherwise, fixation in the scrotum is carried out correspondingly to the inguinal approach. In up to 20% of cases, an inguinal incision will be compulsory to correct an associated inguinal hernia [94]. Any testicular or epididymal appendages can be easily identified and removed. A systematic review shows that the overall success rates ranged from 88 to 100%, with rates of recurrence and post-operative testicular atrophy or hypotrophy < 1% [87]. Another systematic review and meta-analysis revealed similar outcome data regarding post-operative complications, including wound infection, testicular atrophy, testicular reascent, and hernia for palpable low positioned undescended testes. The only significant difference was the shorter operative time [95].

#### 3.2.4.2.2 Non-palpable testes

For non-palpable testes, surgery must clearly determine whether a testis is present or not [96]. If a testis is found, the decision has to be made to remove it or bring it down to the scrotum. An important step in surgery is a thorough re-examination once the boy is under general anaesthesia, since a previously non-palpable testis might be identifiable and subsequently change the surgical approach to standard inguinal orchidopexy, as described above. Otherwise, the easiest and most accurate way to locate an intra-abdominal testis is diagnostic laparoscopy [97]. Subsequent removal or orchidolysis and orchidopexy can be carried out using the same approach to achieve the therapeutic aims [98]. Some tend to start with inguinal surgical exploration, with possible laparoscopy during the procedure [99]. If an ipsilateral scrotal nubbin is suspected, and contralateral compensatory testicular hypertrophy is present, a scrotal incision with removal of the nubbin, thus confirming the vanishing testis, is an option avoiding the need for laparoscopy [100].

During laparoscopy for non-palpable testes, possible anatomical findings include spermatic vessels entering the inguinal canal (40%), an intra-abdominal (40%) or peeping (10%) testis, or blind-ending spermatic vessels confirming vanishing testis (10%) [101].

If there is a vanishing testis, the procedure is finished once blind-ending spermatic vessels are clearly identified. If the vessels enter the inguinal canal, an atrophic testis may be found upon inguinal exploration or a healthy testis that needs to undergo standard orchidopexy [102]. A peeping testis can be placed down in the scrotum laparoscopically or via an inguinal incision [103]. Placement of an intra-abdominal testis can sometimes be a surgical challenge. Usually, testes lying > 2 cm above the internal inguinal ring may not reach the scrotum without division of the testicular vessels [104]. Under such circumstances, a Fowler-Stephens orchidopexy may be an option [105] (see Figure 2).

Proximal cutting and transection of the testicular vessels, with conservation of the collateral arterial blood supply, via the deferential artery and cremasteric vessels comprise the key features of the Fowler-Stephens procedure. A modification with low spermatic vessel ligation has gained popularity, allowing blood supply from the testicular artery to the deferential artery. An additional advantage is the position of the peritoneal incision, leading to a longer structure, to ease later scrotal placement [106]. Due to the nature of these approaches the testis is at risk of hypotrophy or atrophy if the collateral blood supply is insufficient [107]. The testicular survival rate in the one-stage Fowler-Stephens technique varies between 50 and 65% based on post-operative Doppler-ultrasound findings [108]. For two-stage procedures success rates increase up to 90% [109]. The advantages of two-stage orchidopexy, with the second part done usually six months after the first, are to allow for development of collateral blood supply and to create greater testicular mobility [110]. In addition, preservation of the gubernaculum may also decrease the chance of testicular atrophy [111]. An alternative might be microsurgical auto-transplantation, which has a success rate of up to 90%. However, this approach requires skilled and experienced surgeons and is performed in a limited number of centres [112].

### 3.2.4.2.3 Complications of surgical therapy


Surgical complications are usually uncommon, with testicular atrophy being the most serious. A systematic review revealed an overall atrophy rate for primary orchidopexy of 1.83%, 28.1% for one-stage Fowler-Stephens procedure, and 8.2% for the two-stage approach [113]. Other rare complications comprise testicular ascent and vas deferens injury besides local wound infection, dehiscence, and haematoma.

### 3.2.4.2.4 Surgical therapy for undescended testes after puberty

A study on 51 men diagnosed with inguinal unilateral undescended testis and a normal contralateral one, with no history of any previous therapy, demonstrated a wide range of changes upon histological evaluation. Nearly half of the study population still had significant germ cell activity at different maturation levels. Importantly, the incidence of intratubular germ cell neoplasia was 2% [114].

The Panel consensus recommends orchiectomy in post-pubertal boys with an undescended testis and a normal contralateral one in a scrotal position.

**Figure 2: Treatment of unilateral non-palpable undescended testes**



### 3.2.5 **Undescended testes and fertility**

The association of undescended testes with compromised fertility [115] is extensively discussed in the literature and seems to be a result of multiple factors, including germ cell loss, impaired germ cell maturation [116], Leydig cell diminution and testicular fibrosis [117].

Although boys with one undescended testis have a lower fertility rate, they have the same paternity rate as those with bilateral descended testes. Boys with bilateral undescended testes suffer both lower fertility and paternity rates. Fertility rate is the number of offspring born per mating pair, individual or population

whereas paternity reflects the actual potential of fatherhood [118]. The age at which surgical intervention for an undescended testis occurs seems to be an important predictive factor for fertility later in life. Endocrinological studies revealed higher inhibin-B and lower follicle-stimulating hormone (FSH) levels in men who underwent orchidopexy at two years of age compared to individuals who had surgery later, which is indicative of a benefit of earlier orchidopexy [119]. In addition, others demonstrated a relation between undescended testes and increased loss of germ cells and Leydig cells, which is also suggestive of prompt orchidopexy being a significant factor for fertility preservation [120]. Outcome studies for untreated bilateral undescended testes revealed that 100% are oligospermic and 75% azoospermic. Among those successfully treated for bilateral undescended testes, 75% still remain oligospermic and 42% azoospermic [117].

In summary, early surgical correction of undescended testes is highly recommended before twelve months of age, and by eighteen months at the latest for preservation of fertility potential [71].

### 3.2.6 **Undescended testes and malignancy**

Boys who are treated for an undescended testis have an increased risk of developing testicular malignancy. Screening and self-examination both during and after puberty is therefore recommended [121]. A Swedish study, with a cohort of almost 17,000 men (56 developed a testicular tumour) who were treated surgically for undescended testes and followed for 210,000 person-years, showed that management of undescended testes before the onset of puberty decreased the risk of testicular cancer. The relative risk of testicular cancer among those who underwent orchidopexy before thirteen years of age was 2.2 compared to the Swedish general population; this increased to 5.4 for those treated after thirteen years of age [122].

A systematic review and meta-analysis of the literature have also concluded that pre-pubertal orchidopexy may reduce the risk of testicular cancer and that early surgical intervention is indicated in boys with undescended testes [123].

### 3.2.7 **Summary of evidence and recommendations for the management of undescended testes**

Summary of evidence	LE
An undescended testis justifies treatment early in life to avoid loss of spermatogenic potential.	2a
A failed or delayed orchidopexy may increase the risk of testicular malignancy later in life.	2a
The earlier the treatment, the lower the risk of impaired fertility and testicular cancer.	2a
In unilateral undescended testis, fertility rate is reduced whereas paternity rate is not.	1b
In bilateral undescended testes, fertility and paternity rates are impaired.	1b
The treatment of choice for undescended testis is surgical replacement in the scrotum.	1b
The palpable testis is usually treated surgically using an inguinal approach.	2b
The non-palpable testis is most commonly approached laparoscopically.	2b
There is no consensus on the use of hormonal treatment.	2b

Recommendations	Strength rating
Do not offer medical or surgical treatment for retractile testes instead undertake close follow-up on a yearly basis until puberty.	Strong
Perform surgical orchidolysis and orchidopexy before the age of twelve months, and by eighteen months at the latest.	Strong
Evaluate male neonates with bilateral non-palpable testes for possible disorders of sex development.	Strong
Perform a diagnostic laparoscopy to locate an intra-abdominal testicle.	Strong
Hormonal therapy in unilateral undescended testes is of no benefit for future paternity.	Strong

Offer endocrine treatment in case of bilateral undescended testes.	Weak
Inform the patient/caregivers about the increased risk of a later malignancy with an undescended testis in a post-pubertal boy or older and discuss removal in case of a contralateral normal testis in a scrotal position.	Weak

### 3.3 Testicular Tumours in prepubertal boys

#### 3.3.1 Introduction

Testicular tumours account for approximately 1-2% of all paediatric solid tumours [124]. Testicular tumours in prepubertal boys differ in several aspects to testicular tumours in adolescent and adult men: they have a lower incidence, they have a different histologic distribution (teratomas and yolk sac tumours are more common and germ cell tumours are less common) and they are more often benign. An epidemiological study showed that in children under the age of 15 years the incidence is highest in Asia (4.2 per million) and South America (5 per million) and lowest in Europe (2.1 per million) and North America (2.5 per million). This is in contrast to the incidence in adolescent and young adults where the highest incidence is in Europe (137.4 per million), and North America (94.9 per million), while a lower incidence was observed in South and Central America (66.5 per million) and Asia (27.1 per million) [125]. For age distribution in prepubertal boys, there is a small peak around the age of two years [126]. Some studies demonstrated that up to 60-75% of the tumours are benign [124, 127-131]. Intratubular neoplasia (TIN) is practically non-existent in children [132-135]. Testicular tumours can generally be classified as germ cell or stromal tumours. One specific tumour type is the gonadoblastoma, which contains germ cell and stromal cell tumour types and will occur almost exclusively in the setting of disorders of sexual differentiation [136].

In the past 30 years, it has clearly been shown, that there is a fundamental difference between testicular tumours in childhood and those in adulthood - not only in terms of the difference and incidence [125] but also in terms of histology [132]. In prepubertal boys, most intratesticular tumours are benign, whereas post puberty the tumours are most likely malignant.

#### 3.3.2 Clinical presentation

Clinical presentation is a painless scrotal mass in more than 90% of the patients, detected by the caregiver, physician or the patient himself. A history of a trauma, pain or hernia is rare. A hydrocele can be found in 15 – 50% [128, 137]. In boys with early onset of puberty (e.g. early penile and prepubic hair growth) as well as high testosterone and low gonadotropin levels, a Leydig cell tumour should be excluded [138].

In patients presenting with a scrotal mass, paratesticular tumours should also be taken into account as a differential diagnosis. However, these are even less common compared to intratesticular tumours. The spectrum of paratesticular tumours includes benign tumours such as leiomyoma, fibroma, lipoma, haemangioma, cystic lymphangioma and lipoblastoma as well as malignant tumours such as the paratesticular rhabdomyosarcoma with an excellent prognosis and the rare melanotic neuroectodermal tumour of infancy with a high recurrence rate [139-142]. As most of them are benign, intra-operative frozen section should be available during surgery. An organ sparing surgical approach is preferred in benign tumours, whereas in malignant tumour standard orchiectomy is carried out.

#### 3.3.3 Evaluation

To confirm the diagnosis, a high-resolution US examination (7.5 – 12.5 MHz), preferably a doppler ultrasound, is required. The detection rate is almost 100% [143-146]. With high-resolution US, microlithiasis - small hyperdense areas without sound shadows - is increasingly seen in prepubertal boys. A meta-analysis showed that only 4 out of 296 boys (< 19 years of age diagnosed with microlithiasis) developed a testicular tumour of whom two previously had a testicular tumour on the opposite or ipsilateral site [147]. If microlithiasis shows up in patients with additional risk factors for testicular tumour, then the caregivers/patients should be informed about the increased risk and encouraged to carry out regular self-examinations - similar to patients treated for undescended testis [148]. There is no evidence, that regular sonographic follow-up is useful [147]. The risk for infertility may be higher in patients with microlithiasis and if these patients have any sign of infertility later, the risk of developing a tumour seems to be higher compared to patients without microlithiasis and infertility [149]. Due to the low incidence of a contralateral tumour, even in cases of testicular microlithiasis, there is no indication for contralateral testicular biopsy in prepubertal boys.

Age should be taken into account, when tumour markers are used. Human chorionic gonadotropin ( $\beta$ -hCG) is derived from chorion carcinoma, embryonal carcinoma or seminoma. However, these tumours are extremely rare in prepubertal boys and therefore  $\beta$ -hCG is not useful in prepubertal boys. Alpha-fetoprotein (AFP) has a clear limitation of its sensitivity and specificity in the first months of life [137] and sometimes takes up to

twelve months before the serum concentration reaches the known standard values (< 10 ng/mL) [131, 150]. It is produced by > 90% of yolk sac tumours. Teratomas can also produce AFP, but not to that extent of yolk sac tumours [151]. Alpha-fetoprotein should be measured before any therapeutic intervention (tumour enucleation/orchiectomy) and ideally should be available at the time of the procedure. Alpha-fetoprotein has a serum biological half-life of five days and should be measured five days after tumour resection/orchiectomy in those with an elevated AFP. There is no urgent need for pre-operative staging, as this has no consequence before the definitive histology is available.

#### 3.3.4 **Treatment/Management**

If a testicular tumour is suspected, surgery with the option of intra-operative frozen section should be performed. It is not necessary to do this as an emergency procedure. However, in order to confirm the diagnosis and to avoid familial anxiety, the operation should be scheduled as soon as possible, preferably within the next few days. Organ-preserving surgery should be performed, whenever possible. A review article showed that out of 227 patients with organ-sparing surgery only two cases (one in a patient with an epidermoid cyst and one in a patient with a mature teratoma) had a recurrence [152-154].

Orchiectomy could be considered only if normal testicular parenchyma is no longer detectable in the pre-operatively high-resolution ultrasound and/or the AFP is > 100 ng/mL in a > 12-month-old boy: highly suspicious of a yolk sac tumour.

For surgical technique, the Panel is in favour of an inguinal approach. Furthermore, clamping of the vessels has the advantage of a better view, when organ sparing surgery is performed. However, there is no evidence in the literature, that tumour-spread is prevented by clamping the vessels. Whenever possible, testis sparing surgery should be performed along with frozen sections during surgery to confirm the diagnosis (benign vs. malignant tumour) and to confirm if a microscopically margin-negative resection is performed, in which no gross or microscopic tumour remains in the primary tumour bed (R0 resection). In cases of an R0 resection, the tunica is closed and the testis is replaced in the scrotum. In case of R1 resection (removal of all macroscopic disease, but microscopic margins are positive for tumour) confirmed by frozen section in a malignant or potential malignant tumour, an orchiectomy should be performed at the same time of surgery. If the final pathology later demonstrates a R1 resection in a malignant tumour despite intra-operative negative margins on frozen section, an inguinal orchiectomy can safely be performed.

In patients with a malignant tumour (yolk sac tumour, immature teratoma) staging should be performed including an MRI of the abdomen and a CT-scan from the chest. If there is any suspicion of a non-organ confined tumour, the patient should be referred to a paediatric oncologist. In patients with the rare diagnosis of a Granulosa cell tumour, imaging of the abdomen to exclude enlarged lymph nodes is reasonable as this may be a potentially malignant tumour; in those with Sertoli or a Leydig cell tumour, an MRI is recommended, as 10% are malignant and the metastases do not respond very well to chemotherapy or radiation in the adult literature [155, 156]. The TNM classification from 2015 for adult testicular tumours can be used in patients with a malignant tumour [157]. In benign tumours (mature teratoma, epidermoid cysts) no further staging is required.

#### 3.3.5 **Tumour entities in prepubertal boys**

Teratomas are usually benign in prepubertal children and represent the greatest proportion of intratesticular tumours (around 40%) [124, 158]. They present at a median age of 13 months (0-18 months). Only in adolescent and adults, they should be considered as malignant tumours. Histologically they can consist of a combination of the three primitive embryological germ-cell layers (ectoderm, mesoderm and endoderm). Most of these elements shows microscopically mature elements [159]; however, some immature teratomas in this age group have also been reported [160]. To exclude any malignant potential, like focal areas of a yolk-sac tumour, the entire specimen should be investigated. On US examination a heterogenous picture with some calcification is seen [161] and AFP should be less than 100 ng/mL in an infant. After organ-sparing surgery only one recurrence was reported in the literature [154].

Epidermoid cysts are of ectodermal origin and seem to be related to well-differentiated teratomas; they are always benign [159]. Keratin-producing epithelium is responsible for the keratinised-squamous-epithelial deposits, which appear hyperechogenic in an US [161]. Organ-sparing surgery should be performed and if confirmed by histology, there is no need for surveillance despite the fact that one "recurrence" has been reported thirteen years after diagnosis [153].

Juvenile granulosa cell tumours occur usually in the first year of life, typically within the first six months [162]. They are well circumscribed and have a typical yellow-tan appearance; 2/3 have cystic elements, 1/3 solid [162].

The stroma can be fibrous or fibromyxoid. So far, no recurrence has been reported after organ-sparing surgery [162, 163].

**Leydig cell tumours** arising from the testosterone producing Leydig cells should be suspected in boys with early onset of puberty with high testosterone and low gonadotropin levels [138]. Patients are usually between six and ten years of age; the tumours are well circumscribed with yellow-brown nodules. In children there are no reports of malignant Leydig cell tumours and after organ sparing surgery, there are no reported recurrences to date [164, 165]. In the adult literature, there is a malignancy rate of 10% reported and primary retroperitoneal lymphadenectomy should be discussed in cases with enlarged lymph nodes, as these metastases do not respond very well to chemotherapy or radiation [166].

Around 1/5 of the Sertoli-cell tumours occur in children; usually within the first year of life [167]. In the paediatric age group, the large-cell calcifying Sertoli cell tumours (LCCSCT) are the most common tumour variant [168, 169]. They can occur in patients with complex dysplastic syndromes, such as the Carney or Peutz-Jeghers syndrome [169-171]. Except one case report with the histological diagnosis of a malignant LCCSCT [168], all other reported tumours are benign, therefore organ-sparing surgery should be performed.

**Yolk sac tumours** are the predominant prepubertal malignant germ cell tumours and may represent around 15% of the prepubertal tumours in boys [124]. They also have a number of other names: endodermal sinus tumours, juvenile embryonal carcinoma, clear cell carcinoma, orchioblastoma, vitellineum, archenteronoma and sometimes extraembryonal mesoblastoma [172]. They are histologically mostly solid, yellow-grey tumours. They occur usually within the first two years of life [173]. Up to 80-85% of the tumours are organ confined (Stage I) [174]. The tumour usually spreads haematogenously (chest). Twenty percent of those with Stage I disease may develop visible metastasis in 20% within the next two years. In a German study, 14 out of 91 patients with Stage I had a recurrence after observation – all were cured by chemotherapy alone. Four out of five with metastatic disease initially, were cured by chemotherapy after radical orchiectomy [175]. In a published series from China, 21 out of 90 paediatric patients with a Stage I yolk sac tumour received primary chemotherapy. One of the 21 had a recurrence, whereas 29 out of 69 who underwent surveillance after initial orchiectomy had a recurrence. The overall four-year survival rate was 97.8% [173], almost the same recurrence rate has also been reported by American oncology groups [176, 177]. Therefore in patients with Stage I disease (no metastatic disease in the MRI-abdomen and CT scan of the chest as well as normal age-adapted AFP values) close follow-up together with the paediatric oncologists including AFP every two to three months and MRI of the abdomen is recommended, at least for the first two to three years [137]. This is especially recommended in those with invasions of the lymphatic vessels, as this has been shown to be a prognostic factor in one of the recent series [173]. In cases of recurrence, chemotherapy should be performed by paediatric oncologists according to national study protocols.

### 3.3.6 **Follow-up**

Regular US examination is recommended in the follow-up period to detect any recurrence and/or other abnormalities. As there are only a few studies with recurrence after testicular sparing surgery or orchiectomy, no clear recommendation can be made concerning the interval and the duration of follow-up. However, doing an US examination every three to six months within the first year seems reasonable, as few recurrences have been detected at this time and the rate of atrophy is extremely low after organ-sparing surgery [152]. Only in patients with a malignant tumour, regular follow-up examination after the first year of surgery seems reasonable (see above). The follow-up in patients with a Leydig cell tumour should include endocrinological examinations. Using the SEER data base, the five-year relative survival for testicular malignancies for patients < 14 years of age diagnosed with localised testicular cancer was 97.4%, and for those with distant disease 72.6% [178].

### 3.3.7 **Congenital Adrenal Hyperplasia**

Boys with a congenital adrenal hyperplasia (CAH) represent a special group. Up to a third of the patients have so-called testicular adrenal rest tumours (TARTs) This proportion increase with age [179, 180]. It is most likely to be ectopic adrenal cells, which are growing under pathological stimulation from Adrenocorticotrophic Hormone (ACTH) [181]. They have no malignant potential, but they can have a lasting impact on fertility by displacing the normal testicular parenchyma [181, 182]. These patients should be offered US screening and advice on fertility with the option of cryopreservation [182]. As far as is known, no malignant tumour has been described in patients with a typical TART. As a result, the indication for surgical intervention in these patients to rule out a malignant tumour should be offered very cautiously.

Summary of evidence	LE
Testicular tumours in prepubertal boys have a lower incidence and a different histologic distribution compared to the adolescent and adult patients.	2a
In prepubertal boys up to 60-75% of testicular tumours are benign.	3

Recommendations	Strength rating
High-resolution ultrasound (7.5 – 12.5 MHz), preferably a doppler ultrasound, should be performed to confirm the diagnosis.	Strong
Alpha-fetoprotein (AFP) should be determined in prepubertal boys with a testicular tumour before surgery.	Strong
Surgical exploration should be done with the option for frozen section, but not as an emergency operation.	Strong
Organ-preserving surgery should be performed in all benign tumours.	Strong
Staging (MRI abdomen /CT chest) should only be performed in patients with a malignant tumour to exclude metastases.	Strong
Magnetic resonance imaging should only be performed in patients with the potential malignant Leydig or Sertoli-cell-tumours to rule out lymph node enlargement.	Weak
Patients with a non-organ confined tumour should be referred to paediatric oncologists post-operatively.	Weak

### 3.4 Fertility preservation in children and adolescents

The continuous increase in the incidence of paediatric cancers and post-treatment survivorship over the years, coupled with the further development of potentially gonadotoxic therapies, has contributed to the recognition and rapid endorsement of fertility preservation counselling for prepubertal children and adolescents. Patients and caregivers should be informed not only about the impact of gonadotoxic treatments on future fertility but also about fertility-preservation options and their risk-benefit ratio. There are also a number of non-oncological congenital anomalies where fertility preservation can become an issue.

This chapter focuses on basic information on cryopreservation indications and options for paediatric urologists. For more detailed information, we refer to specific guidelines on this topic [183-185].

#### 3.4.1 Ovarian tissue cryopreservation in prepubertal and adolescent girls


Infertility in the paediatric and adolescent population can result from direct gonadal damage from surgery, or gonadal toxicity as a result of chemotherapy or radiation [183]. Frequent indications requiring gonadotoxic therapy include solid tumors, leukemia and benign indications, such as hemoglobinopathies [186]. First-line chemotherapy does not appear to affect the number of primordial follicles [187], rather, it seems to have a significant effect on the health, density and functionality of follicles [188], resulting in a reduction of 10-30% of ovarian reserve, depending on age and menarchal status [189]. The indication and options for fertility preservation should ideally be discussed in a paediatric multidisciplinary fertility preservation team and should consider the toxicity of the planned therapy, the age and menarchal status as well ethical and financial issues [190, 191].

In paediatric and adolescent patients, ovarian tissue retrieval is performed by removal of an entire ovary (or partial ovariectomy) by laparoscopy [192], or in the setting of a laparotomy for surgery of the primary tumor [186, 193]. It is advised to combine these interventions with other medically indicated procedures to minimize any additional anesthetic risks and costs [194]. In postpubertal patients and in the setting of benign disease, oocyte retrieval following prior ovarian stimulation can be performed [195-198]. For patients undergoing brachytherapy of the pelvic region, the technique of temporary laparoscopic ovarian transposition has been described [199].

Ovarian tissue can be re-implanted orthotopically or heterotopically. For fertility purposes, orthotopic transplantation includes implanting ovarian tissue into the peritoneal cavity, the remaining contralateral ovary, the ovarian fossa or the broad peritoneal ligament [200]. Heterotopic transplantation includes transplantation of ovarian tissue into other locations, such as the subcutaneous abdominal wall, the rectus muscle and the forearm. This technique can be used for the recovery of natural endocrine function [200]. The utilization rate of ovarian tissue for ovarian cortex autotransplantation in the pediatric population has been reported to be as low as 2.2-5% [197, 201, 202]. A large case series demonstrated that transplantation of prepubertal cryopreserved

ovarian tissue resulted in induction of spontaneous puberty and pregnancies in a few reported cases. However, there are only a few cases with long-term outcomes reported in the literature [203, 204].

**Figure 3: Ovarian tissue cryopreservation for girls and adolescents**



*Adapted from Anderson et al. [198]*

### 3.4.2 Cryopreservation in prepubertal and adolescent boys

The increase in the incidence of paediatric cancers and post-treatment survivors has also contributed to studies for fertility preservation in prepubertal boys. Gonadoprotective measures aiming at protecting the survival and function of immature germ cells in prepubertal testes, which are highly susceptible to irradiation and chemotherapy, should be the first aim [205]. Attenuation of externally scattered irradiation from fields close to the testes by gonadal shielding has been shown to be effective with respect to testicular growth in survivors [206, 207]. In patients undergoing brachytherapy in the region of the genitals, temporary testicular transposition has been described as a method for fertility preservation [208].

Sperm cryopreservation via masturbation or penile vibration should be the first option in non-azoospermic post pubertal boys. Techniques such as electro ejaculation should only be discussed in very specific circumstances. Cryopreservation of immature testicular tissue, containing spermatogonial stem cells, as a fertility preservation option for this population is still experimental and should be carefully explained to caregivers and patients by a multidisciplinary team [205]. Testicular biopsy procedures do not seem to affect fertility potential due to surgical complications or due to disruption of the blood-testicular barrier, however further studies on this topic are needed [209].

Additional anaesthesia-related risks for testicular sampling should be avoided if possible. The procedure can be combined with any other intervention requiring anaesthesia whenever possible [205].

For benign conditions such as Klinefelter Syndrome, with the potential risk of germ cell loss prior to puberty, bilateral undescended testes cryopreservation has been proposed, but remains controversial and experimental [210-212].

Even though experimental advances have been achieved in non-human primates, many challenges remain to be addressed for prepubertal testes before clinical application.



### 3.4.3 Summary of evidence and recommendations fertility preservation in children and adolescents

Summary of evidence
It is advised to combine any fertility preservation intervention with other medically indicated procedures to minimize additional anesthetic risks and costs.
Ovarian tissue cryopreservation can be used for fertility preservation in pre- and postpubertal girls.
Cryopreservation of immature testicular tissue, containing spermatogonial stem cells, as a fertility preservation option for this population is still experimental and should be well explained to caregivers and patients by a multidisciplinary team.

Recommendations	Strength rating
Inform patients and caregivers about the impact of gonadotoxic treatments on future fertility and about fertility preservation options and their risk-benefit balance.	Strong
Discuss the indications and options for fertility preservation in a pediatric multidisciplinary fertility preservation team and consider the toxicity of the planned therapy, the age and pubertal status as well ethical and financial issues.	Strong

## 3.5 Hydrocele

### 3.5.1 Epidemiology, aetiology and pathophysiology

Hydrocele is defined as a collection of fluid between the parietal and visceral layers of the tunica vaginalis [213]. In males congenital hydrocele is based on failed obliteration of the processus vaginalis between the inguinal canal and scrotum. Similarly, although more rare, in females hydrocele can occur with failed obliteration of the canal of Nuck, a protrusion of peritoneum in the female inguinal canal. There are various types of congenital hydrocele. In communicating hydrocele, intraperitoneal fluid passes into the scrotal tunica vaginalis due to persisting patency of the processus vaginalis (PPV). This must be differentiated from inguinal hernia in which the processus vaginalis is wide enough to allow passage of abdominal viscera or omentum [213]. If obliteration of the processus vaginalis occurs with focal patency of the mid-portion, a hydrocele of the cord occurs. The exact time of spontaneous closure of the inguinal processus vaginalis is not known. Processus vaginalis is present in approximately 80-94% of newborns and in 20% of adults [214]. Scrotal hydroceles without associated patency of the inguinal processus vaginalis may be encountered in newborns [215]. However, such non-communicating hydroceles, are often acquired and based on an imbalance between the secretion and re-absorption of lymphatic fluid, and thus can be found secondary to minor trauma, testicular torsion, epididymitis, varicocele operation (due to ligation of the lymphatics) or may appear as a recurrence after hydrocele repair. Rarely a hydrocele may have an intra-abdominal component, positioned ventral or dorsal to the bladder, the so-called abdominoscrotal hydrocele (ASH). This is considered to be a scrotal hydrocele with an hourglass-shaped extension reaching into the abdomen via the inguinal ring. Abdominoscrotal hydrocele may be associated with testicular dysmorphism related to increased pressure [216, 217].

### 3.5.2 Diagnostic evaluation

The classic description of a communicating hydrocele is that of a hydrocele that fluctuates in size, and is usually related to ambulation. It may be diagnosed by history-taking and physical investigation. The presence of contralateral disease should be addressed during the initial consultation [214]. Transillumination of the scrotum provides the diagnosis in the majority of cases, keeping in mind that fluid filled intestine and some pre-pubertal tumours may transilluminate as well [218, 219]. In hydroceles the swelling is smooth and usually not tender. If there are any doubts about the character of an intrascrotal mass or if the testis is not palpable, scrotal US should be considered, which has nearly 100% sensitivity in detecting intrascrotal lesions. Doppler US studies help to distinguish hydroceles from varicocele and testicular torsion, although these conditions may also be accompanied by a hydrocele [220]. Presence of ASH is suggested by a tense hydrocele or palpable abdominal extension upon compression of the scrotal part of the hydrocele, and can be confirmed by US [217].

### 3.5.3 Management

#### Conservative management

In the majority of infants, observation is warranted at least within the first twelve months because of the tendency of spontaneous resolution [221]. The rate of resolution decreases with age, with 92% resolution below one year old and 43% above three years [222, 223]. Initial observation poses little risk as progression to hernia is rare and does not result in incarceration [221]. There is no evidence that hydrocele risks testicular damage [223]. In acquired hydrocele, suggestive of a non-communicating hydrocele, there is still a reasonable chance

of spontaneous resolution (75%) and expectant management of six to nine months is recommended [224]. In ASH the rate of spontaneous resolution appears lower, although it has been reported [225]. In exemption to the above, the suspicion of a concomitant inguinal hernia or underlying testicular pathology necessitates early surgery [226]. In other cases initial conservative treatment may reduce the number of procedures without increasing morbidity, however persistence of hydrocele is an indication for surgical correction.

#### *Surgical treatment*

In the paediatric age group, surgical correction consists of inguinal ligation of the patent processus vaginalis via inguinal incision with the distal stump being left open. In hydrocele of the cord the cystic mass is excised or unroofed [219, 227, 228]. In expert hands, the incidence of testicular damage during hydrocele or inguinal hernia repair is very low. Laparoscopic hernia repair with percutaneous ligation of the patent inguinal processus vaginalis is a minimally invasive alternative to open inguinal herniorrhaphy [229, 230]. In line with these techniques, various laparoscopic techniques for hydrocele correction have been described. No technique appears to be superior [214].

Laparoscopic correction of a contralateral patent processus may be considered, however a recent meta-analysis found insufficient evidence to recommend this for inguinal hernia [214] and hydrocele was not reported. The incidence of patent contralateral processus appears much higher than the percentage of children developing metachronous hernia (63% vs 8%) [214]. Thus, to prevent metachronous inguinal hernia the number needed to treat is relatively high (NNT=18) [231]. For acquired, non-communicating hydrocele the scrotal approach (Lord or Jaboulay/Winkelmann technique) is used.

In ASH most case series describe resection of the abdominal component which is connected to the scrotal, but not to the inguinal processus vaginalis. The incidence of complications for this procedure is higher than in regular hydrocele repair [225] and can result in testicular loss and atrophy, causing some to question if resection is necessary [217, 225]. Larger series are needed to assess optimal management. Testicular dysmorphism may recover following surgery [216]. Sclerosing agents should not be used because of the risk of chemical peritonitis in communicating processus vaginalis [219].

#### **3.5.4 Summary of evidence and recommendations for the management of hydrocele**

<b>Summary of evidence</b>
In the majority of infants, surgical treatment of hydrocele is not indicated within the first twelve months due to the tendency for spontaneous resolution. Little risk is taken by initial observation as progression to hernia is rare.
In acquired hydrocele initial expectant is recommended, unless hernia or testicular pathology are suspected.
In the paediatric age group, an operation would generally involve ligation of the patent processus vaginalis via inguinal incision.

<b>Recommendations</b>	<b>Strength rating</b>
Observe hydroceles in the majority of infants prior to considering surgical treatment.	Strong
Perform early surgery if there is suspicion of a concomitant inguinal hernia or underlying testicular pathology.	Strong
Perform ultrasound in case of doubt about the character of an intrascrotal mass, or suspicion of an abdominoscrotal hydrocele.	Strong
Close the processus vaginalis at the inguinal ring.	Strong
Do not use sclerosing agents in children with hydroceles, because of the risk for chemical peritonitis.	Strong

### **3.6 Acute scrotum**

#### **3.6.1 Epidemiology, aetiology and pathophysiology**

Acute scrotum is a paediatric urological emergency, most commonly caused by torsion of the testis or appendix testis, or epididymitis/epididymo-orchitis [232-237]. Other causes of acute scrotal pain are idiopathic scrotal oedema, mumps orchitis, varicocele, scrotal haematoma, incarcerated hernia, appendicitis or systemic disease (e.g. Henoch-Schönlein purpura) [238-250]. Trauma can also be a cause of acute scrotum due to post-traumatic haematomas, testicular contusion, rupture, dislocation or torsion [251-256]. Scrotal fat necrosis has also been reported to be an uncommon cause of mild-to-moderate scrotal pain in pre-pubertal overweight boys after exposure to cold [257].

In this chapter testicular torsion and epididymitis are discussed, while recurrent epididymitis is discussed in the chapter dealing with infections. Torsion of the testis occurs most often in the neonatal period and around puberty, whereas torsion of the appendix testis occurs over a wider age range [258]. Epididymitis affects two age groups: less than one year and twelve to fifteen years [259, 260]. One study predicted the annual incidence of epididymitis around 1.2 per 1,000 children [261].

Perinatal torsion of the testis most often occurs prenatally. Bilateral torsion comprises 11-21% of all perinatal cases [262]. Most cases of perinatal torsion are extravaginal, in contrast to the usual intravaginal torsion which occurs during puberty.

### 3.6.2 **Diagnostic evaluation**

Patients usually present with scrotal pain, except in neonatal torsion. The sudden onset of invalidating pain in combination with vomiting is typical for torsion of the testis or appendix testis [263, 264].

In general, the duration of symptoms at presentation is shorter in testicular torsion (69% present within twelve hours) and torsion of the appendix testis (62%) compared to epididymitis (31%) [234, 235, 260]. Prepubertal males are more likely to present with atypical symptoms and delayed presentation and diagnosis, leading to delayed surgical intervention and a higher rate of orchiectomy, compared to postpubertal boys [265].

In the early phase, location of the pain can lead to diagnosis. Patients with acute epididymitis experience a tender epididymis, whereas patients with testicular torsion are more likely to have a tender testicle, in case of torsion of the appendix testis there may be isolated tenderness of the superior pole of the testis [260].

An abnormal (horizontal) position of the testis is more frequent in testicular torsion than epididymitis [234]. Looking for absence of the cremasteric reflex is a simple method with 100% sensitivity and 66% specificity for testicular torsion [259, 264] (LE: 3). Elevation of the scrotum may reduce complaints in epididymitis, but not in testicular torsion.

Fever occurs more often in epididymitis (11-19%). The classical sign of a "blue dot" was found only in 10-23% of patients with torsion of the appendix testis [233, 234, 259, 266]. In many cases, it is not easy to determine the cause of acute scrotum based on history and physical examination alone [232-237, 259, 266]. A positive urine culture is only found in a few patients with epididymitis [236, 259, 266, 267]. It should be remembered that a normal urinalysis does not exclude epididymitis. Similarly, an abnormal urinalysis does not exclude testicular torsion.

Doppler US is useful to evaluate acute scrotum, with 63.6-100% sensitivity and 97-100% specificity, a positive predictive value of 100% and negative predictive value of 97.5% [268-273] (LE: 3). The use of Doppler US may reduce the number of patients with acute scrotum undergoing scrotal exploration, but it is operator-dependent and can be difficult to perform in pre-pubertal patients [270, 274]. It may also show a misleading arterial flow in the early phases of torsion and in partial or intermittent torsion. Of key importance, persistent arterial flow does not exclude testicular torsion. In a multicentre study of 208 boys with torsion of the testis, 24% had normal or increased testicular vascularisation [270]. A comparison with the other side should always be done.

Better results were reported using high-resolution US (HRUS) for direct visualisation of the spermatic cord twist with a sensitivity of 97.3% and specificity of 99% [270, 275] (LE: 2). A so-called positive whirlpool sign (the presence of a spiral-like pattern), has a pooled sensitivity and specificity of 0.73 (95% CI; 0.65-0.79) and 0.99 (95% CI; 0.92-0.99), respectively, and may be viewed as a definitive sign for testicular torsion. But its role in neonates is limited [276].

Scintigraphy and, more recently, dynamic contrast-enhanced subtraction MRI of the scrotum also provide a comparable sensitivity and specificity to US [277-280]. These investigations may be used when diagnosis is less likely and if torsion of the testis still cannot be excluded from history and physical examination. This should be done without inordinate delays for emergency intervention [266].

The diagnosis of acute epididymitis in boys is mainly based on clinical judgement and adjunctive investigation. However, it should be remembered that findings of secondary inflammatory changes in the absence of evidence of an extra-testicular nodule by Doppler US might suggest an erroneous diagnosis of epididymitis in children with torsion of the appendix testes [281]. Pre-pubertal boys with acute epididymitis have an incidence of underlying urogenital anomalies of 25-27.6%. Complete urological evaluation in all children with acute epididymitis is still debatable [236, 259, 261].

### 3.6.3 **Management**

#### 3.6.3.1 **Epididymitis**

In pre-pubertal boys, the aetiology is usually unclear, with an underlying pathology in about 25%. A urine culture is usually negative, and unlike in older boys, a sexually transmitted disease is very rare.

Antibiotic treatment, although often started, is not indicated in most cases unless urinalysis and urine culture show a bacterial infection [261, 282]. Epididymitis is usually self-limiting and with supportive therapy (i.e. minimal physical activity and analgesics) heals without any sequelae (LE: 3). However, bacterial epididymitis can be complicated by abscess or necrotic testis and surgical exploration is required [283].

#### 3.6.3.2 *Testicular torsion*

Manual detorsion of the testis is done without anaesthesia, and should be attempted in all patients if possible, because it is associated with improved surgical salvage rates [284]. It should initially be done by outward rotation of the testis - like opening a book -, unless the pain increases or if there is obvious resistance. Success is defined as the immediate relief of all symptoms and normal findings at physical examination [285] (LE: 3). Doppler US may be used for guidance [286]. Bilateral orchiopexy is still required after successful detorsion. This should not be done as an elective procedure, but rather immediately following detorsion. One study reported residual torsion during exploration in 17 out of 53 patients, including eleven patients who had reported pain relief after manual detorsion [285, 287].

External cooling before exploration may be effective in reducing ischaemia reperfusion injury and preserving the viability of the torsed and the contralateral testis [288]. Medical treatments aimed at limiting such injury remain experimental [289-292].

Torsion of the appendix testis can be managed non-operatively with the use of anti-inflammatory analgesics (LE: 4). During the six-week follow-up, clinically and with US, no testicular atrophy was revealed. Surgical exploration is done in equivocal cases and in patients with persistent pain [273]. Although metachronous torsion of the appendix testis may occur in up to 8.5%, it is not necessary to explore the contralateral side, given the benign nature of the problem. Besides it has been demonstrated that the NNT is 24 [293].

#### 3.6.3.3 *Surgical treatment*

Testicular torsion is an urgent condition which requires prompt surgical treatment. The two most important determinants of early salvage rate of the testis are the time between onset of symptoms and detorsion, and the degree of cord twisting [294]. Severe testicular atrophy occurred after torsion for as little as four hours when the turn was  $> 360^\circ$ . In cases of incomplete torsion ( $180-360^\circ$ ), with symptom duration up to twelve hours, no atrophy was observed. However, a necrotic or severely atrophied testis was found in all cases of torsion  $> 360^\circ$  and symptom duration  $> 24$  hours [295].

Early surgical intervention with detorsion (mean torsion time less than thirteen hours) was found to preserve fertility [296]. Urgent surgical exploration is mandatory in all cases of testicular torsion within 24 hours of symptom onset. In patients with testicular torsion  $> 24$  hours, exploration may be performed as a semi-elective exploration procedure [294, 295] (LE: 3), unless there is a clear history of torsion-detorsion in which urgent exploration should still be considered. In case of prolonged torsion ( $> 24$  hours) it is still subject to debate whether the surgically detorsed testis should be preserved. An alternative to detorsion and fixation may be to perform orchiectomy. A study found that sperm quality was preserved after both orchiectomy and orchidopexy in comparison to normal control men, although orchiectomy resulted in better sperm morphology [297]. Incision of the tunica albuginea with tunica vaginalis graft to prevent or treat compartment syndrome has also been suggested [298].

In neonates with signs of testicular torsion at birth the duration of symptoms will not be clear. The decision to perform surgical exploration should be weighed against the general condition of the child. In this age group the operation can safely be done under spinal anaesthesia. New onset of symptoms of testicular torsion in neonates should be considered a surgical emergency similar to older boys.

During exploration, fixation of the contralateral testis is also performed. It is good clinical practice to also perform fixation of the contralateral testis in prenatal and neonatal torsion, although there is no literature to support this, and to remove an atrophied testicle [299]. Recurrence after orchidopexy is rare (4.5%) and may occur several years later. There is no consensus recommendation about the preferred type of fixation and suture material [300].

#### 3.6.4 *Follow-up*

Patients require follow-up mainly for fertility issues and hormonal consequences. Despite timely and adequate detorsion and fixation of the testicle, up to half of the patients may develop testicular atrophy, even when intraoperatively assessed as viable, and should be counselled accordingly [301, 302].

##### 3.6.4.1 *Fertility*

The results vary and are conflicting. In one study, unilateral torsion of the testis seriously intervened with subsequent spermatogenesis in about 50% of the patients and produced borderline impairment in another 20% [279]. Although, 30% of affected testicles with mumps orchitis show a degree of atrophy, long-term outcome in terms of fertility is not conclusive [303].

A study showed a normal pregnancy rate after unilateral testicular torsion, with no difference between the patients undergoing orchidopexy and those after orchidectomy [304].

#### 3.6.4.2 Subfertility

Subfertility is found in 36-39% of patients after torsion. Semen analysis may be normal in only 5-50% in long-term follow-up [294]. Early surgical intervention (mean torsion time less than thirteen hours) with detorsion was found to preserve fertility, but a prolonged torsion period (mean 70 hours) followed by orchidectomy jeopardised fertility [296].

Subfertility and infertility are consequences of direct injury to the testis after the torsion. This is caused by the cut-off of blood supply, but also by post-ischaemia-reperfusion injury that is caused after the detorsion when oxygen-derived free radicals are rapidly circulated within the testicular parenchyma [294].

#### 3.6.4.3 Androgen levels

Even though the levels of FSH, luteinising hormone (LH) and testosterone are higher in patients after testicular torsion compared to normal controls, endocrine testicular function remains in the normal range after testicular torsion [297].

#### 3.6.4.4 Unanswered questions

Although testicular torsion is a common problem, the mechanism of neonatal and prenatal torsion is still not exactly known, as well as whether fixation of the contralateral testicle in these cases is really necessary. The influence of an atrophied testicle on fertility is also unclear.

Summary of evidence	LE
Diagnosis of testicular torsion is based on presentation and physical exam.	-
Doppler US is an effective imaging tool to evaluate acute scrotum and comparable to scintigraphy and dynamic contrast-enhanced subtraction MRI.	2a
Neonates with acute scrotum should be treated as surgical emergencies.	3

Recommendations	Strength rating
Testicular torsion is a paediatric urological emergency and requires immediate treatment.	Strong
In neonates with testicular torsion perform orchidopexy of the contralateral testicle. In prenatal torsion the timing of surgery is usually dictated by clinical findings.	Weak
Base the clinical decision on physical examination. The use of Doppler ultrasound to evaluate acute scrotum is useful, but this should not delay the intervention.	Strong
Manage torsion of the appendix testis conservatively. Perform surgical exploration in equivocal cases and in patients with persistent pain.	Strong
Perform urgent surgical exploration in all cases of testicular torsion within 24 hours of symptom onset. In prenatal torsion the timing of surgery is usually dictated by clinical findings.	Strong

## 3.7 Hypospadias

### 3.7.1 Epidemiology, aetiology and pathophysiology

#### 3.7.1.1 Epidemiology

The total prevalence of hypospadias in Europe is 18.6 new cases per 10,000 births (5.1-36.8) according to the EUROCAT registry-based study. This incidence was stable over the period of 2001 to 2010 [305, 306]. The mean worldwide prevalence of hypospadias according to an extended systematic literature review varies: Europe 19.9 (range: 1-464), North America 34.2 (6-129.8), South America 5.2 (2.8-110), Asia 0.6-69, Africa 5.9 (1.9-110), and Australia 17.1-34.8. There are conflicting data on the recent trends of prevalence – different trends in Europe and an increasing trend in the USA [307, 308].

#### 3.7.2 Risk factors

Risk factors associated with hypospadias are likely to be genetic, placental and/or environmental [305, 306] (LE: 2b). Interactions between genetic and environmental factors may help explain non-replication in genetic studies of hypospadias. Single nucleotide polymorphisms seemed to influence hypospadias risk only in exposed cases [306, 309] (LE: 2b).

- An additional family member with hypospadias is found in 7% of families, but this is more predominant in anterior and middle forms [309-312].
- Endocrine disorders can be detected in rare cases.
- Babies with a low birth weight have a higher risk of hypospadias [309-312].
- Over the last 25 years, a significant increase in the incidence of hypospadias has been found.
- Endocrines disruptors are one component of a multi-factorial model for hypospadias.
- The use of oral contraceptives prior to pregnancy has not been associated with an increased risk of hypospadias in offspring, but their use after conception increased the risk of middle and posterior hypospadias [310-313] (LE: 2a).

### 3.7.3 **Classification systems**

Hypospadias are usually classified based on the anatomical location of the proximally displaced urethral orifice:

- distal-anterior hypospadias (located on the glans or distal shaft of the penis and the most common type of hypospadias);
- intermediate-middle (penile);
- proximal-posterior (penoscrotal, scrotal, perineal).

The pathology may be different after skin release and should be reclassified accordingly. Anatomical location of the meatus may not always be enough to explain the severity and the complex nature of this pathology. Therefore, a simple classification related to severity of the problem, which considers penile length, glans size, shape, urethral plate quality and penile curvature is commonly used. In that classification there are two types: mild hypospadias (glanular or penile isolated hypospadias without associated chordee, micropenis or scrotal anomaly); and severe hypospadias (penoscrotal, perineal hypospadias with associated chordee and scrotal anomalies).

### 3.7.4 **Diagnostic evaluation**

Most hypospadias patients are easily diagnosed at birth (except for the megameatus intact prepuce variant which can only be seen after retraction of foreskin). Diagnosis includes a description of the local findings:

- position, shape and width of the orifice;
- presence of atretic urethra and division of corpus spongiosum;
- appearance of the preputial hood and scrotum;
- size of the penis;
- curvature of the penis on erection.

The diagnostic evaluation also includes an assessment of associated anomalies, which are:

- cryptorchidism (in up to 10% of cases of hypospadias);
- open processus vaginalis or inguinal hernia (in 9-15%).

Severe hypospadias with unilaterally or bilaterally impalpable testis, or with ambiguous genitalia, requires a complete genetic and endocrine work-up immediately after birth to exclude DSD, especially congenital adrenal hyperplasia. Urine trickling and ballooning of the urethra requires exclusion of meatal stenosis. The relationship between the severity of the hypospadias and associated anomalies of the upper or lower urinary tract were not confirmed [314] (LE: 3).

### 3.7.5 **Management**

#### 3.7.5.1 *Indication for reconstruction and therapeutic objectives*

Differentiation between functionally necessary and aesthetically feasible operative procedures is important for therapeutic decision making.

The indications for surgery are:

- proximally located (ectopic) meatus causing ventrally deflected or spraying urinary stream;
- meatal stenosis;
- anterior curvature of the penis;
- cleft glans;
- rotated penis with abnormal cutaneous raphe;
- preputial hood;
- penoscrotal transposition;
- split scrotum.

Physical examination should check all anatomic components of the penis and evaluate the degree and nature of abnormality in each component. The examination should evaluate location of the meatus, the degree of

proximal spongiosal hypoplasia, presence and degree of penile curvature, width and depth of the urethral plate, size of the glans, degree of ventral skin deficiency, availability of the foreskin and scrotal abnormalities like penoscrotal transposition and bifid scrotum.

As all surgical procedures carry the risk of complications, thorough pre-operative counselling of the caregiver is crucial.

To achieve an overall acceptable functional and cosmetic outcome, the penile curvature must be corrected and a neo-urethra of an adequate size with opening on the glans formed with proper skin coverage of the penile shaft [315] (LE: 4) (Figure 4). The use of magnifying spectacles and fine synthetic absorbable suture materials (6.0-7.0) are required. As in any penile surgery, exceptional prudence should be adopted with the use of cautery. Bipolar cautery is recommended. Knowledge of a variety of surgical reconstructive techniques, wound care and post-operative treatment are essential for a satisfactory outcome.

#### 3.7.5.2 *Pre-operative hormonal treatment*

There is a lack of high-quality evidence to support that pre-operative hormonal treatment with androgen stimulation improves surgical outcomes. Yet, this treatment in the form of systemic testosterone, topical testosterone, and derivatives like dihydrotestosterone (DHT) and hCG are commonly being used to increase glans size pre-operatively to allow better tubularisation of the urethral plate and decrease the incidence of glans dehiscence. This treatment is usually limited to patients with proximal hypospadias, a small appearing penis, reduced glans circumference or reduced urethral plate [313, 316, 317]. Studies have shown that it leads to significant enlargement of the glans and shaft of the penis (LE: 1b) [318, 319].

Moderate quality evidence from three randomised studies demonstrate significantly lower rates of urethracutaneous fistulae and re-operation rates in patients who received pre-operative hormonal treatment [320].

Pre-operative testosterone administration is most often well tolerated. Transient side effects on child's behaviour, increased genital pigmentation, appearance of pubic hair, penile skin irritation and redness, increased erections and peri-operative bleeding have been reported, but no persistent side effects related to hormonal stimulation have been reported in the literature. There is also no evidence about possible effects on bone maturation [317, 320, 321].

There are concerns regarding the negative impacts of testosterone on wound-healing and increased bleeding during surgery. Cessation of therapy is recommended one or two months prior to surgery to avoid adverse effects during or after surgery [322].

#### 3.7.5.3 *Age at surgery*

The age at surgery for primary hypospadias repair is usually 6-18 (24) months [315, 323, 324] (LE: 3). Age at surgery is not a risk factor for urethroplasty complication in pre-pubertal tubularised incised plate urethroplasty (TIP) repair [323] (LE: 2b). Complication rate after primary TIP repair was 2.5 times higher in adults than in the paediatric group according to a prospective controlled study [325] (LE: 2a).

#### 3.7.5.4 *Penile curvature*

If present, penile curvature is often released by degloving the penis (skin chordee) and by excision of the connective tissue of the genuine chordee on the ventral aspect of the penis in up to 70% [326]. The urethral plate has well vascularised connective tissue and does not cause curvature in most cases [327, 328]. The residual curvature is caused by corporeal disproportion and requires straightening of the penis, mostly using dorsal midline plication or orthoplasty (modification of the Nesbit plication with or without elevation of the neurovascular bundle). In more severe curvature (> 45°), which is often combined with a short urethral plate requiring transection, ventral penile lengthening is recommended to prevent shortening of the penis. This consists of a ventral transverse incision of the tunica albuginea extending from the 3 to 9 o'clock position patched with tunica vaginalis flap or graft, or in several short ventral corporotomies without grafting (LE: 2b) [329]. After the ventral lengthening, a shorter dorsal midline plication is usually added.

According to a retrospective study, dorsal plication remained significantly associated with recurrent ventral curvature independently of the other factors. Ventral corporeal grafting for severe penile curvature gives good long-term results and safety profiles for erectile function [330] (LE: 2b).

#### 3.7.5.5 *Urethral reconstruction*

The mainstay of hypospadias repair is preservation of the well-vascularised urethral plate and its use for urethral reconstruction has become standard practice in hypospadias repair [328]. Mobilisation of the corpus spongiosum/ urethral plate and the bulbar urethra decreases the need for urethral plate transection [329] (LE: 2b).

If the urethral plate is wide, it can be tubularised following the Thiersch-Duplay technique. If the plate is too narrow to be simply tubularised, it is recommended relaxing the plate by a midline incision and its subsequent tubularisation according to the Snodgrass-Orkiszewski TIP technique. This technique has become the treatment of choice in distal- and mid-penile hypospadias [331-334]. If the incision of the plate is deep, it is recommended to cover the raw surface with inner preputial (or buccal) inlay graft in primary and secondary repairs [335]. This also enables extension of the incision beyond the end of the plate to prevent meatal stenosis [336, 337] (LE: 2a).


For distal forms of hypospadias, a range of other techniques is available (e.g. Mathieu, urethral advancement) [338] (LE: 2b). The TIP technique has become an option for proximal hypospadias as well [331-334, 339]. However, urethral plate elevation and urethral mobilisation should not be combined with TIP repair because it results in focal devascularisation of the neo-urethra with symptomatic stricture development [340] (LE: 2b). The onlay technique using a preputial island flap is a standard repair, preferred in proximal hypospadias, if a plate is unhealthy or too narrow [326]. An onlay preputial graft is an option for single-stage repair [341] (LE: 2b).

If the continuity of the urethral plate cannot be preserved, single or two-stage repairs are used. For the former, a modification of the tubularised flap (Duckett tube), such as a tube-onlay or an inlay-onlay flap, or onlay flap on albuginea are used to prevent urethral stricture [342-344] (LE: 3); alternatively the Koyanagi-Hayashi technique is used [345-348]. The two-stage procedure has become preferable over the past few years because of lower recurrence of ventral curvature and more favourable results with variable long-term complication rates [337, 342, 349-353].

### 3.7.5.6 Re-do hypospadias repairs

For re-do hypospadias repairs, no definitive guidelines can be given. All the above-mentioned procedures are used in different ways and are often modified according to the individual findings and needs of the patient.

**Figure 4: Algorithm for the management of hypospadias**



DSD = disorders of sex development; TIP = tubularised incised plate urethroplasty; MAGPI = meatal advancement and glanuloplasty incorporated.



### 3.7.5.7 *Penile reconstruction following formation of the neo-urethra*

Following formation of the neo-urethra, the procedure is completed by glansplasty and by reconstruction of the penile skin. If there is a shortage of skin covering, the preputial double-face technique or placement of the suture line into the scrotum according to Cecil-Michalowski is used. In countries where circumcision is not routinely performed, preputial reconstruction can be considered. Preputial reconstruction carries a risk of specific complications but does not seem to increase the risk of urethroplasty complications [354]. In TIP repair, the use of a preputial dartos flap reduces the fistula rate [331, 332] (LE: 2b).

### 3.7.5.8 *Urine drainage and wound dressing*

Urine is drained transurethrally (e.g. dripping stent) or with a suprapubic tube. No drainage after distal hypospadias repair is another option [355, 356]. Circular dressing with slight compression, as well as prophylactic antibiotics during surgery, are established procedures [356] (LE: 4). Post-operative prophylaxis after hypospadias repair has limited benefit and it only reduces the risk of asymptomatic bacteriuria [357-359] (LE: 2b). There is no consensus on duration of stenting and dressing.

### 3.7.5.9 *Outcome*

Some studies have tried to determine risk factors for complications after hypospadias repair. An analysis of prospectively collected data found glans size (width < 14 mm), proximal meatal location and re-operation as independent risk factors for urethral complication [356, 360]. Low surgeon volume independently increases the risk of fistula, stricture or diverticulum repair [356, 361] (LE: 3).

A meta-analysis of complication rates of TIP repair found lower complication rates and incidence of re-operations in primary distal repairs (in 4.5%) than in primary proximal repairs (in 12.2%) and in secondary repair (in 23.3%) [331-334, 338, 356]. One should expect a predictable outcome with complication rates below 10% in distal hypospadias (fistula, meatal stenosis, dehiscence, recurrent ventral curvature, and haematoma) [361, 362]. A similar incidence of fistula (3.4-3.6%) can be expected after the Mathieu and TIP repairs of distal hypospadias [339, 363-365].

The complication rates of TIP and onlay repairs of primary severe hypospadias are similar, 24% and 27%, respectively. It is higher in free graft and in preputial island tube urethroplasty [326]. There is no strong evidence to suggest that the use of inlay grafts in TIP repair improves the outcome [366].

The complication rates of single-stage Koyanagi and Hayashi modification repairs go up 61%, according to a comparative study [345, 356]. Staged buccal mucosa graft requires a redo grafting in 13% of patients, after the second stage more than one third of patients have complications, mostly with some degree of graft fibrosis [364, 367]. A long-term study on two-stage flap repair showed a complication rate of 68% [356]; another study showed a re-operation rate of 28% [337, 356].

### 3.7.6 *Follow-up*

Long-term follow-up is necessary up to adolescence to detect urethral stricture, voiding dysfunctions and recurrent penile curvature, diverticula, glanular dehiscence [368]. Up to half of complications requiring re-operation present after the first year post-operatively [369] (LE: 2b).

Obstructive flow curve is common after hypospadias repair and while most are not clinically significant, long-term follow-up is required [370-373] (LE: 2a). Urine flow is significantly lower in patients after hypospadias surgery, especially in those who had corrected chordee, but without significant association with lower urinary symptoms (LUTS) [374] (LE: 2a).

Objective scoring systems have been developed in order to evaluate the results of hypospadias surgery (HOSE) [375] (LE: 2b) and cosmetic appearance (HOPE-Hypospadias Objective Penile Evaluation) [376] (LE: 2a). The Pediatric Penile Perception Score (PPPS) is a reliable instrument to assess penile self-perception in children after hypospadias repair and for appraisal of the surgical result by caregivers and uninvolved urologists [377] (LE: 2a). Cosmetic results were judged more optimistically by surgeons as compared to caregivers using validated tools [378]. Current scoring systems have deficiencies in terms of patient reported outcomes, the long term outcomes and sexual function [379].

Adolescents and adults, who have undergone hypospadias repair in childhood, have a slightly higher rate of dissatisfaction with penile size, especially proximal hypospadias patients, but their sexual behaviour is not different from that of control groups [380, 381] (LE: 2a-b). Another long-term follow-up of men born with hypospadias revealed, in a controlled study, that these patients are less satisfied with penile cosmetic outcome

according to all parameters of the PPPS; there was a difference in penile length (9.7 vs. 11.6 cm) and more patients had lower maximum urinary flow. More prominent results were found in proximal hypospadias vs. controls [356, 382].

According to a systematic review of long-term patient satisfaction with cosmetic outcomes [383]:

- patient perception of penile size does not differ greatly from the norm;
- patients approaching puberty have a more negative perception and are more critical about the cosmetic outcomes of surgery;
- patients report high levels of perception of deformity and social embarrassment.

There is a wide range of parameters that are measured to assess outcome after hypospadias surgery in the literature. There is a need for age-specific core outcome set [384].

The majority of identified instruments focused on post-operative cosmetic satisfaction, with only one instrument considering urinary function, and no instruments evaluating sexual function and psychosocial sequelae [385].

### 3.7.7 Summary of evidence and recommendations for the management of hypospadias

Summary of evidence	LE
The suggested age at surgery for primary hypospadias repair is 6-18 (24) months.	3
The therapeutic objectives are to correct the penile curvature, to form a neo-urethra of an adequate size, to bring the new meatus to the tip of the glans, if possible, and to achieve an overall acceptable cosmetic appearance.	4
Androgen stimulation therapy results in increased penile length and glans circumference.	1b
The complication rate is about 10% in distal and 25% in proximal hypospadias one-stage repairs.	3
Higher and variable rates (between 28 and 68%) can occur in two-stage repairs.	2b
Sexual functions are usually well preserved but patients report high levels of perception of deformity and social embarrassment.	

Recommendations	Strength rating
At birth, differentiate isolated hypospadias from disorders of sex development which are mostly associated with cryptorchidism or micropenis.	Strong
Counsel caregivers on functional indications for surgery, aesthetically feasible operative procedures (psychological, cosmetic indications) and possible complications.	Strong
In children diagnosed with proximal hypospadias and a small appearing penis, reduced glans circumference or reduced urethral plate, pre-operative hormonal androgen stimulation treatment is an option and the body of evidence to accentuate its harms and benefits is inadequate.	Weak
For distal hypospadias, offer Duplay-Thiersch urethroplasty, original and modified tubularised incised plate urethroplasty; use the onlay urethroplasty or two-stage procedures in more severe hypospadias. A treatment algorithm is presented (Figure 4). Correct significant (> 30 degrees) curvature of the penis.	Weak
Ensure long-term follow-up to detect urethral stricture, voiding dysfunctions and recurrent penile curvature, ejaculation disorder, and to evaluate patient's satisfaction.	Strong
Use validated objective scoring systems to assist in evaluating the functional and cosmetic outcome.	Strong

## 3.8 Congenital penile curvature

### 3.8.1 Epidemiology, aetiology and pathophysiology

Congenital penile curvature presents penile bending of a normally formed penis due to corporal disproportion. The incidence at birth is 0.6% and congenital penile curvature is caused by asymmetry of the cavernous bodies and an orthotopic meatus [386] because of developmental arrest during embryogenesis [387]. On the other hand, the incidence of clinically significant congenital penile curvature is much lower, because the extent of the curvature and its associated sexual dysfunction varies widely [388]. Most of the cases are ventral deviations (48%), followed by lateral (24%), dorsal (5%), and a combination of ventral and lateral (23%) [389]. Most ventral

curvatures are associated with hypospadias due to chordee or ventral dysplasia of cavernous bodies [390]. Similarly, dorsal curvature is mostly associated with exstrophy/epispadias complex. Congenital penile curvature can decrease sexual quality of life in adults and successful repair can restore patients' psychosocial and sexual wellbeing [391].

Curvature > 30° is considered clinically significant; curvature > 60° may interfere with satisfactory sexual intercourse in adulthood (LE: 4). Minor penile curvature may be the result of ventral penile skin deficiency only and should be distinguished from corporal anomalies. For penile curvature associated with hypospadias or epispadias refer to the relevant chapters.

### 3.8.2 **Diagnostic evaluation**

Penile curvature is frequently not documented until later in childhood since the penis only appears abnormal when erect. Patients are usually concerned with the aesthetic and/or functional aspects of their penis [392]. Besides exact history taking to exclude any possibility of acquired penile curvature (e.g. post-traumatic), a thorough clinical examination is mandatory. In addition, photo documentation of the erect penis clearly showing the curvature from different angles serves as a pre-requisite in pre-operative evaluation [393]. The exact degree of curvature is generally determined at the time of surgery using an artificial erection test.

### 3.8.3 **Management**

The treatment is surgical, starting with an artificial erection to determine the degree of curvature and to check symmetry after the repair [394]. The ultimate goal of any surgical method used to correct the curvature is to achieve corpora of similar size. Various procedures are in use ranging from simple de-gloving and plication procedures, to corporal rotation, use of free dermal or tunica vaginalis grafts, to complete penile disassembly techniques [395, 396]. Reviews comparing the outcome of Nesbit/modified Nesbit procedures [397] to plication procedures [398] were able to demonstrate that while there is a decreased risk of complications and loss of sensation, it remains unclear whether plication techniques can lead to increased risk of recurrence [399, 400]. Altogether these methods include the risk of post-operative shortening of the penis with an average loss of 2.5 cm in stretched penile length depending on the pre-operative degree of curvature and the type of repair used [401-403].

Recently the non-corporotomy technique has been introduced with promising results enabling correction of any degree of ventral curvature with neither shortening of the penis nor the risk of post-operative erectile dysfunction [404].

### 3.8.4 **Summary of evidence and recommendations for the management of congenital penile curvature**

Summary of evidence	LE
Isolated congenital penile curvature is relatively uncommon.	2a
Congenital penile curvature is often associated with hypospadias.	2a
Diagnosis is usually made late in childhood.	2a
The penis only appears abnormal when erect.	1b
Congenital penile curvature can cause aesthetic as well as functional sexual problems.	1b
Congenital penile curvature is treated with surgery.	1b
The goal of surgery is to achieve corpora of similar size.	1b

Recommendations	Strength rating
Ensure that a thorough medical history is taken and a full clinical examination done to rule out associated anomalies in boys presenting with congenital curvature.	Strong
Provide photo documentation of the erect penis from different angles as a prerequisite in the pre-operative evaluation.	Strong
Perform surgery after weighing aesthetic as well as functional implications of the curvature.	Weak
At the beginning as well as at the end of surgery, perform artificial erection tests.	Strong

### 3.9 Varicocele in children and adolescents

#### 3.9.1 *Epidemiology, aetiology and pathophysiology*

Varicocele is defined as an abnormal dilatation of testicular veins in the pampiniformis plexus caused by venous reflux. It is unusual in boys under ten years of age and becomes more frequent at the beginning of puberty. It is found in 14-20% of adolescents, with a similar incidence during adulthood. It appears mostly on the left side (78-93% of cases). Right-sided varicoceles are less common; they are usually noted only when bilateral varicoceles are present and seldom occur as an isolated finding [405-407].

Varicocele develops during accelerated body growth and increased blood flow to the testes, by a mechanism that is not clearly understood. Genetic factors may be present [408, 409]. An anatomic abnormality leading to impaired venous drainage is expressed by the considerable prevalence of the left side condition where the internal spermatic vein drains into the renal vein. Varicocele can induce apoptotic pathways because of heat stress, androgen deprivation and accumulation of toxic materials [410, 411]. In 70% of patients with grade II and III varicocele, left testicular volume loss was found. Abnormal reproductive hormonal levels (increased serum levels of FSH and LH, and decreased levels of inhibin B) and semen quality were reported in varicocele patients and were directly related to varicocele severity [412-414]. Severe histological damage is found in 20% of adolescents affected, with abnormal findings in 46% of affected adolescents. Histological findings are similar in children or adolescents and in infertile men. In about 20% of adolescents with varicocele, fertility problems will arise [415]. The adverse influence of varicocele increases with time.

#### 3.9.2 *Classification systems*

Varicocele is classified into 3 grades [416]:

- Grade I - Valsalva positive (palpable at Valsalva manoeuvre only);
- Grade II - palpable (palpable without the Valsalva manoeuvre);
- Grade III - visible (visible at distance).

#### 3.9.3 *Diagnostic evaluation*

Varicocele, being mostly asymptomatic, is generally noticed by the patient or caregivers, or discovered by the paediatrician at a routine visit. The diagnosis depends upon the clinical finding of a collection of dilated and tortuous veins in the upright posture; the veins are more pronounced when the patient performs the Valsalva manoeuvre. Clinical examination should include evaluation of the size of both testicles to detect a smaller testis.

In pre-pubertal boys and in isolated right varicocele, a renal US should be routinely added in order to rule out a secondary varicocele due to any retroperitoneal tumour extending into the renal vein and inferior vena cava.

Testicular volume is measured by US examination or by orchidometer. In adolescents, a testis that is smaller by > 2 mL or 20% compared to the other testis is considered to be hypotrophic [417]. Venous reflux into the plexus pampiniformis is diagnosed using Doppler US colour flow mapping in the supine and upright position and with Valsalva manoeuvre [418]. Venous reflux detected on US only is classified as subclinical varicocele. Severity of reflux on Doppler US was shown to correlate with testicular damage [413].

Sperm analysis in principle allows assessment of testicular function, but the World Health Organization (WHO) parameters are not intended for pre-pubertal patients, and spontaneous improvements of abnormal sperm analyses has been observed in pre-pubertal patients [419]. Moreover, sperm analysis encounters cultural/ethical barriers in children [420]. Therefore, semen analysis is not widely used and it is generally recommended only in older adolescents.

In order to assess testicular injury in adolescents with varicocele, supranormal FSH and LH responses to the luteinising hormone-releasing hormone (LHRH) stimulation test are considered reliable, because histopathological testicular changes have been found in these patients [421, 422].

#### 3.9.4 *Management*

There is no evidence that treatment of varicocele at paediatric age will offer a better andrological outcome than an operation performed later and earlier diagnosis should not convey a more pressing need to intervene [423, 424]. Beneficial effect of pubertal screening and treatment for varicocele regarding the preservation of fertility and final chance of paternity is controversial [425-427]. The recommended indication criteria for correction for varicocele in children and adolescents are [406]:

- varicocele associated with a small testis (this should be confirmed on two subsequent visits performed six months apart) as asynchronous testicular growth can account for a temporary asymmetry also in a considerable number of healthy adolescents [428].

Additional scenarios where varicocele treatment can be considered on a case by case basis include:

- symptomatic varicocele [427]. Pain is present in 2-10% of varicoceles. The association between varicocele and pain is unclear and patients should be informed that pain can persist after varicocelectomy in 20% of cases [429];

- additional testicular condition affecting fertility such as a contralateral testicular condition;
- bilateral palpable varicocele;
- pathological sperm quality (in older adolescents);
- cosmetic reasons related to their scrotal swelling.

A reduced total testicular volume (left + right) in comparison with normal testes is a promising indication criterion, once the normal values are available [414, 423]. Repair of a large varicocele, causing physical or psychological discomfort, may also be considered. Other varicoceles should be followed-up until a reliable sperm analysis can be performed.

#### 3.9.4.1 *Surgical management*

Surgical intervention is based on ligation or occlusion of the internal spermatic veins.

Ligation is performed at different levels:

- inguinal (or subinguinal) microsurgical ligation;
- suprainguinal ligation, using open or laparoscopic techniques [430-433].

The advantage of the former is the lower invasiveness of the procedure, while the advantage of the latter is a considerably lower number of veins to be ligated and safety of the incidental division of the internal spermatic artery at the suprainguinal level.

For surgical ligation, some form of optical magnification (microscopic or laparoscopic) should be used because the internal spermatic artery is 0.5 mm in diameter at the level of the internal ring [430, 432]. In suprainguinal approach, an artery sparing varicocelectomy may not offer any advantage in regards to catch-up growth and is associated with a higher incidence of recurrent varicocele [434, 435].

Lymphatic-sparing varicocelectomy is preferred to prevent hydrocele formation and testicular hypertrophy development and to achieve a better testicular function according to the LHRH stimulation test [430, 431, 436, 437]. The methods of choice are subinguinal or inguinal microsurgical (microscopic) repairs, or suprainguinal open or laparoscopic lymphatic-sparing repairs [430, 432, 438, 439]. In the later, intrascrotal/ intratesticular injection of isosulphan blue was recommended to visualise the lymphatic vessels [440, 441]

#### 3.9.4.2 *Radiological management*

Angiographic occlusion of the internal spermatic veins also meets the requirements of lymphatic sparing repair. It is based on retrograde or antegrade sclerotisation of the internal spermatic veins [442, 443]. However, although this method is less invasive and may not require general anaesthesia, it is associated with radiation burden, which is less controllable in the antegrade technique [406, 442, 443].

There is low to moderate level of evidence that radiological or surgical treatment of adolescent varicocele is associated with improved testicular size/growth and sperm concentration. Several authors reported testicular catch-up growth after varicocelectomy in adolescents [444, 445]. An average proportion of catch-up growth of 76.4% (range: 52.6-93.8%) has been found according to a meta-analysis [446] (LE: 2a). However, this may partly be attributable to testicular oedema associated with the division of lymphatic vessels [436]. Improvement in sperm parameters has been demonstrated after adolescent varicocelectomy [421, 447-449]. In one study, microsurgical varicocele repair in adolescents with varicocele significantly increases paternity rates and decreases time to conception post-operatively, but this needs to be confirmed in other series. The ultimate effects on fertility and paternity rates are not known [450].

The Panel conducted a systematic review and meta-analysis regarding the treatment of varicocele in children and adolescents [451]. Of 1,550 articles identified, 98 articles including 16,130 patients were eligible for inclusion (12 RCTs, 47 NRSs and 39 case series). The key findings are summarised in the following paragraphs:

The meta-analysis of the twelve RCTs revealed that varicocele treatment improved testicular volume (mean difference 1.52 ml, 95% CI 0.73-2.31) and increased total sperm concentration (mean difference 25.54, 95% CI 12.84-38.25) when compared with observation. Lymphatic sparing surgery significantly decreased hydrocele rates ( $p=0.02$ ) and the OR was 0.08 (95% CI 0.01, 0.67). Due to the lack of RCTs, it was not possible to identify a surgical technique as being superior to the others. It remains unclear whether open surgery or laparoscopy is more successful for varicocele treatment (OR ranged from 0.13 to 2.84).

The success rates of the treatment (disappearance of varicocele) were between 85.1% and 100% whereas the complication rates were between 0% and 29% in the included studies. The most common complication reported was hydrocele. Resolution of pain after treatment was more than 90% in the reported series.

The major reason for varicocele recurrence is the persistence of branched spermatic veins that were not ligated during the initial repair. Treatment of recurrence is warranted only in those patients with clinical recurrence that show no improvement in testicular asymmetry or remain symptomatic. Treatment of recurrence can be surgical or via embolisation. Generally, a technique different from the primary repair is recommended to operate in a virgin field [452].

In conclusion, moderate evidence exists on the benefits of varicocele treatment in children and adolescents in terms of testicular volume and sperm concentration. Current evidence does not demonstrate superiority of any of the surgical/interventional techniques regarding treatment success. Lymphatic sparing surgery significantly decreases hydrocele formation. Long-term outcomes, including paternity and fertility, still remain unknown.

In conclusion, moderate evidence exists on the benefits of varicocele treatment in children and adolescents in terms of testicular volume and sperm concentration. Current evidence does not demonstrate superiority of any of the surgical/interventional techniques regarding treatment success. Lymphatic sparing surgery significantly decreases hydrocele formation. Long-term outcomes, including paternity and fertility, still remain unknown.

### 3.9.5 Summary of evidence and recommendations for the management of varicocele

Summary of evidence	LE
Varicocele becomes more frequent at the onset of puberty and is found in 14-20% of adolescents.	3
Testicular problems are reported in up to 20% of patients, but the final effect on paternity is unknown.	3
After adolescent varicocelectomy, left testis catch-up growth and improvement in sperm parameters has been demonstrated.	1a
There is no evidence that treatment of varicocele at paediatric age will offer a better andrological outcome than an operation performed later.	2
Division of testicular lymphatics leads to hydrocele in up to 40% and to testicular hypertrophy.	
Lymphatic sparing surgery significantly decrease hydrocele rates.	

Recommendations	Strength rating
Examine varicocele in the standing position and classify into three grades.	Strong
Use scrotal ultrasound to evaluate testicular volume and to detect venous reflux in the supine and upright position and during Valsalva maneuver.	Strong
In all pre-pubertal boys with a varicocele and in all isolated right varicoceles, perform standard abdominal ultrasound to rule out a retroperitoneal mass.	Strong
Inform caregivers and patients and offer surgery for varicocele associated with a persistent small testis (size difference of > 2 mL or 20%).	Strong
Varicocele treatment can be also considered under the following circumstances: <ul style="list-style-type: none"> <li>• symptomatic varicocele;</li> <li>• additional testicular condition affecting fertility such as a contralateral testicular condition;</li> <li>• bilateral palpable varicocele;</li> <li>• pathological sperm quality (in older adolescents);</li> <li>• cosmetic reasons related to their scrotal swelling.</li> </ul>	Weak
Use some form of optical magnification (microscopic or laparoscopic magnification) for surgical ligation.	Strong
Use lymphatic-sparing varicocelectomy to prevent hydrocele formation.	Strong

## 3.10 Urinary tract infections in children

### 3.10.1 Epidemiology, aetiology and pathophysiology

Urinary tract infections (UTIs) represent the most common bacterial infections in children [453-455]. There are several classification systems used to define a UTI. In neonates, the symptoms differ in many aspects from those in infants and children. The prevalence is higher; there is a male predominance; infections caused by other organisms than *Escherichia coli* are more frequent; and there is a higher risk of urosepsis [456, 457].

In children presenting with urinary symptoms a pooled prevalence of UTI was 7.8% (CI: 6.6-8.9) [456]. The incidence varies depending on age and sex. One meta-analysis showed that in children presenting

with fever in the first three months of life UTIs were present in 7.5% of girls, 2.4% (CI: 1.4-3.5) of circumcised boys, and 20.1% (CI: 16.8-23.4) of uncircumcised boys [456]. The incidence for boys is highest during the first six months of life (5.3%) and decreases with age to around 2% for the ages 0-6 years. In girls, UTIs are less common during the first six months of life (2%) and incidence increases with age to around 11% for the ages 0-6 years [458].

Associated risk factors for recurrent UTIs include bladder and bowel dysfunction (BBD), vesicoureteral reflux (VUR) and obesity [459-461]. In older children a delay in treatment is more often seen than in younger infants [462]. These risk factors in combination with delay in treatment have been associated with renal scarring [463]. Recurrent febrile UTIs, especially in combination with high-grade VUR, lead to renal scarring [464, 465]. Each new febrile UTI increases the risk of renal scarring with an incidence of renal scarring after the first UTI, of 2.8% (CI:1.2-5.8), 25.7% (CI:12.5-43.3) after the second infection and up to 28.6% (CI:8.4-58.1) after 3 or more febrile UTIs [465].

The leading causative organism for UTIs has been *E. coli*, but other bacteriae have been rising in prevalence. In a large European study *E. Coli* was found in less than 50% of urine cultures. *Klebsiella pneumoniae*, *Enterobacter spp.*, *Enterococcus spp.*, *Pseudomonas spp.*, *Proteus spp.* and *Candida spp.* are more frequent in nosocomial infections than in community-acquired UTIs, even though, their prevalence has increased outside of the hospital setting [466]. Neonatal UTI is frequently complicated by bacteraemia. In a retrospective study, 12.4% of blood cultures from neonates admitted for UTI were positive for bacteraemia [467], however, it is less frequent in community-acquired than in nosocomial UTI [467, 468].

### 3.10.2 **Classification systems**

There are five widely used classification systems according to; site, severity, episode, symptoms and complicating factors. For acute treatment, site and severity are most important.

#### 3.10.2.1 *Classification according to site*

Lower urinary tract infection (cystitis) is an inflammatory condition of the urinary bladder mucosa with general signs and symptoms including infection, dysuria, frequency, urgency, malodorous urine, enuresis, haematuria, and suprapubic pain.

Upper urinary tract infection (pyelonephritis) is a diffuse pyogenic infection of the renal pelvis and parenchyma. The onset of pyelonephritis is generally abrupt. Clinical signs and symptoms include fever (> 38°C), chills, costovertebral angle or flank pain, and tenderness.

#### 3.10.2.2 *Classification according to severity*

In a lower UTI, children may have only mild pyrexia; are able to take fluids and oral medication; are only slightly or not dehydrated; and have a good expected level of compliance. When a low level of compliance is expected, such children should be managed as those with severe UTI. In severe UTI, infection is related to the presence of fever of > 39°C, the feeling of being ill, persistent vomiting, and moderate or severe dehydration. Most severe UTIs are upper urinary tract infections.

#### 3.10.2.3 *Classification according to episode first/persistent/recurrent/breakthrough*

The first UTI may be a sign of anatomical anomalies. Anatomical evaluation is recommended (see below). Recurrent infection can be divided into unresolved and persistent infection.

In unresolved infection, initial therapy is inadequate for elimination of bacterial growth in the urinary tract (inadequate therapy, inadequate antimicrobial urinary concentration [poor renal concentration/gastrointestinal malabsorption], and infection involving multiple organisms with differing antimicrobial susceptibilities).

Persistent infection is caused by re-emergence of bacteria from a site within the urinary tract coming from a nidus for persistent infection that cannot be eradicated (e.g. infected stones, non-functioning or poorly functioning kidneys/renal segments, ureteral stumps after nephrectomy, necrotic papillae, urachal cyst, urethral diverticulum, peri-urethral gland, vesicointestinal, rectourethral or vesicovaginal fistulas). The same pathogen is identified in recurrent infections, but episodes of sterile urine may occur during and shortly following antimicrobial treatment.

A breakthrough infection in patients under antibacterial prophylaxis is usually caused by resistant bacteria, parental non-compliance and/or severe urogenital anomalies [469, 470].

In re-infection, each episode can be caused by a variety of new infecting organisms, in contrast to bacterial persistence in which the same infecting organism is always isolated. However, the most common general pathogenic species is *E. coli*, which occurs in many different serotypes. Therefore, recurrent *E. coli* UTI does not equate to infection with the same organism.

#### 3.10.2.4 *Classification according to symptoms*

Children may have typical or atypical symptoms regarding a UTI. In neonates and infants the most common symptoms are fever, vomiting, lethargy and/or irritability. Infants and children may have non-specific signs such as poor appetite, failure to thrive, lethargy, irritability, vomiting or diarrhoea. Toilet trained children may report cystitis symptoms along with fever/flank pain.

Asymptomatic bacteriuria indicates attenuation of uropathogenic bacteria by the host, or colonisation of the bladder by non-virulent bacteria that are incapable of activating a symptomatic response (no leukocyturia, no symptoms). Asymptomatic UTI includes leukocyturia but no other symptoms.

Symptomatic UTI, includes irritative voiding symptoms, suprapubic pain (cystitis), fever and malaise (pyelonephritis). Cystitis may represent early recognition of an infection destined to become pyelonephritis, or bacterial growth controlled by a balance of virulence and host response.

#### 3.10.2.5 *Classification according to complicating factors*

In uncomplicated UTI, infection occurs in a patient with a morphologically and functionally normal upper and lower urinary tract, normal renal function and competent immune system. This category includes mostly isolated or recurrent bacterial cystitis and is usually associated with a narrow spectrum of infecting pathogens that are easily eradicated by a short course of oral antimicrobial agents. Patients can be managed on an outpatient basis, with an emphasis on documenting resolution of bacteriuria, followed by elective evaluation for potential anatomical or functional abnormalities of the urinary tract [471].

A complicated UTI occurs in children with known mechanical or functional pathology of the urinary tract. Mechanical obstruction is commonly due to the presence of posterior urethral valves, strictures or stones, independent of their location. Functional obstruction often results from lower urinary tract dysfunction (LUTD) of either neurogenic or non-neurogenic origin and dilating VUR. Patients with complicated UTI require hospitalisation and parenteral antibiotics. Prompt anatomical evaluation of the urinary tract is critical to exclude the presence of significant abnormalities [472]. If mechanical or functional abnormalities are present, adequate drainage of the infected urinary tract is necessary.

### 3.10.3 **Diagnostic evaluation**

#### 3.10.3.1 *Medical history*

Medical history includes the question of a primary (first) or secondary (recurring) infection; possible malformations of the urinary tract (e.g. pre- or post-natal US screening); prior operation; family history; and, whether there is constipation or presence of lower urinary tract symptoms (LUTS).

#### 3.10.3.2 *Clinical signs and symptoms*

Neonates with severe UTI can present with non-specific symptoms (failure to thrive, jaundice, hyperexcitability) and without fever. In neonates it is important to rule out a co-existing meningitis [473]. Urinary tract infection is the cause of fever in 4.1-7.5% of children who present to a paediatric clinic [474, 475]. Septic shock is unusual, even with very high fever. Signs of a UTI may be vague and unspecific in small children, but later on, when they are more than two years old, frequent voiding, dysuria and suprapubic, abdominal or lumbar pain can be detected.

#### 3.10.3.3 *Physical examination*

Physical examination includes a general examination of the throat, lymph nodes, abdomen (constipation, palpable and painful kidney, or palpable bladder), flank, the back (stigmata of spina bifida or sacral agenesis), genitalia (phimosis, labial adhesion, vulvitis, epididymo-orchitis), measurement of body weight and temperature.

#### 3.10.3.4 *Urine sampling, analysis and culture*

Urine sampling has to be performed before any antimicrobial agent is administered. The technique for obtaining urine for urinalysis as well as culture affects the rate of contamination, which influences interpretation of the results. Especially in early infancy, it can be challenging and depends on the mode of urine sampling [476].

##### 3.10.3.4.1 *Urine sampling*

Urine must be collected under defined conditions and investigated as soon as possible to confirm or exclude UTI, especially in children with fever. In neonates, infants and non-toilet-trained children, there are four main methods with varying contamination rates and invasiveness to obtain urine:

(1) Plastic bag attached to the cleaned genitalia: Although this technique is most often used in daily practice, contamination rates are high with around 50-60% [477]. It is helpful when the culture results are negative. Also, if the dipstick is negative for both leukocyte esterase and nitrite, or microscopic analysis is negative for both pyuria and bacteriuria, UTI can be excluded without the need for confirmatory culture [478].



(2) Clean-catch urine (CCU) collection: The infant is placed in the lap of a caregiver or member of the nursing staff, who holds a sterile foil bowl underneath the infant's genitalia. The infant is offered oral fluids and urine collection is awaited [479]. Suprapubic tapping alternated with paravertebral lumbar massage can stimulate spontaneous voiding [477, 480]. There seems to be a good correlation between the results of urine culture obtained by this method and suprapubic aspiration (SPA), with a false-positive rate of 5% and false-negative rate of 12% [479, 481]; however, the contamination rate is higher for CCU with up to 26% compared to catheterisation 10% and SPA 1% [477, 482]. In one prospective cohort study in infants below the age of six months, the success rate was 49% and the contamination rate 16% with some differences in the culture results between those obtained by CCU and those by more invasive methods [483].

(3) Transurethral bladder catheterisation: is the fastest and safest method to obtain a reliable urine sample for microscopic and bacteriological evaluation to rule out or to document a UTI in non-toilet trained infants and children.

(4) Suprapubic bladder aspiration: This is the most invasive but also the most sensitive method to obtain an uncontaminated urine sample in this age group [484, 485]. For suprapubic puncture ultrasound imaging should be performed to assess bladder filling. A two-step procedure where the CCU is screened and a catheter or SPA confirmation of the positive screens is used can lead to a reduction in invasive procedures [477, 482]. In older, toilet-trained children who can void on command, after carefully retracting the foreskin and cleaning the glans penis in boys and spreading the labia and cleaning the peri-urethral area in girls, the use of clean catch, especially midstream urine, could be an acceptable technique for obtaining urine. After cleaning the urethral meatus and perineum with gauze and liquid soap twice, the risk of contamination was reduced from 23.9% (41/171) to 7.8% (14/171) in a randomised trial [486].

#### 3.10.3.4.2 Urinalysis

There are three methods that are commonly used for urinalysis:

(1) Dipsticks: These are appealing because they provide rapid results, do not require microscopy, and are ready to use. Leukocyte esterase (as a surrogate marker for pyuria) and nitrite (which is converted from dietary nitrates by most Gram-negative enteric bacteria in the urine) are the most frequent markers, and are usually combined in a dipstick test. The conversion of dietary nitrates to nitrites by bacteria takes approximately four hours in the bladder [481, 487]. Using only nitrate sticks to screen febrile children < 2 years of age has a too low sensitivity and relevant UTIs can be missed. However, the specificity is high for children at any age [488, 489]. In febrile infants < 90 days old urine dipstick tests using CCU samples can be used for screening for a UTI when nitrites and leukocyte esterase combined are used with a sensitivity of 86% and a specificity of 80% [490].

(2) Microscopy: This is the standard method of assessing pyuria after centrifugation of the urine with a threshold of five white blood cells (WBCs) per high-power field (25 WBC/ $\mu$ L) [491]. In uncentrifuged urine, > 10 WBC/ $\mu$ L has been demonstrated to be sensitive for UTI [492] and this could perform well in clinical situations [493]. However, this is rarely done in an outpatient setting. No significant differences were found between dipsticks and microscopy testing for UTI [489]. A meta-analysis showed, that only microscopy with Gram staining has a higher sensitivity compared to dipsticks [494].

(3) Flow imaging analysis technology: This is being used increasingly to classify particles in uncentrifuged urine specimens [495]. The numbers of WBCs, squamous epithelial cells and red cells correlate well with those found by manual methods [481]. Flow cytometry-based bacterial and leukocyte count analysis when using a cut-off value of 250 bacteria/ $\mu$ L in the presence of leukocyturia has a sensitivity of 0.97 and specificity of 0.91 for diagnosing UTI [496].

#### 3.10.3.4.3 Urine culture


After negative results for dipstick, microscopic or automated urinalysis, urine culture is generally not necessary, especially if there is an alternative source of fever. If the dipstick result is positive, confirmation by urine culture is strongly recommended.

It is unclear what represents a significant UTI. In patients with a severe UTI,  $\geq 105$  cfu/mL can be expected. However, the count can vary and be related to the method of specimen collection, diuresis, and time and temperature of storage until cultivation occurs [457]. Clean-catch urine, midstream and catheterisation urine cultures can be considered positive as 10<sup>3</sup> - 10<sup>4</sup> cfu/mL in a monoculture, and any counts obtained after SPA should be considered as significant. Mixed cultures are indicative of contamination. In febrile children < 4 months of age a cut-off value of 10<sup>3</sup> cfu/mL can be used when clinical and laboratory findings match and a correct sampling method has been used [497].

A negative culture with the presence of pyuria may be due to incomplete antibiotic treatment, urolithiasis, or foreign bodies in the urinary tract, and infections caused by *Mycobacterium tuberculosis* or *Chlamydia trachomatis*.

A flowchart was developed as guidance during the basic diagnostic evaluation and subsequent management of febrile children with clinical symptoms of UTI, Figure 5.

**Figure 5: Diagnostic evaluation and subsequent management of a febrile child with clinical symptoms of UTI**



CRP = C-reactive protein; AB = antibiotic.

### 3.10.3.5 Imaging

#### 3.10.3.5.1 Ultrasound

Renal and bladder US within 24 hours is advised in infants with febrile UTI to exclude obstruction of the upper and lower urinary tract. Abnormal results are found in 15% of cases, and 1-2% have abnormalities that require prompt action (e.g., additional evaluation, referral or surgery) [478]. When a renal US is performed in all children presenting with a UTI, 7% will have an abnormal US warranting further investigations [498]. The sensitivity to detect high-grade VUR with US was found to be 0.59 (CI: 0.45-0.72) with a specificity of 0.79 (CI: 0.65-0.87) [499]. Renal US should be performed before and after voiding. Post-void residual (PVR) urine should be measured in toilet-trained children to exclude voiding abnormalities as a cause of UTI. Elevated PVR urine volume predicts recurrence of UTIs in toilet-trained children [500]. When peri-renal or psoas abscesses or renal masses are seen on US, it is important to consider xanthogranulomatous pyelonephritis, and subsequent CT imaging is proposed [501].

#### 3.10.3.5.2 Radionuclide scanning/MRI

Changes in dimercaptosuccinic acid (DMSA) clearance during acute UTI indicate pyelonephritis or parenchymal damage, correlated with the presence of dilating reflux and the risk of further pyelonephritis episodes, breakthrough infections [502] and future renal scarring. In the acute phase of a febrile UTI (up to four to six weeks), DMSA-scan can demonstrate pyelonephritis by perfusion defects. Renal scars can be detected after three to six months [503]. Diffusion-weighted MRI has shown to accurately diagnose acute pyelonephritis and reveal late renal scars and could be an alternative to DMSA; therefore, avoiding radion burden [504]. The average effective radiation dose of a single DMSA scan was 2.84 (1-12) mSv in one study [505]. These findings are different in neonates. After the first symptomatic, community-acquired UTI, the majority of renal units with


VUR grade III or higher had normal early DMSA scanning [506]. The sensitivity of the DMSA scan to detect VUR is 0.75 (CI: 0.67-0.81) with a specificity of 0.48 (CI: 0.38-0.57), and a negative DMSA scan resulting in a very low probability of high-grade VUR [507].

### 3.10.3.5.3 Voiding cystourethrography/urosonography

The optimum method to exclude or confirm VUR is VCUG. The timing of VCUG does not influence the presence or severity of VUR [508]. Performance of early VCUG in patients with proven sterile urine does not cause any significant morbidity [509]. Using harmonic voiding urosonography may be an alternative to the standard VCUG avoiding radiation [510]. Visualisation of the urethra may be difficult with this technique.

It is important to diagnose high-grade VUR after the first UTI since this is an important risk for renal scarring. On the other hand, physicians want to avoid unnecessary VCUG investigations at the same time, given its invasive character and radiation burden [498, 511]. Various studies have investigated the risk factors for high-grade VUR and a top down approach is feasible. The most important risk factors for high-grade VUR and subsequent renal scarring are: abnormal renal US, high fever UTI and non-E. Coli infections. Different top down strategies with selective VCUG investigations have been proposed [512-516]. Based on these studies we recommend the following updated diagnostic strategy (see Figure 6).

**Figure 6: Diagnosis strategy for first febrile UTI**



UTI = urinary tract infection; VUR = vesicoureteral reflux; i.v. = intravenous; BBD = bladder and bowel dysfunction.

## 3.10.4 Management

### 3.10.4.1 Administration route of antibacterial therapy

The choice between oral and parenteral therapy should be based on patient age; clinical suspicion of urosepsis; illness severity; refusal of fluids, food and/or oral medication; vomiting; diarrhoea; non-compliance; and complicated pyelonephritis (e.g. urinary obstruction). As a result of the increased incidence of urosepsis and severe pyelonephritis in newborns and infants aged less than two months, parenteral antibiotic therapy is recommended. Electrolyte disorders with life-threatening hyponatraemia and hyperkalaemia based on pseudohypoaldosteronism can occur in these cases [517, 518].

The choice of agent is also based on local antimicrobial sensitivity patterns, and should later be adjusted according to sensitivity-testing of the isolated uropathogen [481]. Not all available antibiotics are approved by national health authorities, especially in infancy. When recent urinary cultures are available use these sensitivity patterns in the choice for treatment. In children who require intravenous treatment tobramycin or gentamicin is recommended if there is normal kidney function. When abnormal kidney function is suspected, ceftriaxon or cefotaxime are alternative treatment options. In children who can receive oral treatment without any known resistant urinary cultures, cefixime or amoxicillin-clavulanate are the empirical treatment options [519]. Some studies have demonstrated that once daily parenteral administration of gentamicin or ceftriaxone in a day treatment centre is safe, effective and cost-effective in children with UTI [520-522]. Delaying treatment in children with a febrile UTI for more than 48-72 hours increases the risk of renal scars [463, 507].

#### 3.10.4.2 Duration of therapy

Prompt adequate treatment of UTI can prevent the spread of infection and renal scarring. In newborns and young infants with a febrile UTI, up to 20% may have a positive blood culture [467, 472]. Children with bacteremia did not show significant clinical differences with non-bacteremic infants, but did receive longer parental treatment [523]. In late infancy, there are no differences between strategies regarding the incidence of parenchymal scars, as diagnosed with DMSA scan [524]. Outcomes of short courses (one to three days) are inferior to seven to fourteen-day courses [481]. However, a simple cystitis can be treated with three to five days of antibiotics [519]. No significant difference in recurrent UTIs and rehospitalisation was found between seven day parental treatment and longer regimens for bacteremic UTI in younger infants [525]. In young infants a short course of parental treatment with early conversion to oral antibiotics may be considered. The use of exclusively oral therapy with a third-generation cephalosporin (e.g. cefixime or ceftibuten) has been demonstrated to be equivalent to the usual two to four days intravenous therapy followed by oral treatment [526-529]. Similar data have been shown for amoxicillin-clavulanate [530]. If ambulatory therapy is chosen, adequate surveillance, medical supervision and, if necessary, adjustment of therapy must be guaranteed. In the initial phase of therapy, a close ambulant contact to the family is advised [531].

In complicated UTI, uropathogens other than *E. coli*, such as *Proteus mirabilis*, *Klebsiella* spp., *Pseudomonas aeruginosa*, enterococci and staphylococci are more often the causative pathogens [472]. A temporary urinary diversion (transurethral catheter, suprapubic cystostomy, percutaneous nephrostomy or ureteral stenting) might be required in case of failure of conservative treatment in obstructive uropathy. Children with acute focal bacterial nephritis often present without pyuria and significant bacteriuria. For the majority of children, the pathogenesis is related to ascending infection due to pre-existing uropathy, especially VUR or urinary obstruction. Initial management consists of broad-spectrum antibiotics with good tissue penetration. A treatment regimen of a total of three weeks with initial intravenous and subsequently oral therapy tailored to the pathogen identified in culture is recommended [532].

#### 3.10.4.3 Antimicrobial agents

There is a great difference in the prevalence of antibiotic resistance of uropathogenic *E. coli* in different countries, with increased high resistance patterns in countries outside of the Organisation for Economic Co-operation and Development (OECD) [533]. There are upcoming reports of UTIs caused by extended spectrum  $\beta$ -lactamase-producing enterobacteriaceae (ESBL) in children, with pooled numbers of UTI caused by ESBL producing bacteria of around 14% [534]. Within OECD countries the prevalence of resistance was 53% for ampicillin, 24% for trimethoprim, 8% for co-amoxiclav, 2% for ciproxin and 1% for nitrofurantoin [533]. Several risk factors and determinants for UTIs caused by ESBL and non-*E. coli* bacteriae have been identified: history of infection, recent hospitalisation, short-term exposure to antibiotics, and prophylaxis [533, 535, 536]. Overall, oral nitrofurantoin seems to be a good empirical choice in the treatment of cystitis [537].

The choice of antibiotics should be guided by good antibiotic stewardship. It is important to be aware of the local resistance patterns. These are variable between countries and moreover between hospitals. Local antibiotic protocols and web-based recommendations can guide the choice for type of antibiotic therapy. The individual patient's previous urine cultures should also be taken into account in this decision. The daily dosage of antibiotics is depended on the age, weight of the child as well as on renal and liver function.

#### 3.10.4.4 Preventative measures

Recurrent UTIs are problematic because the symptoms are bothersome to children and recurrent febrile UTIs will also result in renal scarring [465]. Therefore, it is important to prevent the incidence of recurrent UTIs.

##### 3.10.4.4.1 Chemoprophylaxis

Chemoprophylaxis is commonly used to prevent UTIs in children. However, with the increasing bacterial resistance numbers, it should be carefully considered which patients should receive antibacterial prophylaxis. The evidence for the use of antibacterial prophylaxis has been conflicting. Its use causes a reduction of the

number of recurrent symptomatic UTIs, but long-term use of antibacterial prophylaxis has also been associated with increased microbial resistance [469, 538]. Its use did not reduce newly acquired renal damage in children with first or second UTI [538]. However, when used in patients with anatomic abnormalities of the urinary system a reduction in UTIs and subsequent renal scarring was shown [469, 538]. In children with BBD and VUR, a benefit was seen in the reduction of recurrent UTI with the use of antimicrobial prophylaxis [539, 540] (see also Chapter 3.15 on VUR). For the specific group of patients with incomplete bladder emptying with properly performed clean intermittent catheterisation but still suffering from recurrent UTIs the intravesical application of gentamycin has proven to be effective [541].

**Table 1: Drugs for antibacterial prophylaxis\***

Substance	Prophylactic dosage (mg/kg bw/d)	Limitations in neonates and infants
Trimethoprim**	2	Not recommended under 6 weeks of age
Trimethoprim Sulfamethoxazole	1-2 10-15	Not recommended under two months of age
Sulfamethoxazole	1-2	Until three months of age
Nitrofurantoin**	1-2	Not recommended under two months of age
Cefaclor	10	No age limitations
Cefixim	2	Preterms and newborns

\* Reproduced with permission from the International Consultation on Urological Diseases (ICUD), International Consultation on Urogenital Infections, 2009. Copyright© by the European Association of Urology [542].

\*\* Substances of first choice are nitrofurantoin and trimethoprim. In exceptional cases, oral cephalosporin can be used.

#### 3.10.4.4.2 Dietary supplements

Cranberry, mostly as juice, has been shown to prevent UTIs in healthy children, while in children with urogenital abnormalities, cranberries appear to be just as effective as antibiotic prophylaxis [543]. The results for probiotics are somewhat more conflicting, with one systematic review not ruling out any effect [335] and a RCT showing promising results in children with normal urogenital anatomy [544]. A meta-analysis could not demonstrate a beneficial effect, only as an adjuvant to antibiotic prophylaxis [545].

Other supplements of interest were Vitamin A, which showed promising results in preventing renal scarring in children with acute pyelonephritis [546, 547]. The use of Vitamin E could possibly improve the symptoms of UTI [548]. More studies into these supplements are warranted.

#### 3.10.4.4.3 Preputium

A risk reduction of recurrent UTI regarding the preputium has been shown in two studies. When a physiologic phimosis is present in boys with a UTI the use of steroid cream significantly reduced recurrent UTIs [41]. In boys with recurrent UTIs and hydronephrosis present, ten boys would need to be circumcised to prevent one UTI [39].

#### 3.10.4.4.4 Bladder and bowel dysfunction

Bladder and bowel dysfunction is a risk factor for which each child with UTI should be screened upon presentation [460]. Normalisation of micturition disorders or bladder overactivity is important to lower the rate of UTI recurrence. If there are signs of BBD at infection-free intervals, further diagnosis and effective treatment are strongly recommended [540]. Treatment of constipation leads to a decrease in UTI recurrence and a multidisciplinary approach is recommended [460, 539, 540]. Therefore, exclusion of BBD is strongly recommended in any toilet-trained child with febrile and/or recurrent UTI, and it should be treated (For treatment see chapter 3.11 on LUTS).

#### 3.10.4.5 Monitoring of UTI

With successful treatment, urine usually becomes sterile after 24 hours, and leukocyturia normally disappears within three to four days. Normalisation of body temperature can be expected within 24-48 hours after the start of therapy in 90% of cases. In patients with prolonged fever and failing recovery, treatment-resistant uropathogens or the presence of congenital uropathy or acute urinary obstruction should be considered. Repeated US examination is recommended in these cases.

Procalcitonin (among other laboratory inflammatory parameters such as C-reactive protein and leukocyte count) can be used as reliable serum marker for early prediction of renal parenchymal inflammation [549]. A cut-off value of serum procalcitonin of 1.0 ng/mL has been shown to be predictive of acute

pyelonephritis in young children [550]. In patients with febrile UTI, serum electrolytes and blood cell counts should be followed up.

### 3.10.5 Summary of evidence and recommendations for the management of UTI in children

Summary of evidence	LE
Urinary tract infection represents the most common bacterial infection in children less than 2 years of age. The incidence varies depending on age and sex.	1b
Classifications are made according to the site, episode, severity, symptoms and complicating factors. For acute treatment, site and severity are most important.	2b
The number of colony forming units (cfu) in the urine culture can vary, however, any colony count of one specimen indicates a high suspicion for UTI.	2b
Due to increasing resistance numbers good antibiotic stewardship should guide the choice of antibiotics, taking into account local resistance patterns, old urine cultures (when available) and clinical parameters.	2a
Preventive measures against recurrent UTIs include: chemoprophylaxis (oral and intravesical), cranberries, probiotics and Vitamin A and E.	2a
Urinalysis by dipstick yields rapid results, but it should be used with caution. Microscopic investigation is the standard method of assessing pyuria after centrifugation.	2a
During acute UTI both DMSA and diffusion-weighted MRI can confirm pyelonephritis or parenchymal damage.	2a

Recommendations	LE	Strength rating
Take a medical history, assess clinical signs and symptoms and perform a physical examination to diagnose children suspected of having a urinary tract infection (UTI).	3	Strong
Exclude bladder- and bowel dysfunction in any toilet-trained child with febrile and/or recurrent UTI.	3	Strong
Clean catch urine can be used for screening for UTI. Bladder catheterisation and suprapubic bladder aspiration to collect urine can be used for urine cultures.	2a	Strong
Do not use plastic bags for urine sampling in non-toilet-trained children since it has a high risk of false-positive results.	2a	Strong
Midstream urine is an acceptable technique for toilet-trained children.	2a	Strong
The choice between oral and parenteral therapy should be based on patient age; clinical suspicion of urosepsis; illness severity; refusal of fluids, food and/or oral medication; vomiting; diarrhoea; non-compliance; complicated pyelonephritis.	2a	Strong
Treat febrile UTIs with four to seven day courses of oral or parenteral therapy.	1b	Strong
Treat complicated febrile UTI with broad-spectrum antibiotics.	1b	Strong
Offer long-term antibacterial prophylaxis in case of high susceptibility to UTI and risk of acquired renal damage and lower urinary tract symptoms.	1b	Strong
In selected cases consider dietary supplements as an alternative or add-on preventive measure.	2a	Strong
In infants with febrile UTI use renal and bladder ultrasound to exclude obstruction of the upper and lower urinary tract within 24 hours.	2a	Strong
In infants, exclude vesicoureteric reflux (VUR) after first episode of febrile UTI with a non-E. Coli infection. In children more than one year of age with an E. Coli infection, exclude VUR after the second febrile UTI.	2a	Strong

## 3.11 Day-time lower urinary tract conditions

### 3.11.1 Terminology, classification, epidemiology and pathophysiology

Urinary incontinence in children may be caused by congenital anatomical or neurologic abnormalities such as ectopic ureter, bladder exstrophy or myelomeningocele (MMC). In many children, however, there is no such obvious cause for the incontinence, and they are referred as having functional bladder problems. The most recent International Children's Continence Society (ICCS) document suggests using the term day-time lower urinary tract (LUT) conditions to group together all functional bladder problems in children.

Normal storage and emptying of the bladder at a socially accepted place and time is mostly achieved by age three to four. Children with LUT conditions would present with failure to achieve continence (being still wet after the age of four), urgency, weak stream, hesitancy, frequency and accompanied UTIs. Isolated night-time wetting without any day-time symptoms is known as 'enuresis' and considered as a different entity [551].

As different studies have used varying definitions and criteria, it is difficult to give reliable percentages regarding the incidence of this problem. Reported prevalence ranges widely from 1% to 20% [552-560]. Due to increasing awareness and better access to specialised health care, the prevalence seems to be increasing [561, 562].

Lower urinary tract conditions in children may be due to disturbances of the filling phase, the voiding phase or a combination of both in varying severity. Mainly the conditions are divided into either overactive bladder (OAB) or dysfunctional voiding. They can, of course, coincide and one may even be causative of the other. Dysfunctional bowel emptying may also be part of the clinical problems and BBD is the term used to cover concomitant bladder and bowel disturbances.

Lower urinary tract conditions are considered to be the result of incomplete or delayed maturation of the bladder sphincter complex. The pons is considered to be responsible for detrusor sphincter co-ordination while the cortical area is responsible for inhibition of the micturition reflex and voluntary initiation of micturition. Therefore overactivity would be the result of delayed maturation of cortical control, while dysfunctional voiding would be the result of non-maturation of the co-ordination. Detrusor overactivity should not be considered as a sole bladder based problem but more a symptom of a centrally located dysfunction affecting bladder, bowel and even mood and behaviour [563].

A link between LUT and behavioural disorders such as ADHD (attention deficit/ hyperactivity disorder) has also been shown [564-566].

#### *3.11.1.1 Filling-phase (storage) dysfunctions*

In filling-phase dysfunctions, the detrusor can be overactive, as in OAB, or underactive, as in underactive bladder (UAB). Overactivity of the bladder is the most common problem, seen mostly around five to seven years of age. This may lead to disturbances characterised by urgency, frequency and at times urgency incontinence. Some children habitually postpone micturition leading to voiding postponement. Therefore, holding manoeuvres such as leg crossing and squatting can often be seen in this group. Recurrent UTIs are common and high-pressure state of the bladder can be a cause of VUR. Constipation can be an additional aetiological factor, which needs to be assessed. In children with an underactive detrusor, voiding occurs with reduced or minimal detrusor contractions with post-void residuals. Urinary tract infections, straining to void, constipation and incontinence is common. Incontinence often occurs when the bladder is over-distended in the form of overflow incontinence.

#### *3.11.1.2 Voiding-phase (emptying) dysfunctions*

In voiding-phase (emptying), incomplete relaxation or tightening of the sphincteric mechanism and pelvic floor muscles results in staccato voiding pattern (continuous urine flow with periodic reductions in flow rate precipitated by bursts of pelvic floor activity) or an interrupted voiding pattern (unsustained detrusor contractions resulting in infrequent and incomplete voiding, with micturition in fractions). The general term for this condition is dysfunctional voiding and is associated with elevated bladder pressures and PVRs. Symptoms will vary depending on the severity of inco-ordination between bladder and the sphincter. Staccato voiding is in less severe forms and interrupted voiding and straining is in more severe forms. The co-existence of constipation and LUTD and recurrent UTI is well described [567]. There is no evidence to conclude if bladder problems or bowel problems are the leading cause. The prevalence of constipation in older children varies from 5 to 27%. Approximately 90% of them being functional constipation without an organic cause. In children with functional constipation the prevalence of bladder symptoms have been shown to be as high as 64% [568, 569].

In incomplete emptying, high voiding pressures generated by bladder working against a functional obstruction caused by non-relaxing sphincter may induce not only UTIs but also VUR. It has been shown that LUTD is more significant for the occurrence of UTI than VUR itself [570]. In the majority of children with dysfunctional voiding the recurrent infections disappear following successful treatment, which confirms the hypothesis that dysfunctional voiding is the main factor responsible for the infections. Spontaneous resolution of VUR may also be seen after successful treatment of dysfunctional voiding.

#### **3.11.2 Diagnostic evaluation**

The evaluation of LUT conditions includes medical and voiding history (bladder diaries and structured

questionnaires), a physical examination, a urinalysis, and uroflowmetry with PVR. The upper urinary tract (UUT) needs to be evaluated in children with recurrent infections and dysfunctional voiding. Uroflowmetry can be combined with pelvic floor electromyography to demonstrate overactivity of the pelvic floor muscles during voiding. Urodynamic studies are usually reserved for patients with therapy resistant dysfunctional voiding and those not responding to treatment who are being considered for invasive treatment [566, 571-574].

In addition to a comprehensive medical history a detailed voiding diary provides documentation of voiding and defecation habits, frequency of micturition, voided volumes, night-time urine output, number and timing of incontinence episodes, and fluid intake. A voiding diary should at least be done for two days, although longer observation periods are preferred. A voiding diary provides information about storage function and incontinence frequency, while a pad test can help to quantify the urine loss. In the paediatric age group, where the history is taken from both the caregivers and child together, a structured approach is recommended using a questionnaire. Many signs and symptoms related to voiding and wetting will be unknown to the caregivers and should be specifically requested, using the questionnaire as a checklist. Some symptom scorings have been developed and validated [575, 576]. Although the reliability of questionnaires are limited they are practical in a clinical setting to check the presence of symptoms and have also been shown to be reliable to monitor the response to treatment. History taking should also include assessment of bowel function. For evaluation of bowel function in children, the Bristol Stool Scale is an easy-to-use tool [577, 578].

Urinalysis and urinary culture are essential to evaluate for UTI. Since transient voiding symptoms are common in the presence of UTI, exclusion of UTI is essential before further management of symptoms. During clinical examination, genital inspection and observation of the lumbosacral spine and the lower extremities are necessary to exclude obvious uropathy and neuropathy.

Uroflowmetry with PVR evaluates the emptying ability, while an UUT US screens for (secondary) anatomical changes. A flow rate which reaches its maximum quickly and levels off ('tower shape') may be indicative of over-active bladder whereas interrupted or staccato voiding patterns may be seen in dysfunctional voiding. Plateau uroflowmetry patterns are usually seen in anatomic obstruction of flow. A single uroflowmetry test may not always be representative of the clinical situation and multiple uroflowmetry tests, which all give a similar result, are more reliable. Uroflowmetry examination should be done when there is desire to empty the bladder and the voided volume should at least be 50% of the age-expected capacity  $[(\text{age in years}) + 1] \times 30 \text{ mL}$  for the children. While testing the child in a clinical environment, the impact of stress and mood changes on bladder function should also be taken into account [579, 580].

In the case of treatment failure re-evaluation is warranted and (video)-urodynamic (VUD) studies and neurological evaluation may be considered. Sometimes, there are minor, underlying, urological or neurological problems, which can only be suspected using VUD. In these cases, structured psychological interviews to assess social stress should be added [581] (LE: 1b).

Video-urodynamics may also be used as initial investigational tool in patients with suspicion of reflux. In this case reflux may be observed along with bladder dynamics. In the case of anatomical problems, such as posterior urethral valve (PUV) problems, syringocoeles, congenital obstructive posterior urethral membrane (COPUM) or Moormann's ring, it may be necessary to perform cystoscopy with treatment. If neuropathic disease is suspected, MRI of the lumbosacral spine and medulla can help to exclude tethered cord, lipoma or other rare conditions.

### 3.11.3 **Management**

The treatment of LUTD involves a multimodal approach, involving strategies such as behavioural modification, and anticholinergic medication along with underlying and potentially complicating conditions such as constipation and UTIs.

Behavioural modification, mostly referred to as urotherapy, is a term which covers all non-pharmacological and non-surgical treatment modalities. It includes standardisation of fluid intake, bowel management; timed voiding and basic relaxed voiding education. The child and family are educated about normal bladder function and responses to urgency. Voiding regimens are instituted and UTIs and any constipation are treated. Treatment is aimed at optimising bladder emptying and inducing full relaxation of the urinary sphincter or pelvic floor prior to and during voiding.

Strategies to achieve these goals include:

1. Information and demystification, which includes explanation about normal LUT function and how a particular child deviates from normal function.
2. Instructions about what to do about the problem:



- Regular voiding habits, sound voiding posture, pelvic floor awareness and training to relax pelvic floor and avoiding holding manoeuvres.
- Lifestyle advice, regarding fluid intake, prevention of constipation, etc.
- Registration of symptoms and voiding habits using bladder diaries or frequency-volume charts.
- Support and encouragement via regular follow-up by the caregiver.

Recurrent UTIs and constipation should also be treated and prevented during the treatment period. In case of combined BBD it is advised to treat the bowel dysfunction first [561] as LUTS may disappear after successful management of bowel dysfunction.

Addition of other strategies, as below, may be needed:

- Pelvic floor muscle awareness practices with repeated sessions of biofeedback visualisation of uroflow curves and/or pelvic floor activity and relaxation.
- Clean intermittent self-catheterisation for large PVR volumes of urine.
- Antimuscarinic drug therapy if detrusor overactivity is present.
- If the bladder neck is associated with increased resistance to voiding,  $\alpha$ -blocker drugs may be introduced.

Treatment efficacy can be evaluated by improvement in bladder emptying and resolution of associated symptoms. Controlled studies of the various interventions are needed. As with detrusor overactivity, the natural history of untreated dysfunctional voiding is not well delineated and optimum duration of therapy is poorly described. A high success rate has been described for urotherapy programmes, independent of the components of the programme. However, the evidence level is low as most studies of urotherapy programmes are retrospective and non-controlled [582]. A Cochrane analysis found very little evidence that can help to make evidence-based treatment decisions [583].

### 3.11.3.1 *Specific interventions*

As well as urotherapy, there are some specific interventions, including physiotherapy (e.g. pelvic floor exercises), biofeedback, alarm therapy and neuromodulation. Although good results with these treatment modalities have been reported, the level of evidence remains low, since only a few RCTs were published [584-590].

A systematic review reports that biofeedback is an effective, non-invasive method of treating dysfunctional voiding, and approximately 80% of children benefited from this treatment. However, most reports were of low level of evidence and studies of more solid design such as RCTs should be conducted [591]. A more recently published multicentre controlled trial of cognitive treatment, placebo, oxybutynin and bladder and pelvic floor training did not report better results with oxybutynin and pelvic floor training compared to standard urotherapy [581] (LE: 1b).

Two RCTs on underactive bladder without neurophatic disease have been published. Transcutaneous interferential electrical stimulation and animated biofeedback with pelvic floor exercise have been shown to be effective [592, 593]. In some cases, pharmacotherapy may be added. Some studies on orthosympathomimetics have been published with a low level of evidence [594].

Overactive bladder is common in the paediatric population. Although a stepwise approach starting with behavioural therapy is advised, antimuscarinic agents remain the mainstay of medical treatment for OAB. Oxybutynin is the most commonly used antimuscarinic in the paediatric population. The response to antimuscarinics varies and many children experience serious side effects. Although there have been reports about the use of tolterodine, fesoterodine, trospium, propiverine, and solifenacin in children, to date, most of them are off-label depending on age and national regulations. A few RCTs have been published, one on tolterodine showed safety but not efficacy [595], while another on propiverine showed both safety and efficacy [596]. The study on solifenacin showed its efficacy with side effects like constipation and electrocardiogram changes [597].

The difference in results is probably due to study design. Despite the low level of evidence for the use of anticholinergics and antimuscarinics, their use is recommended because of the large number of studies reporting a positive effect on OAB symptoms. Although  $\alpha$ -blocking agents are used occasionally, an RCT showed no benefit [598]. Botulinum toxin injection seems promising, but can only be used off-label [599].

A meta-analysis reports that neuromodulation therapy may lead to better partial improvement of nonneurogenic OAB; however, it may not render a definitive complete response. Office-based neuromodulation seems more efficacious than self-administered neuromodulation [600]. These new treatment modalities can only be

recommended for standard therapy-resistant cases [601]. Despite early successful treatment, there is evidence that there is a high recurrence rate of symptoms in the long term which necessitates long-term follow-up [602]. In addition, many patients may present later in adulthood with different forms of LUTD [603].

### 3.11.4 **Summary of evidence and recommendations for the management of day-time lower urinary tract conditions**

Summary of evidence	LE
The term 'bladder bowel dysfunction' should be used rather than 'dysfunctional elimination syndrome and voiding dysfunction'.	4
Day-time LUTS has a high prevalence (1% to 20%).	2

Recommendations	LE	Strength rating
Use two day voiding diaries and/or structured questionnaires for objective evaluation of symptoms, voiding drinking habits and response to treatment.	2	Strong
Use a stepwise approach, starting with the least invasive treatment in managing day-time lower urinary tract dysfunction in children.	4	Weak
Initially offer urotherapy involving bladder rehabilitation and bowel management.	2	Weak
If bladder bowel dysfunction is present, treat bowel dysfunction first, before treating the lower urinary tract condition.	2	Weak
Use pharmacotherapy (mainly antispasmodics and anticholinergics) as second line therapy in overactive bladder.	1	Strong
Use antibiotic prophylaxis if there are recurrent infections.	2	Weak
Re-evaluate in case of treatment failure; this may consist of (video) urodynamics MRI of lumbosacral spine and other diagnostic modalities, guiding to off-label treatment which should only be offered in highly experienced centres.	3	Weak

## 3.12 **Monosymptomatic nocturnal enuresis – bedwetting**

### 3.12.1 **Epidemiology, aetiology and pathophysiology**

Monosymptomatic nocturnal enuresis (NE), also known as bedwetting, is defined as an intermittent nocturnal incontinence. It is a relatively frequent symptom in children, 5-10% at seven years of age and 1–2% in adolescents. There is a gender difference in the incidence: two boys to one girl at any age [604]. With a spontaneous yearly resolution rate of 15% (at any age), it is considered as a relatively benign condition [579, 605]. Seven out of 100 seven-year-old bedwetting children will continue to wet their bed into adulthood. Nocturnal enuresis is considered primary when a child has not yet had a prolonged period of being dry (six months). The term "secondary NE" is used when a child or adult begins wetting again after having stayed dry. Non-monosymptomatic NE is defined as the condition of NE in association with day-time lower urinary tracts symptoms (LUTS, recurrent UTIs and/or bowel dysfunction) [605, 606]. The presence of constipation has a negative association with bladder capacity [607].

Nocturnal enuresis has significant secondary stressful, emotional and social consequences for the child and their caregivers. A lower quality of life has been reported for children with NE compared to controls and NE can influence relationships with friends and family [608-611]. Therefore, treatment is advised from the age of six to seven years onwards considering mental status, family expectations, social issues, and cultural background.

There is a clear hereditary factor in NE. If none of the parents or their immediate relatives has suffered from bedwetting, the child has a 15% chance of wetting its bed. If one of the parents, or their immediate relatives have suffered from bedwetting, the chance of bedwetting increases to 44%, and if both parents have a positive history the chance increases to 77%. However, from a genetic point of view, enuresis is a complex and heterogeneous disorder. Loci have been described on chromosomes 12, 13 and 22 [606].

Children with NE are considered deep but poor sleepers due to high arousal thresholds and frequently disturbed sleep. High arousal threshold is the most important pathophysiological factor in the aetiology of NE: the child does not wake up when the bladder is full. Full night polysomnographic recordings support this hypothesis by demonstrating the disruption of children's sleep microstructure [612]. In addition to the high arousal threshold, there needs to be an imbalance between night-time urine output and night-time bladder capacity [579, 605, 606]. Recently, attention has been given to the chronobiology of micturition in which the existence of a circadian clock in kidney, brain and bladder is postulated [613].

A high incidence of comorbidity and correlation between nocturnal urine production and sleep disordered breathing, such as obstructive sleep apnoea, has been found and investigated [614]. Symptoms such as habitual snoring, apnoeas, excessive sweating at night and mouth breathing in the patient history or via sleep questionnaires, such as the BEARS questionnaire [615], can lead to the detection of sleep disorders and/or adenotonsillar hypertrophy. When present, a consultation with the ENT specialist can be considered [616]. Obesity is associated with a higher incidence of NE and a lower efficacy for treatment [617]. The presence of allergic diseases has been recognised as a risk factor of NE and with a greater risk for more allergic episodes [618-620].

It is important to consider the child's and family's psychological status as primary NE has been associated with psychopathology, such as Attention Deficit Hyperactivity Disorder (ADHD) and depressive symptoms [621, 622]. In children with ADHD symptoms of NE are more severe and it is important to inform the child and the parents about a delayed success rate and higher relapse rate compared to children without ADHD [623].

### 3.12.2 **Diagnostic evaluation**

The diagnosis is mainly obtained by history-taking. Focused questions to differentiate monosymptomatic vs. non-monosymptomatic, primary vs. secondary, comorbid factors such as behavioural or psychological problems and sleep disorder breathing, should be asked. In addition, a two-day complete micturition and drinking diary, which records day-time bladder function and drinking habits will further exclude comorbid factors such as LUTS and polydipsia.

Specific attention should be made regarding bowel movements as irregular bowel movements can change the diagnosis from monosymptomatic NE to non-monosymptomatic NE. If constipation or faecal incontinence is found (it is reported in up to 20% of children with NE), it should be treated simultaneously, and the family should be informed that constipation can negatively influence treatment outcomes [624, 625].

The night-time urine production should be registered by weighing the night-time diapers in the morning and adding the first morning voided volume [626]. The night-time urine production should be recorded over (at least) a two-week period to diagnose an eventual differentiation between a high night-time production (more than 130% of the age expected bladder capacity) vs. a night-time OAB.

A physical examination should be performed with special attention to the back of the child (to exclude any neurological problem), the external genitalia and surrounding skin, as well as to the condition of the clothes (wet underwear or encopresis).

Urine analysis is indicated if there is a sudden onset of bedwetting, a suspicion or history of UTIs, or inexplicable polydipsia.

A uroflowmetry and US is indicated only if there is a history of previous urethral or bladder surgery and presence of daytime urinary symptoms. For further evaluation, see Section 3.10 on Day-time LUT conditions.

There is no clinical indication nor use for a functional MRI (fMRI) in the diagnostic of NE. Research is ongoing, however one of the main issues is the fact that the MRI is performed in an awake state, whereas the NE is a solely event during sleep. The use of fMRI in the elucidation of the NE's neuropathological mechanisms has not yet been fruitful [627, 628].

### 3.12.3 **Management**

Before introducing any form of possible treatment, it is of utmost importance to explain the bedwetting condition to the child and the caregivers in order to demystify the problem. Parents should be encouraged to seek medical attention for their bedwetting children and be informed that it is known that the quality of life of parents with a child with NE is negatively impaired. Medical providers assisting families with a child must be aware of this fact and therefore guide parents, by explaining that the key role for treating a child with NE is the ability to understand and the co-operation of the child itself [629].

Since the COVID-19 pandemic situation and promotion of virtual contacts between doctors and patients, it has been shown that telemedicine is a good method of closely follow-up and can be used for follow-up after treatment [630].

#### 3.12.3.1 *Supportive treatment measures*

Initially, supportive measures including normal and regular eating and drinking habits should be reviewed, stressing normal fluid intake during the day and reducing fluid intake in the hours before sleep. Keeping a chart depicting wet and dry nights, also called as basic bladder advice, has not been shown to be successful in the early treatment of NE [631]. To assure good sleep quality, specifically in children with NE, it is also recommended to limit the use of electronic devices before bedtime [632].

Referral for psychological support should be advised and followed-up for patients with NE and their families, especially if the NE comorbid factor is developmental, attention or learning difficulties, family problems, parental distress and possible punishment of the child are observed. Parental stress levels are higher compared to parents of non-NE children [633] and anger is found to be the most common parental reaction towards NE children [634], this would explain why childhood traumas such as neglect and abuse are more often seen in children with NE [635]. Psychological interventions with parents of NE children were shown to significantly improve their coping mechanisms [636].

#### 3.12.3.2 *Wetting alarm treatment*

The nocturnal alarm treatment relies on the use of a device that is activated by getting wet. The goal of this therapeutic approach is that the child wakes up by the alarm, which can be acoustic or tactile, either by itself or with the help of a caregiver. Their method of action is to repeat the awakening and therefore change the high arousal to a low arousal threshold, specifically when a status of full bladder is reached. In the most recent Cochrane review (even though the quality of the included studies was low), several studies have shown that alarm treatment will reduce the number of wet nights a week. An alarm treatment has a higher complete response rate and a low relapse rate compared to no treatment at all [637]. In the event of relapse after initial success, one should actively investigate for OAB [638]. The recommended length of therapy with the alarm treatment continues to be uncertain, varying from 8-12 weeks (ICCS) to 16-20 weeks [639].

Regular follow-up will improve the success. It is of utmost importance that the child plays an active role in the alarm treatment, is willing to continue and understand the purpose of the treatment modality.

#### 3.12.3.3 *Medical treatment*

If the child and the family would like to act on the high night-time urine production and eventual night-time OAB, they should be able and willing to adjust their drinking habits and take either desmopressin or a combination of desmopressin and an anticholinergic drug.

Success rates of 70% can be obtained with Desmopressin, either as tablets (200-400 µg), or as sublingual Desmopressin oral lyophilisate (120-240 µg). A rare side-effect is water intoxication which can be prevented by adequate water intake. The dosage of 120 µg has been shown to be effective and safe [640]. A structured titration increase up to 240 µg has been shown to be effective [641]. Predictive factors for success with Desmopressin have been identified: older children, in children with fewer wet nights and high night-time urine production [642]. Children that show a good response on low-dose Desmopressin are more likely to show a complete response during the maintenance period [643]. When poor responses are seen on Desmopressin be aware of low compliance [644]. Relapse rates can be high after Desmopressin discontinuation [579], it is unclear if structured withdrawal will result in lower relapse rates [645, 646]. A nasal spray is no longer recommended due to the increased risk of overdose [647].

In the event of Desmopressin-resistant treatment for NE or if a suspicion exists for night-time OAB, combination of Desmopressin with anticholinergics is safe and efficient, even after cessation of treatment [648-651]. With night-time OAB a treatment failure to Desmopressin can be explained because of the bladder reservoir dysfunction [652]. There is no indication for monotherapy with an anticholinergic drug [653].

Alarm and Desmopressin treatment have comparable efficacy in achieving >50% reduction in wet nights. Alarms offer superior treatment response (OR: 2.89, 95% CI 1.38 to 6.04) and lower relapse rates (OR: 0.25, 95% CI 0.12 to 0.50) in children [654]. Multimodal treatment can achieve a partial or full response in 80% of children. However, side effects are seen in up to 30% of children [655].

#### 3.12.3.4 *Electrical neuromodulation*

Several systematic reviews and randomized trials have documented potential benefits of electrical neural stimulation for NE. However, the quality of the included studies was low and different types of electrical neural stimulation, such as intra-anal stimulation and interferential current stimulation have been included [656-659]. The one RCT that compares transcutaneous electrical nerve stimulation to placebo demonstrates no anti-enuretic effect [660].

#### 3.12.3.5 *Complementary treatments:*


A Cochrane review showed no benefit for treatments such as hypnosis, psychotherapy, acupuncture, chiropractic and medicinal herbs for the treatment of NE [661].

#### 3.12.3.6 *Conservative “wait and see” approach*

If the child and its family is unable to comply with a treatment, if the treatment options are not possible for the

family situation, and if there is no social pressure, a “wait and see” approach can be chosen. However, in this approach, it is important to emphasise the fact that the child should wear diapers at night to ensure a normal quality of sleep [662]. The success rate of wait and see is 15% per year, independent of age. Figure 6 presents stepwise assessment and management options for NE.

**Figure 7: A stepwise assessment and management options for NE**



ENT = ear, nose and throat.

### 3.12.4 Summary of evidence and recommendations for the management of monosymptomatic enuresis

Summary of evidence	LE
Chronobiology of micturition, in which the existence of a circadian clock has been proven in kidney, brain and bladder, and disturbances in this chronobiology play a major role in the pathophysiology of enuresis.	1

Recommendations	LE	Strength rating
Do not treat children less than five years of age in whom spontaneous cure is likely, but inform the family about the involuntary nature, the high incidence of spontaneous resolution and the fact that punishment will not help to improve the condition.	2	Strong

Use micturition diaries or questionnaires to exclude day-time symptoms.	2	Strong
Perform a urine test to exclude the presence of infection or potential causes such as diabetes insipidus.	2	Strong
Offer supportive measures in conjunction with other treatment modalities, of which pharmacological and alarm treatment are the two most important.	1	Strong
Offer desmopressin in proven night-time polyuria.	1	Strong
Offer alarm treatment in motivated and compliant families.	1	Strong

### 3.13 Management of neurogenic bladder

#### 3.13.1 *Epidemiology, aetiology and pathophysiology*

Neurogenic detrusor-sphincter dysfunction (NDS) can develop as a result of a lesion at any level in the nervous system. This condition contributes to various forms of LUTD, which may lead to incontinence, UTIs, VUR, and ultimately to renal scarring and renal failure requiring dialysis and/or transplantation. Conservative treatment starting in the first year of life is the first choice, however, surgery may be required at a later stage to establish adequate bladder storage, continence and drainage later on [663]. The main goals of treatment concerning the urinary tract are prevention of UTI's, urinary tract deterioration, achievement of continence at an appropriate age and promoting as good as possible QoL [4, 5]. With regard to the associated bowel dysfunction, stool continence, with evacuation at a social acceptable moment, is another goal as well as education and treatment of disturbance in sexual function. Due to the increased risk of development of latex allergy, latex-free products (e.g., gloves, catheters etc.) should be used from the very beginning whenever possible [664].

Neurogenic bladder in children with myelodysplasia presents with various patterns of Detrusor-Sphincter-Dyssynergia with a wide range of severity [665]. About 12% of neonates with myelodysplasia have no signs of neuro-urological dysfunction at birth [666]. Newborns with myelodysplasia who initially have normal urodynamic studies are at risk for neurological deterioration secondary to spinal cord tethering, especially during the first six years of life. Close follow-up of these children is important for the early diagnosis and timely surgical correction of tethered spinal cord, and for the prevention of progressive urinary tract deterioration [666]. At birth, the majority of patients have normal UUTs, but up to 60% develop upper tract deterioration due to bladder changes, UTI and /or VUR, if not treated properly [667-670]. Even today in a contemporary series around 50% of the patients are incontinent and 15% have an impaired renal function at the age of 29 years [671]. A systematic review concerning the outcome of adult meningocele patients demonstrated that around 37% (8-85%) are continent, 25% have some degree of renal damage and 1.3% end stage renal failure [672]. The term "continence" is used differently in the reports, and the definition of "always dry" was used in only a quarter of the reports [673]. A nationwide survey in USA showed, that less than 50% of the adult spina population reported being continent [674], which demonstrates the need for better consulting and lifelong support.

The most common presentation at birth is myelodysplasia. The incidence of neural tube defects in Europe is 9.1 per 10,000 births and has not decreased in recent years, despite longstanding recommendations concerning folic acid supplementations [675]. The term myelodysplasia includes a group of developmental anomalies that result from defects in neural tube closure. Lesions include spina bifida aperta and occulta, meningocele, lipomyelomeningocele, or myelomeningocele. Myelomeningocele is by far the most common defect seen and the most detrimental.

With antenatal screening spina bifida can be diagnosed before birth with the possibility of intrauterine closure of the defect [676, 677]. Traumatic and neoplastic spinal lesions of the cord are less frequent in children but can also cause severe urological problems. Other congenital malformations or acquired diseases can cause a neurogenic bladder, such as total or partial sacral agenesis which can be part of the caudal regression syndrome [678]. In any child presenting with anorectal malformation (ARM) and cloacal malformations, the development of a neurogenic bladder is possible [679]. Patients with cerebral palsy may also present with varying degrees of voiding dysfunction, usually in the form of uninhibited bladder contractions (often due to spasticity of the pelvic floor and sphincter complex) and wetting. Finally, "non-neurogenic neurogenic" bladder dysfunction, such as Hinman or Ochoa syndrome, have been described, in which no neurogenic anomaly can be found, but severe bladder dysfunction as seen in neurogenic bladders is present [680, 681].

#### 3.13.2 *Classification systems*

As bladder sphincter dysfunction is poorly correlated with the type and spinal level of the neurological lesion, urodynamic and functional classifications are much more practical for defining LUT pathology and planning treatment in children.

The bladder and sphincter are two units working in harmony to act as a single functional unit. In patients with a neurogenic disorder, the storage and emptying phase of the bladder function can be disturbed. The bladder and sphincter may be either overactive or underactive and present in four different combinations. This classification system is based on urodynamic findings [682-684]:

- Overactive sphincter and overactive bladder.
- Overactive sphincter and underactive bladder.
- Underactive sphincter and overactive bladder.
- Underactive sphincter and underactive bladder.

### 3.13.3 **Diagnostic evaluation**

Today several guidelines and timetables are used [685-687]. The Panel advocate proactive management in children with spinal dysraphism. In those with a safe bladder during the first urodynamic investigation, the next urodynamic investigation can be delayed until one year of age [4].

#### 3.13.3.1 *History and clinical evaluation*

History should include questions on clean intermittent catheterisation (CIC) frequency, urine leakage, bladder capacity, UTI, medication, bowel function as well as changes in neurological status. A thorough clinical evaluation is mandatory including the external genitalia and the back. A two-day diary, recording drinking volume and times as well as CIC intervals, bladder volume and leakage can provide additional information about the efficacy of the treatment.

#### 3.13.3.2 *Laboratory and urinalysis*

After the first week of life, plasma creatinine level should be obtained, later in life; cystatin level is more accurate [688, 689]. If there is any sign of decreased renal function, physicians should be encouraged to optimize the treatment as much as possible. The criteria for urine analysis are the same as for UTI (refer to Chapter 3.10). However, it is much easier for caregivers or patients to obtain catheter urine in patients who are on CIC. They can also perform a dip stick analysis to screen for UTI at home. (For relevance see Section 3.12.4.5). Albuminuria is an early marker of renal disease also in children with neurogenic bladder [690].

#### 3.13.3.3 *Ultrasound*

At birth, US of the kidneys and bladder should be performed and then repeated at least annually. If there are any clinical changes in between, another US should be performed. Dilatation of the UUT should be reported according to the classification system of the Society of Foetal Urology [691], including the measurement of caliceal dilatation and anterior posterior diameter of the renal pelvis. Residual urine and bladder wall thickness should also be noted. A dilated ureter behind the bladder should be recorded. Bladder wall thickness has been shown not to be predictive of high pressures in the bladder during voiding and storage and cannot be used as a non-invasive tool to judge the risk for the UUT [692].

#### 3.13.3.4 *Urodynamic studies/videourodynamic*

Urodynamic studies (UD) are one of the most important diagnostic tools in patients with neurogenic bladders. In newborns with spina bifida aperta), the first UD should be performed after the phase of spinal shock after closure, usually between the second and third months of life [693]. Especially in newborns, performing and interpretation of UD may be difficult, as no normal values exist. After that it should be repeated annually, depending on the clinical situation. During and after puberty bladder capacity, maximum detrusor pressure and detrusor leak point pressure increase significantly [694]. Therefore, during this time, a careful follow-up is mandatory.

##### 3.13.3.4.1 *Preparation before urodynamic studies*

Before any UD a urine analysis should be undertaken. The first assessment should be done under antibiotic prophylaxis. A Cochrane analysis of nine randomised controlled trials showed, that the administration of prophylactic antibiotics compared to placebo reduced the risk of significant bacteriuria from 12% to 4% after UD studies. However, this was without significant difference for symptomatic UTI (20% vs. 28%), fever or discomfort [695]. If there is significant bacteriuria, antibacterial treatment should be discussed; especially in older patients a single dose may be sufficient [696].

Generally, UD-parameters should include:

- the cystometric capacity;
- the intravesical filling pressure;
- detrusor compliance;
- the intravesical pressure at the moment of voiding or leakage;

- the presence or absence of detrusor overactivity;
- the competence of the internal and external sphincter;
- the degree of synergy of the detrusor and sphincter during voiding;
- the PVR volume.

In infants, information on detrusor filling pressure and the pressure and bladder volume at which the child voids or leaks can be obtained [693]. Detrusor leak point pressure is more accurate than abdominal leak point pressure but keeping the rectal probe in an infant in place can be challenging [693]. Addition of fluoroscopy (video-urodynamic study) will provide information about presence of VUR, at what pressures VUR occurs and the configuration of the bladder neck during filling and leakage or voiding.

#### 3.13.3.4.2 Uroflowmetry

Unlike in children with non-neurogenic voiding dysfunction, uroflowmetry can rarely be used since most affected patients do not void spontaneously. In those with cerebral palsy, non-neurogenic-neurogenic bladder or other neurological conditions allowing active voiding it may be a practical tool. It provides an objective way of assessing the efficiency of voiding, while recording of pelvic floor activity with electromyography (EMG) can be used to evaluate synergy between detrusor and the sphincter. PVR urine volume is measured by US. The main limitation of uroflowmetry is the compliance of the child to follow instructions [697-700].

#### 3.13.3.5 Urodynamic studies

The standards of the ICCS should be applied to UD in patients with neurogenic bladders and accordingly reported [571, 683]. Natural fill UD in children with neurogenic bladder detects more overactivity compared with diagnoses delivered by conventional UD [701, 702]. It may be an option in patients where the findings in the conventional UD are inconsistent with clinical symptoms and other clinical findings [702].

#### 3.13.3.6 Voiding cystourethrogram

If video-urodynamic equipment is not available, a VCUG with UD is an alternative to confirm or exclude VUR and visualise the LUT including the urethra.

#### 3.13.3.7 Renal scan

DMSA (Technetium Dimercapto-Succinic Acid) Renal scan is the gold standard to evaluate renal parenchyma. In contemporary series, renal scars can be detected in up to 46% as patients get older [703-705]. In a recent study 4 out of 68 children had renal scarring, 3 had a history of febrile UTI and one a vesicoureteral reflux [655]. A positive DMSA-Scan correlates well with hypertension in adulthood, whereas US has a poor correlation with renal scars [705]. Therefore, a DMSA scan as a baseline evaluation in the first year of life is recommended.

### 3.13.4 Management

The medical care of children with neurogenic bladder requires an on-going multidisciplinary approach. There is some controversy about optimal timing of the management; proactive vs. expectant management [706-708]. Even with a close expectant management e.g. in one series 11 out of 60 need augmentation within a follow-up of 16 years and 7 out of 58 had a decrease in total renal function, which was severe in two [709]. During the treatment it should also be taken into account in spina bifida patients, that QoL is related to urinary incontinence independent of the type and level of spinal dysraphism and the presence or absence of a liquor shunt [710].

Foetal open and endoscopic surgery for meningomyelocele are performed to close the defect as early as possible in order to reduce neurological, orthopaedic and urological problems [711]. In the MOMS-Trial, Brooks *et al.* found no difference between those closed in utero vs. those closed after birth concerning the need for CIC [677], but less bladder trabeculation was found in the prenatal surgery group. Mean gestation age (28.3 vs. 35.2) seems to have no initial impact on bladder function in the first few years of life [712]. Two European series showed, that there is a possible benefit of open intrauterine closure on urinary continence showing normal bladder function in up to 33% at least in the first 2-3 years of life [713] [714]. Despite these promising reports [712, 715-717], caregivers need to be aware of the high risk of developing a neurogenic bladder as demonstrated by a Brazilian group [718]. Regular and close follow-up examinations including UD are indicated in all these patients.

#### 3.13.4.1 Early management with intermittent catheterisation

Starting intermittent catheterisation (IC) soon after birth and closure of the defect by the neurosurgeon in all infants has shown to decrease renal complications and the need for later augmentation [719-722]. In infants without any clear sign of outlet obstruction, this may be delayed but only in very selected cases. These infants should be monitored very closely for UTIs and changes of the urinary tract with US and UD. The early initiation of CIC in the new-born period makes it easier for caregivers to master the procedure and for children to accept it, as they grow older [723, 724]. Up to 90% of patients will perform CIC [725].



A Cochrane review as well as a recent study showed, that there is a lack of evidence to state that the incidence of UTI is affected by use of sterile or clean technique, coated or uncoated catheters, single (sterile) or multiple use (clean) catheters, self-catheterisation or catheterisation by others, or by any other strategy [726-730]. Looking at the microbiological milieu of the catheter, there was a trend for reduced recovery of potentially pathogenic bacteria with the use of hydrophilic catheters. Also, a trend for a higher patient satisfaction with the use of hydrophilic catheters was seen [731]. Based on the current data, it is not possible to state that one catheter type, technique or strategy is better than any other.

#### 3.13.4.2 Medical therapy

Antimuscarinic/anticholinergic medication reduces/prevents detrusor overactivity and lowers intravesical pressure [732, 733]. Effects and side effects depend on the distribution of the M1-M5 receptors [734]. In the bladder, the subtype M2 and M3 are present [733, 735]. Oxybutynin is the most frequently used in children with neurogenic bladder with a success rate of up to 93% [736, 737]. Dose-dependent side-effects (such as dry mouth, facial flushing, blurred vision heat intolerance etc.) limit its use. Intravesical administration gives a significant higher bioavailability due to the circumvention of the intestinal first pass metabolism, as well as possible local influence on C-fiber-related activity and can be responsible for different clinical effect [738, 739].

Intravesical administration should be considered in patients with severe side-effects, as long-term results demonstrated that it was well-tolerated and effective [740, 741]. Transdermal administration also leads to a substantially lower ratio of N-desethyloxybutynin to oxybutynin plasma levels, however, there are treatment-related skin reactions in 12 out of 41 patients [742]. There are some concerns about central anticholinergic adverse effects associated with oxybutynin [743, 744]. A double blinded cross-over trial, as well as a case control study, showed no deleterious effect on children's attention and memory [705, 745]. Tolterodine, solifenacin, fesoterodin, trospium chloride and propiverine and their combinations can also be used in children [746-754].

The oral dosage for oxybutynin is up to 0.2 mg/kg [733] given three times daily. The intravesical dosage can be up to 0.7 mg/kg/daily and transdermal 1.3-3.9 mg/daily. The dosage of the other drugs is: Tolterodine 0.5 – 4 mg/day divided in two doses, Solifenacin 1.25 up to 10 mg per day (single dose), fesoterodine 4-8 mg per day (single dose) Propiverin 0.8 mg/kg/day divided in two dosages and trospium chloride up to 3 times 15 mg starting with 3 times 5 mg. Except for oxybutynin, all other anticholinergic drugs are off-label use, which should be explained to the caregivers.

Early prophylactic treatment with anticholinergics showed a lower rate of renal deterioration as well as a lower rate of progression to bladder augmentation [719, 755]. Beta-3 agonists like mirabegron as an adjuvant treatment has been shown to be effective and safe in some recent studies of children (> five years) and adolescents [756-759].

Alpha-adrenergic antagonists may facilitate emptying in children with neurogenic bladder [760]. Doxazosin with an initial dose of 0.5 to 1.0 mg or tamsulosin hydrochloride in a medium (0.0002-0.0004 mg/kg/day) or high dose (0.0004-0.0008 mg/kg/day) has been given to children with neurogenic bladders [760-762]. It was well tolerated but not effective at least in one study [761].

Botulinum toxin A injections: In neurogenic bladders that are refractory to anticholinergics, the off-label use of suburothelial or intramuscular injection of onabotulinum toxin A into the detrusor muscle is a treatment option [653, 654]. In children, continence could be achieved in 32-100% of patients, a decrease in maximum detrusor pressure of 32% to 54%, an increase of maximum cystometric capacity from 27% to 162%, and an improvement in bladder compliance of 28%-176% [653]. Onabotulinum toxin A seems to be more effective in bladders with obvious detrusor muscle over-activity, whereas non-compliant bladders without obvious contractions are unlikely to respond [763, 764]. Also, the injections into the trigone seems to be save in regard of reflux and upper tract damage; if it has some benefit is not further investigated [657]. Of the patients with failed augmentation cystoplasty, 43% responded well to intra-detrusor onabotulinum toxin A injections in a recent series of 30 patients [765].

The most used dose of onabotulinum toxin A is 10 to 12 U/kg with a maximum dose between 200 U and 360 U [766]. A randomized trail demonstrated, that 200IE have greater efficacy in reducing bladder pressure and increasing bladder capacity compared to 50 or 100IE [767]. Onabotulinum toxin A can be effective between three to twelve (0-25) months and repeated injections are effective up to ten years in one study [768-770].

Urethral sphincter onabotulinum toxin A injection has been shown to be effective in decreasing urethral resistance and improve voiding. The evidence is still too low to recommend its routine use in decreasing outlet resistance, but it could be considered as an alternative in refractory cases [771, 772].

#### Neuromodulation

Intravesical electrical stimulation of the bladder [773-775], sacral nerve stimulation [776, 777] and transcutaneous neuromodulation [668] are still experimental and cannot be recommended outside of clinical trials. The same is true for the intradural somatic-to-autonomic nerve anastomosis [778, 779].

#### Urethral Dilatation

The aim is to lower the pop-off pressure by lowering the detrusor leak-point pressure by dilatation of the external sphincter under general anaesthesia up to 36 Charr. Some studies showed, that especially in females, the procedure is safe and in selected patients, effective [780-782].

#### Vesicostomy

Vesicostomy - preferably a Blocksom stoma [783] - is an option to reduce bladder pressure in children/new-borns, if the caregivers are incontinent with IC and/or IC through the urethra is extremely difficult or impossible [784]. Especially in the young infant with severe upper tract dilatation or infections, a vesicostomy should be considered. In some patients it may be also a good long-term solution to prevent infection and renal deterioration [785]. Drawbacks are the difficulty fitting and maintaining a collecting appliance in older patients. A cystostomy button may be an alternative, with a complication rate (mostly UTI) of up to 34% within a mean follow-up of 37 months [786].

#### 3.13.4.3 Management of faecal incontinence

Children with neurogenic bladder usually have also a neurogenic bowel function. Faecal incontinence may have an even greater impact on QoL, as the odour can be a reason for social isolation. The aim of each treatment is to obtain a smooth, regular bowel emptying and to achieve continence and independence. The regime should be tailored to the patient's need, which may change over time. Beside a diet with small portioned fibre food and adequate fluid intake to keep a good fluid balance [733], follow-up options should be offered to the patients and caregivers.

In the beginning, faecal incontinence is managed most commonly with mild laxatives, such as mineral oil, combined with enemas to facilitate removal of bowel contents. To enable the child to defecate once a day at a given time, rectal suppositories as well as digital stimulation by parents or caregivers can be used. Today, transanal irrigation is one of the most important treatments for patients with neurogenic bowel incontinence. Regular irrigations significantly reduce the risk for faecal incontinence also in the long run in up to 90% of the patients [787]. The risk of irrigation induced perforation of the bowel is estimated as one per 50,000 [678]. During childhood, most children depend on the help of the caregivers. Later in some patients, transanal irrigation becomes difficult or impossible due to anatomic or social circumstances. In these patients antegrade irrigation using a MACE-stoma (Malone Antegrade Continence Enema) is an option, which can also be placed in the left abdomen [788, 789]. In a long-term study of 105 patients with a MACE stoma, 69% had successful bowel management. They were started on normal saline, but some switched to GoLYTELY (PEG-3350 and electrolyte solution). Additives (biscodyl, glycerin etc.) were needed in 34% of patients. Stomal complications occurred in 63% (infection, leakage, and stenosis) of patients, 33% required surgical revision and 6% eventually required diverting ostomies [790]. In addition, patients need to be informed, that the antegrade irrigation is also time consuming taking at least 20-60 minutes.

#### 3.13.4.4 Urinary tract infection

Urinary tract infections are common in children with neurogenic bladders. However, there is no consensus in most European centres, for prevention, diagnosing and treating UTIs in children with neurogenic bladders performing CIC [791]. Although bacteriuria is seen in more than half of children on CIC, patients who are asymptomatic do not need treatment [792]. Continuous antibiotic prophylaxis (CAP) creates more bacterial resistance as demonstrated by a randomized study. Those that stopped the prophylaxis had reduced bacterial resistance, however, 38 out of 88 started antibiotic prophylaxis again due to recurrent UTIs or the caregivers request [793]. A cohort study with 20 patients confirmed these findings. Continuous antibiotic prophylaxis was not protective against the development of symptomatic UTIs and new renal scarring but increased the risk of bacterial resistance [794]. A randomized study in 20 children showed that cranberry capsules significantly reduced the UTI-rate as well as the rate of bacteriuria [795]. If VUR is present, prophylactic antibiotics should be started when patients experience recurrent UTIs [796, 797].

#### 3.13.4.4.1 Urinary tract infection and clean intermittent catheterisation

The incidence of asymptomatic bacteriuria ranges between 42%-76% [723, 733, 798]. A cross-over study in 40 children with neurogenic bladder demonstrated, that the reuse of CIC-catheters for up to three weeks compared to one week increased the prevalence of bacteriuria from 34% to 74% (it was 60% at the start of the study). During the study-period of eighteen weeks, none of the patients developed a febrile UTI [799]. There is no medical benefit in performing CAP in children with neurogenic bladder, who perform CIC [733]. In those with recurrent UTI, intravesical instillation of gentamycin or neomycin/polymyxin may be an option [800, 801].

#### Reflux

Secondary reflux in patients with neurogenic bladder increases the risk for pyelonephritis. The treatment is primarily related to bladder function including anticholinergic therapy, CIC and may be later augmentation [802]. Those with early and post-therapy persistent reflux during videourodynamic studies at low pressure have a higher risk of pyelonephritis [803]. Patients with a high-grade reflux before augmentation have a higher risk of persistent symptomatic reflux after the enterocystoplasty [804]. Therefore simultaneous ureteral re-implantation in high-grade symptomatic reflux especially in those with low-pressure high-grade reflux should be discussed with the patient/caregivers. Endoscopic treatment has a failure rate of up to 75% after a median follow-up of 4.5 years [805] which is in contrast to the open techniques with a higher success rate but may have an increased risk of inducing obstruction [806].

#### 3.13.4.5 Sexuality

Sexuality, while not an issue in childhood, becomes progressively more important as the patient gets older. This issue has historically been overlooked in individuals with myelodysplasia. However, patients with myelodysplasia do have sexual encounters [807]. The prevalence of precocious puberty is higher in girls with meningomyelocele [808]. Studies indicate that at least 15-20% of males are capable of fathering children and 70% of females can conceive and carry a pregnancy to term. It is therefore important to counsel patients about sexual development in early adolescence.

Women seem to be more sexually active than men in some studies from the Netherlands and the USA [807, 809]. The level of the lesion was the main predictor to be sexually active [810, 811]. Erectile function can be improved by sildenafil in up to 80% of the male patients [812, 813]. Neurosurgical anastomosis between the inguinal nerve and the dorsal penile nerve in patients with a lesion below L3 and disturbed sensation is still to be considered as an experimental treatment [809, 814]. Only 17% to one third of the patients talk to their doctors about sexuality, 25–68% were informed by their doctors about reproductive function [807]. Continence seems to play an important role too. Nine out eleven females without sexual dysfunction reported continence, whereas 50 out of 59 with sexual dysfunction have some urinary incontinence in a recent study [815]. Therefore, early discussion about sexuality in the adolescent is recommended and should be promoted by the paediatric urologist taking care of these patients.

#### 3.13.4.6 Bladder augmentation

In patients where conservative treatment including onabotulinum toxin A (for indication see 3.12.4.3) fails to keep a low-pressure reservoir with a good capacity and compliance, bladder augmentation should be offered. For augmentation, ileal and colonic segments can be used [816]. Gastric segments are rarely used due to its associated complications like the haematuria-dysuria syndrome as well as secondary malignancies, which arise earlier than with other intestinal segments [817-820]. Enterocystoplasty increases bladder capacity, reduces storage pressure and can improve UUT drainage [821]. A good socially acceptable continence rate can be achieved with or without additional bladder outlet procedures [822]. In those, who are not able to perform CIC through the urethra, a continent cutaneous channel should be offered. One recent study in 10 patients showed that thoracic epidural analgesia appears to be a safe and effective opioid sparing option to assist with postoperative pain management following lower urinary tract reconstruction [823]. Surgical complications and revision rate in this group of patients is high. The 30-day all over event rate in the American College of Surgeons' National Surgical Quality Database is approximately 30% (23-33%) with a re-operation rate in this short time period of 13% [824, 825]. In these patients with long-life expectancy the complication rate clearly increases with the follow-up period [826]. The ten-year cumulative complication incidence from the Paediatric Health Information System showed a rate of bladder rupture in up to 6.4%, small bowel obstruction in up to 10.3%, bladder stones in 36%, pyelonephritis in more than a third of the patients and a re-augmentation rate of up to 13% [827]. Bladder perforation, as one of the worst complications, occurs in 3-13% [828]. The rate of VP-shunt infections after gastrointestinal and urological procedures ranges between 0-22%. In a recent study, bowel preparation seems not to have a significant influence on the infection rate (10.5% vs. 8.3%) [829]. Not only surgical complications must be considered; also metabolic complications and consequences after incorporating bowel segments have to be taken into account, such as imbalance of the acid base balance, decrease in vitamin

B12 levels and loss of bone density. Stool frequency can increase as well as diarrhoea after exclusion of bowel segments [830] and last, but not least, these patients have a lifelong increased risk to develop secondary malignancies [831, 832]. Therefore, a lifelong follow-up of these patients is required including physical examination, US, blood gas analysis, (pH and base excess), renal function and vitamin B12 if Ileum is used. Endoscopic evaluation starting ten years after augmentation is not cost-effective [833, 834], but may prevent some advanced cancer. Woodhouse *et al.* do not recommend cystoscopy within the first fifteen years after surgery [835]. The real value of annual cystoscopic evaluation has not been proven by any study. Urodynamic studies after bladder augmentation are only indicated, if upper tract dilatation and/or incontinence after the operation has not improved [836].

Adverse effects of intestinal cystoplasties can be avoided by the use of ureterocystoplasty. The combination of a small contracted bladder, associated with a severe dilation of the ureter of a non-functioning kidney is quite rare. The technique was first described in 1973 by Eckstein [837]; the success rate depends on patient selection and the re-augmentation rate can reach 73% [838, 839].

Auto-augmentation with partial detrusorectomy or detrusor myotomy creating a diverticulum avoids metabolic complications with the use of intestinal segments. The reports are conflicting, therefore, it may be used in selected cases [840-843]. For a successful outcome, a pre-operative bladder capacity of 75-80% of the expected volume seems necessary [841, 844]. Seromuscular cystoplasty has also not proven to be as successful as standard augmentation with intestine [845]. Tissue engineering, even if successful in vitro and some animal models, does not reach the results by using intestinal segments with a higher complication rate [846, 847]. Therefore, these alternatives for bladder augmentation should be considered as experimental and should be used only in controlled trials.

#### 3.13.4.7 Bladder outlet procedures

No available medical treatment has been validated to increase bladder outlet resistance. Alpha-adrenergic receptor stimulation of the bladder neck has not been effective [760]. Using fascial slings with autologous fascial strip or artificial material a continence rate between 40-100% can be achieved. In most cases this is achieved in combination with bladder augmentation [848-853]. Catheterising through a reconstructed bladder neck or a urethra compressed by a sling may not be easy; many surgeons prefer to combine this approach with a catheterisable channel [706]. In contrast to the autologous slings, artificial slings in girls with CIC through the urethra have a high complication rate [854]. In males, it may be an option [855], however as long as long-term results are missing, this method has to be classified as experimental and should only be carried out in studies. Artificial urinary sphincters were introduced by Scott in 1973 [856]. The continence rates in the literature in selected patients can be up to 83% [857, 858]. Post-pubertal patients, who can void voluntarily are good candidates, if they are manually dexterous. In very selected patients, CIC through the sphincter in an augmented bladder is possible [858]. The erosion rate can be up to 29% and the revision rate up to 100% depending on the follow-up time [852].

Patients, who underwent a bladder neck procedure only, have a chance of > 30% for an augmentation and/or onabotulinum toxin A injections >30% later on; half of them developed new upper tract damage in that time [859-861]. In patients with a good bladder capacity and bladder compliance without an indication for bladder augmentation, up to 40% will need augmentation later on [860]. Therefore, close follow-up of these patients with UD is required to avoid upper tract damage and chronic renal failure.

Bladder neck reconstruction is used mostly in exstrophy patients with acceptable results. However, in children with a neurogenic bladder the results are less favourable [862]. In most patients, the creation of a continent catheterisable stoma is necessary due to difficulties in performing the CIC via the urethra. In one series, 10% to a third still performed CIC via the urethra with a re-operation rates between 67% and 79% after a median follow-up between seven and ten years [863]. In patients who are still incontinent after a bladder outlet procedure, bladder neck closure with a continent catheterisable stoma is an option. The combination of a sling procedure together with a urethral lengthening procedure may improve the continence rates [864].

Bulking agents have a low success rate (10-40%), which is in most cases only temporary [865-867]. However, it does not adversely affect the outcome of further definite surgical procedures [865].

Bladder neck closure is often seen as the last resort to gain urinary continence in those patients with persistent urinary incontinence through the urethra. In girls, the transection is done between bladder neck and urethra and in boys above the prostate with preservation of the neurovascular bundle. It is an effective method to achieve continence together with a catheterisable cutaneous channel +/- augmentation as a primary or secondary

procedure [868, 869]. A complication rate of up to a third and a vesicourethral/vesicovaginal fistula in up to 15% should be considered [870], together with a higher risk for bladder stones, bladder perforation and deterioration of the upper tract function, if the patient is not compliant with CIC and bladder irrigations [870, 871].

#### 3.13.4.8 *Catheterisable cutaneous channel*

In most patients with a neurogenic bladder CIC is required. If this is not possible, or very time and/or resource consuming via the urethra, a continent cutaneous catheterisable channel should be offered as well as in those with bladder outlet procedures. It is especially beneficial to wheelchair-bound patients who often have difficulty with urethral catheterisation or are dependent on others to catheterise the bladder. In long-term studies the revision rate due to stenosis or incontinence can be as high as 50-60% depending on the type of channel [872, 873].

The stoma can be placed at the umbilicus or in the lower right abdominal wall using a VQZ plasty [874]. It should be carefully evaluated pre-operatively: it is extremely important that the patient can reach the stoma easily. Sometimes it has to be placed in the upper abdominal wall due to severe scoliosis mostly associated with obesity.

#### 3.13.4.9 *Continent and incontinent cutaneous urinary diversion*

Incontinent urinary diversion should be considered in patients who are not willing or able to perform a CIC and who need urinary diversion because of upper tract deterioration or gain urinary continence due to social reasons. In children and adolescents, the colonic conduit has shown to have less complications compared to the ileal conduit [875-878]. Total bladder replacement is extremely rare in children and adolescents, but may be necessary in some adults due to secondary malignancies or complications with urinary diversions. Any type of major bladder and bladder outlet construction should be performed in centres with sufficient experience in the surgical technique, and with experienced healthcare personnel to carry out post-operative follow-up [822, 879, 880].

Algorithms can be used for management of these patients (Figures 8 and 9).

#### 3.13.5 **Follow-up**

Neurogenic bladder patients require lifelong follow-up including not only urological aspects but also neurological and orthopaedic aspects. Regular investigation of upper and lower urinary tract is mandatory. In patients with changes of the function of the upper and/or lower urinary tract, a complete neurological re-investigation should be recommended including a total spine MRI to exclude a secondary tethered cord or worsening of the hydrocephalus. In addition, if some neurological changes are observed a complete investigation of the urinary tract should be undertaken.


A recent study of this guideline panel revealed that the priorities of patients for future expectations were as following in decreasing order: GoL, surgical techniques, development of new medications and sexuality/fertility issues. Male spina bifida patients preferred new medications and sex/fertility issues more, whereas females favoured QoL issues improvement more. These factors should be considered during long-term management [2].

In those patients with urinary tract reconstruction using bowel segments, regular investigations concerning renal function, acid base balance and vitamin B12 status are mandatory to avoid metabolic complications. There is an increased risk for secondary malignancies in patients with a neurogenic bladder either with or without enteric bladder augmentations [881-885]. Therefore, patients need to be informed of this risk and possible signs like haematuria. Although there are insufficient data on follow-up schemes to discover secondary malignancies, after a reasonable follow-up time (e.g. ten to fifteen years), an annual cystoscopy can be considered.

#### 3.13.6 **Self-organisation of patients**


As patients' self-organisations can support the parents, caregivers and the patients in all aspects of their daily life, patients should be encouraged to join these organisations.

**Figure 8a: Management of children with myelodysplasia with a neurogenic bladder**  
**Flowchart - First year of life**




*RBUS = Renal bladder ultrasound; UTI = urinary tract infection; VUD = videourodynamic; VCUG = voiding cystourethrography; CMG = cystometrogram; DMSA = dimercaptosuccinic acid; AB = antibiotics.*

**Figure 8b: Management of children with myelodysplasia with a neurogenic bladder**  
**Flowchart - 18 months - 4 years of age**



*RBUS = Renal bladder ultrasound; UTI = urinary tract infection; VUD = videourodynamic; VCUG = voiding cystourethrography; CMG = cystometrogram; DMSA = dimercaptosuccinic acid; AB = antibiotics*


**Figure 8c: Management of children with myelodysplasia with a neurogenic bladder**  
**Flowchart - 5 years to adulthood**



*RBUS = Renal bladder ultrasound; UTI = urinary tract infection; VUD = videourodynamic; VCUG = voiding cystourethrography; CMG = cystometrogram; DMSA = dimercaptosuccinic acid.*



Figure 9: Algorithm for the management of children with myelodysplasia with a neurogenic bladder



CAP = continuous antibiotic prophylaxis; CIC = clean intermittent catheterisation; US = ultrasound; VCUG = voiding cystourethrography; VUD = videourodynamic; VUR = vesicoureteric reflux.

### 3.13.7 Summary of evidence and recommendations for the management of neurogenic bladder

Summary of evidence	LE
Neurogenic detrusor-sphincter dysfunction (NDS) may result in different forms of LUTD and ultimately result in incontinence, UTIs, VUR, and renal scarring.	2a
In children, the most common cause of NDS is myelodysplasia (a group of developmental anomalies that result from defects in neural tube closure).	2
Bladder sphincter dysfunction correlates poorly with the type and level of the spinal cord lesion. Therefore, urodynamic and functional classifications are more practical in defining the extent of the pathology and in guiding treatment planning.	2a

Children with neurogenic bladder can have disturbances of bowel function as well as urinary function which require monitoring and, if needed, management.	2a
The main goals of treatment are prevention of urinary tract deterioration and achievement of continence at an appropriate age.	2a
Injection of botulinum toxin into the detrusor muscle in children who are refractory to anticholinergics, has been shown to have beneficial effects on clinical and urodynamic variables.	2a

Recommendations	LE	Strength rating
Urodynamic studies should be performed in every patient with spina bifida as well as in every child with high suspicion of a neurogenic bladder to estimate the risk for the upper urinary tract and to evaluate the function of the detrusor and the sphincter.	2	Strong
In all newborns, intermittent catheterisation (IC) should be started soon after birth. In those with a clear underactive sphincter and no overactivity, starting IC may be delayed. If IC is delayed, closely monitor babies for urinary tract infections, upper tract changes (US) and the lower tract (UD).	3	Strong
Start early anticholinergic medication in the newborns with suspicion of an overactive detrusor.	2	Strong
The use of suburothelial or intradetrusor injection of onabotulinum toxin A is an alternative and a less invasive option in children who are refractory to anticholinergics in contrast to bladder augmentation.	2	Strong
Treatment of faecal incontinence is important to gain continence and independence. Treatment should be started with mild laxatives, rectal suppositories as well as digital stimulation. If not sufficient transanal irrigation is recommended, if not practicable or feasible, a Malone antegrade colonic enema (MACE)/Antegrade continence enema (ACE) stoma should be discussed.	3	Strong
Ileal or colonic bladder augmentation is recommended in patients with therapy resistant overactivity of the detrusor, small capacity and poor compliance, which may cause upper tract damage and incontinence. The risk of surgical and non-surgical complications and consequences outweigh the risk of permanent damage of the upper urinary tract +/- incontinence due to the detrusor.	2	Strong
In patients with a neurogenic bladder and a weak sphincter, a bladder outlet procedure should be offered. It should be done in most patients together with a bladder augmentation.	3	Weak
Creation of a continent cutaneous catheterisable channel should be offered to patients who have difficulties in performing an IC through the urethra.	3	Weak
A life-long follow-up of renal and reservoir function should be available and offered to every patient. Addressing sexuality and fertility starting before/during puberty should be offered.	3	Weak
Urinary tract infections are common in children with neurogenic bladders, however, only symptomatic UTIs should be treated.	3	Weak

### 3.14 Dilatation of the upper urinary tract (UPJ and UVJ obstruction)

#### 3.14.1 *Epidemiology, aetiology and pathophysiology*

Dilatation of the upper urinary tract (UUT) remains a significant clinical challenge in deciding which patient will benefit from treatment. Ureteropelvic junction (UPJ) obstruction is defined as impaired urine flow from the pelvis into the proximal ureter with subsequent dilatation of the collecting system and the potential to damage the kidney. It is the most common pathological cause of neonatal hydronephrosis [886]. It has an overall incidence of 1:1,500 and a ratio of males to females of 2:1 in newborns.

Ureterovesical junction (UVJ) obstruction is an obstructive condition of the distal ureter as it enters the bladder, commonly called a primary obstructive megaureter. Megaureters are the second most likely cause of pathological neonatal hydronephrosis. They occur more often in males and are more likely to occur on the left side [887]. It can be very difficult to define 'obstruction' as there is no clear division between 'obstructed' and 'non-obstructed' urinary tracts. Currently, the most popular definition is that an obstruction represents any restriction to urinary outflow that, if left untreated, will cause progressive renal deterioration [888].

### 3.14.2 **Diagnostic evaluation**

The widespread use of US during pregnancy has resulted in a higher detection rate for antenatal hydronephrosis [889]. The challenge in the management of dilated UUT is to decide which child should be observed, which should be managed medically, and which requires surgical intervention. Despite the wide range of diagnostic tests, there is no single test that can accurately distinguish obstructive from non-obstructive cases (see Figure 10).

#### 3.14.2.1 *Antenatal ultrasound*

Usually between the 16th and 18th weeks of pregnancy, the kidneys are visualised routinely, when almost all amniotic fluid consists of urine. The most sensitive time for foetal urinary tract evaluation is the 28th week. If dilatation is detected, US should focus on:

- laterality, severity of dilatation, and echogenicity of the kidneys;
- hydronephrosis or hydro-ureteronephrosis;
- bladder volume and bladder emptying;
- sex of the child;
- amniotic fluid volume [890].

#### 3.14.2.2 *Postnatal ultrasound*

Since transitory neonatal dehydration lasts about 48 hours after birth, imaging should be performed following this period of postnatal oliguria. However, in severe cases (bilateral dilatation, solitary kidney, oligohydramnios), immediate postnatal sonography is recommended [891]. Ultrasound should assess the anteroposterior diameter of the renal pelvis, calyceal dilatation, kidney size, thickness of the parenchyma, cortical echogenicity, ureters, bladder wall and residual urine.

#### 3.14.2.3 *Voiding cystourethrogram*

In newborns with identified UUT dilatation, the primary or important associated factors that must be detected include:


- vesicoureteral reflux (found in up to 25% of affected children) [892];
- urethral valves;
- ureteroceles;
- diverticula;
- neurogenic bladder.

Conventional VCUG is the method of choice for primary diagnostic procedures [893].

#### 3.14.2.4 *Diuretic renography*

Diuretic renography is the most commonly used diagnostic tool to detect the severity and functional significance of problems with urine transport. Technetium-99m (<sup>99m</sup>Tc) mercaptoacetyltriglycine (MAG3) is the radionuclide of choice. It is important to perform the study under standardised circumstances (hydration, transurethral catheter) after the fourth and sixth weeks of life [894]. Oral fluid intake is encouraged prior to the examination. At fifteen minutes before the injection of the radionuclide, it is mandatory to administer normal saline intravenous infusion at a rate of 15 mL/kg over 30 minutes, with a subsequent maintenance rate of 4 mL/kg/h throughout the entire time of the investigation [895]. The recommended dose of furosemide is 1 mg/kg for infants during the first year of life, while 0.5 mg/kg should be given to children aged one to sixteen years, up to a maximum dose of 40 mg.

**Figure 10: Diagnostic algorithm for dilatation of the upper urinary tract**



\* A diagnostic work-up including VCUG must be discussed with the caregivers, as it is possible that, even if reflux is detected, it may have absolutely no clinical impact. However, it should be borne in mind that reflux has been detected in up to 25% of cases of prenatally detected and postnatally confirmed hydronephrosis [803].

US = ultrasound.

### 3.14.3 Management

#### 3.14.3.1 Prenatal management

Counselling the caregivers of an affected child is one of the most important aspects of care. The prognosis is hopeful for a hydronephrotic kidney, even if it is severely affected, as it may still be capable of meaningful renal function, unlike a severely hypoplastic and dysplastic kidney.

It is important to be able to tell the caregivers exactly when they will have a definitive diagnosis for their child and what this diagnosis will mean. In some cases, however, it will be immediately obvious that the child is severely affected; there will be evidence of massive bilateral dilatation, bilateral hypoplastic dysplasia, progressive bilateral dilatation with oligohydramnios, and pulmonary hypoplasia.

Intrauterine intervention is rarely indicated and should only be performed in well-experienced centres [896].

##### 3.14.3.1.1 Antibiotic prophylaxis for antenatal hydronephrosis

The benefits and harms of continuous antibiotic prophylaxis (CAP) vs. observation in patients with antenatal hydronephrosis are controversial. Currently, only two RCTs have been published, one of which is a pilot trial [897] and the other publication is only available as a congress abstract [898]. Both publications present incomplete data and outcomes.

The Panel conducted a SR assessing the literature from 1980 onwards [899]. The key findings are summarised below.

Due to the heterogeneity of the published literature it was not possible to draw strong conclusions as to whether CAP is superior to observation alone in children diagnosed with antibiotic prophylaxis for antenatal hydronephrosis (ANH). In the first RCT, a prospective longitudinal study [897], female gender, uncircumcised males, lack of CAP, high-grade hydronephrosis, hydroureteronephrosis and VUR were found to be the independent predictors for the development of UTI. The second RCT included in the SR, was published as an abstract only, presented limited data [898]. This trial seemed to focus mainly on patients with ANH and VUR and did not report any beneficial effect of CAP on UTI rates, but details on the study population were limited.

Key findings of the SR are that CAP may or may not be superior to observation in children with antenatal hydronephrosis in terms of decreasing UTI. Due to the low data quality it was also not possible to establish whether boys or girls are at a greater risk of developing a UTI, or ascertain whether the presence or absence of VUR impacts UTI rates. A correlation between VUR-grade and UTI could not be established either. However, noncircumcised infants, children diagnosed with high-grade hydronephrosis and hydroureteronephrosis were shown to be at higher risk of developing a UTI.

The SR also tried to identify the most effective antibiotic regimen and present data on adverse effects but, due to heterogeneity, the available data could not be statistically compared. The most commonly used antibiotic in infants with antenatal hydronephrosis is trimethoprim, but only one study reported side effects [897].

In conclusion, based on the available evidence, the benefits and harms of CAP in children with antenatal hydronephrosis remain unproven. Uncircumcised infants and infants with hydroureteronephrosis and highgrade hydronephrosis are more likely to develop a UTI. Continuous antibiotic prophylaxis should be reserved for this sub-group of children who are proven to be at high risk.

#### 3.14.3.2 UPJ obstruction

It is most important that management decisions are made on the basis of serial investigations that have used the same technique and have been performed by the same institution under standardised circumstances. According to a Cochrane review, non-surgical management of unilateral UPJ obstruction in infants less than two years old is also an option. However the high risk of bias of the included studies limits the evidence of this systematic review [900].

Symptomatic obstruction (recurrent flank pain, UTI) requires surgical correction using a pyeloplasty, according to the standardised open technique of Hynes and Anderson [901]. In experienced hands, laparoscopic or retroperitoneoscopic techniques and robot-assisted techniques have the same success rates as standard open procedures. In asymptomatic cases, conservative follow-up is the treatment of choice. A recent interventional study suggested that, in operated infants less than six months, inserting a stent (transanastomotic stent) decreases the complication rates compared to stentless approach [902]. However the results should be taken cautiously since there are successful reported stentless procedures in other age groups.

Indications for surgical intervention comprise impaired split renal function (< 40%), a decrease of split renal function of > 10% in subsequent studies, poor drainage function after the administration of furosemide, increased anteroposterior diameter on US, and grade III and IV dilatation as defined by the Society for Fetal Urology [691].

Well-established benefits of conventional laparoscopy over open surgery are the decreased length of hospital stay, better cosmesis, less post-operative pain and early recovery [903, 904]. A recent meta-analysis in children has shown that laparoscopic pyeloplasty (LP) was associated with decreased length of hospital stay and complication rates but prolonged operative time when compared to open pyeloplasty (OP). Additionally, both LP and OP had equal success rates [905]. Laparoscopic pyeloplasty can also be performed for re-do cases with the same advantages of the primary cases [906]. Robotic-assisted laparoscopic pyeloplasty (RALP) has all the same advantages as LP plus better manoeuvrability, improved vision, ease in suturing and increased ergonomics but higher costs [907, 908]. A recent study comparing RALP and LP has shown similar postoperative outcomes with exception of decreased operative time for RALP [909]. There does not seem to be any clear benefit of minimal invasive procedures in a very young child but current data is insufficient to defer a cut-off age.

#### 3.14.3.3 Megaureter

The treatment options of secondary megaureters are reviewed in Chapter 3.15.3.

##### 3.14.3.3.1 Non-operative management

If a functional study reveals and confirms adequate ureteral drainage, conservative management is the best option. Initially, low-dose prophylactic antibiotics within the first year of life are recommended for the prevention of UTIs, although there are no existing prospective randomised trials evaluating the benefit of this regimen [910]. With spontaneous remission rates of up to 85% in primary megaureter cases, surgical management is no longer recommended, except for megaureters with recurrent UTIs, deterioration of split renal function and significant obstruction [911].

##### 3.14.3.3.2 Surgical management

In general, surgery is indicated for symptomatic children, if there is a drop in function in conservative follow-up and hydroureteronephrosis is increasing [912]. Data suggest that children with a ureteric diameter of > 10-15 mm are more likely to require intervention [913].

The initial approach to the ureter can be either intravesical, extravesical or combined. Straightening the ureter is necessary without devascularisation. Ureteral tapering should enhance urinary flow into the bladder. The ureter must be tapered to achieve a diameter for an anti-reflux repair. Several tailoring techniques exist, such as ureteral imbrication or excisional tapering [914]. Some institutions perform endoscopic stenting, but there are still no long-term data and no prospective randomised trials to confirm their outcome. A systematic review assessed the success rates of endoscopic management of primary obstructive megaureters [915]. It was reported that endoscopic managements including; stent placement, balloon dilatation and incision can be an alternative

treatment in patients > 1 years of age. One third of those patients required further surgical correction. Furthermore, the long-term outcome of endoscopic management is still unknown. Therefore the EAU Paediatric Urology Guidelines Panel can not recommend endoscopic management routinely since the type of intervention and the management outcomes are unclear.

#### 3.14.4 **Conclusion**

The use of routine perinatal sonography has resulted in increased detection of hydronephrosis caused by UPJ or UVJ obstruction. Meticulous and repeat postnatal evaluation is mandatory to try to identify obstructive cases at risk of renal deterioration and requiring surgical reconstruction. Surgical methods are standardised and have a good clinical outcome.

#### 3.14.5 **Summary of evidence and recommendations for the management of UPJ-, UVJ-obstruction**

Summary of evidence	LE
Nowadays, most hydronephrotic kidneys have already been diagnosed prenatally during a maternal US investigation.	2
Ureteropelvic junction obstruction is the leading pathological cause of hydronephrotic kidneys (40%).	1
In children diagnosed with antenatal hydronephrosis, a systematic review could not establish any benefits or harms related to continuous antibiotic prophylaxis.	1b
In children diagnosed with antenatal hydronephrosis, non-circumcised infants (LE: 1a), children diagnosed with high-grade hydronephrosis (LE: 2) and hydroureteronephrosis (LE: 1b) were shown to be at higher risk of developing UTI.	2

Recommendations	LE	Strength rating
Include serial ultrasound (US) and subsequent diuretic renogram and sometimes voiding cystourethrography in postnatal investigations.	2	Strong
Offer continuous antibiotic prophylaxis to the subgroup of children with antenatal hydronephrosis who are at high risk of developing urinary tract infection like uncircumcised infants, children diagnosed with hydroureteronephrosis and high-grade hydronephrosis, respectively.	2	Weak
Decide on surgical intervention based on the time course of the hydronephrosis and the impairment of renal function.	2	Weak
Offer surgical intervention in case of an impaired split renal function due to obstruction or a decrease of split renal function in subsequent studies and increased anteroposterior diameter on the US, and grade IV dilatation as defined by the Society for Fetal Urology.	2	Weak
Offer pyeloplasty when ureteropelvic junction obstruction has been confirmed clinically or with serial imaging studies proving a substantially impaired or decrease in function.	2	Weak
Do not offer surgery as a standard for primary megaureters since the spontaneous remission rates are as high as 85%.	2	Strong

### 3.15 **Vesicoureteric reflux**

Lack of robust prospective RCTs limits the strength of the established guidelines for the management of VUR. The scientific literature for reflux disease is still limited and thus the level of evidence is generally low. Most of the studies are retrospective, include different patient groups, and have poor stratification of quality. Also, there is a high risk of presenting misleading results by combining different types of studies when systematically extracting data. Therefore, for reflux disease, it is unfortunately not possible to produce recommendations based on high-quality studies.

These Guidelines aim to provide a practical approach to the treatment of VUR based on risk analysis and selective indications for both diagnostics and intervention. Although the Panel have tried to summarise most of the possible scenarios in one single table, the table itself is still quite busy. The Panel strongly share the view that making simple and practical guidelines would underestimate the complexity of VUR as a sign of a wide range of pathologies [916]. In a recent publication the EAU and ESPU Pediatric Guidelines Panel summarized and updated this chapter [1611].

### 3.15.1 **Epidemiology, aetiology and pathophysiology**

Vesicoureteric reflux is an anatomical and/or functional disorder with potentially serious consequences, such as renal scarring, hypertension and renal failure. Patients with VUR present with a wide range of severity, and a good proportion of reflux patients do not develop renal scars and probably do not need any intervention [917]. Vesicoureteric reflux is a very common urological anomaly in children, with an incidence of nearly 1%.

Genetic analysis studies revealed monogenic causes for VUR and significant differentiation of innate immunity and epithelial function genes in children with VUR/UTIs compared to controls [918-920]. The main management goal is the preservation of kidney function, by minimising the risk of pyelonephritis. By defining and analysing the risk factors for each patient (i.e. age, sex, reflux grade, LUTD, anatomical abnormalities, and kidney status), it is possible to identify those patients with a potential risk of UTIs and renal scarring. Controversy persists over the optimal management of VUR, particularly the choice of diagnostic procedures, treatment (medical, endoscopic or surgical), and the timing of treatment.

Many children present without symptoms of UTI and, because invasive diagnostic procedures are performed only when clinically indicated, the exact prevalence of VUR is unknown. However, the prevalence of VUR in non-symptomatic children has been estimated at 0.4-1.8% [921]. Among infants prenatally identified with hydronephrosis on US, who were screened for VUR, the prevalence was 16.2% (7-35%) [922]. Siblings of children with VUR had a 27.4% (3-51%) risk of also having VUR, whereas the offspring of parents with VUR had a higher incidence of 35.7% (21.2-61.4%) [922].

However, reflux detected by sibling screening is associated with lower grades [827] and significantly earlier resolution [923]. When VUR is discovered in siblings after UTI, it is usually high-grade and associated with a high incidence of reflux nephropathy, particularly if the sibling is male and the grade of reflux was high in the index patient [924].

The incidence of VUR is much higher among children with UTIs (30-50%, depending on age). Urinary tract infections are more common in girls than boys due to anatomical differences. However, among all children with UTIs, boys are more likely to have VUR than girls (29% vs. 14%). Boys also tend to have higher grades of VUR diagnosed at younger ages, although their VUR is more likely to resolve itself [925-928].

There is a clear co-prevalence between LUTD and VUR [929]. Lower urinary tract dysfunction refers to the presence of LUTS, including urge, urge incontinence, weak stream, hesitancy, frequency and UTIs, which reflect the filling and/or emptying dysfunction and may be accompanied with bowel problems [929]. Some studies have described a prevalence of 40-60% for VUR in children with LUTD [930]. A published Swedish Reflux trial has demonstrated LUTD in 34% of patients, and subdivision into groups characteristic of children revealed that 9% had isolated overactive bladder and 24% had voiding phase dysfunction [931].

The spontaneous resolution of VUR is dependent on age at presentation, sex, grade, laterality, mode of clinical presentation, and anatomy [932]. Faster resolution of VUR is more likely with age less than one year at presentation, lower grade of reflux (grade 1-3), and asymptomatic presentation with prenatal hydronephrosis or sibling reflux. The overall resolution rate is high in congenital high-grade VUR during the first years of life. In several Scandinavian studies, the complete resolution rate for high-grade VUR has been reported at > 25%, which is higher than the resolution rate for VUR detected after infancy [931, 933, 934].

The presence of renal cortical abnormality, bladder dysfunction, and breakthrough febrile UTIs are negative predictive factors for reflux resolution [935-937].

Dilating VUR increases the risk of developing acute pyelonephritis and renal scarring. Untreated recurrent UTIs may have a negative impact on somatic growth and medical status of the child. Evidence of renal scarring is present in 10-40% of children with symptomatic VUR, resulting from either congenital dysplasia and/or acquired post-infectious damage, which may have a negative impact on somatic growth and general well-being [938-940].

Scar rates vary in different patient groups. Patients with higher grades of VUR present with higher rates of renal scars. In those with prenatal hydronephrosis, renal scarring occurs in 10% of patients [941-946], whereas in patients with LUTD, this may increase up to 30% [704, 940, 947]. Renal scarring may adversely affect renal growth and function, with bilateral scarring increasing the risk of insufficiency. Reflux nephropathy (RN) may be the most common cause of childhood hypertension. Follow-up studies have shown that 10-20% of children with RN develop hypertension or end-stage renal disease [948].

### 3.15.2 **Diagnostic evaluation**

The diagnostic work-up should aim to evaluate the overall health and development of the child, the presence of UTIs, renal status, the presence of VUR, and LUT function. A basic diagnostic work-up comprises a detailed medical history (including family history, and screening for LUTD), physical examination including blood pressure measurement, urinalysis (assessing proteinuria), urine culture, and serum creatinine in patients with bilateral renal parenchymal abnormalities.

The standard imaging tests include renal and bladder US, VCUG and nuclear renal scans. Ultrasound

and VCUG could be considered as complementary techniques [949]. The criterion standard in diagnosis of VUR is VCUG, especially at the initial work-up. This test provides precise anatomical detail and allows grading of VUR [950]. In 1985, the International Reflux Study Committee introduced a uniform system for the classification of VUR [951, 952] (Table 2). The grading system combines two earlier classifications and is based upon the extent of retrograde filling and dilatation of the ureter, renal pelvis and calyces on VCUG [952].

Radionuclide studies for detection of reflux have lower radiation exposure than VCUG, but the anatomical details depicted are inferior [953]. Recent studies on alternative imaging modalities for detection on VUR have yielded good results with voiding US and magnetic resonance VCUG [954-957]. Contrast enhanced voiding urosonography (ceVUS) with intravesical instillation of different ultrasound contrast agents has been shown to be highly sensitive giving comparable results with conventional VCUG while avoiding exposure to ionising radiation [510, 958-960]. However, despite the concerns about ionising radiation and its invasive nature, conventional VCUG still remains the gold standard because it allows better determination of the grade of VUR (in a single or duplicated kidney) and assessment of the bladder and urethral configuration. Intrarenal reflux (IRR) is associated with renal scarring development and it can be diagnosed on the images acquired during the voiding phase of the standard 4-staged VCUG and on ceVUS [961, 962].

**Table 2: Grading system for VUR on VCUG, according to the International Reflux Study Committee [963].**

<b>Grade I</b>	Reflux does not reach the renal pelvis; varying degrees of ureteral dilatation
<b>Grade II</b>	Reflux reaches the renal pelvis; no dilatation of the collecting system; normal fornices
<b>Grade III</b>	Mild or moderate dilatation of the ureter, with or without kinking; moderate dilatation of the collecting system; normal or minimally deformed fornices
<b>Grade IV</b>	Moderate dilatation of the ureter with or without kinking; moderate dilatation of the collecting system; blunt fornices, but impressions of the papillae still visible
<b>Grade V</b>	Gross dilatation and kinking of the ureter, marked dilatation of the collecting system; papillary impressions no longer visible; intraparenchymal reflux

Dimercaptosuccinic acid is the best nuclear agent for visualising the cortical tissue and differential function between both kidneys. Dimercaptosuccinic acid is taken up by proximal renal tubular cells and is a good indicator of renal parenchyma function. In areas of acute inflammation or scarring, DMSA uptake is poor and appears as cold spots. Dimercaptosuccinic acid scans are therefore used to detect and monitor renal scarring. A baseline DMSA scan at the time of diagnosis can be used for comparison with successive scans later during follow-up [964]. Dimercaptosuccinic acid can also be used as a diagnostic tool during suspected episodes of acute pyelonephritis [965]. Children with a normal DMSA scan during acute UTI have a low-risk of renal damage [965, 966].

Video-urodynamic studies are only important in patients in whom secondary reflux is suspected, such as those with spina bifida or boys in whom VCUG is suggestive of PUV. In the case of LUTS, diagnosis and follow-up can be limited to non-invasive tests (e.g. voiding charts, US, or uroflowmetry) [929]. Cystoscopy has a limited role in evaluating reflux, except for infravesical obstruction or ureteral anomalies that might influence therapy.

### 3.15.2.1 Recommendations for diagnosis of VUR

Recommendations	Strength rating
For diagnosis of VUR apart from VCUG , ceVUS is another option.	Weak

### 3.15.2.2 Infants presenting with prenatally diagnosed hydronephrosis

Ultrasound of the kidney and bladder is the first standard evaluation tool for children with prenatally diagnosed hydronephrosis. It is non-invasive and provides reliable information regarding kidney structure, size, parenchymal thickness and collecting system dilatation [967, 968].

Ultrasound should be delayed until the first week after birth because of early oliguria in the neonate. It is essential to evaluate the bladder, as well as the kidneys. The degree of dilatation in the collecting system under US, when the bladder is both full and empty, may provide significant information about the presence of VUR. Bladder wall thickness and configuration may be an indirect sign of LUTD and reflux. The absence of hydronephrosis on postnatal US excludes the presence of significant obstruction; however, it does not exclude VUR.

Monitoring with careful US avoids unnecessary invasive and irradiating examinations. The first two



US scans within the first one to two months of life are highly accurate for defining the presence or absence of renal pathology. In infants with two normal, successive scans, VUR is rare, and if present it is likely to be low-grade [941, 969]. The degree of hydronephrosis is not a reliable indicator for the presence of VUR, even though cortical abnormalities are more common in high-grade hydronephrosis [922]. The presence of cortical abnormalities on US (defined as cortical thinning and irregularity, as well as increased echogenicity) warrants the use of VCUG for detecting VUR [922]. Dimercaptosuccinic acid provides more reliable and quantitative measurement of the degree of cortical abnormalities, first detected with US.

The use of VCUG is recommended in patients with US findings of bilateral high-grade hydronephrosis, duplex kidneys with hydronephrosis, ureterocele, ureteric dilatation, and abnormal bladders, because the likelihood of VUR is much higher. In all other conditions, the use of VCUG to detect reflux is optional [922, 943, 970-972].

When infants who are diagnosed with prenatal hydronephrosis become symptomatic with UTIs, further evaluation with VCUG should be considered [971]. Patients with severe hydronephrosis and those whose hydronephrosis is sustained or progressive, need further evaluation to exclude obstruction.

### 3.15.2.3 Siblings and offspring of reflux patients

The screening of asymptomatic siblings and offspring is controversial. Some authors think that early identification of children with VUR may prevent episodes of UTI and therefore renal scarring, whereas others think that screening asymptomatic individuals is likely to result in significant over-treatment of clinically insignificant VUR. In screened populations the prevalence of VUR is 27.4% in siblings and 35.7% in offspring [963]. The overall estimate for renal cortical abnormalities is 19.3% (11-54%), with 27.8% having renal damage in cohorts of symptomatic and asymptomatic children combined. In asymptomatic siblings only, the rate of renal damage is 14.4% (0-100%). Although early screening and therefore early diagnosis and treatment appears to be more effective than late screening in preventing further renal damage [922, 924, 973, 974], screening in all siblings and offspring cannot be recommended based on the available evidence. The lack of RCTs for screened patients to assess clinical health outcomes makes evidence-based guideline recommendations difficult.

### 3.15.2.4 Recommendations for paediatric screening of VUR

Recommendations	Strength rating
Inform parents of children with vesicoureteric reflux (VUR) that siblings and offspring have a high prevalence of VUR.	Strong

### 3.15.2.5 Children with febrile urinary tract infections

A routine recommendation of VCUG at zero to two years of age after the first proven febrile UTI is the safest approach as the evidence for the criteria to selecting patients for reflux detection is weak. Upon diagnosing a child with the first febrile UTI, the risk factors: age (> 6 months), presence of sepsis, WBC count ( $\geq 15\ 000/\text{mm}^3$ ), and abnormal renal US results, can be used for the generation of a predictive score for VUR presence [975]. (See Section 3.9 on urinary tract infections in children).

Children with febrile infections and abnormal renal US findings may have higher risk of developing renal scars and they should all be evaluated for reflux [513]. If reflux is diagnosed, further evaluation has traditionally consisted of a DMSA scan.

An alternative "top-down" approach is also an option, as suggested by several studies in the literature. This approach carries out an initial DMSA scan close to the time of a febrile UTI, to determine the presence of pyelonephritis, which is then followed by VCUG if the DMSA scan reveals kidney involvement. A normal DMSA scan with no subsequent VCUG will fail to identify VUR in 5-27% of cases, with the missed VUR presumably being less significant. In contrast, a normal DMSA scan with no VCUG avoids unnecessary VCUG in > 50% of those screened [503, 976-978].

### 3.15.2.6 Children with lower urinary tract symptoms and vesicoureteric reflux

Detection of LUTD is essential in treating children with VUR. It is suggested that reflux with LUTD resolves faster after LUTD correction, and that patients with LUTD are at higher risk for developing UTI and renal scarring [928, 979]. The co-existence of both conditions should be explored in any patient who has VUR. If there are symptoms suggestive of LUTD (e.g. urgency, wetting, constipation or holding manoeuvres), an extensive history and examination, including voiding charts, uroflowmetry and residual urine determination, will reliably diagnose underlying LUTD.

Among toilet-trained children, those with both LUTD and VUR are at higher risk of developing recurrent UTIs than children with isolated VUR [540]. Bladder and bowel dysfunction is common in toilet-trained

children presenting with UTI with or without primary VUR. A subgroup meta-analysis also shows that functional constipation is common in these children, with almost every third child affected by it. It was also found that the presence of both BBD and VUR doubles the risk of recurrence of UTI; hence, all children presenting with UTI should be carefully evaluated for presence of BBD and managed accordingly [980].

In LUTD, VUR is often low-grade and US findings are normal, and there is no indication for performing VCUG in all children with LUTD, but the presence of febrile infections should be meticulously investigated. The co-existence of LUTD and VUR means it would be better to do a test covering both conditions, such as a VUDS. Any patient with LUTD and a history of febrile UTI should be investigated with a VUDS, if available. Furthermore, any child who fails standard therapy for LUTD should undergo urodynamic investigation. At this stage, combining a urodynamic study with VCUG is highly recommended.

### 3.15.3 **Disease management**

There are two main treatment approaches: conservative (non-surgical and surgical).

#### 3.15.3.1 *Non-surgical therapy*

The objective of conservative therapy is prevention of febrile UTI. It is based on the understanding that:

- Vesicoureteric reflux can resolve spontaneously, mostly in young patients with low-grade reflux. Renal scarring is also a significant risk factor for breakthrough UTI and could be used to determine those at risk of symptomatic VUR persistence [981];
- Resolution is nearly 80% in VUR grades I and II and 30-50% in VUR grades III-V within four to five years of follow-up;
- Spontaneous resolution is low for bilateral high-grade reflux [982];
- Vesicoureteric reflux is very unlikely to damage the kidney postnatally when patients are free of infection and have normal LUT function;
- There is no evidence that small scars even bilateral can cause hypertension, renal insufficiency or problems during pregnancy. Indeed, these are possible only in cases of severe bilateral renal damage;
- The conservative approach includes watchful waiting, intermittent or continuous antibiotic prophylaxis, and bladder and bowel rehabilitation in those with LUTD [704, 979, 983-985];
- Circumcision during early infancy may be considered as part of the conservative approach as it is effective in reducing the risk of infection in normal children [986].

##### 3.15.3.1.1 Follow-up

Regular follow-up with imaging studies (e.g. VCUG, nuclear cystography, or DMSA scan) is part of the conservative management to monitor spontaneous resolution and kidney status. Vesicoureteral reflux increases the risk of febrile UTI and renal scarring especially when in combination with LUTD. Constipation in VUR patients with UTI is common and the prevalence can reach 27%. Assessment and management of all toilet trained children presenting with UTI should be a part of conservative follow-up [980]. During the conservative management of high-grade infant reflux, spontaneous downgrading and resolution of VUR is more likely. However this also depends on gender, breakthrough UTI, renal damage type and bladder dysfunction. Practical scoring systems for making decisions on further treatment, surveillance, prophylaxis or surgical intervention exist [987]. Conservative management should be dismissed in all cases of febrile breakthrough infections, despite prophylaxis, and intervention should be considered.

##### 3.15.3.1.2 Continuous antibiotic prophylaxis

Many prospective studies have evaluated the role of continuous antibiotic prophylaxis in the prevention of recurrent UTI and renal scarring.

It is clear that antibiotic prophylaxis may not be needed in every reflux patient [988-990]. Trials show the benefit of CAP is none or minimal in low-grade reflux. Continuous antibiotic prophylaxis is useful in patients with grade III and IV reflux in preventing recurrent infections but its use in preventing further renal damage is not proven. For VUR children receiving CAP, younger age at the initial diagnosis of UTI ( $\leq 12$  months), bilateral VUR, and BBD are independent risk factors for the occurrence of break through UTIs [991]. Toilet-trained children and children with LUTD derive better benefit from CAP [990, 992-996]. The RIVUR trial was the largest, randomised, placebo-controlled, double blind, multi-centre study, involving 607 children aged 2-72 months with grade I-IV VUR. The RIVUR study showed that prophylaxis reduced the risk of recurrent UTI by 50% but not renal scarring and its consequences (hypertension and renal failure), at the cost of increased antimicrobial resistance. The benefit of prophylaxis was insignificant in patients with grade III or IV VUR and in the absence of LUTD [997-1000]. Additional review of the RIVUR data based on a risk classification system defines a high-risk group (uncircumcised males; presence of BBD and high grade reflux) who would benefit from a antibiotic prophylaxis significantly. In the context of management with CAP in VUR patients, this should be viewed as a spectrum and a shift from 'absolute' CAP in dilated VUR towards a 'selective' risk-based approach and should be supported

[1001]. It may be difficult and risky to select patients who do not need CAP. A safe approach would be to use CAP in most cases. Decision-making may be influenced by the presence of risk factors for UTI, such as young age, high-grade VUR, status of toilet-training/LUTS, female sex, and circumcision status. Although the literature does not provide any reliable information about the duration of CAP in reflux patients, a practical approach would be to use CAP until after children have been toilet-trained and ensuring that there is no LUTD.

The literature generally consists of prescribing daily antibiotics at one quarter to one half the regular therapeutic dose. Trimethoprim-sulfamethoxazole, amoxicillin and nitrofurantoin are the most commonly used CAP agents. A child with a UTI and significant VUR can still be recommended to be treated conservatively at first, with surgical care reserved for non-compliance for CAP, breakthrough UTIs under CAP and significant VUR that persists of long-term follow-up [991, 1002].

Determination of optimal timing to discontinue CAP is controversial however patients administered CAP for less than a year after the last febrile UTI and those with bilateral VUR are likely to have more frequent recurrence. Administration of CAP more than one year after the last febrile UTI can potentially be beneficial to avoid recurrent UTIs [1003]. Active surveillance of UTI is needed after CAP is discontinued. The follow-up scheme and the decision to perform an anti-reflux procedure or discontinuation of CAP should be tailored for each VUR case together with the patient and caregivers. It is strongly advised that the advantages and disadvantages should be discussed in detail and easy/early access to healthcare during febrile UTIs should be taken into consideration.

One of the biggest concerns of CAP for patients, caregivers and physicians is the long-term effects of CAP. As a secondary outcome of the RIVUR study, TMP-SMZ prophylaxis for two years did not reveal any adverse effect on complete blood count (CBC), serum electrolytes and creatinine and such routine laboratory tests in otherwise healthy children is not mandatory [1004]. Impact of long-term CAP on gut microbiota in children with VUR is controversial and requires more research [1005, 1006].

Continuous antibiotic prophylaxis, for prevention of UTIs in symptomatic VUR, which diagnosed during the work-up of antenatal hydronephrosis, is recommended in the first year of life. However, the current literature remains unclear whether infants diagnosed with asymptomatic VUR during the antenatal hydronephrosis work-up will also benefit from CAP [1007].

Recommendations	Strength rating
Initially treat all symptomatic patients diagnosed within the first year of life with continuous antibiotic prophylaxis, regardless of the grade of reflux or presence of renal scars.	Weak
Offer immediate, parenteral antibiotic treatment for febrile breakthrough infections.	Strong
Initially manage all children presenting at age one to five years conservatively.	Strong
Offer close surveillance without antibiotic prophylaxis to children presenting with lower grades of reflux and without symptoms.	Strong
Ensure that a detailed investigation for the presence of lower urinary tract dysfunction (LUTD) is done in all and especially in children after toilet-training. If LUTD is found, the initial treatment should always be for LUTD.	Strong

### 3.15.3.2 Surgical treatment

Surgical treatment can be carried out by endoscopic injection of bulking agents or ureteral re-implantation.

#### 3.15.3.2.1 Subureteric injection of bulking materials

With the availability of biodegradable substances, endoscopic subureteric injection of bulking agents has become an alternative to long-term antibiotic prophylaxis and open surgical intervention in the treatment of VUR in children. Using cystoscopy, a bulking material is injected beneath the intramural part of the ureter in a submucosal location. The injected bulking agent elevates the ureteral orifice and supports the distal ureter, lengthens the submucosal tunnel so that coaptation is increased. This results in narrowing of the lumen, which prevents reflux of urine into the ureter, while still allowing its antegrade flow. Reflux timing during VCUG can be used to predict the success rate of endoscopic treatment, since reflux occurring only during the voiding phase has a higher success than filling phase VUR [1008].

Several bulking agents have been used over the past two decades, including polytetrafluoroethylene (PTFE or Teflon™), collagen, autologous fat, polydimethylsiloxane, silicone, chondrocytes, a solution of dextranomer/hyaluronic acid (D/HA) (Deflux™, Dexell®) and more recently polyacrylatepolyalcohol copolymer hydrogel (PPC) (Vantris®) [1009, 1010].

Although the best results have been obtained with PTFE [1011], due to concerns about particle migration, PTFE has not been approved for use in children [1012]. Although they are all biocompatible, other compounds such

as collagen and chondrocytes have failed to provide a good outcome. Deflux™ was approved by the USA FDA in 2001 for the treatment of VUR in children. Injection can be performed under the ureteric orifice to create a volcanic appearance or by using a hydrodistension technique to the ureteric orifice followed by injection to the intramural ureter.

In a meta-analysis [1013] of 5,527 patients and 8,101 renal units, the reflux resolution rate (by ureter) following one treatment for grades I and II reflux was 78.5%, 72% for grade III, 63% for grade IV, and 51% for grade V. If the first injection was unsuccessful, the second treatment had a success rate of 68% and the third treatment 34%. The aggregate success rate with one or more injections was 85%. The success rate was significantly lower for duplicated (50%) vs. single (73%) systems, and neuropathic (62%) vs. normal (74%) bladders. The required injection volume of PPC and D/HA to achieve the same success rate can differ between agents and is generally less for PPC [1014, 1015].

Ureteral diameter ratio is a relatively recent objective measurement and appears to be a new predictive tool for clinical outcome and success after endoscopic injection of VUR [1016].

Obstruction at UVJ (UVJO) may happen in the long term follow-up after endoscopic correction of reflux. Patients with high-grade reflux and dilated ureters are at risk of late obstruction. Although in the short term (3-6 months) follow-up success rates and UVJ obstruction seems to be comparable in the long run, it is significantly more common when polyacrylate-polyalcohol copolymer is used as bulking substance [1017-1020]. The ureteral reimplantation following a failed endoscopic surgery is more challenging after PPC and distal ureter can not be preserved and requires excision due to fibrosis [1015]. Although ureteral fibrosis or inflammatory changes following Vantris injection causing UVJO has been shown to be similar to other injection materials, still PPC demonstrates a higher obstruction rate [1021].

Clinical validation of the effectiveness of anti-reflux endoscopy is currently hampered by the lack of methodologically appropriate studies. In the most recent prospective, randomised trials comparing three treatment arms: i) endoscopic injection; ii) antibiotic prophylaxis; iii) surveillance without antibiotic prophylaxis in 203 children aged one to two years with grade III/IV reflux, endoscopic treatment gave the highest resolution rate of 71% compared to 39% and 47% for treatment arms ii and iii, respectively, after two years' follow-up. The recurrence rate at two years after endoscopic treatment was 20%. The occurrence of febrile UTIs and scar formation was highest in the surveillance group at 57% and 11%, respectively. New scar formation rate was higher with endoscopic injection (7%) compared with antibiotic prophylaxis (0%) [1022]. Longer follow-up studies are needed to validate these findings.

High grade VUR in infants can be treated with injection therapy and the resolution rate is higher than that of prophylaxis. However, this can not be recommended for all high grade infants with VUR since not only all are symptomatic and but also resolution or downgrading can be achieved at favourable conditions such as unilaterality, grade IV and low residual urine [1023, 1024].

#### 3.15.3.2.2 Open surgical techniques

Various intra- and extravesical techniques have been described for the surgical correction of reflux. Although different methods have specific advantages and complications, they all share the basic principle of lengthening the intramural part of the ureter by submucosal embedding of the ureter. All techniques have been shown to be safe with a low rate of complications and excellent success rates (92-98%) [1025].

The most popular and reliable open procedure is cross trigonal re-implantation described by Cohen [1019]. The main concern with this procedure is the difficulty of accessing the ureters endoscopically, if needed, when the child is older. Alternatives are suprahiatal re-implantation (Politano-Leadbetter technique) and infrahiatal re-implantation (Glenn-Anderson technique). If an extravesical procedure (Lich-Gregoir) is planned, cystoscopy should be performed pre-operatively to assess the bladder mucosa and the position and configuration of the ureteric orifices. In bilateral reflux, an intravesical anti-reflux procedure may be considered, because simultaneous bilateral extravesical reflux repair carries an increased risk of temporary post-operative urine retention [1026]. Overall, all surgical procedures offer very high and similar success rates for correcting VUR.

#### 3.15.3.2.3 Laparoscopy and robot-assisted

There have been a considerable number of case series of transperitoneal, extravesical and pneumovesicoscopic intravesical ureteral re-implantation, which have shown the feasibility of the techniques. A recent systemic review and meta-analysis comparing laparoscopic extravesical (LEVUR) vs. transvesicoscopic ureteral reimplantation (TVUR), revealed both to be good alternatives in terms of success and complication rates. Laparoscopic extravesical ureteral reimplantation is generally biasly preferred for unilateral low grade cases and therefore appears to have a higher success and shorter hospital stay [1020].

Various anti-reflux surgeries have been performed with the robot and the extravesical approach is the most commonly used. Although initial reports give comparable outcomes to their open surgical counterparts in terms

of successful resolution of reflux, recent meta-analysis of results of Robotic-Assisted Laparoscopic Ureteral Reimplantation (RALUR) are within a wide range of variation and on average they are poor compared to open surgery. Operative times, costs and post-operative complications leading to secondary interventions are higher with RALUR but post-operative pain and hospital stay is less compared to open surgery [1027-1030].

In addition, laparoscopic- or robotic-assisted approaches are more invasive than endoscopic correction and their advantages over open surgery are still debated. Therefore, at present, a laparoscopic approach cannot be recommended as a routine procedure. It can be offered as an alternative to the caregivers in centres where there is established experience [986, 1031-1039]. Older children with complex anatomy and/or following a failed injection or open reimplant, can specifically benefit from RALUR since the robotic approach can facilitate the exposure. RALUR can be performed uni or bilateral, although caution is advised in bilateral cases due to the risk of transient retention [1028].

*De novo* hydronephrosis up to 30% can occur after extravesical RALUR and behave similarly to open ureteral reimplantation which is self resolving in the overwhelming majority of cases [1040].

### 3.15.4 **Summary of evidence and recommendations for the management of vesicoureteric reflux in childhood**

Summary of evidence	LE
There is no evidence that correction of persistent low-grade reflux (grades I-III) without symptoms and normal kidneys offers a significant benefit.	3
The traditional approach of initial medical treatment after diagnosis and shifting to interventional treatment in case of breakthrough infections and new scar formation needs to be challenged, because the treatment should be tailored to different risk groups.	4
Surgical correction should be considered in patients with persistent high-grade reflux (grades IV/V). There is no consensus about the timing and type of surgical correction. The outcome of reimplantation is better than endoscopic correction for higher grades of reflux, whereas satisfactory results can be achieved by endoscopic injection for lower grades.	3
The choice of management depends on the presence of renal scars, clinical course, grade of reflux, ipsilateral renal function, bilaterality, bladder function, associated anomalies of the urinary tract, age, compliance, and parental preference. Febrile UTI, high-grade reflux, bilaterality, and cortical abnormalities are considered to be risk factors for possible renal damage. The presence of LUTD is an additional risk factor for new scars.	4

Recommendations	Strength rating
Offer reimplantation or endoscopic correction to patients with frequent breakthrough infections.	Weak
Offer reimplantation to patients with persistent high-grade reflux and endoscopic correction for lower grades of reflux.	Strong
Offer surgical repair to children above the age of one presenting with high-grade reflux and abnormal renal parenchyma.	Weak
Offer surgical correction, if parents prefer definitive therapy to conservative management.	Strong
Select the most appropriate management option based on: <ul style="list-style-type: none"> <li>• the presence of renal scars;</li> <li>• clinical course;</li> <li>• the grade of reflux;</li> <li>• ipsilateral renal function;</li> <li>• bilaterality;</li> <li>• bladder function;</li> <li>• associated anomalies of the urinary tract;</li> <li>• age and gender;</li> <li>• compliance;</li> <li>• parental preference.</li> </ul> Refer to Table 3 for risk factors and follow-up.	Weak
In high-risk patients who already have renal impairment, a more aggressive, multi-disciplinary approach is needed.	Strong

**Table 3: Management and follow-up according to different risk groups**

Risk Groups	Presentation	Initial treatment	Comment	Follow-up
High	Symptomatic male or female patients after toilet-training with high-grade reflux (grades IV-V), abnormal kidneys and LUTD	Initial treatment is always for LUTD with CAP; intervention may be considered in cases of BT infections or persistent reflux	Greater possibility of earlier intervention	More aggressive follow-up for UTI and LUTD; full re-evaluation after 6 months
High	Symptomatic male or female patients after toilet-training with high-grade reflux (grade IV-V), abnormal kidneys and no LUTD	Intervention should be considered	Reimplantation has better results than endoscopic surgery	Post-operative VCUG on indication only; follow-up of kidney status until after puberty
Moderate	Symptomatic male or female patients before toilet-training, with high-grade reflux and abnormal kidneys	CAP is the initial treatment. Intervention may be considered in cases of BT infections or persistent reflux	Spontaneous resolution is higher in males	Follow-up for UTI/ hydronephrosis; full re-evaluation after 12-24 months
Moderate	Asymptomatic patients (PNH or sibling) with high-grade reflux and abnormal kidneys	CAP is the initial treatment. Intervention may be considered in cases of BT, infections or persistent reflux		Follow-up for UTI/ hydronephrosis; full re-evaluation after 12-24 months
Moderate	Symptomatic male or female patients after toilet-training, with high-grade reflux and normal kidneys with LUTD	Initial treatment is always for LUTD with CAP. Intervention may be considered in cases of BT infections or persistent reflux	In case of persistent LUTD, despite urotherapy, intervention should be considered. The choice of intervention is controversial	Follow-up for UTI and LUTD, kidney status; full re-evaluation after successful urotherapy
Moderate	Symptomatic male or female patients after toilet-training with low-grade reflux, abnormal kidneys with or without LUTD	Choice of treatment is controversial. Endoscopic treatment may be an option. LUTD treatment should be given if needed		Follow-up for UTI, LUTD, and kidney status until after puberty
Moderate	All symptomatic patients with normal kidneys, with low-grade reflux, with LUTD	Initial treatment is always for LUTD with or without CAP		Follow-up for UTI and LUTD
Low	All symptomatic patients with normal kidneys, with low-grade reflux, with no LUTD	No treatment or CAP	If no treatment is given, parents should be informed about risk of infection	Follow-up for UTI
Low	All asymptomatic patients with normal kidneys with low-grade reflux	No treatment or CAP in infants	If no treatment is given, parents should be informed about risk of infection	Follow-up for UTI

BT = breakthrough; CAP = continuous antibiotic prophylaxis; LUTD = lower urinary tract dysfunction; PNH =

*prenatal diagnosed hydronephrosis; UTI = urinary tract infection; VCUG = voiding cystourethrography.*

### **3.16 Urinary stone disease**

#### **3.16.1 Epidemiology, aetiology and pathophysiology**

Paediatric stone disease is an important clinical problem in paediatric urology practice. Due to its recurrent nature, every effort should be made to discover the underlying metabolic abnormality so that it can be treated appropriately. The main goal is to maintain a stone-free state with close follow-up, although it may not be possible in some circumstances (e.g. oxalosis or nephrocalcinosis).

Bladder stones are still common in under-developed areas of the world and are usually ammonium acid urate and uric acid stones, strongly implicating dietary factors [1041, 1042]. Hypocitraturia is the most common metabolic abnormality, followed by hypercalciuria [1043]. Patients with augmented bladder constitute another important group with a risk of up to 15% [1044].

The incidence and characteristics of stones show a wide geographical variation in children. Although urinary stone disease is generally considered to be a relatively rare disease, it is quite common in some parts of the world. Paediatric stone disease is endemic in Turkey, Pakistan and in some South Asian, African and South American countries. However, recent epidemiological studies have shown that the incidence of paediatric stone disease is also increasing in the Western world [1045-1047]; especially in girls, Caucasian ethnicity, African Americans and older children [1048]. More than 70% of stones in children contain calcium oxalate, while infectious stones are found more frequently in younger children [1049]. The risk for stone recurrence among childhood stone formers has been reported to be 35-50%. No sex differences could be found regarding the stone recurrence risk [1050, 1051].

#### **3.16.2 Classification systems**

Urinary stone formation is the result of a complex process involving genetic, dietary, metabolic, anatomical factors and presence of infection.

##### **3.16.2.1 Calcium stones**

Calcium stones are usually made from calcium oxalate or calcium phosphate. Super-saturation of calcium (hypercalciuria) and oxalate (hyperoxaluria) or decreased concentration of inhibitors, such as citrate (hypocitraturia) or magnesium (hypomagnesemia) play a major role in the formation of calcium oxalate stones. Higher super-saturations of calcium oxalate were shown to be associated with multiple stone disease [1052].

*Hypercalciuria:* This is defined by a 24-hour urinary calcium excretion of more than 4 mg/kg/day (0.1 mmol/kg/day) in a child weighing < 60 kg. In infants younger than three months, 5 mg/kg/day (0.125 mmol/kg/day) is considered to be the upper limit for normal calcium excretion [1053].

Hypercalciuria can be classified as either idiopathic or secondary. Idiopathic hypercalciuria is diagnosed when clinical, laboratory, and radiographic investigations fail to delineate an underlying cause leading to hypercalcaemia. Urinary calcium may increase in patients with high sodium chloride intake.

Secondary hypercalciuria occurs when a known process produces excessive urinary calcium. In secondary hypercalcaemic hypercalciuria, a high serum calcium level may be due to increased bone resorption (hyperparathyroidism, hyperthyroidism, immobilisation, acidosis, metastatic disease) or gastrointestinal hyperabsorption (hypervitaminosis D) [1054].

A good screening test for hypercalciuria compares the ratio of urinary calcium to creatinine. The normal calcium-to-creatinine ratio in children is less than 0.2. If the calculated ratio is higher than 0.2, repeat-testing is indicated. Neonates and infants have a higher calcium excretion and lower creatinine excretion than older children [1053, 1054]. If the follow-up ratios are normal, then no additional testing for hypercalciuria is needed.

However, if the ratio remains elevated, a timed 24-hour urine collection should be obtained and the calcium excretion calculated. The 24-hour calcium excretion test is the standard criterion for the diagnosis of hypercalciuria. If calcium excretion is higher than 4 mg/kg/day (0.1 mmol/kg/day), the diagnosis of hypercalciuria is confirmed and further evaluation is warranted: levels of serum bicarbonate, creatinine, alkaline phosphatase, calcium, phosphorus, magnesium, pH, and parathyroid hormone. Freshly voided urine should be measured for pH [1053-1055]. In addition to calcium, the 24-hour urine analysis should also include phosphorus, sodium, magnesium, uric acid, citrate and oxalate.

Initial management is always to increase fluid intake and urinary flow. Dietary modification is a mandatory part of effective therapy. The child should be referred to a dietician to accurately assess the daily intake of calcium, animal protein, and sodium. Dietary sodium restriction is recommended as well as

maintenance of calcium intake consistent with the daily needs of the child [1056]. A brief trial of a low calcium diet can be carried out to determine if exogenous calcium intake and/or calcium hyperabsorption is contributing to high urinary calcium. Any recommendation to restrict calcium intake below the daily needs of the child should be avoided. Moreover, low calcium intake is a risk factor for stone formation [1057] (LE: 3).

Hydrochlorothiazide and other thiazide-type diuretics may be used to treat idiopathic hypercalciuria, especially with calcium renal leak, at a starting dosage of 0.5-1 mg/kg/day [1058-1061] (LE: 3). In long-term use of thiazide-type diuretics, a decrease in hypocalciuric effect may be seen after the third month and may cause hypokalemia, hypocitraturia, hyperuricaemia and hypomagnesaemia. Therefore, control of blood and serum values should be performed in regular intervals. Citrate therapy is also useful if citrate levels are low or if hypercalciuria persists, despite other therapies [1058, 1062] (LE: 4).

*Hyperoxaluria:* Only 10-15% of oxalate is dietary. The average child excretes less than 50 mg (0.57 mmol)/1.73 m<sup>2</sup>/day [1063-1065], while infants excrete four times as much. Hyperoxaluria may result from increased dietary intake, enteric hyperabsorption (as in short bowel syndrome) or an inborn error of metabolism.

In rare primary hyperoxaluria, one of the two liver enzymes that play a role in the metabolism of oxalate may be deficient. With increased deposition of calcium oxalate in the kidneys, renal failure may ensue, resulting in deposition of calcium oxalate in other tissues (oxalosis). The diagnosis is made upon laboratory findings of severe hyperoxaluria and clinical symptoms. The definitive diagnosis requires a liver biopsy to assay the enzyme activity. Patients with primary hyperoxaluria exhibit a substantial clinical burden such as renal stones, UTIs and pain, requiring frequent healthcare resource use [1066].

Other forms of hyperoxaluria, as mentioned earlier, may be due to hyperabsorption of oxalate in inflammatory bowel syndrome, pancreatitis and short bowel syndrome. Yet, the majority of children have 'mild' (idiopathic) hyperoxaluria, with only mildly elevated urine oxalate levels in these cases. The treatment of hyperoxaluria consists of the promotion of high urine flow, restriction of dietary oxalate and regular calcium intake. Pyridoxine may be useful in reducing urine levels, especially in primary hyperoxaluria. Citrate administration increases inhibitory urine activity [1058, 1067] (LE: 4).

*Hypocitraturia:* Citrate is a urinary stone inhibitor. It acts by binding to calcium and by directly inhibiting the growth and aggregation of calcium oxalate as well as calcium phosphate crystals. Thus low urine citrate may be a significant cause of calcium stone disease. In adults, hypocitraturia is the excretion of urinary citrate of less than 320 mg/day (1.5 mmol/day); this value must be adjusted for children depending on body size [1068-1070]. Hypocitraturia usually occurs in the absence of any concurrent symptoms or any known metabolic derangements. It may also occur in association with any metabolic acidosis, distal tubular acidosis or diarrhoeal syndromes.

Environmental factors that lower urinary citrate include a high protein intake and excessive salt intake. Many reports emphasise the significance of hypocitraturia in paediatric calcium stone disease. The presence of hypocitraturia ranges from 30% to 60% in children with calcium stone disease [1069, 1071]. The urine calcium-to-citrate ratios were higher in recurrent calcium stone forming children than solitary formers [1068, 1072].

The restoration of normal citrate levels is advocated to reduce stone formation, although there are few relevant studies in children. Hypocitraturia is treated by potassium citrate at a starting dose of 1 mEq/kg, given in two divided doses [1059] (LE: 3). The side effects of potassium citrate are very rare and most of the time they include non-specific gastrointestinal complaints. Potassium citrate should be used with caution in hyperkalemic and chronic renal failure conditions.

### 3.16.2.2 *Uric acid stones*

Uric acid stones are responsible for urinary calculi in 4-8% of children. Uric acid is the end product of purine metabolism. Hyperuricosuria is the main cause of uric acid stone formation in children. A daily output of uric acid of more than 10 mg/kg/day (0.6 mmol/kg/day) is considered to be hyperuricosuria [1058]. The formation of uric acid stones is mainly dependent on the presence of an acidic urinary composition. Uric acid dissociation and solubility is strongly reduced at a pH of < 5.8. As the pH becomes more alkaline, uric acid crystals become more soluble and the risk of uric acid stone formation is reduced.

In the familial or idiopathic form of hyperuricosuria, children usually have normal serum uric acid levels. In other children, it can be caused by uric acid overproduction secondary to inborn errors of metabolism, myeloproliferative disorders or other causes of cell breakdown. Hyperuricosuria is also caused by high purine and protein intake. Although hyperuricosuria is a risk factor for calcium oxalate stone formation in adults, this does not appear to be a significant risk factor in children. Uric acid stones are non-opaque stones. Plain x-rays are insufficient to show uric acid stones, and renal sonography and spiral CT are used for diagnosis.



Alkalinisation of urine is the mainstay of therapy and prevention for uric acid stones. Citrate preparations are useful as alkalinising agents. Maintaining a urine pH of 6 to 6.5 is sufficient to prevent uric acid stones [1058]. In patients who failed conservative measures with sustaining hyperuricosuria and hyperuricemia, stone recurrences or myeloproliferative diseases, allopurinol (10 mg/kg) may be used. This medication may cause several drug reactions (rash, diarrhoea, eosinophilia) and should be cautiously used in chronic renal failure patients.

### 3.16.2.3 Cystine stones

Cystinuria is the cause of cystine stone formation and accounts for 2-6% of all urinary stones in children. Cystinuria is an incompletely recessive autosomal disorder characterised by failure of renal tubules to reabsorb four basic amino acids: cystine, ornithine, lysine and arginine.

Of these four amino acids, only cystine has poor solubility in urine, so that only cystine stones may form in the case of excessive excretion in urine. Cystine solubility is pH-dependent, with cysteine precipitation beginning at pH levels < 7.0. Other metabolic conditions, such as hypercalciuria, hypocitraturia and hyperuricosuria, may accompany cystinuria, so leading to the formation of mixed-composition stones. Cystine stones are faintly radiopaque and may be difficult to visualise on regular radiograph studies. They are also hard in texture and more difficult to disintegrate by extracorporeal shockwave lithotripsy (SWL). Cystinuric patients present with larger stones at the time of diagnosis, higher new stone formation rates, and are at higher risk of surgery [1073].

The medical treatment for cystine stones aims to reduce cystine saturation in urine and increase its solubility. The initial treatment consists of maintaining a high urine flow and the use of alkalinising agents, such as potassium citrate to maintain urine pH at above 7.0 (better above 7.5). If this treatment fails, the use of  $\alpha$ -mercaptopyropionyl glycine or D-penicillamin may increase cystine solubility and reduce cystine levels in urine and prevent stone formation. Side effects of these drugs are mostly mild and include gastrointestinal complaints (alterations in taste and odour), fever and rash, however they can be associated with severe side effects, such as bone marrow depression, nephrotic syndrome and epidermolysis [1074].

### 3.16.2.4 Infection stones (struvite stones)

Infection-related stones constitute nearly 5% of urinary stones in children, though incidence increases over 10% in younger ages [1075] and in non-endemic regions [1049, 1076]. Bacteria capable of producing urease enzyme (*Proteus*, *Klebsiella*, *Pseudomonas*) are responsible for the formation of such stones.

Urease converts urea into ammonia and bicarbonate, alkalinising the urine and further converting bicarbonate into carbonate. In the alkaline environment, triple phosphates form, eventually resulting in a supersaturated environment of magnesium ammonium phosphate and carbonate apatite, which in turn leads to stone formation.

In addition to bacterial elimination, stone elimination is essential for treatment, as stones will harbour infection and antibiotic treatment will not be effective. Consideration should be given to investigating any congenital problem that causes stasis and infection. Genitourinary tract anomalies predispose to formation of such stones.

### 3.16.3 Diagnostic evaluation

Presentation tends to be age-dependent, with symptoms such as flank pain and haematuria being more common in older children. Non-specific symptoms (e.g. irritability, vomiting) are common in very young children. Haematuria, usually visible, occurring with or without pain, is less common in children. However, non-visible haematuria may be the sole indicator and is more common in children. In some cases, urinary infection may be the only finding leading to radiological imaging in which a stone is identified [1077, 1078].

#### 3.16.3.1 Imaging

Generally, US should be used as a first approach. Renal US is very effective for identifying stones in the kidney. Many radiopaque stones can be identified with a simple abdominal flat-plate examination. The most sensitive test for identifying stones in the urinary system (especially for ureteric stones) is non-contrast helical CT scanning. It is safe and rapid, with 97% sensitivity and 96% specificity [1079-1081]. Despite its high diagnostic accuracy, because of the potential radiation hazards, its use should be reserved for cases with non-informative US and/or plain abdominal radiograph. Low dose protocols have also been developed with the goal of reducing radiation dose with adequate image quality [1082]. Intravenous pyelography is rarely used in children, but may be needed to delineate the caliceal anatomy prior to percutaneous or open surgery.

#### 3.16.3.2 Metabolic evaluation

Due to the high incidence of predisposing factors for urolithiasis in children and high stone recurrence rates, every child with a urinary stone should be given a complete metabolic evaluation [1041, 1074, 1083-1085]. A


limited urinary metabolic evaluation (24-h calcium, 24h-citrate, and 24h-oxalate and low urinary volume) is able to detect the vast majority of clinically significant metabolic abnormalities [1086]. However, most of the time collections are inadequate and have to be repeated [1087].

Metabolic evaluation includes:

- family and patient history of metabolic problems and dietary habits;
- analysis of stone composition (following stone analysis, metabolic evaluation can be modified according to the specific stone type);
- electrolytes, blood/urea/nitrogen (BUN), creatinine, calcium, phosphorus, alkaline phosphatase, uric acid, total protein, carbonate, albumin, and parathyroid hormone (if there is hypercalcaemia);
- spot urinalysis and urine culture, including ratio of calcium to creatinine;
- urine tests, including a 24-hour urine collection for calcium, phosphorus, magnesium, oxalate, uric acid citrate, protein, and creatinine clearance;
- 24-hour cystine analysis if cystinuria is suspected (positive sodium nitroprusside test, cystine stone, cystine hexagonal crystals in urine).

Figure 11 provides an algorithm of how to perform metabolic investigations in urinary stone disease in children and how to plan medical treatment accordingly.

**Figure 11: Algorithm for metabolic investigations in urinary stone disease in children**



*Ca = calcium; HCTZ = hydrochlorothiazide; Mg = magnesium; Ox = oxalate; PTH = parathyroid hormone; SWL = extracorporeal shockwave lithotripsy; RTA = renal tubular acidosis; Uric A = uric acid.*

### 3.16.3.3 *Urolithiasis in infants*

Approximately 9 to 23% of paediatric urolithiasis patients are under one year old. Infantile urolithiasis appears to be a separate entity since the aetiology and the clinical course of the disease is different than in other age groups. A study on 2,513 children with urolithiasis demonstrated that microlithiasis (< 3mm) in infants should be differentiated from other age groups since the majority of them (85%) resolve spontaneously after one year of follow-up. It has also been shown that underlying metabolic abnormality is different than in older children. In this specific age group, calcium oxalate stones are not as common as in older age groups, whereas ammonium acid urate stones are more common [1042, 1088]. However if the stone size increases or the patient becomes symptomatic during follow-up, it should be treated appropriately. Another study found that only 15% of infantile urolithiasis required intervention after one year follow-up and the only predictor for intervention was the size of the stone [1089]. Two other studies concluded that stone size larger than 4.5 mm and 5 mm in infants are more likely to require intervention [1090, 1091]. Therefore observation should be the primary option for the majority of the infantile urolithiasis; if the patient becomes symptomatic or there is an increase in size, intervention can be discussed.

If an intervention is planned, SWL, RIRS or PCNL can be offered depending on the characteristics of the stone and the patient. All treatment modalities were found to be feasible with high success rates in infants [1092-1094].

### 3.16.4 **Management**

Adequate fluid intake and restricting the use of salt within daily allowance range are the general recommendations besides the specific medical treatment against the detected metabolic abnormalities. With the advance of technology, stone management has changed from open surgical approaches to endoscopic techniques that are less invasive. Deciding on the type of treatment depends on the number, size, location, stone composition and the anatomy of the urinary tract [1084, 1095, 1096]. Expectant management is the initial management in children with asymptomatic small size stones (< 4-5 mm ) with a possibility of spontaneous clearance. A recent study in a paediatric population showed that stone size > 6.7mm and haematuria were negative predictors for spontaneous stone passage [1097]. There is no consensus on the size of stones for different ages eligible for clearance and the duration of conservative follow-up. Adult literature reveals the benefits of medical expulsive therapy (MET) using  $\alpha$ -blockers. Although, experience in children is limited showing different results [1098], a meta-analysis of three randomised and two retrospective studies demonstrate that treatment with MET results in increased odds of spontaneous ureteral stone passage and a low rate of adverse events [1085, 1099]. Stone size, and ureteral wall thickness were found to be highly predictive for MET success; patient age, BMI, stone density and degree of hydronephrosis had no predictive value in this aspect [1100]. Another RCT in the age group of 6-14 years comparing the effectivity of Silodosin, Tamsulosin and placebo as MET for distal ureteric stones less than 1 cm revealed higher stone expulsion rate for Silodosin (89.3%), compared to Tamsulosin (74.5%) and placebo (51.8%) in children [1101]. A Cochrane review including 125 children from 1-18 years old with Ca-containing idiopathic nephrolithiasis showed that oral potassium citrate may reduce recurrence after SWL; however a substantial number of children stopped medication due to adverse events [1102].

Currently, most paediatric stones can easily be managed by SWL, RIRS or PCNL. Only a small portion of children with anatomical abnormalities may require other types of surgical intervention (open, robotic, laparoscopic). All attempts must be made to completely remove all stones since post-operative residual fragments pass spontaneously in only 20-25% of cases [1103, 1104]. A congenital obstructive uropathy should be managed together with stone removal therapy to prevent recurrence.

#### 3.16.4.1 *Extracorporeal shockwave lithotripsy*

Many reports confirm that SWL can be performed in children with no suspicion of long-term morbidity of the kidney [1105-1112].

The mean number of shockwaves for each treatment is approximately 1,800 and 2,000 (up to 4,000 if needed) and the mean power settings vary between 14 kV and 21 kV. Recently, two separate RCTs compared the outcomes of low vs. intermediate frequency during SWL and found no significant difference [1113, 1114]. The use of US and digital fluoroscopy has significantly decreased the radiation exposure and it has been shown that children are exposed to significantly lower doses of radiation compared to adults [1095, 1115, 1116]. Concerns about anaesthesia no longer present a problem due to advances in technique and medication, even in the infant age group. The type of anaesthesia should be general or dissociative for children under ten years of age, whereas conventional intravenous sedation or patient-controlled analgesia is an option for older children who

are able to co-operate [1117] (LE: 2b). The general perception of paediatric SWL requiring anaesthesia has been challenged by a study showing that SWL without anaesthesia can be performed safely with comparable success rates in co-operative children > 9 years of age [1118].

Stone-free rates are significantly affected by various factors. Regardless of the location, as the stone size increases, the stone-free rates decrease and retreatment rate increases. The stone-free rates for < 1 cm, 1-2 cm, > 2 cm and overall, were reported as nearly 90%, 80%, 60% and 80%, respectively. As the stone size increases, the need for additional sessions increases [1095, 1115, 1116, 1119-1123]. Previous history of open surgery also decrease the success of SWL [1124].

Localisation of the calculi has been described as a significant factor affecting the success rates in different studies. Stones in the renal pelvis and upper ureter seem to respond better to SWL. For these locations, the stone clearance rates are nearly 90%. However, SWL was found to be less effective for caliceal stones; particularly the lower caliceal stones. Several studies reported stone-free rates for isolated lower caliceal stones varying between 50% and 62% [1123, 1125, 1126].

Shockwave lithotripsy can also be used to treat ureteral calculi. However, this is a more specific issue and controversial. The success rates with SWL are less for distal ureteric stones. There may also be technical problems with localisation and focusing of ureteric stones in children [1123, 1126-1128].

The type of machine used significantly influences success rates and complications. First-generation machines can deliver more energy to a larger focal zone, resulting in higher fragmentation rates in a single therapy. However, general anaesthesia is usually required due to the intolerable discomfort associated with a first-generation machine. Later-generation machines have a smaller focal zone and deliver less energy, and have a lower risk of pulmonary trauma, however, additional treatments may be needed. The success rate is higher in younger children [1121].

Although stenting does not affect stone clearance, overall complication rates are higher and hospital stay is longer in the unstented patient with larger stones [1121, 1123]. Stenting is essential in solitary kidneys undergoing SWL treatment. Children with a large stone burden have a high risk of developing Steinstrasse and urinary obstruction and should be followed more closely for the risk of prolonged urinary tract obstruction after SWL. Post-SWL stent or nephrostomy tube placement may be needed in prolonged obstruction [1074, 1120].

The Hounsfield Unit (HU) of stone on non-contrast tomography has also been shown to be a predictive factor for success in children and SWL was found to be more successful in stones with HU less than 600 [1104] and 1,000 [1129]. Two nomogram studies revealed male gender, younger age, smaller stone size, single stone, non-lower pole localisation and negative history for previous intervention are favourable factors for stone clearance in paediatric SWL [1130, 1131]. A comparative study reported that these two nomograms are independent predictors of stone-free rate following SWL in paediatric patients [1132]. A systematic review confirmed that those two nomograms have equal value in predicting outcomes of SWL in children [1133]. Although, the invention of miniaturised endoscopic instruments seems to reduce the importance and popularity of SWL, it has the advantage of not carrying the risk of certain complications related to endoscopic surgeries and also with less post-operative emergency visits, pain and anaesthetic sessions [1134, 1135]. Complications arising from SWL in children are usually self-limiting and transient. The most common are::

- renal colic;
- transient hydronephrosis;
- dermal ecchymosis;
- UTI;
- formation of Steinstrasse;
- sepsis;
- rarely, haemoptysis.

In children with sterile pre-operative urine cultures, antibiotic prophylaxis to decrease infectious complications is not recommended [1136]. However, every effort should be made to sterilise the urine before performing SWL, ureteroscopy (URS), or percutaneous nephrolithotomy (PCNL).

#### 3.16.4.2 Percutaneous nephrolithotomy

Shockwave lithotripsy is the first choice for treating most renal paediatric stones. However, percutaneous renal surgery should be used for larger and complex stones. Pre-operative evaluation, indication and surgical technique are similar in children and adults. In most cases, percutaneous nephrolithotomy (PCNL) is used as monotherapy, but is also used as an adjunctive procedure to other therapies.

The use of adult-sized instruments, in association with an increased number of tracts and sheath size, seems to increase blood loss. However, the development of small-calibre instruments (miniPCNL, ultraminiPCNL, superminiPCNL and microperc) means that PCNL can be used in children. Miniaturised PCNL has several advantages compared to standard PCNL, such as a smaller skin incision, single-step dilation and sheath placement, good working access for paediatric instruments, variable length, and lower cost [1136-1138].

As monotherapy, PCNL is considerably effective and safe. The reported stone-free rates in the recent literature are between 86.9% and 98.5% after a single session. These rates increase with adjunctive measures, such as second-look PCNL, SWL and URS. Even in complete staghorn cases, a clearance rate of 89% has been achieved following a single session [1139-1144]. The mean post-operative hospital stay is between one to four days and is much shorter than open surgery [1145]. The less invasive nature of this technique has made it superior to open surgery for treating renal stones in children [1146-1153].

The most frequently reported complications of PCNL in children are bleeding, post-operative fever or infection, and persistent urinary leakage. Bleeding requiring transfusion is reported in less than 10% [1149, 1152, 1154-1157] and is closely associated with stone burden, operative time, sheath size and the number of tracts [1149, 1150, 1158]. In recent studies, post-operative infectious complications, such as fever with or without documented UTI, are reported as less than 15% [1149, 1152, 1154, 1155, 1157, 1159] and the origin of fever is not always found to be the infection. Due to the smaller size of the probes, laser energy is easier to use in smaller instruments and is more useful for paediatric cases [1139, 1160-1162].

Using high power laser (> 40 W) during PCNL is feasible and may be helpful in the treatment of staghorn stones [1163], but it should be kept in mind, that increased temperatures inside the smaller paediatric kidney might lead to tissue damage, which has been shown in simulation models [1164].

With the availability of smaller size instruments, miniaturised PCNL ('miniperc') through a 13F or 14F sheath [1138, 1159, 1165] as well as ultramini-PCNL (UMP) through 12F sheaths [1166] have become possible, with decreased transfusion rates [1159]. The mini- and supermini- PCNL (SMP) were shown to have higher efficacy with low complication rates (< Clavien grade 3b) which were deemed to be a safe alternative to SWL by some authors [1146, 1167]. In this study, 108 children under 12 years old with single stone (10-20mm) in the renal pelvis or calyces were randomised into two groups; either miniPCNL or SWL. Stone-free rate (SFR) after single session was significantly higher for PCNL (88.9%) compared to SWL (55.6%) [1146]. After second and third sessions, SWL success increased to 88.8% [1168]. The complication rates were 22.2% in PCNL and 14.8% in SWL without statistical significance.

The SMP was shown to be advantageous over mini-PCNL in terms of complications with similar stone-free rates [1168, 1169]. This miniaturisation has been further developed into the technique of 'micro-perc' using a 4.85F 'all-seeing needle'. This technique enables the stone to be fragmented by a laser *in situ* and left for spontaneous passage [1170]. A study revealed that microperc provides a similar SFR with similar complication rates and a lower additional treatment rate compared with SWL in the treatment of kidney stone disease in children [1171]. For stones 10-20 mm, micro-PCNL was shown to have comparable results, with less bleeding, compared to mini-PCNL [1147] and similar outcomes with less anaesthetic sessions compared to RIRS [1153]. As experience has accumulated in adult cases, new approaches have started to be applied in children, including tubeless PCNL. This technique has been used in uncomplicated surgery for stones < 2 cm, with patients left either with an indwelling catheter or double J stent in the ureter [1156, 1172] or totally tubeless [1173]. Moreover, use of US for establishment of access is gaining popularity [1148, 1151, 1174].

Traditionally, PCNL in children is performed in prone position. Another trend in the literature is the performance of PCNL in flank-free modified supine position in children [1174, 1175]. The proposed advantages are shorter operative time and enabling a simultaneous ureteroscopic procedure without changing the position of the patient. In a recent study, 55 paediatric patients with kidney stones who underwent UMP were randomised into two groups; flank-free modified supine position (FFMS) versus prone position. Stone free rates and complications rates were similar but the operative time was found to be shorter for supine position [1176].

For post-operative pain management, two randomised controlled trials showed that intercostal nerve block or erector spinae bloc were shown to provide effective post-operative analgesia in paediatric patients [1177, 1178].

#### 3.16.4.3 Ureterorenoscopy

The increasing availability of smaller size endourological equipment has made it possible to manage paediatric ureteral stones using endoscopic techniques.

The technique used in children is similar to the one used in adults. It is strongly recommended that guidewires are used and the procedure is performed using direct vision. Routine balloon dilation of the ureterovesical junction and ureteral stenting are controversial. In general, ureteric dilatation is being performed only in selected cases. There is a tendency to use hydrodilatation more because it is similarly effective [1139, 1179, 1180].

Different lithotripsy techniques, including ultrasonic, pneumatic and laser lithotripsy, have all been shown to be safe and effective. Due to the smaller size of the probes, laser energy is easier to use in smaller instruments and is more useful for paediatric cases [1181].

All studies reporting the use of endoscopy for ureteric stones in children have clearly demonstrated that there is no significant risk of ureteric strictures or reflux with this mode of therapy. The risk of post-operative hydronephrosis depends on the presence of impacted stone and ureteral injury during operation [1182]. A multi-institutional study on the use of semi-rigid ureteroscopy for ureteral calculi in children showed that the procedure is effective with a 90% SFR and efficacy quotient. The study also focused on the factors affecting the complication rates. The authors found that, although operating time, age, institutional experience, orifice dilation, stenting and stone burden were significant on univariate analysis, multivariate analysis revealed that operating time was the only significant parameter affecting the complication rate [1179]. However, for proximal ureteral stones semi-rigid ureteroscopy is not a good first option because of higher complication and failure rates [1183].

A literature review contains a growing number of case series on the use of flexible ureterorenoscopic interventions in children. Both intrarenal and ureteric stones can be treated using this approach [1184-1189]. In these series, the authors generally did not use active orifice dilation, but attempted to use a ureteral sheath where possible. However, an important problem was the inability to obtain retrograde access to the ureter in approximately half of the cases [1185, 1187]. This problem can be overcome by stenting and leaving the stent indwelling for passive dilation of the orifice, and performing the procedure in a second session. The success rates varied between 60 and 100%, with a negligible number of complications [1184, 1186-1188, 1190]. The need for additional procedures was related to stone size [1188]. Radiation exposure during URS can be minimised by using Flat Panel Detector c-Arms while simultaneously improving image quality [1191].

One RCT and four other comparative studies showed that retrograde intra-renal surgery (RIRS) had similar stone-free rates compared to SWL after three months, with fewer sessions [1134, 1192-1195]. However for stones larger than 20 mm, RIRS monotherapy has lower stone-free rates than mini-PCNL with the advantages of decreased radiation exposure, fewer complications and shorter hospital stay [1196]. In contrast, for stones between 10-20 mm, RIRS has similar success and complication rates and shorter hospital stay and low radiation exposure when compared to micro-PCNL [1197]. A recent systematic review revealed that compared with the other two treatments, PCNL had a longer operative time, fluoroscopy time and hospital stay. Shockwave lithotripsy had a shorter hospital stay, higher retreatment rate and auxiliary rate in comparison with the other two treatments. It was also shown that PCNL presented a higher efficacy quotient than the other two treatments, and RIRS had a lower efficiency than SWL and PCNL. In the subgroup analysis of paediatric patients with stone  $\leq$  20 mm, the comparative results were similar to those described above, except for the higher complication rate of PCNL than SWL [1198].

#### 3.16.4.4 *Open or laparoscopic stone surgery*

Most stones in children can be managed by SWL and endoscopic techniques. However, in some situations, open surgery is inevitable. Good candidates for open stone surgery include very young children with large stones and/or a congenitally obstructed system, which also requires surgical correction. Open surgery is also necessary in children with severe orthopaedic deformities that limit positioning for endoscopic procedures.

In centres with well-established experience, a laparoscopic approach may be a good alternative for some cases as a last resort before open surgery. Suitable candidates include patients who have a history of previously failed endoscopic procedures, complex renal anatomy (ectopic or retrorenal colon), concomitant UPJ obstruction or caliceal diverticula, mega-ureter, or large impacted stones. Laparoscopic stone surgery via conventional or a robot-assisted transperitoneal or retroperitoneal approach can be attempted. However, there is limited experience with these techniques and they are not routine therapeutic modalities [1199-1202].

Bladder stones in children can usually be managed by endoscopic techniques. A recent randomised trial compared transurethral cystolithotripsy versus percutaneous cystolithotripsy for bladder stones smaller than 30 mm and found similar success and complication rates with success rates more than 95% [1203]. Open surgery may also be used for very large bladder stones or for bladder stones caused by an anatomical problem.

In addition to the advantages and disadvantages of each treatment modality for the specific size and location of the stone, consideration has to be given to the availability of the instruments and the experience with each treatment modality before the choice of technique is made. Recommendations for interventional management are given in Table 4.

**Table 4: Recommendations for management in paediatric stones**

Stone size and localisation*	Primary treatment option	Alternative treatment options	Comment
Infant microlithiasis (<3mm, any location)	Observation	Intervention and/or medical treatment	Individualised decision according to size progression, symptoms and metabolic factors.
Staghorn stones	PCNL	Open/SWL	Multiple sessions and accesses with PCNL may be needed. Combination with SWL may be useful.
Pelvis < 10 mm	SWL	RIRS/PCNL	
Pelvis 10-20 mm	SWL/PCNL/RIRS		Multiple sessions with SWL may be needed. PCNL and RIRS have a similar recommendation grade.
Pelvis > 20 mm	PCNL	SWL/RIRS	Multiple sessions with SWL may be needed.
Lower pole calyx < 10mm	Observation or SWL	PCNL/RIRS	Stone clearance after SWL is lower than other locations.
Lower pole calyx > 10mm	PCNL	RIRS/SWL	Anatomical variations are important for complete clearance after SWL.
Upper ureteric stones	SWL	URS	Flexible scopes may be needed in case of retropulsion.
Lower ureteric stones	URS	SWL	
Bladder stones	Endoscopic (transurethral or percutaneous)	SWL/Open	Open is easier and with less operative time with large stones.

\* Cystine and uric acid stones excluded.

PCNL = percutaneous nephrolithotomy; SWL = shockwave lithotripsy; RIRS = retrograde intrarenal surgery; URS = ureteroscopy.

### 3.16.5 Summary of evidence and recommendations for the management of urinary stones

Summary of evidence	LE
The incidence of stone disease in children is increasing.	2
Contemporary surgical treatment is based on minimally invasive modalities. Open surgery is very rarely indicated.	2a
The term 'clinically insignificant residual fragments' is not appropriate for children since most of them become symptomatic and require intervention.	2b
Majority of the kidney stones < 3 mm in infants resolve spontaneously.	3

Recommendations	Strength rating
Use plain abdominal X-ray and ultrasound as the primary imaging techniques for the diagnosis and follow-up of stones.	Strong
Use low-dose non-contrast computed tomography in cases with a doubtful diagnosis, especially of ureteral stones or complex cases requiring surgery.	Strong
Perform a metabolic evaluation in any child with urinary stone disease. Any kind of interventional treatment should be supported with medical treatment for the underlying metabolic abnormality, if detected.	Strong
Limit open surgery under circumstances in which the child is very young with large stones, in association with congenital problems requiring surgical correction and/or with severe orthopaedic deformities that limit positioning for endoscopic procedures.	Strong
Observe infant microlithiasis, unless symptoms occur or size increases significantly.	Strong

### 3.17 Obstructive pathology of renal duplication: ureterocele and ectopic ureter

#### 3.17.1 *Epidemiology, aetiology and pathophysiology*

Ureterocele and ectopic ureter are the two main anomalies associated with complete renal duplication, but they also occur in a single system. At present, antenatal US detects both conditions in the majority of cases if associated with obstruction, and diagnosis is confirmed after birth by further examination. Later in life, these anomalies are revealed by clinical symptoms: UTI, pain, calculus formation, disturbances of micturition, and urinary incontinence. There is a wide variation of symptoms in patients with ureterocele (from the asymptomatic patient to urosepsis, urinary retention and upper tract dilatation after birth).

##### 3.17.1.1 *Ureterocele*

Ureterocele is four to seven times more frequent in female than in male patients; the overall incidence in autopsies is around one in 4,000 children. Around 80% is associated with the upper pole ureter in duplicated systems and 20% in single systems. About 10% of ureteroceles are bilateral [1204].

##### 3.17.1.2 *Ectopic ureter*

Ectopic ureter is less frequent than ureterocele (10 in 19,046 autopsies), but is also more common in female patients (male to female ratio is 1:5). Some remain asymptomatic, therefore, the true incidence is difficult to determine [1205]. Eighty per cent of ectopic ureters are associated with complete renal duplication; however, in male patients about 50% of ectopic ureters are associated with a single system [1206]. The incidence of ectopic ureter is 3.5% in patients with anorectal malformations [1207].

#### 3.17.2 *Classification systems*

##### 3.17.2.1 *Ureterocele*

Ureterocele is a cystic dilatation that develops in the intravesical part of the submucosal ureter. The aetiology remains unclear [1208-1210]. A single-system ureterocele is associated with a kidney with one ureter, and in duplex systems, the ureterocele belongs to the upper pole.

Ureteroceles usually cause obstruction of the upper pole, but the degree of obstruction and functional impairment is variable according to the type of ureterocele and upper pole dysplasia. In the orthotopic form, there is often no or only mild obstruction, and frequently the function of the moiety is normal or slightly impaired, and the corresponding ureter may be dilated. Cystic renal dysplasia is also associated with a single system ureterocele [1211]. Vesicoureteral reflux can be observed in 50% on the ipsilateral side and 20% on the contralateral side. Reflux into the ureterocele is uncommon [1212]. In the ectopic form, the upper pole is altered, frequently dysplastic, and hypo-functional or non-functional [1213]. The corresponding ureter is a mega-ureter. In the caeco-ureterocele (see definition below), the upper pole of the renal duplication is dysplastic and non-functional. Histological evaluation demonstrated that the changes represent a process of maldevelopment and may not result from infections or obstruction [1213].

##### 3.17.2.1.1 *Ectopic (extravesical) ureterocele*

If any portion of the ureterocele extends into the bladder neck or urethra, it is called an ectopic ureterocele. Ectopic ureterocele is the most common form of ureterocele (> 80%). It can be voluminous, dissociating the trigone and slipping into the urethra, and may prolapse through the urethral meatus (caeco-ureterocele). The ureterocele orifice is tight, and located in the bladder itself or below the neck. The ureter corresponding to the lower pole moiety is raised by the ureterocele and is frequently refluxing or compressed by the ureterocele, leading to an obstructive mega-ureter. A contralateral renal duplication is associated with 50% of cases. Occasionally, large ureteroceles are responsible for reflux or obstruction of the contralateral upper tract.

##### 3.17.2.1.2 *Orthotopic (intravesical) ureterocele*

The intravesical or orthotopic ureterocele is completely located in the bladder. Intravesical ureteroceles are mostly combined with a single kidney system and account for about 15% of cases. It is diagnosed more in older children or adults.

##### 3.17.2.2 *Ectopic ureter*

The term ectopic ureter describes a ureter with the orifice located at the bladder neck, in the urethra or outside the urinary tract. The ureter can drain the upper pole of a duplex or single system. There is a fundamental difference between the sexes. In boys, the ectopic orifice is never below the external sphincter.

In girls, the ureteral orifice may be located [1214]:

- in the urethra, from the bladder neck to the meatus (35%);
- in the vaginal vestibule (34%);
- in the vagina (25%);
- in the uterus and Fallopian tube (6%).



In boys, the ureteral orifice may be located [1214]:

- in the posterior urethra (47%);
- in the prostatic utricle (10%);
- in the seminal vesicles (33%);
- in the vas deferens or ejaculatory ducts (10%).

### 3.17.3 **Diagnostic evaluation**

#### 3.17.3.1 *Ureterocele*

Prenatal US easily reveals voluminous obstructive ureteroceles [1215]. In cases with a small upper pole or a slightly obstructive ureterocele, prenatal diagnosis is difficult. If prenatal diagnosis is impossible, the following clinical symptoms, besides incidental findings, can reveal the congenital anomaly at birth or later:

- At birth, a prolapsed and sometimes strangulated ureterocele may be observed in front of the urethral orifice. In a newborn boy, it might cause acute urinary retention, simulating urethral valves.
- The early symptom of pyelonephritis in either sex may lead to the diagnosis.
- Later symptoms can include dysuria, recurrent cystitis and urgency.

In cases of prenatal diagnosis, at birth US confirms the ureteral dilatation that ends at the upper pole of a renal duplication. It also demonstrates the presence of a ureterocele in the bladder, with a dilated ureter behind the bladder.

At this point, it is important to assess the function of the upper pole using nuclear renography of the region of interest. This is best assessed with DMSA, however this requires a careful systematic review of the images [1216]. Magnetic resonance urography may visualise the morphological status of the upper pole and lower moieties and of the contralateral kidney as well as it can detect renal scars [1217, 1218]. Using functional MR urography, differential renal function can be assessed with low intra- and interobserver variability [1219]. Based on the prevalence of high-grade reflux, VCUG is mandatory for identifying ipsilateral or contralateral reflux and assessing the degree of intra-urethral prolapse of the ureterocele [1220]. Urethrocystoscopy may reveal the pathology in cases where it is difficult to make the differential diagnosis between ureterocele and ectopic mega-ureter.

#### 3.17.3.2 *Ectopic ureter*

Most of the ectopic mega-ureters are diagnosed primarily by US. In some cases, clinical symptoms can lead to diagnosis:

- In neonates: dribbling of urine, pyuria, and acute pyelonephritis.
- In young girls: permanent urinary incontinence besides normal voiding, or significant vaginal discharge as the equivalent of incontinence; an ectopic orifice may be found in the meatal region [1221].
- In pre-adolescent boys: epididymitis is the usual clinical presentation and the seminal vesicle may be palpable.

Ultrasound, radionuclide studies (DMSA, VCUG, MR urography, high-resolution MRI, and cystoscopy) are the diagnostic tools to assess function, to detect reflux and rule out ipsilateral compression of the lower pole and urethral obstruction [1222]. In some cases, the large ectopic ureter presses against the bladder and can look like a pseudo-ureterocele [1223].

Girls who present with life-long minimal urinary incontinence, never being dry, normal bladder function, complete emptying, and normal US are very suspicious for ectopic ureter. This needs to be excluded or confirmed by MRI as it is the most sensitive method [1224].

### 3.17.4 **Management**

#### 3.17.4.1 *Ureterocele*

Management is controversial with a choice between a non-operative approach, endoscopic decompression, ureteral re-implantation, partial nephroureterectomy, or complete primary reconstruction [1225-1230]. The choice of a therapeutic modality depends on the following criteria: clinical status of the patient (e.g. urosepsis); patient age; function of the upper pole; presence of reflux or obstruction of the ipsilateral or contralateral ureter; presence of bladder neck obstruction caused by ureterocele; intravesical or ectopic ureterocele; and caregivers' and the surgeon's preferences [1230]. When the diagnosis is made by US, prophylactic antibiotic treatment maybe indicated until a VCUG is performed.

##### 3.17.4.1.1 Early treatment

In the presence of febrile infection or obstruction at the bladder neck, immediate endoscopic incision or puncture of the ureterocele is recommended. In a clinically asymptomatic child with a ureterocele and a non or hypofunctional upper pole, without significant obstruction of the lower pole and without bladder outlet


obstruction, prophylactic antibiotic treatment is given until follow-up procedures are instigated. Decompression of the dilated system facilitates later reconstructive surgery [1231, 1232].

### 3.17.4.1.2 Re-evaluation

Active surveillance is an option for antenatally detected ureterocele, but long-term follow-up is necessary [1233]. Conservative treatment may be adopted in asymptomatic patients without any bladder outlet obstruction, severe hydronephrosis of the ureterocele moiety or high-grade (over grade III) reflux [1230, 1234]. A meta-analysis showed that, after primary ureterocele-incision, the re-operation rate is higher in those with an ectopic ureterocele compared to those with an intravesical ureterocele [1226]. Secondary surgery is necessary if decompression is not effective, significant reflux is present, or there is obstruction of the ipsi- or contralateral ureters, and/or bladder neck obstruction or retained ureterocele [1235].

Surgery may vary from upper pole nephrectomy to complete unilateral LUT reconstruction [1229, 1236-1238]. In an ectopic ureterocele with severe hydronephrosis and without reflux, the primary upper tract approach without endoscopic decompression (partial upper-pole nephroureterectomy, pyelo/ureteropyelo/ureterostomy and upper-pole ureterectomy) has an 80% chance of being the definitive treatment [1230, 1239]. Also a LUT approach in those with a poorly or non-functioning upper pole is an option [1240]. Today, despite successful surgery, some authors think, that surgery may not be necessary at all in some patients [1241], as less aggressive surgical treatment and non-operative management over time can achieve the same functional results [1242]. There is emerging evidence on Minimally Invasive surgical approach (laparoscopic and robot assisted) for upper pole nephrectomy with similar operating time to open surgery [1243, 1244].

**Figure 12: Algorithm for the management of duplex system ureteroceles after the first 3-6 months of life [1245]**



DSU = duplex system ureterocele; HUN = hydronephrosis; UPPN = upper pole partial nephrectomy; VUR = vesicoureteric reflux to the lower pole.

Obstruction is considered to be the presence of non-refluxing dilatation of non-ureterocele-bearing moieties (especially of the lower pole) or of an obstructive drainage pattern on diuretic renography.

### 3.17.4.2 Ectopic ureter

In the majority of cases, the upper pole is dysplastic and poorly functioning. There are a variety of therapeutic options, each with its advantages and disadvantages. In non-functioning moieties with recurrent infections, heminephro-ureterectomy is a definite solution. Ureteral reconstruction (ureteral re-implantation/ureteroureterostomy/ureteropyelostomy and upper-pole ureterectomy) are other therapeutic options especially

in cases in which the upper pole has function worth preserving. These procedures can be performed through an open laparoscopic or robotic assisted approach [1244, 1246-1248]. So far there is no superior approach [1249]. In patients with bilateral single ectopic ureters (a very rare condition), an individual approach depending on the sex and renal and bladder function of the patient is necessary. Usually the bladder neck is insufficient in these patients [1250].

**3.17.5 Summary of evidence and recommendations for the management of obstructive pathology of renal duplication: ureterocele and ectopic ureter**

Summary of evidence	LE
Ureterocele and ectopic ureter are associated with complete renal duplication, but they also occur in a single system.	1
In most cases, in young children (first years of life) diagnosis is done by US.	1
In older children clinical symptoms will prompt assessment.	1
Management includes a conservative approach, endoscopic decompression, partial nephroureterectomy, or complete primary reconstruction. Choice of treatment will depend on: <ul style="list-style-type: none"> <li>clinical status of the patient (e.g., urosepsis);</li> <li>patient age;</li> <li>function of the upper pole;</li> <li>presence of reflux or obstruction of the ipsilateral or contralateral ureter;</li> <li>presence of bladder neck obstruction caused by ureterocele;</li> <li>intravesical or ectopic ureterocele.</li> </ul>	3

Recommendations			LE	Strength rating
Ureterocele	Diagnosis	Use ultrasound (US), radionuclide studies (mercaptoacetyl triglycine (MAG3)/ dimercaptosuccinic acid (DMSA)), voiding cystourethrography (VCUG), magnetic resonance urography, high-resolution magnetic resonance imaging (MRI), and cystoscopy to assess function, to detect reflux and rule out ipsilateral compression of the lower pole and urethral obstruction.	3	Weak
	Treatment	Select treatment based on symptoms, function and reflux as well on surgical and parenteral choices: observation, endoscopic decompression, ureteral re-implantation, partial nephroureterotomy, complete primary reconstruction. Offer, early endoscopic decompression to patients with an obstructing ureterocele.	3	Weak
Ectopic ureter	Diagnosis	Use US, DMSA scan, VCUG or MRI for a definitive diagnosis.	3	Weak
	Treatment	Treatment In non-functioning moieties with recurrent infections, heminephro-ureterectomy is a definitive solution. Ureteral reconstruction (ureteral re-implantation/ureteroureterostomy/ ureteropyelostomy and upper pole ureterectomy) are other therapeutic option especially in cases in which the upper pole has function worth preserving.	3	Weak

**3.18 Disorders/Differences of sex development**

**3.18.1 Introduction**

Formerly called 'intersex disorders', this constellation of conditions has been the subject of a consensus document in which it was decided that the term 'intersex' should be changed to 'disorders/differences of sex development' (DSD), however the original term is still used in the resolution of the Parliamentary Assembly of the Council of Europe (see below) [1251].

The new classification has arisen due to advances in knowledge of the molecular genetic causes of abnormal sexual development, controversies inherent to clinical management, and ethical issues. Controversial and negative terminology, e.g., 'pseudohermaphroditism' and 'hermaphroditism', have been renamed according to new pathophysiological insights. Furthermore, some conditions presenting with severe male genital malformation, such as penile agenesis and cloacal exstrophy, which could not previously be categorised, have now also been included. The term 'disorders/differences of sex development' is proposed to indicate congenital conditions with atypical development of chromosomal, gonadal or anatomical sex.

In addition to this, in 2017 the Parliamentary Assembly of the Council of Europe decided on a resolution termed: "Promoting the human rights of and eliminating discrimination against intersex people" [1252]. The Assembly concluded that the majority of 'intersex' people (cited verbatim from the resolution) were physically healthy and that only a few suffered from medical conditions that put their health at risk. Furthermore, they stated that the prevailing medical view at that time was that the bodies of 'intersex' children could, and should be made to conform to either a male or a female paradigm, often through surgical and/or hormonal intervention, and that this should be performed as early as possible so that these children could then be raised in the gender corresponding to their assigned sex. The Parliamentary Assembly considered that this approach involved serious breaches of physical integrity and autonomy, with many cases concerning very young children or infants who were unable to give informed consent and whose gender identity was unknown.

Therefore, the Parliamentary Assembly called on Council of Europe member states to effectively protect children's rights to physical integrity and bodily autonomy, and to empowering 'intersex' people with the following rights: Medically unnecessary sex-"normalising" surgery, sterilisation and other treatments practised on 'intersex' children without their informed consent should be prohibited, and in addition that it has to be ensured that, except in cases where the life of the child is at immediate risk, any treatment that seeks to alter the sex characteristics of the child including their gonads, genitals or internal sex organs, is deferred until such time as the child is able to participate in the decision, based on the right to self-determination, and on the principle of free and informed consent. The Panel refers to the consensus documents mentioned above as well as on the Parliamentary Assembly resolution. This chapter will focus on what is relevant for the practising paediatric urologist, as they are likely to be involved in neonates with DSD conditions.

Overall, evidence-based literature on DSD is sparse. There are no RCTs, and most studies are based on retrospective, clinical descriptive studies, or on expert opinion. An exception is made in relation to the risk of gonadal cancer, for which the level of evidence is higher [1253].

Disorders/differences of sex development can present as a prenatal diagnosis, neonatal diagnosis, or late diagnosis. Prenatal diagnosis can be based on karyotype or sonographic findings; A neonatal diagnosis is based on genital ambiguity, and a late diagnosis is usually made as a result of early or delayed puberty. In this guideline, the focus is on the neonatal presentation, where the paediatric urologist plays a more central role. There have been several publications over the last couple of decades exploring the role of prenatal corticosteroid treatment of patients with congenital adrenal hyperplasia. The Endocrine Society still proclaims their use to be restricted to research settings, and that this treatment remains experimental [1254, 1255]. For late diagnoses, we refer to endocrinology and gynaecology guidelines on precocious and delayed puberty, where paediatric urologists play a less central role [1256, 1257].

Dealing with neonates with DSD requires a multi-disciplinary approach, which should ideally include geneticists, neonatologists, paediatric and adult endocrinologists, paediatric urologists, gynaecologists, psychologists, ethicists and social workers. Each team member should ideally be experienced in DSD and a team should have treated enough patients to ensure experience.

A discrepancy is often perceived between research topics proposed by research scientists and those considered important by DSD patients [1258]. As a result of this discrepancy, collaborative networks such as the 'dsd-LIFE' consortium, have been established to include research scientists, health professionals, patient families, and support groups (available from: <https://www.dsd-life.eu/home/index.html>). In the dsd-LIFE study, there is a focus on what patients and care-givers consider to be a priority, and research is then carried out around that issue. In addition, the newly established European Reference Network (ERN) covering rare endocrine conditions (Endo-ERN) considers patient participation in research and database management to be crucial (available from: <https://endo-ern.eu/>).

### 3.18.2 *International Consensus Statements on DSD Management*

There have been four published consensus statements in relation to the investigations and management of DSD. In general, these statements have focused on the impact of DSD on older age groups, the importance of long-term prospective multi-disciplinary, multi-centre data collection with a focus on patient reported outcomes.

The ultimate ambition is to preserve physical and psychological function in these future adults [1259]. The consensus proposal from European Society of Paediatric Radiology task force predominantly focused on imaging modalities and calls for the optimisation of US in initial and interval assessments of anatomy, with MR imaging and cystovaginography used as adjunctive modalities [1260]. The COST Action BM1303 working group 1 consensus statement from Europe raised the concern of the effects of delayed genital and gonadal surgery on physical, psychological, and sexual well-being, as well as the potential malignant risks of retained gonads. Support tools need to be developed to help guide affected families and children with a balance struck between surgery and the protection of human rights [1258]. The Canadian consensus statement broadly concurs with the above but differs slightly from their European counterparts. It suggests that sex assignment need not take place at birth, and there should be a recognition of the harms caused in the past by a paucity of information to parents, and that decisions involving surgery should take place involving a shared decision model. This consensus finally suggests that data is insufficient to determine the correct timing of surgery [1261].

### 3.18.3 **Current classification of DSD conditions**

There have been a number of published updates since the International Consensus Conference on 'intersex' and its subsequent publications on the classification of the various conditions of DSD. The latest of these was published by the Global DSD Update Consortium in 2016 [1262]. As the field of DSD is continuously developing, and knowledge and viewpoints change over time, an effort has been made to consider diversity, inclusion, and equality, and therefore representatives from support and advocacy groups continue to be invited, with an aim to focus on patient care and the best possible quality of life.

According to the international consensus in 2005, DSDs have been defined as congenital conditions within which the development of chromosomal, gonadal and/or anatomic sex is atypical. The changes that were made according to terminology are as follows:

**46XX DSD** – This was formerly termed female pseudohermaphrodite, over-virilisation of an XX female, and masculinisation of an XX female. In this group the vast majority is due to classic congenital adrenal hyperplasia (CAH) with various degrees of masculinisation. Among all DSD conditions together, 46XX CAH patients comprise approximately 80% cases. These conditions are extremely important since they can be potentially life threatening days after birth due to a salt-loss phenomenon, and immediate medical care is mandatory.

**46XY DSD** – Previously termed male pseudohermaphroditism, undervirilisation of an XY male, and undermasculinisation of an XY male. This group is often quite heterogenous and includes the partial androgen insensitivity syndrome (PAIS), as well as the complete androgen insensitivity syndrome (CAIS) formerly called testicular feminisation.

**Sex chromosome mosaicism DSD (45X; 45X/46XY; 47XXY)** – This cohort consists of multiple variants with the mixed gonadal dysgenesis being the most important one. Many have a normal male phenotype and others may have asymmetric genitalia. One scrotal half often contains a gonad which is likely to be a testis whereas the other side is more in keeping with a labia majora with usually no palpable gonad, which will most likely be a streak gonad.

**Ovotesticular DSD** – This was previously described as a 'true hermaphrodite' because of the presence of ovarian and testicular tissue co-existing in the same individual meaning. There is great variability in phenotype with uni- or bilateral undescended gonads, which can present as one ovary and one testis, or as one or two ovotestes.

**Non-hormonal/non-chromosomal DSD** – This cohort was introduced as well, including newborns with cloacal exstrophy where bladder and intestines are exposed through a midline mesenchymal defect resulting from the failure of the cloacal membrane to retract, which then ruptures. Others in this cohort include patients with aphallia, and severe micropenis. The latter one is a normally formed penis with a stretched length of < 2.5 standard deviation below the mean [1251, 1263]. Micropenis should be distinguished from buried and webbed penis, which are usually of normal size. The length of the penis is measured on the dorsal aspect, while stretching the penis, from the pubic symphysis to the tip of the glans [1251].

### 3.18.4 **Diagnostic evaluation**

#### 3.18.4.1 *The neonatal emergency*

The first step is to recognise the possibility of DSD (Table 5) and to refer the newborn baby immediately to a tertiary paediatric centre, fully equipped with neonatal, genetics, endocrinology and paediatric urology units. A diagnosis of a 46XX DSD as a result of congenital adrenal hyperplasia (the most common form of DSD) should not be delayed, and represents a neonatal emergency situation due to the possibility of salt loss which can be fatal.

**Table 5: Findings in a newborn suggesting the possibility of DSD**  
(adapted from the American Academy of Pediatrics)

<b>Apparent male</b>
Severe hypospadias associated with bifid scrotum
Undescended testis/testes with hypospadias
Bilateral non-palpable testes in a full-term apparently male infant
<b>Apparent female</b>
Clitoral hypertrophy of any degree, non-palpable gonads
Vulva with single opening
Indeterminate
Ambiguous genitalia

#### 3.18.4.2 Family history and clinical examination

A careful family history must be taken followed by a thorough clinical examination including various laboratory tests and imaging modalities (Table 6).

**Table 6: Diagnostic work-up of neonates with DSD**

<b>History (family, maternal, neonatal)</b>
Parental consanguinity
Previous DSD or genital anomalies
Previous neonatal deaths
Primary amenorrhoea or infertility in other family members
Maternal exposure to androgens
Failure to thrive, vomiting, diarrhoea of the neonate
<b>Physical examination</b>
Pigmentation of genital and areolar area
Hypospadias or urogenital sinus
Size of phallus
Palpable and/or symmetrical gonads
Blood pressure
<b>Investigations</b>
Blood analysis: 17-hydroxyprogesterone, electrolytes, LH, FSH, TST, cortisol, ACTH
Urine: adrenal steroids
Genetics: karyotype, next-generation sequencing-based molecular diagnostics, WES
Ultrasound
Genitogram
hCG stimulation test to confirm presence of testicular tissue
Androgen-binding studies
Endoscopy

*ACTH = adrenocorticotropic hormone; FSH = follicle-stimulating hormone; hCG = human chorionic gonadotropin; LH = luteinising hormone; TST = testosterone; WES = whole exome sequencing.*

A thorough and standardised clinical examination in a neonate presenting with ambiguous genitalia is important. In addition to an accurate description of the ambiguous genitalia, detailed information should be documented on the palpability and localisation of the gonads. Data gathered through the various examinations described below should help the team to come to a final diagnosis. Medical photography can be useful, however this requires sensitivity and consent [1264].

*Palpable gonad:* If it is possible to feel a gonad, it is most likely to be a testis; this clinical finding therefore virtually excludes 46XX DSD.

*Phallus:* The phallus length, width, and glans width should be measured. A cotton bud placed at the suprapubic base of the implant of the stretched phallus allows for a good measurement of phallic length.

*Urogenital sinus opening:* The opening of the urogenital sinus must be well evaluated. A single opening has to be identified as well as a hymenal ring. Attention needs to be paid to the fusion of the labioscrotal folds as well as whether they show rugae or some discolouration.

*Ultrasound* can help to describe the palpated gonads or to detect non-palpable gonads [1260]. Mullerian structures like the vagina or utricular structures can be evaluated as well [1265, 1266].

*Genitography* can provide some more information on the urogenital sinus, especially on the exact position of the confluence. Moreover, it gives evidence of possible duplication of the vagina.

*Invasive diagnostics* under general anaesthesia can be helpful in some cases. During genito-cystoscopy, the urogenital sinus can be evaluated as well as the level of confluence. It allows also for evaluation of the vagina or utriculus, the possible presence of a cervix at the top of the vagina.

*Laparoscopy* is necessary to obtain a final diagnosis on the presence of impalpable gonads and on the presence of Mullerian structures. If indicated, a gonadal biopsy can be performed [1267, 1268].

*Genetics* has a increasing role in the diagnostic process of DSD. Karyotyping is usually at the beginning of the diagnostic process. Although next-generation sequencing-based molecular diagnostics and whole exome sequencing (WES) are becoming the gold standard for genetic evaluation, it may be difficult to prove variant causality or relate the genotype to the clinical presentation [1269].

These investigations will help to distinguish between various conditions of DSD, and provide a rapid diagnosis of congenital adrenal hyperplasia (CAH).

### 3.18.5 **Gender assignment**

In the current climate, it goes without saying that open, honest, and complete communication with caregivers and eventually the affected person is mandatory. Educational and psychological support regarding the impact is needed for each individual to make sense of their condition, relate to their community, and establish relationships. The lack of outcome data and different preferences make it challenging to determine whether and when to pursue gonadal or genital surgery. Shared decision making is critical, combining expert healthcare knowledge and the right of a patient or caregivers to make fully informed decisions. This entails a process of education, sharing of risks/benefits, articulating the uncertainties in DSD care and outcomes in addition to providing time for the patient and family to articulate back the risks and benefits of each option. The goal of all involved should be to individualise and prioritise each patient.

However, prior published adverse outcomes have led to recommendations to delay unnecessary surgery to an age when the patient can give informed consent. Surgery that alters appearance is not considered urgent. In 2017 the Parliamentary Assembly of the Council of Europe, the European Society for Paediatric Urology (ESPU) as well as the Societies for Paediatric Urology have taken a position in the debate on surgery for DSD [1252, 1270, 1271]. In an open letter to the Council of Europe, the European Society for Paediatric Urology expressed its attitude to the abovementioned resolution and concentrated on a worrying issue dealing with medicosurgical care for children with DSD. It states that surgical interventions in children with DSD only being applied in emergency conditions is discordant with the definition of health according to the WHO, stating that health is not merely the absence of disease, but is a much broader concept, including physical, mental, and social domains. This especially applies to children, as favourable physical, social and emotional conditions are all critical factors for their optimal growth and development, which enables them to reach their full potential at an adult age. As social and emotional interactions with the parents or caregivers, being the most important adults in a young child's life, form the basis for their future, treatment of children with DSD can best be organised in a patient- and family-centred multi-disciplinary setting, in an atmosphere based on openness, commitment and trust. Physicians, who daily take care of children with a variety of congenital conditions, the same as their parents or caregivers, are committed to the current as well as the future health and well-being of all children entrusted to their care. In contrast to what is alleged in the recommendation, parents and caregivers implicitly act in the best

interest of their children and should be respected as their outstanding representatives, and should not be put aside by claiming prohibition regulations regarding the well-informed decisions they make on their behalf. Finally in a published open letter, the ESPU advocate keeping dialogue open with the professionals active in specialised centres for multi-disciplinary, patient- and family-centred care as well as with patient societies, for which the present resolution is recognised as being a solid starting base [1272].

#### *Genital surgery*

The decision to proceed with genital surgery is acknowledged to be controversial. Patient-reported outcomes from adult patients who previously underwent early genital surgery demonstrate considerable variation, with perspectives dependent on, but not limited to, diagnostic category, gender, prior experience with surgical procedures, and contact with support groups [1273].

The majority of patients who have undergone surgery rated their appearance as satisfactory from an anatomical perspective. However, functional results were found to be less satisfactory due to the development of vaginal stenosis, or diminished sensation in the clitoris or the glans penis [1274]. Clinical decision-making with respect to genital surgery in patients with a DSD should not be made wantonly, but advisedly, in a patient and family-centred multi-disciplinary setting, on a case-by-case basis. These decisions should be supported and audited by improving information on long-term outcomes, informed consent, and contact with support groups at both an individual and an institutional level.

#### **3.18.6 Risk of tumour development**

The dysgenetic gonads of individuals with DSD have an increased risk of developing germ cell neoplasia *in situ* (GCNIS), previously known as carcinoma *in situ*, and overt germ cell cancer (GCC) as compared to the general population [1275]. The highest prevalence of GCC is seen in conditions characterised by disturbed gonadal development and in the presence of the Y chromosome or parts thereof (SRY & GBY encompassing regions) [1276]. In a large dsd-LIFE study the overall prevalence of neoplastic lesions was 12%. Subanalysis demonstrated a significantly higher prevalence of 36% in patients with 46 XY gonadal dysgenesis as compared with other DSD subtypes [1277]. Conversely, patients with testosterone biosynthesis disorders and androgen action disturbances (46XY DSD group) have a much lower risk (1-15%) for GCNIS development during childhood and had a limited tendency towards invasive progression of the lesions. It has been hypothesised that a certain level of testosterone activity seems to be needed for GCNIS to progress to overt malignancy [1278, 1279]. An overview of the risks of malignancy in different subtypes of DSD is shown in Table 7.

The issue of whether gonads should be removed and the timing of such surgery remains controversial and has been altogether questioned in some forms of DSD. Patients with, for example, CAIS benefit from the presence of testicles and the resultant aromatisation of the naturally occurring testosterone to oestrogens. The risk of malignant gonadal transformation in this subcategory is low (1.5%) with cases of malignancy first appearing after the second decade of life, thus allowing for the safe deferral of gonadectomy until after puberty [1279, 1280]. This is however less clear for other subtypes of DSD, and needs to be assessed for each case according to several factors such as patient age, underlying DSD subtype and especially the presence of a Y chromosome. In such cases, the location of the gonad, possible fertility, hormonal potential of the gonad and the possibility of gonadal monitoring together with surgical/anaesthetic risks incurred by gonadectomy should be taken into account [1253, 1272]. In general, intra-abdominal gonads have to be brought down to a superficial position or pexied to the abdominal wall to allow for monitoring, self examination and ultrasound guided biopsies. High-risk gonads that fail to be brought down, or streak-like gonads should be removed based on a risk-benefit analysis, and after appropriate inter-disciplinary review [1253, 1272]. Biopsies should be reviewed by an experienced pathologist and specialised immunohistochemistry is recommended for measurement of expressions of PLAP and octamer-binding transcription factors 3 and 4, as it may be difficult to differentiate between GCNIS and delayed germ cell maturation in infants. Non-invasive markers such as serum microRNA (miRNA) for early-stage malignancy detection, have been developed, but have yet to be implemented in clinical practice [1253, 1269].



**Table 7: Risk of malignancy in different subtypes of DSD** (Adapted from Looijenga *et al.*, [1281])

Risk	DSD	Malignancy risk (%)
High	Gonadal dysgenesis, with Y, abdominal gonad	15-35
	PAIS non-scrotal gonad	50
	Frasier syndrome	60
	Denys-Drash with Y	40
Intermediate	Turner syndrome with Y	12
	17 $\beta$ - hydroxysteroid dehydrogenase deficiency	28
	Gonadal dysgenesis with Y	Unknown
	PAIS scrotal gonad	Unknown
Low	Complete androgen insensitivity syndrome	2
	Ovotesticular DSD	3
	Turner syndrome without Y	1
No	5-Alpha Reductase Deficiency	0
	Leydig cell hyperplasia	0

### 3.18.7 Quality of life

In general, adult patients with DSD report good quality of life and physical health, however there is an increased risk for both somatic and psychiatric morbidities [1282]. Furthermore, a lower quality of life was reported in the domain “social relationships”, which relates to personal relationships and sexual health [1283, 1284]. In addition, patients with DSD report higher levels of psychological distress and mental health problems [1285, 1286]. These elements should be included in the multi-disciplinary and holistic health care for these patients.

A person’s experienced gender is a fundamental aspect of one’s sense of self. Gender incongruence can occur when there is incongruence between the physical and experienced gender, and if this causes significant distress it fulfills the criteria for the diagnosis gender dysphoria, according to the “Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)” of the American Psychiatric Association [1287]. Gender dysphoria is reported low in women with CAH, CAIS and complete gonadal dysgenesis favoring female sex of rearing. Gender dysphoria is reported high in females with 5- $\alpha$  reductase deficiency and 17 $\beta$ -Hydroxysteroid dehydrogenase-3 deficiency. Gender dysphoria is reported variable in PAIS or mixed gonadal dysgenesis [1288]. Approximately 3% of DSD patients undergo a gender change after puberty, which is a small group, but larger when compared to the general population [1289, 1290].

### 3.18.8 Recommendations for the management of disorders/differences of sex development

Recommendations	Strength rating
Do not delay diagnosis and treatment of any neonate presenting with ambiguous genitalia since salt-loss in a 46XX CAH girl can be fatal.	Strong
Refer children to experienced centres where neonatology, endocrinology, (paediatric) urology, psychology and transition to adult care are guaranteed.	Strong
Utilise a multi-disciplinary approach and a shared decision model in patients with DSD conditions including: a. Gender assignment b. Genital surgery (in accordance with national regulations) c. Gonadectomy	Strong
Do not underestimate the significant effects on psychological and psychiatric health, quality of life, personal relationships, and sexual function in individuals with DSD.	Strong
Ensure full disclosure to patients and caregivers that the presence of a Y-chromosome in dysgenetic gonads results in a higher malignancy risk	Strong

### 3.19 Congenital lower urinary tract obstruction (CLUTO)

#### Introduction

The term congenital lower urinary tract obstruction (CLUTO) is used for intrauterine dilatation of the bladder and/or the upper urinary tract. During pregnancy the diagnosis is usually based on ultrasound examinations. There is a broad spectrum of conditions that could cause an intrauterine dilatation of the urinary tract. Congenital lower urinary tract obstruction is most commonly the result of posterior urethral valves (PUV), in approximately 60% of cases. Postpartum diagnosis, however comprises any number of anatomical and functional disorders/anomalies/malformations causing dilatation e.g. anterior urethral valves, urethral atresia/stenosis, prune belly syndrome, dilating VUR, cloacal malformation, prolapsing ureterocele, megacystis-microcolon-intestinal hypoperistalsis or megacystis-megaureter syndrome [1291].

Due to the heterogeneity and the rare spectrum of clinical manifestations of CLUTO, referral of such cases is recommended to a tertiary centre with multidisciplinary expertise in prenatal and postnatal management of obstructive uropathies [1291].

#### Megacystis

In the first trimester, fetal megacystis is defined as a bladder with a longitudinal diameter  $\geq 7$  mm. A longitudinal (craniocaudal) diameter between 7-12 mm in the first trimester is usually transient, disappearing in about 90% of cases during the second trimester. A measurement  $> 15$  mm however, indicates CLUTO is unlikely to resolve [1291]. In the second and third trimester, megacystis is defined by an enlarged bladder failing to empty during an extended US examination lasting at least 40 minutes. Two thirds of cases are secondary to CLUTO and the remainder are associated with genetic syndromes, developmental or chromosomal abnormalities, including anorectal malformations, of which 14% were normal or had an isolated urological abnormality (e.g. VUR, Duplex system) [1291, 1292]. In a systematic review  $\geq 45\%$  of megacystis cases were shown to be associated with oligohydramnios and 15% had chromosomal abnormalities [1293]. Final diagnoses included PUV (57%), urethral atresia/stenosis (7%), prune-belly syndrome (4%), megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) (1%), cloacal abnormality (0.7%) and undefined pathologies (36.5%) [1293].

The prognosis of the fetus depends on the underlying pathology, the timing of diagnosis, the presence of oligo/anhydramnios and bladder volume.

#### 3.19.1 Posterior urethral valves

##### 3.19.1.1 Epidemiology and pathophysiology

Posterior urethral valves are one of the few life-threatening congenital anomalies of the urinary tract found during the neonatal period. The risk for chronic kidney disease (CKD) is estimated to reach 32% and 20% for end-stage renal disease (ESRD), as reported in a systemic review [1294]. Up to 17% of paediatric ESRD can be attributed to PUV [1295]. An incidence of PUV of 1 in 7000-8000 live-births has been estimated [1296, 1297].

The kidneys start to produce urine at around the tenth week of antenatal life. The intrauterine obstruction leads to a decreased urine output, which could result in oligo- or anhydramnios. Amniotic fluid is necessary for normal development of the lungs and its absence may lead to pulmonary hypoplasia.

An obstruction at the level of the urethra affects the whole urinary tract to varying degrees:

- The prostatic urethra is distended and the ejaculatory ducts may be dilated due to urinary reflux.
- The bladder neck is hypertrophied and rigid.
- The hypertrophied bladder may occasionally have multiple diverticulae.
- Nearly all valve patients have dilatation of the upper urinary tract. This may be due to the valve itself and the high pressure in the bladder, or due to obstruction of the ureterovesical junction by the hypertrophied bladder.
- If there is secondary VUR, the affected kidney functions poorly in most cases.

Secondary VUR is observed in at least 50% of patients with PUV [1298]. It is generally accepted that unilateral high grade VUR associated with ipsilateral renal dysplasia acts as a 'pressure pop-off valve', which would protect the contralateral kidney, leading to a better prognosis [1299]. Other types of pop-off mechanism include large bladder diverticulae, urinary extravasation, with or without urinary ascites and a patent urachus [1300]. Protective effects of pop-off phenomena on renal function remain however equivocal, as long-term outcomes from different studies have been discrepant, with some studies showing a protective effect [1301, 1302] while others have shown no protective benefit [1303-1305]. A possible explanation for such discrepancy could relate to differences in defining the exact nature of what constitutes a pop-off mechanism.

#### 3.19.2 Classification systems of the urethral valves

Up until today, the original classification by Hugh Hampton Young is the most commonly used classification

[1306], which described three categories: type I, type II and type III. However, today, only type I and type III are found to be obstructive. Hampton Young's descriptions of type I and III are as follows:

*Type I* (90-95%): In the most common type there is a ridge lying on the floor of the urethra, continuous with the verumontanum, which takes an anterior course and divides into two fork-like processes in the region of the bulbo-membranous junction [1306].

*Type III*: Has been found at different levels of the posterior urethra and which apparently bears no relation to the verumontanum. This obstruction attaches to the entire circumference of the urethra, with a small opening in the centre [1296].

### 3.19.3 **Diagnostic evaluation**

During prenatal US screening, hydroureteronephrosis and a distended bladder are suspicious signs of a urethral valve. A thick-walled bladder seems to better predict PUV than a dilated posterior urethra ('keyhole' sign) [1307]. However, differentiation between obstructive and non-obstructive aetiologies on prenatal US is challenging, as both have a similar sonographic appearance [1308]. In the presence of increased echogenicity of the kidney, dilatation of the urinary tract and oligohydramnios, the diagnosis of a PUV should strongly be considered. Prenatal US is adequate in most of the cases (90%) [1309]. However, in some circumstances when technical ultrasound conditions are poor, fetal MRI may provide additional information [1310].

Postnatally, creatinine, blood urea nitrogen and electrolytes should be monitored closely during the first few days. Initial management includes a multi-disciplinary team involving a paediatric nephrologist. The clinician must be aware of a noteworthy association between PUV and undescended testicles (UDT) and/or inguinal hernia [1311]. Undescended testicles occurred in 12–17 % of PUV which is consistent with a 10-fold increase [1312].

A voiding cystourethrogram (VCUG) (including lateral views of the urethra during the voiding phase without a catheter *in situ*) is recommended to assess the presence of a PUV. This study is essential whenever there is a question of an infravesical obstruction, as the urethral anatomy is well outlined during voiding. The extent of posterior urethral deformity – as expressed by the posterior urethral height: width ratio – appears to correlate positively with nadir creatinine at twelve months of age [1313]. Nuclear renography with split renal function is important in assessing contributory renal function and/or scarring (DMSA or MAG3).

### 3.19.4 **Management**

#### 3.19.4.1 **Prenatal treatment**

Most cases of PUV are suspected prenatally [1296, 1314, 1315].

The potential for spontaneous resolution of bladder enlargement, and the timing of renal imaging are the main obstacles for prenatal intervention. As renal dysplasia is irreversible, it is important to identify those fetuses with good renal function [1316].

Prenatal interventions aim to restore amniotic fluid volume and attenuate the risk of pulmonary hypoplasia or further renal damage [1317]. Decision for prenatal intervention can be based on a staging system that is composed of renal ultrasonographic findings, amnion amount and fetal urine biochemistry [1315]. Early intervention (before the age of sixteen weeks of gestation) may be beneficial for the renal function, however making the correct diagnosis and the detection of other severe comorbidities is extremely difficult at this time point [1318]. Later interventions are mostly of benefit for lung development, but not for renal function [1319]. There are however emerging reports of interventions as early as the end of first trimester, with results pointing to a potential preservation of long-term renal function. These reports are still preliminary, the techniques used are intricate and can be associated with a higher risk of foetal demise in these very frail and tiny patients [1320-1322].

Foetal urine samples before 23 weeks of gestation ( $\beta_2$ -microglobulin, sodium, chloride and calcium) may be helpful to distinguish between those who could benefit from intrauterine therapy and those in whom the outcome is most likely to be compromised [1323].

Normal biochemistry; a sodium level below 100 mmol/L, a chloride value of < 90 mmol/L, calcium <8 mg/dL, and  $\beta_2$ -microglobulin <6 mg/L obtained in the first fetal urine sample or biochemistry that improves between two sequential samplings, the latter scenario prompting fetal intervention, was associated with high fetal survival and normal renal function at five years in a small study [1324]. The status of amnion fluid, the appearance of the kidneys as well as the fetal urine biochemistry may be helpful in counselling. Proteomic analysis of fetal urine using a 12 peptide signature expressed in fetuses who go on to develop ESRD by the age of two years, may show promise in assessing CLUTO. This should be considered as experimental.

The placing of a vesicoamniotic shunt (VAS) is a prenatal treatment designed to restore amniotic fluid cycling. There is a reported complication rate of 21-59% with dislocation of the shunt being the most common [1317]. The PLUTO-trial (randomised study) failed to show a long-term benefit on renal function by placing a VAS [1325]. A meta-analysis on interventions for CLUTO reported that VAS resulted in a higher perinatal survival rate than conservative management (57.1% vs 38.8%), with no significant differences in six to twelve month survival, two-year survival or postnatal renal function [1326]. Foetal cystoscopy with laser ablation has a high complication rate without evidence for the effectiveness of these interventions [1327]. To avoid the severe complication of the laser ablation, balloon dilation has been tried [1328]. The number of patients and designs of these studies are insufficient to yield any recommendations. Parental information is very important and the natural history of CLUTO including the postnatal outcomes with or without prenatal treatment as well as the uncertainties and/or controversies about CLUTO diagnosis and treatment should be discussed [1317].

#### 3.19.4.2 Postnatal treatment

##### *Bladder drainage*

Following delivery, the bladder should be drained transurethrally, or suprapubically. This catheter drainage tube can then be used to perform a VCUG to confirm the diagnosis.

##### *Valve ablation*

When the medical situation of the neonate has stabilised, the next step is to perform an endoscopic valve ablation provided the urethra is accessible with available equipment. In cases where the urethra is too small, urinary diversion should be maintained until valve ablation can be performed. Small paediatric cystoscopes and resectoscopes are available either to incise, ablate or to resect the valve at the 5, 7 and/or 12 o'clock positions, depending on the surgeon's preference. It is important to avoid extensive electrocoagulation, as the most common complication of this procedure is stricture formation. Two studies demonstrated a lower urethral stricture rate using the cold knife compared to diathermy [1329, 1330]. Currently, no strong evidence exists to support the use of laser ablation of PUVs; preliminary studies on the use of Holmium YAG and Thulium lasers, show that laser fulguration is safe and effective [1331]. Within the three months following initial treatment, effectiveness of the treatment should be demonstrated either by clinical improvement (ultrasound and renal function), control VCUG or a re-look cystoscopy, depending on the clinical course [1332-1334].

##### *Bladder neck incision*

Bladder neck incision has been suggested as a means of managing secondary bladder neck obstruction [1335]. There is no current evidence which demonstrates that bladder neck incision has a role in preventing reintervention or rehospitalisation rates, and therefore cannot be recommended as a routine management option.

##### *Vesicostomy*

A vesicostomy is indicated if the child is too small to undergo endoscopic surgery, has failed endoscopic valve ablation, or has shown no clinic-biochemical improvement following valve ablation. This is an alternative to prolonged catheter drainage and has been shown to stabilise/improve the upper tracts in up to 90% cases [1336]. The most prevalent vesicostomy procedure in children was described by Blocksom and modified by Duckett [1337]. Key technical points are to ensure an adequate mobilization of the bladder dome to enable a tension-free anastomosis with the fascia and skin. Common complication following vesicostomy are stomal stenosis, mucosal prolapse, peristomal dermatitis, and bladder calculi. The risk of prolapse is usually due to an extensive bladder mobilization and due to placement of the stoma too inferior on the abdominal wall, allowing the posterior bladder wall to evert through the stoma.

##### *High diversion*

In cases where bladder drainage is insufficient to prevent recurrent infections of the upper tract, improve renal function and/or a decrease upper tract dilatation, high urinary diversion should be considered. The choice of urinary diversion depends on the surgeon's preference for high loop ureterostomy, ring ureterostomy, end ureterostomy or pyelostomy, with each technique having its advantages and disadvantages [1338-1340]. Diversion can delay progression to end stage renal failure [1341].

Vesicoureteric reflux is very common in PUV patients (up to 72%) and it is described bilaterally in up to 32% [1342]. A prospective observational study identified high grade VUR as an independent risk factor for developing febrile UTIs especially in the first nine months of life, therefore antibiotic prophylaxis should be considered in such patients [1343]. Furthermore, circumcision can be discussed in order to further reduce the risk of UTIs [1343]. In the aforementioned multicentred randomized controlled trial, after two years of follow-up, this study demonstrated a statistically significant effect of circumcision as an adjunct to antibiotic prophylaxis in

preventing febrile UTIs. The hazard ratio for developing a febrile UTI in the group with antibiotics alone was 10.3 (95% confidence interval: 1.3–82.5) compared with the combined prophylactic antibiotics and circumcision group.

Early administration of oxybutynin may improve bladder function as shown in one study with eighteen patients [1344], and enhances resolution of hydronephrosis and VUR as shown in a randomized controlled study of 49 patients. Oxybutynin treatment had, however no discernible effect on renal function or risk of UTI [1335]. High-grade VUR is usually associated with a poorly functioning kidney however, early removal of a non-functioning renal unit in an asymptomatic patient seems to be unnecessary. Deterioration of renal function without an anatomical obstruction and higher urine output (polyuria) may lead to an overdistension of the bladder during the night. Drainage of the bladder during the night by a catheter may be beneficial for the hydronephrosis as well as for renal function [1345, 1346]. Patients with high daytime post void residual urine volumes may benefit from clean intermittent catheterisation (CIC) [1347]. In those who do not want, or are not able to perform CIC via the urethra, the placement of a catheterizable channel is a good alternative [1348].

Clean intermittent catheterization has been shown to delay the onset of dialysis in patients with chronic kidney disease, progressing to ESRD and has also resulted in significantly better ten-year graft survival rates in transplanted patients [1349, 1350].

### 3.19.5 **Follow-up**


Several prognostic factors for the prediction of future renal function have been described. Different serum nadir creatinine levels are given in the literature (0.85 mg/dl – 1.2 mg/dl [ $\mu\text{mol/L}$ ]) [1313, 1351-1354]. Renal parenchymal quantity (total renal parenchymal area) and quality (corticomedullary differentiation and renal echogenicity) on initial postnatal ultrasound also have prognostic value [1355].

Life-long monitoring of these patients is mandatory, as bladder dysfunction ('valve bladder') is common and the delay in day- and night-time continence is a significant problem [1356]. Urodynamic studies play an important role in the management of patients with valve bladder especially in those with suspicion of bladder dysfunction [1357, 1358], however there is no consensus as to optimal timing or frequency of such studies. Poor bladder sensation and compliance, detrusor overactivity and polyuria (especially at night) and their combination are responsible for bladder dysfunction. In those with bladder overactivity, anticholinergic therapy can improve bladder function. In patients with poor bladder emptying,  $\alpha$ -blockers can be used to reduce the post-void residual [1359, 1360].

Chronic kidney disease develops in up to 65% of PUV patients and about 20% of these progress towards ESRD [1361]. Renal transplantation in these patients can be performed safely and effectively [1362, 1363]. Deterioration of the graft function is mainly related to lower urinary tract dysfunction (LUTD) [1362]. An assessment and treatment algorithm is provided in Figure 13.

There is limited data pertaining to sexual function and fertility in patients with PUV. Long-term studies have demonstrated normal erectile function and fertility potential [1364, 1365]. However, a negative influence of the individual patient's fertility has to be taken into account as these patients have a higher risk for bilateral cryptorchidism, recurrent epididymitis and ESRD [1364].

Figure 13: An algorithm on the assessment, management and follow-up of newborns with possible PUV



CIC = clean intermittent catheterisation; OAB = overactive bladder; PUV = posterior urethral valve; RF = renal function; UT = urinary tract; UUT = upper urinary tract; VCUG = voiding cystourethrogram.

• **Anterior urethral valve (AUV)**

Anterior urethral valve is a semilunar or iris-like band of tissue on ventral aspect of urethra. It can be isolated, or seen in association with anterior urethral diverticulum. The aetiology of isolated AUV is speculated to be secondary to congenital urethral obstruction, malunion of glanular and penile urethra, congenital cystic dilatation of periurethral glands or ruptured distal lip of a syringocele [1366]. It can be present in the bulbous urethra, the penoscrotal junction and penile urethra. Patients may present with poor urinary stream, penile ballooning, UTI or haematuria. Anterior urethral valves were classified by Firlit depending on the presence of diverticulum and dilatation of urethra and upper tract [1367]. The diagnosis is based on a VCUG with possible findings of dilated or elongated posterior urethra, dilatation of the anterior urethra, thickened trabeculated bladder, hypertrophied bladder neck, VUR, and urethral diverticula. In doubtful cases retrograde urethrography may be helpful showing linear filling defect along the ventral wall, or it may show a dilated urethra ending in a smooth bulge or an abrupt change in the calibre of the dilated urethra on VCUG [1368].

Treatment is mainly by endoscopic valve ablation. In selected patients, temporary diversion may be considered until the child is big enough for endoscopy. Open surgery is reserved for patients with very large diverticulum

and defective spongiosum. Renal failure may develop in 22%, the risk being highest in patients with pre-treatment azotaemia, VUR and UTI [1369].

- **Anterior urethral diverticulum (AUD)**

Common postnatal presenting features of AUD are compressible ventral penile swelling, urinary postmicturition dribble, voiding difficulty, poor stream, and recurrent UTIs [1370-1372]. Diagnosis is by VCUG with or without a retrograde urethrogram. In small AUD, endoscopic cutting or deroofting of distal lip of the diverticulum can be sufficient treatment. Larger diverticulum requires excision with subsequent two layered urethroplasty; or marsupialisation with staged urethroplasty. In cases of urosepsis and obstructive uropathy, a suprapubic catheter or temporary urinary diversion (vesicostomy or proximal cutaneous urethroostomy) may be indicated prior to definitive surgical management [1373, 1374]. Anatomically, AUVs have normal corpus spongiosum development whereas AUDs do not [1374].

- **Syringocele**

Cowper's glands are two bulbourethral glands that are located within the urogenital diaphragm which open into the urethra 1-2 cm distal to the sphincter. Syringocele is the cystic dilatation of these glands. The aetiology can be congenital or acquired (trauma or infection). It has been classified as simple, imperforate, perforate and ruptured [1375]. A simpler grouping is suggested as to merge simple, perforate and ruptured ones into "open syringocele" and imperforate to "closed syringocele". Closed syringoceles cause obstructive symptoms and open ones act as a diverticulae and cause post-voiding dripping and sometimes obstruction [1376]. Depending on the syringocele type, patients can present with post-void dribbling, urethral discharge, UTI, perineal pain, haematuria, obstructive voiding symptoms, dysuria or retention. Diagnosis is based on antegrade and/or retrograde urethrogram which shows a cystic defect distal to prostate. If such studies are inconclusive, US and/or MRI may be used. Asymptomatic syringoceles can be managed conservatively. Endoscopic deroofting with various energy sources (cold knife, electrocautery and holmium laser) in both obstructing and non-obstructing syringoceles is an effective method of marsupialisation [1377]. In cases where endoscopic approach is not feasible open correction may be considered.

- **Cobb's collar**

Cobb's collar is a congenital membranous stricture of the bulbar urethra. It is different from congenital obstructive posterior urethral membrane (COPUM), is independent of the veru montanum and external sphincter and is believed to represent a persistence of part of the urogenital membrane [1378]. Voiding cystourethrogram shows narrowing in the proximal bulbar urethra with folds extending proximally, a dilated posterior urethra, prominent bladder neck and other findings of infravesical obstruction. Treatment with endoscopic cold-knife incision showed lower recurrence rates than electrocautery [1379].

- **Urethral atresia/hypoplasia**

Male urethral atresia is congenital, complete obstruction of the urethra caused by a membrane that is usually located at the distal end of the prostatic urethra. The urethra distal to this point is usually hypoplastic, presumably from lack of fetal voiding [1380]. Urethral atresia is associated with bladder distention, VUR, hydronephrosis and renal dysplasia [1381]. Most cases reported have the phenotypic characteristics of the prune belly syndrome. Antenatal intervention may be beneficial in terms of fetal survival [1382]. Although progressive augmentation by dilating the urethra anterior (PADUA) procedure was described as a treatment modality, the majority of cases require some form of supra-vesical diversion [1380, 1381].

- **Posterior Urethral Polyps (PUP)**

Although, PUP does not cause antenatal hydronephrosis, it could cause obstruction later on in life. Posterior Urethral Polyps is a polypoid, pedunculated, fibroepithelial lesion arising in the posterior urethra proximal to the veru montanum. It lies on the floor of the urethra with its tip reaching into the bladder neck and obstruction occurs because of distal displacement of the polyp during micturition [1383]. Patients complain of dysuria, haematuria and obstructive symptoms such as poor urinary stream, intermittent retention episodes. Diagnosis can be suspected by VCUG and/or US but is confirmed during cystourethroscopy. Treatment is usually by endoscopic resection of the polyp. The course of the disease is benign and no recurrences have been reported in the literature [1384, 1385].

### 3.19.6 Summary of evidence and recommendations for the management of posterior urethral valves

Summary of evidence	LE
Posterior urethral valves are one of the few life-threatening congenital anomalies of the urinary tract.	1b
Antenatal therapy could be considered based on ultrasound findings, fetal urine biochemistry, amniotic fluid level, and chromosomal status.	4
Serum creatinine nadir above 0.85 mg/dL is correlated with a poor prognosis.	2a
Neonatal circumcision as an adjunct to antibiotic prophylaxis in PUV patients significantly decreases the risk of developing febrile UTIs during the first two years of life.	1b
Early pharmacological management with oxybutynin may improve bladder function.	1b
Despite optimal treatment, 20% of patients will develop ESRD.	2a
Renal transplantation in these patients is safe and effective, if the bladder function is managed.	3

Recommendations	Strength rating
Drain the bladder in new-borns with a suspected diagnosis of infravesical obstruction and place on antibiotic prophylaxis	Strong
Perform a voiding cystourethrography (VCUG) in patients in whom a diagnosis of posterior urethral valves (PUV) is suspected.	Strong
Attempt endoscopic valve ablation after bladder drainage and stabilisation of the child.	Weak
Consider neonatal circumcision as an adjunct to antibiotic prophylaxis to decrease the risk of urinary tract infection in those with a PUV, especially in the presence of high grade vesicoureteric reflux.	Strong
Offer prolonged urinary diversion (suprapubic/transurethral) for bladder drainage if the child is too small for valve ablation.	Strong
Use serum creatinine nadir as a prognostic marker.	Strong
Assess split renal function by dimercaptosuccinic acid (DMSA) scan or mercaptoacetyltriglycine (MAG3) clearance.	Strong
Consider high urinary diversion if bladder drainage is insufficient to drain the upper urinary tract, or in the absence of clinico-biochemical improvement.	Strong
Monitor and manage bladder and renal function lifelong.	Strong

## 3.20 Rare Conditions in Childhood

### 3.20.1 Urachal remnants

#### 3.20.1.1 Introduction

The urachus is an embryonic structure arising as a result of the separation of the allantois from the ventral cloaca. The allantois appears on day sixteen as a tiny, fingerlike outpouching from the caudal wall of the yolk sac, which is contiguous with the ventral cloaca at one end and the umbilicus at the other. The ventral portion of the cloaca develops into the bladder after cloacal division by the urogenital septum. Thus, the bladder initially extends all the way to the umbilicus [1386]. With progressive foetal development, as the bladder descends into the pelvis, the attachment between the umbilicus and the urachus becomes looser and the apical portion progressively narrows to a small, epithelialised, fibromuscular strand by the fourth or fifth month of gestation. The urachus then obliterates completely by birth, forming the median umbilical ligament [1387-1389].

The urachus varies from 3 to 10 cm in length and from 8 to 10 mm in diameter. It is a three-layered tubular structure, the innermost layer being lined with transitional epithelium, the middle layer composed of connective tissue, and the outermost muscular layer in continuity with the detrusor muscle [1390].

Urachal remnants (URs) originate from failure of the obliteration of the allantois, resulting in a urachal anomaly such as (1) urachal sinus, (2) urachal cyst, (3) vesico-urachal diverticulum, and (4) patent urachus [1387, 1388, 1391]. Most often the urachal anomaly is asymptomatic, but it occasionally may become infected, may cause urinary symptoms, or develop a urachal carcinoma in later life [1390, 1392].



### 3.20.1.2 Epidemiology

Reports of occurrence rates in the literature vary broadly from a very rare disease in the older literature to a fairly common problem. Robert *et al.* found that URs were present in 61.7% of patients younger than 16 years [1393]. They also noted that the frequency of URs decreased with increasing age. This supports a physiological regression of URs with age. Stopak *et al.* attributed this upsurge to increased awareness among community paediatricians and improvements in US that made visualisation of urachal remnants easier [1394].

Clinical studies and paediatric autopsy studies in the past have shown a much lower incidence. Rubin found an incidence of 1 in 7,610 cases of patent urachus and 1 in 5,000 cases of urachal cysts [1395]. Nix *et al.* noted three anomalies out of 1,168,760 hospital admissions, and Blichert-Toft *et al.* reported five UR cases out of 40,000 patients [1396, 1397]. The incidence rate in males is a little higher than in females [1398, 1399].

The range of the various URs reported in the literature is 10% to 48% for patent urachus, 31% to 43% for urachal cyst, 18% to 43% for urachal sinus and 3% to 4% for urachal diverticulum [1400, 1401].

### 3.20.1.3 Symptoms

A patent urachus causes continuous or intermittent urine leakage from the umbilicus causing umbilical granulation and erythema in infants [1400]. A urachal cyst is usually diagnosed (1) incidentally, or (2) when it becomes infected causing abdominal pain and discharge of pus from the umbilicus or recurrent UTIs when it drains into the bladder.

The most common symptom is umbilical granulation, discharge and erythema in infants and abdominal pain in older children [1400].

Other symptoms of infected urachal anomalies can vary from high fever, abdominal pain, urinary tract infections, LUTS and/or an abdominal mass [1401-1405]. A urachal diverticulum is often asymptomatic and is usually found incidentally during investigations for other problems. An alternating sinus can empty either into the bladder or the umbilicus and this characteristic is responsible for various presentations [1406]. Infection has been reported as the most common complication in urachal anomalies [1407]. Severe infection may develop into peritonitis and sepsis. Cultures from umbilical discharge usually show *Staphylococcus*, *Streptococcus* and *E. Coli* [1408].

#### **Other congenital anomalies:**

Ashley found a simultaneous anomaly in 17 of 46 children, of which VUR was the most common anomaly (6 patients) [1409]. Other investigators reported associated anomalies in cases of persistent URs including meatal stenosis, hypospadias, umbilical and inguinal hernias, cryptorchidism, anal atresia, omphalocele, ureteropelvic obstruction and most frequently, VUR [1399, 1410-1412].

### 3.20.1.4 Diagnosis

In the majority of cases with complaints of a UR, a careful history and physical examination will confirm the suspicion of a UR. In many patients this can be confirmed by US studies [1393]. An MRI or CT scan may be necessary in a minority of children [1404]. Because of the association with other congenital abnormalities, other studies such as a VCUG or cystoscopy may be undertaken as well. In general, the VCUG is only undertaken when the child also presents with UTI or when the US shows signs of upper tract abnormalities. For the diagnosis per se it is not necessary [1413]; however, a VCUG may be useful for defining the type of urachal anomaly and evaluating a population that may be at higher risk for VUR.

### 3.20.1.5 Treatment

If a UR is symptomatic, the standard approach has been surgical removal. In most cases it should be done as an elective procedure, following appropriate treatment of active inflammation, and infection is possible. Pre-operative IV-dosage of antibiotic like Cefazolin is generally sufficient. A Pfannenstiel, periumbilical or infraumbilical midline incision can all be used for the open surgical approach [1403, 1414]. Even in symptomatic infants a more conservative approach is possible as well, especially in children less than six months old. Observation and treatment with antibiotics if necessary and radiographic monitoring are a safe approach [1400, 1415, 1416]. Dethlefs *et al.* reported a 90% successful outcome [1402], while Naiditch *et al.* reported that 44 of 78 symptomatic patients resolved under observation [1405]. More recently the laparoscopic approach has been advocated, and shown to be safe [1416-1418]. Surgery is not without risk. The rate of complications following surgical removal varies from 0 to 20%: usually wound infections [1394, 1402-1405, 1414]. Considering the probable additional risk of anaesthesia in very young children any surgical procedure needs to be assessed carefully [1419, 1420].

### 3.20.1.6 Pathology of removed remnants

Removed specimens may show inflammation or a cystic structure [1402]. Patients presenting without symptoms are as likely to have epithelial elements in the UR as those presenting with symptoms [1404].

### 3.20.1.7 Urachal cancer

Urachal anomalies are thought to be associated with an increased risk of bladder adenocarcinoma in adults, and urachal adenocarcinoma has an estimated incidence of 0.18 per 100,000 individuals yearly [1421]. These cases account for 0.1 to 0.3% of all bladder malignancies and 20 to 39% of bladder adenocarcinomas [1422]. Urachal adenocarcinoma (UrC) is very rare, especially when one considers that up to 62% of children under 16 years of age may have a UR [1393, 1423]. A study by Copp *et al.* found no association between the presence of UR symptoms and the presence or absence of epithelial tissue in pathology specimens, leading them to conclude that UR symptoms have poor predictive value for malignancy potential in these remnants [1399].

Gleason *et al.* found that 5,721 URs would need to be excised to prevent a single case of urachaladenocarcinoma out of the nearly 65,000 patients reviewed [1421]. Assuming that epithelium is required in the development of urachal adenocarcinoma, the extrapolated Number Needed to Treat (NNT) would be more than 8,000, as nearly 30% of urachal anomalies are void of an epithelial component. Less than 5% of urachal cancers have a non-epithelial origin such as sarcoma [1424]. The presenting symptoms in adults are different from those in children: in a study of 130 adult patients, Ashley *et al.* found that 49% presented with haematuria and 27% with pain. In 51% a urachal carcinoma was diagnosed: adenocarcinoma, with 58% high grade cancer. In addition, 20% had metastases at diagnosis, the overall 5-year cancer specific survival rate in the UrC cohort was 49% [1425]. Stasis of urine and crystallisation promoters such as mucus or desquamated epithelium in the UR are most likely the cause for malignant degeneration as well as stone formation in the adult patient. At present no long-term follow-up on untreated UR in children is available and there is no evidence that urachal anomalies in children increase the likelihood of future malignancy [1400, 1426].

### 3.20.1.8 Conclusion

Urachal remnants appear to be more common than previously reported. During the first 6-12 months of life spontaneous resolution is common. Excision of symptomatic urachal anomalies is an effective and safe means of treatment, with minimal morbidity. However, most patients with simple and asymptomatic lesions do not appear to benefit from excision, as the risk of malignancy later in life is vanishingly remote. Early intervention (< 6 months of age) should be reserved for patients with persistent documented urine draining from the urachus or a documented abscess. Incidental (US) UR management remains a challenge and should be done with patient and family involvement to make the most informed decision. While surgical intervention has minimal risk and morbidity, it is performed unnecessarily in a large proportion of asymptomatic patients due to the unnecessary removal of non-epithelial containing urachal anomalies and the inability to predict which anomalies will undergo malignant transformation [1427].

### 3.20.1.9 Recommendation for management of urachal remnants

Recommendations	Strength rating
Urachal remnants (URs) with no epithelial tissue carry little risk of malignant transformation.	Strong
Asymptomatic and non-specific atretic urachal remnants can safely be managed non-operatively.	Strong
Urachal remnants incidentally identified during diagnostic imaging for non-specific symptoms should also be observed non-operatively since they tend to resolve spontaneously.	Strong
A small UR, especially at birth, may be viewed as physiological.	Strong
Urachal remnants in patients younger than 6 months are likely to resolve with non-operative management.	Strong
Follow-up: is necessary only when symptomatic for 6 to 12 months.	Strong
Surgical excision of URs solely as a preventive measure against later malignancy appears to have minimal support in the literature.	Strong
Only symptomatic URs should be safely removed by open or laparoscopic approach.	Strong
A voiding cystourethrogram is only recommended when presenting with febrile UTIs.	

### 3.20.2 **Papillary tumours of the bladder in children and adolescents (Papillary urothelial neoplasm of low malignant potential or transitional cell carcinoma)**

#### 3.20.2.1 *Incidence*

Papillary tumours of the bladder in children and adolescents are extremely rare and are different from papillary tumours in adults. A “grape-like” papillary tumour in young children will be more likely a rhabdomyosarcoma of the bladder, which are not the focus of this guideline. A papillary tumour in older children or adolescents will be more likely be a papillary urothelial neoplasm of low malignant potential (PUNLMP) [1428]. Children with risk factors, such as previous bladder surgery and immunosuppressive medication can also develop a nephrogenic adenoma of the bladder, also presenting as a papillary tumour of the bladder.

#### 3.20.2.2 *Differences and similarities of papillary tumours of the bladder in children and adults*

##### **Gender**

The overall the risk of a papillary tumour in the bladder in paediatric and young adult patients is approximately double in males compared to females [1429].

#### 3.20.2.3 *Risk factors*

The majority of these patients have no identifiable risk factors.

#### 3.20.2.4 *Presentation*

The most common symptom at presentation is haematuria; other less common symptoms include abdominal pain, storage LUTS including frequency, dysuria and at times obstructive symptoms [1429].

#### 3.20.2.5 *Investigations and treatment*

Ultrasound of the genitourinary tract is the first investigation of choice. It is an excellent screening tool and can often accurately diagnose the nature and location of lesion. In children and adolescents, a bladder US of the full bladder is more sensitive compared with adults due to reduced abdominal fat and thinner muscle layer [1430]. In the event of a need to differentiate the renal or bladder origin of the haematuria, a red blood cell morphology will reveal isomorphic blood cells, differentiating a bladder origin. Urine cytology can be performed, however it has very limited value likely due to the low-grade nature of these tumours in children. Cystoscopy should be reserved if a bladder tumour is suspected on imaging for simultaneous diagnosis and treatment, transurethral resection of the tumour. In children, cystoscopy requires general anaesthesia [1431].

#### 3.20.2.6 *Histology*

All the lesions in the children and adolescent age-group are identified as papillary and over 85% are solitary [1430]. Papillary bladder tumours in patients younger than twenty years of age have low-grade non-invasive disease (WHO classification) [1432]. These findings let pathologists conclude that in children and adolescents, a papillary bladder tumour can be classified as Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP). PUNLMP has minimal or no cytological atypia and it differs from low grade transitional cell carcinoma (TCC) which has cytologic atypia, hyperchromatic nuclei and scattered mitosis [1433].

#### 3.20.2.7 *Additional treatment*

*Mitomycin C* and *Bacillus Calmette-Guérin* have both been used in children but there is no evidence of their efficacy due to the rarity of TCC, and especially of high grade TCC [1429]. Hence, as per current evidence, there is no place for instillations in children.

#### 3.20.2.8 *Prognosis, recurrence and surveillance*

The prognosis of papillary tumours of the bladder in children is overall good. The recurrence rate in children and adolescents varies from 8 to 15% [1428-1430]. Mean time to recurrence can vary from 11 to 29 months depending on the study, with recurrences occurring up to 90 months from diagnosis; though 64% occur in the first year [1429]. In certain cases, recurrences can be fairly aggressive [1430].

Strategies are based on the guidelines and protocols of papillary tumours of the bladder in adults. It is advised to follow-up children and adolescents with a history of a PUNLMP initially with a short interval of three to six months in the first year, and thereafter at least yearly with urinalysis for haematuria and an US of the full bladder. In the event of sudden gross haematuria, the evaluation must be performed immediately. If the tumour was completely resected at primary surgery, standard follow-up cystoscopy is not necessary and may be reserved for children or adolescents with a high recurrence risk or suspected recurrence on bladder US [1430]. The exact duration of follow-up is unknown but this Panel recommends follow-up for at least five years.

**Inflammatory myofibroblastic tumours of the bladder (IMTB)** are rare with nearly 200 cases reported in the literature [1434, 1435]. Around 25% occur in children with a median age at diagnosis of 7.5 years and a median

tumour size of 5.5 cm. Boys and girls are equally affected [1436]. Usually these tumours are benign, with only very few reported malignant cases [1437]. Treatment is mostly surgical with transurethral resection, but local resection, or partial cystectomy maybe needed in selected cases [1436, 1438]. Additionally, a conservative approach is reported [1439]. Histological examination is required to exclude other malignant tumours such as a rhabdomyosarcoma. In children, no recurrence has been reported so far. However due to the malignant potential and few recurrences in adults, follow-up the same as for papillary bladder tumours is recommended.

### **Eosinophilic cystitis**

Though well described in adults, this inflammatory condition is rare in the paediatric population with less than 100 cases reported in the literature to date [1440]. Its etiology remains unknown, but is thought to be incited by IgE mediated attraction of eosinophils to bladder wall followed by mast cell degranulation. It has been linked to medications, specifically antibiotics such as penicillin, chemotherapeutic agents e.g. cyclophosphamide and mitomycin, and chronic bladder catheterisation [1441, 1442]. In children, as opposed to adults, males are more frequently afflicted with seven years being the mean age of presentation, however the condition can be seen throughout childhood even in LUTS [1440, 1443].

Irritative bladder symptoms such as dysuria, frequency, urgency and incontinence are the most frequent and can mimic UTI [1444]. Other symptoms include haematuria, suprapubic tenderness and systemic symptoms. Obstructive manifestations due to mass formation in the bladder wall can result in ureteral obstruction leading to hydro-ureteronephrosis, suprapubic mass in infants in addition to voiding dysfunction [1440, 1443, 1445].

Although associated with allergy only about a third of reported cases had a history of other allergic conditions whereas half had significant eosinophilia or eosinophiluria. Diagnosis is often delayed as symptoms of eosinophilic cystitis (EC) mimic other more common conditions such as UTI and LUTS and most patients will ultimately have undergone imaging studies such as ultrasound, VCUG, CT and MRI, which although not specially diagnostic for the condition, may show bladder wall thickening or even mass formation, with rhabdomyosarcoma constituting an important differential diagnosis. A high index of suspicion for the diagnosis should therefore be maintained when dealing with protracted urinary symptoms not responsive to conventional intervention. Definitive diagnosis can only be attained on tissue biopsy obtained by cystoscopy. Histologically, eosinophilic infiltration of lamina propria and muscularis are seen in acute phases with > 25 eosinophils per high power field considered to be significant [1440, 1443, 1445]. Management is not standardised; removal of any possible allergens is the obvious first step and there are reports of self-limiting course of the disease. However, empirical treatment with corticosteroids, antibiotics, anticholinergics, and antihistamines, in addition to cyclosporine A have been utilised and lead to resolution of symptoms in most cases. Partial cystectomy has been performed in circumscribed lesions that do not disappear spontaneously. No standard follow-up recommendations exist however surveillance is justified as recurrence has been reported in about a third of patients [1440, 1443].

### **Nephrogenic adenoma**

Nephrogenic adenomas (NA) in children are rare benign lesions that usually occur in the setting of previous surgery or chronic irritation of urinary tract [1446]. These benign proliferative lesions are most commonly found in the bladder. There is a significant predominance of girls compared to boys (5:1). The exact pathogenesis is unknown. It is proposed to be a metaplastic process of native urothelium in response to chronic injury. Recent evidence suggest that they can be derived from renal tubular cells that shed, migrate, reimplant and proliferate within urothelial mucosa [1447]. Though they are known to occur concurrently with bladder cancer, there are no *de novo* cases of bladder cancer diagnosed after nephrogenic adenoma. Previous history of bladder surgery such as bladder augmentation or presence of chronic inflammation or irritation is important [1448]. Lesions tend to develop at sites prone to chronic catheterisation injury. Other risk factors include trauma, immunosuppression and radiation. They present with haematuria and storage LUTS with a papillary/polypoid mass on cystoscopy. The recurrence rate is as high as 80% over 4 years [1446]. The final diagnosis is established by cystoscopy and histopathological review of biopsy specimen. Treatment is excision either by transurethral resection which often requires reresections, partial cystectomy or open excision. Again no standard follow-up recommendations exist however regular follow-up with cystoscopy has been advocated especially for patients with augmented bladders as recurrence seem particularly high in this subgroup [1448].

### 3.20.2.9 Summary of evidence and recommendations for papillary tumours of the bladder in children

Summary of evidence	LE
Majority of paediatric patients have no identifiable risk factors for bladder tumours.	3
There is no evidence on intravesical therapy for bladder tumours in children and adolescents.	4
Prognosis of papillary tumours of the bladder in children is good overall.	3
Inflammatory myofibroblastic bladder tumours are usually benign.	3
Paediatric EC cases are in a third of cases associated with a history of allergic conditions and in 50% with significant eosinophilia or eosinophiluria.	4
Paediatric EC patients usually present with irritative and or obstructive urinary symptoms which can mimic UTI or LUTS thereby leading to delayed diagnosis.	4
In paediatric EC definitive diagnosis can only be attained on tissue biopsy obtained by cystoscopy.	4
In EC treatment with corticosteroids, antibiotics, anticholinergics, and antihistamines, in addition to cyclosporine A have been utilised and lead to resolution of symptoms in most cases.	4
No standard follow-up recommendations exist however surveillance is justified as recurrence has been reported in about a third of patients.	4
NA in children are rare benign lesions that usually occur in the setting of previous surgery or chronic irritation of urinary tract and mainly occurring in the bladder.	4
NA usually presents with haematuria and or storage LUTS and with a papillary/polypoid mass on seen on cystoscopy.	4
NA diagnosis is established by cystoscopy and histopathological review of biopsy specimen.	4
NA treatment is excision either by transurethral resection which often requires reresections, partial cystectomy or open excision.	4
NA recurrence rate is high thereby justifying regular follow-up.	4

Recommendations	LE	Strength rating
Ultrasound is the first investigation of choice for the diagnosis of paediatric bladder tumours.	3	Strong
Cystoscopy should be reserved if a bladder tumour is suspected on imaging for diagnosis and treatment.	3 4	Strong Weak
After histological confirmation, inflammatory myofibroblastic bladder tumours should be resected locally.	4	Weak
Follow-up should be every 3-6 months in the first year, and thereafter at least annually with urinalysis and an ultrasound for at least 5 years.	4 4	Strong
Have a high index of suspicion of eosinophilic cystitis (EC) in protracted urinary tract symptoms unresponsive to regular treatment.	4	Strong
Remove any possible allergens as the obvious first step in managing EC.	4	Weak
Eosinophilic cystitis can be managed medically with corticosteroids, antibiotics, anticholinergics, and antihistamines, in addition to cyclosporine A.	4	
Manage nephrogenic adenoma (NA) by resection either transurethral or by open excision.	4	Strong
Regular endoscopic follow-up especially for augmented patients with NA is justified.	4	Weak

### 3.20.3 Penile rare conditions

Paediatric lesions of the penis are uncommon but an important part of the paediatric urological practice. The most common of these lesions are cystic penile lesions followed by vascular malformations and neurogenic lesions [1449]. Soft tissue tumours of the male external genitalia are uncommon, but have been described in the paediatric age group and can be malignant [1450].

#### 3.20.3.1 Cystic lesions

- **Epidermal inclusion cysts** are the most common genital cystic lesion and can occur anywhere on the body in both men and women; in the penis it occurs most commonly over the penile shaft varying from 0.1 to 1

cm in diameter. Their epithelium is lined and filled with keratin. It is a painless swelling and can present in the age group with a history of circumcision. Treatment by total surgical excision is mainly indicated for cosmetic or symptomatic (e.g. infection) reasons and should be performed without rupturing the cyst to avoid recurrence [1451].

- **Mucoid cyst of the penis** is synonymous with parameatal cyst or genitoperineal cyst of median raphe; they are midline developmental cysts arising from ectopic urethral mucosa filled with mucoid material. They present since birth but are usually detected during adolescence or later. They are usually asymptomatic developing over penile ventral surface around glans and require surgical removal for either cosmetic, functional or symptomatic reasons [1452].
- **Median raphe cysts** arise from incomplete closure of genital fold during embryogenesis; they are commonly diagnosed in the first decade of life but can present later as they tend to be asymptomatic [1453]. They are either unilocular or multilocular fluid containing cysts, with a mean size of 0.8 cm but cysts larger than 2 cm have also been reported [1454]. Cysts are centred in dermis, with no connection to urethra or epidermis. Histopathologically, there are 4 types: urethral (urothelium-like epithelium, account for 55% cases), epidermoid, glandular and mixed. They can be treated conservatively and can resolve spontaneously or persist. Cyst aspiration is associated with high risk of recurrence and surgical excision is the treatment of choice. Though most penile cysts are asymptomatic, they may get infected resulting in pain and tenderness. They can also present with ulceration, rupture and urinary obstruction if they are close to the urethral meatus. This along with cosmetic issues means that most caregivers and patients opt for surgical excision.
- **Smegmal cysts or smegmal pearls** can be a differential for the cysts above; they are a benign collection of smegma in the sub-preputial space in uncircumcised boys with anticipated spontaneous resolution [1455].
- **Dermoid cyst** are congenital, asymptomatic, firm, solitary, subcutaneous cystic lesions occurring commonly in the region of the corona involving the foreskin. Histopathologically they contain sweat and sebaceous glands with elements of hair and squamous epithelium. Pilosebaceous cysts have been described on the glans; they are benign and usually diagnosed after excision.

#### 3.20.3.2 Vascular malformations

A broad classification of penile vascular lesions into haemangiomas and vascular malformations was proposed by Ramos in 1999 [1456]. **Haemangiomas** develop rapidly at birth and involute slowly; they also include **pyogenic granulomas** which are benign outgrowths of cutaneous capillary vessels formed usually from chronic irritation [1449]. The growth cycle of infantile haemangiomas is divided into early and late proliferative stages, followed by a slow involution phase, completing growth by nine months of age [1457]. Propranolol is currently first line treatment for infantile haemangiomas, the exact mechanism of action is unknown but can include inhibition of angiogenesis, vasoconstriction among others. The dose is in the range of 1.5-2.5 mg/kg, which needs to be continued for 12 to 18 months and then tapered through active or passive weaning to reduce risk of rebound growth [1457]. Other factors leading to rebound growth after propranolol treatment include deep haemangiomas, which occur in about 38% patients despite propranolol therapy, requiring local therapy such as topical timolol, pulsed dye laser or intralesional steroids. After twelve months, the median improvement with treatment is reported as 81% (range 70-90%) based on VAS scores of serial patient photographs.

Vascular malformations are congenital lesions of capillary, lymphatic and venous (or slow-flow) or arterial/arteriovenous (fast-flow) origin that enlarge slowly as the patient grows. These include **glomus tumours**, which are primarily congenital arteriovenous shunts that develop from thermo-regulatory glomus bodies (fastflow vascular malformations). Glomus tumours of the penis can arise on the glans penis, corpora of the penis and as periurethral masses, sometimes accompanied by glomus tumours of fingers and feet [1458]. These are usually asymptomatic at presentation or may have symptoms such as priapism, palpitation and perineal pain. Glomus tumours are benign despite exhibiting high grade nuclear polymorphism. Vascular malformations are usually benign and treated either with laser, sclerotherapy or surgical excision. However, glomus tumours specifically need surgical treatment and follow-up due to the risk of recurrence from incomplete excision [1459].

#### 3.20.3.3 Neurogenic lesions

**Penile neurofibroma** is an extremely rare lesion arising from perineural and Schwann cells, and occurs usually with evidence of systemic neurofibromatosis or von Recklinghausen syndrome [1460]. They are treated successfully with complete excision [1449]. Rare cases of **malignant schwannomas** on the penis presumably secondary to malignant transformation of benign neurofibromas have been reported in boys with a strong family

history of neurofibromatosis. This type of malignant degeneration of neurofibromatosis occurs in reportedly 5-16% children [1460]. Hence, these patients require long-term follow-up due to risk of recurrence, new tumour formation and malignant transformation.

#### 3.20.3.4 *Soft tissue tumours of penis*

Mesenchymal tumours are rare in the external genitalia and they require excision in order to differentiate between benign and malignant neoplasms. Histopathological characterisation is essential to ensure malignant tumours receive radical treatment with adjuvant therapy or close follow-up [1450].

Presentation is usually of a painless penile mass, that is non-tender and rubbery on examination. Ultrasound maybe useful in characterising the lesion but is not diagnostic; it can exclude urethral invasion if it is close to urethra [1450]. Once an excision biopsy is performed, if aggressive malignant components are found, a further wider resection may be needed.

Fibrosarcoma is a rare non-rhabdomyosarcoma soft tissue tumour that arises from fibrous tissue. The infantile form of **fibrosarcoma** is rare and those occurring on the penis are even rarer in the paediatric age-group. Surgical intervention has a favourable prognosis in the paediatric age group with long-term survival of 90% in sporadic cases [1461]. Myofibroma is a benign congenital lesion that occurs either as a solitary lesion or as a part of myofibromatosis with multiple soft tissue tumours. Excision is necessary for histological diagnosis [1450].

Primary penile **teratomas** are extremely rare subtype of congenital germ cell tumours, and they tend to be asymptomatic and are subdermal on US with no blood flow on Doppler [1462]. They need aggressive treatment with surgical resection due to their unpredictable behavior and unresponsiveness to chemotherapy. Mature teratomas are benign but immature teratoma or even mixed teratomas with immature components can turn malignant and have the potential to metastasise and recur.

#### 3.20.3.5 *Penile Lymphedema*

Lymphedema in adults is usually secondary to malignancy or infectious disease affecting lymphatic drainage. In the paediatric age group, however, lymphedema is usually primary and generally very rare, affecting 1.2 per 100,000 persons under the age of 20 years [1463]. Of these, only a very small fraction relates to the genital region. Regardless of underlying aetiology, inefficient lymphatic drainage leads to accumulation of subcutaneous lymph which causes tissue swelling and inflammation. This in turn stimulates adipose deposition and fibrosis further exacerbating enlargement. With time the edematous tissue becomes vulnerable to infection, chronic cutaneous changes and disfigurement [1464]. Additionally, when occurring in the genital region urological complications may ensue; such as phimosis, haematuria, bleeding, bladder outlet obstruction, pain, dysuria, lymphorrhea and severe psychological distress due to resultant deformity [1465, 1466].

In the largest cohort of male genital oedema in the paediatric age group, 92% of cases were primary; of these only 25% had a discernable familial or syndromic association such as Noonan syndrome, lymphedemadistichiasis or Milroy disease [1465]. Secondary genital lymphedema in children has been reported after inguinal surgery, and non-caseating granulomatous lymphangitis as seen with metastatic Crohn's disease [1465-1467]. Average age of onset was reported to be  $4.5 \pm 6.3$  years with 61% presenting in infancy, 13% in childhood and the remaining 26% in adolescence. Edema is usually penoscrotal in 72%, isolated scrotal in 24% and very rarely confined exclusively to the penis in 4%. Moreover, concomitant lower limb edema is the rule in two thirds of cases [1465].

There is no general consensus on diagnostic work-up of these patients. History and physical examination (including family history) is usually sufficient. However lymphoscintigraphy can be used as a confirmatory test, more so for limb than genital edema where results can be difficult to interpret [1465]. Ultrasonography is nonspecific, but has been advocated by some to exclude secondary lymphedema by examining the patency of iliac and caval vessels [1468]. Magnetic resonance imaging is useful to exclude other differential diagnoses such as other venous or lymphatic anomalies [1465].

Conservative treatment is the accepted first-line treatment. The mainstay is compression therapy to maintain and prevent further swelling. This can be achieved by compression stockings and undergarments. Additionally, close observation and protection of the skin to prevent excoriations and infection is essential [1465, 1468]. Compression therapy is however, less effective on genital oedema than it is on limb edema, especially in growing children. When conservative management fails, and especially in symptomatic cases, or in patients with functional impairment, surgical debulking may be necessary. This can either take the form of circumcision in cases where the foreskin is affected or excision of affected skin and subcutaneous tissues with restructuring

and contouring for optimal cosmetic outcome. Complete skin excision and grafting may also be required [1465-1468]. Surgical management can be challenging and needs to be restricted to patients with significant symptoms. Complications include recurrences, continuous lymphatic leakage, haematoma, infection and poor cosmetic outcome [1463, 1468, 1469].

Summary of evidence	LE
Cystic penile lesions are the commonest paediatric penile lesions followed by vascular malformations and neurogenic lesions.	3
Neurofibroma patients require long-term followup due to risk of recurrence, new tumour formation and malignant transformation.	3
Mesenchymal tumours are rare and require excision in order to differentiate between benign and malignant neoplasms.	3

Recommendations	LE	Strength rating
Treatment of penile cystic lesions is by total surgical excision, it is mainly indicated for cosmetic or symptomatic (e.g. infection) reasons.	4	Weak
Propranolol is currently first line treatment for infantile hemangiomas.	2b	Strong
Conservative management is the first-line treatment for penile lymphedema.	4	Strong
In symptomatic cases or in patients with functional impairment, surgical intervention may become necessary for penile lymphedema.	4	Weak

### 3.21 Emergencies in Paediatric Urology

#### 3.21.1 Acute Scrotum

Refer to Chapter 3.6 "Acute Scrotum"

#### 3.21.2 Paraphimosis

Refer to Chapter 3.1 "Phimosis and other abnormalities of the penile skin"

#### 3.21.3 Priapism

##### 3.21.3.1 Epidemiology, aetiology and pathophysiology

Priapism is a prolonged full or partial erection of the penis unrelated to sexual stimuli lasting  $\geq 4$  hours. Although the prevalence of priapism in children is not well reported in literature, it is considered a rare disease. The most common cause of priapism in children is sickle cell disease (SCD), which accounts for about 65% of all cases, followed by leukemia (10%), trauma (10%), idiopathic (10%) and drugs (5%) [1470]. In patients with SCD, the mean age of the first episode of priapism has been shown to be 15 years old, with 25% presenting prepubertally [1471].

##### 3.21.3.2 Classification

Priapism in children can be divided in four groups: ischaemic (low-flow) priapism, stuttering priapism, non-ischaemic (high-flow) priapism, and neonatal priapism.

Ischaemic (low-flow, veno-occlusive) priapism is the most common form (95%) in children. It presents as a painful, rigid erection, with decreased or absent intracavernous arterial inflow. This is considered a medical emergency, since a duration of  $\geq 4$  hours can cause ischaemia within the corpora cavernosa, and eventually irreversible damage, such as smooth muscle necrosis, corporal fibrosis and erectile dysfunction [1472].

Stuttering priapism presents as recurrent, self-limiting prolonged erections, with intervening periods of detumescence. This often precedes an episode of ischaemic (low-flow) priapism [1473].

Non-ischaemic (high-flow, arterial) priapism is a prolonged erection of the penis lasting  $\geq 4$  hours not associated with ischaemia. The most common cause is penile, perineal or pelvic trauma, which can lead to the development of an arteriolar-sinusoidal or arteriocavernous fistula, and usually has a delayed presentation after trauma (3 hours – 7 days) [1474].

Neonatal priapism is a very rare condition, with only a few case series described in literature. It presents as a prolonged erection of the penis  $\geq 4$  hours in a new-born. Sickle cell disease is not associated with neonatal



priapism due to the presence of foetal haemoglobin. It is most commonly idiopathic, but polycythaemia is the most common cause among the identifiable causes [1475]. It has a favourable natural history and benign pathophysiology.

### 3.21.3.3 Diagnostic evaluation

#### History

A comprehensive history is critical in priapism and can determine the underlying priapism subtype and cause. Key points in the history of a child with priapism are shown in Table 8.

**Table 8: Key points in the history for a child with priapism (adapted from Broderick *et al.* [1476])**

Duration of erection
Presence and severity of pain
Previous episodes of priapism and methods of treatment
Medications or recreational drug use
Sickle cell disease, haemoglobinopathies, hypercoagulable states, vasculitis
Trauma to the pelvis, perineum or penis

#### Physical examination

Inspection and palpation of the penis is recommended to assess the degree of tumescence and rigidity and the involvement of the corpora cavernosa, spongiosum and glans. In ischaemic (low-flow) priapism, typically the glans and corpus spongiosum are flaccid. In non-ischaemic (high-flow) priapism, typically the corpora and the glans are tumescent but not fully rigid (Table 9). If perineal compression results in detumescence, this is suggestive of a non-ischaemic (high-flow) priapism.

#### Penile imaging

Color doppler ultrasonography of the penis and perineum should be performed in all patients. This can support clinical differentiation between ischaemic (low-flow) and non-ischaemic (high-flow) priapism with 100% sensitivity and 73% specificity in adults [1477], where a peak systolic velocity < 50 cm/s and a mean velocity < 6.5cm/s are suspicious for ischaemia [1478].

#### Laboratory testing

Laboratory testing with complete blood count (white blood cell count with blood cell differential platelet count) and specific tests for SCD or other haemoglobinopathies should be performed. When ischaemic (low-flow) priapism is suspected, penile blood gas analysis should be performed to differentiate between ischaemic (low-flow) and non-ischaemic (high-flow) priapism (Table 10). However, when non-ischaemic (high-flow) priapism is suspected, penile blood gas analysis should not be the diagnostic of first choice, due to the invasive nature and need for anesthesia.

**Table 9: Key findings in paediatric priapism (adapted from Donaldson *et al.*, and Broderick *et al.*, [1470, 1476])**

	Ischaemic (low-flow) priapism	Non-ischaemic (high-flow) priapism
Corpora cavernosa fully rigid	Typically	Seldom
Penile pain	Typically	Seldom
History of stuttering priapism	Typically	Seldom
Haematological abnormalities	Typically	Seldom
Abnormal penile blood gas	Typically	Seldom
Perineal trauma	Seldom	Typically

**Table 10: Blood gas analysis (adapted from Broderick et al. [1476])**

Source	pO <sub>2</sub> (mmHg)	pCO <sub>2</sub> (mmHg)	pH
Normal arterial blood (room air) (similar values are found in non-ischaemic priapism)	> 90	< 40	7.40
Normal mixed venous blood (room air)	40	50	7.35
Ischaemic priapism (first corporal aspirate)	< 30	> 60	< 7.25

### 3.21.3.4 Disease Management

Differentiation between ischaemic (low-flow) and non-ischaemic (high-flow) priapism is essential, since clinical management differs between the two. Ischaemic (low-flow) priapism is a medical emergency requiring immediate treatment, where non-ischaemic (high-flow) priapism does not. The management of a child with ischaemic (low-flow) priapism is on most parts similar to adults [1479].

#### Ischaemic (low-flow) priapism


##### Conservative

Although the amount of evidence is low, conservative treatment should be advised (e.g., physical exercise, urination, cold bath, ejaculation, oral/IV fluids, and analgesia), however if symptoms persist ≥ 2 hours, urgent medical care should be sought [1480].

##### Medical

If conservative treatment fails, a step-up approach should be used for the management of priapism [1470]. Firstly, anesthesia should be given for the child, either local anesthesia, dissociative sedation or general anesthesia, depending on availability of paediatric anaesthetic expertise and the age and condition of the child. In SCD there are increased risks for general anaesthesia which should be taken into account [1481]. Subsequently a step-up approach should be used for treatment (Figure 14), adapted from Donaldson and adult priapism guideline [1470, 1479].

**Figure 14: Step-up approach for the management of Ischaemic (low-flow) priapism in children**



### Non-ischaeamic (high-flow) priapism

This is a very rare entity in the paediatric population. The treatment of non-ischaeamic (high-flow) priapism is not emergent. One study demonstrated that conservative management and long-term follow-up yielded no evidence of erectile dysfunction after a median follow-up of 55 months [1482]. Conservative treatment, such as perineal compression or application of ice to the perineum can be successful. If symptoms persist, super-selective angio-embolisation can be performed, however this is technically challenging in children and requires a specialist paediatric vascular radiologist [1483]. Children should be initially treated with a conservative management, reserving embolization for refractory cases [1484].

### Stuttering Priapism, and Priapism associated with Sickle Cell Disease (SCD)

The management of a prolonged erection in stuttering priapism is similar to ischaemic (low-flow) priapism. Further management should focus on the prevention of further episodes. Several agents are proposed in literature, such as  $\alpha$ -adrenergic agonists, PDE-5 inhibitors, hydroxyurea,  $\beta$ -agonists, or gonadotropin-releasing hormone agonists, but evidence is limited.

The acute management of SCD priapism is closely related to that outlined above. The main caveat is that those with SCD should have their disease medically optimized in close conjunction with paediatric haematology/oncology through a multidisciplinary approach. Hydroxyurea may decrease crisis frequency and severity in SCD-associated priapism [1485]. Unlike urgent surgical management performed in the adult population, a minimally invasive management strategy can be implemented in the paediatric population where an extended period of conservative management that avoids operative management under general anesthetic can be effective in about 60% cases [1486].

### Neonatal priapism

Neonatal priapism is usually self-limiting and rarely requires treatment. Careful observation is appropriate in most cases since the majority resolves spontaneously without sequelae. If underlying polycythemia is present, this could be treated by venesection and fluid resuscitation [1487].

#### 3.21.4 Summary of evidence and recommendations for the diagnosis and management of Priapism

Summary of evidence	LE
The most common cause of priapism in children is sickle cell disease.	3
Ischaemic (low-flow, veno-occlusive) priapism is the most common form (95%) in children and is considered a medical emergency.	3
Color doppler ultrasonography of the penis and perineum can support clinical differentiation between ischaemic (low-flow) and non-ischaeamic (high-flow) priapism in children.	2b

Recommendations	Strength rating
Perform a doppler ultrasonography in all patients presenting with priapism.	Strong
In children with ischaemic (low-flow) priapism, perform a full blood count and haemoglobinopathy screen to exclude sickle cell disease or other haematological disorders.	Strong
Adopt a multidisciplinary approach when managing patients with SCD-associated priapism.	Strong
Use a step-wise approach starting with the least invasive therapy in patients with ischaemic (low-flow) priapism.	Strong
Manage neonatal and non-ischaeamic (high-flow) priapism conservatively in the initial management period.	Strong

### Stones

Refer to Chapter 3.16 "Urinary stone disease"

### 3.22 Paediatric urological trauma

Trauma is the leading cause of morbidity and mortality in children [1482]. This is generally caused by either blunt injuries from falls, car accidents, sports injuries, physical assault, sexual abuse, or penetrating injuries, usually due to falls onto sharp objects or from gunshot or knife wounds.

### 3.22.1 Paediatric renal trauma

#### 3.22.1.1 Epidemiology, aetiology and pathophysiology

Of all renal injuries, about 25% occur in children, of which 79% is low-grade (I, II or III) and 21% is high-grade (IV or V) [1483]. The most common cause is blunt abdominal trauma (90%), and in blunt abdominal trauma the kidney is the most commonly affected organ, accounting for about 10% of all blunt abdominal injuries [1484]. Children are more likely than adults to sustain renal injuries after blunt trauma due to several anatomical factors, including decreased perirenal fat, weaker abdominal musculature, a relative large size of the kidney in relation to the rest of the body, foetal lobulations which result in a higher likelihood of a local parenchymal disruption, and a less ossified rib cage [1488]. Blunt renal trauma is frequently associated with injury to other organs as well [1489].

#### 3.22.1.2 Classification systems

Renal injuries are classified according to the kidney injury scale of the American Association for the Surgery of Trauma (Table 11) [1490].

**Table 11: Renal injury classified according to the kidney injury scale of the American Association for the Surgery of Trauma [1490]**

Grade	Type of injury	Description
I	Haematoma and/or contusion	Subcapsular hematoma and/or parenchymal contusion without laceration.
II	Haematoma	Perirenal hematoma confined to Gerota fascia.
	Laceration	Renal parenchymal laceration ≤ 1 cm depth without urinary extravasation.
III	Laceration	Renal parenchymal laceration > 1 cm depth without collecting system rupture or urinary extravasation.
	Vascular	Any injury in the presence of a kidney vascular injury or active bleeding contained within Gerota fascia.
IV	Laceration	<ul style="list-style-type: none"> <li>• Parenchymal laceration extending into urinary collecting system with urinary extravasation;</li> <li>• Renal pelvis laceration and/or complete ureteropelvic disruption.</li> </ul>
	Vascular	<ul style="list-style-type: none"> <li>• Segmental renal vein or artery injury</li> <li>• Active bleeding beyond Gerota fascia into the retroperitoneum or peritoneum;</li> <li>• Segmental or complete kidney infarction(s) due to vessel thrombosis without active bleeding.</li> </ul>
V	Laceration	Shattered kidney with loss of identifiable parenchymal renal anatomy.
	Vascular	<ul style="list-style-type: none"> <li>• Main renal artery or vein laceration or avulsion of hilum</li> <li>• Devascularized kidney with active bleeding</li> </ul>

Vascular injury is defined as a pseudoaneurysm or arteriovenous fistula and appears as a focal collection of vascular contrast that decreases in attenuation with delayed imaging. Active bleeding from a vascular injury presents as vascular contrast, focal or diffuse, that increases in size or attenuation in delayed phase. Vascular thrombosis can lead to organ infarction. Grade based on highest grade assessment made on imaging, at operation or on pathologic specimen. More than one grade of kidney injury may be present and should be classified by the higher grade of injury. Advance one grade for bilateral injuries up to Grade III.

#### 3.22.1.3 Diagnostic evaluation

In a child who has sustained blunt abdominal trauma, renal involvement can often be suspected from the history, physical examination and laboratory evaluation. Renal involvement may be associated with abdominal or flank tenderness, lower rib fractures, fractures of vertebral pedicles, trunk contusions and abrasions, and haematuria. Vital signs should be monitored during the initial evaluation and give the most reliable indication of the urgency of the situation. It is important to consider that children, unlike adults, are able to maintain their blood pressure,

even in the presence of hypovolaemia, due to compliance of the vascular tree and mechanisms for cardiac compensation [1485]. It is compulsory to consider all the clinical aspects involved, including the history, physical examination, consciousness of the child, overall clinical status and laboratory findings to decide on the diagnostic algorithm and whether or not a child needs further imaging studies. In severe renal injuries, 65% of patients suffer gross haematuria and 33% non-visible haematuria, while 2% have no haematuria at all [1486]. There have been several reports of significant renal injuries that manifest with little or even no blood in the urine [1487].

#### 3.22.1.3.1 Choice of imaging method

##### *FAST-ultrasound*

In severe trauma or haemodynamically instable patients, FAST (Focussed Assessment Sonography in Trauma) can be used to identify a hemoperitoneum, with a high specificity (95%) but low sensitivity (33-89%) and negative predictive value (50%). However, sensitivity and specificity for kidney trauma and retroperitoneal hemorrhage is low, therefore it is not recommended as a sole diagnostic tool [1491].

##### *Computed tomography*

Computed tomography scanning is the imaging modality of choice in patients with suspicion of renal injuries, since it is widely available, quick and provides accurate grading [1492]. Ideally it is performed in three phases: the arterial phase to detect vascular injury or active bleeding, the nephrogenic phase to detect parenchymal lacerations, and the delayed phase to detect injury of the collecting system or ureter. Furthermore, CT scanning can detect associated other intra-abdominal injuries, which are frequently associated with renal trauma, especially in grade III – V [1489]. Scanning protocol should be adapted for pediatric patients according to ALARA (as low as reasonable achievable) principles to reduce the amount of ionizing radiation as much as possible.

##### *Ultrasound*

(Contrast-enhanced) ultrasound can be considered as the sole investigation in patients with mild symptoms and no other indications for CT-scanning, where the mechanism of trauma and the condition of the patient do not suggest the presence of injury to other organs or the urinary tract. Although conventional ultrasound is not accurate to grade renal trauma, there could be a role for contrast-enhanced ultrasound (CEUS) to identify parenchymal lesions, however this technique cannot detect injuries to the urinary tract or collecting system since the contrast agent is not excreted by the kidney [1493]. Ultrasound can be performed in follow-up of a renal trauma to reduce the amount of radiation. However, even in high-grade renal trauma, routine repeat imaging may be avoidable in asymptomatic, stable patients [1494].

#### 3.22.1.4 Disease management

The modern management of trauma is multidisciplinary, requiring paediatricians, emergency physicians, surgeons, urologists, and other specialties as required.

Non-surgical conservative management with bed rest, fluids and monitoring has become the standard approach for treating blunt renal trauma. In high-grade renal injuries, a conservative approach is effective and recommended for hemodynamically stable children [1495]. However, this approach requires close clinical observation and intermittent re-assessment of the patient's overall condition. Therefore, a good initial trauma CT with delayed images to check for urinary extravasation is recommended, since patients with a urine leak have higher morbidities, including febrile episodes and an increased requirement of operative or image-guided interventions [1496]. However, early drainage does not seem to prevent persistent urinary extravasation or complications [1497]. Therefore, reserve stenting and/or percutaneous drainage only when the patient is symptomatic [1498]. Emergency intervention is indicated only for haemodynamic instability, and if available angio-embolisation for ongoing or delayed bleeding is preferred compared to open surgery. The results of angio-embolisation were evaluated and were successful in 92% of patients with grade III-IV (294/322) and 76% of grade V (63/82) injuries. Furthermore, the success rate was 90% (312/346) in hemodynamically stable patients, but only 63% (42/66) in hemodynamically unstable patients [1499]. Absolute indications for surgery include persistent bleeding into an expanding or unconfined haematoma with haemodynamic instability. Relative indications for surgery are massive urinary extravasation and extensive non-viable renal tissue [1500].

##### *Follow-up*

In paediatric patients with renal trauma, routine blood pressure checks to diagnose hypertension is recommended in the long-term follow-up since posttraumatic renal hypertension rate varies between 4.2 – 18%, especially in cases with concomitant vascular injury [1495, 1501]. However, there is a dearth of long-term data on the risk of developing hypertension in children.

### 3.22.1.5 Recommendations for the diagnosis and management of paediatric renal trauma

Recommendations	Strength rating
Use imaging in all children who have sustained a blunt or penetrating trauma irrespective of the presence of haematuria, especially when the history reveals a deceleration trauma, direct flank trauma or a fall from a height.	Strong
Use contrast enhanced CT-scanning with delayed images for diagnostic and staging purposes.	Strong
Manage most injured kidneys conservatively.	Strong
Perform angio-embolisation or surgical intervention in case of haemodynamic instability or a Grade V renal injury.	Strong

### 3.22.2 Paediatric ureteral trauma

Injuries to the ureter are rare. The ureter is well protected; the upper part is protected by its close approximation to the vertebral column and paraspinal muscles and the lower part by its route through the bony pelvis. In addition, the ureter is a small target, and both flexible and mobile. This also means that ureteral injuries are caused more often by penetrating trauma than blunt trauma [1502]. Since the ureter is the sole conduit for urinary transport between the kidney and the bladder, any ureteral injury can threaten the function of the ipsilateral kidney.

#### 3.22.2.1 Diagnostic evaluation

As there are no classical clinical symptoms suggestive of ureteral trauma, it is important to carry out a careful diagnostic work-up using different imaging modalities. Unfortunately, initial imaging studies, such as IVP and routine CT scans, are unreliable. A study of eleven disruptions of the ureteropelvic junction found that 72% had a normal or non-diagnostic IVP on initial studies [1502]. Diagnostic accuracy of CT scanning can be improved by performing a delayed CT scan up to ten minutes after injection of the contrast material [1503]. The most sensitive diagnostic test is a retrograde pyelogram.

It is not uncommon for patients to present several days after the injury, when the urinoma produces flank and abdominal pain, nausea and fever. Due to symptoms being often vague, it is important to remain suspicious of a potential undiagnosed urinary injury following significant blunt abdominal trauma in a child.

#### 3.22.2.2 Management

Immediate repair during abdominal exploration is rare. Minimally invasive procedures are the method of choice, especially since many ureteral injuries are diagnosed late after the traumatic event. Percutaneous or nephrostomy tube drainage of urinomas can be successful, as well as internal stenting of ureteral injuries [1504]. If endoscopic management is not possible, primary repair of partial lacerations should be followed by internal stenting. The management of complete lacerations, avulsions or crush injuries depends on the amount of ureter lost and its location. If there is an adequate healthy length of ureter, a primary ureteroureterostomy can be performed. If primary re-anastomosis is not achievable, distal ureteral injuries can be managed using a psoas bladder hitch, Boari flap or even nephropexy. Proximal injuries can be managed using transureteroureterostomy, auto-transplantation or ureteral replacement with bowel or appendix [1505].

### 3.22.2.3 Recommendations for the diagnosis and management of paediatric ureteral trauma

Recommendations	Strength rating
Diagnose suspected ureteral injuries by retrograde pyelogram.	Strong
Manage ureteral injuries endoscopically, using internal stenting or drainage of an urinoma, either percutaneously or via a nephrostomy tube.	Weak

### 3.22.3 Paediatric bladder injuries

The paediatric bladder is less protected than the adult bladder, and is therefore more susceptible to injuries, especially when full, due to:

- Its higher position in the abdomen and its exposure above the bony pelvis.
- The fact that the abdominal wall provides less muscular protection.
- The fact that there is less pelvic and abdominal fat surrounding the bladder to cushion it during trauma.

Blunt trauma is the most common cause of significant bladder injury. In adults, bladder injury is often associated with pelvic fractures. This is less common in children because the paediatric bladder sits above the pelvic ring. In a large prospective study, only 57% of children with pelvic fractures also had a bladder injury compared to 89% of adults [1506].

### 3.22.3.1 Diagnostic evaluation

The characteristic signs of bladder injury are suprapubic pain and tenderness, an inability to urinate, and visible haematuria (95% of injuries). Patients with a pelvic fracture and visible haematuria present with a bladder rupture in up to 45% of cases [1507].

The diagnosis of bladder rupture can be difficult in some cases. The bladder should be imaged both when fully distended and after drainage using standard radiography or with axial imaging (e.g., CT scan). Optimal imaging results are achieved through retrograde filling of the bladder using a catheter. Despite advances in CT imaging, the bladder must still be filled to capacity to accurately diagnose a possible bladder injury [1508].

Blunt injuries to the bladder are categorised as:

- Contusions with damage to the bladder mucosa or muscle, without loss of bladder wall continuity or extravasation.
- Ruptures, which are either intraperitoneal or extraperitoneal.

Intraperitoneal bladder ruptures are more common in children because of the bladder's exposed position and the acute increase in pressure during trauma. These cause the bladder to rupture at its weakest point, i.e., at the dome. Extraperitoneal lesions occur in the lower half of the bladder and are almost always associated with pelvic fractures. A cystogram should demonstrate extravasation into the perivesical soft tissue in a typical flame pattern and the contrast material is confined to the pelvis.

### 3.22.3.2 Management

Contusions usually present with varying degrees of haematuria and are treated with catheter drainage alone.

#### 3.22.3.2.1 Intraperitoneal injuries

The accepted management of intraperitoneal bladder ruptures is open surgical exploration and primary repair. Post-operative drainage with a suprapubic tube is mandatory. Recent data suggest that transurethral drainage may be as effective, with fewer complications, resulting in shorter periods of diversion [1509]. Usually, after about seven to ten days, a repeat cystogram is performed to ensure adequate healing.

#### 3.22.3.2.2 Extraperitoneal injuries

Non-operative, supportive management with catheter drainage for seven to ten days is the method of choice for extraperitoneal bladder rupture. However, if there are bone fragments within the bladder, these must be removed and the bladder must then be repaired and drained, according to the principles for treating intraperitoneal ruptures [1510].

### 3.22.3.3 Recommendations for the diagnosis and management of paediatric bladder injuries

Recommendations	Strength rating
Use retrograde cystography to diagnose suspected bladder injuries.	Strong
Ensure that the bladder has been filled to its full capacity and an additional film is taken after drainage.	Strong
Manage extra-peritoneal bladder ruptures conservatively with a transurethral catheter left in place for seven to ten days.	Strong
Perform surgical exploration in cases of intra-peritoneal bladder ruptures.	Strong

### 3.22.4 Paediatric urethral injuries

Except for the penile part of the urethra, the paediatric urethra is quite well protected. In addition, its shape and elasticity means that the urethra is seldom injured by trauma. However, a urethral injury should be suspected in any patient with a pelvic fracture or significant trauma to the perineum until confirmed otherwise by a diagnostic work-up.

#### 3.22.4.1 Diagnostic evaluation

Patients with suspected urethral trauma and pelvic fractures usually present with a history of severe trauma, often involving other organ systems.

Signs of urethral injury include blood at the meatus, visible haematuria, pain during voiding, or an inability to void. There may also be perineal swelling and haematoma involving the scrotum. A rectal examination to determine the position and fixation of the prostate is important in any male with a suspected urethral injury. The prostate (although small), as well as the bladder, may be displaced up out of the pelvis, especially in membranous urethral trauma.

Radiographic evaluation of the urethra requires a retrograde urethrogram. It is important to expose the entire urethral length, including the bladder neck. If a catheter has already been placed and there is a suspected urethral trauma, the catheter should not be removed. Instead, a small infant catheter can be placed into the distal urethra along the catheter to allow the injection of contrast material for a diagnostic scan [1511].

#### 3.22.4.2 Disease management

As these patients may be unstable due to the nature of their injuries, the urologist's initial responsibility is to provide a method of draining and monitoring urine output.

A transurethral catheter should only be inserted if there is a history of voiding after the traumatic event, and if a rectal and pelvic examination, as described above, has not suggested a urethral rupture. If the catheter does not pass easily, an immediate retrograde urethrogram should be performed. A suprapubic tube may be placed in the emergency department percutaneously, or even in the operating room if the patient has to undergo immediate exploration because of other life-threatening injuries.

There are often no associated injuries with a bulbar urethral or straddle injury and management is therefore usually straightforward. In these cases, a transurethral catheter is the best option for preventing urethral bleeding and/or painful voiding [1512].

The initial management of posterior urethral injuries remains controversial, mainly regarding the long-term results with primary realignment compared to simple suprapubic drainage with later reconstruction.

The main goals in the surgical repair of posterior urethral injuries are:

- Providing a stricture-free urethra.
- Avoiding the complications of urinary incontinence and erectile dysfunction.

#### *Anterior urethral injury*

The data for anterior urethral injury repair is much the same as for adults. Small lacerations can be repaired by simple closure. Complete ruptures without extensive tissue loss are treated with anastomotic repair [1513]. Penetrating injuries require peri- and post-operative antibiotic treatment [1514].

Immediate urethroplasty is generally performed in blunt injuries. The long term-outcomes (patency rate, potency rate) of adult patients treated with immediate urethroplasty is similar to these initially treated with suprapubic diversion and delayed urethroplasty [1515]. The main advantage of performing immediate urethroplasty is that this strategy significantly reduces the time to spontaneous voiding from two to six months to three weeks on average. Spongiosal contusion and haematoma during immediate urethroplasty will make the operation technically more demanding; therefore, immediate urethroplasty should be performed by a dedicated urethral surgeon [1516].

#### *Posterior urethral injury*

Unlike anterior urethral injuries with immediate realignment, in children with posterior urethral injuries, a staged approach with delayed repair may be more appropriate.

In children, there is significantly less experience with delayed repair, with a large paediatric series of delayed repair in 68 boys reporting successful voiding and continence rate of 90% [1517]. Another study reported strictures and erectile dysfunction in 67% of boys, although all the boys were continent post-operatively [1310]. A follow-up study on fifteen patients who underwent delayed urethroplasty for blunt urethral trauma during childhood reported high long-term success rates, with a low rate of long-term urinary and sexual dysfunction in adulthood [1518].

#### *Revision surgery*

A large study of revision urethroplasty analysing revision urethroplasty following pelvic floor urethral injuries in children and adolescents demonstrated that these injuries appeared to be more common in the developing world, with more complex findings and longer gaps. These patients in support of the above findings were best managed with delayed transperineal repair with self-reported success of up to 85% [1519]. On the other hand, a small prospective study demonstrated good results with immediate primary endoscopic realignment in patients with posterior urethral and bladder neck injuries [1520]. This may serve as an alternative to those with permitting



endoscopic anatomy post-injury. A large study exploring outcomes on different urethroplasty techniques in both boys and girls demonstrated that most paediatric pelvic floor urethral injuries can be addressed through a transperineal approach with reasonable long-term outcomes (>80%), however up to 25% patient require further endoscopic/open procedures during follow-up. In challenging cases salvage procedures utilizing vascular-based flaps as a urethral substitute can yield good results, however the numbers lost to follow-up were significant at 40.6% [1521].

In a study of eighteen boys undergoing urethroplasty for strictures (traumatic/iatrogenic), post-void dribbling and urgency were the main patient-reported outcome measures (PROMs) following surgery, with universally high satisfaction rates. PROMs are an important consideration for urologists performing these procedures on children, as they will likely need continued long-term follow-up [1522]. In those who have previously experienced a failed urethroplasty following pelvic-fracture associated urethral injuries, most cases of recurrent posterior urethral strictures of < 3 cm in length can be operated through a perineal urethroplasty with reasonable success rates. Complex and long-segment (higher than 3 cm) strictures require use of ancillary procedures like transpubic urethroplasty, substitution urethroplasty and Mitrofanoff appendicovesostomy with complication rates in adolescents of 33% [1523].

3.22.4.3 *Recommendations for the diagnosis and management of paediatric trauma*

Recommendations	Strength rating
Assess the urethra by retrograde urethrogram in case of suspected urethral injury.	Strong
Perform a rectal examination to determine the position of the prostate.	Strong
Manage urethral injuries conservatively initially if a transurethral catheter can be placed.	Strong
Manage posterior urethral injuries by either: <ul style="list-style-type: none"> <li>primary drainage with a suprapubic catheter alone and delayed repair</li> <li>primary re-alignment with a transurethral catheter</li> </ul>	Weak

3.22.5 **Urosepsis**

Refer to Chapter 3.10 "Urinary tract infections in children".

**3.23 Peri-operative management**

3.23.1 *Pre-operative fasting, intra-operative fluid therapy, post-operative feeding, fasting and fluid management*

3.23.1.1 *Epidemiology, aetiology and pathophysiology*

Children have a different total body fluid distribution, renal physiology and electrolyte requirements, as well as weaker cardiovascular compensation mechanisms, compared to adults [1524]. During development, children have a high metabolic rate and lower fat and nutrient stores which means they are more susceptible to metabolic disturbances caused by surgical stress [1525]. The metabolic response to anaesthesia and surgery in infants and children is related to the severity of the operation [1526].

3.23.1.2 *Disease management*

3.23.1.2.1 *Pre-operative fasting*

Pre-operative fasting has been advocated for elective surgery to avoid the complications associated with pulmonary aspiration during induction of anaesthesia. New regimens include an one hour limitation for clear liquids [1527, 1528] without increased risk of pulmonary aspiration [1529]. Several studies have shown that fasting times in clinical practice often exceed the guidelines with average fasting times of six to ten hours [1528-1530]. Compared to adults, children have a higher metabolic rate and low glycogen stores and impaired gluconeogenesis, which makes hypoglycaemia an important issue to consider, especially in children < 36 months old [1528]. Therefore, it is important to prevent extended fasting times. Clear-liquid carbohydrate drinks have been proposed to reduce these fasting times [1531]. The presence of Type I diabetes does not necessitate different fasting instructions from those for healthy children [1532]. Depending on the length and the scale of the procedure, special attention to appropriate insulin administration, management of hypo- and hyperglycaemia as well as other metabolic abnormalities, is required [1533].

Table 12 provides the current guidelines for pre-operative fasting for elective surgery [1532].

**Table 12: Pre-operative fasting times for elective surgery**

Ingested material	Minimum fasting period (hours)
Clear liquids	1
Breast milk	3
Formula milk-based products	4
Light meal	6

### 3.23.1.2.2 Maintenance therapy and intra-operative fluid therapy

The goal of intra-operative fluid management is to sustain homeostasis by providing the appropriate amount of parenteral fluid; this maintains adequate intravascular volume, cardiac output, and oxygen delivery to tissues at a time when normal physiological functions have been altered by surgical stress and anaesthetic agents.

The main goal of intra-operative fluid management is to maintain a normal extracellular fluid volume (EFV). During the intra-operative period fluid deficits may be induced by pre-operative fasting, blood loss or third-space losses.

### 3.23.1.2.3 Post-operative feeding, fasting and fluid management

It is not obligatory to check serum chemistry after uncomplicated surgery in children with normal pre-operative renal and hepatic function. However, if oral intake has been postponed for > 24 hours (e.g., as in intestinal surgery), there is an increased risk of electrolyte abnormalities, requiring further assessment and subsequent management, particularly with potassium. Post-operative findings, such as decreased bowel movements and ileus, may be signs of hypokalaemia.

Children who undergo interventions to relieve any kind of obstructive diseases deserve particular attention, especially due to the risk of polyuria as a result of post-obstructive diuresis [1534]. In children who develop polyuria, it is important to monitor fluid intake and urine output, as well as renal function and serum electrolytes. If necessary, clinicians should not hesitate in consulting with a paediatric nephrologist.

In children who have undergone non-abdominal surgery, studies have suggested that gastric motility returns to normal one hour after emergence from anaesthesia [1535]. Early post-operative intake of fluid in children who have undergone minor or non-abdominal urological surgery is associated with reduced post-operative vomiting and lower opioid use [1536] and is therefore encouraged.

Intraperitoneal surgery and the use of bowel may lead to decreased bowel motility in the postoperative period which can lead to paralytic ileus. Experimental and clinical studies have shown that traditional restriction of oral intake, after abdominal surgery, has no basis on scientific evidence and adverse effect on tissue regeneration and enzymatic function has been reported. Due to those deleterious effects of fasting, early enteral nutrition is preferred to parenteral nutrition [1537]. In new-borns, early intragastric, small-volume breast is well tolerated in the post-operative period and seems to provide a trophic effect on gut mucosa [1537].

Chewing gum is a type of sham feeding that promotes intestinal motility, via cephalic-vagal stimulation. It is usually well tolerated and accepted by older children without any contraindication. Although the evidence is limited, it can potentially enhance bowel recovery in the postoperative period in children [1538].

The ERAS protocol is a patient-centred, multimodal approach to optimize postoperative recovery. This protocol includes pre- and intraoperative element such as minimal pre-operative fasting and careful intra-operative fluid management and focuses on post-operative care. The post-operative ERAS protocol suggests starting clear fluid intake on the evening of surgery and a normal diet the day after surgery and thereby early discontinuation of IV fluids. Further focus is on early mobilization, preventing epidurals and omitting or early removal of external tubes [1539].

The implementation of an ERAS protocol has resulted in a shorter length of hospital stays, faster bowel recovery and reduced the needs of post-operative opioid-free administration [1539, 1540]. The implementation of ERAS protocols does not seem to result in higher complication and readmission rates; instead, some studies have even demonstrated a significant reduction in complication occurrence [1539]. When implementing ERAS in children with neurological abnormalities special attention should be given to bowel management with pre-operative treatment of constipation and early post-operative continuation of routine bowel management.

### 3.23.1.3 Summary of evidence and recommendations for the management of peri-operative fluid management

Summary of evidence	LE
The current evidence recommends reducing clear fluid fasting to 1 h, reducing breast milk fasting to 3h, reducing formula milk-based products to 4h and allowing a light meal 6h before anaesthesia induction for elective procedures.	1
Following abdominal surgery ERAS protocols can be used to reduce recovery times and complications.	1

Recommendations	Strength rating
Ensure shorter pre-operative fasting periods for elective surgeries (one hour for clear liquids, three hours for breast milk, four hours for formula milk-based products and six hours for a light meal).	Strong
Start early postoperative oral fluid intake in all patients scheduled for minor surgical procedures.	Strong
Use enhanced recovery after surgery protocols for abdominal surgery in children with pre-existing normal bowel function.	Strong

### 3.23.2 Post-operative pain management: general information

#### 3.23.2.1 Epidemiology, aetiology and pathophysiology

The provision of adequate pain control requires proper pain evaluation, accurate choice of drug and route of administration, and consideration of age, physical condition and type of surgery and anaesthesia [1541].

#### 3.23.2.2 Diagnostic evaluation

Assessment of pain is the first step in pain management. Several pain assessment tools have been validated according to the child's age, cultural background, mental status, communication skills and physiological reactions [1542]. Depending on the child's age, the 0-10 Numeric Rating Scale, Faces Revised Pain Scale, Face Legs Activity, Cry and Consolability Scale (FLACC) or Colour Analog Scale, can be used [1543]. One of the most important topics in paediatric pain management is informing and involving the child and caregivers during this process. Patient-family-controlled- analgesia is the preferred pain management in the hospital and at home if provided with the correct information [1544, 1545].

#### 3.23.2.3 Disease management

##### 3.23.2.3.1 Drugs and route of administration

Pre-emptive analgesia is an important concept that aims to induce the suppression of pain before neural hypersensitisation occurs [1546]. Regional anaesthesia is given intra-operatively which can include a regional nerve block or local wound infiltration and has proven to reduce the need for post-operative analgesia [1547]. The WHO's 'pain ladder' is a useful tool for the pain management strategy [1548]. Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) are the first choice. As they become insufficient to prevent pain, weak and strong opioids are added to oral drugs to achieve balanced analgesia. A proposed strategy for postoperative analgesia may be as follows:

1. Intra-operative regional block and/or local wound infiltration.
2. Paracetamol + NSAID.
3. Paracetamol + NSAID + weak opioid (e.g., tramadol or codeine).
4. Paracetamol + NSAID + strong opioid (e.g., morphine, fentanyl, oxycodone or pethidine).

The use of opioids in children has long held a standard role in the post-operative management of pain. Increased recognition of the adverse effects of opioids and prolonged opioid dependency demand a balanced intra-operative administration of opioids [1549]. Intra-operative adequate dosage of paracetamol and NSAIDs results in a decrease in opioid requirement in children [1550, 1551].

##### 3.23.2.3.2 Circumcision

Circumcision requires anaesthesia and proper pain management [1552]. Potential analgesic interventions during circumcision include the use of a dorsal penile nerve block (DPNB) or ring block, topical anaesthetics (depending on age, weight and body surface), and sucrose preferably in combination [1547, 1553]. Caudal blockade methods have similar efficacy compared to DPNB [1554]. However, caregivers should be informed about the more frequent incidence of post-operative motor weakness and micturition problems [1553, 1554].

### 3.23.2.3.3 Penile, inguinal, and scrotal surgery

Caudal blocks and peripheral nerve blocks (DPNB and pudendal) are commonly used methods for analgesia in hypospadias surgery. Several agents with different doses, concentrations and administration techniques have been used. All have been shown to have adequate postoperative analgesic properties and no increase in post-operative complications was seen [1547, 1555, 1556]. Severe bladder spasms caused by the presence of the bladder catheter can be managed with antimuscarinic medications.

For inguinoscrotal surgery, various regional anaesthesia methods have been investigated, such as transversus abdominis plane block, quadratus lumborum nerve block, ilioinguinal/iliohypogastric nerve blocks and caudal blocks. All have been shown to have adequate postoperative analgesic properties [1557]. Additional local anaesthetics such as clonidine or dexmedetomidine has been shown to prolong the analgesic effect [1558, 1559].

### 3.23.2.3.4 Bladder and kidney surgery

Continuous local infusion (pain catheter) reduces the need for post-operative opioids [1560-1562], as well as systemic (intravenous) application of analgesics [1563], has been shown to be effective. Ketorolac (NSAID) is an effective agent that decreases the frequency and severity of bladder spasms, the length of post-operative hospital stay and costs and intraoperative opioid administration [1564]. Open kidney surgery is particularly painful because all three muscle layers are cut during conventional flank incision. A dorsal lumbotomy incision may be a good alternative in small children because of the shorter post-operative hospital stay and earlier return to oral intake and unrestricted daily activity [1565]. Caudal and paravertebral blocks continuous epidural analgesia, as well as rectus sheath and transversus abdominis plane blocks have decreased post-operative morphine requirement after abdominal and renal surgery [1566-1568].

### 3.23.2.4 Summary of evidence and recommendations for the management of post-operative pain

Summary of evidence	LE
Adequate paracetamol and NSAIDs use reduces opioid need postoperatively.	1

Recommendations	Strength rating
Prevent/treat pain in children of all ages.	Strong
Evaluate pain using age-compatible assessment tools.	Strong
Use pre-emptive and balanced analgesia in order to decrease opioids requirements.	Strong

### 3.23.3 Antibiotics management: general information

It is well established that peri-operative antibiotics prevent infections following surgery, but limited data are available for antibiotic management in paediatric genitourinary procedures. Antibiotic prophylaxis carried the risk of developing drug-resistant bacteria and adverse effects such as allergic reactions. Furthermore, in childhood some antibiotics are not recommended and their use is discouraged except for in severe cases.

In 2020 Snyder *et al.*, conducted one of the first systematic reviews on perioperative antibiotic practices in the paediatric urology literature [1569]. They reported that the majority of the articles did not provide accurate information on peri-operative antibiotic practices. Other studies demonstrated wide variations in practice patterns for antibiotic usage among paediatric urologists [356, 1570].

Perioperative prophylactic antibiotics in hypospadias repair have been widely debated in the literature. A meta-analysis demonstrated a high risk of bias and a low level of evidence, in terms of postoperative prophylactic antibiotics preventing complications following hypospadias repair [359]. On the contrary, a consensus exists for no perioperative antibiotics following circumcision [1569].

A prospective, randomized, controlled, non-blinded, non-placebo study was performed on the effectiveness of continuous antibiotic prophylaxis in patients with JJ stents, with a total of 105 patients. They concluded that continuous antibiotic prophylaxis reduced the incidence of febrile UTIs, especially in children with a history of febrile UTI and LUTS [1571].

There is a need for standardization of perioperative antibiotic usage for paediatric urological operations, however, a lack of prospective studies and RCT's are the main barriers for creating evidence-based guidelines on this particular topic.

### 3.23.4 **Thromboprophylaxis management: general information**

Thromboprophylaxis in children involves preventive measures aimed at reducing the risk of blood clot formation. Unlike adults, the majority of children do not require thromboprophylaxis after surgery. It is only considered in certain high-risk situations such as underlying medical conditions like malignancies, congenital heart disease etc. Moreover, there are very limited data on the safety and efficacy of anticoagulants in paediatric practice.

#### 3.23.4.1 *Epidemiology, aetiology, pathophysiology*

The incidence of venous thrombo-embolism (VTE) in children is low, but has increased due to an increased use of central venous catheters (CVL) and an improvement in detection [1572]. Some authors suggest an incidence of five to eight cases of symptomatic VTE per 10,000 hospital admissions (0.05%-0.08%) but the true incidence may be higher as the majority of VTEs are clinically silent in children [1573]. In infants, VTE is most often associated with sepsis, congenital haematological disorders, and malignancies. At adolescence, the physiology of the coagulation system matures and additional risk factors such as smoking, obesity, pregnancy, and oestrogen-containing oral contraceptives become relevant. There is a 2:1 preponderance of females among adolescents who develop VTE.

The risk of VTE after urological surgery has been shown to have an incidence of 0.12%, which increases to 0.2% for prolonged hospitalization [1574, 1575].

Before adolescence, the absolute risk of VTE following major surgery, trauma, or immobilization is low, even in children who have thrombophilia [1576]. Therefore, thromboprophylaxis is not recommended.

The risk of developing VTE should focus on adolescents (> 13 years) particularly those with one or more risk factors such as those mentioned above [1577].

General preventive measures are fundamental to prevent VTE and should include: adequate peri- and post-operative hydration, early mobilization after surgery and removal of CVLs as soon as possible. In post-pubertal girls undergoing any kind of surgery, consideration should be given to withholding the combined contraceptive pill for four weeks prior to planned surgery, particularly if there is a strong family history of thrombosis or a known thrombophilic risk factor [1573].

#### 3.23.4.2 *Diagnostic evaluation*

Identifying thrombophilic risk factors in the family and patient history is important. Symptoms are similar to adult patients with pain, oedema of the dependent areas and development of collateral vessel circulation. However, children with VTE also have some unique presentations such as purpura fulminans. As with adults, the diagnosis of VTE in the upper venous system, is confirmed using doppler ultrasound and if necessary with venography. However, the optimal diagnostic test for lower limb VTE and pulmonary embolism in children is undefined at the present time but ultrasound is the first approach [1578].

#### 3.23.4.3 *Disease management*

The aims of antithrombotic therapy in children are similar to those for adults with VTE. Management of childhood VTE is often complex, due to the frequent co-existence of medical and surgical diseases, and the fact that limited data is available on the efficacy and safety of these drugs in paediatric practice. A multidisciplinary management approach should be sought.

#### *Medical device and physiological mechanism for thromboprophylaxis*

Physical treatments for thromboprophylaxis are the same used for adult patients: graduated compression stockings (GCS), intermittent pneumatic compression (IPC) devices and venous foot-pumps (VFPs). No paediatric sizes of GCS or IPC are yet available, so they are applicable only to older patients, usually those over 40 kg in weight or older than thirteen years. Intermittent pneumatic compression devices have been used for intra- operative use in children aged thirteen years and over who weigh > 40 kg and who are expected to have prolonged surgery [1573, 1577].

The evidence to use these devices is significantly less than for anticoagulant options and few data are available in children and adolescents [1579]. They should be combined with pharmacological prophylaxis. Early mobilization and good hydration should be encouraged in all age patients.

#### 3.23.4.4 *Pharmacological treatment for thromboprophylaxis*

The use of anticoagulant agents to prevent VTE is very limited in children. None of the preparations are licensed in the paediatric age group. Low molecular weight heparins (LMWHs) have become the mainstay anticoagulant in the paediatric population, both for prophylaxis and treatment due to the more predictable pharmacokinetics compared with unfractionated heparin. Low molecular weight heparins allow less frequent monitoring, and have a lower incidence of serious side-effects. Compared with adult patients, children require higher doses of

LMWH, which decrease with age due to a decreased thrombin production and a high renal clearance. The most commonly used drugs are enoxaparin and dalteparin and the major bleeding rate for prophylactic use of LMWH is low [1573, 1577, 1580].

Children older than thirteen years with multiple risk factors for thrombosis should be considered for thromboprophylaxis with LMWH especially if immobilization for more than 48 hours is expected [1580].

#### 3.23.4.5 Prevention of CVL-related VTE

The presence of a CVL is the most significant risk factor for VTE in children. CVLs placed in the right internal jugular seem to be associated with a lower risk of VTE. There is also evidence that femoral CVLs are associated with a particularly high risk for thrombosis in children [1573]

Thromboprophylaxis did not prevent CVL-related VTE both in prospective studies and RCTs because the majority of these thrombi were transient and resolved spontaneously without therapy [1581].

#### 3.23.4.6 Summary of evidence and recommendations for the management of thromboprophylaxis management

Summary of evidence	LE
The incidence of perioperative thromboembolic events in the paediatric population is generally very low.	1
Patients > 13 years of age with additional risk factors should be considered for venous thrombo-embolism prophylaxis.	1
Standard anti-thrombotic prophylaxis is not recommended due to a lack of high quality RCTs and accepted guidelines concerning perioperative thromboprophylaxis in children.	4

Recommendations	Strength rating
Use physical methods for venous thrombo-embolism prophylaxis (VTE) risk reduction in older children and adolescents who are at increased risk of VTE.	Strong
Consider low molecular weight heparin VTE prophylaxis in children, particularly adolescents, with additional risk factors.	Strong

#### 3.23.5 Premedication management: general information

The majority of children undergoing anaesthesia and surgery develop anxiety that could lead to adverse reactions. Many factors may influence preoperative anxiety [1582]. Anxiety and distress can be prevented or relieved combining: premedication, distraction techniques and parental or caregivers presence. Non-pharmacological age-appropriate methods such as play therapy, toys, storybooks, videos, tablet, mobile phone, can all be useful. A successful plan must therefore take into account the age and temperament of the child [1583].

The most important goal of premedication is to alleviate patients' anxiety and facilitates a smooth separation of the child from their parents/caregivers. Pre-anaesthetic sedatives in children have to be given in a timely fashion pre-operatively, and include midazolam, clonidine, ketamine and dexmedetomidine are used as premedication but no consensus has been reached on the best choice against pre-operative anxiety. Clinicians should select the appropriate premedication depending on the patient's age, disease and psychological status [1584].

Topical anaesthesia should be used to reduce or eliminate the pain and anxiety of an intravenous access placement when an intravenous induction is required. The most commonly used local anaesthetic creams requires 20 to 60 minutes for maximal effect but they can cause vasoconstriction that could make the vein harder to see and cannulate [1582, 1584].

#### 3.23.5.1 Recommendations for premedication management: general recommendations

Recommendations	Strength rating
Use non-pharmacological age-appropriate premedication methods to decrease anxiety levels in children before surgery.	Weak
Use pharmacological premedication to decrease anxiety levels in children and monitor for potential side effects.	Strong

### **3.24 Basic principles of laparoscopic surgery in children**

#### **3.24.1 Epidemiology, aetiology and pathophysiology**

The use of laparoscopy and robot-assisted laparoscopic surgery is rapidly increasing and has gained widespread acceptance for many urological surgeries in children [1585]. Laparoscopy is commonly performed for non-palpable testis, nephrectomy, heminephrectomy, varicocelectomy, pyeloplasty, ureteral reimplantation. This expanding scope related to technological advancements allows surgeons to perform more complex procedures in a minimally invasive fashion even in infants and younger children. Generally, well established benefits of minimally invasive surgery are decreased pain, shorter convalescence and better cosmetics compared to traditional open surgery [907, 1586]. When comparing the transperitoneal and retroperitoneal approach, there was no difference in recovery of bowel function [1587]. Additional advantages of robotic surgery over conventional laparoscopy include ergonomics, 3D vision, better manoeuvrability, decreased tremor and easy learning curve. Limitations to be considered are increased operative time, smaller working space at young age, cost and experience of the surgeon and anaesthesiologist. While the success and complication rates are comparable for nephrectomy and pyeloplasty advantages of laparoscopy and robotic surgery for ureteral reimplantation have not been proven and this can only be recommended for experienced centres.

As worldwide experience increases, there is an accumulating awareness about the physiological consequences related to intra- and retroperitoneal CO<sub>2</sub> insufflation in children. In contrast to traditional open surgery pneumoperitoneum may have physiological responses which require close monitoring during surgery and should be taken seriously.

#### **3.24.2 Technical considerations and physiological consequences**

##### **3.24.2.1 Pre-operative evaluation**

Laparoscopy in children requires specific anaesthetic precautions. Physiological effects of CO<sub>2</sub> pneumoperitoneum, positioning of the patient and in potentially increased operative time need to be considered by the anaesthesiology team. Therefore, a detailed medical examination and risk assessment is mandatory pre-operatively. Especially the cardiac and pulmonary system should be assessed since increased intra-abdominal pressure may lead to decreased ventricular preload [1588].

##### **3.24.2.2 Abdominal insufflation**

Abdominal insufflation is the main principle of laparoscopic surgery to create working space for the surgeon. Carbon dioxide is most commonly used for insufflation in laparoscopic centres throughout the world. Other alternatives reported are nitrous oxide, helium, argon and air. However, CO<sub>2</sub> is considered to be the best available gas as it is colourless, cheap, has high solubility in the vascular system [1589] and is excreted by the pulmonary system making it the safest option. Smaller children and infants absorb more CO<sub>2</sub> than older children [1590], suggesting the need for more attention both during and early after laparoscopic surgery for these children.

Most complications of laparoscopy are attributable to gaining access to the abdominal cavity. One study reporting complications of > 5,400 paediatric laparoscopic surgeries showed that there was an overall complication rate of 5.3% of which 4.2% were related to problematic insufflation (subcutaneous emphysema, gas embolism, injury to the organs and vascular structures, mis-insufflation etc.) [1591]. There are two main and well-established techniques for initial access to the abdomen or retroperitoneum: open technique (Hasson) and Veress needle. Studies comparing these two different access techniques in paediatric laparoscopic urological procedures showed similar complication rates [1592]. The vast majority of the complications were minor and related to lack of surgical experience. Particularly in infants and smaller children, the open access technique is recommended by the Panel to reduce the chance of complications.

Elasticity of the abdominal wall is age-related and is higher in infants and small children compared to older children [1593].

Pneumoperitoneal pressure (PnP in mmHg) is one of the critical points that needs to be carefully considered by laparoscopic surgeons. An RCT compared two different pneumoperitoneal pressure groups (6-8 mmHg vs. 9-10 mmHg) in infants less than 10 kg [1594]. It demonstrated that higher pressures were associated with more pronounced respiratory and haemodynamic changes as well as increased post-operative pain scores and prolonged time to resume feeding.

##### **3.24.2.3 Pulmonary effects**

After intra-abdominal insufflation the diaphragm is pushed upwards due to increased abdominal pressure. This leads to decreased total pulmonary compliance. Combined with CO<sub>2</sub> absorption this may lead to hypercarbia and acidosis, particularly in case of prolonged operative time or low pulmonary reserve such as in infants.

Trendelenburg position may also aggravate the situation in operations in the pelvic region, such as anti-reflux or bladder neck surgeries. Several studies revealed increased end tidal CO<sub>2</sub> (ET CO<sub>2</sub>) related to CO<sub>2</sub> absorption [1590, 1595, 1596]. One study showed a 33% increase in ET CO<sub>2</sub> in the majority of neonatal laparoscopic and thoracoscopic procedures [1597]. Shorter operative time and lower intra-abdominal pressures decrease the risk of increased ET CO<sub>2</sub>. Hypoxemia is rarely seen, even in neonates and can easily be adjusted by increasing minute ventilation. These findings highlight the importance of close monitoring of the children.

#### 3.24.2.4 Cardiovascular effects

Intra-abdominal pressure, CO<sub>2</sub> absorption and positioning may also affect the cardiovascular system. It has been shown in adults that after initiation of pneumoperitoneum, cardiac output and stroke volume decrease while mean arterial pressure, central venous pressure and systemic vascular resistance increase [1598]. Similar outcomes have been reported during paediatric laparoscopy with some nuances. Cardiac output was 30% decreased while blood pressure remained stable during laparoscopic orchidopexy with PnP of 10 mmHg in children between aged 6-30 months [1599]. When PnP was lowered from 12 mmHg to 6 mmHg, cardiac index and other vascular parameters normalised [1600]. Using high intra-abdominal pressures in infants with congenital cardiac abnormalities may result in re-opening of cardiac shunts such as the foramen ovale and ductus arteriosus [1601]. Although cardiovascular effects of using high PnP are clinically measurable, they may not have a significant clinical impact on healthy children. However, it is clear that using lower pressures is safer especially in smaller children.

#### 3.24.2.5 Effects on renal function

A study measuring renal oxygenation with NIRS (Near-infrared spectroscopy) during laparoscopy showed that pneumoperitoneum might have a negative effect on renal oxygenation [1602]. However, this effect was reversible after desufflation. Other studies showed pneumoperitoneum may also have adverse effects on renal blood flow [1603]. High intra-abdominal pressures and reverse Trendelenburg position may cause decreased glomerular filtration rate and decreased urine output. One study has shown that 88% of infants and 14% of children more than one year old develop anuria within 45 minutes after initiation of PnP with 8 mmHg [1604]. However, urine output recovers with temporary polyuria after the operation. Although the clinical relevance of decreased urine output seems insignificant, it is important to monitor the fluid and electrolyte balance of the children during and after laparoscopic surgery.

#### 3.24.2.6 Effects on neurological system

Another effect of pneumoperitoneum is increased intracranial pressure (ICP) which normalises after desufflation of the abdomen [1605]. Trendelenburg position, high PnP and hypoventilation are additional risk factors for increased ICP. Laparoscopy is therefore contraindicated in patients with intracranial space occupying lesions [1606]. Children with ventriculo-peritoneal shunts require precautions with regards to shunt drainage, however laparoscopy is not contraindicated [1607].

#### 3.24.2.7 Comparison of robot-assisted laparoscopic surgery versus laparoscopic surgery

No physiological differences are expected between the two approaches since pneumoperitoneum needs to be achieved in the same manner. However, a systematic review comparing robot-assisted laparoscopic pyeloplasty to conventional laparoscopy in infants and children showed no differences in terms of operative success and redo rates between the two techniques [1608]. As for operative time, hospital length of stay and complication rates, the robotic approach appears to be slightly superior in children [909, 1609]. However, in the infant population, operative time was longer in the robot-assisted approach as compared to conventional laparoscopy and there was a higher complication rate, mainly due to a higher rate of port-site hernias [1610]. The robot-assisted approach might aid in filling the gap to minimally invasive surgery for paediatric urologists as it has a shorter learning curve and does not necessarily require prior laparoscopic experience. Downsides to the robotic approach are the size of the instruments, accessibility and costs [909, 1608].



### 3.24.3 Summary of evidence and recommendations for laparoscopy in children

Summary of evidence	LE
Laparoscopy and robotic-assisted laparoscopic surgery can safely be performed in children	1
The general benefits of laparoscopy are decreased pain, shorter convalescence and better cosmetics compared to traditional open surgery.	1
Limitations to be considered are increased operative time, smaller working space with young age, cost, surgeon and anaesthesiologist experience.	1
Pneumoperitoneum may have physiological effects which require close monitoring during surgery and should be taken seriously.	2

Recommendations	Strength rating
Use lower intra-abdominal pressure (6-8 mmHg) during laparoscopic surgery in infants and smaller children.	Strong
Use open access for laparoscopy in infants and smaller children.	Strong
Monitor for laparoscopy-related cardiac, pulmonary and diuretic responses.	Strong

## 4. REFERENCES

1. Bogaert, G., *et al.* Practical recommendations of the EAU-ESPU guidelines committee for monosymptomatic enuresis-Bedwetting. *Neurourol Urodyn*, 2020. 39: 489.  
<https://pubmed.ncbi.nlm.nih.gov/31793066>
2. Dogan, H.S., *et al.* Are EAU/ESPU pediatric urology guideline recommendations on neurogenic bladder well received by the patients? Results of a survey on awareness in spina bifida patients and caregivers. *Neurourol Urodyn*, 2019. 38: 1625.  
<https://pubmed.ncbi.nlm.nih.gov/31102557>
3. Radmayr, C., *et al.* Management of undescended testes: European Association of Urology/European Society for Paediatric Urology Guidelines. *J Pediatr Urol*, 2016. 12: 335.  
<https://pubmed.ncbi.nlm.nih.gov/27687532>
4. Stein, R., *et al.* EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. *Neurourol Urodyn*, 2020. 39: 45.  
<https://pubmed.ncbi.nlm.nih.gov/31724222>
5. Stein, R., *et al.* EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part II operative management. *Neurourol Urodyn*, 2020. 39: 498.  
<https://pubmed.ncbi.nlm.nih.gov/31794087>
6. Stein, R., *et al.* Urinary tract infections in children: EAU/ESPU guidelines. *Eur Urol*, 2015. 67: 546.  
<https://pubmed.ncbi.nlm.nih.gov/25477258>
7. Tekgul, S., *et al.* EAU guidelines on vesicoureteral reflux in children. *Eur Urol*, 2012. 62: 534.  
<https://pubmed.ncbi.nlm.nih.gov/22698573>
8. Riedmiller, H., *et al.* EAU guidelines on paediatric urology. *Eur Urol*, 2001. 40: 589.  
<https://pubmed.ncbi.nlm.nih.gov/11752871>
9. Phillips, B., *et al.* Oxford Centre for Evidence-Based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009.
10. Guyatt, G.H., *et al.* Going from evidence to recommendations. *BMJ*, 2008. 336: 1049.  
<https://pubmed.ncbi.nlm.nih.gov/18467413>
11. Osborn, L.M., *et al.* Hygienic care in uncircumcised infants. *Pediatrics*, 1981. 67: 365.  
<https://pubmed.ncbi.nlm.nih.gov/7243473>
12. Herzog, L.W., *et al.* The frequency of foreskin problems in uncircumcised children. *Am J Dis Child*, 1986. 140: 254.  
<https://pubmed.ncbi.nlm.nih.gov/3946358>
13. Gairdner, D. The Fate of the Foreskin: A Study of Circumcision. *Obstet Gynecol Surv.*, 1950. Oct;5(5): 699.  
<https://pubmed.ncbi.nlm.nih.gov/15408299>
14. Oster, J. Further fate of the foreskin. Incidence of preputial adhesions, phimosis, and smegma among Danish schoolboys. *Arch Dis Child*, 1968. 43: 200.  
<https://pubmed.ncbi.nlm.nih.gov/5689532>
15. Babu, R., *et al.* Ballooning of the foreskin and physiological phimosis: is there any objective evidence of obstructed voiding? *BJU Int*, 2004. 94: 384.  
<https://pubmed.ncbi.nlm.nih.gov/15291873>
16. Clifford, I.D., *et al.* Paediatric paraphimosis. *Emerg Med Australas*, 2016. 28: 96.  
<https://pubmed.ncbi.nlm.nih.gov/26781045>
17. Morris, B.J., *et al.* Penile Inflammatory Skin Disorders and the Preventive Role of Circumcision. *Int J Prev Med*, 2017. 8: 32.  
<https://pubmed.ncbi.nlm.nih.gov/28567234>
18. Jayakumar, S., *et al.* Balanitis xerotica obliterans in children and its incidence under the age of 5 years. *J Pediatr Urol*, 2012. 8: 272.  
<https://pubmed.ncbi.nlm.nih.gov/21705275>
19. Li, J., *et al.* Underestimation of genital lichen sclerosus incidence in boys with phimosis: results from a systematic review. *Pediatr Surg Int*, 2018. 34: 1245.  
<https://pubmed.ncbi.nlm.nih.gov/30264374>
20. Celis, S., *et al.* Balanitis xerotica obliterans in children and adolescents: a literature review and clinical series. *J Pediatr Urol*, 2014. 10: 34.  
<https://pubmed.ncbi.nlm.nih.gov/24295833>
21. Shalaby, M., *et al.* Megaprepuce: a systematic review of a rare condition with a controversial surgical management. *Pediatr Surg Int*, 2021. 37: 815.  
<https://pubmed.ncbi.nlm.nih.gov/33760967>

22. McGregor, T.B., *et al.* Pathologic and physiologic phimosis: approach to the phimotic foreskin. *Can Fam Physician*, 2007. 53: 445.  
<https://pubmed.ncbi.nlm.nih.gov/17872680>
23. Nguyen, A.T.M., *et al.* Balanitis xerotica obliterans: an update for clinicians. *Eur J Pediatr*, 2020. 179: 9.  
<https://pubmed.ncbi.nlm.nih.gov/31760506>
24. Kuehhas, F.E., *et al.* Incidence of balanitis xerotica obliterans in boys younger than 10 years presenting with phimosis. *Urol Int*, 2013. 90: 439.  
<https://pubmed.ncbi.nlm.nih.gov/23296396>
25. Management of Abnormalities of the External Genitalia in Boys, Lane S. Palmer & Jeffrey S. Palmer, Editors. 2021, Campbell-Walsh Urology,.
26. Moreno, G., *et al.* Topical corticosteroids for treating phimosis in boys. *Cochrane Database Syst Rev*, 2014. 2014: CD008973.  
<https://pubmed.ncbi.nlm.nih.gov/25180668>
27. ter Meulen, P.H., *et al.* A conservative treatment of phimosis in boys. *Eur Urol*, 2001. 40: 196.  
<https://pubmed.ncbi.nlm.nih.gov/11528198>
28. Elmore, J.M., *et al.* Topical steroid therapy as an alternative to circumcision for phimosis in boys younger than 3 years. *J Urol*, 2002. 168: 1746.  
<https://pubmed.ncbi.nlm.nih.gov/12352350>
29. Zavras, N., *et al.* Conservative treatment of phimosis with fluticasone propionate 0.05%: a clinical study in 1185 boys. *J Pediatr Urol*, 2009. 5: 181.  
<https://pubmed.ncbi.nlm.nih.gov/19097823>
30. Chamberlin, J.D., *et al.* Randomized open-label trial comparing topical prescription triamcinolone to over-the-counter hydrocortisone for the treatment of phimosis. *J Pediatr Urol*, 2019. 15: 388 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31130504>
31. Reddy, S., *et al.* Local steroid therapy as the first-line treatment for boys with symptomatic phimosis - a long-term prospective study. *Acta Paediatr*, 2012. 101: e130.  
<https://pubmed.ncbi.nlm.nih.gov/22103624>
32. Ghysel, C., *et al.* Long-term efficiency of skin stretching and a topical corticoid cream application for unretractable foreskin and phimosis in prepubertal boys. *Urol Int*, 2009. 82: 81.  
<https://pubmed.ncbi.nlm.nih.gov/19172103>
33. Sridharan, K., *et al.* Topical corticosteroids for phimosis in children: a network meta-analysis of randomized clinical trials. *Pediatr Surg Int*, 2021. 37: 1117.  
<https://pubmed.ncbi.nlm.nih.gov/33991205>
34. Golubovic, Z., *et al.* The conservative treatment of phimosis in boys. *Br J Urol*, 1996. 78: 786.  
<https://pubmed.ncbi.nlm.nih.gov/8976781>
35. Pileggi, F.O., *et al.* Is suppression of hypothalamic-pituitary-adrenal axis significant during clinical treatment of phimosis? *J Urol*, 2010. 183: 2327.  
<https://pubmed.ncbi.nlm.nih.gov/20400146>
36. Wiswell, T.E. The prepuce, urinary tract infections, and the consequences. *Pediatrics*, 2000. 105: 860.  
<https://pubmed.ncbi.nlm.nih.gov/10742334>
37. Hiraoka, M., *et al.* Meatus tightly covered by the prepuce is associated with urinary infection. *Pediatr Int*, 2002. 44: 658.  
<https://pubmed.ncbi.nlm.nih.gov/12421265>
38. To, T., *et al.* Cohort study on circumcision of newborn boys and subsequent risk of urinary-tract infection. *Lancet*, 1998. 352: 1813.  
<https://pubmed.ncbi.nlm.nih.gov/9851381>
39. Ellison, J.S., *et al.* Neonatal Circumcision and Urinary Tract Infections in Infants With Hydronephrosis. *Pediatrics*, 2018. 142.  
<https://pubmed.ncbi.nlm.nih.gov/29880703>
40. Ladenhauf, H.N., *et al.* Reduced bacterial colonisation of the glans penis after male circumcision in children—a prospective study. *J Pediatr Urol*, 2013. 9: 1137.  
<https://pubmed.ncbi.nlm.nih.gov/23685114>
41. Chen, C.J., *et al.* The use of steroid cream for physiologic phimosis in male infants with a history of UTI and normal renal ultrasound is associated with decreased risk of recurrent UTI. *J Pediatr Urol*, 2019. 15: 472 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31345734>
42. Larke, N.L., *et al.* Male circumcision and penile cancer: a systematic review and meta-analysis. *Cancer Causes Control*, 2011. 22: 1097.  
<https://pubmed.ncbi.nlm.nih.gov/21695385>

43. Pedersini, P., *et al.* "Trident" preputial plasty for phimosis in childhood. *J Pediatr Urol*, 2017. 13: 278 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28359779>
44. Benson, M., *et al.* Prepuce sparing: Use of Z-plasty for treatment of phimosis and scarred foreskin. *J Pediatr Urol*, 2018. 14: 545 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29909192>
45. Miernik, A., *et al.* Complete removal of the foreskin—why? *Urol Int*, 2011. 86: 383.  
<https://pubmed.ncbi.nlm.nih.gov/21474914>
46. Thompson, H.C., *et al.* Report of the ad hoc task force on circumcision. *Pediatrics*, 1975. 56: 610.  
<https://pubmed.ncbi.nlm.nih.gov/1174384>
47. American Academy of Pediatrics: Report of the Task Force on Circumcision. *Pediatrics*, 1989. 84: 388.  
<https://pubmed.ncbi.nlm.nih.gov/2664697>
48. Anand, A., *et al.* Mannitol for paraphimosis reduction. *Urol Int*, 2013. 90: 106.  
<https://pubmed.ncbi.nlm.nih.gov/23257575>
49. DeVries, C.R., *et al.* Reduction of paraphimosis with hyaluronidase. *Urology*, 1996. 48: 464.  
<https://pubmed.ncbi.nlm.nih.gov/8804504>
50. Weiss, H.A., *et al.* Complications of circumcision in male neonates, infants and children: a systematic review. *BMC Urol*, 2010. 10: 2.  
<https://pubmed.ncbi.nlm.nih.gov/20158883>
51. Hung, Y.C., *et al.* A Longitudinal Population Analysis of Cumulative Risks of Circumcision. *J Surg Res*, 2019. 233: 111.  
<https://pubmed.ncbi.nlm.nih.gov/30502236>
52. Pradhan, A., *et al.* 10 Years' Experience in Balanitis Xerotica Obliterans: A Single-Institution Study. *Eur J Pediatr Surg*, 2019. 29: 302.  
<https://pubmed.ncbi.nlm.nih.gov/30130825>
53. Homer, L., *et al.* Meatal stenosis in boys following circumcision for lichen sclerosus (balanitis xerotica obliterans). *J Urol*, 2014. 192: 1784.  
<https://pubmed.ncbi.nlm.nih.gov/24992332>
54. Sijstermans, K., *et al.* The frequency of undescended testis from birth to adulthood: a review. *Int J Androl*, 2008. 31: 1.  
<https://pubmed.ncbi.nlm.nih.gov/17488243>
55. Berkowitz, G.S., *et al.* Prevalence and natural history of cryptorchidism. *Pediatrics*, 1993. 92: 44.  
<https://pubmed.ncbi.nlm.nih.gov/8100060>
56. Kaefer, M., *et al.* The incidence of intersexuality in children with cryptorchidism and hypospadias: stratification based on gonadal palpability and meatal position. *J Urol*, 1999. 162: 1003.  
<https://pubmed.ncbi.nlm.nih.gov/10458421>
57. Kollin, C., *et al.* Cryptorchidism: a clinical perspective. *Pediatr Endocrinol Rev*, 2014. 11 Suppl 2: 240.  
<https://pubmed.ncbi.nlm.nih.gov/24683948>
58. Caesar, R.E., *et al.* The incidence of the cremasteric reflex in normal boys. *J Urol*, 1994. 152: 779.  
<https://pubmed.ncbi.nlm.nih.gov/7912745>
59. Barthold, J.S., *et al.* The epidemiology of congenital cryptorchidism, testicular ascent and orchiopexy. *J Urol*, 2003. 170: 2396.  
<https://pubmed.ncbi.nlm.nih.gov/14634436>
60. Turek, P.J., *et al.* The absent cryptorchid testis: surgical findings and their implications for diagnosis and etiology. *J Urol*, 1994. 151: 718.  
<https://pubmed.ncbi.nlm.nih.gov/7905931>
61. Rabinowitz, R., *et al.* Late presentation of cryptorchidism: the etiology of testicular re-ascent. *J Urol*, 1997. 157: 1892.  
<https://pubmed.ncbi.nlm.nih.gov/9112557>
62. Cendron, M., *et al.* Anatomical, morphological and volumetric analysis: a review of 759 cases of testicular maldescent. *J Urol*, 1993. 149: 570.  
<https://pubmed.ncbi.nlm.nih.gov/8094761>
63. Braga, L.H., *et al.* Is there an optimal contralateral testicular cut-off size that predicts monorchism in boys with nonpalpable testicles? *J Pediatr Urol*, 2014. 10: 693.  
<https://pubmed.ncbi.nlm.nih.gov/25008806>
64. Hurwitz, R.S., *et al.* How well does contralateral testis hypertrophy predict the absence of the nonpalpable testis? *J Urol*, 2001. 165: 588.  
<https://pubmed.ncbi.nlm.nih.gov/11176443>

65. Hodhod, A., *et al.* Testicular hypertrophy as a predictor for contralateral monorchism: Retrospective review of prospectively recorded data. *J Pediatr Urol*, 2016. 12: 34 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26279100>
66. Elert, A., *et al.* Population-based investigation of familial undescended testis and its association with other urogenital anomalies. *J Pediatr Urol*, 2005. 1: 403.  
<https://pubmed.ncbi.nlm.nih.gov/18947580>
67. Hrebinko, R.L., *et al.* The limited role of imaging techniques in managing children with undescended testes. *J Urol*, 1993. 150: 458.  
<https://pubmed.ncbi.nlm.nih.gov/8100860>
68. Tasian, G.E., *et al.* Diagnostic performance of ultrasound in nonpalpable cryptorchidism: a systematic review and meta-analysis. *Pediatrics*, 2011. 127: 119.  
<https://pubmed.ncbi.nlm.nih.gov/21149435>
69. Elder, J.S. Ultrasonography is unnecessary in evaluating boys with a nonpalpable testis. *Pediatrics*, 2002. 110: 748.  
<https://pubmed.ncbi.nlm.nih.gov/12359789>
70. Wenzler, D.L., *et al.* What is the rate of spontaneous testicular descent in infants with cryptorchidism? *J Urol*, 2004. 171: 849.  
<https://pubmed.ncbi.nlm.nih.gov/14713841>
71. Park, K.H., *et al.* Histological evidences suggest recommending orchiopexy within the first year of life for children with unilateral inguinal cryptorchid testis. *Int J Urol*, 2007. 14: 616.  
<https://pubmed.ncbi.nlm.nih.gov/17645605>
72. Engeler, D.S., *et al.* Early orchiopexy: prepubertal intratubular germ cell neoplasia and fertility outcome. *Urology*, 2000. 56: 144.  
<https://pubmed.ncbi.nlm.nih.gov/10869645>
73. Forest, M.G., *et al.* Undescended testis: comparison of two protocols of treatment with human chorionic gonadotropin. Effect on testicular descent and hormonal response. *Horm Res*, 1988. 30: 198.  
<https://pubmed.ncbi.nlm.nih.gov/2907898>
74. Rajfer, J., *et al.* Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone. *N Engl J Med*, 1986. 314: 466.  
<https://pubmed.ncbi.nlm.nih.gov/2868413>
75. Pyorala, S., *et al.* A review and meta-analysis of hormonal treatment of cryptorchidism. *J Clin Endocrinol Metab*, 1995. 80: 2795.  
<https://pubmed.ncbi.nlm.nih.gov/7673426>
76. Rajfer, J., *et al.* The incidence of intersexuality in patients with hypospadias and cryptorchidism. *J Urol*, 1976. 116: 769.  
<https://pubmed.ncbi.nlm.nih.gov/12377>
77. Lala, R., *et al.* Combined therapy with LHRH and HCG in cryptorchid infants. *Eur J Pediatr*, 1993. 152 Suppl 2: S31.  
<https://pubmed.ncbi.nlm.nih.gov/8101810>
78. Forest, M.G., *et al.* Effects of human chorionic gonadotropin, androgens, adrenocorticotropin hormone, dexamethasone and hyperprolactinemia on plasma sex steroid-binding protein. *Ann N Y Acad Sci*, 1988. 538: 214.  
<https://pubmed.ncbi.nlm.nih.gov/2847619>
79. Aycan, Z., *et al.* Evaluation of low-dose hCG treatment for cryptorchidism. *Turk J Pediatr*, 2006. 48: 228.  
<https://pubmed.ncbi.nlm.nih.gov/17172066>
80. Hesse, V., *et al.* Three injections of human chorionic gonadotropin are as effective as ten injections in the treatment of cryptorchidism. *Horm Res*, 1988. 30: 193.  
<https://pubmed.ncbi.nlm.nih.gov/2907897>
81. Hagberg, S., *et al.* Treatment of undescended testes with intranasal application of synthetic LH-RH. *Eur J Pediatr*, 1982. 139: 285.  
<https://pubmed.ncbi.nlm.nih.gov/6133757>
82. Hadziselimovic, F., *et al.* Treatment with a luteinizing hormone-releasing hormone analogue after successful orchiopexy markedly improves the chance of fertility later in life. *J Urol*, 1997. 158: 1193.  
<https://pubmed.ncbi.nlm.nih.gov/9258170>
83. Kollin, C., *et al.* Surgical treatment of unilaterally undescended testes: testicular growth after randomization to orchiopexy at age 9 months or 3 years. *J Urol*, 2007. 178: 1589.  
<https://pubmed.ncbi.nlm.nih.gov/17707045>

84. Cortes, D., *et al.* Hormonal treatment may harm the germ cells in 1 to 3-year-old boys with cryptorchidism. *J Urol*, 2000. 163: 1290.  
<https://pubmed.ncbi.nlm.nih.gov/10737531>
85. Ritzen, E.M. Undescended testes: a consensus on management. *Eur J Endocrinol*, 2008. 159 Suppl 1: S87.  
<https://pubmed.ncbi.nlm.nih.gov/18728121>
86. Hildorf, S., *et al.* Fertility Potential is Compromised in 20% to 25% of Boys with Nonsyndromic Cryptorchidism despite Orchiopexy within the First Year of Life. *J Urol*, 2020. 203: 832.  
<https://pubmed.ncbi.nlm.nih.gov/31642739>
87. Novaes, H.F., *et al.* Single scrotal incision orchiopexy - a systematic review. *Int Braz J Urol*, 2013. 39: 305.  
<https://pubmed.ncbi.nlm.nih.gov/23849581>
88. Docimo, S.G. The results of surgical therapy for cryptorchidism: a literature review and analysis. *J Urol*, 1995. 154: 1148.  
<https://pubmed.ncbi.nlm.nih.gov/7637073>
89. Ziylan, O., *et al.* Failed orchiopexy. *Urol Int*, 2004. 73: 313.  
<https://pubmed.ncbi.nlm.nih.gov/15604574>
90. Prentiss, R.J., *et al.* Undescended testis: surgical anatomy of spermatic vessels, spermatic surgical triangles and lateral spermatic ligament. *J Urol*, 1960. 83: 686.  
<https://pubmed.ncbi.nlm.nih.gov/14434738>
91. Kozminski, D.J., *et al.* Orchiopexy without Transparenchymal Fixation Suturing: A 29-Year Experience. *J Urol*, 2015. 194: 1743.  
<https://pubmed.ncbi.nlm.nih.gov/26141850>
92. Martin, J.M., *et al.* Is radiotherapy a good adjuvant strategy for men with a history of cryptorchism and stage I seminoma? *Int J Radiat Oncol Biol Phys*, 2010. 76: 65.  
<https://pubmed.ncbi.nlm.nih.gov/19362785>
93. Na, S.W., *et al.* Single scrotal incision orchiopexy for children with palpable low-lying undescended testis: early outcome of a prospective randomized controlled study. *Korean J Urol*, 2011. 52: 637.  
<https://pubmed.ncbi.nlm.nih.gov/22025961>
94. Parsons, J.K., *et al.* The low scrotal approach to the ectopic or ascended testicle: prevalence of a patent processus vaginalis. *J Urol*, 2003. 169: 1832.  
<https://pubmed.ncbi.nlm.nih.gov/12686856>
95. Feng, S., *et al.* Single scrotal incision orchiopexy versus the inguinal approach in children with palpable undescended testis: a systematic review and meta-analysis. *Pediatr Surg Int*, 2016. 32: 989.  
<https://pubmed.ncbi.nlm.nih.gov/27510940>
96. Wayne, C., *et al.* What is the ideal surgical approach for intra-abdominal testes? A systematic review. *Pediatr Surg Int*, 2015. 31: 327.  
<https://pubmed.ncbi.nlm.nih.gov/25663531>
97. Cortesi, N., *et al.* Diagnosis of bilateral abdominal cryptorchidism by laparoscopy. *Endoscopy*, 1976. 8: 33.  
<https://pubmed.ncbi.nlm.nih.gov/16743>
98. Jordan, G.H., *et al.* Laparoscopic single stage and staged orchiopexy. *J Urol*, 1994. 152: 1249.  
<https://pubmed.ncbi.nlm.nih.gov/7915336>
99. Chandrasekharam, V.V. Laparoscopy vs inguinal exploration for nonpalpable undescended testis. *Indian J Pediatr*, 2005. 72: 1021.  
<https://pubmed.ncbi.nlm.nih.gov/16388149>
100. Snodgrass, W.T., *et al.* Scrotal exploration for unilateral nonpalpable testis. *J Urol*, 2007. 178: 1718.  
<https://pubmed.ncbi.nlm.nih.gov/17707015>
101. Cisek, L.J., *et al.* Current findings in diagnostic laparoscopic evaluation of the nonpalpable testis. *J Urol*, 1998. 160: 1145.  
<https://pubmed.ncbi.nlm.nih.gov/9719296>
102. Patil, K.K., *et al.* Laparoscopy for impalpable testes. *BJU Int*, 2005. 95: 704.  
<https://pubmed.ncbi.nlm.nih.gov/15784081>
103. Elderwy, A.A., *et al.* Laparoscopic versus open orchiopexy in the management of peeping testis: a multi-institutional prospective randomized study. *J Pediatr Urol*, 2014. 10: 605.  
<https://pubmed.ncbi.nlm.nih.gov/25042877>
104. Kirsch, A.J., *et al.* Surgical management of the nonpalpable testis: the Children's Hospital of Philadelphia experience. *J Urol*, 1998. 159: 1340.  
<https://pubmed.ncbi.nlm.nih.gov/9507881>

105. Fowler, R., *et al.* The role of testicular vascular anatomy in the salvage of high undescended testes. *Aust N Z J Surg*, 1959. 29: 92.  
<https://pubmed.ncbi.nlm.nih.gov/13849840>
106. Koff, S.A., *et al.* Treatment of high undescended testes by low spermatic vessel ligation: an alternative to the Fowler-Stephens technique. *J Urol*, 1996. 156: 799.  
<https://pubmed.ncbi.nlm.nih.gov/8683787>
107. Esposito, C., *et al.* Exploration of inguinal canal is mandatory in cases of non palpable testis if laparoscopy shows elements entering a closed inguinal ring. *Eur J Pediatr Surg*, 2010. 20: 138.  
<https://pubmed.ncbi.nlm.nih.gov/19746341>
108. Wu, C.Q., *et al.* Revisiting the success rate of one-stage Fowler-Stephens orchiopexy with postoperative Doppler ultrasound and long-term follow-up: a 15-year single-surgeon experience. *J Pediatr Urol*, 2020. 16: 48.  
<https://pubmed.ncbi.nlm.nih.gov/31784377>
109. Radmayr, C., *et al.* Long-term outcome of laparoscopically managed nonpalpable testes. *J Urol*, 2003. 170: 2409.  
<https://pubmed.ncbi.nlm.nih.gov/14634439>
110. Baker, L.A., *et al.* A multi-institutional analysis of laparoscopic orchidopexy. *BJU Int*, 2001. 87: 484.  
<https://pubmed.ncbi.nlm.nih.gov/11298039>
111. Dave, S., *et al.* Open versus laparoscopic staged Fowler-Stephens orchiopexy: impact of long loop vas. *J Urol*, 2009. 182: 2435.  
<https://pubmed.ncbi.nlm.nih.gov/19765743>
112. Wacksman, J., *et al.* Laparoscopically assisted testicular autotransplantation for management of the intraabdominal undescended testis. *J Urol*, 1996. 156: 772.  
<https://pubmed.ncbi.nlm.nih.gov/8683780>
113. Penson, D., *et al.* Effectiveness of hormonal and surgical therapies for cryptorchidism: a systematic review. *Pediatrics*, 2013. 131: e1897.  
<https://pubmed.ncbi.nlm.nih.gov/23690511>
114. Koni, A., *et al.* Histopathological evaluation of orchiectomy specimens in 51 late postpubertal men with unilateral cryptorchidism. *J Urol*, 2014. 192: 1183.  
<https://pubmed.ncbi.nlm.nih.gov/24840535>
115. Trussell, J.C., *et al.* The relationship of cryptorchidism to fertility. *Curr Urol Rep*, 2004. 5: 142.  
<https://pubmed.ncbi.nlm.nih.gov/15028208>
116. Hadziselimovic, F., *et al.* The importance of both an early orchidopexy and germ cell maturation for fertility. *Lancet*, 2001. 358: 1156.  
<https://pubmed.ncbi.nlm.nih.gov/11597673>
117. Lee, P.A. Fertility after cryptorchidism: epidemiology and other outcome studies. *Urology*, 2005. 66: 427.  
<https://pubmed.ncbi.nlm.nih.gov/16098371>
118. Chua, M.E., *et al.* Hormonal therapy using gonadotropin releasing hormone for improvement of fertility index among children with cryptorchidism: a meta-analysis and systematic review. *J Pediatr Surg*, 2014. 49: 1659.  
<https://pubmed.ncbi.nlm.nih.gov/25475814>
119. Coughlin, M.T., *et al.* Age at unilateral orchiopexy: effect on hormone levels and sperm count in adulthood. *J Urol*, 1999. 162: 986.  
<https://pubmed.ncbi.nlm.nih.gov/10458417>
120. Tasian, G.E., *et al.* Age at orchiopexy and testis palpability predict germ and Leydig cell loss: clinical predictors of adverse histological features of cryptorchidism. *J Urol*, 2009. 182: 704.  
<https://pubmed.ncbi.nlm.nih.gov/19539332>
121. Dieckmann, K.P., *et al.* Clinical epidemiology of testicular germ cell tumors. *World J Urol*, 2004. 22: 2.  
<https://pubmed.ncbi.nlm.nih.gov/15034740>
122. Pettersson, A., *et al.* Age at surgery for undescended testis and risk of testicular cancer. *N Engl J Med*, 2007. 356: 1835.  
<https://pubmed.ncbi.nlm.nih.gov/17476009>
123. Walsh, T.J., *et al.* Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. *J Urol*, 2007. 178: 1440.  
<https://pubmed.ncbi.nlm.nih.gov/17706709>
124. Pohl, H.G., *et al.* Prepubertal testis tumors: actual prevalence rate of histological types. *J Urol*, 2004. 172: 2370.  
<https://pubmed.ncbi.nlm.nih.gov/15538270>

125. Kusler, K.A., *et al.* International testicular cancer incidence rates in children, adolescents and young adults. *Cancer Epidemiol*, 2018. 56: 106.  
<https://pubmed.ncbi.nlm.nih.gov/30130682>
126. Schneider, D.T., *et al.* Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols. *Pediatr Blood Cancer*, 2004. 42: 169.  
<https://pubmed.ncbi.nlm.nih.gov/14752882>
127. Taskinen, S., *et al.* Testicular tumors in children and adolescents. *J Pediatr Urol*, 2008. 4: 134.  
<https://pubmed.ncbi.nlm.nih.gov/18631909>
128. Metcalfe, P.D., *et al.* Pediatric testicular tumors: contemporary incidence and efficacy of testicular preserving surgery. *J Urol*, 2003. 170: 2412.  
<https://pubmed.ncbi.nlm.nih.gov/14634440>
129. Shukla, A.R., *et al.* Experience with testis sparing surgery for testicular teratoma. *J Urol*, 2004. 171: 161.  
<https://pubmed.ncbi.nlm.nih.gov/14665867>
130. Nerli, R.B., *et al.* Prepubertal testicular tumors: our 10 years experience. *Indian J Cancer*, 2010. 47: 292.  
<https://pubmed.ncbi.nlm.nih.gov/20587905>
131. Wu, D., *et al.* Prepubertal testicular tumors in China: a 10-year experience with 67 cases. *Pediatr Surg Int*, 2018. 34: 1339.  
<https://pubmed.ncbi.nlm.nih.gov/30324570>
132. Hawkins, E., *et al.* The prepubertal testis (prenatal and postnatal): its relationship to intratubular germ cell neoplasia: a combined Pediatric Oncology Group and Children's Cancer Study Group. *Hum Pathol*, 1997. 28: 404.  
<https://pubmed.ncbi.nlm.nih.gov/9104938>
133. Manivel, J.C., *et al.* Intratubular germ cell neoplasia in testicular teratomas and epidermoid cysts. Correlation with prognosis and possible biologic significance. *Cancer*, 1989. 64: 715.  
<https://pubmed.ncbi.nlm.nih.gov/2663131>
134. Renedo, D.E., *et al.* Intratubular germ cell neoplasia (ITGCN) with p53 and PCNA expression and adjacent mature teratoma in an infant testis. An immunohistochemical and morphologic study with a review of the literature. *Am J Surg Pathol*, 1994. 18: 947.  
<https://pubmed.ncbi.nlm.nih.gov/7741838>
135. Rushton, H.G., *et al.* Testicular sparing surgery for prepubertal teratoma of the testis: a clinical and pathological study. *J Urol*, 1990. 144: 726.  
<https://pubmed.ncbi.nlm.nih.gov/2388338>
136. Roth, L.M., *et al.* Gonadoblastoma: origin and outcome. *Hum Pathol*, 2020. 100: 47.  
<https://pubmed.ncbi.nlm.nih.gov/31805291>
137. Ahmed, H.U., *et al.* Testicular and paratesticular tumours in the prepubertal population. *Lancet Oncol*, 2010. 11: 476.  
<https://pubmed.ncbi.nlm.nih.gov/20434716>
138. Henderson, C.G., *et al.* Enucleation for prepubertal leydig cell tumor. *J Urol*, 2006. 176: 703.  
<https://pubmed.ncbi.nlm.nih.gov/16813923>
139. Soles, B.S., *et al.* Melanotic Neuroectodermal Tumor of Infancy. *Arch Pathol Lab Med*, 2018. 142: 1358.  
<https://pubmed.ncbi.nlm.nih.gov/30407852>
140. Yada, K., *et al.* Intrascrotal lipoblastoma: report of a case and the review of literature. *Surg Case Rep*, 2016. 2: 34.  
<https://pubmed.ncbi.nlm.nih.gov/27059472>
141. Marulaiah, M., *et al.* Testicular and paratesticular pathology in children: a 12-year histopathological review. *World J Surg*, 2010. 34: 969.  
<https://pubmed.ncbi.nlm.nih.gov/20151127>
142. Walterhouse, D.O., *et al.* Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. *J Clin Oncol*, 2018. 36: JCO2018789388.  
<https://pubmed.ncbi.nlm.nih.gov/30351998>
143. Akbar, S.A., *et al.* Multimodality imaging of paratesticular neoplasms and their rare mimics. *Radiographics*, 2003. 23: 1461.  
<https://pubmed.ncbi.nlm.nih.gov/14615558>
144. Esen, B., *et al.* Should we rely on Doppler ultrasound for evaluation of testicular solid lesions? *World J Urol*, 2018. 36: 1263.  
<https://pubmed.ncbi.nlm.nih.gov/29572727>



145. Lock, G. [Contrast-enhanced ultrasonography of testicular tumours]. *Urologe A*, 2019. 58: 1410.  
<https://pubmed.ncbi.nlm.nih.gov/31712858>
146. Tallen, G., *et al.* High reliability of scrotal ultrasonography in the management of childhood primary testicular neoplasms. *Klin Padiatr*, 2011. 223: 131.  
<https://pubmed.ncbi.nlm.nih.gov/21462100>
147. Yu, C.J., *et al.* Incidence characteristics of testicular microlithiasis and its association with risk of primary testicular tumors in children: a systematic review and meta-analysis. *World J Pediatr*, 2020. 16: 585.  
<https://pubmed.ncbi.nlm.nih.gov/31853884>
148. Ludwikowski, B., *et al.* (2016) S2kHodenhochstand – Maldescensus testis.
149. Barbonetti, A., *et al.* Testicular Cancer in Infertile Men With and Without Testicular Microlithiasis: A Systematic Review and Meta-Analysis of Case-Control Studies. *Front Endocrinol (Lausanne)*, 2019. 10: 164.  
<https://pubmed.ncbi.nlm.nih.gov/30949131>
150. Schneider, D.T., *et al.* Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood. *Pediatr Hematol Oncol*, 2001. 18: 11.  
<https://pubmed.ncbi.nlm.nih.gov/11205836>
151. Ross, J.H., *et al.* Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry. *J Urol*, 2002. 168: 1675.  
<https://pubmed.ncbi.nlm.nih.gov/12352332>
152. Radford, A., *et al.* Testicular-sparing surgery in the pediatric population: multicenter review of practice with review of the literature. *Curr Opin Urol*, 2019. 29: 481.  
<https://pubmed.ncbi.nlm.nih.gov/31205272>
153. Friend, J., *et al.* Benign scrotal masses in children - some new lessons learned. *J Pediatr Surg*, 2016. 51: 1737.  
<https://pubmed.ncbi.nlm.nih.gov/27558482>
154. Hisamatsu, E., *et al.* Prepubertal testicular tumors: a 20-year experience with 40 cases. *Int J Urol*, 2010. 17: 956.  
<https://pubmed.ncbi.nlm.nih.gov/21046693>
155. Fankhauser, C.D., *et al.* Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. *J Urol*, 2020. 203: 949.  
<https://pubmed.ncbi.nlm.nih.gov/31845841>
156. Grogg, J., *et al.* Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. *Oncologist*, 2020. 25: 585.  
<https://pubmed.ncbi.nlm.nih.gov/32043680>
157. Albers, P., *et al.* Guidelines on Testicular Cancer: 2015 Update. *Eur Urol*, 2015. 68: 1054.  
<https://pubmed.ncbi.nlm.nih.gov/26297604>
158. Little, T., *et al.* Paediatric testicular tumours in a New Zealand centre. *N Z Med J*, 2017. 130: 68.  
<https://pubmed.ncbi.nlm.nih.gov/29240742>
159. Williamson, S.R., *et al.* The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. *Histopathology*, 2017. 70: 335.  
<https://pubmed.ncbi.nlm.nih.gov/27747907>
160. Hasegawa, T., *et al.* A case of immature teratoma originating in intra-abdominal undescended testis in a 3-month-old infant. *Pediatr Surg Int*, 2006. 22: 570.  
<https://pubmed.ncbi.nlm.nih.gov/16736229>
161. Chang, M.Y., *et al.* Prepubertal Testicular Teratomas and Epidermoid Cysts: Comparison of Clinical and Sonographic Features. *J Ultrasound Med*, 2015. 34: 1745.  
<https://pubmed.ncbi.nlm.nih.gov/26324756>
162. Kao, C.S., *et al.* Juvenile granulosa cell tumors of the testis: a clinicopathologic study of 70 cases with emphasis on its wide morphologic spectrum. *Am J Surg Pathol*, 2015. 39: 1159.  
<https://pubmed.ncbi.nlm.nih.gov/26076062>
163. Shukla, A.R., *et al.* Juvenile granulosa cell tumor of the testis:: contemporary clinical management and pathological diagnosis. *J Urol*, 2004. 171: 1900.  
<https://pubmed.ncbi.nlm.nih.gov/15076304>
164. Luckie, T.M., *et al.* A Multicenter Retrospective Review of Pediatric Leydig Cell Tumor of the Testis. *J Pediatr Hematol Oncol*, 2019. 41: 74.  
<https://pubmed.ncbi.nlm.nih.gov/29554024>

165. Emre, S., et al. Testis sparing surgery for Leydig cell pathologies in children. *J Pediatr Urol*, 2017. 13: 51 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27773621>
166. Geminiani, J.J., et al. Testicular Leydig Cell Tumor with Metachronous Lesions: Outcomes after Metastasis Resection and Cryoablation. *Case Rep Urol*, 2015. 2015: 748495.  
<https://pubmed.ncbi.nlm.nih.gov/26525589>
167. Talon, I., et al. Sertoli cell tumor of the testis in children: reevaluation of a rarely encountered tumor. *J Pediatr Hematol Oncol*, 2005. 27: 491.  
<https://pubmed.ncbi.nlm.nih.gov/16189443>
168. Li, G., et al. Prepubertal Malignant Large Cell Calcifying Sertoli Cell Tumor of the Testis. *Urology*, 2018. 117: 145.  
<https://pubmed.ncbi.nlm.nih.gov/29626571>
169. Borer, J.G., et al. The spectrum of Sertoli cell tumors in children. *Urol Clin North Am*, 2000. 27: 529.  
<https://pubmed.ncbi.nlm.nih.gov/10985152>
170. Wilson, D.M., et al. Testicular tumors with Peutz-Jeghers syndrome. *Cancer*, 1986. 57: 2238.  
<https://pubmed.ncbi.nlm.nih.gov/3697923>
171. Alleemudder, A., et al. A case of Carney complex presenting as acute testicular pain. *Urol Ann*, 2016. 8: 360.  
<https://pubmed.ncbi.nlm.nih.gov/27453662>
172. Coppes, M.J., et al. Primary testicular and paratesticular tumors of childhood. *Med Pediatr Oncol*, 1994. 22: 329.  
<https://pubmed.ncbi.nlm.nih.gov/8127257>
173. Ye, Y.L., et al. Relapse in children with clinical stage I testicular yolk sac tumors after initial orchiectomy. *Pediatr Surg Int*, 2019. 35: 383.  
<https://pubmed.ncbi.nlm.nih.gov/30539226>
174. Grady, R.W. Current management of prepubertal yolk sac tumors of the testis. *Urol Clin North Am*, 2000. 27: 503.  
<https://pubmed.ncbi.nlm.nih.gov/10985149>
175. Haas, R.J., et al. Testicular germ cell tumors, an update. Results of the German cooperative studies 1982-1997. *Klin Padiatr*, 1999. 211: 300.  
<https://pubmed.ncbi.nlm.nih.gov/10472566>
176. Rogers, P.C., et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9048 and Children’s Cancer Group 8891. *J Clin Oncol*, 2004. 22: 3563.  
<https://pubmed.ncbi.nlm.nih.gov/15337806>
177. Schlatter, M., et al. Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children’s Cancer Group/Pediatric Oncology Group. *J Pediatr Surg*, 2003. 38: 319.  
<https://pubmed.ncbi.nlm.nih.gov/12632342>
178. Alane, S.R., et al. Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. *Urology*, 2016. 95: 128.  
<https://pubmed.ncbi.nlm.nih.gov/27235751>
179. Claahsen-van der Grinten, H.L., et al. Increased prevalence of testicular adrenal rest tumours during adolescence in congenital adrenal hyperplasia. *Horm Res Paediatr*, 2014. 82: 238.  
<https://pubmed.ncbi.nlm.nih.gov/25195868>
180. Merke, D.P., et al. Management of adolescents with congenital adrenal hyperplasia. *Lancet Diabetes Endocrinol*, 2013. 1: 341.  
<https://pubmed.ncbi.nlm.nih.gov/24622419>
181. Claahsen-van der Grinten, H.L., et al. Testicular adrenal rest tumours in congenital adrenal hyperplasia. *Int J Pediatr Endocrinol*, 2009. 2009: 624823.  
<https://pubmed.ncbi.nlm.nih.gov/19956703>
182. Chaudhari, M., et al. Testicular adrenal rest tumor screening and fertility counseling among males with congenital adrenal hyperplasia. *J Pediatr Urol*, 2018. 14: 155 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29330018>
183. Dittrich, R., et al. Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) - Recommendations and Statements for Girls and Women. *Geburtshilfe Frauenheilkd*, 2018. 78: 567.  
<https://pubmed.ncbi.nlm.nih.gov/29962516>
184. Mulder, R.L., et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol*, 2021. 22: e45.  
<https://pubmed.ncbi.nlm.nih.gov/33539753>

185. Mulder, R.L., *et al.* Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol*, 2021. 22: e57.  
<https://pubmed.ncbi.nlm.nih.gov/33539754>
186. Poirot, C.J., *et al.* Feasibility of ovarian tissue cryopreservation for prepubertal females with cancer. *Pediatr Blood Cancer*, 2007. 49: 74.  
<https://pubmed.ncbi.nlm.nih.gov/16977608>
187. Duncan, F.E., *et al.* Pediatric and Teen Ovarian Tissue Removed for Cryopreservation Contains Follicles Irrespective of Age, Disease Diagnosis, Treatment History, and Specimen Processing Methods. *J Adolesc Young Adult Oncol*, 2015. 4: 174.  
<https://pubmed.ncbi.nlm.nih.gov/26697267>
188. Pampanini, V., *et al.* Impact of first-line cancer treatment on the follicle quality in cryopreserved ovarian samples from girls and young women. *Hum Reprod*, 2019. 34: 1674.  
<https://pubmed.ncbi.nlm.nih.gov/31411325>
189. El Issaoui, M., *et al.* Effect of first line cancer treatment on the ovarian reserve and follicular density in girls under the age of 18 years. *Fertil Steril*, 2016. 106: 1757.  
<https://pubmed.ncbi.nlm.nih.gov/27717554>
190. Behl, S., *et al.* Consult and procedure incidence outcomes following establishment of a fertility preservation program for children with cancer. *J Assist Reprod Genet*, 2021. 38: 495.  
<https://pubmed.ncbi.nlm.nih.gov/33389381>
191. Ben-Aharon, I., *et al.* Optimizing the process of fertility preservation in pediatric female cancer patients - a multidisciplinary program. *BMC Cancer*, 2016. 16: 620.  
<https://pubmed.ncbi.nlm.nih.gov/27506811>
192. Rowell, E.E., *et al.* Laparoscopic unilateral oophorectomy for ovarian tissue cryopreservation in children. *J Pediatr Surg*, 2019. 54: 543.  
<https://pubmed.ncbi.nlm.nih.gov/30782317>
193. Poirot, C., *et al.* Human ovarian tissue cryopreservation: indications and feasibility. *Hum Reprod*, 2002. 17: 1447.  
<https://pubmed.ncbi.nlm.nih.gov/12042259>
194. Babayev, S.N., *et al.* Evaluation of ovarian and testicular tissue cryopreservation in children undergoing gonadotoxic therapies. *J Assist Reprod Genet*, 2013. 30: 3.  
<https://pubmed.ncbi.nlm.nih.gov/23242649>
195. Lavery, S.A., *et al.* The medical and ethical challenges of fertility preservation in teenage girls: a case series of sickle cell anaemia patients prior to bone marrow transplant. *Hum Reprod*, 2016. 31: 1501.  
<https://pubmed.ncbi.nlm.nih.gov/27112701>
196. Manuel, S.L., *et al.* Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population. *J Assist Reprod Genet*, 2020. 37: 699.  
<https://pubmed.ncbi.nlm.nih.gov/31828481>
197. Poirot, C., *et al.* Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of age facing highly gonadotoxic treatment. Twenty years of experience at a single center. *Acta Obstet Gynecol Scand*, 2019. 98: 630.  
<https://pubmed.ncbi.nlm.nih.gov/30919447>
198. Anderson, R.A., *et al.* Ovarian tissue cryopreservation for fertility preservation: clinical and research perspectives. *Hum Reprod Open*, 2017. 2017: hox001.  
<https://pubmed.ncbi.nlm.nih.gov/30895221>
199. de Lambert, G., *et al.* A new surgical approach of temporary ovarian transposition for children undergoing brachytherapy: technical assessment and dose evaluation. *J Pediatr Surg*, 2014. 49: 1177.  
<https://pubmed.ncbi.nlm.nih.gov/24952812>
200. Arapaki, A., *et al.* Ovarian Tissue Cryopreservation in Children and Adolescents. *Children (Basel)*, 2022. 9.  
<https://pubmed.ncbi.nlm.nih.gov/36010146>
201. Jadoul, P., *et al.* Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases. *Hum Reprod*, 2017. 32: 1046.  
<https://pubmed.ncbi.nlm.nih.gov/28333228>
202. Rodriguez-Wallberg, K.A., *et al.* A prospective study of women and girls undergoing fertility preservation due to oncologic and non-oncologic indications in Sweden-Trends in patients' choices and benefit of the chosen methods after long-term follow up. *Acta Obstet Gynecol Scand*, 2019. 98: 604.  
<https://pubmed.ncbi.nlm.nih.gov/30723910>

203. Demeestere, I., *et al.* Live birth after autograft of ovarian tissue cryopreserved during childhood. *Hum Reprod*, 2015. 30: 2107.  
<https://pubmed.ncbi.nlm.nih.gov/26062556>
204. Matthews, S.J., *et al.* Successful pregnancy in a woman previously suffering from beta-thalassemia following transplantation of ovarian tissue cryopreserved before puberty. *Minerva Ginecol*, 2018. 70: 432.  
<https://pubmed.ncbi.nlm.nih.gov/29696941>
205. Wyns, C., *et al.* Fertility preservation for prepubertal boys: lessons learned from the past and update on remaining challenges towards clinical translation. *Hum Reprod Update*, 2021. 27: 433.  
<https://pubmed.ncbi.nlm.nih.gov/33326572>
206. Ishiguro, H., *et al.* Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence. *Bone Marrow Transplant*, 2007. 39: 483.  
<https://pubmed.ncbi.nlm.nih.gov/17334386>
207. Sayan, M., *et al.* Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantation. *Bone Marrow Transplant*, 2016. 51: 997.  
<https://pubmed.ncbi.nlm.nih.gov/26950374>
208. de Lambert, G., *et al.* Testicular transposition in children undergoing brachytherapy for bladder and/or prostate rhabdomyosarcoma. *J Pediatr Surg*, 2018. 53: 1428.  
<https://pubmed.ncbi.nlm.nih.gov/29753523>
209. Kanbar, M., *et al.* Long-term follow-up of boys who have undergone a testicular biopsy for fertility preservation. *Hum Reprod*, 2021. 36: 26.  
<https://pubmed.ncbi.nlm.nih.gov/33259629>
210. Thorup, J., *et al.* Selecting Infants With Cryptorchidism and High Risk of Infertility for Optional Adjuvant Hormonal Therapy and Cryopreservation of Germ Cells: Experience From a Pilot Study. *Front Endocrinol (Lausanne)*, 2018. 9: 299.  
<https://pubmed.ncbi.nlm.nih.gov/29922233>
211. Johnson, E.K., *et al.* Gonadal Tissue Cryopreservation for Children with Differences of Sex Development. *Horm Res Paediatr*, 2019. 92: 84.  
<https://pubmed.ncbi.nlm.nih.gov/31509845>
212. Giudice, M.G., *et al.* Male fertility preservation in DSD, XXY, pre-gonadotoxic treatments - Update, methods, ethical issues, current outcomes, future directions. *Best Pract Res Clin Endocrinol Metab*, 2019. 33: 101261.  
<https://pubmed.ncbi.nlm.nih.gov/30718080>
213. Kapur, P., *et al.* Pediatric hernias and hydroceles. *Pediatr Clin North Am*, 1998. 45: 773.  
<https://pubmed.ncbi.nlm.nih.gov/9728185>
214. Morini, F., *et al.* Surgical Management of Pediatric Inguinal Hernia: A Systematic Review and Guideline from the European Pediatric Surgeons' Association Evidence and Guideline Committee. *Eur J Pediatr Surg*, 2022. 32: 219.  
<https://pubmed.ncbi.nlm.nih.gov/33567466>
215. Rubenstein, R.A., *et al.* Benign intrascrotal lesions. *J Urol*, 2004. 171: 1765.  
<https://pubmed.ncbi.nlm.nih.gov/15076274>
216. Xu, W., *et al.* Abdominoscrotal hydrocele: excision of sac may not be necessary. *J Pediatr Urol*, 2020. 16: 494 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32694088>
217. Cozzi, D.A., *et al.* Infantile abdominoscrotal hydrocele: a not so benign condition. *J Urol*, 2008. 180: 2611.  
<https://pubmed.ncbi.nlm.nih.gov/18950814>
218. Lin, H.C., *et al.* Testicular teratoma presenting as a transilluminating scrotal mass. *Urology*, 2006. 67: 1290 e3.  
<https://pubmed.ncbi.nlm.nih.gov/16750249>
219. Skoog, S.J. Benign and malignant pediatric scrotal masses. *Pediatr Clin North Am*, 1997. 44: 1229.  
<https://pubmed.ncbi.nlm.nih.gov/9326960>
220. Chaudhry, H., *et al.* Pitfalls and Practical Challenges in Imaging of the Pediatric Scrotum. *Ultrasound Q*, 2022. 38: 208.  
<https://pubmed.ncbi.nlm.nih.gov/36054277>
221. Koski, M.E., *et al.* Infant communicating hydroceles--do they need immediate repair or might some clinically resolve? *J Pediatr Surg*, 2010. 45: 590.  
<https://pubmed.ncbi.nlm.nih.gov/20223325>

222. Hori, S., *et al.* Trends in treatment outcomes of hydrocele in Japanese children: A single-institute experience. *Int J Urol*, 2020. 27: 946.  
<https://pubmed.ncbi.nlm.nih.gov/32748516>
223. Kurobe, M., *et al.* The outcomes of conservative management and the natural history of asymptomatic hydroceles in children. *Pediatr Surg Int*, 2020. 36: 1189.  
<https://pubmed.ncbi.nlm.nih.gov/32700002>
224. Christensen, T., *et al.* New onset of hydroceles in boys over 1 year of age. *Int J Urol*, 2006. 13: 1425.  
<https://pubmed.ncbi.nlm.nih.gov/17083397>
225. Khorasani, M., *et al.* The treatment of abdominoscrotal hydrocele: Is there a role for nonoperative management? *J Pediatr Surg*, 2016. 51: 815.  
<https://pubmed.ncbi.nlm.nih.gov/27261560>
226. Stylianos, S., *et al.* Incarceration of inguinal hernia in infants prior to elective repair. *J Pediatr Surg*, 1993. 28: 582.  
<https://pubmed.ncbi.nlm.nih.gov/8483072>
227. Alp, B.F., *et al.* Comparison of the inguinal and scrotal approaches for the treatment of communicating hydrocele in children. *Kaohsiung J Med Sci*, 2014. 30: 200.  
<https://pubmed.ncbi.nlm.nih.gov/24656161>
228. Oh, J.H., *et al.* Hydrocelectomy via scrotal incision is a valuable alternative to the traditional inguinal approach for hydrocele treatment in boys. *Investig Clin Urol*, 2018. 59: 416.  
<https://pubmed.ncbi.nlm.nih.gov/30402575>
229. Grimsby, G.M., *et al.* Non-absorbable sutures are associated with lower recurrence rates in laparoscopic percutaneous inguinal hernia ligation. *J Pediatr Urol*, 2015. 11: 275 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26233553>
230. Saka, R., *et al.* Safety and efficacy of laparoscopic percutaneous extraperitoneal closure for inguinal hernias and hydroceles in children: a comparison with traditional open repair. *J Laparoendosc Adv Surg Tech A*, 2014. 24: 55.  
<https://pubmed.ncbi.nlm.nih.gov/24180356>
231. Muensterer, O.J., *et al.* Contralateral processus closure to prevent metachronous inguinal hernia: A systematic review. *Int J Surg*, 2019. 68: 11.  
<https://pubmed.ncbi.nlm.nih.gov/31185313>
232. Cavusoglu, Y.H., *et al.* Acute scrotum – etiology and management. *Indian J Pediatr*, 2005. 72: 201.  
<https://pubmed.ncbi.nlm.nih.gov/15812112>
233. Klin, B., *et al.* Epididymitis in childhood: a clinical retrospective study over 5 years. *Isr Med Assoc J*, 2001. 3: 833.  
<https://pubmed.ncbi.nlm.nih.gov/11729579>
234. Makela, E., *et al.* A 19-year review of paediatric patients with acute scrotum. *Scand J Surg*, 2007. 96: 62.  
<https://pubmed.ncbi.nlm.nih.gov/17461315>
235. McAndrew, H.F., *et al.* The incidence and investigation of acute scrotal problems in children. *Pediatr Surg Int*, 2002. 18: 435.  
<https://pubmed.ncbi.nlm.nih.gov/12415374>
236. Sakellaris, G.S., *et al.* Acute epididymitis in Greek children: a 3-year retrospective study. *Eur J Pediatr*, 2008. 167: 765.  
<https://pubmed.ncbi.nlm.nih.gov/17786475>
237. Varga, J., *et al.* Acute scrotal pain in children—ten years' experience. *Urol Int*, 2007. 78: 73.  
<https://pubmed.ncbi.nlm.nih.gov/17192737>
238. Bingol-Kologlu, M., *et al.* An exceptional complication following appendectomy: acute inguinal and scrotal suppuration. *Int Urol Nephrol*, 2006. 38: 663.  
<https://pubmed.ncbi.nlm.nih.gov/17160451>
239. Dayanir, Y.O., *et al.* Epididymoorchitis mimicking testicular torsion in Henoch-Schonlein purpura. *Eur Radiol*, 2001. 11: 2267.  
<https://pubmed.ncbi.nlm.nih.gov/11702171>
240. Diamond, D.A., *et al.* Neonatal scrotal haematoma: mimicker of neonatal testicular torsion. *BJU Int*, 2003. 91: 675.  
<https://pubmed.ncbi.nlm.nih.gov/12699483>
241. Ha, T.S., *et al.* Scrotal involvement in childhood Henoch-Schonlein purpura. *Acta Paediatr*, 2007. 96: 552.  
<https://pubmed.ncbi.nlm.nih.gov/17306010>
242. Hara, Y., *et al.* Acute scrotum caused by Henoch-Schonlein purpura. *Int J Urol*, 2004. 11: 578.  
<https://pubmed.ncbi.nlm.nih.gov/15242376>

243. Klin, B., *et al.* Acute idiopathic scrotal edema in children--revisited. *J Pediatr Surg*, 2002. 37: 1200.  
<https://pubmed.ncbi.nlm.nih.gov/12149702>
244. Krause, W. Is acute idiopathic scrotal edema in children a special feature of neutrophilic eccrine hidradenitis? *Dermatology*, 2004. 208: 86; author reply 86.  
<https://pubmed.ncbi.nlm.nih.gov/14730248>
245. Matsumoto, A., *et al.* Torsion of the hernia sac within a hydrocele of the scrotum in a child. *Int J Urol*, 2004. 11: 789.  
<https://pubmed.ncbi.nlm.nih.gov/15379947>
246. Myers, J.B., *et al.* Torsion of an indirect hernia sac causing acute scrotum. *J Pediatr Surg*, 2004. 39: 122.  
<https://pubmed.ncbi.nlm.nih.gov/14694389>
247. Ng, K.H., *et al.* An unusual presentation of acute scrotum after appendicitis. *Singapore Med J*, 2002. 43: 365.  
<https://pubmed.ncbi.nlm.nih.gov/12437045>
248. Singh, S., *et al.* Acute scrotum in children: a rare presentation of acute, non-perforated appendicitis. *Pediatr Surg Int*, 2003. 19: 298.  
<https://pubmed.ncbi.nlm.nih.gov/12682749>
249. van Langen, A.M., *et al.* Acute idiopathic scrotal oedema: four cases and a short review. *Eur J Pediatr*, 2001. 160: 455.  
<https://pubmed.ncbi.nlm.nih.gov/11475590>
250. Vlazakis, S., *et al.* Right acute hemiscrotum caused by insertion of an inflamed appendix. *BJU Int*, 2002. 89: 967.  
<https://pubmed.ncbi.nlm.nih.gov/12010250>
251. D'Andrea, A., *et al.* US in the assessment of acute scrotum. *Crit Ultrasound J*, 2013. 5 Suppl 1: S8.  
<https://pubmed.ncbi.nlm.nih.gov/23902859>
252. Davis, J.E., *et al.* Scrotal emergencies. *Emerg Med Clin North Am*, 2011. 29: 469.  
<https://pubmed.ncbi.nlm.nih.gov/21782069>
253. Jimoh, B.M., *et al.* Idiopathic scrotal hematoma in neonate: a case report and review of the literature. *Case Rep Urol*, 2014. 2014: 212914.  
<https://pubmed.ncbi.nlm.nih.gov/24982811>
254. Matzek, B.A., *et al.* Traumatic testicular dislocation after minor trauma in a pediatric patient. *J Emerg Med*, 2013. 45: 537.  
<https://pubmed.ncbi.nlm.nih.gov/23899815>
255. Wright, S., *et al.* Emergency ultrasound of acute scrotal pain. *Eur J Emerg Med*, 2015. 22: 2.  
<https://pubmed.ncbi.nlm.nih.gov/24910960>
256. Yusuf, G.T., *et al.* A review of ultrasound imaging in scrotal emergencies. *J Ultrasound*, 2013. 16: 171.  
<https://pubmed.ncbi.nlm.nih.gov/24432171>
257. Remer, E.M., *et al.* ACR Appropriateness Criteria (R) acute onset of scrotal pain--without trauma, without antecedent mass. *Ultrasound Q*, 2012. 28: 47.  
<https://pubmed.ncbi.nlm.nih.gov/22357246>
258. Tanaka, K., *et al.* Acute scrotum and testicular torsion in children: a retrospective study in a single institution. *J Pediatr Urol*, 2020. 16: 55.  
<https://pubmed.ncbi.nlm.nih.gov/31874735>
259. Kadish, H.A., *et al.* A retrospective review of pediatric patients with epididymitis, testicular torsion, and torsion of testicular appendages. *Pediatrics*, 1998. 102: 73.  
<https://pubmed.ncbi.nlm.nih.gov/9651416>
260. Sauvat, F., *et al.* [Age for testicular torsion?]. *Arch Pediatr*, 2002. 9: 1226.  
<https://pubmed.ncbi.nlm.nih.gov/12536102>
261. Somekh, E., *et al.* Acute epididymitis in boys: evidence of a post-infectious etiology. *J Urol*, 2004. 171: 391.  
<https://pubmed.ncbi.nlm.nih.gov/14665940>
262. Yerkes, E.B., *et al.* Management of perinatal torsion: today, tomorrow or never? *J Urol*, 2005. 174: 1579.  
<https://pubmed.ncbi.nlm.nih.gov/16148656>
263. Boettcher, M., *et al.* Clinical and sonographic features predict testicular torsion in children: a prospective study. *BJU Int*, 2013. 112: 1201.  
<https://pubmed.ncbi.nlm.nih.gov/23826981>
264. Nelson, C.P., *et al.* The cremasteric reflex: a useful but imperfect sign in testicular torsion. *J Pediatr Surg*, 2003. 38: 1248.  
<https://pubmed.ncbi.nlm.nih.gov/12891505>

265. Goetz, J., *et al.* A comparison of clinical outcomes of acute testicular torsion between prepubertal and postpubertal males. *J Pediatr Urol*, 2019. 15: 610.  
<https://pubmed.ncbi.nlm.nih.gov/31690483>
266. Mushtaq, I., *et al.* Retrospective review of paediatric patients with acute scrotum. *ANZ J Surg*, 2003. 73: 55.  
<https://pubmed.ncbi.nlm.nih.gov/12534742>
267. Murphy, F.L., *et al.* Early scrotal exploration in all cases is the investigation and intervention of choice in the acute paediatric scrotum. *Pediatr Surg Int*, 2006. 22: 413.  
<https://pubmed.ncbi.nlm.nih.gov/16602024>
268. Baker, L.A., *et al.* An analysis of clinical outcomes using color doppler testicular ultrasound for testicular torsion. *Pediatrics*, 2000. 105: 604.  
<https://pubmed.ncbi.nlm.nih.gov/10699116>
269. Gunther, P., *et al.* Acute testicular torsion in children: the role of sonography in the diagnostic workup. *Eur Radiol*, 2006. 16: 2527.  
<https://pubmed.ncbi.nlm.nih.gov/16724203>
270. Kalfa, N., *et al.* Multicenter assessment of ultrasound of the spermatic cord in children with acute scrotum. *J Urol*, 2007. 177: 297.  
<https://pubmed.ncbi.nlm.nih.gov/17162068>
271. Karmazyn, B., *et al.* Clinical and sonographic criteria of acute scrotum in children: a retrospective study of 172 boys. *Pediatr Radiol*, 2005. 35: 302.  
<https://pubmed.ncbi.nlm.nih.gov/15503003>
272. Lam, W.W., *et al.* Colour Doppler ultrasonography replacing surgical exploration for acute scrotum: myth or reality? *Pediatr Radiol*, 2005. 35: 597.  
<https://pubmed.ncbi.nlm.nih.gov/15761770>
273. Schalamon, J., *et al.* Management of acute scrotum in children—the impact of Doppler ultrasound. *J Pediatr Surg*, 2006. 41: 1377.  
<https://pubmed.ncbi.nlm.nih.gov/16863840>
274. Pepe, P., *et al.* Does color Doppler sonography improve the clinical assessment of patients with acute scrotum? *Eur J Radiol*, 2006. 60: 120.  
<https://pubmed.ncbi.nlm.nih.gov/16730939>
275. Kalfa, N., *et al.* Ultrasonography of the spermatic cord in children with testicular torsion: impact on the surgical strategy. *J Urol*, 2004. 172: 1692.  
<https://pubmed.ncbi.nlm.nih.gov/15371792>
276. McDowall, J., *et al.* The ultrasonographic “whirlpool sign” in testicular torsion: valuable tool or waste of valuable time? A systematic review and meta-analysis. *Emerg Radiol*, 2018. 25: 281.  
<https://pubmed.ncbi.nlm.nih.gov/29335899>
277. Nussbaum Blask, A.R., *et al.* Color Doppler sonography and scintigraphy of the testis: a prospective, comparative analysis in children with acute scrotal pain. *Pediatr Emerg Care*, 2002. 18: 67.  
<https://pubmed.ncbi.nlm.nih.gov/11973493>
278. Paltiel, H.J., *et al.* Acute scrotal symptoms in boys with an indeterminate clinical presentation: comparison of color Doppler sonography and scintigraphy. *Radiology*, 1998. 207: 223.  
<https://pubmed.ncbi.nlm.nih.gov/9530319>
279. Terai, A., *et al.* Dynamic contrast-enhanced subtraction magnetic resonance imaging in diagnostics of testicular torsion. *Urology*, 2006. 67: 1278.  
<https://pubmed.ncbi.nlm.nih.gov/16765192>
280. Yuan, Z., *et al.* Clinical study of scrotum scintigraphy in 49 patients with acute scrotal pain: a comparison with ultrasonography. *Ann Nucl Med*, 2001. 15: 225.  
<https://pubmed.ncbi.nlm.nih.gov/11545192>
281. Karmazyn, B., *et al.* Duplex sonographic findings in children with torsion of the testicular appendages: overlap with epididymitis and epididymoorchitis. *J Pediatr Surg*, 2006. 41: 500.  
<https://pubmed.ncbi.nlm.nih.gov/16516624>
282. Lau, P., *et al.* Acute epididymitis in boys: are antibiotics indicated? *Br J Urol*, 1997. 79: 797.  
<https://pubmed.ncbi.nlm.nih.gov/9158522>
283. Abul, F., *et al.* The acute scrotum: a review of 40 cases. *Med Princ Pract*, 2005. 14: 177.  
<https://pubmed.ncbi.nlm.nih.gov/15863992>
284. Dias Filho, A.C., *et al.* Improving Organ Salvage in Testicular Torsion: Comparative Study of Patients Undergoing vs Not Undergoing Preoperative Manual Detorsion. *J Urol*, 2017. 197: 811.  
<https://pubmed.ncbi.nlm.nih.gov/27697579>
285. Cornel, E.B., *et al.* Manual derotation of the twisted spermatic cord. *BJU Int*, 1999. 83: 672.  
<https://pubmed.ncbi.nlm.nih.gov/10233577>

286. Garel, L., *et al.* Preoperative manual detorsion of the spermatic cord with Doppler ultrasound monitoring in patients with intravaginal acute testicular torsion. *Pediatr Radiol*, 2000. 30: 41.  
<https://pubmed.ncbi.nlm.nih.gov/10663509>
287. Sessions, A.E., *et al.* Testicular torsion: direction, degree, duration and disinformation. *J Urol*, 2003. 169: 663.  
<https://pubmed.ncbi.nlm.nih.gov/12544339>
288. Haj, M., *et al.* Effect of external scrotal cooling on the viability of the testis with torsion in rats. *Eur Surg Res*, 2007. 39: 160.  
<https://pubmed.ncbi.nlm.nih.gov/17341878>
289. Akcora, B., *et al.* The protective effect of darbepoetin alfa on experimental testicular torsion and detorsion injury. *Int J Urol*, 2007. 14: 846.  
<https://pubmed.ncbi.nlm.nih.gov/17760753>
290. Aksoy, H., *et al.* Dehydroepiandrosterone treatment attenuates reperfusion injury after testicular torsion and detorsion in rats. *J Pediatr Surg*, 2007. 42: 1740.  
<https://pubmed.ncbi.nlm.nih.gov/17923206>
291. Unal, D., *et al.* Protective effects of trimetazidine on testicular ischemia-reperfusion injury in rats. *Urol Int*, 2007. 78: 356.  
<https://pubmed.ncbi.nlm.nih.gov/17495496>
292. Yazihan, N., *et al.* Protective role of erythropoietin during testicular torsion of the rats. *World J Urol*, 2007. 25: 531.  
<https://pubmed.ncbi.nlm.nih.gov/17690891>
293. Koh, Y.H., *et al.* Testicular Appendage Torsion-To Explore the Other Side or Not? *Urology*, 2020. 141: 130.  
<https://pubmed.ncbi.nlm.nih.gov/32283168>
294. Visser, A.J., *et al.* Testicular function after torsion of the spermatic cord. *BJU Int*, 2003. 92: 200.  
<https://pubmed.ncbi.nlm.nih.gov/12887467>
295. Tryfonas, G., *et al.* Late postoperative results in males treated for testicular torsion during childhood. *J Pediatr Surg*, 1994. 29: 553.  
<https://pubmed.ncbi.nlm.nih.gov/8014814>
296. Anderson, M.J., *et al.* Semen quality and endocrine parameters after acute testicular torsion. *J Urol*, 1992. 147: 1545.  
<https://pubmed.ncbi.nlm.nih.gov/1593686>
297. Arap, M.A., *et al.* Late hormonal levels, semen parameters, and presence of antisperm antibodies in patients treated for testicular torsion. *J Androl*, 2007. 28: 528.  
<https://pubmed.ncbi.nlm.nih.gov/17287456>
298. Figueroa, V., *et al.* Comparative analysis of detorsion alone versus detorsion and tunica albuginea decompression (fasciotomy) with tunica vaginalis flap coverage in the surgical management of prolonged testicular ischemia. *J Urol*, 2012. 188: 1417.  
<https://pubmed.ncbi.nlm.nih.gov/22906680>
299. Monteilh, C., *et al.* Controversies in the management of neonatal testicular torsion: A meta-analysis. *J Pediatr Surg*, 2019. 54: 815.  
<https://pubmed.ncbi.nlm.nih.gov/30098810>
300. Mor, Y., *et al.* Testicular fixation following torsion of the spermatic cord—does it guarantee prevention of recurrent torsion events? *J Urol*, 2006. 175: 171.  
<https://pubmed.ncbi.nlm.nih.gov/16406900>
301. Lian, B.S., *et al.* Factors Predicting Testicular Atrophy after Testicular Salvage following Torsion. *Eur J Pediatr Surg*, 2016. 26: 17.  
<https://pubmed.ncbi.nlm.nih.gov/26509312>
302. MacDonald, C., *et al.* A systematic review and meta-analysis revealing realistic outcomes following paediatric torsion of testes. *J Pediatr Urol*, 2018. 14: 503.  
<https://pubmed.ncbi.nlm.nih.gov/30404723>
303. Philip, J., *et al.* Mumps orchitis in the non-immune postpubertal male: a resurgent threat to male fertility? *BJU Int*, 2006. 97: 138.  
<https://pubmed.ncbi.nlm.nih.gov/16336344>
304. Gielchinsky, I., *et al.* Pregnancy Rates after Testicular Torsion. *J Urol*, 2016. 196: 852.  
<https://pubmed.ncbi.nlm.nih.gov/27117442>
305. Bergman, J.E., *et al.* Epidemiology of hypospadias in Europe: a registry-based study. *World J Urol*, 2015. 33: 2159.  
<https://pubmed.ncbi.nlm.nih.gov/25712311>



306. Morera, A.M., *et al.* A study of risk factors for hypospadias in the Rhone-Alpes region (France). *J Pediatr Urol*, 2006. 2: 169.  
<https://pubmed.ncbi.nlm.nih.gov/18947603>
307. Springer, A., *et al.* Worldwide prevalence of hypospadias. *J Pediatr Urol*, 2016. 12: 152 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26810252>
308. van der Zanden, L.F., *et al.* Exploration of gene-environment interactions, maternal effects and parent of origin effects in the etiology of hypospadias. *J Urol*, 2012. 188: 2354.  
<https://pubmed.ncbi.nlm.nih.gov/23088992>
309. Fredell, L., *et al.* Heredity of hypospadias and the significance of low birth weight. *J Urol*, 2002. 167: 1423.  
<https://pubmed.ncbi.nlm.nih.gov/11832761>
310. Lund, L., *et al.* Prevalence of hypospadias in Danish boys: a longitudinal study, 1977-2005. *Eur Urol*, 2009. 55: 1022.  
<https://pubmed.ncbi.nlm.nih.gov/19155122>
311. Mouriquand, O.D., *et al.*, Hypospadias., in *Pediatric Urology*, J. Gearhart, R. Rink & P.D.E. Mouriquand, Editors. 2001, WB Saunders: Philadelphia.
312. van Rooij, I.A., *et al.* Risk factors for different phenotypes of hypospadias: results from a Dutch case-control study. *BJU Int*, 2013. 112: 121.  
<https://pubmed.ncbi.nlm.nih.gov/23305310>
313. Netto, J.M., *et al.* Hormone therapy in hypospadias surgery: a systematic review. *J Pediatr Urol*, 2013. 9: 971.  
<https://pubmed.ncbi.nlm.nih.gov/23602841>
314. Chariatte, V., *et al.* Uroradiological screening for upper and lower urinary tract anomalies in patients with hypospadias: a systematic literature review. *Evid Based Med*, 2013. 18: 11.  
<https://pubmed.ncbi.nlm.nih.gov/22815315>
315. Belman, A.B., Hypospadias and chordee, in *Clinical Pediatric Urology* A.B. Belman, L.R. King & S.A. Kramer, Editors. 2002, Martin Dunitz: London.
316. Malik, R.D., *et al.* Survey of pediatric urologists on the preoperative use of testosterone in the surgical correction of hypospadias. *J Pediatr Urol*, 2014. 10: 840.  
<https://pubmed.ncbi.nlm.nih.gov/24726783>
317. Wright, I., *et al.* Effect of preoperative hormonal stimulation on postoperative complication rates after proximal hypospadias repair: a systematic review. *J Urol*, 2013. 190: 652.  
<https://pubmed.ncbi.nlm.nih.gov/23597451>
318. Rynja, S.P., *et al.* Testosterone prior to hypospadias repair: Postoperative complication rates and long-term cosmetic results, penile length and body height. *J Pediatr Urol*, 2018. 14: 31 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29174377>
319. Paiva, K.C., *et al.* Biometry of the hypospadiac penis after hormone therapy (testosterone and estrogen): A randomized, double-blind controlled trial. *J Pediatr Urol*, 2016. 12: 200 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27321554>
320. Chua, M.E., *et al.* Preoperative hormonal stimulation effect on hypospadias repair complications: Meta-analysis of observational versus randomized controlled studies. *J Pediatr Urol*, 2017. 13: 470.  
<https://pubmed.ncbi.nlm.nih.gov/28939350>
321. Kaya, C., *et al.* The role of pre-operative androgen stimulation in hypospadias surgery. *Transl Androl Urol*, 2014. 3: 340.  
<https://pubmed.ncbi.nlm.nih.gov/26816790>
322. Menon, P., *et al.* Outcome of urethroplasty after parenteral testosterone in children with distal hypospadias. *J Pediatr Urol*, 2017. 13: 292 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28111208>
323. Bush, N.C., *et al.* Age does not impact risk for urethroplasty complications after tubularized incised plate repair of hypospadias in prepubertal boys. *J Pediatr Urol*, 2013. 9: 252.  
<https://pubmed.ncbi.nlm.nih.gov/22542204>
324. Perlmutter, A.E., *et al.* Impact of patient age on distal hypospadias repair: a surgical perspective. *Urology*, 2006. 68: 648.  
<https://pubmed.ncbi.nlm.nih.gov/16979730>
325. Bhat, A., *et al.* Comparison of variables affecting the surgical outcomes of tubularized incised plate urethroplasty in adult and pediatric hypospadias. *J Pediatr Urol*, 2016. 12: 108 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26778183>

326. Castagnetti, M., *et al.* Surgical management of primary severe hypospadias in children: systematic 20-year review. *J Urol*, 2010. 184: 1469.  
<https://pubmed.ncbi.nlm.nih.gov/20727541>
327. Baskin, L.S., *et al.* Changing concepts of hypospadias curvature lead to more onlay island flap procedures. *J Urol*, 1994. 151: 191.  
<https://pubmed.ncbi.nlm.nih.gov/8254812>
328. Hollowell, J.G., *et al.* Preservation of the urethral plate in hypospadias repair: extended applications and further experience with the onlay island flap urethroplasty. *J Urol*, 1990. 143: 98.  
<https://pubmed.ncbi.nlm.nih.gov/2294275>
329. Snodgrass, W., *et al.* Straightening ventral curvature while preserving the urethral plate in proximal hypospadias repair. *J Urol*, 2009. 182: 1720.  
<https://pubmed.ncbi.nlm.nih.gov/19692004>
330. Braga, L.H., *et al.* Ventral penile lengthening versus dorsal plication for severe ventral curvature in children with proximal hypospadias. *J Urol*, 2008. 180: 1743.  
<https://pubmed.ncbi.nlm.nih.gov/18721961>
331. el-Kassaby, A.W., *et al.* Modified tubularized incised plate urethroplasty for hypospadias repair: a long-term results of 764 patients. *Urology*, 2008. 71: 611.  
<https://pubmed.ncbi.nlm.nih.gov/18295308>
332. El-Sherbiny, M.T., *et al.* Comprehensive analysis of tubularized incised-plate urethroplasty in primary and re-operative hypospadias. *BJU Int*, 2004. 93: 1057.  
<https://pubmed.ncbi.nlm.nih.gov/15142164>
333. Orkiszewski, M., *et al.* Morphology and urodynamics after longitudinal urethral plate incision in proximal hypospadias repairs: long-term results. *Eur J Pediatr Surg*, 2004. 14: 35.  
<https://pubmed.ncbi.nlm.nih.gov/15024677>
334. Snodgrass, W.T., *et al.* Tubularized incised plate hypospadias repair for distal hypospadias. *J Pediatr Urol*, 2010. 6: 408.  
<https://pubmed.ncbi.nlm.nih.gov/19837000>
335. Schwentner, C., *et al.* Interim outcome of the single stage dorsal inlay skin graft for complex hypospadias reoperations. *J Urol*, 2006. 175: 1872.  
<https://pubmed.ncbi.nlm.nih.gov/16600785>
336. Ahmed, M., *et al.* Is combined inner preputial inlay graft with tubularized incised plate in hypospadias repair worth doing? *J Pediatr Urol*, 2015. 11: 229 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26119452>
337. Pippi Salle, J.L., *et al.* Proximal hypospadias: A persistent challenge. Single institution outcome analysis of three surgical techniques over a 10-year period. *J Pediatr Urol*, 2016. 12: 28 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26279102>
338. Meyer-Junghanel, L., *et al.* Experience with repair of 120 hypospadias using Mathieu's procedure. *Eur J Pediatr Surg*, 1995. 5: 355.  
<https://pubmed.ncbi.nlm.nih.gov/8773227>
339. Pfistermuller, K.L., *et al.* Meta-analysis of complication rates of the tubularized incised plate (TIP) repair. *J Pediatr Urol*, 2015. 11: 54.  
<https://pubmed.ncbi.nlm.nih.gov/25819601>
340. Snodgrass, W.T., *et al.* Urethral strictures following urethral plate and proximal urethral elevation during proximal TIP hypospadias repair. *J Pediatr Urol*, 2013. 9: 990.  
<https://pubmed.ncbi.nlm.nih.gov/23707201>
341. Cambareri, G.M., *et al.* Hypospadias repair with onlay preputial graft: a 25-year experience with long-term follow-up. *BJU Int*, 2016. 118: 451.  
<https://pubmed.ncbi.nlm.nih.gov/26780179>
342. Castagnetti, M., *et al.* Primary severe hypospadias: comparison of reoperation rates and parental perception of urinary symptoms and cosmetic outcomes among 4 repairs. *J Urol*, 2013. 189: 1508.  
<https://pubmed.ncbi.nlm.nih.gov/23154207>
343. Kocvara, R., *et al.* Inlay-onlay flap urethroplasty for hypospadias and urethral stricture repair. *J Urol*, 1997. 158: 2142.  
<https://pubmed.ncbi.nlm.nih.gov/9366331>
344. Perovic, S., *et al.* Onlay island flap urethroplasty for severe hypospadias: a variant of the technique. *J Urol*, 1994. 151: 711.  
<https://pubmed.ncbi.nlm.nih.gov/8308994>
345. Catti, M., *et al.* Original Koyanagi urethroplasty versus modified Hayashi technique: outcome in 57 patients. *J Pediatr Urol*, 2009. 5: 300.  
<https://pubmed.ncbi.nlm.nih.gov/19457720>

346. DeFoor, W., *et al.* Results of single staged hypospadias surgery to repair penoscrotal hypospadias with bifid scrotum or penoscrotal transposition. *J Urol*, 2003. 170: 1585.  
<https://pubmed.ncbi.nlm.nih.gov/14501667>
347. Hayashi, Y., *et al.* Neo-modified Koyanagi technique for the single-stage repair of proximal hypospadias. *J Pediatr Urol*, 2007. 3: 239.  
<https://pubmed.ncbi.nlm.nih.gov/18947743>
348. Koyanagi, T., *et al.* One-stage repair of hypospadias: is there no simple method universally applicable to all types of hypospadias? *J Urol*, 1994. 152: 1232.  
<https://pubmed.ncbi.nlm.nih.gov/8072111>
349. Ahmed, S., *et al.* Buccal mucosal graft for secondary hypospadias repair and urethral replacement. *Br J Urol*, 1997. 80: 328.  
<https://pubmed.ncbi.nlm.nih.gov/9284210>
350. Bracka, A. Hypospadias repair: the two-stage alternative. *Br J Urol*, 1995. 76 Suppl 3: 31.  
<https://pubmed.ncbi.nlm.nih.gov/8535768>
351. Lam, P.N., *et al.* 2-stage repair in infancy for severe hypospadias with chordee: long-term results after puberty. *J Urol*, 2005. 174: 1567.  
<https://pubmed.ncbi.nlm.nih.gov/16148653>
352. Mokhless, I.A., *et al.* The multistage use of buccal mucosa grafts for complex hypospadias: histological changes. *J Urol*, 2007. 177: 1496.  
<https://pubmed.ncbi.nlm.nih.gov/17382762>
353. Stanasel, I., *et al.* Complications following Staged Hypospadias Repair Using Transposed Preputial Skin Flaps. *J Urol*, 2015. 194: 512.  
<https://pubmed.ncbi.nlm.nih.gov/25701546>
354. Castagnetti, M., *et al.* Does Preputial Reconstruction Increase Complication Rate of Hypospadias Repair? 20-Year Systematic Review and Meta-Analysis. *Front Pediatr*, 2016. 4: 41.  
<https://pubmed.ncbi.nlm.nih.gov/27200322>
355. Chalmers, D.J., *et al.* Distal hypospadias repair in infants without a postoperative stent. *Pediatr Surg Int*, 2015. 31: 287.  
<https://pubmed.ncbi.nlm.nih.gov/25475503>
356. Hsieh, M.H., *et al.* Surgical antibiotic practices among pediatric urologists in the United States. *J Pediatr Urol*, 2011. 7: 192.  
<https://pubmed.ncbi.nlm.nih.gov/20537590>
357. Kanaroglou, N., *et al.* Is there a role for prophylactic antibiotics after stented hypospadias repair? *J Urol*, 2013. 190: 1535.  
<https://pubmed.ncbi.nlm.nih.gov/23416639>
358. Meir, D.B., *et al.* Is prophylactic antimicrobial treatment necessary after hypospadias repair? *J Urol*, 2004. 171: 2621.  
<https://pubmed.ncbi.nlm.nih.gov/15118434>
359. Chua, M.E., *et al.* The use of postoperative prophylactic antibiotics in stented distal hypospadias repair: a systematic review and meta-analysis. *J Pediatr Urol*, 2019. 15: 138.  
<https://pubmed.ncbi.nlm.nih.gov/30527683>
360. Bush, N.C., *et al.* Glans size is an independent risk factor for urethroplasty complications after hypospadias repair. *J Pediatr Urol*, 2015. 11: 355 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26320396>
361. Lee, O.T., *et al.* Predictors of secondary surgery after hypospadias repair: a population based analysis of 5,000 patients. *J Urol*, 2013. 190: 251.  
<https://pubmed.ncbi.nlm.nih.gov/23376710>
362. Braga, L.H., *et al.* Tubularized incised plate urethroplasty for distal hypospadias: A literature review. *Indian J Urol*, 2008. 24: 219.  
<https://pubmed.ncbi.nlm.nih.gov/19468401>
363. Wang, F., *et al.* Systematic review and meta-analysis of studies comparing the perimeatal-based flap and tubularized incised-plate techniques for primary hypospadias repair. *Pediatr Surg Int*, 2013. 29: 811.  
<https://pubmed.ncbi.nlm.nih.gov/23793987>
364. Wilkinson, D.J., *et al.* Outcomes in distal hypospadias: a systematic review of the Mathieu and tubularized incised plate repairs. *J Pediatr Urol*, 2012. 8: 307.  
<https://pubmed.ncbi.nlm.nih.gov/21159560>
365. Winberg, H., *et al.* Postoperative outcomes in distal hypospadias: a meta-analysis of the Mathieu and tubularized incised plate repair methods for development of urethrocutaneous fistula and urethral stricture. *Pediatr Surg Int*, 2019. 35: 1301.  
<https://pubmed.ncbi.nlm.nih.gov/31372729>

366. Alshafei, A., *et al.* Comparing the outcomes of tubularized incised plate urethroplasty and dorsal inlay graft urethroplasty in children with hypospadias: a systematic review and meta-analysis. *J Pediatr Urol*, 2020. 16: 154.  
<https://pubmed.ncbi.nlm.nih.gov/32061491>
367. Leslie, B., *et al.* Critical outcome analysis of staged buccal mucosa graft urethroplasty for prior failed hypospadias repair in children. *J Urol*, 2011. 185: 1077.  
<https://pubmed.ncbi.nlm.nih.gov/21256520>
368. Howe, A.S., *et al.* Management of 220 adolescents and adults with complications of hypospadias repair during childhood. *Asian J Urol*, 2017. 4: 14.  
<https://pubmed.ncbi.nlm.nih.gov/29264201>
369. Spinoit, A.F., *et al.* Hypospadias repair at a tertiary care center: long-term followup is mandatory to determine the real complication rate. *J Urol*, 2013. 189: 2276.  
<https://pubmed.ncbi.nlm.nih.gov/23306089>
370. Andersson, M., *et al.* Hypospadias repair with tubularized incised plate: Does the obstructive flow pattern resolve spontaneously? *J Pediatr Urol*, 2011. 7: 441.  
<https://pubmed.ncbi.nlm.nih.gov/20630805>
371. Andersson, M., *et al.* Normalized Urinary Flow at Puberty after Tubularized Incised Plate Urethroplasty for Hypospadias in Childhood. *J Urol*, 2015. 194: 1407.  
<https://pubmed.ncbi.nlm.nih.gov/26087380>
372. Gonzalez, R., *et al.* Importance of urinary flow studies after hypospadias repair: a systematic review. *Int J Urol*, 2011. 18: 757.  
<https://pubmed.ncbi.nlm.nih.gov/21883491>
373. Hueber, P.A., *et al.* Long-term functional outcomes of distal hypospadias repair: a single center retrospective comparative study of TIPs, Mathieu and MAGPI. *J Pediatr Urol*, 2015. 11: 68 e1.  
<https://pubmed.ncbi.nlm.nih.gov/25824882>
374. Perera, M., *et al.* Long-term urethral function measured by uroflowmetry after hypospadias surgery: comparison with an age matched control. *J Urol*, 2012. 188: 1457.  
<https://pubmed.ncbi.nlm.nih.gov/22906660>
375. Holland, A.J., *et al.* HOSE: an objective scoring system for evaluating the results of hypospadias surgery. *BJU Int*, 2001. 88: 255.  
<https://pubmed.ncbi.nlm.nih.gov/11488741>
376. van der Toorn, F., *et al.* Introducing the HOPE (Hypospadias Objective Penile Evaluation)-score: a validation study of an objective scoring system for evaluating cosmetic appearance in hypospadias patients. *J Pediatr Urol*, 2013. 9: 1006.  
<https://pubmed.ncbi.nlm.nih.gov/23491983>
377. Weber, D.M., *et al.* The Penile Perception Score: an instrument enabling evaluation by surgeons and patient self-assessment after hypospadias repair. *J Urol*, 2013. 189: 189.  
<https://pubmed.ncbi.nlm.nih.gov/23174225>
378. Haid, B., *et al.* Penile appearance after hypospadias correction from a parent's point of view: Comparison of the hypospadias objective penile evaluation score and parents penile perception score. *J Pediatr Urol*, 2016. 12: 33 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26725130>
379. Krull, S., *et al.* Outcome after Hypospadias Repair: Evaluation Using the Hypospadias Objective Penile Evaluation Score. *Eur J Pediatr Surg*, 2018. 28: 268.  
<https://pubmed.ncbi.nlm.nih.gov/28505692>
380. Moriya, K., *et al.* Long-term cosmetic and sexual outcome of hypospadias surgery: norm related study in adolescence. *J Urol*, 2006. 176: 1889.  
<https://pubmed.ncbi.nlm.nih.gov/16945681>
381. Rynja, S.P., *et al.* Functional, cosmetic and psychosexual results in adult men who underwent hypospadias correction in childhood. *J Pediatr Urol*, 2011. 7: 504.  
<https://pubmed.ncbi.nlm.nih.gov/21429804>
382. Ortqvist, L., *et al.* Long-term followup of men born with hypospadias: urological and cosmetic results. *J Urol*, 2015. 193: 975.  
<https://pubmed.ncbi.nlm.nih.gov/25268894>
383. Adams, J., *et al.* Reconstructive surgery for hypospadias: A systematic review of long-term patient satisfaction with cosmetic outcomes. *Indian J Urol*, 2016. 32: 93.  
<https://pubmed.ncbi.nlm.nih.gov/27127350>
384. Leunbach, T.L., *et al.* A Systematic Review of Core Outcomes for Hypospadias Surgery. *Sex Dev*, 2019. 13: 165.  
<https://pubmed.ncbi.nlm.nih.gov/31865321>

385. Sullivan, K.J., *et al.* Assessing quality of life of patients with hypospadias: A systematic review of validated patient-reported outcome instruments. *J Pediatr Urol*, 2017. 13: 19.  
<https://pubmed.ncbi.nlm.nih.gov/28089292>
386. Nyirady, P., *et al.* Management of congenital penile curvature. *J Urol*, 2008. 179: 1495.  
<https://pubmed.ncbi.nlm.nih.gov/18295273>
387. Baskin, L.S., *et al.* Neuroanatomical ontogeny of the human fetal penis. *Br J Urol*, 1997. 79: 628.  
<https://pubmed.ncbi.nlm.nih.gov/9126098>
388. Ebbehoj, J., *et al.* Congenital penile angulation. *Br J Urol*, 1987. 60: 264.  
<https://pubmed.ncbi.nlm.nih.gov/3676675>
389. Kelami, A. Congenital penile deviation and its treatment with the Nesbit-Kelami technique. *Br J Urol*, 1987. 60: 261.  
<https://pubmed.ncbi.nlm.nih.gov/3676674>
390. Yachia, D., *et al.* The incidence of congenital penile curvature. *J Urol*, 1993. 150: 1478.  
<https://pubmed.ncbi.nlm.nih.gov/8411431>
391. Mayer, M., *et al.* Patient satisfaction with correction of congenital penile curvature. *Actas Urol Esp (Engl Ed)*, 2018. 42: 414.  
<https://pubmed.ncbi.nlm.nih.gov/29292041>
392. Hsieh, J.T., *et al.* Correction of congenital penile curvature using modified tunical plication with absorbable sutures: the long-term outcome and patient satisfaction. *Eur Urol*, 2007. 52: 261.  
<https://pubmed.ncbi.nlm.nih.gov/17234333>
393. Sasso, F., *et al.* Penile curvature: an update for management from 20 years experience in a high volume centre. *Urologia*, 2016. 83: 130.  
<https://pubmed.ncbi.nlm.nih.gov/27103093>
394. Gittes, R.F., *et al.* Injection technique to induce penile erection. *Urology*, 1974. 4: 473.  
<https://pubmed.ncbi.nlm.nih.gov/4418594>
395. Schultheiss, D., *et al.* Congenital and acquired penile deviation treated with the essed plication method. *Eur Urol*, 2000. 38: 167.  
<https://pubmed.ncbi.nlm.nih.gov/10895008>
396. Yachia, D. Modified corporoplasty for the treatment of penile curvature. *J Urol*, 1990. 143: 80.  
<https://pubmed.ncbi.nlm.nih.gov/2294269>
397. Rehman, J., *et al.* Results of surgical treatment for abnormal penile curvature: Peyronie's disease and congenital deviation by modified Nesbit plication (tunica shaving and plication). *J Urol*, 1997. 157: 1288.  
<https://pubmed.ncbi.nlm.nih.gov/9120923>
398. Poulsen, J., *et al.* Treatment of penile curvature—a retrospective study of 175 patients operated with plication of the tunica albuginea or with the Nesbit procedure. *Br J Urol*, 1995. 75: 370.  
<https://pubmed.ncbi.nlm.nih.gov/7735803>
399. Leonardo, C., *et al.* Plication corporoplasty versus Nesbit operation for the correction of congenital penile curvature. A long-term follow-up. *Int Urol Nephrol*, 2012. 44: 55.  
<https://pubmed.ncbi.nlm.nih.gov/21559790>
400. Cayan, S., *et al.* Comparison of Patient's Satisfaction and Long-term Results of 2 Penile Plication Techniques: Lessons Learned From 387 Patients With Penile Curvature. *Urology*, 2019. 129: 106.  
<https://pubmed.ncbi.nlm.nih.gov/30954611>
401. Cavallini, G., *et al.* Pilot study to determine improvements in subjective penile morphology and personal relationships following a Nesbit plication procedure for men with congenital penile curvature. *Asian J Androl*, 2008. 10: 512.  
<https://pubmed.ncbi.nlm.nih.gov/18097530>
402. Vatne, V., *et al.* Functional results after operations of penile deviations: an institutional experience. *Scand J Urol Nephrol Suppl*, 1996. 179: 151.  
<https://pubmed.ncbi.nlm.nih.gov/8908683>
403. Ziegelmann, M.J., *et al.* Clinical characteristics and surgical outcomes in men undergoing tunica albuginea plication for congenital penile curvature who present with worsening penile deformity. *World J Urol*, 2020. 38: 305.  
<https://pubmed.ncbi.nlm.nih.gov/31079186>
404. Shaer, O., *et al.* Shaer's Corporal Rotation III: Shortening-Free Correction of Congenital Penile Curvature-The Noncorporotomy Technique. *Eur Urol*, 2016. 69: 129.  
<https://pubmed.ncbi.nlm.nih.gov/26298209>
405. Akbay, E., *et al.* The prevalence of varicocele and varicocele-related testicular atrophy in Turkish children and adolescents. *BJU Int*, 2000. 86: 490.  
<https://pubmed.ncbi.nlm.nih.gov/10971279>

406. Kogan, S.J., The pediatric varicocele. , in Pediatric urology, J.P. Gearhart, R.C. Rink & P.D.E. Mouriquand, Editors. 2001, WB Saunders: Philadelphia.
407. Oster, J. Varicocele in children and adolescents. An investigation of the incidence among Danish school children. *Scand J Urol Nephrol*, 1971. 5: 27.  
<https://pubmed.ncbi.nlm.nih.gov/5093090>
408. Santana, V.P., *et al.* Genetics and epigenetics of varicocele pathophysiology: an overview. *J Assist Reprod Genet*, 2017. 34: 839.  
<https://pubmed.ncbi.nlm.nih.gov/28523408>
409. Griffiths, L., *et al.* The role of inheritance in the development of adolescent varicoceles. *Transl Androl Urol*, 2018. 7: 920.  
<https://pubmed.ncbi.nlm.nih.gov/30505728>
410. Belardin, L.B., *et al.* Alterations in the proliferative/apoptotic equilibrium in semen of adolescents with varicocele. *J Assist Reprod Genet*, 2016. 33: 1657.  
<https://pubmed.ncbi.nlm.nih.gov/27629121>
411. Barradas, V., *et al.* Evaluation of oxidative stress in seminal plasma of adolescents with varicocele. *Reprod Fertil*, 2021. 2: 141.  
<https://pubmed.ncbi.nlm.nih.gov/35128449>
412. Damsgaard, J., *et al.* Varicocele Is Associated with Impaired Semen Quality and Reproductive Hormone Levels: A Study of 7035 Healthy Young Men from Six European Countries. *Eur Urol*, 2016. 70: 1019.  
<https://pubmed.ncbi.nlm.nih.gov/27423503>
413. Zampieri, N. Hormonal evaluation in adolescents with varicocele. *J Pediatr Urol*, 2021. 17: 49 e1.  
<https://pubmed.ncbi.nlm.nih.gov/33281047>
414. Van Batavia, J.P., *et al.* Total Motile Sperm Count in Adolescent Boys with Varicocele is Associated with Hormone Levels and Total Testicular Volume. *J Urol*, 2021. 205: 888.  
<https://pubmed.ncbi.nlm.nih.gov/33026928>
415. The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. *World Health Organization. Fertil Steril*, 1992. 57: 1289.  
<https://pubmed.ncbi.nlm.nih.gov/1601152>
416. Dubin, L., *et al.* Varicocele size and results of varicocelectomy in selected subfertile men with varicocele. *Fertil Steril*, 1970. 21: 606.  
<https://pubmed.ncbi.nlm.nih.gov/5433164>
417. Diamond, D.A., *et al.* Relationship of varicocele grade and testicular hypotrophy to semen parameters in adolescents. *J Urol*, 2007. 178: 1584.  
<https://pubmed.ncbi.nlm.nih.gov/17707046>
418. Tasci, A.I., *et al.* Color doppler ultrasonography and spectral analysis of venous flow in diagnosis of varicocele. *Eur Urol*, 2001. 39: 316.  
<https://pubmed.ncbi.nlm.nih.gov/11275726>
419. Chu, D.I., *et al.* The natural history of semen parameters in untreated asymptomatic adolescent varicocele patients: A retrospective cohort study. *J Pediatr Urol*, 2017. 13: 77 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27815047>
420. Fine, R.G., *et al.* Barriers to use of semen analysis in the adolescent with a varicocele: Survey of patient, parental, and practitioner attitudes. *J Pediatr Urol*, 2016. 12: 41 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26342542>
421. Okuyama, A., *et al.* Surgical repair of varicocele at puberty: preventive treatment for fertility improvement. *J Urol*, 1988. 139: 562.  
<https://pubmed.ncbi.nlm.nih.gov/3343743>
422. Aragona, F., *et al.* Correlation of testicular volume, histology and LHRH test in adolescents with idiopathic varicocele. *Eur Urol*, 1994. 26: 61.  
<https://pubmed.ncbi.nlm.nih.gov/7925532>
423. Kurtz, M.P., *et al.* Prepubertal presentation of varicocele does not affect outcomes. *J Pediatr Urol*, 2015. 11: 73 e1.  
<https://pubmed.ncbi.nlm.nih.gov/25837706>
424. Keene, D.J., *et al.* Sperm concentration and forward motility are not correlated with age in adolescents with an idiopathic varicocele and symmetrical testicular volumes. *J Pediatr Surg*, 2016. 51: 293.  
<https://pubmed.ncbi.nlm.nih.gov/26811206>
425. Zampieri, N., *et al.* Semen analysis in patients treated for varicocele in pediatric age: are surgical outcomes enough to preserve the fertility potential? *Am J Clin Exp Urol*, 2018. 6: 149.  
<https://pubmed.ncbi.nlm.nih.gov/30038947>

426. Patil, N., *et al.* Varicocelectomy in adolescents - Does it safeguard future fertility? A single centre experience. *J Pediatr Urol*, 2022. 18: 5 e1.  
<https://pubmed.ncbi.nlm.nih.gov/34980555>
427. Bogaert, G., *et al.* Pubertal screening and treatment for varicocele do not improve chance of paternity as adult. *J Urol*, 2013. 189: 2298.  
<https://pubmed.ncbi.nlm.nih.gov/23261480>
428. Vagane, D., *et al.* Testicular asymmetry in healthy adolescent boys. *BJU Int*, 2018. 122: 654.  
<https://pubmed.ncbi.nlm.nih.gov/29461677>
429. Abrol, N., *et al.* Painful varicoceles: Role of varicocelectomy. *Indian J Urol*, 2014. 30: 369.  
<https://pubmed.ncbi.nlm.nih.gov/25378815>
430. Goldstein, M., *et al.* Microsurgical inguinal varicocelectomy with delivery of the testis: an artery and lymphatic sparing technique. *J Urol*, 1992. 148: 1808.  
<https://pubmed.ncbi.nlm.nih.gov/1433614>
431. Hopps, C.V., *et al.* Intraoperative varicocele anatomy: a microscopic study of the inguinal versus subinguinal approach. *J Urol*, 2003. 170: 2366.  
<https://pubmed.ncbi.nlm.nih.gov/14634418>
432. Kocvara, R., *et al.* Lymphatic sparing laparoscopic varicocelectomy: a microsurgical repair. *J Urol*, 2005. 173: 1751.  
<https://pubmed.ncbi.nlm.nih.gov/15821575>
433. Riccabona, M., *et al.* Optimizing the operative treatment of boys with varicocele: sequential comparison of 4 techniques. *J Urol*, 2003. 169: 666.  
<https://pubmed.ncbi.nlm.nih.gov/12544340>
434. Fast, A.M., *et al.* Adolescent varicocelectomy: does artery sparing influence recurrence rate and/or catch-up growth? *Andrology*, 2014. 2: 159.  
<https://pubmed.ncbi.nlm.nih.gov/24339439>
435. Kim, K.S., *et al.* Impact of internal spermatic artery preservation during laparoscopic varicocelectomy on recurrence and the catch-up growth rate in adolescents. *J Pediatr Urol*, 2014. 10: 435.  
<https://pubmed.ncbi.nlm.nih.gov/24314819>
436. Kocvara, R., *et al.* Division of lymphatic vessels at varicocelectomy leads to testicular oedema and decline in testicular function according to the LH-RH analogue stimulation test. *Eur Urol*, 2003. 43: 430.  
<https://pubmed.ncbi.nlm.nih.gov/12667726>
437. Marmar, J., *et al.* New scientific information related to varicoceles. *J Urol*, 2003. 170: 2371.  
<https://pubmed.ncbi.nlm.nih.gov/14634419>
438. Minevich, E., *et al.* Inguinal microsurgical varicocelectomy in the adolescent: technique and preliminary results. *J Urol*, 1998. 159: 1022.  
<https://pubmed.ncbi.nlm.nih.gov/9474223>
439. Mirilas, P., *et al.* Microsurgical subinguinal varicocelectomy in children, adolescents, and adults: surgical anatomy and anatomically justified technique. *J Androl*, 2012. 33: 338.  
<https://pubmed.ncbi.nlm.nih.gov/21835913>
440. Oswald, J., *et al.* The use of isosulphan blue to identify lymphatic vessels in high retroperitoneal ligation of adolescent varicocele—avoiding postoperative hydrocele. *BJU Int*, 2001. 87: 502.  
<https://pubmed.ncbi.nlm.nih.gov/11298043>
441. Esposito, C., *et al.* Near-Infrared fluorescence imaging using indocyanine green (ICG): Emerging applications in pediatric urology. *J Pediatr Urol*, 2020. 16: 700.  
<https://pubmed.ncbi.nlm.nih.gov/32747308>
442. Fayad, F., *et al.* Percutaneous retrograde endovascular occlusion for pediatric varicocele. *J Pediatr Surg*, 2011. 46: 525.  
<https://pubmed.ncbi.nlm.nih.gov/21376204>
443. Thon, W.F., *et al.* Percutaneous sclerotherapy of idiopathic varicocele in childhood: a preliminary report. *J Urol*, 1989. 141: 913.  
<https://pubmed.ncbi.nlm.nih.gov/2926889>
444. Kass, E.J., *et al.* Reversal of testicular growth failure by varicocele ligation. *J Urol*, 1987. 137: 475.  
<https://pubmed.ncbi.nlm.nih.gov/3820376>
445. Paduch, D.A., *et al.* Repair versus observation in adolescent varicocele: a prospective study. *J Urol*, 1997. 158: 1128.  
<https://pubmed.ncbi.nlm.nih.gov/9258155>
446. Li, F., *et al.* Effect of varicocelectomy on testicular volume in children and adolescents: a meta-analysis. *Urology*, 2012. 79: 1340.  
<https://pubmed.ncbi.nlm.nih.gov/22516359>

447. Laven, J.S., *et al.* Effects of varicocele treatment in adolescents: a randomized study. *Fertil Steril*, 1992. 58: 756.  
<https://pubmed.ncbi.nlm.nih.gov/1426322>
448. Nork, J.J., *et al.* Youth varicocele and varicocele treatment: a meta-analysis of semen outcomes. *Fertil Steril*, 2014. 102: 381.  
<https://pubmed.ncbi.nlm.nih.gov/24907913>
449. Pinto, K.J., *et al.* Varicocele related testicular atrophy and its predictive effect upon fertility. *J Urol*, 1994. 152: 788.  
<https://pubmed.ncbi.nlm.nih.gov/8022015>
450. Locke, J.A., *et al.* Treatment of varicocele in children and adolescents: A systematic review and meta-analysis of randomized controlled trials. *J Pediatr Urol*, 2017. 13: 437.  
<https://pubmed.ncbi.nlm.nih.gov/28851509>
451. Silay, M.S., *et al.* Treatment of Varicocele in Children and Adolescents: A Systematic Review and Meta-analysis from the European Association of Urology/European Society for Paediatric Urology Guidelines Panel. *Eur Urol*, 2019. 75: 448.  
<https://pubmed.ncbi.nlm.nih.gov/30316583>
452. Rotker, K., *et al.* Recurrent varicocele. *Asian J Androl*, 2016. 18: 229.  
<https://pubmed.ncbi.nlm.nih.gov/26806078>
453. Hoberman, A., *et al.* Prevalence of urinary tract infection in febrile infants. *J Pediatr*, 1993. 123: 17.  
<https://pubmed.ncbi.nlm.nih.gov/8320616>
454. Marild, S., *et al.* Incidence rate of first-time symptomatic urinary tract infection in children under 6 years of age. *Acta Paediatr*, 1998. 87: 549.  
<https://pubmed.ncbi.nlm.nih.gov/9641738>
455. O'Brien, K., *et al.* Prevalence of urinary tract infection (UTI) in sequential acutely unwell children presenting in primary care: exploratory study. *Scand J Prim Health Care*, 2011. 29: 19.  
<https://pubmed.ncbi.nlm.nih.gov/21323495>
456. Shaikh, N., *et al.* Prevalence of urinary tract infection in childhood: a meta-analysis. *Pediatr Infect Dis J*, 2008. 27: 302.  
<https://pubmed.ncbi.nlm.nih.gov/18316994>
457. Zorc, J.J., *et al.* Clinical and demographic factors associated with urinary tract infection in young febrile infants. *Pediatrics*, 2005. 116: 644.  
<https://pubmed.ncbi.nlm.nih.gov/16140703>
458. Ladomenou, F., *et al.* Incidence and morbidity of urinary tract infection in a prospective cohort of children. *Acta Paediatr*, 2015. 104: e324.  
<https://pubmed.ncbi.nlm.nih.gov/25736706>
459. Shaikh, N., *et al.* Predictors of Antimicrobial Resistance among Pathogens Causing Urinary Tract Infection in Children. *J Pediatr*, 2016. 171: 116.  
<https://pubmed.ncbi.nlm.nih.gov/26794472>
460. Zaffanello, M., *et al.* Management of constipation in preventing urinary tract infections in children: a concise review. *The European Research Journal*, 2019. 5: 236.  
<https://www.researchgate.net/publication/327723739>
461. Grier, W.R., *et al.* Obesity as a Risk Factor for Urinary Tract Infection in Children. *Clin Pediatr (Phila)*, 2016. 55: 952.  
<https://pubmed.ncbi.nlm.nih.gov/26810625>
462. Hum, S.W., *et al.* Risk Factors for Delayed Antimicrobial Treatment in Febrile Children with Urinary Tract Infections. *J Pediatr*, 2019. 205: 126.  
<https://pubmed.ncbi.nlm.nih.gov/30340935>
463. Karavanaki, K.A., *et al.* Delayed treatment of the first febrile urinary tract infection in early childhood increased the risk of renal scarring. *Acta Paediatr*, 2017. 106: 149.  
<https://pubmed.ncbi.nlm.nih.gov/27748543>
464. Swerkersson, S., *et al.* Urinary tract infection in small children: the evolution of renal damage over time. *Pediatr Nephrol*, 2017. 32: 1907.  
<https://pubmed.ncbi.nlm.nih.gov/28681079>
465. Shaikh, N., *et al.* Association of Renal Scarring With Number of Febrile Urinary Tract Infections in Children. *JAMA Pediatr*, 2019. 173: 949.  
<https://pubmed.ncbi.nlm.nih.gov/31381021>
466. Alberici, I., *et al.* Pathogens causing urinary tract infections in infants: a European overview by the ESCAPE study group. *Eur J Pediatr*, 2015. 174: 783.  
<https://pubmed.ncbi.nlm.nih.gov/25428232>



467. Magin, E.C., *et al.* Efficacy of short-term intravenous antibiotic in neonates with urinary tract infection. *Pediatr Emerg Care*, 2007. 23: 83.  
<https://pubmed.ncbi.nlm.nih.gov/17351406>
468. Sastre, J.B., *et al.* Urinary tract infection in the newborn: clinical and radio imaging studies. *Pediatr Nephrol*, 2007. 22: 1735.  
<https://pubmed.ncbi.nlm.nih.gov/17665222>
469. Williams, G., *et al.* Long-term antibiotics for preventing recurrent urinary tract infection in children. *Cochrane Database Syst Rev*, 2019. 4: CD001534.  
<https://pubmed.ncbi.nlm.nih.gov/30932167>
470. Yiee, J.H., *et al.* Prospective blinded laboratory assessment of prophylactic antibiotic compliance in a pediatric outpatient setting. *J Urol*, 2012. 187: 2176.  
<https://pubmed.ncbi.nlm.nih.gov/22503029>
471. Burns, M.W., *et al.* Pediatric urinary tract infection. Diagnosis, classification, and significance. *Pediatr Clin North Am*, 1987. 34: 1111.  
<https://pubmed.ncbi.nlm.nih.gov/3658502>
472. Beetz, R., *et al.* [Urinary tract infections in infants and children – a consensus on diagnostic, therapy and prophylaxis]. *Urologe A*, 2007. 46: 112.  
<https://pubmed.ncbi.nlm.nih.gov/17225140>
473. Tebruegge, M., *et al.* The age-related risk of co-existing meningitis in children with urinary tract infection. *PLoS One*, 2011. 6: e26576.  
<https://pubmed.ncbi.nlm.nih.gov/22096488>
474. Craig, J.C., *et al.* The accuracy of clinical symptoms and signs for the diagnosis of serious bacterial infection in young febrile children: prospective cohort study of 15 781 febrile illnesses. *BMJ*, 2010. 340: c1594.  
<https://pubmed.ncbi.nlm.nih.gov/20406860>
475. Lin, D.S., *et al.* Urinary tract infection in febrile infants younger than eight weeks of Age. *Pediatrics*, 2000. 105: E20.  
<https://pubmed.ncbi.nlm.nih.gov/10654980>
476. Tullus, K. Difficulties in diagnosing urinary tract infections in small children. *Pediatr Nephrol*, 2011. 26: 1923.  
<https://pubmed.ncbi.nlm.nih.gov/21773821>
477. Kauffman, J.D., *et al.* Risk factors and associated morbidity of urinary tract infections in pediatric surgical patients: A NSQIP pediatric analysis. *J Pediatr Surg*, 2020. 55: 715.  
<https://pubmed.ncbi.nlm.nih.gov/31126686>
478. Whiting, P., *et al.* Rapid tests and urine sampling techniques for the diagnosis of urinary tract infection (UTI) in children under five years: a systematic review. *BMC Pediatr*, 2005. 5: 4.  
<https://pubmed.ncbi.nlm.nih.gov/15811182>
479. Ramage, I.J., *et al.* Accuracy of clean-catch urine collection in infancy. *J Pediatr*, 1999. 135: 765.  
<https://pubmed.ncbi.nlm.nih.gov/10586183>
480. Altuntas, N., *et al.* Midstream Clean-Catch Urine Culture Obtained by Stimulation Technique versus Catheter Specimen Urine Culture for Urinary Tract Infections in Newborns: A Paired Comparison of Urine Collection Methods. *Med Princ Pract*, 2020. 29: 326.  
<https://pubmed.ncbi.nlm.nih.gov/31665720>
481. Subcommittee on Urinary Tract Infection, S.C.o.Q.I., *et al.* Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics*, 2011. 128: 595.  
<https://pubmed.ncbi.nlm.nih.gov/21873693>
482. Tosif, S., *et al.* Contamination rates of different urine collection methods for the diagnosis of urinary tract infections in young children: an observational cohort study. *J Paediatr Child Health*, 2012. 48: 659.  
<https://pubmed.ncbi.nlm.nih.gov/22537082>
483. Labrosse, M., *et al.* Evaluation of a New Strategy for Clean-Catch Urine in Infants. *Pediatrics*, 2016. 138.  
<https://pubmed.ncbi.nlm.nih.gov/27542848>
484. Buys, H., *et al.* Suprapubic aspiration under ultrasound guidance in children with fever of undiagnosed cause. *BMJ*, 1994. 308: 690.  
<https://pubmed.ncbi.nlm.nih.gov/8142792>
485. Kiernan, S.C., *et al.* Ultrasound guidance of suprapubic bladder aspiration in neonates. *J Pediatr*, 1993. 123: 789.  
<https://pubmed.ncbi.nlm.nih.gov/8229492>

486. Vaillancourt, S., *et al.* To clean or not to clean: effect on contamination rates in midstream urine collections in toilet-trained children. *Pediatrics*, 2007. 119: e1288.  
<https://pubmed.ncbi.nlm.nih.gov/17502345>
487. Powell, H.R., *et al.* Urinary nitrite in symptomatic and asymptomatic urinary infection. *Arch Dis Child*, 1987. 62: 138.  
<https://pubmed.ncbi.nlm.nih.gov/3548604>
488. Coulthard, M.G. Using urine nitrite sticks to test for urinary tract infection in children aged < 2 years: a meta-analysis. *Pediatr Nephrol*, 2019. 34: 1283.  
<https://pubmed.ncbi.nlm.nih.gov/30895368>
489. Mori, R., *et al.* Diagnostic performance of urine dipstick testing in children with suspected UTI: a systematic review of relationship with age and comparison with microscopy. *Acta Paediatr*, 2010. 99: 581.  
<https://pubmed.ncbi.nlm.nih.gov/20055779>
490. Herreros, M.L., *et al.* Performing a urine dipstick test with a clean-catch urine sample is an accurate screening method for urinary tract infections in young infants. *Acta Paediatr*, 2018. 107: 145.  
<https://pubmed.ncbi.nlm.nih.gov/28940750>
491. Hildebrand, W.L., *et al.* Suprapubic bladder aspiration in infants. *Am Fam Physician*, 1981. 23: 115.  
<https://pubmed.ncbi.nlm.nih.gov/7234629>
492. Hoberman, A., *et al.* Is urine culture necessary to rule out urinary tract infection in young febrile children? *Pediatr Infect Dis J*, 1996. 15: 304.  
<https://pubmed.ncbi.nlm.nih.gov/8866798>
493. Herr, S.M., *et al.* Enhanced urinalysis improves identification of febrile infants ages 60 days and younger at low risk for serious bacterial illness. *Pediatrics*, 2001. 108: 866.  
<https://pubmed.ncbi.nlm.nih.gov/11581437>
494. Williams, G.J., *et al.* Absolute and relative accuracy of rapid urine tests for urinary tract infection in children: a meta-analysis. *Lancet Infect Dis*, 2010. 10: 240.  
<https://pubmed.ncbi.nlm.nih.gov/20334847>
495. Mayo, S., *et al.* Clinical laboratory automated urinalysis: comparison among automated microscopy, flow cytometry, two test strips analyzers, and manual microscopic examination of the urine sediments. *J Clin Lab Anal*, 2008. 22: 262.  
<https://pubmed.ncbi.nlm.nih.gov/18623125>
496. Broeren, M., *et al.* Urine flow cytometry is an adequate screening tool for urinary tract infections in children. *Eur J Pediatr*, 2019. 178: 363.  
<https://pubmed.ncbi.nlm.nih.gov/30569406>
497. Akagawa, Y., *et al.* Optimal bacterial colony counts for the diagnosis of upper urinary tract infections in infants. *Clin Exp Nephrol*, 2020. 24: 253.  
<https://pubmed.ncbi.nlm.nih.gov/31712943>
498. Broadis, E., *et al.* 'Targeted top down' approach for the investigation of UTI: A 10-year follow-up study in a cohort of 1000 children. *J Pediatr Urol*, 2016. 12: 39 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26586296>
499. Shaikh, N.A., *et al.* Is ultrasound detect renal infections? *Medical Forum Monthly*, 2016. 27: 16.  
[https://www.researchgate.net/publication/316504667\\_Is\\_ultrasound\\_detect\\_renal\\_infections](https://www.researchgate.net/publication/316504667_Is_ultrasound_detect_renal_infections)
500. Chang, S.J., *et al.* Elevated postvoid residual urine volume predicting recurrence of urinary tract infections in toilet-trained children. *Pediatr Nephrol*, 2015. 30: 1131.  
<https://pubmed.ncbi.nlm.nih.gov/25673516>
501. Stoica, I., *et al.* Xanthogranulomatous pyelonephritis in a paediatric cohort (1963-2016): Outcomes from a large single-center series. *J Pediatr Urol*, 2018. 14: 169 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29233628>
502. Shiraishi, K., *et al.* Risk factors for breakthrough infection in children with primary vesicoureteral reflux. *J Urol*, 2010. 183: 1527.  
<https://pubmed.ncbi.nlm.nih.gov/20172558>
503. Quirino, I.G., *et al.* Combined use of late phase dimercapto-succinic acid renal scintigraphy and ultrasound as first line screening after urinary tract infection in children. *J Urol*, 2011. 185: 258.  
<https://pubmed.ncbi.nlm.nih.gov/21074813>
504. Bosakova, A., *et al.* Diffusion-weighted magnetic resonance imaging is more sensitive than dimercaptosuccinic acid scintigraphy in detecting parenchymal lesions in children with acute pyelonephritis: A prospective study. *J Pediatr Urol*, 2018. 14: 269 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29588142>

505. Michaud, J.E., *et al.* Cost and radiation exposure in the workup of febrile pediatric urinary tract infections. *J Surg Res*, 2016. 203: 313.  
<https://pubmed.ncbi.nlm.nih.gov/27363638>
506. Siomou, E., *et al.* Implications of 99mTc-DMSA scintigraphy performed during urinary tract infection in neonates. *Pediatrics*, 2009. 124: 881.  
<https://pubmed.ncbi.nlm.nih.gov/19661052>
507. Shaikh, N., *et al.* Early Antibiotic Treatment for Pediatric Febrile Urinary Tract Infection and Renal Scarring. *JAMA Pediatr*, 2016. 170: 848.  
<https://pubmed.ncbi.nlm.nih.gov/27455161>
508. Mazzi, S., *et al.* Timing of voiding cystourethrography after febrile urinary tract infection in children: a systematic review. *Arch Dis Child*, 2020. 105: 264.  
<https://pubmed.ncbi.nlm.nih.gov/31466991>
509. Spencer, J.D., *et al.* The accuracy and health risks of a voiding cystourethrogram after a febrile urinary tract infection. *J Pediatr Urol*, 2012. 8: 72.  
<https://pubmed.ncbi.nlm.nih.gov/21126919>
510. Ntoulia, A., *et al.* Contrast-enhanced voiding urosonography (ceVUS) with the intravesical administration of the ultrasound contrast agent Optison for vesicoureteral reflux detection in children: a prospective clinical trial. *Pediatr Radiol*, 2018. 48: 216.  
<https://pubmed.ncbi.nlm.nih.gov/29181582>
511. Lee, L.C., *et al.* The role of voiding cystourethrography in the investigation of children with urinary tract infections. *Can Urol Assoc J*, 2016. 10: 210.  
<https://pubmed.ncbi.nlm.nih.gov/27713802>
512. Pauchard, J.Y., *et al.* Avoidance of voiding cystourethrography in infants younger than 3 months with *Escherichia coli* urinary tract infection and normal renal ultrasound. *Arch Dis Child*, 2017. 102: 804.  
<https://pubmed.ncbi.nlm.nih.gov/28408468>
513. Shaikh, N., *et al.* Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. *JAMA Pediatr*, 2014. 168: 893.  
<https://pubmed.ncbi.nlm.nih.gov/25089634>
514. Rianthavorn, P., *et al.* Probabilities of Dilating Vesicoureteral Reflux in Children with First Time Simple Febrile Urinary Tract Infection, and Normal Renal and Bladder Ultrasound. *J Urol*, 2016. 196: 1541.  
<https://pubmed.ncbi.nlm.nih.gov/27181502>
515. Bahat, H., *et al.* Predictors of grade 3-5 vesicoureteral reflux in infants  $\leq$  2 months of age with pyelonephritis. *Pediatr Nephrol*, 2019. 34: 907.  
<https://pubmed.ncbi.nlm.nih.gov/30588547>
516. Mola, G., *et al.* Selective imaging modalities after first pyelonephritis failed to identify significant urological anomalies, despite normal antenatal ultrasounds. *Acta Paediatr*, 2017. 106: 1176.  
<https://pubmed.ncbi.nlm.nih.gov/28437563>
517. Nandagopal, R., *et al.* Transient Pseudohypoaldosteronism due to Urinary Tract Infection in Infancy: A Report of 4 Cases. *Int J Pediatr Endocrinol*, 2009. 2009: 195728.  
<https://pubmed.ncbi.nlm.nih.gov/19946403>
518. Tutunculer, F., *et al.* Transient Pseudohypoaldosteronism in an infant with urinary tract anomaly. *Pediatr Int*, 2004. 46: 618.  
<https://pubmed.ncbi.nlm.nih.gov/15491397>
519. Robinson, J.L., *et al.* Management of urinary tract infections in children in an era of increasing antimicrobial resistance. *Expert Rev Anti Infect Ther*, 2016. 14: 809.  
<https://pubmed.ncbi.nlm.nih.gov/27348347>
520. Contopoulos-Ioannidis, D.G., *et al.* Extended-interval aminoglycoside administration for children: a meta-analysis. *Pediatrics*, 2004. 114: e111.  
<https://pubmed.ncbi.nlm.nih.gov/15231982>
521. Dore-Bergeron, M.J., *et al.* Urinary tract infections in 1- to 3-month-old infants: ambulatory treatment with intravenous antibiotics. *Pediatrics*, 2009. 124: 16.  
<https://pubmed.ncbi.nlm.nih.gov/19564278>
522. Gauthier, M., *et al.* Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center. *Pediatrics*, 2004. 114: e469.  
<https://pubmed.ncbi.nlm.nih.gov/15466073>
523. Roman, H.K., *et al.* Diagnosis and management of bacteremic urinary tract infection in infants. *Hosp Pediatr*, 2015. 5: 1.  
<https://pubmed.ncbi.nlm.nih.gov/25554753>

524. Bouissou, F., *et al.* Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. *Pediatrics*, 2008. 121: e553.  
<https://pubmed.ncbi.nlm.nih.gov/18267977>
525. Desai, S., *et al.* Parenteral Antibiotic Therapy Duration in Young Infants With Bacteremic Urinary Tract Infections. *Pediatrics*, 2019. 144: e20183844.  
<https://pubmed.ncbi.nlm.nih.gov/31431480>
526. Hodson, E.M., *et al.* Antibiotics for acute pyelonephritis in children. *Cochrane Database Syst Rev*, 2007: CD003772.  
<https://pubmed.ncbi.nlm.nih.gov/17943796>
527. Craig, J.C., *et al.* Antibiotic prophylaxis and recurrent urinary tract infection in children. *N Engl J Med*, 2009. 361: 1748.  
<https://pubmed.ncbi.nlm.nih.gov/19864673>
528. Neuhaus, T.J., *et al.* Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. *Eur J Pediatr*, 2008. 167: 1037.  
<https://pubmed.ncbi.nlm.nih.gov/18074149>
529. Hoberman, A., *et al.* Oral versus initial intravenous therapy for urinary tract infections in young febrile children. *Pediatrics*, 1999. 104: 79.  
<https://pubmed.ncbi.nlm.nih.gov/10390264>
530. Salomonsson, P., *et al.* Best oral empirical treatment for pyelonephritis in children: Do we need to differentiate between age and gender? *Infect Dis (Lond)*, 2016. 48: 721.  
<https://pubmed.ncbi.nlm.nih.gov/27300266>
531. Mak, R.H., *et al.* Are oral antibiotics alone efficacious for the treatment of a first episode of acute pyelonephritis in children? *Nat Clin Pract Nephrol*, 2008. 4: 10.  
<https://pubmed.ncbi.nlm.nih.gov/17971799>
532. Janett, S., *et al.* Pyuria and microbiology in acute bacterial focal nephritis: a systematic review. *Minerva Med*, 2019. 110: 232.  
<https://pubmed.ncbi.nlm.nih.gov/30809996>
533. Bryce, A., *et al.* Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by *Escherichia coli* and association with routine use of antibiotics in primary care: systematic review and meta-analysis. *BMJ*, 2016. 352: i939.  
<https://pubmed.ncbi.nlm.nih.gov/26980184>
534. Flokas, M.E., *et al.* Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. *J Infect*, 2016. 73: 547.  
<https://pubmed.ncbi.nlm.nih.gov/27475789>
535. Fostira, E., *et al.* Short-term antibiotic exposure affected the type and resistance of uropathogens similar to long-term antibiotic prophylaxis in children hospitalised for urinary tract infections. *Acta Paediatr*, 2020. 109: 1260.  
<https://pubmed.ncbi.nlm.nih.gov/31746494>
536. Uyar Aksu, N., *et al.* Childhood urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria: Risk factors and empiric therapy. *Pediatr Int*, 2017. 59: 176.  
<https://pubmed.ncbi.nlm.nih.gov/27501161>
537. Kara, A., *et al.* The use of nitrofurantoin for children with acute cystitis caused by extended-spectrum Beta-lactamase-producing *Escherichia coli*. *J Pediatr Urol*, 2019. 15: 378 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31014984>
538. Alsubaie, S.S., *et al.* Current status of long-term antibiotic prophylaxis for urinary tract infections in children: An antibiotic stewardship challenge. *Kidney Res Clin Pract*, 2019. 38: 441.  
<https://pubmed.ncbi.nlm.nih.gov/31739385>
539. Keren, R., *et al.* Risk Factors for Recurrent Urinary Tract Infection and Renal Scarring. *Pediatrics*, 2015. 136: e13.  
<https://pubmed.ncbi.nlm.nih.gov/26055855>
540. Shaikh, N., *et al.* Recurrent Urinary Tract Infections in Children With Bladder and Bowel Dysfunction. *Pediatrics*, 2016. 137.  
<https://pubmed.ncbi.nlm.nih.gov/26647376>
541. Dray, E.V., *et al.* Recurrent urinary tract infections in patients with incomplete bladder emptying: is there a role for intravesical therapy? *Transl Androl Urol*, 2017. 6: S163.  
<https://pubmed.ncbi.nlm.nih.gov/28791235>
542. Naber, K.G., *et al.*, EAU/International Consultation on Urological Infections 2010, European Association of Urology: The Netherlands.

543. Durham, S.H., *et al.* Cranberry Products for the Prophylaxis of Urinary Tract Infections in Pediatric Patients. *Ann Pharmacother*, 2015. 49: 1349.  
<https://pubmed.ncbi.nlm.nih.gov/26400007>
544. Sadeghi-Bojd, S., *et al.* Efficacy of Probiotic Prophylaxis After The First Febrile Urinary Tract Infection in Children With Normal Urinary Tracts. *J Pediatric Infect Dis Soc*, 2020. 9: 305.  
<https://pubmed.ncbi.nlm.nih.gov/31100124>
545. Hosseini, M., *et al.* The efficacy of probiotics in prevention of urinary tract infection in children: A systematic review and meta-analysis. *J Pediatr Urol*, 2017. 13: 581.  
<https://pubmed.ncbi.nlm.nih.gov/29102297>
546. Kahbazi, M., *et al.* Vitamin A supplementation is effective for improving the clinical symptoms of urinary tract infections and reducing renal scarring in girls with acute pyelonephritis: a randomized, double-blind placebo-controlled, clinical trial study. *Complement Ther Med*, 2019. 42: 429.  
<https://pubmed.ncbi.nlm.nih.gov/30670279>
547. Zhang, G.Q., *et al.* The effect of vitamin A on renal damage following acute pyelonephritis in children: a meta-analysis of randomized controlled trials. *Pediatr Nephrol*, 2016. 31: 373.  
<https://pubmed.ncbi.nlm.nih.gov/25980468>
548. Yousefichaijan, P., *et al.* Vitamin E as adjuvant treatment for urinary tract infection in girls with acute pyelonephritis. *Iranian Journal of Kidney Diseases*, 2015. 9: 97.  
<https://pubmed.ncbi.nlm.nih.gov/25851287>
549. Kotoula, A., *et al.* Comparative efficacies of procalcitonin and conventional inflammatory markers for prediction of renal parenchymal inflammation in pediatric first urinary tract infection. *Urology*, 2009. 73: 782.  
<https://pubmed.ncbi.nlm.nih.gov/19152962>
550. Zhang, H., *et al.* Diagnostic value of serum procalcitonin for acute pyelonephritis in infants and children with urinary tract infections: an updated meta-analysis. *World J Urol*, 2016. 34: 431.  
<https://pubmed.ncbi.nlm.nih.gov/26142087>
551. Austin, P.F., *et al.* The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society. *Neurourol Urodyn*, 2016. 35: 471.  
<https://pubmed.ncbi.nlm.nih.gov/25772695>
552. Bakker, E., *et al.* Voiding habits and wetting in a population of 4,332 Belgian schoolchildren aged between 10 and 14 years. *Scand J Urol Nephrol*, 2002. 36: 354.  
<https://pubmed.ncbi.nlm.nih.gov/12487740>
553. Hellstrom, A.L., *et al.* Micturition habits and incontinence in 7-year-old Swedish school entrants. *Eur J Pediatr*, 1990. 149: 434.  
<https://pubmed.ncbi.nlm.nih.gov/2332015>
554. Soderstrom, U., *et al.* Urinary and faecal incontinence: a population-based study. *Acta Paediatr*, 2004. 93: 386.  
<https://pubmed.ncbi.nlm.nih.gov/15124844>
555. Sureshkumar, P., *et al.* A population based study of 2,856 school-age children with urinary incontinence. *J Urol*, 2009. 181: 808.  
<https://pubmed.ncbi.nlm.nih.gov/19110268>
556. Bloom, D.A., *et al.* Toilet habits and continence in children: an opportunity sampling in search of normal parameters. *J Urol*, 1993. 149: 1087.  
<https://pubmed.ncbi.nlm.nih.gov/8483218>
557. Bower, W.F., *et al.* The epidemiology of childhood enuresis in Australia. *Br J Urol*, 1996. 78: 602.  
<https://pubmed.ncbi.nlm.nih.gov/8944518>
558. Mattsson, S. Urinary incontinence and nocturia in healthy schoolchildren. *Acta Paediatr*, 1994. 83: 950.  
<https://pubmed.ncbi.nlm.nih.gov/7819693>
559. Sureshkumar, P., *et al.* Daytime urinary incontinence in primary school children: a population-based survey. *J Pediatr*, 2000. 137: 814.  
<https://pubmed.ncbi.nlm.nih.gov/11113838>
560. Vaz, G.T., *et al.* Prevalence of lower urinary tract symptoms in school-age children. *Pediatr Nephrol*, 2012. 27: 597.  
<https://pubmed.ncbi.nlm.nih.gov/21969094>
561. Borch, L., *et al.* Bladder and bowel dysfunction and the resolution of urinary incontinence with successful management of bowel symptoms in children. *Acta Paediatr*, 2013. 102: e215.  
<https://pubmed.ncbi.nlm.nih.gov/23368903>

562. Veiga, M.L., et al. Constipation in children with isolated overactive bladders. *J Pediatr Urol*, 2013. 9: 945.  
<https://pubmed.ncbi.nlm.nih.gov/23462384>
563. Franco, I. Overactive bladder in children. Part 1: Pathophysiology. *J Urol*, 2007. 178: 761.  
<https://pubmed.ncbi.nlm.nih.gov/17631323>
564. Niemczyk, J., et al. Incontinence in children with treated attention-deficit/hyperactivity disorder. *J Pediatr Urol*, 2015. 11: 141 e1.  
<https://pubmed.ncbi.nlm.nih.gov/25863677>
565. Chang, S.J., et al. Treatment of daytime urinary incontinence: A standardization document from the International Children's Continence Society. *Neurourol Urodyn*, 2017. 36: 43.  
<https://pubmed.ncbi.nlm.nih.gov/26473630>
566. Hoebeke, P., et al. Diagnostic evaluation of children with daytime incontinence. *J Urol*, 2010. 183: 699.  
<https://pubmed.ncbi.nlm.nih.gov/20022025>
567. Hjalmas, K., et al. Lower urinary tract dysfunction and urodynamics in children. *Eur Urol*, 2000. 38: 655.  
<https://pubmed.ncbi.nlm.nih.gov/11096254>
568. Ambartsumyan, L., et al. Simultaneous urodynamic and anorectal manometry studies in children: insights into the relationship between the lower gastrointestinal and lower urinary tracts. *Neurogastroenterol Motil*, 2016. 28: 924.  
<https://pubmed.ncbi.nlm.nih.gov/27214097>
569. van Summeren, J., et al. Bladder Symptoms in Children With Functional Constipation: A Systematic Review. *J Pediatr Gastroenterol Nutr*, 2018. 67: 552.  
<https://pubmed.ncbi.nlm.nih.gov/30212423>
570. Chen, J.J., et al. Infant vesicoureteral reflux: a comparison between patients presenting with a prenatal diagnosis and those presenting with a urinary tract infection. *Urology*, 2003. 61: 442.  
<https://pubmed.ncbi.nlm.nih.gov/12597964>
571. Bauer, S.B., et al. International Children's Continence Society standardization report on urodynamic studies of the lower urinary tract in children. *Neurourol Urodyn*, 2015. 34: 640.  
<https://pubmed.ncbi.nlm.nih.gov/25998310>
572. Parekh, D.J., et al. The use of radiography, urodynamic studies and cystoscopy in the evaluation of voiding dysfunction. *J Urol*, 2001. 165: 215.  
<https://pubmed.ncbi.nlm.nih.gov/11125409>
573. Pfister, C., et al. The usefulness of a minimal urodynamic evaluation and pelvic floor biofeedback in children with chronic voiding dysfunction. *BJU Int*, 1999. 84: 1054.  
<https://pubmed.ncbi.nlm.nih.gov/10571635>
574. Schewe, J., et al. Voiding dysfunction in children: role of urodynamic studies. *Urol Int*, 2002. 69: 297.  
<https://pubmed.ncbi.nlm.nih.gov/12444287>
575. Akbal, C., et al. Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population. *J Urol*, 2005. 173: 969.  
<https://pubmed.ncbi.nlm.nih.gov/15711352>
576. Farhat, W., et al. The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. *J Urol*, 2000. 164: 1011.  
<https://pubmed.ncbi.nlm.nih.gov/10958730>
577. Burgers, R.E., et al. Management of functional constipation in children with lower urinary tract symptoms: report from the Standardization Committee of the International Children's Continence Society. *J Urol*, 2013. 190: 29.  
<https://pubmed.ncbi.nlm.nih.gov/23313210>
578. Chang, S.J., et al. Constipation is associated with incomplete bladder emptying in healthy children. *Neurourol Urodyn*, 2012. 31: 105.  
<https://pubmed.ncbi.nlm.nih.gov/22038844>
579. Neveus, T., et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. *J Urol*, 2006. 176: 314.  
<https://pubmed.ncbi.nlm.nih.gov/16753432>
580. Yang, S.S., et al. Home uroflowmetry for the evaluation of boys with urinary incontinence. *J Urol*, 2003. 169: 1505.  
<https://pubmed.ncbi.nlm.nih.gov/12629404>
581. van Gool, J.D., et al. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence. *Neurourol Urodyn*, 2014. 33: 482.  
<https://pubmed.ncbi.nlm.nih.gov/23775924>

582. Campos, R.M., *et al.* Comparative, prospective, and randomized study between urotherapy and the pharmacological treatment of children with urinary incontinence. *Einstein (Sao Paulo)*, 2013. 11: 203. <https://pubmed.ncbi.nlm.nih.gov/23843062>
583. Buckley, B.S., *et al.* Conservative interventions for treating functional daytime urinary incontinence in children. *Cochrane Database Syst Rev*, 2019. 9: CD012367. <https://pubmed.ncbi.nlm.nih.gov/31532563>
584. Hoebeke, P., *et al.* Assessment of lower urinary tract dysfunction in children with non-neuropathic bladder sphincter dysfunction. *Eur Urol*, 1999. 35: 57. <https://pubmed.ncbi.nlm.nih.gov/9933796>
585. Barroso, U., Jr., *et al.* Electrical stimulation for lower urinary tract dysfunction in children: a systematic review of the literature. *Neurourol Urodyn*, 2011. 30: 1429. <https://pubmed.ncbi.nlm.nih.gov/21717502>
586. Bower, W.F., *et al.* A review of non-invasive electro neuromodulation as an intervention for non-neurogenic bladder dysfunction in children. *Neurourol Urodyn*, 2004. 23: 63. <https://pubmed.ncbi.nlm.nih.gov/14694460>
587. De Paepe, H., *et al.* Pelvic-floor therapy in girls with recurrent urinary tract infections and dysfunctional voiding. *Br J Urol*, 1998. 81 Suppl 3: 109. <https://pubmed.ncbi.nlm.nih.gov/9634033>
588. Hellstrom, A.L. Urotherapy in children with dysfunctional bladder. *Scand J Urol Nephrol Suppl*, 1992. 141: 106. <https://pubmed.ncbi.nlm.nih.gov/1609245>
589. Lordelo, P., *et al.* Prospective study of transcutaneous parasacral electrical stimulation for overactive bladder in children: long-term results. *J Urol*, 2009. 182: 2900. <https://pubmed.ncbi.nlm.nih.gov/19846164>
590. Vijverberg, M.A., *et al.* Bladder rehabilitation, the effect of a cognitive training programme on urge incontinence. *Eur Urol*, 1997. 31: 68. <https://pubmed.ncbi.nlm.nih.gov/9032538>
591. Desantis, D.J., *et al.* Effectiveness of biofeedback for dysfunctional elimination syndrome in pediatrics: a systematic review. *J Pediatr Urol*, 2011. 7: 342. <https://pubmed.ncbi.nlm.nih.gov/21527216>
592. Kajbafzadeh, A.M., *et al.* Transcutaneous interferential electrical stimulation for the management of non-neuropathic underactive bladder in children: a randomised clinical trial. *BJU Int*, 2016. 117: 793. <https://pubmed.ncbi.nlm.nih.gov/26086897>
593. Ladi-Seyedian, S., *et al.* Management of non-neuropathic underactive bladder in children with voiding dysfunction by animated biofeedback: a randomized clinical trial. *Urology*, 2015. 85: 205. <https://pubmed.ncbi.nlm.nih.gov/25444633>
594. Featherstone, N., *et al.* Ephedrine hydrochloride: novel use in the management of resistant non-neurogenic daytime urinary incontinence in children. *J Pediatr Urol*, 2013. 9: 915. <https://pubmed.ncbi.nlm.nih.gov/23332206>
595. Nijman, R.J., *et al.* Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. *J Urol*, 2005. 173: 1334. <https://pubmed.ncbi.nlm.nih.gov/15758796>
596. Marschall-Kehrel, D., *et al.* Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. *Eur Urol*, 2009. 55: 729. <https://pubmed.ncbi.nlm.nih.gov/18502028>
597. Newgreen, D., *et al.* Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder. *J Urol*, 2017. 198: 928. <https://pubmed.ncbi.nlm.nih.gov/28506854>
598. Kramer, S.A., *et al.* Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. *J Urol*, 2005. 173: 2121. <https://pubmed.ncbi.nlm.nih.gov/15879863>
599. Hoebeke, P., *et al.* The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. *J Urol*, 2006. 176: 328. <https://pubmed.ncbi.nlm.nih.gov/16753434>
600. Fernandez, N., *et al.* Neurostimulation Therapy for Non-neurogenic Overactive Bladder in Children: A Meta-analysis. *Urology*, 2017. 110: 201. <https://pubmed.ncbi.nlm.nih.gov/28823638>

601. Groen, L.A., *et al.* Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience. *J Urol*, 2012. 188: 1313.  
<https://pubmed.ncbi.nlm.nih.gov/22902022>
602. Beksac, A.T., *et al.* Postvoid residual urine is the most significant non-invasive diagnostic test to predict the treatment outcome in children with non-neurogenic lower urinary tract dysfunction. *J Pediatr Urol*, 2016. 12: 215 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27233211>
603. Bower, W.F., *et al.* The transition of young adults with lifelong urological needs from pediatric to adult services: An international children's continence society position statement. *Neurourol Urodyn*, 2017. 36: 811.  
<https://pubmed.ncbi.nlm.nih.gov/27177245>
604. Butler, R.J., *et al.* Nocturnal enuresis at 7.5 years old: prevalence and analysis of clinical signs. *BJU Int*, 2005. 96: 404.  
<https://pubmed.ncbi.nlm.nih.gov/16042739>
605. Lackgren, G., *et al.* Nocturnal enuresis: a suggestion for a European treatment strategy. *Acta Paediatr*, 1999. 88: 679.  
<https://pubmed.ncbi.nlm.nih.gov/10419258>
606. Neveus, T., *et al.* Enuresis—background and treatment. *Scand J Urol Nephrol Suppl*, 2000: 1.  
<https://pubmed.ncbi.nlm.nih.gov/11196246>
607. Ma, Y., *et al.* Functional constipation and bladder capacity and severity of enuresis in children: A correlation study. *Int J Clin Exp Med* 2018. 11: 806.  
<https://www.ijcem.com/files/ijcem0058710.pdf>
608. Rangel, R.A., *et al.* Quality of life in enuretic children. *Int Braz J Urol*, 2021. 47: 535.  
<https://pubmed.ncbi.nlm.nih.gov/33620999>
609. Iscan, B., *et al.* Evaluation of health-related quality of life and affecting factors in child with enuresis. *J Pediatr Urol*, 2020. 16: 195 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32008988>
610. Collis, D., *et al.* The impact of bowel and bladder problems on children's quality of life and their parents: A scoping review. *Child Care Health Dev*, 2019. 45: 1.  
<https://pubmed.ncbi.nlm.nih.gov/30328126>
611. Jonson Ring, I., *et al.* Nocturnal enuresis impaired children's quality of life and friendships. *Acta Paediatr*, 2017. 106: 806.  
<https://pubmed.ncbi.nlm.nih.gov/28199734>
612. Soster, L.A., *et al.* Non-REM Sleep Instability in Children With Primary Monosymptomatic Sleep Enuresis. *J Clin Sleep Med*, 2017. 13: 1163.  
<https://pubmed.ncbi.nlm.nih.gov/28859716>
613. Negoro, H., *et al.* Chronobiology of micturition: putative role of the circadian clock. *J Urol*, 2013. 190: 843.  
<https://pubmed.ncbi.nlm.nih.gov/23429068>
614. Wada, H., *et al.* Nocturnal enuresis and sleep disordered breathing in primary school children: Potential implications. *Pediatr Pulmonol*, 2018. 53: 1541.  
<https://pubmed.ncbi.nlm.nih.gov/30203928>
615. Martinez Cayuelas, L., *et al.* Evaluation of sleep hygiene and prevalence of sleep disorders in patients with monosymptomatic enuresis. Usefulness of the BEARS sleep screening tool. *Actas Urol Esp (Engl Ed)*, 2020. 44: 477.  
<https://pubmed.ncbi.nlm.nih.gov/32600875>
616. Lehmann, K.J., *et al.* The role of adenotonsillectomy in the treatment of primary nocturnal enuresis in children: A systematic review. *J Pediatr Urol*, 2018. 14: 53 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28986091>
617. Ma, Y., *et al.* Association between enuresis and obesity in children with primary monosymptomatic nocturnal enuresis. *Int Braz J Urol*, 2019. 45: 790.  
<https://pubmed.ncbi.nlm.nih.gov/31184451>
618. Yilmaz-Durmus, S., *et al.* The association between monosymptomatic enuresis and allergic diseases in children. *Turk J Pediatr*, 2018. 60: 415.  
<https://pubmed.ncbi.nlm.nih.gov/30859766>
619. Lai, P.H., *et al.* Allergic rhinitis and the associated risk of nocturnal enuresis in children: a population-based cohort study. *Int Forum Allergy Rhinol*, 2018. 8: 1260.  
<https://pubmed.ncbi.nlm.nih.gov/30281945>



620. Tsai, J.D., *et al.* Association between allergic disease, sleep-disordered breathing, and childhood nocturnal enuresis: a population-based case-control study. *Pediatr Nephrol*, 2017. 32: 2293.  
<https://pubmed.ncbi.nlm.nih.gov/28735503>
621. de Sena Oliveira, A.C., *et al.* Attention deficit and hyperactivity disorder and nocturnal enuresis co-occurrence in the pediatric population: a systematic review and meta-analysis. *Pediatr Nephrol*, 2021. 36: 3547.  
<https://pubmed.ncbi.nlm.nih.gov/34009466>
622. Kessel, E.M., *et al.* Predictors and Outcomes of Childhood Primary Enuresis. *J Am Acad Child Adolesc Psychiatry*, 2017. 56: 250.  
<https://pubmed.ncbi.nlm.nih.gov/28219491>
623. Kovacevic, L., *et al.* Children with nocturnal enuresis and attention deficit hyperactivity disorder: A separate entity? *J Pediatr Urol*, 2018. 14: 47 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28867160>
624. Ma, Y., *et al.* Constipation in nocturnal enuresis may interfere desmopressin management success. *J Pediatr Urol*, 2019. 15: 177 e1.  
<https://pubmed.ncbi.nlm.nih.gov/30594475>
625. Jansson, E., *et al.* Rectal diameter assessment in enuretic children-exploring the association between constipation and bladder function. *Ups J Med Sci*, 2018. 123: 179.  
<https://pubmed.ncbi.nlm.nih.gov/30176757>
626. Hjalmas, K., *et al.* Nocturnal enuresis: an international evidence based management strategy. *J Urol*, 2004. 171: 2545.  
<https://pubmed.ncbi.nlm.nih.gov/15118418>
627. Dang, J., *et al.* Pathogenesis and brain functional imaging in nocturnal enuresis: A review. *Exp Biol Med (Maywood)*, 2021. 246: 1483.  
<https://pubmed.ncbi.nlm.nih.gov/33715529>
628. Wang, M., *et al.* Morphometric Magnetic Resonance Imaging Study in Children With Primary Monosymptomatic Nocturnal Enuresis. *Front Pediatr*, 2018. 6: 103.  
<https://pubmed.ncbi.nlm.nih.gov/29707531>
629. Yilmaz, E.S., *et al.* Effect of education given to children with enuresis on quality of life. *J Pediatr Urol*, 2021. 17: 648 e1.  
<https://pubmed.ncbi.nlm.nih.gov/34518125>
630. Smith, E., *et al.* Telemedicine Versus Traditional for Follow-Up Evaluation of Enuresis. *Telemed J E Health*, 2021. 27: 213.  
<https://pubmed.ncbi.nlm.nih.gov/32539570>
631. Caldwell, P.H., *et al.* Simple behavioural interventions for nocturnal enuresis in children. *Cochrane Database Syst Rev*, 2013. 7: CD003637.  
<https://pubmed.ncbi.nlm.nih.gov/23881652>
632. Surmeli Doven, S. The effect of using entertainment and communication devices before sleep on nocturnal enuresis. *Pediatr Int*, 2020. 62: 492.  
<https://pubmed.ncbi.nlm.nih.gov/31860151>
633. Roccella, M., *et al.* Parental Stress and Parental Ratings of Behavioral Problems of Enuretic Children. *Front Neurol*, 2019. 10: 1054.  
<https://pubmed.ncbi.nlm.nih.gov/31681143>
634. Tai, T.T., *et al.* Parental perception and factors associated with treatment strategies for primary nocturnal enuresis. *J Pediatr Urol*, 2017. 13: 272 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28190701>
635. Durmaz, O., *et al.* Psychiatric dimensions in mothers of children with primary nocturnal enuresis: A controlled study. *J Pediatr Urol*, 2017. 13: 62 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27665376>
636. Sa, C.A., *et al.* Psychological Intervention with Parents Improves Treatment Results and Reduces Punishment in Children with Enuresis: A Randomized Clinical Trial. *J Urol*, 2021. 205: 570.  
<https://pubmed.ncbi.nlm.nih.gov/32924749>
637. Caldwell, P.H., *et al.* Alarm interventions for nocturnal enuresis in children. *Cochrane Database Syst Rev*, 2020. 5: CD002911.  
<https://pubmed.ncbi.nlm.nih.gov/32364251>
638. Apos, E., *et al.* Enuresis Management in Children: Retrospective Clinical Audit of 2861 Cases Treated with Practitioner-Assisted Bell-and-Pad Alarm. *J Pediatr*, 2018. 193: 211.  
<https://pubmed.ncbi.nlm.nih.gov/29246468>

639. Kosilov, K.V., *et al.* The optimal duration of alarm therapy use in children with primary monosymptomatic nocturnal enuresis. *J Pediatr Urol*, 2018. 14: 447 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29773463>
640. Ferrara P, *et al.* Oral Desmopressin Lyophilisate Formulation (MELT): Efficacy and Safety in Children and Adults. *Biomed Pharmacol J*, 2018. 11.  
[https://biomedpharmajournal.org/vol11no1/oral-desmopressin-lyophilisate-formulation-melt-  
efficacy-and-safety-in-children-and-adults/](https://biomedpharmajournal.org/vol11no1/oral-desmopressin-lyophilisate-formulation-melt-efficacy-and-safety-in-children-and-adults/)
641. Neveus, T., *et al.* Management and treatment of nocturnal enuresis-an updated standardization document from the International Children's Continence Society. *J Pediatr Urol*, 2020. 16: 10.  
<https://pubmed.ncbi.nlm.nih.gov/32278657>
642. Van Herzele, C., *et al.* Predictive parameters of response to desmopressin in primary nocturnal enuresis. *J Pediatr Urol*, 2015. 11: 200 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26059526>
643. Liu, J., *et al.* Exploration of the Optimal Desmopressin Treatment in Children With Monosymptomatic Nocturnal Enuresis: Evidence From a Chinese Cohort. *Front Pediatr*, 2020. 8: 626083.  
<https://pubmed.ncbi.nlm.nih.gov/33569362>
644. Radojicic, Z., *et al.* Low compliance contribute to insufficient Desmopressin response of primary monosymptomatic nocturnal enuresis and the role of voiding school. *BMC Pediatr*, 2021. 21: 244.  
<https://pubmed.ncbi.nlm.nih.gov/34016082>
645. Chua, M.E., *et al.* Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis. *Pediatrics*, 2016. 138.  
<https://pubmed.ncbi.nlm.nih.gov/27343233>
646. Issi, Y., *et al.* Does desmopressin withdrawal strategy affect relapse rates in monosymptomatic enuresis treatment? *Eur J Pediatr*, 2021. 180: 1453.  
<https://pubmed.ncbi.nlm.nih.gov/33389072>
647. Dehoorne, J.L., *et al.* Desmopressin toxicity due to prolonged half-life in 18 patients with nocturnal enuresis. *J Urol*, 2006. 176: 754.  
<https://pubmed.ncbi.nlm.nih.gov/16813936>
648. Shim, M., *et al.* Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial. *Investig Clin Urol*, 2021. 62: 331.  
<https://pubmed.ncbi.nlm.nih.gov/33834643>
649. Ghanavati, P.M., *et al.* A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial. *Int Braz J Urol*, 2021. 47: 73.  
<https://pubmed.ncbi.nlm.nih.gov/32840337>
650. Kazi, A., *et al.* Comparative response of Desmopressin versus Combination Therapy (Desmopressin + Oxybutynin) in Children with Nocturnal Enuresis. *Pak J Med Sci*, 2020. 36: 1263.  
<https://pubmed.ncbi.nlm.nih.gov/32968391>
651. Song, P., *et al.* Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis. *BJU Int*, 2019. 123: 388.  
<https://pubmed.ncbi.nlm.nih.gov/30216627>
652. Borg, B., *et al.* Evidence of reduced bladder capacity during nighttime in children with monosymptomatic nocturnal enuresis. *J Pediatr Urol*, 2018. 14: 160 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29174376>
653. Yucel, S., *et al.* Anticholinergics do not improve cure rate of alarm treatment of monosymptomatic nocturnal enuresis. *Urology*, 2011. 77: 721.  
<https://pubmed.ncbi.nlm.nih.gov/21215431>
654. Peng, C.C., *et al.* Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis. *Sci Rep*, 2018. 8: 16755.  
<https://pubmed.ncbi.nlm.nih.gov/30425276>
655. Meyer, S.I.R., *et al.* Efficacy and safety of multimodal treatment in nocturnal enuresis - A retrospective cohort study. *J Pediatr Urol*, 2021. 17: 447 e1.  
<https://pubmed.ncbi.nlm.nih.gov/33820712>
656. Souza, T.M.P., *et al.* Electrical nerve stimulation therapy in refractory primary monosymptomatic enuresis - A systematic review. *J Pediatr Urol*, 2021. 17: 295.  
<https://pubmed.ncbi.nlm.nih.gov/33712372>

657. Abdelhalim, N.M., *et al.* A comparative study of transcutaneous interferential electrical stimulation and transcutaneous electrical nerve stimulation on children with primary nocturnal enuresis: a randomized clinical trial. *Int Urol Nephrol*, 2020. 52: 409.  
<https://pubmed.ncbi.nlm.nih.gov/31758382>
658. Cui, H., *et al.* The efficacy of electrical stimulation in treating children with nocturnal enuresis: A systematic review and meta-analysis. *Neurourol Urodyn*, 2019. 38: 2288.  
<https://pubmed.ncbi.nlm.nih.gov/31397008>
659. Chua, M.E., *et al.* Neurostimulation Therapy for Pediatric Primary Enuresis: A Meta-analysis. *Urology*, 2017. 106: 183.  
<https://pubmed.ncbi.nlm.nih.gov/28476683>
660. Jorgensen, C.S., *et al.* Transcutaneous Electrical Nerve Stimulation in Children with Monosymptomatic Nocturnal Enuresis: A Randomized, Double-Blind, Placebo Controlled Study. *J Urol*, 2017. 198: 687.  
<https://pubmed.ncbi.nlm.nih.gov/28747281>
661. Huang, T., *et al.* Complementary and miscellaneous interventions for nocturnal enuresis in children. *Cochrane Database Syst Rev*, 2011: CD005230.  
<https://pubmed.ncbi.nlm.nih.gov/22161390>
662. Kushnir, J., *et al.* Night diapers use and sleep in children with enuresis. *Sleep Med*, 2013. 14: 1013.  
<https://pubmed.ncbi.nlm.nih.gov/23890954>
663. Johnston, A.W., *et al.* Pediatric Neurogenic Bladder and Bowel Dysfunction: Will My Child Ever Be out of Diapers? *Eur Urol Focus*, 2020. 6: 838.  
<https://pubmed.ncbi.nlm.nih.gov/31982364>
664. Rendeli, C., *et al.* Latex sensitisation and allergy in children with myelomeningocele. *Childs Nerv Syst*, 2006. 22: 28.  
<https://pubmed.ncbi.nlm.nih.gov/15703967>
665. Bauer, S.B. Neurogenic bladder: etiology and assessment. *Pediatr Nephrol*, 2008. 23: 541.  
<https://pubmed.ncbi.nlm.nih.gov/18270749>
666. Tarcan, T., *et al.* Long-term followup of newborns with myelodysplasia and normal urodynamic findings: Is followup necessary? *J Urol*, 2001. 165: 564.  
<https://pubmed.ncbi.nlm.nih.gov/11176436>
667. McGuire, E.J., *et al.* Upper urinary tract deterioration in patients with myelodysplasia and detrusor hypertonia: a followup study. *J Urol*, 1983. 129: 823.  
<https://pubmed.ncbi.nlm.nih.gov/6842712>
668. Hopps, C.V., *et al.* Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. *J Urol*, 2003. 169: 305.  
<https://pubmed.ncbi.nlm.nih.gov/12478177>
669. Bauer, S.B. The argument for early assessment and treatment of infants with spina bifida *Dialogues in Pediatric Urology* 2000. 23: 2.
670. Sillen, U., *et al.* Development of the urodynamic pattern in infants with myelomeningocele. *Br J Urol*, 1996. 78: 596.  
<https://pubmed.ncbi.nlm.nih.gov/8944517>
671. Thorup, J., *et al.* Urological outcome after myelomeningocele: 20 years of follow-up. *BJU Int*, 2011. 107: 994.  
<https://pubmed.ncbi.nlm.nih.gov/20860652>
672. Veenboer, P.W., *et al.* Upper and lower urinary tract outcomes in adult myelomeningocele patients: a systematic review. *PLoS One*, 2012. 7: e48399.  
<https://pubmed.ncbi.nlm.nih.gov/23119003>
673. Lloyd, J.C., *et al.* Reviewing definitions of urinary continence in the contemporary spina bifida literature: a call for clarity. *J Pediatr Urol*, 2013. 9: 567.  
<https://pubmed.ncbi.nlm.nih.gov/23507290>
674. Wiener, J.S., *et al.* Bladder Management and Continence Outcomes in Adults with Spina Bifida: Results from the National Spina Bifida Patient Registry, 2009 to 2015. *J Urol*, 2018. 200: 187.  
<https://pubmed.ncbi.nlm.nih.gov/29588216>
675. Khoshnood, B., *et al.* Long term trends in prevalence of neural tube defects in Europe: population based study. *BMJ*, 2015. 351: h5949.  
<https://pubmed.ncbi.nlm.nih.gov/26601850>
676. Adzick, N.S., *et al.* A randomized trial of prenatal versus postnatal repair of myelomeningocele. *N Engl J Med*, 2011. 364: 993.  
<https://pubmed.ncbi.nlm.nih.gov/21306277>

677. Brock, J.W., 3rd, *et al.* Bladder Function After Fetal Surgery for Myelomeningocele. *Pediatrics*, 2015. 136: e906.  
<https://pubmed.ncbi.nlm.nih.gov/26416930>
678. Torre, M., *et al.* Long-term urologic outcome in patients with caudal regression syndrome, compared with meningomyelocele and spinal cord lipoma. *J Pediatr Surg*, 2008. 43: 530.  
<https://pubmed.ncbi.nlm.nih.gov/18358295>
679. Maerzheuser, S., *et al.* German network for congenital uro-rectal malformations: first evaluation and interpretation of postoperative urological complications in anorectal malformations. *Pediatr Surg Int*, 2011. 27: 1085.  
<https://pubmed.ncbi.nlm.nih.gov/21792651>
680. Hinman, F., *et al.* Vesical and Ureteral Damage from Voiding Dysfunction in Boys Without Neurologic or Obstructive Disease. *Journal of Urology*, 2017. 197: S127.  
<https://pubmed.ncbi.nlm.nih.gov/614018984>
681. Ochoa, B. Can a congenital dysfunctional bladder be diagnosed from a smile? The Ochoa syndrome updated. *Pediatr Nephrol*, 2004. 19: 6.  
<https://pubmed.ncbi.nlm.nih.gov/14648341>
682. Drzewiecki, B.A., *et al.* Urodynamic testing in children: indications, technique, interpretation and significance. *J Urol*, 2011. 186: 1190.  
<https://pubmed.ncbi.nlm.nih.gov/21849190>
683. Bauer, S.B., *et al.* Predictive value of urodynamic evaluation in newborns with myelodysplasia. *JAMA*, 1984. 252: 650.  
<https://pubmed.ncbi.nlm.nih.gov/6737668>
684. Madersbacher, H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. *Paraplegia*, 1990. 28: 217.  
<https://pubmed.ncbi.nlm.nih.gov/2235029>
685. Wide, P., *et al.* Renal preservation in children with neurogenic bladder-sphincter dysfunction followed in a national program. *J Pediatr Urol*, 2012. 8: 187.  
<https://pubmed.ncbi.nlm.nih.gov/21411372>
686. Stein, R., Assion, C, Beetz, R, *et al* Diagnostik und Therapie der neurogenen Blasenfunktionsstörungen bei Patienten mit Meningomyelocele. AWMF online, 2013. [http://www.awmf.org/uploads/tx\\_szleitlinien/043-047L\\_S2k\\_neurogenen\\_Blasenfunktionsst%C3%B6rungen\\_mit\\_Meningomyelocele\\_2013\\_01.pdf](http://www.awmf.org/uploads/tx_szleitlinien/043-047L_S2k_neurogenen_Blasenfunktionsst%C3%B6rungen_mit_Meningomyelocele_2013_01.pdf): 1.  
<https://register.awmf.org/de/leitlinien/detail/043-047>
687. Joseph, D.B., *et al.* Urologic guidelines for the care and management of people with spina bifida. *J Pediatr Rehabil Med*, 2020. 13: 479.  
<https://pubmed.ncbi.nlm.nih.gov/33252091>
688. Fox, J.A., *et al.* Cystatin C as a marker of early renal insufficiency in children with congenital neuropathic bladder. *Journal of Urology*, 2014. 191: 1602.  
<https://pubmed.ncbi.nlm.nih.gov/53070137>
689. Dangle, P.P., *et al.* Cystatin C-calculated Glomerular Filtration Rate-A Marker of Early Renal Dysfunction in Patients With Neuropathic Bladder. *Urology*, 2017. 100: 213.  
<https://pubmed.ncbi.nlm.nih.gov/27542858>
690. Millner, R.O., *et al.* Albuminuria in Pediatric Neurogenic Bladder: Identifying an Earlier Marker of Renal Disease. *Urology*, 2019. 133: 199.  
<https://pubmed.ncbi.nlm.nih.gov/31454657>
691. Fernbach, S.K., *et al.* Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. *Pediatr Radiol*, 1993. 23: 478.  
<https://pubmed.ncbi.nlm.nih.gov/8255658>
692. Kim, W.J., *et al.* Can Bladder Wall Thickness Predict Videourodynamic Findings in Children with Spina Bifida? *Journal of Urology*, 2015.  
<https://pubmed.ncbi.nlm.nih.gov/604477610>
693. Bauer, S.B., *et al.* International Children's Continence Society's recommendations for initial diagnostic evaluation and follow-up in congenital neuropathic bladder and bowel dysfunction in children. *Neurourol Urodyn*, 2012. 31: 610.  
<https://pubmed.ncbi.nlm.nih.gov/22532312>
694. Almodhen, F., *et al.* Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele. *J Urol*, 2007. 178: 1479.  
<https://pubmed.ncbi.nlm.nih.gov/17706702>

695. Foon, R., *et al.* Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies. *Cochrane Database Syst Rev*, 2012. 10: CD008224.  
<https://pubmed.ncbi.nlm.nih.gov/23076941>
696. Shekarriz, B., *et al.* Lack of morbidity from urodynamic studies in children with asymptomatic bacteriuria. *Urology*, 1999. 54: 359.  
<https://pubmed.ncbi.nlm.nih.gov/10443739>
697. Aoki, H., *et al.* [Evaluation of neurogenic bladder in patients with spinal cord injury using a CMG.EMG study and CMG.UFM.EMG study]. *Hinyokika Kyo*, 1985. 31: 937.  
<https://pubmed.ncbi.nlm.nih.gov/4061211>
698. Bradley, C.S., *et al.* Urodynamic evaluation of the bladder and pelvic floor. *Gastroenterol Clin North Am*, 2008. 37: 539.  
<https://pubmed.ncbi.nlm.nih.gov/18793995>
699. Casado, J.S., *et al.* [Urodynamic assessment of the voiding phase in childhood]. *Arch Esp Urol*, 2002. 55: 177.  
<https://pubmed.ncbi.nlm.nih.gov/12014050>
700. Wen, J.G., *et al.* Cystometry techniques in female infants and children. *Int Urogynecol J Pelvic Floor Dysfunct*, 2000. 11: 103.  
<https://pubmed.ncbi.nlm.nih.gov/10805268>
701. Zermann, D.H., *et al.* Diagnostic value of natural fill cystometry in neurogenic bladder in children. *Eur Urol*, 1997. 32: 223.  
<https://pubmed.ncbi.nlm.nih.gov/9286658>
702. Jorgensen, B., *et al.* Natural fill urodynamics and conventional cystometrogram in infants with neurogenic bladder. *J Urol*, 2009. 181: 1862.  
<https://pubmed.ncbi.nlm.nih.gov/19233391>
703. Shiroyanagi, Y., *et al.* The Significance of <sup>99m</sup>Tc-Dimercapto-Succinic Acid Renal Scan in Children With Spina Bifida During Long-Term Followup. *Journal of Urology*, 2009. 181: 2262.  
<https://pubmed.ncbi.nlm.nih.gov/50456257>
704. Leonardo, C.R., *et al.* Risk factors for renal scarring in children and adolescents with lower urinary tract dysfunction. *Pediatr Nephrol*, 2007. 22: 1891.  
<https://pubmed.ncbi.nlm.nih.gov/17874252>
705. Veenboer, P.W., *et al.* Behavioral effects of long-term antimuscarinic use in patients with spinal dysraphism: a case control study. *J Urol*, 2013. 190: 2228.  
<https://pubmed.ncbi.nlm.nih.gov/23792150>
706. Snow-Lisy, D.C., *et al.* Update on Urological Management of Spina Bifida from Prenatal Diagnosis to Adulthood. *J Urol*, 2015. 194: 288.  
<https://pubmed.ncbi.nlm.nih.gov/25839383>
707. Lee, B., *et al.* British Association of Paediatric Urologists consensus statement on the management of the neuropathic bladder. *J Pediatr Urol*, 2016. 12: 76.  
<https://pubmed.ncbi.nlm.nih.gov/26946946>
708. Kessler, T.M., *et al.* Early proactive management improves upper urinary tract function and reduces the need for surgery in patients with myelomeningocele. *Neurourol Urodyn*, 2006. 25: 758.  
<https://pubmed.ncbi.nlm.nih.gov/16986135>
709. Jorgensen, B., *et al.* Long-term follow-up in spinal dysraphism: outcome of renal function and urinary and faecal continence. *Scand J Urol Nephrol*, 2010. 44: 95.  
<https://pubmed.ncbi.nlm.nih.gov/20187759>
710. Olesen, J.D., *et al.* The association between urinary continence and quality of life in paediatric patients with spina bifida and tethered cord. *Paediatrics and Child Health (Canada)*, 2013. 18: e32.  
<https://pubmed.ncbi.nlm.nih.gov/369869653>
711. Araujo Junior, E., *et al.* Outcomes of infants followed-up at least 12 months after fetal open and endoscopic surgery for meningomyelocele: a systematic review and meta-analysis. *J Evid Based Med*, 2016. 9: 125.  
<https://pubmed.ncbi.nlm.nih.gov/27305320>
712. Leal da Cruz, M., *et al.* A 4-Year Prospective Urological Assessment of In Utero Myelomeningocele Repair-Does Gestational Age at Birth Have a Role in Later Neurogenic Bladder Pattern? *J Urol*, 2017. 197: 1550.  
<https://pubmed.ncbi.nlm.nih.gov/27988193>
713. Mazzone, L., *et al.* Urological Outcome after Fetal Spina Bifida Repair: Data from the Zurich Cohort. *Fetal Diagn Ther*, 2020. 47: 882.  
<https://pubmed.ncbi.nlm.nih.gov/32894833>

714. Pastuszka, A., *et al.* Prenatal myelomeningocele repair improves urinary continence and reduces the risk of constipation. *Neurourol Urodyn*, 2018. 37: 2792.  
<https://pubmed.ncbi.nlm.nih.gov/30058735>
715. Carr, M.C. Urological results after fetal myelomeningocele repair in pre-MOMS trial patients at the children's hospital of Philadelphia. *Fetal Diagnosis and Therapy*, 2015. 37: 211.  
<https://pubmed.ncbi.nlm.nih.gov/53238520>
716. Danzer, E., *et al.* Long-term neurofunctional outcome, executive functioning, and behavioral adaptive skills following fetal myelomeningocele surgery. *Am J Obstet Gynecol*, 2016. 214: 269 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26440692>
717. Horst, M., *et al.* Prenatal myelomeningocele repair: Do bladders better? *Neurourol Urodyn*, 2017. 36: 1651.  
<https://pubmed.ncbi.nlm.nih.gov/27862250>
718. Macedo, A., Jr., *et al.* In utero myelomeningocele repair and urological outcomes: the first 100 cases of a prospective analysis. Is there an improvement in bladder function? *BJU Int*, 2019. 123: 676.  
<https://pubmed.ncbi.nlm.nih.gov/30548158>
719. Kaefer, M., *et al.* Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. *J Urol*, 1999. 162: 1068.  
<https://pubmed.ncbi.nlm.nih.gov/10458433>
720. Dik, P., *et al.* Early start to therapy preserves kidney function in spina bifida patients. *Eur Urol*, 2006. 49: 908.  
<https://pubmed.ncbi.nlm.nih.gov/16458416>
721. Li, Y., *et al.* Application of clean intermittent catheterization for neurogenic bladder in infants less than 1 year old. *NeuroRehabilitation*, 2018. 42: 377.  
<https://pubmed.ncbi.nlm.nih.gov/29660959>
722. Elzeneini, W., *et al.* Early start of clean intermittent catheterization versus expectant management in children with spina bifida. *J Pediatr Surg*, 2019. 54: 322.  
<https://pubmed.ncbi.nlm.nih.gov/30558962>
723. Joseph, D.B., *et al.* Clean, intermittent catheterization of infants with neurogenic bladder. *Pediatrics*, 1989. 84: 78.  
<https://pubmed.ncbi.nlm.nih.gov/2740179>
724. Lindehall, B., *et al.* Long-term intermittent catheterization: the experience of teenagers and young adults with myelomeningocele. *J Urol*, 1994. 152: 187.  
<https://pubmed.ncbi.nlm.nih.gov/8201663>
725. Traff, H., *et al.* Patient-Reported Outcomes of Bladder and Bowel Control in Children with Spina Bifida. *Children (Basel)*, 2021. 8.  
<https://pubmed.ncbi.nlm.nih.gov/33802114>
726. Prieto, J., *et al.* Intermittent catheterisation for long-term bladder management [Systematic Review]. *Cochrane Database of Systematic Reviews*, 2014. 9: 9.  
<https://pubmed.ncbi.nlm.nih.gov/25208303>
727. Madero-Morales, P.A., *et al.* Randomized Clinical Trial Using Sterile Single Use and Reused Polyvinylchloride Catheters for Intermittent Catheterization with a Clean Technique in Spina Bifida Cases: Short-Term Urinary Tract Infection Outcomes. *J Urol*, 2019. 202: 153.  
<https://pubmed.ncbi.nlm.nih.gov/30916625>
728. Kiddoo, D., *et al.* Randomized Crossover Trial of Single Use Hydrophilic Coated vs Multiple Use Polyvinylchloride Catheters for Intermittent Catheterization to Determine Incidence of Urinary Infection. *J Urol*, 2015. 194: 174.  
<https://pubmed.ncbi.nlm.nih.gov/25584995>
729. Moore, K.N., *et al.* Long-term bladder management by intermittent catheterisation in adults and children. *Cochrane Database Syst Rev*, 2007: CD006008.  
<https://pubmed.ncbi.nlm.nih.gov/17943874>
730. Lindehall, B., *et al.* Complications of clean intermittent catheterization in young females with myelomeningocele: 10 to 19 years of followup. *J Urol*, 2007. 178: 1053.  
<https://pubmed.ncbi.nlm.nih.gov/17632181>
731. Lucas, E.J., *et al.* Comparison of the microbiological milieu of patients randomized to either hydrophilic or conventional PVC catheters for clean intermittent catheterization. *Journal of Pediatric Urology*, 2016. 12: 172.e1.  
<https://pubmed.ncbi.nlm.nih.gov/608794113>
732. Andersson, K.E., *et al.* Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. *Curr Opin Urol*, 2009. 19: 380.  
<https://pubmed.ncbi.nlm.nih.gov/19448545>

733. Rawashdeh, Y.F., *et al.* International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children. *Neurourol Urodyn*, 2012. 31: 615.  
<https://pubmed.ncbi.nlm.nih.gov/22532368>
734. Abrams, P., *et al.* Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. *Br J Pharmacol*, 2006. 148: 565.  
<https://pubmed.ncbi.nlm.nih.gov/16751797>
735. Hegde, S.S., *et al.* Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. *Life Sci*, 1999. 64: 419.  
<https://pubmed.ncbi.nlm.nih.gov/10069505>
736. Goessl, C., *et al.* Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. *Urology*, 1998. 51: 94.  
<https://pubmed.ncbi.nlm.nih.gov/9457296>
737. Lee, J.H., *et al.* Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational study. *Korean J Urol*, 2014. 55: 828.  
<https://pubmed.ncbi.nlm.nih.gov/25512818>
738. Krause, P., *et al.* Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. *J Urol*, 2013. 190: 1791.  
<https://pubmed.ncbi.nlm.nih.gov/23669567>
739. Van Meel, T.D., *et al.* The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity. *Neurourol Urodyn*, 2010. 29: 391.  
<https://pubmed.ncbi.nlm.nih.gov/19787712>
740. Humblet, M., *et al.* Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. *Neurourol Urodyn*, 2015. 34: 336.  
<https://pubmed.ncbi.nlm.nih.gov/24436114>
741. Guerra, L.A., *et al.* Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. *J Urol*, 2008. 180: 1091.  
<https://pubmed.ncbi.nlm.nih.gov/18639290>
742. Cartwright, P.C., *et al.* Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. *J Urol*, 2009. 182: 1548.  
<https://pubmed.ncbi.nlm.nih.gov/19683731>
743. Gish, P., *et al.* Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases. *J Pediatr*, 2009. 155: 432.  
<https://pubmed.ncbi.nlm.nih.gov/19732583>
744. Todorova, A., *et al.* Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. *J Clin Pharmacol*, 2001. 41: 636.  
<https://pubmed.ncbi.nlm.nih.gov/11402632>
745. Giramonti, K.M., *et al.* The effects of anticholinergic drugs on attention span and short-term memory skills in children. *Neurourol Urodyn*, 2008. 27: 315.  
<https://pubmed.ncbi.nlm.nih.gov/17828786>
746. Reddy, P.P., *et al.* Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. *J Pediatr Urol*, 2008. 4: 428.  
<https://pubmed.ncbi.nlm.nih.gov/19013412>
747. Mahanta, K., *et al.* Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. *J Pediatr Urol*, 2008. 4: 118.  
<https://pubmed.ncbi.nlm.nih.gov/18631906>
748. Bolduc, S., *et al.* Double anticholinergic therapy for refractory overactive bladder. *J Urol*, 2009. 182: 2033.  
<https://pubmed.ncbi.nlm.nih.gov/19695628>
749. Bolduc, S., *et al.* Prospective open label study of solifenacin for overactive bladder in children. *J Urol*, 2010. 184: 1668.  
<https://pubmed.ncbi.nlm.nih.gov/20728124>
750. Christoph, F., *et al.* Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity. *Urol Int*, 2007. 79: 55.  
<https://pubmed.ncbi.nlm.nih.gov/17627170>

751. Schulte-Baukloh, H., *et al.* Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. *J Pediatr Urol*, 2012. 8: 386.  
<https://pubmed.ncbi.nlm.nih.gov/21907623>
752. Franco, I., *et al.* Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. *J Pediatr Urol*, 2020. 16: 180 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32007426>
753. Nadeau, G., *et al.* Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: Long-term results of a prospective open-label study. *Can Urol Assoc J*, 2014. 8: 175.  
<https://pubmed.ncbi.nlm.nih.gov/25024786>
754. Ramsay, S., *et al.* A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study. *Can Urol Assoc J*, 2020. 14: 192.  
<https://pubmed.ncbi.nlm.nih.gov/31977308>
755. Lee, A.S., *et al.* How early is early? Effect of oxybutynin on bladder dynamics within the first year of life in patients with spina bifida. *J Pediatr Urol*, 2020. 16: 168 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32115375>
756. Sager, C., *et al.* Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction. *J Pediatr Urol*, 2020. 16: 655 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32800710>
757. Park, J.S., *et al.* Efficacy and safety of mirabegron, a beta3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. *World J Urol*, 2019. 37: 1665.  
<https://pubmed.ncbi.nlm.nih.gov/30511212>
758. Rittig, S., *et al.* The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. *J Pediatr Urol*, 2020. 16: 31 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31787582>
759. Baka-Ostrowska, M., *et al.* Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study. *Neurourol Urodyn*, 2021. 40: 1490.  
<https://pubmed.ncbi.nlm.nih.gov/34058027>
760. Austin, P.F., *et al.* alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. *J Urol*, 1999. 162: 1064.  
<https://pubmed.ncbi.nlm.nih.gov/10458432>
761. Homsy, Y., *et al.* Phase IIb/III dose ranging study of tamsulosin as treatment for children with neuropathic bladder. *Journal of Urology*, 2011. 186: 2033.  
<https://pubmed.ncbi.nlm.nih.gov/51634187>
762. Tsuda, Y., *et al.* Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. *Br J Clin Pharmacol*, 2010. 70: 88.  
<https://pubmed.ncbi.nlm.nih.gov/20642551>
763. Horst, M., *et al.* Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. *Neurourol Urodyn*, 2011. 30: 1546.  
<https://pubmed.ncbi.nlm.nih.gov/21674597>
764. Danacioglu, Y.O., *et al.* Factors predicting the success of intradetrusor onabotulinum toxin-A treatment in children with neurogenic bladders due to myelomeningocele: The outcomes of a large cohort. *J Pediatr Urol*, 2021. 17: 520 e1.  
<https://pubmed.ncbi.nlm.nih.gov/33712371>
765. Toia, B., *et al.* The efficacy of onabotulinumtoxinA in patients with previous failed augmentation cystoplasty: Cohort series and literature review. *Neurourol Urodyn*, 2020. 39: 1831.  
<https://pubmed.ncbi.nlm.nih.gov/32572987>
766. Hascoet, J., *et al.* Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review. *Neurourol Urodyn*, 2017. 36: 557.  
<https://pubmed.ncbi.nlm.nih.gov/27187872>
767. Austin, P.F., *et al.* OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children. *Neurourol Urodyn*, 2021. 40: 493.  
<https://pubmed.ncbi.nlm.nih.gov/33305474>



768. Sager, C., *et al.* Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder. *Pediatric Surgery International*, 2014. 30: 79.  
<https://pubmed.ncbi.nlm.nih.gov/52736614>
769. Tiryaki, S., *et al.* Botulinum injection is useless on fibrotic neuropathic bladders. *Journal of Pediatric Urology*, 2015. 11: 27.e1.  
<https://pubmed.ncbi.nlm.nih.gov/602765187>
770. Greer, T., *et al.* Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. *J Pediatr Urol*, 2016. 12: 94 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26472538>
771. Franco, I., *et al.* The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children. *J Urol*, 2007. 178: 1775.  
<https://pubmed.ncbi.nlm.nih.gov/17707430>
772. Mokhless, I., *et al.* Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder. *J Urol*, 2006. 176: 1767.  
<https://pubmed.ncbi.nlm.nih.gov/16945643>
773. Hagerty, J.A., *et al.* Intravesical electrotherapy for neurogenic bladder dysfunction: a 22-year experience. *J Urol*, 2007. 178: 1680.  
<https://pubmed.ncbi.nlm.nih.gov/17707024>
774. Boone, T.B., *et al.* Transurethral intravesical electrotherapy for neurogenic bladder dysfunction in children with myelodysplasia: a prospective, randomized clinical trial. *J Urol*, 1992. 148: 550.  
<https://pubmed.ncbi.nlm.nih.gov/1640520>
775. Cheng, E.Y., *et al.* Bladder stimulation therapy improves bladder compliance: results from a multi-institutional trial. *J Urol*, 1996. 156: 761.  
<https://pubmed.ncbi.nlm.nih.gov/8683778>
776. Guys, J.M., *et al.* Sacral neuromodulation for neurogenic bladder dysfunction in children. *J Urol*, 2004. 172: 1673.  
<https://pubmed.ncbi.nlm.nih.gov/15371787>
777. Lansen-Koch, S.M., *et al.* Sacral nerve modulation for defaecation and micturition disorders in patients with spina bifida. *Colorectal Dis*, 2012. 14: 508.  
<https://pubmed.ncbi.nlm.nih.gov/21689346>
778. Xiao, C.G., *et al.* An artificial somatic-central nervous system-autonomic reflex pathway for controllable micturition after spinal cord injury: preliminary results in 15 patients. *J Urol*, 2003. 170: 1237.  
<https://pubmed.ncbi.nlm.nih.gov/14501733>
779. Tuite, G.F., *et al.* Urological Outcome of the Xiao Procedure in Children with Myelomeningocele and Lipomyelomeningocele Undergoing Spinal Cord Detethering. *J Urol*, 2016. 196: 1735.  
<https://pubmed.ncbi.nlm.nih.gov/27288694>
780. Wan, J. The role of urethral dilation in managing pediatric neurogenic bladder dysfunction. *Curr Urol Rep*, 2009. 10: 153.  
<https://pubmed.ncbi.nlm.nih.gov/19239821>
781. Park, J.M., *et al.* External urethral sphincter dilation for the management of high risk myelomeningocele: 15-year experience. *J Urol*, 2001. 165: 2383.  
<https://pubmed.ncbi.nlm.nih.gov/11371982>
782. Bloom, D.A., *et al.* Urethral dilation improves bladder compliance in children with myelomeningocele and high leak point pressures. *J Urol*, 1990. 144: 430.  
<https://pubmed.ncbi.nlm.nih.gov/2374216>
783. Blocksom, B.H., Jr. Bladder pouch for prolonged tubeless cystostomy. *J Urol*, 1957. 78: 398.  
<https://pubmed.ncbi.nlm.nih.gov/13476506>
784. Lee, M.W., *et al.* Intractable high-pressure bladder in female infants with spina bifida: clinical characteristics and use of vesicostomy. *Urology*, 2005. 65: 568.  
<https://pubmed.ncbi.nlm.nih.gov/15780378>
785. Fischer, K.M., *et al.* Follow-up and Outcomes of Patients With Long-term Cutaneous Vesicostomies at a Single Institution. *Urology*, 2020. 144: 255.  
<https://pubmed.ncbi.nlm.nih.gov/32580017>
786. Mosiello, G., *et al.* Button Cystostomy: Is it Really a Safe and Effective Therapeutic Option in Pediatric Patients With Neurogenic Bladder? *Urology*, 2017. 101: 73.  
<https://pubmed.ncbi.nlm.nih.gov/27693876>
787. Alhazmi, H., *et al.* Long-term results using a transanal irrigation system (Peristeen((R))) for treatment of stool incontinence in children with myelomeningocele. *J Pediatr Urol*, 2019. 15: 34 e1.  
<https://pubmed.ncbi.nlm.nih.gov/30245057>

788. Malone, P.S., *et al.* Preliminary report: the antegrade continence enema. *Lancet*, 1990. 336: 1217.  
<https://pubmed.ncbi.nlm.nih.gov/1978072>
789. Anselmo, C.B., *et al.* Left-colon antegrade enema (LACE): Long-term experience with the Macedo-Malone approach. *Neurourol Urodyn*, 2017. 36: 111.  
<https://pubmed.ncbi.nlm.nih.gov/26417710>
790. Siddiqui, A.A., *et al.* Long-term follow-up of patients after antegrade continence enema procedure. *J Pediatr Gastroenterol Nutr*, 2011. 52: 574.  
<https://pubmed.ncbi.nlm.nih.gov/21502828>
791. Zegers, B.S., *et al.* Urinary tract infections in children with spina bifida: an inventory of 41 European centers. *Pediatr Nephrol*, 2009. 24: 783.  
<https://pubmed.ncbi.nlm.nih.gov/19066975>
792. Hansson, S., *et al.* Untreated bacteriuria in asymptomatic girls with renal scarring. *Pediatrics*, 1989. 84: 964.  
<https://pubmed.ncbi.nlm.nih.gov/2587151>
793. Zegers, S.H., *et al.* The influence of antibiotic prophylaxis on bacterial resistance in urinary tract infections in children with spina bifida. *BMC Infect Dis*, 2017. 17: 63.  
<https://pubmed.ncbi.nlm.nih.gov/28081719>
794. Akil, I., *et al.* Do patients with neurogenic bladder treated with clean intermittent catheterization need antibacterial prophylaxis? *Turkish Journal of Medical Sciences*, 2016. 46: 1151.  
<https://pubmed.ncbi.nlm.nih.gov/610966080>
795. Mutlu, H., *et al.* Urinary tract infection prophylaxis in children with neurogenic bladder with cranberry capsules: randomized controlled trial. *ISRN Pediatr*, 2012. 2012: 317280.  
<https://pubmed.ncbi.nlm.nih.gov/22811926>
796. Johnson, H.W., *et al.* A short-term study of nitrofurantoin prophylaxis in children managed with clean intermittent catheterization. *Pediatrics*, 1994. 93: 752.  
<https://pubmed.ncbi.nlm.nih.gov/8165073>
797. Schlager, T.A., *et al.* Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. *J Pediatr*, 1998. 132: 704.  
<https://pubmed.ncbi.nlm.nih.gov/9580774>
798. Schlager, T.A., *et al.* Effect of a single-use sterile catheter for each void on the frequency of bacteriuria in children with neurogenic bladder on intermittent catheterization for bladder emptying. *Pediatrics*, 2001. 108: E71.  
<https://pubmed.ncbi.nlm.nih.gov/11581479>
799. Kanaheswari, Y., *et al.* Urinary tract infection and bacteriuria in children performing clean intermittent catheterization with reused catheters. *Spinal Cord*, 2015. 53: 209.  
<https://pubmed.ncbi.nlm.nih.gov/25420498>
800. Huen, K.H., *et al.* Neomycin-polymyxin or gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on clean intermittent catheterization. *J Pediatr Urol*, 2019. 15: 178 e1.  
<https://pubmed.ncbi.nlm.nih.gov/30611650>
801. Marei, M.M., *et al.* Intravesical gentamicin instillation for the treatment and prevention of urinary tract infections in complex paediatric urology patients: evidence for safety and efficacy. *J Pediatr Urol*, 2021. 17: 65 e1.  
<https://pubmed.ncbi.nlm.nih.gov/33309610>
802. Misseri, R., *et al.* Reflux in cystoplasties. *Arch Esp Urol*, 2008. 61: 213.  
<https://pubmed.ncbi.nlm.nih.gov/18491737>
803. Soygur, T., *et al.* The need for ureteric re-implantation during augmentation cystoplasty: video-urodynamic evaluation. *BJU Int*, 2010. 105: 530.  
<https://pubmed.ncbi.nlm.nih.gov/19583716>
804. Helmy, T.E., *et al.* Vesicouretral reflux with neuropathic bladder: studying the resolution rate after ileocystoplasty. *Urology*, 2013. 82: 425.  
<https://pubmed.ncbi.nlm.nih.gov/23639239>
805. Polackwich, A.S., *et al.* Long-term followup after endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid copolymer in patients with neurogenic bladder. *J Urol*, 2012. 188: 1511.  
<https://pubmed.ncbi.nlm.nih.gov/22910250>
806. Engel, J.D., *et al.* Surgical versus endoscopic correction of vesicoureteral reflux in children with neurogenic bladder dysfunction. *J Urol*, 1997. 157: 2291.  
<https://pubmed.ncbi.nlm.nih.gov/9146655>

807. Verhoef, M., *et al.* Sex education, relationships, and sexuality in young adults with spina bifida. *Arch Phys Med Rehabil*, 2005. 86: 979.  
<https://pubmed.ncbi.nlm.nih.gov/15895345>
808. Elias, E.R., *et al.* Precocious puberty in girls with myelodysplasia. *Pediatrics*, 1994. 93: 521.  
<https://pubmed.ncbi.nlm.nih.gov/8115222>
809. Cardenas, D.D., *et al.* Sexual functioning in adolescents and young adults with spina bifida. *Arch Phys Med Rehabil*, 2008. 89: 31.  
<https://pubmed.ncbi.nlm.nih.gov/18164327>
810. Gatti, C., *et al.* Predictors of successful sexual partnering of adults with spina bifida. *J Urol*, 2009. 182: 1911.  
<https://pubmed.ncbi.nlm.nih.gov/19695634>
811. Lassmann, J., *et al.* Sexual function in adult patients with spina bifida and its impact on quality of life. *J Urol*, 2007. 178: 1611.  
<https://pubmed.ncbi.nlm.nih.gov/17707040>
812. Palmer, J.S., *et al.* Erectile dysfunction in patients with spina bifida is a treatable condition. *J Urol*, 2000. 164: 958.  
<https://pubmed.ncbi.nlm.nih.gov/10958716>
813. Bong, G.W., *et al.* Sexual health in adult men with spina bifida. *ScientificWorldJournal*, 2007. 7: 1466.  
<https://pubmed.ncbi.nlm.nih.gov/17767363>
814. Overgoor, M.L., *et al.* Increased sexual health after restored genital sensation in male patients with spina bifida or a spinal cord injury: the TOMAX procedure. *J Urol*, 2013. 189: 626.  
<https://pubmed.ncbi.nlm.nih.gov/23079372>
815. Motta, G.L., *et al.* The impact of neurogenic bladder bowel dysfunction in the sexuality of female spina bifida patients. *J Pediatr Urol*, 2021. 17: 288 e1.  
<https://pubmed.ncbi.nlm.nih.gov/33546979>
816. Stein, R., *et al.* Bladder augmentation and urinary diversion in patients with neurogenic bladder: surgical considerations. *J Pediatr Urol*, 2012. 8: 153.  
<https://pubmed.ncbi.nlm.nih.gov/22264521>
817. Castellan, M., *et al.* Complications after use of gastric segments for lower urinary tract reconstruction. *J Urol*, 2012. 187: 1823.  
<https://pubmed.ncbi.nlm.nih.gov/22425048>
818. Nguyen, D.H., *et al.* The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. *J Urol*, 1993. 150: 707.  
<https://pubmed.ncbi.nlm.nih.gov/8326629>
819. Boissier, R., *et al.* What is the outcome of paediatric gastrocystoplasty when the patients reach adulthood? *BJU International*, 2016. 118: 980.  
<https://pubmed.ncbi.nlm.nih.gov/613250595>
820. Bogaert, G.A., *et al.* The physiology of gastrocystoplasty: once a stomach, always a stomach. *J Urol*, 1995. 153: 1977.  
<https://pubmed.ncbi.nlm.nih.gov/7752376>
821. Herschorn, S., *et al.* Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. *Urology*, 1998. 52: 672.  
<https://pubmed.ncbi.nlm.nih.gov/9763092>
822. Medel, R., *et al.* Urinary continence outcome after augmentation ileocystoplasty as a single surgical procedure in patients with myelodysplasia. *J Urol*, 2002. 168: 1849.  
<https://pubmed.ncbi.nlm.nih.gov/12352374>
823. Roth, J.D., *et al.* Epidural Analgesia Decreases Narcotic Requirements in Patients with Low Level Spina Bifida Undergoing Urological Laparotomy for Neurogenic Bladder and Bowel. *J Urol*, 2019. 201: 169.  
<https://pubmed.ncbi.nlm.nih.gov/30577407>
824. McNamara, E.R., *et al.* 30-Day morbidity after augmentation enterocystoplasty and appendicovesicostomy: A NSQIP pediatric analysis. *J Pediatr Urol*, 2015. 11: 209 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26049255>
825. Du, K., *et al.* Enterocystoplasty 30-day outcomes from National Surgical Quality Improvement Program Pediatric 2012. *J Pediatr Surg*, 2015. 50: 1535.  
<https://pubmed.ncbi.nlm.nih.gov/25957024>
826. Szymanski, K.M., *et al.* Additional Surgeries after Bladder Augmentation in Patients with Spina Bifida in the 21st Century. *J Urol*, 2020. 203: 1207.  
<https://pubmed.ncbi.nlm.nih.gov/31951496>

827. Schlomer, B.J., *et al.* Cumulative incidence of outcomes and urologic procedures after augmentation cystoplasty. *J Pediatr Urol*, 2014. 10: 1043.  
<https://pubmed.ncbi.nlm.nih.gov/24766857>
828. Frainey, B.T., *et al.* Complications of Pediatric Bladder Reconstruction in the Adult Patient. *Current Bladder Dysfunction Reports*, 2020. 15: 173.  
<https://link.springer.com/article/10.1007/s11884-020-00584-2>
829. Casperon, K.J., *et al.* Ventriculoperitoneal shunt infections after bladder surgery: is mechanical bowel preparation necessary? *J Urol*, 2011. 186: 1571.  
<https://pubmed.ncbi.nlm.nih.gov/21855924>
830. Stein, R., *et al.* Bladder augmentation and urinary diversion in patients with neurogenic bladder: non-surgical considerations. *J Pediatr Urol*, 2012. 8: 145.  
<https://pubmed.ncbi.nlm.nih.gov/21493159>
831. Biardeau, X., *et al.* Risk of malignancy after augmentation cystoplasty: A systematic review. *Neurourol Urodyn*, 2016. 35: 675.  
<https://pubmed.ncbi.nlm.nih.gov/25867054>
832. Higuchi, T.T., *et al.* Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. *J Urol*, 2010. 184: 2492.  
<https://pubmed.ncbi.nlm.nih.gov/20961577>
833. Higuchi, T.T., *et al.* Annual endoscopy and urine cytology for the surveillance of bladder tumors after enterocystoplasty for congenital bladder anomalies. *J Urol*, 2011. 186: 1791.  
<https://pubmed.ncbi.nlm.nih.gov/21944100>
834. Kokorowski, P.J., *et al.* Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis. *J Urol*, 2011. 186: 1437.  
<https://pubmed.ncbi.nlm.nih.gov/21855939>
835. Hamid, R., *et al.* Routine surveillance cystoscopy for patients with augmentation and substitution cystoplasty for benign urological conditions: is it necessary? *BJU Int*, 2009. 104: 392.  
<https://pubmed.ncbi.nlm.nih.gov/19239457>
836. Lopez Pereira, P., *et al.* Are urodynamic studies really needed during bladder augmentation follow-up? *Journal of Pediatric Urology*, 2009. 5: 30.  
<https://pubmed.ncbi.nlm.nih.gov/50262453>
837. Eckstein, H.B., *et al.* Uretero-Cystoplastik. *Akt. Urol*, 1973. 4: 255
838. Youssif, M., *et al.* Augmentation ureterocystoplasty in boys with valve bladder syndrome. *J Pediatr Urol*, 2007. 3: 433.  
<https://pubmed.ncbi.nlm.nih.gov/18947790>
839. Husmann, D.A., *et al.* Ureterocystoplasty: indications for a successful augmentation. *J Urol*, 2004. 171: 376.  
<https://pubmed.ncbi.nlm.nih.gov/14665935>
840. Marte, A., *et al.* A long-term follow-up of autoaugmentation in myelodysplastic children. *BJU Int*, 2002. 89: 928.  
<https://pubmed.ncbi.nlm.nih.gov/12010242>
841. Cartwright, P.C. Bladder autoaugmentation (partial detrusor myectomy)—where does it stand after 2 decades? *J Urol*, 2013. 190: 1643.  
<https://pubmed.ncbi.nlm.nih.gov/23954194>
842. Chrzan, R., *et al.* Detrusorectomy reduces the need for augmentation and use of antimuscarinics in children with neuropathic bladders. *J Pediatr Urol*, 2013. 9: 193.  
<https://pubmed.ncbi.nlm.nih.gov/22364713>
843. Hansen, E.L., *et al.* Promising long-term outcome of bladder autoaugmentation in children with neurogenic bladder dysfunction. *J Urol*, 2013. 190: 1869.  
<https://pubmed.ncbi.nlm.nih.gov/23707450>
844. Dik, P., *et al.* Detrusorectomy for neuropathic bladder in patients with spinal dysraphism. *J Urol*, 2003. 170: 1351.  
<https://pubmed.ncbi.nlm.nih.gov/14501768>
845. Bandi, G., *et al.* Comparison of traditional enterocystoplasty and seromuscular colocolocystoplasty lined with urothelium. *J Pediatr Urol*, 2007. 3: 484.  
<https://pubmed.ncbi.nlm.nih.gov/18947800>
846. Joseph, D.B., *et al.* Autologous cell seeded biodegradable scaffold for augmentation cystoplasty: phase II study in children and adolescents with spina bifida. *J Urol*, 2014. 191: 1389.  
<https://pubmed.ncbi.nlm.nih.gov/24184366>

847. Atala, A., *et al.* Tissue-engineered autologous bladders for patients needing cystoplasty. *Lancet*, 2006. 367: 1241.  
<https://pubmed.ncbi.nlm.nih.gov/16631879>
848. Austin, P.F., *et al.* Advantages of rectus fascial slings for urinary incontinence in children with neuropathic bladders. *J Urol*, 2001. 165: 2369.  
<https://pubmed.ncbi.nlm.nih.gov/11398778>
849. Guys, J.M., *et al.* Endoscopic treatment of urinary incontinence: long-term evaluation of the results. *J Urol*, 2001. 165: 2389.  
<https://pubmed.ncbi.nlm.nih.gov/11371983>
850. Holmes, N.M., *et al.* Placement of artificial urinary sphincter in children and simultaneous gastrocystoplasty. *J Urol*, 2001. 165: 2366.  
<https://pubmed.ncbi.nlm.nih.gov/11371944>
851. Kassouf, W., *et al.* Collagen injection for treatment of urinary incontinence in children. *J Urol*, 2001. 165: 1666.  
<https://pubmed.ncbi.nlm.nih.gov/11342951>
852. Kryger, J.V., *et al.* Surgical management of urinary incontinence in children with neurogenic sphincteric incompetence. *J Urol*, 2000. 163: 256.  
<https://pubmed.ncbi.nlm.nih.gov/10604371>
853. Kryger, J.V., *et al.* Long-term results of artificial urinary sphincters in children are independent of age at implantation. *J Urol*, 2001. 165: 2377.  
<https://pubmed.ncbi.nlm.nih.gov/11371981>
854. Pannek, J., *et al.* Clinical usefulness of the transobturator sub-urethral tape in the treatment of stress urinary incontinence in female patients with spinal cord lesion. *J Spinal Cord Med*, 2012. 35: 102.  
<https://pubmed.ncbi.nlm.nih.gov/22525323>
855. Groen, L.A., *et al.* The advance male sling as a minimally invasive treatment for intrinsic sphincter deficiency in patients with neurogenic bladder sphincter dysfunction: A pilot study. *Neurourology and Urodynamics*, 2012. 31: 1284.  
<https://pubmed.ncbi.nlm.nih.gov/52138240>
856. Scott, F.B., *et al.* Treatment of incontinence secondary to myelodysplasia by an implantable prosthetic urinary sphincter. *South Med J*, 1973. 66: 987.  
<https://pubmed.ncbi.nlm.nih.gov/4582131>
857. Gonzalez, R., *et al.* Artificial sphincters in children with neurogenic bladders: long-term results. *J Urol*, 1982. 128: 1270.  
<https://pubmed.ncbi.nlm.nih.gov/7154183>
858. Khene, Z.E., *et al.* Artificial Urinary Sphincter in Male Patients with Spina Bifida: Comparison of Perioperative and Functional Outcomes between Bulbar Urethra and Bladder Neck Cuff Placement. *J Urol*, 2018. 199: 791.  
<https://pubmed.ncbi.nlm.nih.gov/29037862>
859. Grimsby, G.M., *et al.* Long-Term Outcomes of Bladder Neck Reconstruction without Augmentation Cystoplasty in Children. *Journal of Urology*, 2016. 195: 155.  
<https://pubmed.ncbi.nlm.nih.gov/607365426>
860. Weaver, J.K., *et al.* Clinical outcomes after increasing bladder outlet resistance without augmentation cystoplasty in neurogenic bladder. *J Pediatr Urol*, 2021. 17: 235 e1.  
<https://pubmed.ncbi.nlm.nih.gov/33342678>
861. Smith, M.C., *et al.* Need for botulinum toxin injection and bladder augmentation after isolated bladder outlet procedure in pediatric patients with myelomeningocele. *J Pediatr Urol*, 2020. 16: 32 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31839471>
862. Hayes, M.C., *et al.* The Pippi Salle urethral lengthening procedure; experience and outcome from three United Kingdom centres. *BJU Int*, 1999. 84: 701.  
<https://pubmed.ncbi.nlm.nih.gov/10510119>
863. Szymanski, K.M., *et al.* Long-term outcomes of the Kropp and Salle urethral lengthening bladder neck reconstruction procedures. *J Pediatr Urol*, 2016. 12: 403 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27687531>
864. Churchill, B.M., *et al.* Improved continence in patients with neurogenic sphincteric incompetence with combination tubularized posterior urethroplasty and fascial wrap: the lengthening, narrowing and tightening procedure. *J Urol*, 2010. 184: 1763.  
<https://pubmed.ncbi.nlm.nih.gov/20728163>
865. Alova, I., *et al.* Long-term effects of endoscopic injection of dextranomer/hyaluronic acid based implants for treatment of urinary incontinence in children with neurogenic bladder. *J Urol*, 2012. 188: 1905.  
<https://pubmed.ncbi.nlm.nih.gov/22998918>

866. Guys, J.M., *et al.* Endoscopic injection with polydimethylsiloxane for the treatment of pediatric urinary incontinence in the neurogenic bladder: long-term results. *J Urol*, 2006. 175: 1106.  
<https://pubmed.ncbi.nlm.nih.gov/16469633>
867. De Vocht, T.F., *et al.* Long-term results of bulking agent injection for persistent incontinence in cases of neurogenic bladder dysfunction. *J Urol*, 2010. 183: 719.  
<https://pubmed.ncbi.nlm.nih.gov/20022056>
868. De Troyer, B., *et al.* A comparative study between continent diversion and bladder neck closure versus continent diversion and bladder neck reconstruction in children. *Journal of Pediatric Urology*, 2011. 7: 209.  
<https://pubmed.ncbi.nlm.nih.gov/50916701>
869. Kavanagh, A., *et al.* Bladder neck closure in conjunction with enterocystoplasty and Mitrofanoff diversion for complex incontinence: closing the door for good. *J Urol*, 2012. 188: 1561.  
<https://pubmed.ncbi.nlm.nih.gov/22910244>
870. Shpall, A.I., *et al.* Bladder neck closure with lower urinary tract reconstruction: technique and long-term followup. *J Urol*, 2004. 172: 2296.  
<https://pubmed.ncbi.nlm.nih.gov/15538252>
871. Landau, E.H., *et al.* Bladder neck closure in children: a decade of followup. *J Urol*, 2009. 182: 1797.  
<https://pubmed.ncbi.nlm.nih.gov/19692069>
872. Deuker, M., *et al.* Long-term outcome after urinary diversion using the ileocecal segment in children and adolescents: Complications of the efferent segment. *J Pediatr Urol*, 2016. 12: 247 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27282550>
873. Faure, A., *et al.* Bladder continent catheterizable conduit (the Mitrofanoff procedure): Long-term issues that should not be underestimated. *Journal of Pediatric Surgery*, 2016. 11.  
<https://pubmed.ncbi.nlm.nih.gov/613179474>
874. Landau, E.H., *et al.* Superiority of the VQZ over the tubularized skin flap and the umbilicus for continent abdominal stoma in children. *J Urol*, 2008. 180: 1761.  
<https://pubmed.ncbi.nlm.nih.gov/18721990>
875. Stein, R., *et al.* Urinary diversion in children and adolescents with neurogenic bladder: the Mainz experience. Part III: Colonic conduit. *Pediatr Nephrol*, 2005. 20: 932.  
<https://pubmed.ncbi.nlm.nih.gov/15864655>
876. Cass, A.S., *et al.* A 22-year followup of ileal conduits in children with a neurogenic bladder. *J Urol*, 1984. 132: 529.  
<https://pubmed.ncbi.nlm.nih.gov/6471190>
877. Dunn, M., *et al.* The long-term results of ileal conduit urinary diversion in children. *Br J Urol*, 1979. 51: 458.  
<https://pubmed.ncbi.nlm.nih.gov/534825>
878. Middleton, A.W., Jr., *et al.* Ileal conduits in children at the Massachusetts General Hospital from 1955 to 1970. *J Urol*, 1976. 115: 591.  
<https://pubmed.ncbi.nlm.nih.gov/1271557>
879. Mitchell, M.E., *et al.* Intestinocystoplasty and total bladder replacement in children and young adults: followup in 129 cases. *J Urol*, 1987. 138: 579.  
<https://pubmed.ncbi.nlm.nih.gov/3625861>
880. Shekarriz, B., *et al.* Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. *Urology*, 2000. 55: 123.  
<https://pubmed.ncbi.nlm.nih.gov/10654908>
881. Garnier, S., *et al.* Malignancy after Augmentation Enterocystoplasty: A Nationwide Study of Natural History, Prognosis and Oncogene Panel Analysis. *J Urol*, 2020. 204: 136.  
<https://pubmed.ncbi.nlm.nih.gov/31957550>
882. Husmann, D.A., *et al.* Long-term follow up of enteric bladder augmentations: the risk for malignancy. *J Pediatr Urol*, 2008. 4: 381.  
<https://pubmed.ncbi.nlm.nih.gov/18653384>
883. Muhlbauer, J., *et al.* Bladder cancer in patients with spina bifida: a serious risk. *World J Urol*, 2021. 39: 1531.  
<https://pubmed.ncbi.nlm.nih.gov/32632554>
884. Austin, J.C., *et al.* Patients with spina bifida and bladder cancer: atypical presentation, advanced stage and poor survival. *J Urol*, 2007. 178: 798.  
<https://pubmed.ncbi.nlm.nih.gov/17631349>
885. Sammer, U., *et al.* Do we need surveillance urethro-cystoscopy in patients with neurogenic lower urinary tract dysfunction? *PLoS ONE*, 2015. 10 (10) (no pagination).  
<https://pubmed.ncbi.nlm.nih.gov/607232372>

886. Lebowitz, R.L., *et al.* Neonatal hydronephrosis: 146 cases. *Radiol Clin North Am*, 1977. 15: 49.  
<https://pubmed.ncbi.nlm.nih.gov/139634>
887. Brown, T., *et al.* Neonatal hydronephrosis in the era of sonography. *AJR Am J Roentgenol*, 1987. 148: 959.  
<https://pubmed.ncbi.nlm.nih.gov/3034009>
888. Koff, S.A. Problematic ureteropelvic junction obstruction. *J Urol*, 1987. 138: 390.  
<https://pubmed.ncbi.nlm.nih.gov/3599261>
889. Gunn, T.R., *et al.* Antenatal diagnosis of urinary tract abnormalities by ultrasonography after 28 weeks' gestation: incidence and outcome. *Am J Obstet Gynecol*, 1995. 172: 479.  
<https://pubmed.ncbi.nlm.nih.gov/7856673>
890. Grignon, A., *et al.* Ureteropelvic junction stenosis: antenatal ultrasonographic diagnosis, postnatal investigation, and follow-up. *Radiology*, 1986. 160: 649.  
<https://pubmed.ncbi.nlm.nih.gov/3526403>
891. Flasher, S.C., *et al.*, Ureteropelvic junction, in *Clinical Pediatric Urology*. 1976, WB Saunders: Philadelphia.
892. Thomas, D.F. Prenatally detected uropathy: epidemiological considerations. *Br J Urol*, 1998. 81 Suppl 2: 8.  
<https://pubmed.ncbi.nlm.nih.gov/9602790>
893. Ebel, K.D. Uroradiology in the fetus and newborn: diagnosis and follow-up of congenital obstruction of the urinary tract. *Pediatr Radiol*, 1998. 28: 630.  
<https://pubmed.ncbi.nlm.nih.gov/9716640>
894. O'Reilly, P., *et al.* Consensus on diuresis renography for investigating the dilated upper urinary tract. Radionuclides in Nephrourology Group. Consensus Committee on Diuresis Renography. *J Nucl Med*, 1996. 37: 1872.  
<https://pubmed.ncbi.nlm.nih.gov/8917195>
895. Choong, K.K., *et al.* Volume expanded diuretic renography in the postnatal assessment of suspected uretero-pelvic junction obstruction. *J Nucl Med*, 1992. 33: 2094.  
<https://pubmed.ncbi.nlm.nih.gov/1460498>
896. Reddy, P.P., *et al.* Prenatal diagnosis. Therapeutic implications. *Urol Clin North Am*, 1998. 25: 171.  
<https://pubmed.ncbi.nlm.nih.gov/9633572>
897. Braga, L.H., *et al.* Pilot randomized, placebo controlled trial to investigate the effect of antibiotic prophylaxis on the rate of urinary tract infection in infants with prenatal hydronephrosis. *J Urol*, 2014. 191: 1501.  
<https://pubmed.ncbi.nlm.nih.gov/24679865>
898. Craig, J., *et al.*, Long-term antibiotics to prevent urinary tract infection in children with isolated vesicoureteric reflux: a placebo-controlled randomized trial. , in *Australian and New Zeland Society of Nephrology 38th Annual Scientific Meeting 2002: Sydney*.
899. Silay, M.S., *et al.* Role of antibiotic prophylaxis in antenatal hydronephrosis: A systematic review from the European Association of Urology/European Society for Paediatric Urology Guidelines Panel. *J Pediatr Urol*, 2017. 13: 306.  
<https://pubmed.ncbi.nlm.nih.gov/28462806>
900. Weitz, M., *et al.* Surgery versus non-surgical management for unilateral ureteric-pelvic junction obstruction in newborns and infants less than two years of age. *Cochrane Database Syst Rev*, 2016. 7: CD010716.  
<https://pubmed.ncbi.nlm.nih.gov/27416073>
901. Novick, A.C., *et al.*, *Surgery of the kidney*, in *Campell's Urology*. 1998, WB Saunders: Philadelphia.
902. Nasser, F.M., *et al.* Dismembered Pyeloplasty in Infants 6 Months Old or Younger With and Without External Trans-anastomotic Nephrostent: A Prospective Randomized Study. *Urology*, 2017. 101: 38.  
<https://pubmed.ncbi.nlm.nih.gov/27693478>
903. Reddy, M.N., *et al.* The laparoscopic pyeloplasty: is there a role in the age of robotics? *Urol Clin North Am*, 2015. 42: 43.  
<https://pubmed.ncbi.nlm.nih.gov/25455171>
904. Tasian, G.E., *et al.* The robotic-assisted laparoscopic pyeloplasty: gateway to advanced reconstruction. *Urol Clin North Am*, 2015. 42: 89.  
<https://pubmed.ncbi.nlm.nih.gov/25455175>
905. Huang, Y., *et al.* An updated meta-analysis of laparoscopic versus open pyeloplasty for ureteropelvic junction obstruction in children. *Int J Clin Exp Med*, 2015. 8: 4922.  
<https://pubmed.ncbi.nlm.nih.gov/26131065>

906. Alhazmi, H.H. Redo laparoscopic pyeloplasty among children: A systematic review and meta-analysis. *Urol Ann*, 2018. 10: 347.  
<https://pubmed.ncbi.nlm.nih.gov/30386084>
907. Cundy, T.P., *et al.* Meta-analysis of robot-assisted vs conventional laparoscopic and open pyeloplasty in children. *BJU Int*, 2014. 114: 582.  
<https://pubmed.ncbi.nlm.nih.gov/25383399>
908. Trevisani, L.F., *et al.* Current controversies in pediatric urologic robotic surgery. *Curr Opin Urol*, 2013. 23: 72.  
<https://pubmed.ncbi.nlm.nih.gov/23169150>
909. Silay, M.S., *et al.* Laparoscopy versus robotic-assisted pyeloplasty in children: preliminary results of a pilot prospective randomized controlled trial. *World J Urol*, 2020. 38: 1841.  
<https://pubmed.ncbi.nlm.nih.gov/31435732>
910. Arena, F., *et al.* Conservative treatment in primary neonatal megaureter. *Eur J Pediatr Surg*, 1998. 8: 347.  
<https://pubmed.ncbi.nlm.nih.gov/9926303>
911. Peters, C.A., *et al.* Congenital obstructed megaureters in early infancy: diagnosis and treatment. *J Urol*, 1989. 142: 641.  
<https://pubmed.ncbi.nlm.nih.gov/2746792>
912. Onen, A., *et al.* Long-term followup of prenatally detected severe bilateral newborn hydronephrosis initially managed nonoperatively. *J Urol*, 2002. 168: 1118.  
<https://pubmed.ncbi.nlm.nih.gov/12187248>
913. Shukla, A.R., *et al.* Prenatally detected primary megaureter: a role for extended followup. *J Urol*, 2005. 173: 1353.  
<https://pubmed.ncbi.nlm.nih.gov/15758800>
914. Sripathi, V., *et al.* Primary obstructive megaureter. *J Pediatr Surg*, 1991. 26: 826.  
<https://pubmed.ncbi.nlm.nih.gov/1895193>
915. Doudt, A.D., *et al.* Endoscopic Management of Primary Obstructive Megaureter: A Systematic Review. *J Endourol*, 2018. 32: 482.  
<https://pubmed.ncbi.nlm.nih.gov/29676162>
916. Lee, T., *et al.* Impact of Clinical Guidelines on Voiding Cystourethrogram Use and Vesicoureteral Reflux Incidence. *J Urol*, 2018. 199: 831.  
<https://pubmed.ncbi.nlm.nih.gov/28866466>
917. Fanos, V., *et al.* Antibiotics or surgery for vesicoureteric reflux in children. *Lancet*, 2004. 364: 1720.  
<https://pubmed.ncbi.nlm.nih.gov/15530633>
918. Liu, J.L., *et al.* Responsible genes in children with primary vesicoureteral reflux: findings from the Chinese Children Genetic Kidney Disease Database. *World J Pediatr*, 2021. 17: 409.  
<https://pubmed.ncbi.nlm.nih.gov/34059960>
919. Liang, D., *et al.* DNA copy number variations in children with vesicoureteral reflux and urinary tract infections. *PLoS One*, 2019. 14: e0220617.  
<https://pubmed.ncbi.nlm.nih.gov/31404082>
920. Shahrokhzadeh, S., *et al.* Association of Genetic Polymorphisms in GSTP1, GSTM1, and GSTT1 Genes with Vesicoureteral Reflux Susceptibility in the Children of Southeast Iran. *Iran J Public Health*, 2020. 49: 1364.  
<https://pubmed.ncbi.nlm.nih.gov/33083304>
921. Sargent, M.A. What is the normal prevalence of vesicoureteral reflux? *Pediatr Radiol*, 2000. 30: 587.  
<https://pubmed.ncbi.nlm.nih.gov/11009294>
922. Skoog, S.J., *et al.* Pediatric Vesicoureteral Reflux Guidelines Panel Summary Report: Clinical Practice Guidelines for Screening Siblings of Children With Vesicoureteral Reflux and Neonates/Infants With Prenatal Hydronephrosis. *J Urol*, 2010. 184: 1145.  
<https://pubmed.ncbi.nlm.nih.gov/20650494>
923. Estrada, C.R., Jr., *et al.* Nomograms for predicting annual resolution rate of primary vesicoureteral reflux: results from 2,462 children. *J Urol*, 2009. 182: 1535.  
<https://pubmed.ncbi.nlm.nih.gov/19683762>
924. Pirker, M.E., *et al.* Renal scarring in familial vesicoureteral reflux: is prevention possible? *J Urol*, 2006. 176: 1842.  
<https://pubmed.ncbi.nlm.nih.gov/16945668>
925. Alsaywid, B.S., *et al.* High grade primary vesicoureteral reflux in boys: long-term results of a prospective cohort study. *J Urol*, 2010. 184: 1598.  
<https://pubmed.ncbi.nlm.nih.gov/20728178>



926. Hannula, A., *et al.* Vesicoureteral reflux in children with suspected and proven urinary tract infection. *Pediatr Nephrol*, 2010. 25: 1463.  
<https://pubmed.ncbi.nlm.nih.gov/20467791>
927. Menezes, M., *et al.* Familial vesicoureteral reflux—is screening beneficial? *J Urol*, 2009. 182: 1673.  
<https://pubmed.ncbi.nlm.nih.gov/19692047>
928. Noe, H.N. The long-term results of prospective sibling reflux screening. *J Urol*, 1992. 148: 1739.  
<https://pubmed.ncbi.nlm.nih.gov/1433599>
929. Koff, S.A., *et al.* The relationship among dysfunctional elimination syndromes, primary vesicoureteral reflux and urinary tract infections in children. *J Urol*, 1998. 160: 1019.  
<https://pubmed.ncbi.nlm.nih.gov/9719268>
930. Ural, Z., *et al.* Bladder dynamics and vesicoureteral reflux: factors associated with idiopathic lower urinary tract dysfunction in children. *J Urol*, 2008. 179: 1564.  
<https://pubmed.ncbi.nlm.nih.gov/18295262>
931. Sillen, U., *et al.* The Swedish reflux trial in children: v. Bladder dysfunction. *J Urol*, 2010. 184: 298.  
<https://pubmed.ncbi.nlm.nih.gov/20488486>
932. Sarhan, O., *et al.* Critical analysis of the outcome of primary unilateral vesicoureteral reflux in a medium volume center. *African Journal of Urology*, 2020. 26: 49.  
<https://www.researchgate.net/publication/346247587>
933. Esbjorner, E., *et al.* Management of children with dilating vesico-ureteric reflux in Sweden. *Acta Paediatr*, 2004. 93: 37.  
<https://pubmed.ncbi.nlm.nih.gov/14989437>
934. Sjostrom, S., *et al.* Spontaneous resolution of high grade infantile vesicoureteral reflux. *J Urol*, 2004. 172: 694.  
<https://pubmed.ncbi.nlm.nih.gov/15247764>
935. Knudson, M.J., *et al.* Predictive factors of early spontaneous resolution in children with primary vesicoureteral reflux. *J Urol*, 2007. 178: 1684.  
<https://pubmed.ncbi.nlm.nih.gov/17707023>
936. Sjostrom, S., *et al.* Predictive factors for resolution of congenital high grade vesicoureteral reflux in infants: results of univariate and multivariate analyses. *J Urol*, 2010. 183: 1177.  
<https://pubmed.ncbi.nlm.nih.gov/20096864>
937. Yeung, C.K., *et al.* Renal and bladder functional status at diagnosis as predictive factors for the outcome of primary vesicoureteral reflux in children. *J Urol*, 2006. 176: 1152.  
<https://pubmed.ncbi.nlm.nih.gov/16890714>
938. Mohanan, N., *et al.* Renal parenchymal damage in intermediate and high grade infantile vesicoureteral reflux. *J Urol*, 2008. 180: 1635.  
<https://pubmed.ncbi.nlm.nih.gov/18708232>
939. Olbing, H., *et al.* New renal scars in children with severe VUR: a 10-year study of randomized treatment. *Pediatr Nephrol*, 2003. 18: 1128.  
<https://pubmed.ncbi.nlm.nih.gov/14523634>
940. Peters, C., *et al.* Vesicoureteral reflux associated renal damage: congenital reflux nephropathy and acquired renal scarring. *J Urol*, 2010. 184: 265.  
<https://pubmed.ncbi.nlm.nih.gov/20483150>
941. Coplen, D.E., *et al.* Correlation of prenatal and postnatal ultrasound findings with the incidence of vesicoureteral reflux in children with fetal renal pelvic dilatation. *J Urol*, 2008. 180: 1631.  
<https://pubmed.ncbi.nlm.nih.gov/18718617>
942. Estrada, C.R., *et al.* Vesicoureteral reflux and urinary tract infection in children with a history of prenatal hydronephrosis—should voiding cystourethrography be performed in cases of postnatally persistent grade II hydronephrosis? *J Urol*, 2009. 181: 801.  
<https://pubmed.ncbi.nlm.nih.gov/19095265>
943. Lee, R.S., *et al.* Antenatal hydronephrosis as a predictor of postnatal outcome: a meta-analysis. *Pediatrics*, 2006. 118: 586.  
<https://pubmed.ncbi.nlm.nih.gov/16882811>
944. Mallik, M., *et al.* Antenatally detected urinary tract abnormalities: more detection but less action. *Pediatr Nephrol*, 2008. 23: 897.  
<https://pubmed.ncbi.nlm.nih.gov/18278521>
945. Phan, V., *et al.* Vesicoureteral reflux in infants with isolated antenatal hydronephrosis. *Pediatr Nephrol*, 2003. 18: 1224.  
<https://pubmed.ncbi.nlm.nih.gov/14586679>

946. Ylinen, E., *et al.* Risk of renal scarring in vesicoureteral reflux detected either antenatally or during the neonatal period. *Urology*, 2003. 61: 1238.  
<https://pubmed.ncbi.nlm.nih.gov/12809909>
947. Naseer, S.R., *et al.* New renal scars in children with urinary tract infections, vesicoureteral reflux and voiding dysfunction: a prospective evaluation. *J Urol*, 1997. 158: 566.  
<https://pubmed.ncbi.nlm.nih.gov/9224361>
948. Mathias, S., *et al.* Risk factors for renal scarring and clinical morbidity in children with high-grade and low-grade primary vesicoureteral reflux. *J Pediatr Urol*, 2022. 18: 225 e1.  
<https://pubmed.ncbi.nlm.nih.gov/35094942>
949. Naseri, M., *et al.* Diagnostic Values of Kidney Ultrasonography for Vesicoureteral Reflux (VUR) and High Grade VUR. *Iran J Kidney Dis*, 2021. 15: 328.  
<https://pubmed.ncbi.nlm.nih.gov/34582367>
950. Darge, K., *et al.* Current status of vesicoureteral reflux diagnosis. *World J Urol*, 2004. 22: 88.  
<https://pubmed.ncbi.nlm.nih.gov/15173954>
951. Lebowitz, R.L., *et al.* International system of radiographic grading of vesicoureteric reflux. International Reflux Study in Children. *Pediatr Radiol*, 1985. 15: 105.  
<https://pubmed.ncbi.nlm.nih.gov/3975102>
952. Westwood, M.E., *et al.* Further investigation of confirmed urinary tract infection (UTI) in children under five years: a systematic review. *BMC Pediatr*, 2005. 5: 2.  
<https://pubmed.ncbi.nlm.nih.gov/15769296>
953. Snow, B.W., *et al.* Non-invasive vesicoureteral reflux imaging. *J Pediatr Urol*, 2010. 6: 543.  
<https://pubmed.ncbi.nlm.nih.gov/20488755>
954. Darge, K. Voiding urosonography with US contrast agents for the diagnosis of vesicoureteric reflux in children. II. Comparison with radiological examinations. *Pediatr Radiol*, 2008. 38: 54.  
<https://pubmed.ncbi.nlm.nih.gov/17639371>
955. Papadopoulou, F., *et al.* Harmonic voiding urosonography with a second-generation contrast agent for the diagnosis of vesicoureteral reflux. *Pediatr Radiol*, 2009. 39: 239.  
<https://pubmed.ncbi.nlm.nih.gov/19096835>
956. Takazakura, R., *et al.* Magnetic resonance voiding cystourethrography for vesicoureteral reflux. *J Magn Reson Imaging*, 2007. 25: 170.  
<https://pubmed.ncbi.nlm.nih.gov/17154372>
957. Murakami, N., *et al.* Ureteral dilatation detected in magnetic resonance imaging predicts vesicoureteral reflux in children with urinary tract infection. *PLoS One*, 2018. 13: e0209595.  
<https://pubmed.ncbi.nlm.nih.gov/30576373>
958. Duran, C., *et al.* Contrast-enhanced Voiding Urosonography for Vesicoureteral Reflux Diagnosis in Children. *Radiographics*, 2017. 37: 1854.  
<https://pubmed.ncbi.nlm.nih.gov/29019761>
959. Oh, S., *et al.* Contrast-enhanced voiding ultrasonography to detect intrarenal reflux in children: comparison with 99mTc-DMSA renal scans. *Ultrasonography*, 2022. 41: 502.  
<https://pubmed.ncbi.nlm.nih.gov/35295068>
960. Nalçacıoğlu, H., *et al.* Assessment of Positioned Instillation of Contrast Cystography in Children with Recurrent Urinary Tract Infections. *Journal of Urological Surgery*, 2020. 7: 58.  
<https://www.researchgate.net/publication/339611760>
961. Schneider, K.O., *et al.* Intrarenal reflux, an overlooked entity - retrospective analysis of 1,166 voiding cystourethrographies in children. *Pediatr Radiol*, 2019. 49: 617.  
<https://pubmed.ncbi.nlm.nih.gov/30683961>
962. Simicic Majce, A., *et al.* Intrarenal Reflux in the Light of Contrast-Enhanced Voiding Urosonography. *Front Pediatr*, 2021. 9: 642077.  
<https://pubmed.ncbi.nlm.nih.gov/33738272>
963. Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee. *Pediatrics*, 1981. 67: 392.  
<https://pubmed.ncbi.nlm.nih.gov/7017578>
964. Scherz, H.C., *et al.* The selective use of dimercaptosuccinic acid renal scans in children with vesicoureteral reflux. *J Urol*, 1994. 152: 628.  
<https://pubmed.ncbi.nlm.nih.gov/8021985>
965. Hoberman, A., *et al.* Imaging studies after a first febrile urinary tract infection in young children. *N Engl J Med*, 2003. 348: 195.  
<https://pubmed.ncbi.nlm.nih.gov/12529459>

966. Hong, I.K., *et al.* Prediction of vesicoureteral reflux in children with febrile urinary tract infection using relative uptake and cortical defect in DMSA scan. *Pediatr Neonatol*, 2018. 59: 618.  
<https://pubmed.ncbi.nlm.nih.gov/29576374>
967. Grazioli, S., *et al.* Antenatal and postnatal ultrasound in the evaluation of the risk of vesicoureteral reflux. *Pediatr Nephrol*, 2010. 25: 1687.  
<https://pubmed.ncbi.nlm.nih.gov/20524012>
968. Lidefelt, K.J., *et al.* Antenatal hydronephrosis: infants with minor postnatal dilatation do not need prophylaxis. *Pediatr Nephrol*, 2008. 23: 2021.  
<https://pubmed.ncbi.nlm.nih.gov/18560902>
969. Hafez, A.T., *et al.* Analysis of trends on serial ultrasound for high grade neonatal hydronephrosis. *J Urol*, 2002. 168: 1518.  
<https://pubmed.ncbi.nlm.nih.gov/12352447>
970. Lee, J.H., *et al.* Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection. *J Urol*, 2008. 179: 1524.  
<https://pubmed.ncbi.nlm.nih.gov/18295269>
971. Sidhu, G., *et al.* Outcome of isolated antenatal hydronephrosis: a systematic review and meta-analysis. *Pediatr Nephrol*, 2006. 21: 218.  
<https://pubmed.ncbi.nlm.nih.gov/16362721>
972. Visuri, S., *et al.* Postnatal imaging of prenatally detected hydronephrosis-when is voiding cystourethrogram necessary? *Pediatr Nephrol*, 2018. 33: 1751.  
<https://pubmed.ncbi.nlm.nih.gov/29626243>
973. Houle, A.M., *et al.* Impact of early screening for reflux in siblings on the detection of renal damage. *BJU Int*, 2004. 94: 123.  
<https://pubmed.ncbi.nlm.nih.gov/15217445>
974. Puri, P., *et al.* Urinary tract infection and renal damage in sibling vesicoureteral reflux. *J Urol*, 1998. 160: 1028.  
<https://pubmed.ncbi.nlm.nih.gov/9719271>
975. Lertdumrongluk, K., *et al.* Predictive score for vesicoureteral reflux in children with a first febrile urinary tract infection. *Int J Urol*, 2021. 28: 573.  
<https://pubmed.ncbi.nlm.nih.gov/33745167>
976. Hansson, S., *et al.* Dimercapto-succinic acid scintigraphy instead of voiding cystourethrogram for infants with urinary tract infection. *J Urol*, 2004. 172: 1071.  
<https://pubmed.ncbi.nlm.nih.gov/15311040>
977. Herz, D., *et al.* 5-year prospective results of dimercapto-succinic acid imaging in children with febrile urinary tract infection: proof that the top-down approach works. *J Urol*, 2010. 184: 1703.  
<https://pubmed.ncbi.nlm.nih.gov/20728131>
978. Preda, I., *et al.* Normal dimercaptosuccinic acid scintigraphy makes voiding cystourethrogram unnecessary after urinary tract infection. *J Pediatr*, 2007. 151: 581.  
<https://pubmed.ncbi.nlm.nih.gov/18035134>
979. Colen, J., *et al.* Dysfunctional elimination syndrome is a negative predictor for vesicoureteral reflux. *J Pediatr Urol*, 2006. 2: 312.  
<https://pubmed.ncbi.nlm.nih.gov/18947628>
980. Meena, J., *et al.* Prevalence of Bladder and Bowel Dysfunction in Toilet-Trained Children With Urinary Tract Infection and/or Primary Vesicoureteral Reflux: A Systematic Review and Meta-Analysis. *Front Pediatr*, 2020. 8: 84.  
<https://pubmed.ncbi.nlm.nih.gov/32300575>
981. Loukogeorgakis, S.P., *et al.* Renal scarring is the most significant predictor of breakthrough febrile urinary tract infection in patients with simplex and duplex primary vesico-ureteral reflux. *J Pediatr Urol*, 2020. 16: 189 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31953013>
982. Elder, J.S., *et al.* Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. *J Urol*, 1997. 157: 1846.  
<https://pubmed.ncbi.nlm.nih.gov/9112544>
983. Dias, C.S., *et al.* Risk factors for recurrent urinary tract infections in a cohort of patients with primary vesicoureteral reflux. *Pediatr Infect Dis J*, 2010. 29: 139.  
<https://pubmed.ncbi.nlm.nih.gov/20135833>
984. Wheeler, D.M., *et al.* Interventions for primary vesicoureteric reflux. *Cochrane Database Syst Rev*, 2004: CD001532.  
<https://pubmed.ncbi.nlm.nih.gov/15266449>

985. Williams, G.J., *et al.* Long-term antibiotics for preventing recurrent urinary tract infection in children. *Cochrane Database Syst Rev*, 2006: CD001534.  
<https://pubmed.ncbi.nlm.nih.gov/16855971>
986. Singh-Grewal, D., *et al.* Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. *Arch Dis Child*, 2005. 90: 853.  
<https://pubmed.ncbi.nlm.nih.gov/15890696>
987. Sjostrom, S., *et al.* A scoring system for predicting downgrading and resolution of high-grade infant vesicoureteral reflux. *Acta Paediatr*, 2021. 110: 347.  
<https://pubmed.ncbi.nlm.nih.gov/32511799>
988. Greenfield, S.P. Antibiotic prophylaxis in pediatric urology: an update. *Curr Urol Rep*, 2011. 12: 126.  
<https://pubmed.ncbi.nlm.nih.gov/21229337>
989. Greenfield, S.P., *et al.* Vesicoureteral reflux: the RIVUR study and the way forward. *J Urol*, 2008. 179: 405.  
<https://pubmed.ncbi.nlm.nih.gov/18076937>
990. Brandstrom, P., *et al.* The Swedish reflux trial in children: IV. Renal damage. *J Urol*, 2010. 184: 292.  
<https://pubmed.ncbi.nlm.nih.gov/20494369>
991. Su, D., *et al.* Risk factors for breakthrough urinary tract infection in children with vesicoureteral reflux receiving continuous antibiotic prophylaxis. *Transl Pediatr*, 2022. 11: 1.  
<https://pubmed.ncbi.nlm.nih.gov/35242647>
992. Garin, E.H., *et al.* Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. *Pediatrics*, 2006. 117: 626.  
<https://pubmed.ncbi.nlm.nih.gov/16510640>
993. Montini, G., *et al.* Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. *Pediatrics*, 2008. 122: 1064.  
<https://pubmed.ncbi.nlm.nih.gov/18977988>
994. Pennesi, M., *et al.* Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. *Pediatrics*, 2008. 121: e1489.  
<https://pubmed.ncbi.nlm.nih.gov/18490378>
995. Roussey-Kesler, G., *et al.* Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study. *J Urol*, 2008. 179: 674.  
<https://pubmed.ncbi.nlm.nih.gov/18082208>
996. Investigators, R.T., *et al.* Antimicrobial prophylaxis for children with vesicoureteral reflux. *N Engl J Med*, 2014. 370: 2367.  
<https://pubmed.ncbi.nlm.nih.gov/24795142>
997. Wang, H.H., *et al.* Efficacy of antibiotic prophylaxis in children with vesicoureteral reflux: systematic review and meta-analysis. *J Urol*, 2015. 193: 963.  
<https://pubmed.ncbi.nlm.nih.gov/25196653>
998. de Bessa, J., Jr., *et al.* Antibiotic prophylaxis for prevention of febrile urinary tract infections in children with vesicoureteral reflux: a meta-analysis of randomized, controlled trials comparing dilated to nondilated vesicoureteral reflux. *J Urol*, 2015. 193: 1772.  
<https://pubmed.ncbi.nlm.nih.gov/25817142>
999. Hidas, G., *et al.* Predicting the Risk of Breakthrough Urinary Tract Infections: Primary Vesicoureteral Reflux. *J Urol*, 2015. 194: 1396.  
<https://pubmed.ncbi.nlm.nih.gov/26066405>
1000. Mathews, R., *et al.* The role of antimicrobial prophylaxis in the management of children with vesicoureteral reflux—the RIVUR study outcomes. *Adv Chronic Kidney Dis*, 2015. 22: 325.  
<https://pubmed.ncbi.nlm.nih.gov/26088078>
1001. Wang, Z.T., *et al.* A Reanalysis of the RIVUR Trial Using a Risk Classification System. *J Urol*, 2018. 199: 1608.  
<https://pubmed.ncbi.nlm.nih.gov/29198997>
1002. Xie, M., *et al.* Do Various Treatment Modalities of Vesicoureteral Reflux Have Any Adverse Effects in Pediatric Patients? A Meta-Analysis. *Urol Int*, 2021. 105: 1002.  
<https://pubmed.ncbi.nlm.nih.gov/34555831>
1003. Anraku, T., *et al.* Retrospective Analysis to Determine the Optimal Timing to Discontinue Continuous Antibiotic Prophylaxis in Patients with Primary Vesicoureteral Reflux. *Urol Int*, 2019. 102: 462.  
<https://pubmed.ncbi.nlm.nih.gov/30917379>

1004. Nadkarni, M.D., *et al.* Laboratory Findings After Urinary Tract Infection and Antimicrobial Prophylaxis in Children With Vesicoureteral Reflux. *Clin Pediatr (Phila)*, 2020. 59: 259.  
<https://pubmed.ncbi.nlm.nih.gov/31888378>
1005. Akagawa, Y., *et al.* Impact of Long-Term Low Dose Antibiotic Prophylaxis on Gut Microbiota in Children. *J Urol*, 2020. 204: 1320.  
<https://pubmed.ncbi.nlm.nih.gov/32614253>
1006. Morello, W., *et al.* Low-Dose Antibiotic Prophylaxis Induces Rapid Modifications of the Gut Microbiota in Infants With Vesicoureteral Reflux. *Front Pediatr*, 2021. 9: 674716.  
<https://pubmed.ncbi.nlm.nih.gov/34222145>
1007. Leigh, J., *et al.* Antibiotic prophylaxis for prevention of urinary tract infections in the first year of life in children with vesicoureteral reflux diagnosed in the workup of antenatal hydronephrosis: a systematic review. *Pediatr Nephrol*, 2020. 35: 1639.  
<https://pubmed.ncbi.nlm.nih.gov/32350666>
1008. Han, D.S., *et al.* Reflux Timing Is a Predictor of Successful Endoscopic Treatment of Vesicoureteral Reflux. *Urology*, 2019. 124: 237.  
<https://pubmed.ncbi.nlm.nih.gov/30385258>
1009. Dogan, H.S., *et al.* Factors affecting the success of endoscopic treatment of vesicoureteral reflux and comparison of two dextranomer based bulking agents: does bulking substance matter? *J Pediatr Urol*, 2015. 11: 90 e1.  
<https://pubmed.ncbi.nlm.nih.gov/25791422>
1010. Kocherov, S., *et al.* Multicenter survey of endoscopic treatment of vesicoureteral reflux using polyacrylate-polyalcohol bulking copolymer (Vantris). *Urology*, 2014. 84: 689.  
<https://pubmed.ncbi.nlm.nih.gov/25168553>
1011. Puri, P., *et al.* Multicenter survey of endoscopic treatment of vesicoureteral reflux using polytetrafluoroethylene. *J Urol*, 1998. 160: 1007.  
<https://pubmed.ncbi.nlm.nih.gov/9719265>
1012. Steyaert, H., *et al.* Migration of PTFE paste particles to the kidney after treatment for vesico-ureteric reflux. *BJU Int*, 2000. 85: 168.  
<https://pubmed.ncbi.nlm.nih.gov/10619969>
1013. Elder, J.S., *et al.* Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. *J Urol*, 2006. 175: 716.  
<https://pubmed.ncbi.nlm.nih.gov/16407037>
1014. Tekin, A., *et al.* Changing bulking agent may require change in injection volume for endoscopic treatment of vesicoureteral reflux. *Int Braz J Urol*, 2018. 44: 1194.  
<https://pubmed.ncbi.nlm.nih.gov/30325612>
1015. Garcia-Aparicio, L., *et al.* Randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR). *World J Urol*, 2018. 36: 1651.  
<https://pubmed.ncbi.nlm.nih.gov/29725806>
1016. Payza, A.D., *et al.* Can distal ureteral diameter measurement predict primary vesicoureteral reflux clinical outcome and success of endoscopic injection? *J Pediatr Urol*, 2019. 15: 515 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31420285>
1017. Ben-Meir, D., *et al.* Late-onset Uretero-vesical Junction Obstruction Following Endoscopic Injection of Bulking Material for the Treatment of Vesico-ureteral Reflux. *Urology*, 2017. 101: 60.  
<https://pubmed.ncbi.nlm.nih.gov/27993711>
1018. Warchol, S., *et al.* Endoscopic correction of vesicoureteral reflux in children using polyacrylate-polyalcohol copolymer (Vantris): 5-years of prospective follow-up. *Cent European J Urol*, 2017. 70: 314.  
<https://pubmed.ncbi.nlm.nih.gov/29104797>
1019. Okawada, M., *et al.* Incidence of ureterovesical obstruction and Cohen antireflux surgery after Deflux(R) treatment for vesicoureteric reflux. *J Pediatr Surg*, 2018. 53: 310.  
<https://pubmed.ncbi.nlm.nih.gov/29217322>
1020. Babu, R., *et al.* A systematic review & meta-analysis comparing outcomes of endoscopic treatment of primary vesico ureteric reflux in children with polyacrylate poly alcohol copolymer versus dextranomer hyaluronic acid. *J Pediatr Surg*, 2022. 57: 683.  
<https://pubmed.ncbi.nlm.nih.gov/35197197>
1021. Chertin, B., *et al.* What are the predictive factors leading to ureteral obstruction following endoscopic correction of VUR in the pediatric population? *J Pediatr Urol*, 2018. 14: 538 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29885870>

1022. Holmdahl, G., *et al.* The Swedish reflux trial in children: II. Vesicoureteral reflux outcome. *J Urol*, 2010. 184: 280.  
<https://pubmed.ncbi.nlm.nih.gov/20488469>
1023. Nordenstrom, J., *et al.* The Swedish Infant High-grade Reflux Trial - Bladder function. *J Pediatr Urol*, 2017. 13: 139.  
<https://pubmed.ncbi.nlm.nih.gov/27989639>
1024. Al Hindi, S., *et al.* High-grade vesicoureteral reflux in infants: Our experience with endoscopic subureteric injections. *Urologia*, 2022. 89: 120.  
<https://pubmed.ncbi.nlm.nih.gov/33063631>
1025. Duckett, J.W., *et al.* Surgical results: International Reflux Study in Children--United States branch. *J Urol*, 1992. 148: 1674.  
<https://pubmed.ncbi.nlm.nih.gov/1433586>
1026. Lipski, B.A., *et al.* Voiding dysfunction after bilateral extravesical ureteral reimplantation. *J Urol*, 1998. 159: 1019.  
<https://pubmed.ncbi.nlm.nih.gov/9474222>
1027. Kurtz, M.P., *et al.* Robotic versus open pediatric ureteral reimplantation: Costs and complications from a nationwide sample. *J Pediatr Urol*, 2016. 12: 408 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27593917>
1028. Esposito, C., *et al.* Robot-assisted extravesical ureteral reimplantation (revur) for unilateral vesicoureteral reflux in children: results of a multicentric international survey. *World J Urol*, 2018. 36: 481.  
<https://pubmed.ncbi.nlm.nih.gov/29248949>
1029. Deng, T., *et al.* Robot-assisted laparoscopic versus open ureteral reimplantation for pediatric vesicoureteral reflux: a systematic review and meta-analysis. *World J Urol*, 2018. 36: 819.  
<https://pubmed.ncbi.nlm.nih.gov/29374841>
1030. Boysen, W.R., *et al.* Prospective multicenter study on robot-assisted laparoscopic extravesical ureteral reimplantation (RALUR-EV): Outcomes and complications. *J Pediatr Urol*, 2018. 14: 262 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29503220>
1031. Austin, J.C., *et al.* Vesicoureteral reflux: who benefits from correction. *Urol Clin North Am*, 2010. 37: 243.  
<https://pubmed.ncbi.nlm.nih.gov/20569802>
1032. Canon, S.J., *et al.* Vesicoscopic cross-trigonal ureteral reimplantation: a minimally invasive option for repair of vesicoureteral reflux. *J Urol*, 2007. 178: 269.  
<https://pubmed.ncbi.nlm.nih.gov/17499791>
1033. Chung, P.H., *et al.* Comparing open and pneumovesical approach for ureteric reimplantation in pediatric patients--a preliminary review. *J Pediatr Surg*, 2008. 43: 2246.  
<https://pubmed.ncbi.nlm.nih.gov/19040945>
1034. El-Ghoneimi, A. Paediatric laparoscopic surgery. *Curr Opin Urol*, 2003. 13: 329.  
<https://pubmed.ncbi.nlm.nih.gov/12811298>
1035. Grimsby, G.M., *et al.* Multi-institutional review of outcomes of robot-assisted laparoscopic extravesical ureteral reimplantation. *J Urol*, 2015. 193: 1791.  
<https://pubmed.ncbi.nlm.nih.gov/25301094>
1036. Janetschek, G., *et al.* Laparoscopic ureteral anti-reflux plasty reimplantation. First clinical experience. *Ann Urol (Paris)*, 1995. 29: 101.  
<https://pubmed.ncbi.nlm.nih.gov/7645993>
1037. Jayanthi, V., *et al.* Vesicoscopic ureteral reimplantation: a minimally invasive technique for the definitive repair of vesicoureteral reflux. *Adv Urol*, 2008. 2008: 973616.  
<https://pubmed.ncbi.nlm.nih.gov/19009038>
1038. Marchini, G.S., *et al.* Robotic assisted laparoscopic ureteral reimplantation in children: case matched comparative study with open surgical approach. *J Urol*, 2011. 185: 1870.  
<https://pubmed.ncbi.nlm.nih.gov/21421223>
1039. Riquelme, M., *et al.* Laparoscopic extravesical transperitoneal approach for vesicoureteral reflux. *J Laparoendosc Adv Surg Tech A*, 2006. 16: 312.  
<https://pubmed.ncbi.nlm.nih.gov/16796449>
1040. Kim, E.J., *et al.* Does *de novo* hydronephrosis after pediatric robot-assisted laparoscopic ureteral re-implantation behave similarly to open re-implantation? *J Pediatr Urol*, 2019. 15: 604 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31506239>
1041. Straub, M., *et al.* Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline. *World J Urol*, 2005. 23: 309.  
<https://pubmed.ncbi.nlm.nih.gov/16315051>

1042. Zafar, M.N., *et al.* Composition of urinary calculi in infants: a report from an endemic country. *Urolithiasis*, 2018. 46: 445.  
<https://pubmed.ncbi.nlm.nih.gov/29101428>
1043. Rahman, H.-U., *et al.* Frequency of Metabolic Abnormalities of Vesical Calculus in Children Younger than 10 Yrs of Age. *Pakistan Journal of Medical and Health Sciences*, 2021. 15: 1243.  
<https://pjmhsonline.com/published-issues/2021/june/61243>
1044. Metcalfe, P.D., *et al.* What is the need for additional bladder surgery after bladder augmentation in childhood? *J Urol*, 2006. 176: 1801.  
<https://pubmed.ncbi.nlm.nih.gov/16945653>
1045. Bush, N.C., *et al.* Hospitalizations for pediatric stone disease in United States, 2002-2007. *J Urol*, 2010. 183: 1151.  
<https://pubmed.ncbi.nlm.nih.gov/20096871>
1046. Novak, T.E., *et al.* Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation. *Urology*, 2009. 74: 104.  
<https://pubmed.ncbi.nlm.nih.gov/19428065>
1047. Tasian, G.E., *et al.* Annual Incidence of Nephrolithiasis among Children and Adults in South Carolina from 1997 to 2012. *Clin J Am Soc Nephrol*, 2016. 11: 488.  
<https://pubmed.ncbi.nlm.nih.gov/26769765>
1048. Sas, D.J., *et al.* Increasing incidence of kidney stones in children evaluated in the emergency department. *J Pediatr*, 2010. 157: 132.  
<https://pubmed.ncbi.nlm.nih.gov/20362300>
1049. Kirejczyk, J.K., *et al.* An association between kidney stone composition and urinary metabolic disturbances in children. *J Pediatr Urol*, 2014. 10: 130.  
<https://pubmed.ncbi.nlm.nih.gov/23953243>
1050. Ingvarsdottir, S.E., *et al.* Stone recurrence among childhood kidney stone formers: results of a nationwide study in Iceland. *Urolithiasis*, 2020. 48: 409.  
<https://pubmed.ncbi.nlm.nih.gov/32107578>
1051. Tasian, G.E., *et al.* Kidney Stone Recurrence among Children and Adolescents. *J Urol*, 2017. 197: 246.  
<https://pubmed.ncbi.nlm.nih.gov/27521691>
1052. Saitz, T.R., *et al.* 24 Hour urine metabolic differences between solitary and multiple stone formers: Results of the Collaboration on Urolithiasis in Pediatrics (CUP) working group. *J Pediatr Urol*, 2017. 13: 506 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28526618>
1053. Kruse, K., *et al.* Reference values for urinary calcium excretion and screening for hypercalciuria in children and adolescents. *Eur J Pediatr*, 1984. 143: 25.  
<https://pubmed.ncbi.nlm.nih.gov/6510426>
1054. Sargent, J.D., *et al.* Normal values for random urinary calcium to creatinine ratios in infancy. *J Pediatr*, 1993. 123: 393.  
<https://pubmed.ncbi.nlm.nih.gov/8355114>
1055. Stapleton, F.B., *et al.* Urinary excretion of calcium following an oral calcium loading test in healthy children. *Pediatrics*, 1982. 69: 594.  
<https://pubmed.ncbi.nlm.nih.gov/7079015>
1056. Borghi, L., *et al.* Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. *N Engl J Med*, 2002. 346: 77.  
<https://pubmed.ncbi.nlm.nih.gov/11784873>
1057. Curhan, G.C., *et al.* A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med*, 1993. 328: 833.  
<https://pubmed.ncbi.nlm.nih.gov/8441427>
1058. Bartosh, S.M. Medical management of pediatric stone disease. *Urol Clin North Am*, 2004. 31: 575.  
<https://pubmed.ncbi.nlm.nih.gov/15313066>
1059. Choi, J.N., *et al.* Low-dose thiazide diuretics in children with idiopathic renal hypercalciuria. *Acta Paediatr*, 2011. 100: e71.  
<https://pubmed.ncbi.nlm.nih.gov/21284722>
1060. Naseri, M., *et al.* Role of high-dose hydrochlorothiazide in idiopathic hypercalciuric urolithiasis of childhood. *Iran J Kidney Dis*, 2011. 5: 162.  
<https://pubmed.ncbi.nlm.nih.gov/21525575>
1061. Preminger, G.M., *et al.* Eventual attenuation of hypocalciuric response to hydrochlorothiazide in absorptive hypercalciuria. *J Urol*, 1987. 137: 1104.  
<https://pubmed.ncbi.nlm.nih.gov/3586136>

1062. Tekin, A., *et al.* Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis. *J Urol*, 2002. 168: 2572.  
<https://pubmed.ncbi.nlm.nih.gov/12441986>
1063. Hoppe, B., *et al.* Urinary calcium oxalate saturation in healthy infants and children. *J Urol*, 1997. 158: 557.  
<https://pubmed.ncbi.nlm.nih.gov/9224359>
1064. Neuhaus, T.J., *et al.* Urinary oxalate excretion in urolithiasis and nephrocalcinosis. *Arch Dis Child*, 2000. 82: 322.  
<https://pubmed.ncbi.nlm.nih.gov/10735843>
1065. Turudic, D., *et al.* Calcium oxalate urolithiasis in children: urinary promoters/inhibitors and role of their ratios. *Eur J Pediatr*, 2016. 175: 1959.  
<https://pubmed.ncbi.nlm.nih.gov/27730307>
1066. Wang, X., *et al.* Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study. *Front Med (Lausanne)*, 2021. 8: 703305.  
<https://pubmed.ncbi.nlm.nih.gov/34616753>
1067. Morgenstern, B.Z., *et al.* Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study. *J Pediatr*, 1993. 123: 248.  
<https://pubmed.ncbi.nlm.nih.gov/8345420>
1068. Defoor, W., *et al.* Results of a prospective trial to compare normal urine supersaturation in children and adults. *J Urol*, 2005. 174: 1708.  
<https://pubmed.ncbi.nlm.nih.gov/16148687>
1069. Kovacevic, L., *et al.* From hypercalciuria to hypocitraturia--a shifting trend in pediatric urolithiasis? *J Urol*, 2012. 188: 1623.  
<https://pubmed.ncbi.nlm.nih.gov/22910255>
1070. Tekin, A., *et al.* A study of the etiology of idiopathic calcium urolithiasis in children: hypocitruria is the most important risk factor. *J Urol*, 2000. 164: 162.  
<https://pubmed.ncbi.nlm.nih.gov/10840454>
1071. Celiksoy, M.H., *et al.* Metabolic disorders in Turkish children with urolithiasis. *Urology*, 2015. 85: 909.  
<https://pubmed.ncbi.nlm.nih.gov/25817115>
1072. DeFoor, W., *et al.* Calcium-to-Citrate Ratio Distinguishes Solitary and Recurrent Urinary Stone Forming Children. *J Urol*, 2017. 198: 416.  
<https://pubmed.ncbi.nlm.nih.gov/28365270>
1073. Zu'bi, F., *et al.* Stone growth patterns and risk for surgery among children presenting with hypercalciuria, hypocitraturia and cystinuria as underlying metabolic causes of urolithiasis. *J Pediatr Urol*, 2017. 13: 357 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28865885>
1074. Tekin, A., *et al.* Cystine calculi in children: the results of a metabolic evaluation and response to medical therapy. *J Urol*, 2001. 165: 2328.  
<https://pubmed.ncbi.nlm.nih.gov/11371943>
1075. Gabrielsen, J.S., *et al.* Pediatric urinary stone composition in the United States. *J Urol*, 2012. 187: 2182.  
<https://pubmed.ncbi.nlm.nih.gov/22503021>
1076. Rellum, D.M., *et al.* Pediatric urolithiasis in a non-endemic country: a single center experience from The Netherlands. *J Pediatr Urol*, 2014. 10: 155.  
<https://pubmed.ncbi.nlm.nih.gov/23981680>
1077. Bove, P., *et al.* Reexamining the value of hematuria testing in patients with acute flank pain. *J Urol*, 1999. 162: 685.  
<https://pubmed.ncbi.nlm.nih.gov/10458342>
1078. Sternberg, K., *et al.* Pediatric stone disease: an evolving experience. *J Urol*, 2005. 174: 1711.  
<https://pubmed.ncbi.nlm.nih.gov/16148688>
1079. Memarsadeghi, M., *et al.* Unenhanced multi-detector row CT in patients suspected of having urinary stone disease: effect of section width on diagnosis. *Radiology*, 2005. 235: 530.  
<https://pubmed.ncbi.nlm.nih.gov/15758192>
1080. Oner, S., *et al.* Comparison of spiral CT and US in the evaluation of pediatric urolithiasis. *JBR-BTR*, 2004. 87: 219.  
<https://pubmed.ncbi.nlm.nih.gov/15587558>
1081. Strouse, P.J., *et al.* Non-contrast thin-section helical CT of urinary tract calculi in children. *Pediatr Radiol*, 2002. 32: 326.  
<https://pubmed.ncbi.nlm.nih.gov/11956719>



1082. Kwon, J.K., *et al.* Usefulness of low-dose nonenhanced computed tomography with iterative reconstruction for evaluation of urolithiasis: diagnostic performance and agreement between the urologist and the radiologist. *Urology*, 2015. 85: 531.  
<https://pubmed.ncbi.nlm.nih.gov/25733262>
1083. Alpay, H., *et al.* Clinical and metabolic features of urolithiasis and microlithiasis in children. *Pediatr Nephrol*, 2009. 24: 2203.  
<https://pubmed.ncbi.nlm.nih.gov/19603196>
1084. Skolarikos, A., *et al.* Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. *Eur Urol*, 2015. 67: 750.  
<https://pubmed.ncbi.nlm.nih.gov/25454613>
1085. Untan, I., *et al.* Metabolic risk factors and the role of prophylaxis in pediatric urolithiasis. *J Pediatr Urol*, 2021. 17: 215 e1.  
<https://pubmed.ncbi.nlm.nih.gov/33342680>
1086. Chan, K.H., *et al.* The ability of a limited metabolic assessment to identify pediatric stone formers with metabolic abnormalities. *J Pediatr Urol*, 2018. 14: 331 e1.  
<https://pubmed.ncbi.nlm.nih.gov/30177386>
1087. Chan, K.H., *et al.* Initial collection of an inadequate 24-hour urine sample in children does not predict subsequent inadequate collections. *J Pediatr Urol*, 2019. 15: 74 e1.  
<https://pubmed.ncbi.nlm.nih.gov/30467015>
1088. Bastug, F., *et al.* Comparison of infants and children with urolithiasis: a large case series. *Urolithiasis*, 2022. 50: 411.  
<https://pubmed.ncbi.nlm.nih.gov/35482085>
1089. Andrioli, V., *et al.* Infant nephrolithiasis and nephrocalcinosis: Natural history and predictors of surgical intervention. *J Pediatr Urol*, 2017. 13: 355 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28729176>
1090. Camlar, S.A., *et al.* Characteristics of infant urolithiasis: A single center experience in western Turkey. *J Pediatr Urol*, 2020. 16: 463 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32571536>
1091. Saygili, S.K., *et al.* Natural history of patients with infantile nephrolithiasis: what are the predictors of surgical intervention? *Pediatr Nephrol*, 2021. 36: 939.  
<https://pubmed.ncbi.nlm.nih.gov/33006651>
1092. Asi, T., *et al.* Shockwave lithotripsy for kidney stones as a first-line therapy in children younger than 2 years. *J Pediatr Urol*, 2020. 16: 193 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32037146>
1093. Ahmad T, M.N., Manan F. Safety and Efficacy of Minimally Invasive Percutaneous Nephrolithotomy for Kidney Stones in Infants in Pakistan. *Med Forum*, 2021. 32: 151.  
<https://doi.org/10.1186/s12894-023-01341-3>
1094. Li, J., *et al.* Flexible ureteroscopic lithotripsy for the treatment of upper urinary tract calculi in infants. *Exp Biol Med (Maywood)*, 2017. 242: 153.  
<https://pubmed.ncbi.nlm.nih.gov/27633576>
1095. Raza, A., *et al.* Pediatric urolithiasis: 15 years of local experience with minimally invasive endourological management of pediatric calculi. *J Urol*, 2005. 174: 682.  
<https://pubmed.ncbi.nlm.nih.gov/16006948>
1096. Rizvi, S.A., *et al.* Pediatric urolithiasis: developing nation perspectives. *J Urol*, 2002. 168: 1522.  
<https://pubmed.ncbi.nlm.nih.gov/12352448>
1097. Elmaci, A.M., *et al.* What predicts spontaneous passage of  $\leq 1$  cm ureteral stones in children? *J Pediatr Surg*, 2020. 55: 1373.  
<https://pubmed.ncbi.nlm.nih.gov/31155390>
1098. Shahat, A., *et al.* Is Tamsulosin Effective after Shock Wave Lithotripsy for Pediatric Renal Stones? A Randomized, Controlled Study. *J Urol*, 2016. 195: 1284.  
<https://pubmed.ncbi.nlm.nih.gov/26926538>
1099. Velazquez, N., *et al.* Medical expulsive therapy for pediatric urolithiasis: Systematic review and meta-analysis. *J Pediatr Urol*, 2015. 11: 321.  
<https://pubmed.ncbi.nlm.nih.gov/26165192>
1100. Tuerxun, A., *et al.* Impaction and Prediction: Does Ureteral Wall Thickness Affect the Success of Medical Expulsive Therapy in Pediatric Ureteral Stones? *Urol Int*, 2017. 98: 436.  
<https://pubmed.ncbi.nlm.nih.gov/28052290>
1101. Soliman, M.G., *et al.* Silodosin versus Tamsulosin as Medical Expulsive Therapy for Children with Lower-Third Ureteric Stones: Prospective Randomized Placebo-Controlled Study. *Urol Int*, 2021. 105: 568.  
<https://pubmed.ncbi.nlm.nih.gov/33524970>

1102. Kern, A., *et al.* Medical and dietary interventions for preventing recurrent urinary stones in children. *Cochrane Database Syst Rev*, 2017. 11: CD011252.  
<https://pubmed.ncbi.nlm.nih.gov/29117629>
1103. Dincel, N., *et al.* Are small residual stone fragments really insignificant in children? *J Pediatr Surg*, 2013. 48: 840.  
<https://pubmed.ncbi.nlm.nih.gov/23583144>
1104. El-Assmy, A., *et al.* Clinically Insignificant Residual Fragments: Is It an Appropriate Term in Children? *Urology*, 2015. 86: 593.  
<https://pubmed.ncbi.nlm.nih.gov/26126693>
1105. Akin, Y., *et al.* Long-term effects of pediatric extracorporeal shockwave lithotripsy on renal function. *Res Rep Urol*, 2014. 6: 21.  
<https://pubmed.ncbi.nlm.nih.gov/24892029>
1106. Aksoy, Y., *et al.* Extracorporeal shock wave lithotripsy in children: experience using a mpl-9000 lithotripter. *World J Urol*, 2004. 22: 115.  
<https://pubmed.ncbi.nlm.nih.gov/14740160>
1107. Aldridge, R.D., *et al.* Anesthesia for pediatric lithotripsy. *Paediatr Anaesth*, 2006. 16: 236.  
<https://pubmed.ncbi.nlm.nih.gov/16490086>
1108. McLorie, G.A., *et al.* Safety and efficacy of extracorporeal shock wave lithotripsy in infants. *Can J Urol*, 2003. 10: 2051.  
<https://pubmed.ncbi.nlm.nih.gov/14704109>
1109. Reisiger, K., *et al.* Pediatric nephrolithiasis: does treatment affect renal growth? *Urology*, 2007. 69: 1190.  
<https://pubmed.ncbi.nlm.nih.gov/17572213>
1110. Villanyi, K.K., *et al.* Short-term changes in renal function after extracorporeal shock wave lithotripsy in children. *J Urol*, 2001. 166: 222.  
<https://pubmed.ncbi.nlm.nih.gov/11435873>
1111. Vlajkovic, M., *et al.* Long-term functional outcome of kidneys in children with urolithiasis after ESWL treatment. *Eur J Pediatr Surg*, 2002. 12: 118.  
<https://pubmed.ncbi.nlm.nih.gov/12015657>
1112. Willis, L.R., *et al.* Relationship between kidney size, renal injury, and renal impairment induced by shock wave lithotripsy. *J Am Soc Nephrol*, 1999. 10: 1753.  
<https://pubmed.ncbi.nlm.nih.gov/10446943>
1113. Kaygisiz, O., *et al.* Which frequency is better for pediatric shock wave lithotripsy? Intermediate or low: a prospective randomized study. *World J Urol*, 2021. 39: 3963.  
<https://pubmed.ncbi.nlm.nih.gov/33890144>
1114. Tuncer, M., *et al.* What is the optimal frequency in shock wave lithotripsy for pediatric renal stones? A prospective randomized study. *Urolithiasis*, 2021. 49: 377.  
<https://pubmed.ncbi.nlm.nih.gov/33704540>
1115. Ather, M.H., *et al.* Does size and site matter for renal stones up to 30-mm in size in children treated by extracorporeal lithotripsy? *Urology*, 2003. 61: 212.  
<https://pubmed.ncbi.nlm.nih.gov/12559298>
1116. Muslumanoglu, A.Y., *et al.* Extracorporeal shock wave lithotripsy as first line treatment alternative for urinary tract stones in children: a large scale retrospective analysis. *J Urol*, 2003. 170: 2405.  
<https://pubmed.ncbi.nlm.nih.gov/14634438>
1117. Ugur, G., *et al.* Anaesthetic/analgesic management of extracorporeal shock wave lithotripsy in paediatric patients. *Paediatr Anaesth*, 2003. 13: 85.  
<https://pubmed.ncbi.nlm.nih.gov/12535048>
1118. Tuncer, M., *et al.* Extracorporeal Shock Wave Lithotripsy Management of Renal Stones in Children: Does Anesthesia Affect the Treatment Outcomes on an Age-based Manner? *Urology*, 2017. 107: 218.  
<https://pubmed.ncbi.nlm.nih.gov/28546088>
1119. Afshar, K., *et al.* Outcome of small residual stone fragments following shock wave lithotripsy in children. *J Urol*, 2004. 172: 1600.  
<https://pubmed.ncbi.nlm.nih.gov/15371769>
1120. Al-Busaidy, S.S., *et al.* Pediatric staghorn calculi: the role of extracorporeal shock wave lithotripsy monotherapy with special reference to ureteral stenting. *J Urol*, 2003. 169: 629.  
<https://pubmed.ncbi.nlm.nih.gov/12544330>
1121. Lottmann, H.B., *et al.* Monotherapy extracorporeal shock wave lithotripsy for the treatment of staghorn calculi in children. *J Urol*, 2001. 165: 2324.  
<https://pubmed.ncbi.nlm.nih.gov/11371942>

1122. Rodrigues Netto, N., Jr., *et al.* Extracorporeal shock wave lithotripsy in children. *J Urol*, 2002. 167: 2164.  
<https://pubmed.ncbi.nlm.nih.gov/11956471>
1123. Onal, B., *et al.* The impact of caliceal pelvic anatomy on stone clearance after shock wave lithotripsy for pediatric lower pole stones. *J Urol*, 2004. 172: 1082.  
<https://pubmed.ncbi.nlm.nih.gov/15311043>
1124. Kirli, E.A., *et al.* Does Previous Open Stone Surgery Affect the Outcome of Shock Wave Lithotripsy Treatment in Children? *Urol Int*, 2021. 105: 52.  
<https://pubmed.ncbi.nlm.nih.gov/32862182>
1125. Demirkesen, O., *et al.* Efficacy of extracorporeal shock wave lithotripsy for isolated lower caliceal stones in children compared with stones in other renal locations. *Urology*, 2006. 67: 170.  
<https://pubmed.ncbi.nlm.nih.gov/16413356>
1126. Ozgur Tan, M., *et al.* The impact of radiological anatomy in clearance of lower calyceal stones after shock wave lithotripsy in paediatric patients. *Eur Urol*, 2003. 43: 188.  
<https://pubmed.ncbi.nlm.nih.gov/12565778>
1127. Hochreiter, W.W., *et al.* Extracorporeal shock wave lithotripsy for distal ureteral calculi: what a powerful machine can achieve. *J Urol*, 2003. 169: 878.  
<https://pubmed.ncbi.nlm.nih.gov/12576804>
1128. Landau, E.H., *et al.* Extracorporeal shock wave lithotripsy is highly effective for ureteral calculi in children. *J Urol*, 2001. 165: 2316.  
<https://pubmed.ncbi.nlm.nih.gov/11371970>
1129. McAdams, S., *et al.* Preoperative stone attenuation value predicts success after shock wave lithotripsy in children. *J Urol*, 2010. 184: 1804.  
<https://pubmed.ncbi.nlm.nih.gov/20728112>
1130. Dogan, H.S., *et al.* A new nomogram for prediction of outcome of pediatric shock-wave lithotripsy. *J Pediatr Urol*, 2015. 11: 84 e1.  
<https://pubmed.ncbi.nlm.nih.gov/25812469>
1131. Onal, B., *et al.* Nomogram and scoring system for predicting stone-free status after extracorporeal shock wave lithotripsy in children with urolithiasis. *BJU Int*, 2013. 111: 344.  
<https://pubmed.ncbi.nlm.nih.gov/22672514>
1132. Yanaral, F., *et al.* Shock-wave Lithotripsy for Pediatric Patients: Which Nomogram Can Better Predict Postoperative Outcomes? *Urology*, 2018. 117: 126.  
<https://pubmed.ncbi.nlm.nih.gov/29630952>
1133. Kailavasan, M., *et al.* A systematic review of nomograms used in urolithiasis practice to predict clinical outcomes in paediatric patients. *J Pediatr Urol*, 2022. 18: 448.  
<https://pubmed.ncbi.nlm.nih.gov/35676182>
1134. Ergin, G., *et al.* Shock wave lithotripsy or retrograde intrarenal surgery: which one is more effective for 10-20-mm renal stones in children. *Ir J Med Sci*, 2018. 187: 1121.  
<https://pubmed.ncbi.nlm.nih.gov/29502272>
1135. Marchetti, K.A., *et al.* Extracorporeal shock wave lithotripsy versus ureteroscopy for management of pediatric nephrolithiasis in upper urinary tract stones: multi-institutional outcomes of efficacy and morbidity. *J Pediatr Urol*, 2019. 15: 516 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31326329>
1136. Wu, H.Y., *et al.* Surgical management of children with urolithiasis. *Urol Clin North Am*, 2004. 31: 589.  
<https://pubmed.ncbi.nlm.nih.gov/15313067>
1137. ElSheemy, M.S., *et al.* Lower calyceal and renal pelvic stones in preschool children: A comparative study of mini-percutaneous nephrolithotomy versus extracorporeal shockwave lithotripsy. *Int J Urol*, 2016. 23: 564.  
<https://pubmed.ncbi.nlm.nih.gov/27173126>
1138. Jackman, S.V., *et al.* Percutaneous nephrolithotomy in infants and preschool age children: experience with a new technique. *Urology*, 1998. 52: 697.  
<https://pubmed.ncbi.nlm.nih.gov/9763096>
1139. Desai, M.R., *et al.* Percutaneous nephrolithotomy for complex pediatric renal calculus disease. *J Endourol*, 2004. 18: 23.  
<https://pubmed.ncbi.nlm.nih.gov/15006048>
1140. Badawy, H., *et al.* Percutaneous management of renal calculi: experience with percutaneous nephrolithotomy in 60 children. *J Urol*, 1999. 162: 1710.  
<https://pubmed.ncbi.nlm.nih.gov/10524919>

1141. Boormans, J.L., *et al.* Percutaneous nephrolithotomy for treating renal calculi in children. *BJU Int*, 2005. 95: 631.  
<https://pubmed.ncbi.nlm.nih.gov/15705093>
1142. Dawaba, M.S., *et al.* Percutaneous nephrolithotomy in children: early and late anatomical and functional results. *J Urol*, 2004. 172: 1078.  
<https://pubmed.ncbi.nlm.nih.gov/15311042>
1143. Sahin, A., *et al.* Percutaneous nephrolithotomy in older children. *J Pediatr Surg*, 2000. 35: 1336.  
<https://pubmed.ncbi.nlm.nih.gov/10999692>
1144. Shokeir, A.A., *et al.* Percutaneous nephrolithotomy in treatment of large stones within horseshoe kidneys. *Urology*, 2004. 64: 426.  
<https://pubmed.ncbi.nlm.nih.gov/15351557>
1145. Saber-Khalah, M., *et al.* The feasibility of one-day length of hospital stay after pediatric percutaneous nephrolithotomy. *Urologia*, 2022. 89: 126.  
<https://pubmed.ncbi.nlm.nih.gov/33550942>
1146. Farouk, A., *et al.* Is mini-percutaneous nephrolithotomy a safe alternative to extracorporeal shockwave lithotripsy in pediatric age group in borderline stones? a randomized prospective study. *World J Urol*, 2018. 36: 1139.  
<https://pubmed.ncbi.nlm.nih.gov/29450731>
1147. Karatag, T., *et al.* A Comparison of 2 Percutaneous Nephrolithotomy Techniques for the Treatment of Pediatric Kidney Stones of Sizes 10-20 mm: Microperc vs Miniperc. *Urology*, 2015. 85: 1015.  
<https://pubmed.ncbi.nlm.nih.gov/25917724>
1148. Nouralizadeh, A., *et al.* Fluoroscopy-free ultrasonography-guided percutaneous nephrolithotomy in pediatric patients: a single-center experience. *World J Urol*, 2018. 36: 667.  
<https://pubmed.ncbi.nlm.nih.gov/29349571>
1149. Ozden, E., *et al.* Modified Clavien classification in percutaneous nephrolithotomy: assessment of complications in children. *J Urol*, 2011. 185: 264.  
<https://pubmed.ncbi.nlm.nih.gov/21074805>
1150. Ozden, E., *et al.* Percutaneous renal surgery in children with complex stones. *J Pediatr Urol*, 2008. 4: 295.  
<https://pubmed.ncbi.nlm.nih.gov/18644533>
1151. Simayi, A., *et al.* Clinical application of super-mini PCNL (SMP) in the treatment of upper urinary tract stones under ultrasound guidance. *World J Urol*, 2019. 37: 943.  
<https://pubmed.ncbi.nlm.nih.gov/30167833>
1152. Unsal, A., *et al.* Safety and efficacy of percutaneous nephrolithotomy in infants, preschool age, and older children with different sizes of instruments. *Urology*, 2010. 76: 247.  
<https://pubmed.ncbi.nlm.nih.gov/20022089>
1153. Wang, W., *et al.* Comparing micropercutaneous nephrolithotomy and retrograde intrarenal surgery in treating 1-2 cm solitary renal stones in pediatric patients younger than 3 years. *J Pediatr Urol*, 2019. 15: 517 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31301976>
1154. Dogan, H.S., *et al.* Percutaneous nephrolithotomy in children: does age matter? *World J Urol*, 2011. 29: 725.  
<https://pubmed.ncbi.nlm.nih.gov/21590468>
1155. Guven, S., *et al.* Successful percutaneous nephrolithotomy in children: multicenter study on current status of its use, efficacy and complications using Clavien classification. *J Urol*, 2011. 185: 1419.  
<https://pubmed.ncbi.nlm.nih.gov/21334653>
1156. Khairy Salem, H., *et al.* Tubeless percutaneous nephrolithotomy in children. *J Pediatr Urol*, 2007. 3: 235.  
<https://pubmed.ncbi.nlm.nih.gov/18947742>
1157. Nouralizadeh, A., *et al.* Experience of percutaneous nephrolithotomy using adult-size instruments in children less than 5 years old. *J Pediatr Urol*, 2009. 5: 351.  
<https://pubmed.ncbi.nlm.nih.gov/19230776>
1158. Onal, B., *et al.* Factors affecting complication rates of percutaneous nephrolithotomy in children: results of a multi-institutional retrospective analysis by the Turkish pediatric urology society. *J Urol*, 2014. 191: 777.  
<https://pubmed.ncbi.nlm.nih.gov/24095906>
1159. Bilen, C.Y., *et al.* Percutaneous nephrolithotomy in children: lessons learned in 5 years at a single institution. *J Urol*, 2007. 177: 1867.  
<https://pubmed.ncbi.nlm.nih.gov/17437838>

1160. De Dominicis, M., *et al.* Retrograde ureteroscopy for distal ureteric stone removal in children. *BJU Int*, 2005. 95: 1049.  
<https://pubmed.ncbi.nlm.nih.gov/15839930>
1161. Raza, A., *et al.* Ureteroscopy in the management of pediatric urinary tract calculi. *J Endourol*, 2005. 19: 151.  
<https://pubmed.ncbi.nlm.nih.gov/15798409>
1162. Satar, N., *et al.* Rigid ureteroscopy for the treatment of ureteral calculi in children. *J Urol*, 2004. 172: 298.  
<https://pubmed.ncbi.nlm.nih.gov/15201799>
1163. Bujons, A., *et al.* Mini-percutaneous nephrolithotomy with high-power holmium YAG laser in pediatric patients with staghorn and complex calculi. *J Pediatr Urol*, 2016. 12: 253 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27264051>
1164. Ellison, J.S., *et al.* A simulated model for fluid and tissue heating during pediatric laser lithotripsy. *J Pediatr Urol*, 2020. 16: 626 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32768343>
1165. Jackman, S.V., *et al.* The "mini-perc" technique: a less invasive alternative to percutaneous nephrolithotomy. *World J Urol*, 1998. 16: 371.  
<https://pubmed.ncbi.nlm.nih.gov/9870281>
1166. Dede, O., *et al.* Ultra-mini-percutaneous nephrolithotomy in pediatric nephrolithiasis: both low pressure and high efficiency. *J Pediatr Urol*, 2015. 11: 253 e1.  
<https://pubmed.ncbi.nlm.nih.gov/25964199>
1167. Sarica, K., *et al.* Super-mini percutaneous nephrolithotomy for renal stone less than 25mm in pediatric patients: Could it be an alternative to shockwave lithotripsy? *Actas Urol Esp (Engl Ed)*, 2018. 42: 406.  
<https://pubmed.ncbi.nlm.nih.gov/29273258>
1168. Yuan, D., *et al.* Super-Mini Percutaneous Nephrolithotomy Reduces the Incidence of Postoperative Adverse Events in Pediatric Patients: A Retrospective Cohort Study. *Urol Int*, 2019. 103: 81.  
<https://pubmed.ncbi.nlm.nih.gov/31039558>
1169. Liu, Y., *et al.* Comparison of super-mini PCNL (SMP) versus Miniperc for stones larger than 2 cm: a propensity score-matching study. *World J Urol*, 2018. 36: 955.  
<https://pubmed.ncbi.nlm.nih.gov/29387932>
1170. Desai, M.R., *et al.* Single-step percutaneous nephrolithotomy (microperc): the initial clinical report. *J Urol*, 2011. 186: 140.  
<https://pubmed.ncbi.nlm.nih.gov/21575966>
1171. Hatipoglu, N.K., *et al.* Comparison of shockwave lithotripsy and microperc for treatment of kidney stones in children. *J Endourol*, 2013. 27: 1141.  
<https://pubmed.ncbi.nlm.nih.gov/23713511>
1172. Bilen, C.Y., *et al.* Tubeless mini percutaneous nephrolithotomy in infants and preschool children: a preliminary report. *J Urol*, 2010. 184: 2498.  
<https://pubmed.ncbi.nlm.nih.gov/20961572>
1173. Aghamir, S.M., *et al.* Feasibility of totally tubeless percutaneous nephrolithotomy under the age of 14 years: a randomized clinical trial. *J Endourol*, 2012. 26: 621.  
<https://pubmed.ncbi.nlm.nih.gov/22192104>
1174. Gamal, W., *et al.* Supine pediatric percutaneous nephrolithotomy (PCNL). *J Pediatr Urol*, 2015. 11: 78 e1.  
<https://pubmed.ncbi.nlm.nih.gov/25819602>
1175. Emiliani, E., *et al.* Retrorenal colon in pediatric patients with urolithiasis: Is the supine position for PCNL advantageous? *J Pediatr Urol*, 2022. 18: 741 e1.  
<https://pubmed.ncbi.nlm.nih.gov/35985922>
1176. Desoky, E.A.E., *et al.* Ultra-Mini-Percutaneous Nephrolithotomy in Flank-Free Modified Supine Position vs Prone Position in Treatment of Pediatric Renal Pelvic and Lower Caliceal Stones. *J Endourol*, 2022. 36: 610.  
<https://pubmed.ncbi.nlm.nih.gov/34861776>
1177. Binil, K., *et al.* Intercostal Nerve Block and Peritubal Infiltration with Bupivacaine for Postoperative Analgesia after Percutaneous Nephrolithotomy: A Randomised Clinical Study. *Journal of Clinical and Diagnostic Research*, 2021. 15: UC09.  
<https://www.nejm.org/doi/full/10.1056/NEJMra2116032>
1178. Gultekin, M.H., *et al.* Evaluation of the Efficacy of the Erector Spinae Plane Block for Postoperative Pain in Patients Undergoing Percutaneous Nephrolithotomy: A Randomized Controlled Trial. *J Endourol*, 2020. 34: 267.  
<https://pubmed.ncbi.nlm.nih.gov/31880963>

1179. Dogan, H.S., *et al.* Factors affecting complication rates of ureteroscopic lithotripsy in children: results of multi-institutional retrospective analysis by Pediatric Stone Disease Study Group of Turkish Pediatric Urology Society. *J Urol*, 2011. 186: 1035.  
<https://pubmed.ncbi.nlm.nih.gov/21784482>
1180. Schuster, T.G., *et al.* Ureteroscopy for the treatment of urolithiasis in children. *J Urol*, 2002. 167: 1813.  
<https://pubmed.ncbi.nlm.nih.gov/11912438>
1181. Dogan, H.S., *et al.* Use of the holmium:YAG laser for ureterolithotripsy in children. *BJU Int*, 2004. 94: 131.  
<https://pubmed.ncbi.nlm.nih.gov/15217447>
1182. Gokce, M.I., *et al.* Evaluation of Postoperative Hydronephrosis Following Ureteroscopy in Pediatric Population: Incidence and Predictors. *Urology*, 2016. 93: 164.  
<https://pubmed.ncbi.nlm.nih.gov/26972147>
1183. Citamak, B., *et al.* Semi-Rigid Ureteroscopy Should Not Be the First Option for Proximal Ureteral Stones in Children. *J Endourol*, 2018. 32: 1028.  
<https://pubmed.ncbi.nlm.nih.gov/30226405>
1184. Abu Ghazaleh, L.A., *et al.* Retrograde intrarenal lithotripsy for small renal stones in prepubertal children. *Saudi J Kidney Dis Transpl*, 2011. 22: 492.  
<https://pubmed.ncbi.nlm.nih.gov/21566306>
1185. Corcoran, A.T., *et al.* When is prior ureteral stent placement necessary to access the upper urinary tract in prepubertal children? *J Urol*, 2008. 180: 1861.  
<https://pubmed.ncbi.nlm.nih.gov/18721946>
1186. Dave, S., *et al.* Single-institutional study on role of ureteroscopy and retrograde intrarenal surgery in treatment of pediatric renal calculi. *Urology*, 2008. 72: 1018.  
<https://pubmed.ncbi.nlm.nih.gov/18585764>
1187. Kim, S.S., *et al.* Pediatric flexible ureteroscopic lithotripsy: the children's hospital of Philadelphia experience. *J Urol*, 2008. 180: 2616.  
<https://pubmed.ncbi.nlm.nih.gov/18950810>
1188. Tanaka, S.T., *et al.* Pediatric ureteroscopic management of intrarenal calculi. *J Urol*, 2008. 180: 2150.  
<https://pubmed.ncbi.nlm.nih.gov/18804225>
1189. Li, J., *et al.* Application of flexible ureteroscopy combined with holmium laser lithotripsy and their therapeutic efficacy in the treatment of upper urinary stones in children and infants. *Urol J*, 2019. 16: 343.  
<https://pubmed.ncbi.nlm.nih.gov/30784036>
1190. Erkurt, B., *et al.* Treatment of renal stones with flexible ureteroscopy in preschool age children. *Urolithiasis*, 2014. 42: 241.  
<https://pubmed.ncbi.nlm.nih.gov/24374900>
1191. Lee, J.J., *et al.* Flat Panel Detector c-Arms Are Associated with Dramatically Reduced Radiation Exposure During Ureteroscopy and Produce Superior Images. *J Endourol*, 2021. 35: 789.  
<https://pubmed.ncbi.nlm.nih.gov/33528298>
1192. Mokhless, I.A., *et al.* Retrograde intrarenal surgery monotherapy versus shock wave lithotripsy for stones 10 to 20 mm in preschool children: a prospective, randomized study. *J Urol*, 2014. 191: 1496.  
<https://pubmed.ncbi.nlm.nih.gov/24679882>
1193. Alsagheer, G.A., *et al.* Extracorporeal shock wave lithotripsy (ESWL) versus flexible ureteroscopy (F-URS) for management of renal stone burden less than 2 cm in children: A randomized comparative study. *African Journal of Urology*, 2018. 24: 120.  
<https://www.sciencedirect.com/science/article/pii/S1110570418300110>
1194. Freton, L., *et al.* Extracorporeal Shockwave Lithotripsy Versus Flexible Ureteroscopy for the Management of Upper Tract Urinary Stones in Children. *J Endourol*, 2017. 31: 1.  
<https://pubmed.ncbi.nlm.nih.gov/27824261>
1195. Guler, Y., *et al.* Comparison of extracorporeal shockwave lithotripsy and retrograde intrarenal surgery in the treatment of renal pelvic and proximal ureteral stones  $\leq 2$  cm in children. *Indian J Urol*, 2020. 36: 282.  
<https://pubmed.ncbi.nlm.nih.gov/33376264>
1196. Saad, K.S., *et al.* Percutaneous Nephrolithotomy vs Retrograde Intrarenal Surgery for Large Renal Stones in Pediatric Patients: A Randomized Controlled Trial. *J Urol*, 2015. 194: 1716.  
<https://pubmed.ncbi.nlm.nih.gov/26165587>
1197. Bas, O., *et al.* Comparison of Retrograde Intrarenal Surgery and Micro-Percutaneous Nephrolithotomy in Moderately Sized Pediatric Kidney Stones. *J Endourol*, 2016. 30: 765.  
<https://pubmed.ncbi.nlm.nih.gov/26983791>

1198. He, Q., *et al.* Which is the best treatment of pediatric upper urinary tract stones among extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy and retrograde intrarenal surgery: a systematic review. *BMC Urol*, 2019. 19: 98.  
<https://pubmed.ncbi.nlm.nih.gov/31640693>
1199. Casale, P., *et al.* Transperitoneal laparoscopic pyelolithotomy after failed percutaneous access in the pediatric patient. *J Urol*, 2004. 172: 680.  
<https://pubmed.ncbi.nlm.nih.gov/15247760>
1200. Ghani, K.R., *et al.* Robotic nephrolithotomy and pyelolithotomy with utilization of the robotic ultrasound probe. *Int Braz J Urol*, 2014. 40: 125.  
<https://pubmed.ncbi.nlm.nih.gov/24642160>
1201. Lee, R.S., *et al.* Early results of robot assisted laparoscopic lithotomy in adolescents. *J Urol*, 2007. 177: 2306.  
<https://pubmed.ncbi.nlm.nih.gov/17509345>
1202. Srivastava, A., *et al.* Laparoscopic Ureterolithotomy in Children: With and Without Stent - Initial Tertiary Care Center Experience with More Than 1-Year Follow-Up. *Eur J Pediatr Surg*, 2017. 27: 150.  
<https://pubmed.ncbi.nlm.nih.gov/26878339>
1203. Shahat, A.A., *et al.* A randomised trial comparing transurethral to percutaneous cystolithotripsy in boys. *BJU Int*, 2022. 130: 254.  
<https://pubmed.ncbi.nlm.nih.gov/35044035>
1204. Uson, A.C., *et al.* Ureteroceles in infants and children: a report based on 44 cases. *Pediatrics*, 1961. 27: 971.  
<https://pubmed.ncbi.nlm.nih.gov/13779382>
1205. Prewitt, L.H., Jr., *et al.* The single ectopic ureter. *AJR Am J Roentgenol*, 1976. 127: 941.  
<https://pubmed.ncbi.nlm.nih.gov/998831>
1206. Ahmed, S., *et al.* Single-system ectopic ureters: a review of 12 cases. *J Pediatr Surg*, 1992. 27: 491.  
<https://pubmed.ncbi.nlm.nih.gov/1522464>
1207. Hecht, S., *et al.* Ectopic ureters in anorectal malformations. *Pediatr Surg Int*, 2019. 35: 1005.  
<https://pubmed.ncbi.nlm.nih.gov/31278478>
1208. Chwalla, R. The process of formation of cystic dilatation of the vesical end of the ureter and of diverticula at the ureteral ostium. *J Urol Cutan Ren* 1927. 31: 499.
1209. Stephens, D. Caecoureterocele and concepts on the embryology and aetiology of ureteroceles. *Aust N Z J Surg*, 1971. 40: 239.  
<https://pubmed.ncbi.nlm.nih.gov/5279434>
1210. Tokunaka, S., *et al.* Muscle dysplasia in megaureters. *J Urol*, 1984. 131: 383.  
<https://pubmed.ncbi.nlm.nih.gov/6699978>
1211. Zerin, J.M., *et al.* Single-system ureteroceles in infants and children: imaging features. *Pediatr Radiol*, 2000. 30: 139.  
<https://pubmed.ncbi.nlm.nih.gov/10755749>
1212. Monfort, G., *et al.* Surgical management of duplex ureteroceles. *J Pediatr Surg*, 1992. 27: 634.  
<https://pubmed.ncbi.nlm.nih.gov/1625138>
1213. Upadhyay, J., *et al.* Impact of prenatal diagnosis on the morbidity associated with ureterocele management. *J Urol*, 2002. 167: 2560.  
<https://pubmed.ncbi.nlm.nih.gov/11992089>
1214. Ellerker, A.G. The extravescical ectopic ureter. *Br J Surg*, 1958. 45: 344.  
<https://pubmed.ncbi.nlm.nih.gov/13536326>
1215. Pfister, C., *et al.* The value of endoscopic treatment for ureteroceles during the neonatal period. *J Urol*, 1998. 159: 1006.  
<https://pubmed.ncbi.nlm.nih.gov/9474217>
1216. Kwatra, N., *et al.* Scintigraphic features of duplex kidneys on DMSA renal cortical scans. *Pediatr Radiol*, 2013. 43: 1204.  
<https://pubmed.ncbi.nlm.nih.gov/23385361>
1217. Meneghesso, D., *et al.* Clinico-pathological correlation in duplex system ectopic ureters and ureteroceles: can preoperative work-up predict renal histology? *Pediatr Surg Int*, 2012. 28: 309.  
<https://pubmed.ncbi.nlm.nih.gov/22127487>
1218. Kocyigit, A., *et al.* Efficacy of magnetic resonance urography in detecting renal scars in children with vesicoureteral reflux. *Pediatr Nephrol*, 2014. 29: 1215.  
<https://pubmed.ncbi.nlm.nih.gov/24500707>
1219. Khrichenko, D., *et al.*, Intra- and inter-observer variability of functional MR urography (fMRU) assessment in children, in *Pediatr Radiol*. 2016. p. 666.

1220. Bellah, R.D., *et al.* Ureterocele eversion with vesicoureteral reflux in duplex kidneys: findings at voiding cystourethrography. *AJR Am J Roentgenol*, 1995. 165: 409.  
<https://pubmed.ncbi.nlm.nih.gov/7618568>
1221. Carrico, C., *et al.* Incontinence due to an infraspincteric ectopic ureter: why the delay in diagnosis and what the radiologist can do about it. *Pediatr Radiol*, 1998. 28: 942.  
<https://pubmed.ncbi.nlm.nih.gov/9880638>
1222. Ehammer, T., *et al.* High resolution MR for evaluation of lower urogenital tract malformations in infants and children: feasibility and preliminary experiences. *Eur J Radiol*, 2011. 78: 388.  
<https://pubmed.ncbi.nlm.nih.gov/20138451>
1223. Sumfest, J.M., *et al.* Pseudoureterocele: potential for misdiagnosis of an ectopic ureter as a ureterocele. *Br J Urol*, 1995. 75: 401.  
<https://pubmed.ncbi.nlm.nih.gov/7735809>
1224. Figueroa, V.H., *et al.* Utility of MR urography in children suspected of having ectopic ureter. *Pediatr Radiol*, 2014. 44: 956.  
<https://pubmed.ncbi.nlm.nih.gov/24535117>
1225. Beganovic, A., *et al.* Ectopic ureterocele: long-term results of open surgical therapy in 54 patients. *J Urol*, 2007. 178: 251.  
<https://pubmed.ncbi.nlm.nih.gov/17499769>
1226. Byun, E., *et al.* A meta-analysis of surgical practice patterns in the endoscopic management of ureteroceles. *J Urol*, 2006. 176: 1871.  
<https://pubmed.ncbi.nlm.nih.gov/16945677>
1227. Chertin, B., *et al.* Endoscopic treatment of vesicoureteral reflux associated with ureterocele. *J Urol*, 2007. 178: 1594.  
<https://pubmed.ncbi.nlm.nih.gov/17707044>
1228. Decter, R.M., *et al.* Individualized treatment of ureteroceles. *J Urol*, 1989. 142: 535.  
<https://pubmed.ncbi.nlm.nih.gov/2746775>
1229. Husmann, D., *et al.* Management of ectopic ureterocele associated with renal duplication: a comparison of partial nephrectomy and endoscopic decompression. *J Urol*, 1999. 162: 1406.  
<https://pubmed.ncbi.nlm.nih.gov/10492225>
1230. Castagnetti, M., *et al.* Management of duplex system ureteroceles in neonates and infants. *Nat Rev Urol*, 2009. 6: 307.  
<https://pubmed.ncbi.nlm.nih.gov/19498409>
1231. Monfort, G., *et al.* [Simplified treatment of ureteroceles]. *Chir Pediatr*, 1985. 26: 26.  
<https://pubmed.ncbi.nlm.nih.gov/3995671>
1232. Sander, J.C., *et al.* Outcomes of endoscopic incision for the treatment of ureterocele in children at a single institution. *J Urol*, 2015. 193: 662.  
<https://pubmed.ncbi.nlm.nih.gov/25167992>
1233. Andrioli, V., *et al.* Active surveillance for antenatally detected ureteroceles: Predictors of success. *J Pediatr Urol*, 2018. 14: 243 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29580731>
1234. Han, M.Y., *et al.* Indications for nonoperative management of ureteroceles. *J Urol*, 2005. 174: 1652.  
<https://pubmed.ncbi.nlm.nih.gov/16148674>
1235. Mariyappa, B., *et al.* Management of duplex-system ureterocele. *J Paediatr Child Health*, 2014. 50: 96.  
<https://pubmed.ncbi.nlm.nih.gov/24372828>
1236. Adorisio, O., *et al.* Effectiveness of primary endoscopic incision in treatment of ectopic ureterocele associated with duplex system. *Urology*, 2011. 77: 191.  
<https://pubmed.ncbi.nlm.nih.gov/21168903>
1237. DeFoor, W., *et al.* Ectopic ureterocele: clinical application of classification based on renal unit jeopardy. *J Urol*, 2003. 169: 1092.  
<https://pubmed.ncbi.nlm.nih.gov/12576859>
1238. Jesus, L.E., *et al.* Clinical evolution of vesicoureteral reflux following endoscopic puncture in children with duplex system ureteroceles. *J Urol*, 2011. 186: 1455.  
<https://pubmed.ncbi.nlm.nih.gov/21862045>
1239. Husmann, D.A., *et al.* Ureterocele associated with ureteral duplication and a nonfunctioning upper pole segment: management by partial nephroureterectomy alone. *J Urol*, 1995. 154: 723.  
<https://pubmed.ncbi.nlm.nih.gov/7609163>
1240. Gran, C.D., *et al.* Primary lower urinary tract reconstruction for nonfunctioning renal moieties associated with obstructing ureteroceles. *J Urol*, 2005. 173: 198.  
<https://pubmed.ncbi.nlm.nih.gov/15592074>



1241. Gander, R., *et al.* Evaluation of the Initial Treatment of Ureteroceles. *Urology*, 2016. 89: 113.  
<https://pubmed.ncbi.nlm.nih.gov/26674749>
1242. Pohl, H.G. Recent advances in the management of ureteroceles in infants and children: Why less may be more. *Current Opinion in Urology*, 2011. 21: 322.  
<https://pubmed.ncbi.nlm.nih.gov/51386473>
1243. Villanueva, C.A. Open vs robotic infant ureteroureterostomy. *J Pediatr Urol*, 2019. 15: 390 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31151858>
1244. Herz, D., *et al.* Robot-assisted laparoscopic management of duplex renal anomaly: Comparison of surgical outcomes to traditional pure laparoscopic and open surgery. *J Pediatr Urol*, 2016. 12: 44 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26443241>
1245. Tan, A.H., *et al.* Results of shockwave lithotripsy for pediatric urolithiasis. *J Endourol*, 2004. 18: 527.  
<https://pubmed.ncbi.nlm.nih.gov/15333214>
1246. Biles, M.J., *et al.* Innovation in Robotics and Pediatric Urology: Robotic Ureteroureterostomy for Duplex Systems with Ureteral Ectopia. *J Endourol*, 2016. 30: 1041.  
<https://pubmed.ncbi.nlm.nih.gov/27542552>
1247. Castagnetti, M., *et al.* Dismembered extravescical reimplantation of dilated upper pole ectopic ureters in duplex systems. *J Pediatr Surg*, 2013. 48: 459.  
<https://pubmed.ncbi.nlm.nih.gov/23414887>
1248. Esposito, C., *et al.* A comparison between laparoscopic and retroperitoneoscopic approach for partial nephrectomy in children with duplex kidney: a multicentric survey. *World J Urol*, 2016. 34: 939.  
<https://pubmed.ncbi.nlm.nih.gov/26577623>
1249. Cohen, S.A., *et al.* Examining trends in the treatment of ureterocele yields no definitive solution. *Journal of Pediatric Urology*, 2015. 11: 29.e1.  
<https://pubmed.ncbi.nlm.nih.gov/602651650>
1250. Roy Choudhury, S., *et al.* Spectrum of ectopic ureters in children. *Pediatr Surg Int*, 2008. 24: 819.  
<https://pubmed.ncbi.nlm.nih.gov/18463883>
1251. Lee, P.A., *et al.* Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. *Pediatrics*, 2006. 118: e488.  
<https://pubmed.ncbi.nlm.nih.gov/16882788>
1252. Assembly, P., Parliamentary Assembly, Council of Europe, Promoting the human rights of and eliminating discrimination against intersex people. 2017.
1253. Wolffebuttel, K.P., *et al.* Gonadal dysgenesis in disorders of sex development: Diagnosis and surgical management. *J Pediatr Urol*, 2016. 12: 411.  
<https://pubmed.ncbi.nlm.nih.gov/27769830>
1254. Nowotny, H., *et al.* Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. *Eur J Endocrinol*, 2022. 186: K17.  
<https://pubmed.ncbi.nlm.nih.gov/35235536>
1255. Speiser, P.W., *et al.* Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*, 2010. 95: 4133.  
<https://pubmed.ncbi.nlm.nih.gov/20823466>
1256. Maggi, M., *et al.* Standard operating procedures: pubertas tarda/delayed puberty--male. *J Sex Med*, 2013. 10: 285.  
<https://pubmed.ncbi.nlm.nih.gov/22376050>
1257. Wales, J.K. Disordered pubertal development. *Arch Dis Child Educ Pract Ed*, 2012. 97: 9.  
<https://pubmed.ncbi.nlm.nih.gov/21278425>
1258. Cools, M., *et al.* Caring for individuals with a difference of sex development (DSD): a Consensus Statement. *Nat Rev Endocrinol*, 2018. 14: 415.  
<https://pubmed.ncbi.nlm.nih.gov/29769693>
1259. Ahmed, S.F., *et al.* Society for Endocrinology UK Guidance on the initial evaluation of a suspected difference or disorder of sex development (Revised 2021). *Clin Endocrinol (Oxf)*, 2021. 95: 818.  
<https://pubmed.ncbi.nlm.nih.gov/34031907>
1260. Avni, F.E., *et al.* Plea for a standardized imaging approach to disorders of sex development in neonates: consensus proposal from European Society of Paediatric Radiology task force. *Pediatr Radiol*, 2019. 49: 1240.  
<https://pubmed.ncbi.nlm.nih.gov/31123767>
1261. Romao, R.L.P., *et al.* Pediatric Urologists of Canada (PUC) 2021 position statement: Differences of sex development (AKA disorders of sex development). *Can Urol Assoc J*, 2021. 15: 395.  
<https://pubmed.ncbi.nlm.nih.gov/34847345>

1262. Lee, P.A., *et al.* Global Disorders of Sex Development Update since 2006: Perceptions, Approach and Care. *Horm Res Paediatr*, 2016. 85: 158.  
<https://pubmed.ncbi.nlm.nih.gov/26820577>
1263. Feldman, K.W., *et al.* Fetal phallic growth and penile standards for newborn male infants. *J Pediatr*, 1975. 86: 395.  
<https://pubmed.ncbi.nlm.nih.gov/1113226>
1264. Creighton, S., *et al.* Medical photography: ethics, consent and the intersex patient. *BJU Int*, 2002. 89: 67.  
<https://pubmed.ncbi.nlm.nih.gov/11849163>
1265. Biswas, K., *et al.* Imaging in intersex disorders. *J Pediatr Endocrinol Metab*, 2004. 17: 841.  
<https://pubmed.ncbi.nlm.nih.gov/15270401>
1266. Wright, N.B., *et al.* Imaging children with ambiguous genitalia and intersex states. *Clin Radiol*, 1995. 50: 823.  
<https://pubmed.ncbi.nlm.nih.gov/8536391>
1267. Chertin, B., *et al.* The use of laparoscopy in intersex patients. *Pediatr Surg Int*, 2006. 22: 405.  
<https://pubmed.ncbi.nlm.nih.gov/16521001>
1268. Denes, F.T., *et al.* Laparoscopic management of intersexual states. *Urol Clin North Am*, 2001. 28: 31.  
<https://pubmed.ncbi.nlm.nih.gov/11277066>
1269. Bever, Y.V., *et al.* Under-reported aspects of diagnosis and treatment addressed in the Dutch-Flemish guideline for comprehensive diagnostics in disorders/differences of sex development. *J Med Genet*, 2020. 57: 581.  
<https://pubmed.ncbi.nlm.nih.gov/32303604>
1270. Timing of elective surgery on the genitalia of male children with particular reference to the risks, benefits, and psychological effects of surgery and anesthesia. *American Academy of Pediatrics. Pediatrics*, 1996. 97: 590.  
<https://pubmed.ncbi.nlm.nih.gov/8632952>
1271. Mouriquand, P., *et al.* The ESPU/SPU standpoint on the surgical management of Disorders of Sex Development (DSD). *J Pediatr Urol*, 2014. 10: 8.  
<https://pubmed.ncbi.nlm.nih.gov/24528671>
1272. Wolffebuttel, K.P., *et al.* Open letter to the Council of Europe. *J Pediatr Urol*, 2018. 14: 4.  
<https://pubmed.ncbi.nlm.nih.gov/29548361>
1273. Bennecke, E., *et al.* Early Genital Surgery in Disorders/Differences of Sex Development: Patients' Perspectives. *Arch Sex Behav*, 2021. 50: 913.  
<https://pubmed.ncbi.nlm.nih.gov/33712989>
1274. Rapp, M., *et al.* Self- and proxy-reported outcomes after surgery in people with disorders/differences of sex development (DSD) in Europe (dsd-LIFE). *J Pediatr Urol*, 2021. 17: 353.  
<https://pubmed.ncbi.nlm.nih.gov/33358555>
1275. van der Zwan, Y.G., *et al.* Gonadal maldevelopment as risk factor for germ cell cancer: towards a clinical decision model. *Eur Urol*, 2015. 67: 692.  
<https://pubmed.ncbi.nlm.nih.gov/25240975>
1276. Piazza, M.J., *et al.* Germ Cell Tumors in Dysgenetic Gonads. *Clinics (Sao Paulo)*, 2019. 74: e408.  
<https://pubmed.ncbi.nlm.nih.gov/31721911>
1277. Slowikowska-Hilczler, J., *et al.* Risk of gonadal neoplasia in patients with disorders/differences of sex development. *Cancer Epidemiol*, 2020. 69: 101800.  
<https://pubmed.ncbi.nlm.nih.gov/32905884>
1278. Cools, M., *et al.* Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. *Endocr Rev*, 2006. 27: 468.  
<https://pubmed.ncbi.nlm.nih.gov/16735607>
1279. Chaudhry, S., *et al.* Frequency of gonadal tumours in complete androgen insensitivity syndrome (CAIS): A retrospective case-series analysis. *J Pediatr Urol*, 2017. 13: 498 e1.  
<https://pubmed.ncbi.nlm.nih.gov/28351649>
1280. Weidler, E.M., *et al.* Evolving indications for surgical intervention in patients with differences/disorders of sex development: Implications of deferred reconstruction. *Semin Pediatr Surg*, 2020. 29: 150929.  
<https://pubmed.ncbi.nlm.nih.gov/32571514>
1281. Looijenga, L.H., *et al.* Tumor risk in disorders of sex development (DSD). *Best Pract Res Clin Endocrinol Metab*, 2007. 21: 480.  
<https://pubmed.ncbi.nlm.nih.gov/17875493>

1282. Falhammar, H., *et al.* Health status in 1040 adults with disorders of sex development (DSD): a European multicenter study. *Endocr Connect*, 2018. 7: 466.  
<https://pubmed.ncbi.nlm.nih.gov/29490934>
1283. Rapp, M., *et al.* Multicentre cross-sectional clinical evaluation study about quality of life in adults with disorders/differences of sex development (DSD) compared to country specific reference populations (dsd-LIFE). *Health Qual Life Outcomes*, 2018. 16: 54.  
<https://pubmed.ncbi.nlm.nih.gov/29615040>
1284. Kreukels, B.P.C., *et al.* Sexuality in Adults with Differences/Disorders of Sex Development (DSD): Findings from the dsd-LIFE Study. *J Sex Marital Ther*, 2019. 45: 688.  
<https://pubmed.ncbi.nlm.nih.gov/31034334>
1285. Bennecke, E., *et al.* Health-related quality of life and psychological well-being in adults with differences/disorders of sex development. *Clin Endocrinol (Oxf)*, 2017. 86: 634.  
<https://pubmed.ncbi.nlm.nih.gov/28005277>
1286. de Vries, A.L.C., *et al.* Mental Health of a Large Group of Adults With Disorders of Sex Development in Six European Countries. *Psychosom Med*, 2019. 81: 629.  
<https://pubmed.ncbi.nlm.nih.gov/31232913>
1287. Association, A.P., *Diagnostic and statistical manual of mental disorders*. 5th ed. Arlington, VA. 2013.
1288. Babu, R., *et al.* Gender identity disorder (GID) in adolescents and adults with differences of sex development (DSD): A systematic review and meta-analysis. *J Pediatr Urol*, 2021. 17: 39.  
<https://pubmed.ncbi.nlm.nih.gov/33246831>
1289. Kreukels, B.P.C., *et al.* Gender Dysphoria and Gender Change in Disorders of Sex Development/ Intersex Conditions: Results From the dsd-LIFE Study. *J Sex Med*, 2018. 15: 777.  
<https://pubmed.ncbi.nlm.nih.gov/29606626>
1290. Callens, N., *et al.* Recalled and current gender role behavior, gender identity and sexual orientation in adults with Disorders/Differences of Sex Development. *Horm Behav*, 2016. 86: 8.  
<https://pubmed.ncbi.nlm.nih.gov/27576114>
1291. Capone, V., *et al.* Definition, diagnosis and management of fetal lower urinary tract obstruction: consensus of the ERKNet CAKUT-Obstructive Uropathy Work Group. *Nat Rev Urol*, 2022. 19: 295.  
<https://pubmed.ncbi.nlm.nih.gov/35136187>
1292. Fontanella, F., *et al.* Fetal megacystis: a lot more than LUTO. *Ultrasound Obstet Gynecol*, 2019. 53: 779.  
<https://pubmed.ncbi.nlm.nih.gov/30043466>
1293. Taghavi, K., *et al.* Fetal megacystis: A systematic review. *J Pediatr Urol*, 2017. 13: 7.  
<https://pubmed.ncbi.nlm.nih.gov/27889224>
1294. Hennis, P.M., *et al.* A systematic review on the accuracy of diagnostic procedures for infravesical obstruction in boys. *PLoS One*, 2014. 9: e85474.  
<https://pubmed.ncbi.nlm.nih.gov/24586242>
1295. Hodges, S.J., *et al.* Posterior urethral valves. *ScientificWorldJournal*, 2009. 9: 1119.  
<https://pubmed.ncbi.nlm.nih.gov/19838598>
1296. Malin, G., *et al.* Congenital lower urinary tract obstruction: a population-based epidemiological study. *BJOG*, 2012. 119: 1455.  
<https://pubmed.ncbi.nlm.nih.gov/22925164>
1297. Thakkar, D., *et al.* Epidemiology and demography of recently diagnosed cases of posterior urethral valves. *Pediatr Res*, 2014. 76: 560.  
<https://pubmed.ncbi.nlm.nih.gov/25198372>
1298. Churchill, B.M., *et al.* Emergency treatment and long-term follow-up of posterior urethral valves. *Urol Clin North Am*, 1990. 17: 343.  
<https://pubmed.ncbi.nlm.nih.gov/2186540>
1299. Hoover, D.L., *et al.* Posterior urethral valves, unilateral reflux and renal dysplasia: a syndrome. *J Urol*, 1982. 128: 994.  
<https://pubmed.ncbi.nlm.nih.gov/7176067>
1300. Rittenberg, M.H., *et al.* Protective factors in posterior urethral valves. *J Urol*, 1988. 140: 993.  
<https://pubmed.ncbi.nlm.nih.gov/3139895>
1301. Delefortrie, T., *et al.* Evaluating the impact of pop-off mechanisms in boys with posterior urethral valves. *Front Pediatr*, 2022. 10: 1014422.  
<https://pubmed.ncbi.nlm.nih.gov/36330367>
1302. Massaguer, C., *et al.* Pop-off mechanisms as protective factors against chronic renal disease in children with posterior urethral valves. *Cir Pediatr*, 2022. 35: 180.  
<https://pubmed.ncbi.nlm.nih.gov/36217788>

1303. Cuckow, P.M., *et al.* Long-term renal function in the posterior urethral valves, unilateral reflux and renal dysplasia syndrome. *J Urol*, 1997. 158: 1004.  
<https://pubmed.ncbi.nlm.nih.gov/9258130>
1304. Kleppe, S., *et al.* Impact of prenatal urinomas in patients with posterior urethral valves and postnatal renal function. *J Perinat Med*, 2006. 34: 425.  
<https://pubmed.ncbi.nlm.nih.gov/16965232>
1305. D'Oro, A., *et al.* Are pressure pop-offs beneficial to the bladder in boys with posterior urethral valves? *J Pediatr Urol*, 2020. 16: 488 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32605875>
1306. Young, H.H., *et al.* Congenital obstruction of the posterior urethra. *J Urol*, 3: 289-365, 1919. *J Urol*, 2002. 167: 265.  
<https://pubmed.ncbi.nlm.nih.gov/11743334>
1307. Roy, S., *et al.* [Contribution of ultrasound signs for the prenatal diagnosis of posterior urethral valves: Experience of 3years at the maternity of the Bicetre Hospital]. *J Gynecol Obstet Biol Reprod (Paris)*, 2016. 45: 478.  
<https://pubmed.ncbi.nlm.nih.gov/25980903>
1308. Cheung, K.W., *et al.* Congenital urinary tract obstruction. *Best Pract Res Clin Obstet Gynaecol*, 2019. 58: 78.  
<https://pubmed.ncbi.nlm.nih.gov/30819578>
1309. Kajbafzadeh, A.M., *et al.* Comparison of magnetic resonance urography with ultrasound studies in detection of fetal urogenital anomalies. *J Pediatr Urol*, 2008. 4: 32.  
<https://pubmed.ncbi.nlm.nih.gov/18631889>
1310. Calvo-Garcia, M.A. Imaging Evaluation of Fetal Megacystis: How Can Magnetic Resonance Imaging Help? *Semin Ultrasound CT MR*, 2015. 36: 537.  
<https://pubmed.ncbi.nlm.nih.gov/26614135>
1311. Heikkila, J., *et al.* Posterior Urethral Valves are Often Associated With Cryptorchidism and Inguinal Hernias. *Journal of Urology*, 2008. 180: 715.  
<https://pubmed.ncbi.nlm.nih.gov/18554641>
1312. Wong, J., *et al.* Why do undescended testes and posterior urethral valve occur together? *Pediatr Surg Int*, 2016. 32: 509.  
<https://pubmed.ncbi.nlm.nih.gov/27072813>
1313. Wu, C.Q., *et al.* Posterior urethral morphology on initial voiding cystourethrogram correlates to early renal outcomes in infants with posterior urethral valves. *J Pediatr Urol*, 2022. 18: 813.  
<https://pubmed.ncbi.nlm.nih.gov/35840456>
1314. Johnson, M.P., *et al.* Natural History of Fetal Lower Urinary Tract Obstruction with Normal Amniotic Fluid Volume at Initial Diagnosis. *Fetal Diagn Ther*, 2018. 44: 10.  
<https://pubmed.ncbi.nlm.nih.gov/28700992>
1315. Ruano, R., *et al.* Lower urinary tract obstruction: fetal intervention based on prenatal staging. *Pediatr Nephrol*, 2017. 32: 1871.  
<https://pubmed.ncbi.nlm.nih.gov/28730376>
1316. Freedman, A.L., *et al.* Fetal therapy for obstructive uropathy: past, present.future? *Pediatr Nephrol*, 2000. 14: 167.  
<https://pubmed.ncbi.nlm.nih.gov/10684370>
1317. Ibirogbu, E.R., *et al.* Fetal lower urinary tract obstruction: What should we tell the prospective parents? *Prenat Diagn*, 2020. 40: 661.  
<https://pubmed.ncbi.nlm.nih.gov/32065667>
1318. Debska, M., *et al.* Early vesico-amniotic shunting - does it change the prognosis in fetal lower urinary tract obstruction diagnosed in the first trimester? *Ginekol Pol*, 2017. 88: 486.  
<https://pubmed.ncbi.nlm.nih.gov/29057434>
1319. Saccone, G., *et al.* Antenatal intervention for congenital fetal lower urinary tract obstruction (LUTO): a systematic review and meta-analysis. *J Matern Fetal Neonatal Med*, 2020. 33: 2664.  
<https://pubmed.ncbi.nlm.nih.gov/30501534>
1320. Kohl, T., *et al.* Vesico-amniotic shunt insertion prior to the completion of 16 weeks results in improved preservation of renal function in surviving fetuses with isolated severe lower urinary tract obstruction (LUTO). *J Pediatr Urol*, 2022. 18: 116.  
<https://pubmed.ncbi.nlm.nih.gov/35123910>
1321. Strizek, B., *et al.* Vesicoamniotic Shunting before 17 + 0 Weeks in Fetuses with Lower Urinary Tract Obstruction (LUTO): Comparison of Somatex vs. Harrison Shunt Systems. *J Clin Med*, 2022. 11.  
<https://pubmed.ncbi.nlm.nih.gov/35566484>

1322. Gottschalk, I., *et al.* Single-center outcome analysis of 46 fetuses with megacystis after intrauterine vesico-amniotic shunting with the Somatex(R)intrauterine shunt. *Arch Gynecol Obstet*, 2024. 309: 145.  
<https://pubmed.ncbi.nlm.nih.gov/36604332>
1323. Abdennadher, W., *et al.* Fetal urine biochemistry at 13-23 weeks of gestation in lower urinary tract obstruction: criteria for in-utero treatment. *Ultrasound Obstet Gynecol*, 2015. 46: 306.  
<https://pubmed.ncbi.nlm.nih.gov/25412852>
1324. Koch, A., *et al.* Evaluation of Sequential Urine Analysis when Selecting Candidates for Vesicoamniotic Shunting in Lower Urinary Tract Obstruction. *Fetal Diagn Ther*, 2021. 48: 265.  
<https://pubmed.ncbi.nlm.nih.gov/33756463>
1325. Morris, R.K., *et al.* Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial. *Lancet*, 2013. 382: 1496.  
<https://pubmed.ncbi.nlm.nih.gov/23953766>
1326. Nassr, A.A., *et al.* Effectiveness of vesicoamniotic shunt in fetuses with congenital lower urinary tract obstruction: an updated systematic review and meta-analysis. *Ultrasound Obstet Gynecol*, 2017. 49: 696.  
<https://pubmed.ncbi.nlm.nih.gov/27270578>
1327. Sananes, N., *et al.* Urological fistulas after fetal cystoscopic laser ablation of posterior urethral valves: surgical technical aspects. *Ultrasound Obstet Gynecol*, 2015. 45: 183.  
<https://pubmed.ncbi.nlm.nih.gov/24817027>
1328. Debska, M., *et al.* Urethroplasty with balloon catheterization in fetal lower urinary tract obstruction: observational study of 10 fetuses. *Ultrasound Obstet Gynecol*, 2020. 56: 916.  
<https://pubmed.ncbi.nlm.nih.gov/31763721>
1329. Sarhan, O., *et al.* Surgical complications of posterior urethral valve ablation: 20 years experience. *J Pediatr Surg*, 2010. 45: 2222.  
<https://pubmed.ncbi.nlm.nih.gov/21034948>
1330. Babu, R., *et al.* Early outcome following diathermy versus cold knife ablation of posterior urethral valves. *J Pediatr Urol*, 2013. 9: 7.  
<https://pubmed.ncbi.nlm.nih.gov/22417679>
1331. Pellegrino, C., *et al.* Posterior urethral valves: Role of prenatal diagnosis and long-term management of bladder function; a single center point of view and review of literature. *Front Pediatr*, 2022. 10: 1057092.  
<https://pubmed.ncbi.nlm.nih.gov/36683802>
1332. Smeulders, N., *et al.* The predictive value of a repeat micturating cystourethrogram for remnant leaflets after primary endoscopic ablation of posterior urethral valves. *J Pediatr Urol*, 2011. 7: 203.  
<https://pubmed.ncbi.nlm.nih.gov/20537589>
1333. Shirazi, M., *et al.* Which patients are at higher risk for residual valves after posterior urethral valve ablation? *Korean J Urol*, 2014. 55: 64.  
<https://pubmed.ncbi.nlm.nih.gov/24466400>
1334. Nawaz, G., *et al.* Justification For Re-Look Cystoscopy After Posterior Urethral Valve Fulguration. *J Ayub Med Coll Abbottabad*, 2017. 29: 30.  
<https://pubmed.ncbi.nlm.nih.gov/28712168>
1335. Abdelhalim, A., *et al.* Effect of Early Oxybutynin Treatment on Posterior Urethral Valve Outcomes in Infants: A Randomized Controlled Trial. *J Urol*, 2020. 203: 826.  
<https://pubmed.ncbi.nlm.nih.gov/31821098>
1336. Sharifiaghdas, F., *et al.* Can transient resting of the bladder with vesicostomy reduce the need for a major surgery in some patients? *J Pediatr Urol*, 2019. 15: 379 e1.  
<https://pubmed.ncbi.nlm.nih.gov/31060966>
1337. Duckett, J.W., Jr. Cutaneous vesicostomy in childhood. The Blocksom technique. *Urol Clin North Am*, 1974. 1: 485.  
<https://pubmed.ncbi.nlm.nih.gov/4610950>
1338. Williams, D.I., *et al.* Ring ureterostomy. *Br J Urol*, 1975. 47: 789.  
<https://pubmed.ncbi.nlm.nih.gov/1222345>
1339. Novak, M.E., *et al.* Single-stage reconstruction of urinary tract after loop cutaneous ureterostomy. *Urology*, 1978. 11: 134.  
<https://pubmed.ncbi.nlm.nih.gov/628990>
1340. Ghanem, M.A., *et al.* Long-term followup of bilateral high (sober) urinary diversion in patients with posterior urethral valves and its effect on bladder function. *J Urol*, 2005. 173: 1721.  
<https://pubmed.ncbi.nlm.nih.gov/15821568>

1341. Chua, M.E., *et al.* Impact of Adjuvant Urinary Diversion versus Valve Ablation Alone on Progression from Chronic to End Stage Renal Disease in Posterior Urethral Valves: A Single Institution 15-Year Time-to-Event Analysis. *J Urol*, 2018. 199: 824.  
<https://pubmed.ncbi.nlm.nih.gov/29061539>
1342. Scott, J.E. Management of congenital posterior urethral valves. *Br J Urol*, 1985. 57: 71.  
<https://pubmed.ncbi.nlm.nih.gov/3971107>
1343. Harper, L., *et al.* Circumcision and Risk of Febrile Urinary Tract Infection in Boys with Posterior Urethral Valves: Result of the CIRCUP Randomized Trial. *Eur Urol*, 2022. 81: 64.  
<https://pubmed.ncbi.nlm.nih.gov/34563412>
1344. Casey, J.T., *et al.* Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. *J Urol*, 2012. 188: 1516.  
<https://pubmed.ncbi.nlm.nih.gov/22910256>
1345. Koff, S.A., *et al.* The valve bladder syndrome: pathophysiology and treatment with nocturnal bladder emptying. *J Urol*, 2002. 167: 291.  
<https://pubmed.ncbi.nlm.nih.gov/11743343>
1346. Nguyen, M.T., *et al.* Overnight catheter drainage in children with poorly compliant bladders improves post-obstructive diuresis and urinary incontinence. *J Urol*, 2005. 174: 1633.  
<https://pubmed.ncbi.nlm.nih.gov/16148670>
1347. Neel, K.F. Feasibility and outcome of clean intermittent catheterization for children with sensate urethra. *Can Urol Assoc J*, 2010. 4: 403.  
<https://pubmed.ncbi.nlm.nih.gov/21191500>
1348. King, T., *et al.* Mitrofanoff for valve bladder syndrome: effect on urinary tract and renal function. *J Urol*, 2014. 191: 1517.  
<https://pubmed.ncbi.nlm.nih.gov/24679888>
1349. Rickard, M., *et al.* Comparative outcome analysis of pediatric kidney transplant in posterior urethral valves children with or without pretransplant Mitrofanoff procedure. *Pediatr Transplant*, 2020. 24: e13798.  
<https://pubmed.ncbi.nlm.nih.gov/32741040>
1350. Amesty, M.V., *et al.* Long-Term Renal Transplant Outcome in Patients With Posterior Urethral Valves. Prognostic Factors Related to Bladder Dysfunction Management. *Front Pediatr*, 2021. 9: 646923.  
<https://pubmed.ncbi.nlm.nih.gov/34046373>
1351. Akdogan, B., *et al.* Significance of age-specific creatinine levels at presentation in posterior urethral valve patients. *J Pediatr Urol*, 2006. 2: 446.  
<https://pubmed.ncbi.nlm.nih.gov/18947654>
1352. Sarhan, O., *et al.* Prognostic value of serum creatinine levels in children with posterior urethral valves treated by primary valve ablation. *J Pediatr Urol*, 2010. 6: 11.  
<https://pubmed.ncbi.nlm.nih.gov/19581129>
1353. Coleman, R., *et al.* Nadir creatinine in posterior urethral valves: How high is low enough? *J Pediatr Urol*, 2015. 11: 356 e1.  
<https://pubmed.ncbi.nlm.nih.gov/26292912>
1354. Lemmens, A.S., *et al.* Population-specific serum creatinine centiles in neonates with posterior urethral valves already predict long-term renal outcome. *J Matern Fetal Neonatal Med*, 2015. 28: 1026.  
<https://pubmed.ncbi.nlm.nih.gov/25000449>
1355. Odeh, R., *et al.* Predicting Risk of Chronic Kidney Disease in Infants and Young Children at Diagnosis of Posterior Urethral Valves: Initial Ultrasound Kidney Characteristics and Validation of Parenchymal Area as Forecasters of Renal Reserve. *J Urol*, 2016. 196: 862.  
<https://pubmed.ncbi.nlm.nih.gov/27017936>
1356. Jalkanen, J., *et al.* Controlled Outcomes for Achievement of Urinary Continence among Boys Treated for Posterior Urethral Valves. *J Urol*, 2016. 196: 213.  
<https://pubmed.ncbi.nlm.nih.gov/26964916>
1357. Capitanucci, M.L., *et al.* Long-term bladder function followup in boys with posterior urethral valves: comparison of noninvasive vs invasive urodynamic studies. *J Urol*, 2012. 188: 953.  
<https://pubmed.ncbi.nlm.nih.gov/22819111>
1358. Concodora, C.W., *et al.* The Role of Video Urodynamics in the Management of the Valve Bladder. *Curr Urol Rep*, 2017. 18: 24.  
<https://pubmed.ncbi.nlm.nih.gov/28233231>
1359. Skenazy, J., *et al.* 1618 Alpha Adrenergic Blockade in Neonates with Posterior Urethral Valves. *Journal of Urology*, 2012. 187: e654.  
<https://www.auajournals.org/doi/full/10.1016/j.juro.2012.02.1413>

1360. Bajpai, M., *et al.* Postablation and  $\alpha$ -1 blocker therapy in children with congenital obstructing posterior urethral membrane. *Formosan Journal of Surgery*, 2021. 54: 7.  
[https://doi.org/10.4103/fjs.fjs\\_97\\_20](https://doi.org/10.4103/fjs.fjs_97_20)
1361. Bain, A., *et al.* Renal outcomes of children born with posterior urethral valves at a tertiary center: A 15-year retrospective review. *Can Urol Assoc J*, 2023. 17: 111.  
<https://pubmed.ncbi.nlm.nih.gov/36486177>
1362. Fine, M.S., *et al.* Posterior urethral valve treatments and outcomes in children receiving kidney transplants. *J Urol*, 2011. 185: 2507.  
<https://pubmed.ncbi.nlm.nih.gov/21527196>
1363. Kamal, M.M., *et al.* Impact of posterior urethral valves on pediatric renal transplantation: a single-center comparative study of 297 cases. *Pediatr Transplant*, 2011. 15: 482.  
<https://pubmed.ncbi.nlm.nih.gov/21599816>
1364. Taskinen, S., *et al.* Effects of posterior urethral valves on long-term bladder and sexual function. *Nat Rev Urol*, 2012. 9: 699.  
<https://pubmed.ncbi.nlm.nih.gov/23147930>
1365. Cetin, B., *et al.* Renal, Bladder and Sexual Outcomes in Adult Men with History of Posterior Urethral Valves Treated in Childhood. *Urology*, 2021. 153: 301.  
<https://pubmed.ncbi.nlm.nih.gov/33188791>
1366. Arena, S., *et al.* Anterior urethral valves in children: an uncommon multipathogenic cause of obstructive uropathy. *Pediatr Surg Int*, 2009. 25: 613.  
<https://pubmed.ncbi.nlm.nih.gov/19517125>
1367. Firlit, R.S., *et al.* Obstructing anterior urethral valves in children. *J Urol*, 1978. 119: 819.  
<https://pubmed.ncbi.nlm.nih.gov/566334>
1368. Zia-ul-Miraj, M. Anterior urethral valves: a rare cause of infravesical obstruction in children. *J Pediatr Surg*, 2000. 35: 556.  
<https://pubmed.ncbi.nlm.nih.gov/10770380>
1369. Routh, J.C., *et al.* Predicting renal outcomes in children with anterior urethral valves: a systematic review. *J Urol*, 2010. 184: 1615.  
<https://pubmed.ncbi.nlm.nih.gov/20728183>
1370. Adam, A., *et al.* Congenital anterior urethral diverticulum: antenatal diagnosis with subsequent neonatal endoscopic management. *Urology*, 2015. 85: 914.  
<https://pubmed.ncbi.nlm.nih.gov/25704997>
1371. Gupta, D.K., *et al.* Congenital anterior urethral diverticulum in children. *Pediatr Surg Int*, 2000. 16: 565.  
<https://pubmed.ncbi.nlm.nih.gov/11149395>
1372. Rawat, J., *et al.* Congenital anterior urethral valves and diverticula: diagnosis and management in six cases. *Afr J Paediatr Surg*, 2009. 6: 102.  
<https://pubmed.ncbi.nlm.nih.gov/19661640>
1373. Quoraishi, S.H., *et al.* Congenital anterior urethral diverticulum in a male teenager: a case report and review of the literature. *Case Rep Urol*, 2011. 2011: 738638.  
<https://pubmed.ncbi.nlm.nih.gov/22606624>
1374. Cruz-Diaz, O., *et al.* Anterior urethral valves: not such a benign condition. *Front Pediatr*, 2013. 1: 35.  
<https://pubmed.ncbi.nlm.nih.gov/24400281>
1375. Maizels, M., *et al.* Cowper's syringocele: a classification of dilatations of Cowper's gland duct based upon clinical characteristics of 8 boys. *J Urol*, 1983. 129: 111.  
<https://pubmed.ncbi.nlm.nih.gov/6827661>
1376. Melquist, J., *et al.* Current diagnosis and management of syringocele: a review. *Int Braz J Urol*, 2010. 36: 3.  
<https://pubmed.ncbi.nlm.nih.gov/20202229>
1377. Bevers, R.F., *et al.* Cowper's syringocele: symptoms, classification and treatment of an unappreciated problem. *J Urol*, 2000. 163: 782.  
<https://pubmed.ncbi.nlm.nih.gov/10687976>
1378. Dewan, P.A., *et al.* Congenital urethral obstruction: Cobb's collar or prolapsed congenital obstructive posterior urethral membrane (COPUM). *Br J Urol*, 1994. 73: 91.  
<https://pubmed.ncbi.nlm.nih.gov/8298906>
1379. Nonomura, K., *et al.* Impact of congenital narrowing of the bulbar urethra (Cobb's collar) and its transurethral incision in children. *Eur Urol*, 1999. 36: 144.  
<https://pubmed.ncbi.nlm.nih.gov/10420036>
1380. Gonzalez, R., *et al.* Urethral atresia: long-term outcome in 6 children who survived the neonatal period. *J Urol*, 2001. 165: 2241.  
<https://pubmed.ncbi.nlm.nih.gov/11371953>

1381. Passerini-Glazel, G., *et al.* The P.A.D.U.A. (progressive augmentation by dilating the urethra anterior) procedure for the treatment of severe urethral hypoplasia. *J Urol*, 1988. 140: 1247.  
<https://pubmed.ncbi.nlm.nih.gov/2972844>
1382. Freedman, A.L., *et al.* Long-term outcome in children after antenatal intervention for obstructive uropathies. *Lancet*, 1999. 354: 374.  
<https://pubmed.ncbi.nlm.nih.gov/10437866>
1383. Downs, R.A. Congenital polyps of the prostatic urethra. A review of the literature and report of two cases. *Br J Urol*, 1970. 42: 76.  
<https://pubmed.ncbi.nlm.nih.gov/5435705>
1384. Natsheh, A., *et al.* Fibroepithelial polyp of the bladder neck in children. *Pediatr Surg Int*, 2008. 24: 613.  
<https://pubmed.ncbi.nlm.nih.gov/18097674>
1385. Akbarzadeh, A., *et al.* Congenital urethral polyps in children: report of 18 patients and review of literature. *J Pediatr Surg*, 2014. 49: 835.  
<https://pubmed.ncbi.nlm.nih.gov/24851781>
1386. Parrott, T.S., *et al.*, The bladder and urethra, in *Embryology for surgeons : the embryological basis for the treatment of congenital anomalies* 2nd ed., J.E. Skandalakis & S.W. Gray, Editors. 1994, Williams & Wilkins: Baltimore.
1387. Atala, A., *et al.*, Patent urachus and urachal cysts. *Gellis & Kagan's current pediatric therapy*. Philadelphia: WB Saunders. 1993.
1388. Gearhart JP, J.R., Urachal abnormalities, in *Campbell's urology* 7th edn., P.C. Walsh., A.B. Retik & E.D. Vaughan, Editors. 1998, WB Saunders: Philadelphia.
1389. Moore, K.L., The urogenital system, in *The Developing Human* 3rd edn., K.L. Moore, Editor. 1982, Elsevier Health Sciences: Philadelphia.
1390. Berman, S.M., *et al.* Urachal remnants in adults. *Urology*, 1988. 31: 17.  
<https://pubmed.ncbi.nlm.nih.gov/3122397>
1391. Metwalli, Z.A., *et al.* Imaging features of intravesical urachal cysts in children. *Pediatr Radiol*, 2013. 43: 978.  
<https://pubmed.ncbi.nlm.nih.gov/23370693>
1392. Yohannes, P., *et al.* Laparoscopic radical excision of urachal sinus. *J Endourol*, 2003. 17: 475.  
<https://pubmed.ncbi.nlm.nih.gov/14565877>
1393. Robert, Y., *et al.* Urachal remnants: sonographic assessment. *J Clin Ultrasound*, 1996. 24: 339.  
<https://pubmed.ncbi.nlm.nih.gov/8873855>
1394. Stopak, J.K., *et al.* Trends in surgical management of urachal anomalies. *J Pediatr Surg*, 2015. 50: 1334.  
<https://pubmed.ncbi.nlm.nih.gov/26227313>
1395. Rubin., A.A., *Handbook of Congenital Malformations*. 1967, Philadelphia. PA.
1396. Nix, J.T., *et al.* Congenital patent urachus. *J Urol*, 1958. 79: 264.  
<https://pubmed.ncbi.nlm.nih.gov/13514877>
1397. Blichert-Toft, M., *et al.* Congenital patent urachus and acquired variants. Diagnosis and treatment. Review of the literature and report of five cases. *Acta Chir Scand*, 1971. 137: 807.  
<https://pubmed.ncbi.nlm.nih.gov/5148862>
1398. Holten, I., *et al.* The ultrasonic diagnosis of urachal anomalies. *Australas Radiol*, 1996. 40: 2.  
<https://pubmed.ncbi.nlm.nih.gov/8838878>
1399. Copp, H.L., *et al.* Clinical presentation and urachal remnant pathology: implications for treatment. *J Urol*, 2009. 182: 1921.  
<https://pubmed.ncbi.nlm.nih.gov/19695622>
1400. Galati, V., *et al.* Management of urachal remnants in early childhood. *J Urol*, 2008. 180: 1824.  
<https://pubmed.ncbi.nlm.nih.gov/18721938>
1401. Lipskar, A.M., *et al.* Nonoperative management of symptomatic urachal anomalies. *J Pediatr Surg*, 2010. 45: 1016.  
<https://pubmed.ncbi.nlm.nih.gov/20438945>
1402. Dethlefs, C.R., *et al.* Conservative management of urachal anomalies. *J Pediatr Surg*, 2019. 54: 1054.  
<https://pubmed.ncbi.nlm.nih.gov/30867097>
1403. McCollum, M.O., *et al.* Surgical implications of urachal remnants: Presentation and management. *J Pediatr Surg*, 2003. 38: 798.  
<https://pubmed.ncbi.nlm.nih.gov/12720197>
1404. Yiee, J.H., *et al.* A diagnostic algorithm for urachal anomalies. *J Pediatr Urol*, 2007. 3: 500.  
<https://pubmed.ncbi.nlm.nih.gov/18947803>



1405. Naiditch, J.A., *et al.* Current diagnosis and management of urachal remnants. *J Pediatr Surg*, 2013. 48: 2148.  
<https://pubmed.ncbi.nlm.nih.gov/24094971>
1406. Ward, T.T., *et al.* Infected urachal remnants in the adult: case report and review. *Clin Infect Dis*, 1993. 16: 26.  
<https://pubmed.ncbi.nlm.nih.gov/8448315>
1407. al-Hindawi, M.K., *et al.* Benign non-infected urachal cyst in an adult: review of the literature and a case report. *Br J Radiol*, 1992. 65: 313.  
<https://pubmed.ncbi.nlm.nih.gov/1581788>
1408. Choi, Y.J., *et al.* Urachal anomalies in children: a single center experience. *Yonsei Med J*, 2006. 47: 782.  
<https://pubmed.ncbi.nlm.nih.gov/17191305>
1409. Ashley, R.A., *et al.* Urachal anomalies: a longitudinal study of urachal remnants in children and adults. *J Urol*, 2007. 178: 1615.  
<https://pubmed.ncbi.nlm.nih.gov/17707039>
1410. Lane, V. Congenital patent urachus associated with complete (hypospadiac) duplication of the urethra and solitary crossed renal ectopia. *J Urol*, 1982. 127: 990.  
<https://pubmed.ncbi.nlm.nih.gov/7087008>
1411. Suita, S., *et al.* Urachal remnants. *Semin Pediatr Surg*, 1996. 5: 107.  
<https://pubmed.ncbi.nlm.nih.gov/9138709>
1412. Newman, B.M., *et al.* Advances in the management of infected urachal cysts. *J Pediatr Surg*, 1986. 21: 1051.  
<https://pubmed.ncbi.nlm.nih.gov/3794969>
1413. Little, D.C., *et al.* Urachal anomalies in children: the vanishing relevance of the preoperative voiding cystourethrogram. *J Pediatr Surg*, 2005. 40: 1874.  
<https://pubmed.ncbi.nlm.nih.gov/16338309>
1414. Herr, H.W., *et al.* Urachal carcinoma: contemporary surgical outcomes. *J Urol*, 2007. 178: 74.  
<https://pubmed.ncbi.nlm.nih.gov/17499279>
1415. Nogueras-Ocana, M., *et al.* Urachal anomalies in children: surgical or conservative treatment? *J Pediatr Urol*, 2014. 10: 522.  
<https://pubmed.ncbi.nlm.nih.gov/24321777>
1416. Zieger, B., *et al.* Sonomorphology and involution of the normal urachus in asymptomatic newborns. *Pediatr Radiol*, 1998. 28: 156.  
<https://pubmed.ncbi.nlm.nih.gov/9561533>
1417. Sato, H., *et al.* The current strategy for urachal remnants. *Pediatr Surg Int*, 2015. 31: 581.  
<https://pubmed.ncbi.nlm.nih.gov/25896294>
1418. Gregory, G.C., *et al.* Laparoscopic management of urachal cyst associated with umbilical hernia. *Hernia*, 2011. 15: 93.  
<https://pubmed.ncbi.nlm.nih.gov/20069440>
1419. Block, R.I., *et al.* Are anesthesia and surgery during infancy associated with altered academic performance during childhood? *Anesthesiology*, 2012. 117: 494.  
<https://pubmed.ncbi.nlm.nih.gov/22801049>
1420. DiMaggio, C., *et al.* Early childhood exposure to anesthesia and risk of developmental and behavioral disorders in a sibling birth cohort. *Anesth Analg*, 2011. 113: 1143.  
<https://pubmed.ncbi.nlm.nih.gov/21415431>
1421. Gleason, J.M., *et al.* A comprehensive review of pediatric urachal anomalies and predictive analysis for adult urachal adenocarcinoma. *J Urol*, 2015. 193: 632.  
<https://pubmed.ncbi.nlm.nih.gov/25219697>
1422. Sheldon, C.A., *et al.* Malignant urachal lesions. *J Urol*, 1984. 131: 1.  
<https://pubmed.ncbi.nlm.nih.gov/6361280>
1423. Ueno, T., *et al.* Urachal anomalies: ultrasonography and management. *J Pediatr Surg*, 2003. 38: 1203.  
<https://pubmed.ncbi.nlm.nih.gov/12891493>
1424. Molina, J.R., *et al.* Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. *Cancer*, 2007. 110: 2434.  
<https://pubmed.ncbi.nlm.nih.gov/17932892>
1425. Ashley, R.A., *et al.* Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. *Cancer*, 2006. 107: 712.  
<https://pubmed.ncbi.nlm.nih.gov/16826585>

1426. Arora, H., *et al.* Diagnosis and Management of Urachal Anomalies in Children. *Current Bladder Dysfunction Reports*, 2015. 10: 256.  
<https://link.springer.com/article/10.1007/s11884-015-0310-y>
1427. Heuga, B., *et al.* [Management of urachal remnants in children: Is surgical excision mandatory?]. *Prog Urol*, 2015. 25: 603.  
<https://pubmed.ncbi.nlm.nih.gov/26094100>
1428. Saltsman, J.A., *et al.* Urothelial neoplasms in pediatric and young adult patients: A large single-center series. *J Pediatr Surg*, 2018. 53: 306.  
<https://pubmed.ncbi.nlm.nih.gov/29221636>
1429. Chu, S., *et al.* Transitional Cell Carcinoma in the Pediatric Patient: A Review of the Literature. *Urology*, 2016. 91: 175.  
<https://pubmed.ncbi.nlm.nih.gov/26802795>
1430. Caione, P., *et al.* Nonmuscular Invasive Urothelial Carcinoma of the Bladder in Pediatric and Young Adult Patients: Age-related Outcomes. *Urology*, 2017. 99: 215.  
<https://pubmed.ncbi.nlm.nih.gov/27450943>
1431. Hoenig, D.M., *et al.* Transitional cell carcinoma of the bladder in the pediatric patient. *J Urol*, 1996. 156: 203.  
<https://pubmed.ncbi.nlm.nih.gov/8648805>
1432. Kutarski, P.W., *et al.* Transitional cell carcinoma of the bladder in young adults. *Br J Urol*, 1993. 72: 749.  
<https://pubmed.ncbi.nlm.nih.gov/8281408>
1433. Jaworski, D., *et al.* Diagnostic difficulties in cases of papillary urothelial neoplasm of low malignant potential, urothelial proliferation of uncertain malignant potential, urothelial dysplasia and urothelial papilloma: A review of current literature. *Ann Diagn Pathol*, 2019. 40: 182.  
<https://pubmed.ncbi.nlm.nih.gov/29395466>
1434. Song, D., *et al.* Inflammatory myofibroblastic tumor of urinary bladder with severe hematuria: A Case report and literature review. *Medicine (Baltimore)*, 2019. 98: e13987.  
<https://pubmed.ncbi.nlm.nih.gov/30608442>
1435. Teoh, J.Y., *et al.* Inflammatory myofibroblastic tumors of the urinary bladder: a systematic review. *Urology*, 2014. 84: 503.  
<https://pubmed.ncbi.nlm.nih.gov/25168523>
1436. Collin, M., *et al.* Inflammatory myofibroblastic tumour of the bladder in children: a review. *J Pediatr Urol*, 2015. 11: 239.  
<https://pubmed.ncbi.nlm.nih.gov/25982020>
1437. Wang, X., *et al.* Malignant Inflammatory Myofibroblastic Tumor of the Urinary Bladder in a 14-Year-Old Boy. *J Pediatr Hematol Oncol*, 2015. 37: e402.  
<https://pubmed.ncbi.nlm.nih.gov/26207771>
1438. Houben, C.H., *et al.* Inflammatory myofibroblastic tumor of the bladder in children: what can be expected? *Pediatr Surg Int*, 2007. 23: 815.  
<https://pubmed.ncbi.nlm.nih.gov/17443333>
1439. Alezra, E., *et al.* [Complete resolution of inflammatory myofibroblastic tumor of the bladder after antibiotic therapy]. *Arch Pediatr*, 2016. 23: 612.  
<https://pubmed.ncbi.nlm.nih.gov/27102996>
1440. Sparks, S., *et al.* Eosinophilic cystitis in the pediatric population: a case series and review of the literature. *J Pediatr Urol*, 2013. 9: 738.  
<https://pubmed.ncbi.nlm.nih.gov/23391564>
1441. Kopf, A., *et al.* [Eosinophilic cystitis of allergic origin]. *Presse Med*, 1984. 13: 83.  
<https://pubmed.ncbi.nlm.nih.gov/6229734>
1442. Tsakiri, A., *et al.* Eosinophilic cystitis induced by penicillin. *Int Urol Nephrol*, 2004. 36: 159.  
<https://pubmed.ncbi.nlm.nih.gov/15368685>
1443. Zhou, A.G., *et al.* Mass Forming Eosinophilic Cystitis in Pediatric Patients. *Urology*, 2017. 101: 139.  
<https://pubmed.ncbi.nlm.nih.gov/27840250>
1444. Thompson, R.H., *et al.* Clinical manifestations and functional outcomes in children with eosinophilic cystitis. *J Urol*, 2005. 174: 2347.  
<https://pubmed.ncbi.nlm.nih.gov/16280840>
1445. Claps, A., *et al.* How should eosinophilic cystitis be treated in patients with chronic granulomatous disease? *Pediatr Nephrol*, 2014. 29: 2229.  
<https://pubmed.ncbi.nlm.nih.gov/25037864>
1446. Heidenreich, A., *et al.* Nephrogenic adenoma: A rare bladder tumor in children. *Eur Urol*, 1999. 36: 348.  
<https://pubmed.ncbi.nlm.nih.gov/10473997>

1447. Kao, C.S., *et al.* Nephrogenic adenomas in pediatric patients: a morphologic and immunohistochemical study of 21 cases. *Pediatr Dev Pathol*, 2013. 16: 80.  
<https://pubmed.ncbi.nlm.nih.gov/23597251>
1448. Franke, E.I., *et al.* Nephrogenic adenoma in the augmented bladder. *J Urol*, 2011. 186: 1586.  
<https://pubmed.ncbi.nlm.nih.gov/21862049>
1449. Papali, A.C., *et al.* A review of pediatric glans malformations: a handy clinical reference. *J Urol*, 2008. 180: 1737.  
<https://pubmed.ncbi.nlm.nih.gov/18721953>
1450. Eisner, B.H., *et al.* Pediatric penile tumors of mesenchymal origin. *Urology*, 2006. 68: 1327.  
<https://pubmed.ncbi.nlm.nih.gov/17169655>
1451. Ealai, P.A., *et al.* Penile epidermal inclusion cyst: a rare location. *BMJ Case Rep*, 2015. 2015.  
<https://pubmed.ncbi.nlm.nih.gov/26290567>
1452. De Mendonca, R.R., *et al.* Muroid cyst of the penis: Case report and literature review. *Can Urol Assoc J*, 2010. 4: E155.  
<https://pubmed.ncbi.nlm.nih.gov/21749810>
1453. Syed, M.M.A., *et al.* Median raphe cyst of the penis: a case report and review of the literature. *J Med Case Rep*, 2019. 13: 214.  
<https://pubmed.ncbi.nlm.nih.gov/31301740>
1454. Shao, I.H., *et al.* Male median raphe cysts: serial retrospective analysis and histopathological classification. *Diagn Pathol*, 2012. 7: 121.  
<https://pubmed.ncbi.nlm.nih.gov/22978603>
1455. Sonthalia, S., *et al.* Smegma Pearls in Young Uncircumcised Boys. *Pediatr Dermatol*, 2016. 33: e186.  
<https://pubmed.ncbi.nlm.nih.gov/27071486>
1456. Ramos, L.M., *et al.* Venous malformation of the glans penis: efficacy of treatment with neodymium:yttrium-aluminum-garnet laser. *Urology*, 1999. 53: 779.  
<https://pubmed.ncbi.nlm.nih.gov/10197856>
1457. Shah, S.D., *et al.* Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. *Pediatrics*, 2016. 137.  
<https://pubmed.ncbi.nlm.nih.gov/26952504>
1458. Dagur, G., *et al.* Unusual Glomus Tumor of the Penis. *Curr Urol*, 2016. 9: 113.  
<https://pubmed.ncbi.nlm.nih.gov/27867327>
1459. Saito, T. Glomus tumor of the penis. *Int J Urol*, 2000. 7: 115.  
<https://pubmed.ncbi.nlm.nih.gov/10750892>
1460. Dwosh, J., *et al.* Neurofibroma involving the penis in a child. *J Urol*, 1984. 132: 988.  
<https://pubmed.ncbi.nlm.nih.gov/6436512>
1461. Taib, F., *et al.* Infantile fibrosarcoma of the penis in a 2-year-old boy. *Urology*, 2012. 80: 931.  
<https://pubmed.ncbi.nlm.nih.gov/22854139>
1462. Hu, J., *et al.* Congenital primary penile teratoma in a child. *Urology*, 2014. 83: 1404.  
<https://pubmed.ncbi.nlm.nih.gov/24767514>
1463. Smeltzer, D.M., *et al.* Primary lymphedema in children and adolescents: a follow-up study and review. *Pediatrics*, 1985. 76: 206.  
<https://pubmed.ncbi.nlm.nih.gov/4022694>
1464. Brorson, H. Adipose tissue in lymphedema: the ignorance of adipose tissue in lymphedema. *Lymphology*, 2004. 37: 175.  
<https://pubmed.ncbi.nlm.nih.gov/15693531>
1465. Schook, C.C., *et al.* Male genital lymphedema: clinical features and management in 25 pediatric patients. *J Pediatr Surg*, 2014. 49: 1647.  
<https://pubmed.ncbi.nlm.nih.gov/25475811>
1466. Vricella, G.J., *et al.* Granulomatous lymphangitis. *J Urol*, 2013. 190: 1052.  
<https://pubmed.ncbi.nlm.nih.gov/23773564>
1467. Sackett, D.D., *et al.* Isolated penile lymphedema in an adolescent male: a case of metastatic Crohn's disease. *J Pediatr Urol*, 2012. 8: e55.  
<https://pubmed.ncbi.nlm.nih.gov/22507210>
1468. Bolt, R.J., *et al.* Congenital lymphoedema of the genitalia. *Eur J Pediatr*, 1998. 157: 943.  
<https://pubmed.ncbi.nlm.nih.gov/9835443>
1469. Dandapat, M.C., *et al.* Elephantiasis of the penis and scrotum. A review of 350 cases. *Am J Surg*, 1985. 149: 686.  
<https://pubmed.ncbi.nlm.nih.gov/3993854>

1470. Donaldson, J.F., *et al.* Priapism in children: a comprehensive review and clinical guideline. *J Pediatr Urol*, 2014. 10: 11.  
<https://pubmed.ncbi.nlm.nih.gov/24135215>
1471. Jesus, L.E., *et al.* Priapism in children: review of pathophysiology and treatment. *J Pediatr (Rio J)*, 2009. 85: 194.  
<https://pubmed.ncbi.nlm.nih.gov/19455267>
1472. Spycher, M.A., *et al.* The ultrastructure of the erectile tissue in priapism. *J Urol*, 1986. 135: 142.  
<https://pubmed.ncbi.nlm.nih.gov/3941454>
1473. Adeyoju, A.B., *et al.* Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. *BJU Int*, 2002. 90: 898.  
<https://pubmed.ncbi.nlm.nih.gov/12460353>
1474. Mockford, K., *et al.* Management of high-flow priapism in paediatric patients: a case report and review of the literature. *J Pediatr Urol*, 2007. 3: 404.  
<https://pubmed.ncbi.nlm.nih.gov/18947783>
1475. Guner, E., *et al.* Analysis of the Causes of Newborn Priapism: A Retrospective Clinical Study. *Prague Med Rep*, 2023. 124: 58.  
<https://pubmed.ncbi.nlm.nih.gov/36763832>
1476. Broderick, G.A., *et al.* Priapism: pathogenesis, epidemiology, and management. *J Sex Med*, 2010. 7: 476.  
<https://pubmed.ncbi.nlm.nih.gov/20092449>
1477. Hakim, L.S., *et al.* Evolving concepts in the diagnosis and treatment of arterial high flow priapism. *J Urol*, 1996. 155: 541.  
<https://pubmed.ncbi.nlm.nih.gov/8558656>
1478. von Stempel, C., *et al.* Mean velocity and peak systolic velocity can help determine ischaemic and non-ischaemic priapism. *Clin Radiol*, 2017. 72: 611 e9.  
<https://pubmed.ncbi.nlm.nih.gov/28351471>
1479. EAU Guidelines on Sexual and Reproductive Health. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.
1480. Maples, B.L., *et al.* Treatment of priapism in pediatric patients with sickle cell disease. *Am J Health Syst Pharm*, 2004. 61: 355.  
<https://pubmed.ncbi.nlm.nih.gov/15011763>
1481. Marchant, W.A., *et al.* Anaesthetic management of the child with sickle cell disease. *Paediatr Anaesth*, 2003. 13: 473.  
<https://pubmed.ncbi.nlm.nih.gov/12846703>
1482. McLaughlin, C., *et al.* Timing of mortality in pediatric trauma patients: A National Trauma Data Bank analysis. *J Pediatr Surg*, 2018. 53: 344.  
<https://pubmed.ncbi.nlm.nih.gov/29111081>
1483. Grimsby, G.M., *et al.* Demographics of pediatric renal trauma. *J Urol*, 2014. 192: 1498.  
<https://pubmed.ncbi.nlm.nih.gov/24907442>
1484. McAninch, J.W., *et al.* Renal reconstruction after injury. *J Urol*, 1991. 145: 932.  
<https://pubmed.ncbi.nlm.nih.gov/2016804>
1485. Stein, J.P., *et al.* Blunt renal trauma in the pediatric population: indications for radiographic evaluation. *Urology*, 1994. 44: 406.  
<https://pubmed.ncbi.nlm.nih.gov/8073555>
1486. Stalker, H.P., *et al.* The significance of hematuria in children after blunt abdominal trauma. *AJR Am J Roentgenol*, 1990. 154: 569.  
<https://pubmed.ncbi.nlm.nih.gov/2106223>
1487. Mee, S.L., *et al.* Radiographic assessment of renal trauma: a 10-year prospective study of patient selection. *J Urol*, 1989. 141: 1095.  
<https://pubmed.ncbi.nlm.nih.gov/2709493>
1488. Brown, S.L., *et al.* Are pediatric patients more susceptible to major renal injury from blunt trauma? A comparative study. *J Urol*, 1998. 160: 138.  
<https://pubmed.ncbi.nlm.nih.gov/9628634>
1489. Redmond, E.J., *et al.* Contemporary management of pediatric high grade renal trauma: 10 year experience at a level 1 trauma centre. *J Pediatr Urol*, 2020. 16: 656 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32800481>
1490. Kozar, R.A., *et al.* Organ injury scaling 2018 update: Spleen, liver, and kidney. *J Trauma Acute Care Surg*, 2018. 85: 1119.  
<https://pubmed.ncbi.nlm.nih.gov/30462622>

1491. Coley, B.D., *et al.* Focused abdominal sonography for trauma (FAST) in children with blunt abdominal trauma. *J Trauma*, 2000. 48: 902.  
<https://pubmed.ncbi.nlm.nih.gov/10823534>
1492. Heller, M.T., *et al.* MDCT of renal trauma: correlation to AAST organ injury scale. *Clin Imaging*, 2014. 38: 410.  
<https://pubmed.ncbi.nlm.nih.gov/24667041>
1493. Trinci, M., *et al.* Contrast-enhanced ultrasound (CEUS) in pediatric blunt abdominal trauma. *J Ultrasound*, 2019. 22: 27.  
<https://pubmed.ncbi.nlm.nih.gov/30536214>
1494. Schmidt, J., *et al.* Routine repeat imaging may be avoidable for asymptomatic pediatric patients with renal trauma. *J Pediatr Urol*, 2022. 18: 76 e1.  
<https://pubmed.ncbi.nlm.nih.gov/34872844>
1495. Hagedorn, J.C., *et al.* Pediatric blunt renal trauma practice management guidelines: Collaboration between the Eastern Association for the Surgery of Trauma and the Pediatric Trauma Society. *J Trauma Acute Care Surg*, 2019. 86: 916.  
<https://pubmed.ncbi.nlm.nih.gov/30741880>
1496. Ghani, M.O.A., *et al.* Urine leaks in children sustaining blunt renal trauma. *J Trauma Acute Care Surg*, 2022. 93: 376.  
<https://pubmed.ncbi.nlm.nih.gov/34991128>
1497. Chebbi, A., *et al.* Observation vs. early drainage for grade IV blunt renal trauma: a multicenter study. *World J Urol*, 2021. 39: 963.  
<https://pubmed.ncbi.nlm.nih.gov/32447442>
1498. LeeVan, E., *et al.* Management of pediatric blunt renal trauma: A systematic review. *J Trauma Acute Care Surg*, 2016. 80: 519.  
<https://pubmed.ncbi.nlm.nih.gov/26713980>
1499. Liguori, G., *et al.* The role of angioembolization in the management of blunt renal injuries: a systematic review. *BMC Urol*, 2021. 21: 104.  
<https://pubmed.ncbi.nlm.nih.gov/34362352>
1500. Radmayr, C., *et al.* Blunt renal trauma in children: 26 years clinical experience in an alpine region. *Eur Urol*, 2002. 42: 297.  
<https://pubmed.ncbi.nlm.nih.gov/12234516>
1501. Marcou, M., *et al.* Blunt renal trauma-induced hypertension in pediatric patients: a single-center experience. *J Pediatr Urol*, 2021. 17: 737 e1.  
<https://pubmed.ncbi.nlm.nih.gov/34274236>
1502. Presti, J.C., Jr., *et al.* Ureteral and renal pelvic injuries from external trauma: diagnosis and management. *J Trauma*, 1989. 29: 370.  
<https://pubmed.ncbi.nlm.nih.gov/2926851>
1503. Mulligan, J.M., *et al.* Ureteropelvic junction disruption secondary to blunt trauma: excretory phase imaging (delayed films) should help prevent a missed diagnosis. *J Urol*, 1998. 159: 67.  
<https://pubmed.ncbi.nlm.nih.gov/9400439>
1504. al-Ali, M., *et al.* The late treatment of 63 overlooked or complicated ureteral missile injuries: the promise of nephrostomy and role of autotransplantation. *J Urol*, 1996. 156: 1918.  
<https://pubmed.ncbi.nlm.nih.gov/8911355>
1505. Fernandez Fernandez, A., *et al.* Blunt traumatic rupture of the high right ureter, repaired with appendix interposition. *Urol Int*, 1994. 53: 97.  
<https://pubmed.ncbi.nlm.nih.gov/7801425>
1506. Sivit, C.J., *et al.* CT diagnosis and localization of rupture of the bladder in children with blunt abdominal trauma: significance of contrast material extravasation in the pelvis. *AJR Am J Roentgenol*, 1995. 164: 1243.  
<https://pubmed.ncbi.nlm.nih.gov/7717239>
1507. Hochberg, E., *et al.* Bladder rupture associated with pelvic fracture due to blunt trauma. *Urology*, 1993. 41: 531.  
<https://pubmed.ncbi.nlm.nih.gov/8516988>
1508. Haas, C.A., *et al.* Limitations of routine spiral computerized tomography in the evaluation of bladder trauma. *J Urol*, 1999. 162: 51.  
<https://pubmed.ncbi.nlm.nih.gov/10379738>
1509. Volpe, M.A., *et al.* Is there a difference in outcome when treating traumatic intraperitoneal bladder rupture with or without a suprapubic tube? *J Urol*, 1999. 161: 1103.  
<https://pubmed.ncbi.nlm.nih.gov/10081847>

1510. Richardson, J.R., Jr., *et al.* Non-operative treatment of the ruptured bladder. *J Urol*, 1975. 114: 213.  
<https://pubmed.ncbi.nlm.nih.gov/1159910>
1511. Cass, A.S., *et al.* Urethral injury due to external trauma. *Urology*, 1978. 11: 607.  
<https://pubmed.ncbi.nlm.nih.gov/675928>
1512. Pokorny, M., *et al.* Urological injuries associated with pelvic trauma. *J Urol*, 1979. 121: 455.  
<https://pubmed.ncbi.nlm.nih.gov/439217>
1513. Bjurlin, M.A., *et al.* Clinical characteristics and surgical outcomes of penetrating external genital injuries. *J Trauma Acute Care Surg*, 2013. 74: 839.  
<https://pubmed.ncbi.nlm.nih.gov/23425745>
1514. Kunkle, D.A., *et al.* Evaluation and management of gunshot wounds of the penis: 20-year experience at an urban trauma center. *J Trauma*, 2008. 64: 1038.  
<https://pubmed.ncbi.nlm.nih.gov/18404072>
1515. Zhang, Y., *et al.* Emergency treatment of male blunt urethral trauma in China: Outcome of different methods in comparison with other countries. *Asian J Urol*, 2018. 5: 78.  
<https://pubmed.ncbi.nlm.nih.gov/29736369>
1516. Peng, X., *et al.* Straddle injuries to the bulbar urethra: What is the best choice for immediate management? *J Trauma Acute Care Surg*, 2019. 87: 892.  
<https://pubmed.ncbi.nlm.nih.gov/31205218>
1517. Koraitim, M.M. Posttraumatic posterior urethral strictures in children: a 20-year experience. *J Urol*, 1997. 157: 641.  
<https://pubmed.ncbi.nlm.nih.gov/8996388>
1518. Baradaran, N., *et al.* Long-term follow-up of urethral reconstruction for blunt urethral injury at a young age: urinary and sexual quality of life outcomes. *J Pediatr Urol*, 2019. 15: 224 e1.  
<https://pubmed.ncbi.nlm.nih.gov/30967356>
1519. Joshi, P.M., *et al.* Management of pelvic fracture urethral injuries in the developing world. *World J Urol*, 2020. 38: 3027.  
<https://pubmed.ncbi.nlm.nih.gov/31468131>
1520. Wani, S.A., *et al.* Early primary endoscopic realignment in children with posterior urethral and bladder neck injury. *Journal of Pediatric Endoscopic Surgery*, 2020. 2: 201.  
<https://link.springer.com/article/10.1007/s42804-020-00073-7>
1521. Sreeranga, Y.L., *et al.* Comprehensive analysis of paediatric pelvic fracture urethral injury: a reconstructive centre experience. *BJU Int*, 2022. 130: 114.  
<https://pubmed.ncbi.nlm.nih.gov/35044050>
1522. Waterloos, M., *et al.* Urethroplasty for urethral injuries and trauma-related strictures in children and adolescents: a single-institution experience. *J Pediatr Urol*, 2019. 15: 176 e1.  
<https://pubmed.ncbi.nlm.nih.gov/30581060>
1523. Garg, G., *et al.* Outcome of patients with failed pelvic fracture-associated urethral injury repair: A single centre 10-year experience. *Turk J Urol*, 2019. 45: 139.  
<https://pubmed.ncbi.nlm.nih.gov/30475700>
1524. Nair, S.G., *et al.* Perioperative fluid and electrolyte management in pediatric patients. *Indian J Anaesth*, 2004. 48: 355.  
<https://www.semanticscholar.org/paper/PERIOPERATIVE-FLUID-AND-ELECTROLYTE-MANAGEMENT-IN-Nair-Balachandran/e7edda34a7a109be996556e21e53e41fcf62a628>
1525. Imura, K., *et al.* Perioperative nutrition and metabolism in pediatric patients. *World J Surg*, 2000. 24: 1498.  
<https://pubmed.ncbi.nlm.nih.gov/11193714>
1526. Ward Platt, M.P., *et al.* The effects of anesthesia and surgery on metabolic homeostasis in infancy and childhood. *J Pediatr Surg*, 1990. 25: 472.  
<https://pubmed.ncbi.nlm.nih.gov/2191106>
1527. Andersson, H., *et al.* Introducing the 6-4-0 fasting regimen and the incidence of prolonged preoperative fasting in children. *Paediatr Anaesth*, 2018. 28: 46.  
<https://pubmed.ncbi.nlm.nih.gov/29168341>
1528. Frykholm, P., *et al.* Preoperative fasting in children: review of existing guidelines and recent developments. *Br J Anaesth*, 2018. 120: 469.  
<https://pubmed.ncbi.nlm.nih.gov/29452803>
1529. Andersson, H., *et al.* Low incidence of pulmonary aspiration in children allowed intake of clear fluids until called to the operating suite. *Paediatr Anaesth*, 2015. 25: 770.  
<https://pubmed.ncbi.nlm.nih.gov/25940831>

1530. Fawcett, W.J., *et al.* Pre-operative fasting in adults and children: clinical practice and guidelines. *Anaesthesia*, 2019. 74: 83.  
<https://pubmed.ncbi.nlm.nih.gov/30500064>
1531. Rove, K.O., *et al.* Enhanced recovery after surgery in children: Promising, evidence-based multidisciplinary care. *Paediatr Anaesth*, 2018. 28: 482.  
<https://pubmed.ncbi.nlm.nih.gov/29752858>
1532. Frykholm, P., *et al.* Pre-operative fasting in children: A guideline from the European Society of Anaesthesiology and Intensive Care. *Eur J Anaesthesiol*, 2022. 39: 4.  
<https://pubmed.ncbi.nlm.nih.gov/34857683>
1533. Martin, L.D., *et al.* Perioperative Management of Pediatric Patients With Type 1 Diabetes Mellitus, Updated Recommendations for Anesthesiologists. *Anesth Analg*, 2020. 130: 821.  
<https://pubmed.ncbi.nlm.nih.gov/31688079>
1534. Pedraza Bermeo, A.M., *et al.* Risk factors for postobstructive diuresis in pediatric patients with ureteropelvic junction obstruction, following open pyeloplasty in three high complexity institutions. *J Pediatr Urol*, 2018. 14: 260 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29501380>
1535. Cheng, W., *et al.* Electrogastrographic changes in children who undergo day-surgery anesthesia. *J Pediatr Surg*, 1999. 34: 1336.  
<https://pubmed.ncbi.nlm.nih.gov/10507424>
1536. Chauvin, C., *et al.* Early postoperative oral fluid intake in paediatric day case surgery influences the need for opioids and postoperative vomiting: a controlled randomized trial. *Br J Anaesth*, 2017. 118: 407.  
<https://pubmed.ncbi.nlm.nih.gov/28203729>
1537. Ekingen, G., *et al.* Early enteral feeding in newborn surgical patients. *Nutrition*, 2005. 21: 142.  
<https://pubmed.ncbi.nlm.nih.gov/15723741>
1538. Cavusoglu, Y.H., *et al.* Does gum chewing reduce postoperative ileus after intestinal resection in children? A prospective randomized controlled trial. *Eur J Pediatr Surg*, 2009. 19: 171.  
<https://pubmed.ncbi.nlm.nih.gov/19360548>
1539. Fung, A.C., *et al.* Enhanced recovery after surgery in pediatric urology: Current evidence and future practice. *J Pediatr Urol*, 2023. 19: 98.  
<https://pubmed.ncbi.nlm.nih.gov/35995660>
1540. Arena, S., *et al.* Enhanced Recovery After Gastrointestinal Surgery (ERAS) in Pediatric Patients: a Systematic Review and Meta-analysis. *J Gastrointest Surg*, 2021. 25: 2976.  
<https://pubmed.ncbi.nlm.nih.gov/34244952>
1541. Ivani, G., *et al.* Postoperative analgesia in infants and children: new developments. *Minerva Anesthesiol*, 2004. 70: 399.  
<https://pubmed.ncbi.nlm.nih.gov/15181422>
1542. Stapelkamp, C., *et al.* Assessment of acute pain in children: development of evidence-based guidelines. *Int J Evid Based Healthc*, 2011. 9: 39.  
<https://pubmed.ncbi.nlm.nih.gov/21332662>
1543. Zielinski, J., *et al.* Pain assessment and management in children in the postoperative period: A review of the most commonly used postoperative pain assessment tools, new diagnostic methods and the latest guidelines for postoperative pain therapy in children. *Adv Clin Exp Med*, 2020. 29: 365.  
<https://pubmed.ncbi.nlm.nih.gov/32129952>
1544. Cravero, J.P., *et al.* The Society for Pediatric Anesthesia recommendations for the use of opioids in children during the perioperative period. *Paediatr Anaesth*, 2019. 29: 547.  
<https://pubmed.ncbi.nlm.nih.gov/30929307>
1545. Jonas, D.A. Parent's management of their child's pain in the home following day surgery. *J Child Health Care*, 2003. 7: 150.  
<https://pubmed.ncbi.nlm.nih.gov/14516009>
1546. Woolf, C.J., *et al.* Preemptive analgesia—treating postoperative pain by preventing the establishment of central sensitization. *Anesth Analg*, 1993. 77: 362.  
<https://pubmed.ncbi.nlm.nih.gov/8346839>
1547. Kendall, M.C., *et al.* Regional anesthesia to ameliorate postoperative analgesia outcomes in pediatric surgical patients: an updated systematic review of randomized controlled trials. *Local Reg Anesth*, 2018. 11: 91.  
<https://pubmed.ncbi.nlm.nih.gov/30532585>
1548. Organization., W.H., *Cancer Pain Relief and Palliative Care in Children*. 1998, World Health Organization: Geneva.

1549. Kelley-Quon, L.I., *et al.* Guidelines for Opioid Prescribing in Children and Adolescents After Surgery: An Expert Panel Opinion. *JAMA Surg*, 2021. 156: 76.  
<https://pubmed.ncbi.nlm.nih.gov/33175130>
1550. Wong, I., *et al.* Opioid-sparing effects of perioperative paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) in children. *Paediatr Anaesth*, 2013. 23: 475.  
<https://pubmed.ncbi.nlm.nih.gov/23570544>
1551. Cooney, M.F. Pain Management in Children: NSAID Use in the Perioperative and Emergency Department Settings. *Paediatr Drugs*, 2021. 23: 361.  
<https://pubmed.ncbi.nlm.nih.gov/34046854>
1552. Paix, B.R., *et al.* Circumcision of neonates and children without appropriate anaesthesia is unacceptable practice. *Anaesth Intensive Care*, 2012. 40: 511.  
<https://pubmed.ncbi.nlm.nih.gov/22577918>
1553. Vittinghoff, M., *et al.* Postoperative pain management in children: Guidance from the pain committee of the European Society for Paediatric Anaesthesiology (ESPA Pain Management Ladder Initiative). *Paediatr Anaesth*, 2018. 28: 493.  
<https://pubmed.ncbi.nlm.nih.gov/29635764>
1554. Cyna, A.M., *et al.* Caudal epidural block versus other methods of postoperative pain relief for circumcision in boys. *Cochrane Database Syst Rev*, 2008. 2008: CD003005.  
<https://pubmed.ncbi.nlm.nih.gov/18843636>
1555. Zhu, C., *et al.* Analgesic efficacy and impact of caudal block on surgical complications of hypospadias repair: a systematic review and meta-analysis. *Reg Anesth Pain Med*, 2019. 44: 259.  
<https://pubmed.ncbi.nlm.nih.gov/30700621>
1556. Chan, K.H., *et al.* Comparison of Intraoperative and Early Postoperative Outcomes of Caudal vs Dorsal Penile Nerve Blocks for Outpatient Penile Surgeries. *Urology*, 2018. 118: 164.  
<https://pubmed.ncbi.nlm.nih.gov/29122625>
1557. Hung, T.Y., *et al.* Analgesic Effects of Regional Analgesic Techniques in Pediatric Inguinal Surgeries: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. *Anesth Analg*, 2024. 138: 108.  
<https://pubmed.ncbi.nlm.nih.gov/36571797>
1558. Wang, Y., *et al.* Clonidine as an Additive to Local Anesthetics in Caudal Block for Postoperative Analgesia in Pediatric Surgery: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)*, 2021. 8: 723191.  
<https://pubmed.ncbi.nlm.nih.gov/34595191>
1559. Shah, U.J., *et al.* Efficacy and safety of caudal dexmedetomidine in pediatric infra-umbilical surgery: a meta-analysis and trial-sequential analysis of randomized controlled trials. *Reg Anesth Pain Med*, 2021. 46: 422.  
<https://pubmed.ncbi.nlm.nih.gov/33452203>
1560. Hermansson, O., *et al.* Local delivery of bupivacaine in the wound reduces opioid requirements after intraabdominal surgery in children. *Pediatr Surg Int*, 2013. 29: 451.  
<https://pubmed.ncbi.nlm.nih.gov/23483343>
1561. Hidas, G., *et al.* Application of continuous incisional infusion of local anesthetic after major pediatric urological surgery: prospective randomized controlled trial. *J Pediatr Surg*, 2015. 50: 481.  
<https://pubmed.ncbi.nlm.nih.gov/25746712>
1562. Chalmers, D.J., *et al.* Continuous local anesthetic infusion for children with spina bifida undergoing major reconstruction of the lower urinary tract. *J Pediatr Urol*, 2015. 11: 72 e1.  
<https://pubmed.ncbi.nlm.nih.gov/25819374>
1563. Hong, J.Y., *et al.* Fentanyl-sparing effect of acetaminophen as a mixture of fentanyl in intravenous parent-/nurse-controlled analgesia after pediatric ureteroneocystostomy. *Anesthesiology*, 2010. 113: 672.  
<https://pubmed.ncbi.nlm.nih.gov/20693884>
1564. Mittal, S., *et al.* Trends in opioid and nonsteroidal anti-inflammatory (NSAID) usage in children undergoing common urinary tract reconstruction: A large, single-institutional analysis. *J Pediatr Urol*, 2022. 18: 501 e1.  
<https://pubmed.ncbi.nlm.nih.gov/35803865>
1565. Kumar, R., *et al.* Dorsal lumbotomy incision for pediatric pyeloplasty—a good alternative. *Pediatr Surg Int*, 1999. 15: 562.  
<https://pubmed.ncbi.nlm.nih.gov/10631734>
1566. Hamill, J.K., *et al.* Rectus sheath and transversus abdominis plane blocks in children: a systematic review and meta-analysis of randomized trials. *Paediatr Anaesth*, 2016. 26: 363.  
<https://pubmed.ncbi.nlm.nih.gov/26846889>



1567. Narasimhan, P, *et al.* Comparison of caudal epidural block with paravertebral block for renal surgeries in pediatric patients: A prospective randomised, blinded clinical trial. *J Clin Anesth*, 2019. 52: 105.  
<https://pubmed.ncbi.nlm.nih.gov/30243061>
1568. Martin, L.D., *et al.* Comparison between epidural and opioid analgesia for infants undergoing major abdominal surgery. *Paediatr Anaesth*, 2019. 29: 835.  
<https://pubmed.ncbi.nlm.nih.gov/31140664>
1569. Snyder, E., *et al.* Inclusion of surgical antibiotic regimens in pediatric urology publications: A systematic review. *J Pediatr Urol*, 2020. 16: 595 e1.  
<https://pubmed.ncbi.nlm.nih.gov/32641230>
1570. Kim, J.K., *et al.* Practice variation on use of antibiotics: An international survey among pediatric urologists. *J Pediatr Urol*, 2018. 14: 520.  
<https://pubmed.ncbi.nlm.nih.gov/29843954>
1571. Akinci, A., *et al.* Effect of continuous antibiotic prophylaxis in children with postoperative JJ stents: A prospective randomized study. *J Pediatr Urol*, 2021. 17: 89.  
<https://pubmed.ncbi.nlm.nih.gov/33097422>
1572. Klaassen, I.L.M., *et al.* Are low-molecular-weight heparins safe and effective in children? A systematic review. *Blood Rev*, 2019. 33: 33.  
<https://pubmed.ncbi.nlm.nih.gov/30041977>
1573. Chalmers, E., *et al.* Guideline on the investigation, management and prevention of venous thrombosis in children. *Br J Haematol*, 2011. 154: 196.  
<https://pubmed.ncbi.nlm.nih.gov/21595646>
1574. Takemoto, C.M., *et al.* Hospital-associated venous thromboembolism in children: incidence and clinical characteristics. *J Pediatr*, 2014. 164: 332.  
<https://pubmed.ncbi.nlm.nih.gov/24332452>
1575. Ahn, J.J., *et al.* Incidence and risk factors associated with 30-day post-operative venous thromboembolism: A NSQIP-pediatric analysis. *J Pediatr Urol*, 2018. 14: 335 e1.  
<https://pubmed.ncbi.nlm.nih.gov/29784455>
1576. Journeycake, J.M., *et al.* Thrombosis during infancy and childhood: what we know and what we do not know. *Hematol Oncol Clin North Am*, 2004. 18: 1315.  
<https://pubmed.ncbi.nlm.nih.gov/15511618>
1577. Morgan, J., *et al.* Prevention of perioperative venous thromboembolism in pediatric patients: Guidelines from the Association of Paediatric Anaesthetists of Great Britain and Ireland (APAGBI). *Paediatr Anaesth*, 2018. 28: 382.  
<https://pubmed.ncbi.nlm.nih.gov/29700892>
1578. Sutor, A.H., *et al.* Low-molecular-weight heparin in pediatric patients. *Semin Thromb Hemost*, 2004. 30 Suppl 1: 31.  
<https://pubmed.ncbi.nlm.nih.gov/15085464>
1579. Sharma, M., *et al.* Thromboprophylaxis in a pediatric hospital. *Curr Probl Pediatr Adolesc Health Care*, 2013. 43: 178.  
<https://pubmed.ncbi.nlm.nih.gov/23890025>
1580. Pagowska-Klimek, I. Perioperative thromboembolism prophylaxis in children - is it necessary? *Anaesthesiol Intensive Ther*, 2020. 52: 316.  
<https://pubmed.ncbi.nlm.nih.gov/36851806>
1581. Sharathkumar, A.A., *et al.* Epidemiology and outcomes of clinically unsuspected venous thromboembolism in children: A systematic review. *J Thromb Haemost*, 2020. 18: 1100.  
<https://pubmed.ncbi.nlm.nih.gov/31984669>
1582. Getahun, A.B., *et al.* Magnitude and Factors Associated with Preoperative Anxiety Among Pediatric Patients: Cross-Sectional Study. *Pediatric Health Med Ther*, 2020. 11: 485.  
<https://pubmed.ncbi.nlm.nih.gov/33364873>
1583. Kain, Z.N., *et al.* Preoperative anxiety, postoperative pain, and behavioral recovery in young children undergoing surgery. *Pediatrics*, 2006. 118: 651.  
<https://pubmed.ncbi.nlm.nih.gov/16882820>
1584. Dave, N.M. Premedication and Induction of Anaesthesia in paediatric patients. *Indian J Anaesth*, 2019. 63: 713.  
<https://pubmed.ncbi.nlm.nih.gov/31571684>
1585. Richards, H.W., *et al.* Trends in robotic surgery utilization across tertiary children's hospitals in the United States. *Surg Endosc*, 2021. 35: 6066.  
<https://pubmed.ncbi.nlm.nih.gov/33112985>

1586. Ransford, G.A., *et al.* Predictive factors for early discharge ( $\leq 24$  hours) and re-admission following robotic-assisted laparoscopic pyeloplasty in children. *Can Urol Assoc J*, 2021. 15: E603.  
<https://pubmed.ncbi.nlm.nih.gov/33999802>
1587. Miyano, G., *et al.* Recovery of bowel function after transperitoneal or retroperitoneal laparoscopic pyeloplasty. A multi-center study. *Pediatr Surg Int*, 2021. 37: 1791.  
<https://pubmed.ncbi.nlm.nih.gov/34498175>
1588. Spinelli, G., *et al.* Pediatric anesthesia for minimally invasive surgery in pediatric urology. *Transl Pediatr*, 2016. 5: 214.  
<https://pubmed.ncbi.nlm.nih.gov/27867842>
1589. Menes, T., *et al.* Laparoscopy: searching for the proper insufflation gas. *Surg Endosc*, 2000. 14: 1050.  
<https://pubmed.ncbi.nlm.nih.gov/11116418>
1590. McHoney, M., *et al.* Carbon dioxide elimination during laparoscopy in children is age dependent. *J Pediatr Surg*, 2003. 38: 105.  
<https://pubmed.ncbi.nlm.nih.gov/12592630>
1591. Peters, C.A. Complications in pediatric urological laparoscopy: results of a survey. *J Urol*, 1996. 155: 1070.  
<https://pubmed.ncbi.nlm.nih.gov/8583567>
1592. Passerotti, C.C., *et al.* Patterns and predictors of laparoscopic complications in pediatric urology: the role of ongoing surgical volume and access techniques. *J Urol*, 2008. 180: 681.  
<https://pubmed.ncbi.nlm.nih.gov/18554647>
1593. Zhou, R., *et al.* Abdominal wall elasticity of children during pneumoperitoneum. *J Pediatr Surg*, 2020. 55: 742.  
<https://pubmed.ncbi.nlm.nih.gov/31307782>
1594. Sureka, S.K., *et al.* Safe and optimal pneumoperitoneal pressure for transperitoneal laparoscopic renal surgery in infant less than 10 kg, looked beyond intraoperative period: A prospective randomized study. *J Pediatr Urol*, 2016. 12: 281 e1.  
<https://pubmed.ncbi.nlm.nih.gov/27751832>
1595. Streich, B., *et al.* Increased carbon dioxide absorption during retroperitoneal laparoscopy. *Br J Anaesth*, 2003. 91: 793.  
<https://pubmed.ncbi.nlm.nih.gov/14633746>
1596. Kalfa, N., *et al.* Tolerance of laparoscopy and thoracoscopy in neonates. *Pediatrics*, 2005. 116: e785.  
<https://pubmed.ncbi.nlm.nih.gov/16322135>
1597. Ansari, M.S., *et al.* Risk factors for progression to end-stage renal disease in children with posterior urethral valves. *J Pediatr Urol*, 2010. 6: 261.  
<https://pubmed.ncbi.nlm.nih.gov/19833558>
1598. Meininger, D., *et al.* Effects of posture and prolonged pneumoperitoneum on hemodynamic parameters during laparoscopy. *World J Surg*, 2008. 32: 1400.  
<https://pubmed.ncbi.nlm.nih.gov/18224479>
1599. Gueugniaud, P.Y., *et al.* The hemodynamic effects of pneumoperitoneum during laparoscopic surgery in healthy infants: assessment by continuous esophageal aortic blood flow echo-Doppler. *Anesth Analg*, 1998. 86: 290.  
<https://pubmed.ncbi.nlm.nih.gov/9459234>
1600. Sakka, S.G., *et al.* Transoesophageal echocardiographic assessment of haemodynamic changes during laparoscopic herniorrhaphy in small children. *Br J Anaesth*, 2000. 84: 330.  
<https://pubmed.ncbi.nlm.nih.gov/10793591>
1601. De Waal, E.E., *et al.* Haemodynamic changes during low-pressure carbon dioxide pneumoperitoneum in young children. *Paediatr Anaesth*, 2003. 13: 18.  
<https://pubmed.ncbi.nlm.nih.gov/12535034>
1602. Caliskan, E., *et al.* Evaluation of renal oxygenization in laparoscopic pediatric surgery by near infrared spectroscopy. *Pediatr Surg Int*, 2020. 36: 1077.  
<https://pubmed.ncbi.nlm.nih.gov/32651617>
1603. Demyttenaere, S., *et al.* Effect of pneumoperitoneum on renal perfusion and function: a systematic review. *Surg Endosc*, 2007. 21: 152.  
<https://pubmed.ncbi.nlm.nih.gov/17160650>
1604. Gomez Dammeier, B.H., *et al.* Anuria during pneumoperitoneum in infants and children: a prospective study. *J Pediatr Surg*, 2005. 40: 1454.  
<https://pubmed.ncbi.nlm.nih.gov/16150348>
1605. Halverson, A., *et al.* Evaluation of mechanism of increased intracranial pressure with insufflation. *Surg Endosc*, 1998. 12: 266.  
<https://pubmed.ncbi.nlm.nih.gov/9502709>

1606. Mobbs, R.J., *et al.* The dangers of diagnostic laparoscopy in the head injured patient. *J Clin Neurosci*, 2002. 9: 592.  
<https://pubmed.ncbi.nlm.nih.gov/12383425>
1607. Al-Mufarrej, F., *et al.* Laparoscopic procedures in adults with ventriculoperitoneal shunts. *Surg Laparosc Endosc Percutan Tech*, 2005. 15: 28.  
<https://pubmed.ncbi.nlm.nih.gov/15714153>
1608. Andolfi, C., *et al.* Robot-assisted laparoscopic pyeloplasty in infants and children: is it superior to conventional laparoscopy? *World J Urol*, 2020. 38: 1827.  
<https://pubmed.ncbi.nlm.nih.gov/31506749>
1609. Gonzalez, S.T., *et al.* Multicenter comparative study of open, laparoscopic, and robotic pyeloplasty in the pediatric population for the treatment of ureteropelvic junction obstruction (UPJO). *Int Braz J Urol*, 2022. 48: 961.  
<https://pubmed.ncbi.nlm.nih.gov/36083265>
1610. Chandrasekharam, V.V.S., *et al.* A systematic review and meta-analysis of conventional laparoscopic versus robot-assisted laparoscopic pyeloplasty in infants. *J Pediatr Urol*, 2021. 17: 502.  
<https://pubmed.ncbi.nlm.nih.gov/33812779>
1611. Gnech M., *et al.* Update and Summary of the European Association of Urology/European Society of Paediatric Urology Paediatric Guidelines on Vesicoureteral Reflux in Children. *Eur Urol*. 2024 Jan 4:S0302-2838(23)03298-0.  
<https://pubmed.ncbi.nlm.nih.gov/38182493/>

## 5. CONFLICT OF INTEREST

All members of the Paediatric Urology Guidelines Panel have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: <http://www.uroweb.org/guidelines/>. This Guidelines document was developed with the financial support of the EAU. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

## 6. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

*EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.*

If a publisher and/or location is required, include:

*EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>*

References to individual guidelines should be structured in the following way:

*Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.*